<SEC-DOCUMENT>0001558370-24-016491.txt : 20241227
<SEC-HEADER>0001558370-24-016491.hdr.sgml : 20241227
<ACCEPTANCE-DATETIME>20241227163027
ACCESSION NUMBER:		0001558370-24-016491
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241227
DATE AS OF CHANGE:		20241227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Outlook Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001649989
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				383982704
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37759
		FILM NUMBER:		241586021

	BUSINESS ADDRESS:	
		STREET 1:		111 S. WOOD AVENUE
		STREET 2:		UNIT #100
		CITY:			ISELIN
		STATE:			NJ
		ZIP:			08830
		BUSINESS PHONE:		6096193990

	MAIL ADDRESS:	
		STREET 1:		111 S. WOOD AVENUE
		STREET 2:		UNIT #100
		CITY:			ISELIN
		STATE:			NJ
		ZIP:			08830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oncobiologics, Inc.
		DATE OF NAME CHANGE:	20150804
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>otlk-20240930x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 12/27/2024 4:49:25 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: cb664000-932a-4f8c-8063-cd2c29c9a796 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:otlk="http://www.outlooktherapeutics.com/20240930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>OUTLOOK THERAPEUTICS, INC._September 30, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_n00HlfZxbEWQPFKyyKwVxA">http://www.outlooktherapeutics.com/20240930#ChangeInFairValueOfRedemptionFeature</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_pvNgaBh-KEeANZaROKbW9w">http://www.outlooktherapeutics.com/20240930#ChangeInFairValueOfRedemptionFeature</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_2gdPZ9SMLEuQPHawoXcHxQ" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_4wfYnlIqeUyLM7KCzyDFdQ">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_NEwt-f0xMESfNeKgTqHcvA">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MinimumMember_8zXwjUyVUEWsaFBUXYo-Ug" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_bxPvBnUfBkO5HfmvqqI1rg">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yuNthvJ5dE-37kUZ9LB3Fg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_aurQEKRsiUKUgtUDwMQVZw">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityCentralIndexKey" id="Tc_tgycmRkvhke6BQ4YjhYuuA_2_1">0001649989</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:CurrentFiscalYearEndDate" id="Tc_PuVr5Rio9kidYD8nNWFcnA_3_1">--09-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:DocumentFiscalYearFocus" id="Tc_ULe20hndIk6AsxvpYRzusg_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:DocumentFiscalPeriodFocus" id="Tc_jR6as82Bjk29tHvgqfx2ew_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:AmendmentFlag" id="Tc_2M7ltNkD4U6yEoQOVNZmHg_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_nriUGTcej0qNzzfpnoD1Jg">http://fasb.org/us-gaap/2024#WarrantsAndRightsOutstanding</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_7BYTPZDFbEyyt_JlN9COqA">http://fasb.org/us-gaap/2024#WarrantsAndRightsOutstanding</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" xs:nil="true" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_r2jARt1MuEKZ00q33FOojQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" xs:nil="true" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" name="us-gaap:CommitmentsAndContingencies" id="Hidden_572yibkKwE-f5eshc-7l9Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" xs:nil="true" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" name="us-gaap:PreferredStockValue" id="Hidden_iF2dUt8Qkkehhy_NkHzsNg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" xs:nil="true" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" name="us-gaap:PreferredStockValue" id="Hidden_y3Ew4CJ85UmmLIFLRTmQzg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_EMW4HkbrgEKCDFUdDsHYag">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_0zcG2TyMaUiJsqqzBB469w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_N4pkjJobP0maC3w1WPuLFw">23905635</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_XPEQyVvjd0uleb7M0shZcg">13012833</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" sign="-" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Tc_D-F6tXftw0OusVdnRNHW7Q_2_1">4.06</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" sign="-" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Tc_BOlNF9aIJkSieVBAzgG-Xw_2_2">4.72</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" sign="-" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Tc_Welq6XENEU-kjp--uai4lw_3_1">4.06</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" sign="-" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Tc_jBQsq4VCMUSwRRNkuQ8IFA_3_2">4.72</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Tc_wAXwmPhchUaRScUJ17vMxA_4_1">18548813</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Tc_V3g8oG1nmUSHTqDoCDanCA_4_2">12508817</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Tc_l5Bv_51kJEmc96wNN2XSrQ_5_1">18548813</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Tc_Z-1gFlEx_0aYWeIEZQIiYQ_5_2">12508817</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_3_14_2024_To_3_14_2024_VWPmRYi-3k6pXKO7spUdzw" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_35bPP_NyTECQ2xx8ssQR0g">0.05</ix:nonFraction><ix:nonNumeric contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" name="otlk:DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" id="Hidden_nFi_I78LHEio1BmDRkU8nQ">P10D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_-FJYa8lNSUetfvJA523X1w">http://fasb.org/us-gaap/2024#PrimeRateMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Hidden_DkBDMcGwhUOfLjYffyDfaA">1.5</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="otlk-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3nC_oDhzvUyW3kv-c_voPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2024_To_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_3Dv-BLq7jECeFMzClAG8Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">otlk:GmsVenturesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_9gDHf8RsIEKIozNakQyBHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_tMGVlJe9F0SPML1If6N2Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">otlk:GmsVenturesInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:DirectRegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_14_2024_To_3_14_2024_VWPmRYi-3k6pXKO7spUdzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-14</xbrli:startDate><xbrli:endDate>2024-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aqpTcTgcvEKqWIkMkLyvSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_keL3bo7nE0CNPVnUOmT-gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UoWGYXeAcUmQc5T0sAOkNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eLtmRbHPMk-R2-bot8_N2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0N8PxP9kEu7Rni9SApcXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nab82IT-Gki9oEVbHZmkcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6NrSVQ0gRUCQVI56arDZNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tVVfsw2X4ku21-b-wI1Fsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_t3JCYhRKO0qAD5NVNkzh_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:DirectRegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Eds8gmT6BESQIrdG8MwAiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_pJJcoDJ6gU6lV4j5MOa6zA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2024_Z5sSwB3u8UeB-gHP0Yk07Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2024_To_8_31_2024_Xa-tuAfcY0uN_xgNYumOzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MinimumMember_8zXwjUyVUEWsaFBUXYo-Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MaximumMember_HtgYYVJwm0iJl8VrJguejw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yuNthvJ5dE-37kUZ9LB3Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_urH4VPBGPEWtUdqeC7Beig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-10</xbrli:startDate><xbrli:endDate>2024-12-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RHl_XSAP6E2hmGDCfAw-ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_15_2024_To_4_15_2024_PCVHwACz-E-GaHioJ0Mb4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-15</xbrli:startDate><xbrli:endDate>2024-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2024_To_3_18_2024_T3YCPqRoGE2MDvlAJH7KjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_6SGXL8bLrEG6_8cW5MPZcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:DirectRegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2024_CMktv_oZdUe5aaSem6VwXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_P56yKUXSbkSeAJyaiAzVzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_MHzt-sxje0CSeW0EsqpjLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_xm5rwmnSsUqyr_jq4s9uow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LKsDtuAd_kibOfWHNXl-Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5I3oWKzZqkyIrUS7CKXITQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DOx7DSkcUUK1qwvbqatS0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-22</xbrli:startDate><xbrli:endDate>2020-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_Wd5dAA2oOEitqaUmu8NEFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_Q7ljKxKDCE6cUaMIlRBFDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_RangeAxis_srt_MaximumMember_jnZ5DzV7xUyhrtJAXYQ3mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_Sk5RTQxSUkKzLC9zG8VQXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_7Nz6MTqRk06UkjKgAzcXCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_SE9TpsNiB0SZh02vDR962A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_DIM-yieXZEii39hWIo3zyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_jrGO66RARkOJ5xdVUtPWcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_2gdPZ9SMLEuQPHawoXcHxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_22_2020_dei_LegalEntityAxis_otlk_PRCJointVentureMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_gJdyvVXshEuX-08Mf6ndHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">otlk:PRCJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_iTKqGJl7VU6tkLMN2O_qZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_22_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_bGKy_9nKJ0yCir38nGdxBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-16</xbrli:startDate><xbrli:endDate>2021-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U7MnAhTIHkej02WiFwj3Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3IXjRjrvOUmxyOEeUsHZtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_0FNNd0MQSEGbVAxJkUYUBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_9bYKF4TI30O9lev1VzvfWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_tRV5Gx6Jz0y-S8KiNciwMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qZPC37xTWUe1Gonx3VN-Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kUMWn2QlUkGH1AcNmJxH4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7-lVNsEf202TYs18lInWUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qJ_fPZFQk0y4wnAgsqRsTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_7lqaz_2bqEqu4ykwZdkCvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bEUH4cZ0TUOwGFyu8Z-8Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_VI7IUXbs602kl6vuqYnf0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_tRxOTTUeTkW37kzoC2c6jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2022_To_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_9HupkBCxL0i0_z-wbjRQoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:DebtInstrumentFollowingToMajorTriggerEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_Q4I_32NkR0GngeV1BKZ52Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_9E7IaktkjkmxEa7PB2T1Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ynXa_bg7OkmqRB_LUbXGyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Vnv1HvGas0WeOr-RGPMVOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_md536lyF-ESJilyGxz3vZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_RQ1gGyRoQE2vajTWGBJEqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:DebtInstrumentFollowingToMajorTriggerEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ninrKLLlD0a6ZBI-j6EB3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Afa1M1WaS0SR2fyB14IoaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_SCSz0Z-7s0WGtX-bZHuMVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_otlk_SelexisMember_H9U6x4CDa0-Y6bDTtuTUEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">otlk:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2024_lLMZhv4wdEyjXYMfzCMdRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_6_2024_pDZUs5e-AkWbZ0eR564CBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_tR_1C3dSWUSlzc9QqxzIbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">otlk:GmsVenturesInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_WarrantExpirationDateFebruary22026Member_zdlkKXee3EeGESp4jsin-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:WarrantExpirationDateFebruary22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_5wnuAFtnzkWYbs_N6ZIXsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyTwoDecemberTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyThirdNovemberTwoThousandTwentySixMember_EB2rl2TAN0CnXGRhH5XKvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyThirdNovemberTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentySecondJuneTwoThousandTwentyFiveMember_ZSTbnrDNxUGsk02iJzVFvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentySecondJuneTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_VvsudmHpd0ulTJVNbJMjYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyFourFebruaryTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_z4Qp_byL30eF_-1LyvR3aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyEighthJanuaryTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_tHeUnkmGn0e6bXwpNgxn8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyEighthDecemberTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_7YfxW7oNqECNDRvtIT0roQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:ThirtyFirstMayTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirteenAprilTwoThousandTwentyFiveMember_UmZHRjMnC0qFpaKeOWRUqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:ThirteenAprilTwoThousandTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_FifteenthAprilTwoThousandTwentyNineMember_laMN9AKa2kC-sX-fpIwEWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:FifteenthAprilTwoThousandTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_EighteenMarchTwoThousandTwentyNineMember_0ANP-WX04kCa7auIEgQwfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:EighteenMarchTwoThousandTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2024_ktUhxMsOBk6ial5Q3nMCKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_feX5121kQ0qodVdS2YmgWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NSNiPG1XOE-noQA60o5JOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_CGyuX5E2Lk6tYUEmOYyhpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_JP8U0OONT0eXTY4nRn7zlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_o0ezSlIIp02ostECr3h3Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_9aSINsKIFUCWW7CgnYrY4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MSv0WissdE66_EmEuqeCpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_H3wdezVmCkeyQmMuA4qHQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_MSrK39kxQUu7ngOH5FFwIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_sI6h_SoIjUqmJoYH1Yzl-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rYTA6Gi8qkKqslIZHJezrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OOq4Je4wC0aStmP-fhnlkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jYVe9FMFeUqI7idUL2hGsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3_uEMNY46EulPN5v_asqtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5GDfve-pQk2XYOfwNALJmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_ecX5SQhuQUOy_xktLgPaqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_Wo2tL6zH10-t08OvobXAMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-22</xbrli:startDate><xbrli:endDate>2024-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_A1DDuw-oSUK__0BNs8JxRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_KmQM4eVrbkSrlJCBAuGuLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_24_2024_AKL63YIT7E2IdW942ODtuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_HK570P66lU6uxT7voueYkg"><xbrli:measure>otlk:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA"><xbrli:measure>otlk:Y</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;min-height:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:6.9pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:3pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_2a325c13_4c3e_4e10_9cfe_fd45561e32f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:DocumentType" id="Narr_BYVIonOw2UiMLPTvioMWVw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_04b45d03_b107_4321_b22a_e47f5a4004a3"></a><a id="Tc_6GqBTKTfdUKRQL0ysF95cQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:96.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:DocumentAnnualReport" id="Tc_mSNQlcmq_kq1YLTabQJfdg_1_0"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:DocumentPeriodEndDate" id="Narr_4Twi5fDabkuazRqY5aQ-vQ"><b style="font-size:8pt;font-weight:bold;">September 30, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><a id="_63fd740a_d850_4916_8f36_a4be1fe8078a"></a><a id="Tc_TkryhCMTcEeUUPr7_iz8aw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:96.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:DocumentTransitionReport" id="Tc_5eGuIl-ERUagllWfPrdWSw_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">For the transition period from</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">to</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityFileNumber" id="Narr_qtm5DuQgG0yuV-4O4ri0Uw"><b style="font-size:8pt;font-weight:bold;">001-37759</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityRegistrantName" id="Narr_2vPzpNpRSEGzO7xgqRJRcg"><b style="font-weight:bold;">OUTLOOK THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_acf39240_5280_4e0b_8c83_0eb35eda8f1f"></a><a id="Tc_YjlsNzJus0CCBrr8GX9_PA_2_0"></a><a id="Tc_Yj6nC7BBlk6Pt-11QIIxRg_2_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityIncorporationStateCountryCode" id="Tc_pF-Y2eUyW0Gk-LdXqJhf8w_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityTaxIdentificationNumber" id="Tc_ex6nw9cB1UCl5Bc2PsChoQ_1_2"><b style="font-size:8pt;font-weight:bold;">38-3982704</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of incorporation or organization)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_8cd10448_3363_478f_bf4a_5e58dbbc57d1"></a><a id="Tc_mmzKHrXfuUqOWLwdD8l0bw_1_0"></a><a id="Tc_OIR-w7Em2k2Ksfy9qPFYMQ_2_0"></a><a id="Tc_YGH1hwrAj0GWFGZYPAKBnQ_3_0"></a><a id="Tc_pk8TnufqxEK5pf5K2mBKQQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityAddressAddressLine1" id="Narr_8Fjy8QrUg02UrLfbkDkkuw"><b style="font-size:8pt;font-weight:bold;">111 S. Wood Avenue, Unit #100</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityAddressCityOrTown" id="Narr_WFXBpVUbG0S1kADe5x8BaA"><b style="font-size:8pt;font-weight:bold;">Iselin</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityAddressStateOrProvince" id="Narr_hvvKpFhuDEOPT2PxuzmnLw"><b style="font-size:8pt;font-weight:bold;">New Jersey</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityAddressPostalZipCode" id="Tc_Mz60zDFqFkalSKIpOzh34g_2_2"><b style="font-size:8pt;font-weight:bold;">08852</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:9pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:CityAreaCode" id="Narr_nvnn9bLtZUSTWMZACPaipA"><b style="font-size:8pt;font-weight:bold;">609</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:LocalPhoneNumber" id="Narr_YAF_sb9cEUGMuYeFmOYeuQ"><b style="font-size:8pt;font-weight:bold;">619-3990</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e8f448d6_33e1_45d9_b246_4791ed3321fc"></a><a id="Tc_amkyp5dc5kaftHzaPfI3FA_1_0"></a><a id="Tc_6omktqSK8EmmRTMSWGZM9w_1_2"></a><a id="Tc_RRpfrYpClUmVhsLVEKlKvw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:41.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:bottom;width:41.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:Security12bTitle" id="Tc_89pc9UQEmUucQbHOk-NlIw_2_0"><span style="font-size:8pt;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:TradingSymbol" id="Tc_Ixdw5VIQF06KbXI5jv9AQw_2_2"><span style="font-size:8pt;">OTLK</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:SecurityExchangeName" id="Tc_FAXHr0Hiq06ijLtrsGb40g_2_4"><span style="font-size:8pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt 0pt 3pt 0pt;">Securities Registered Pursuant to Section&#160;12(g)&#160;of the Act: None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_yigGQ98LWUmHI5Sye-8y9Q"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityVoluntaryFilers" id="Narr_Cha3AfbFUUOaAhRGIMHbuw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period than the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityCurrentReportingStatus" id="Narr_-Wry71k0fEiWjE_52Hv6Wg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-family:'Universal Std News w Comm Pi';font-size:8pt;">&#160;</span><span style="font-size:8pt;">No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityInteractiveDataCurrent" id="Narr_xT4q6tj-dk65tY29kQ16vA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> </span><span style="font-size:8pt;">No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="white-space:pre-wrap;"> </span>company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_88e2f645_44d3_4928_b935_78dda41e5217"></a><a id="Tc_pLtpZNjKDEenPIxSDk2wEg_1_0"></a><a id="Tc_y2bam1Zk4U-CaPj-efnwpA_1_1"></a><a id="Tc_aQd2fetLtU6woi3xf9bmIw_1_2"></a><a id="Tc_Ue37EIFDV0CM2FArb-0Oaw_1_3"></a><a id="Tc_bY-FkMEyhkeLwpbck4OY5w_2_1"></a><a id="Tc_2tpOxXKgVUGoqXN-5lQChA_2_2"></a><a id="Tc_ngoyaszGhkqCEw1y5sk2KQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Large accelerated filer </p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;">Accelerated filer </p></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityFilerCategory" id="Tc_4nEM3HuNkUyjjOuUo9tKBg_2_0"><span style="font-size:8pt;">Non-accelerated filer </span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;">Smaller reporting company </p></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntitySmallBusiness" id="Tc_jwqENugvkUCrG3JNva8djw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;margin:0pt;">Emerging growth company </p></td><td style="vertical-align:bottom;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityEmergingGrowthCompany" id="Tc__ZQb9thrF0Kf9EXAnbY0Xg_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management</span><span style="font-family:'Universal Std News w Comm Pi';font-size:8pt;">&#8217;</span><span style="font-size:8pt;">s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:IcfrAuditorAttestationFlag" id="Narr_lJdZGVYJxUmdkZd1YMlBRw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_kiNRNCARsUGOckv55ytAXQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant<span style="font-family:'Universal Std News w Comm Pi';">&#8217;</span>s executive officers during the relevant recovery period pursuant to <span style="font-family:'Universal Std News w Comm Pi';">&#167;</span>240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:EntityShellCompany" id="Narr_Z85DHOpuFESSVc--TTsXDg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-size:8pt;">No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">The aggregate market value of the registrant&#8217;s common stock, held by non-affiliates of the registrant as of March&#160;31, 2024 (which is the last business day of registrant&#8217;s most recently completed second fiscal quarter) based upon the closing market price of such stock on The Nasdaq Capital Market on that date, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" format="ixt:num-dot-decimal" scale="6" contextRef="As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA" decimals="-5" name="dei:EntityPublicFloat" id="Narr_ssRA2bdC3UGgcmc2LujE2g">180.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 3pt 0pt;">As of December 24, 2024, the registrant had outstanding <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_12_24_2024_AKL63YIT7E2IdW942ODtuQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_zen5p-umNUC-uZAA78W7Bw">24,905,635</ix:nonFraction> shares of common stock, par value $0.01 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Part III of this report incorporates information by reference from the Company's definitive proxy statement, which proxy statement is due to be filed with the Securities and Exchange Commission not later than 120 days after September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="iSkippedRange_87687"></a><a id="_ce7cddfd_3885_4e2c_8b12_f54278b5ec7b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">OUTLOOK THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">ANNUAL REPORT ON FORM 10-K</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5975723%;padding-left:0pt;padding-right:0pt;width:101.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">Cautionary Note Regarding Forward-Looking Statements and Industry Data</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">ii</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SELECTEDRISKSAFFECTINGOURBUSINESS_740963"><span style="font-style:normal;font-weight:normal;">Selected Risks Affecting Our Business</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">iii</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_75115"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_522452"><span style="font-style:normal;font-weight:normal;">ITEM 1.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_522452"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_454488"><span style="font-style:normal;font-weight:normal;">ITEM 1A.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_454488"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_222284"><span style="font-style:normal;font-weight:normal;">ITEM 1B.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_222284"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_1C_Cyber"><span style="font-style:normal;font-weight:normal;">ITEM 1C.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_1C_Cyber"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_440075"><span style="font-style:normal;font-weight:normal;">ITEM 2.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_440075"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_843298"><span style="font-style:normal;font-weight:normal;">ITEM 3.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_843298"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_479866"><span style="font-style:normal;font-weight:normal;">ITEM 4.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_479866"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_830844"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">ITEM 5.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_6_Reserved"><span style="font-style:normal;font-weight:normal;">ITEM 6.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item_6_Reserved"><span style="font-style:normal;font-weight:normal;">Reserved.</span></a> </p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">ITEM 7.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">87</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">ITEM 7A.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">101</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8ConsolidatedFinancialStatementsandS"><span style="font-style:normal;font-weight:normal;">ITEM 8.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8ConsolidatedFinancialStatementsandS"><span style="font-style:normal;font-weight:normal;">Consolidated Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">102</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">ITEM 9.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_432274"><span style="font-style:normal;font-weight:normal;">ITEM 9A.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_432274"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_380541"><span style="font-style:normal;font-weight:normal;">ITEM 9B.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_380541"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_435170"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">ITEM 10.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_986273"><span style="font-style:normal;font-weight:normal;">ITEM 11.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_986273"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">ITEM 12.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">ITEM 13.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">ITEM 14.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_613503"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">133</p></td></tr><tr><td style="vertical-align:top;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">ITEM 15.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">133</p></td></tr><tr><td style="vertical-align:top;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_624675"><span style="font-style:normal;font-weight:normal;">ITEM 16.</span></a></p></td><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_624675"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">136</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">In this report, unless otherwise stated or as the context otherwise requires, references to &#8220;Outlook Therapeutics,&#8221; &#8220;Outlook,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Outlook Therapeutics, Inc. (formerly known as Oncobiologics, Inc.) and its consolidated subsidiaries. The Outlook logo, Oncobiologics logo, LYTENAVA and other trademarks or service marks of Outlook Therapeutics, Inc. appearing in this report are the property of Outlook Therapeutics, Inc. This report also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Currency translations between Swiss Francs, or CHF, and U.S. dollars provided herein are based on the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York on September 30, 2024, or CHF 0.9015 = $1.00. We do not represent that CHF were, could have been, or could be, converted into U.S. dollars at such rate or at any other rate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_CAUTIONARY_NOTE_REGARDING"></a><a id="_8cf50fd1_55b5_44d8_9e4d_707052b6c9b5"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of these provisions, including those relating to future events or our future financial performance and financial guidance. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; the negative of terms like these or other comparable terminology, in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this Annual Report on Form 10-K are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong. Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. We discuss many of these risks, uncertainties and other factors in this Annual Report on Form 10-K in greater detail in Item 1A under the heading &#8220;Risk Factors.&#8221; We caution investors that our business and financial performance are subject to substantial risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e4380601_77ca_4f96_8dbc_6562bd60e8a4"></a><a id="SELECTEDRISKSAFFECTINGOURBUSINESS_740963"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SELECTED RISKS AFFECTING OUR BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Investing in our common stock involves numerous risks, including the risks described in &#8220;Part I, Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. These risks include, among others, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses and negative cash flows from operations since our inception and expect to continue to incur significant losses and negative cash flows from operations for at least the next 12 months; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have never generated any revenue from product sales and may never be profitable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There is substantial doubt about our ability to continue as a going concern. We will need to raise substantial additional funding to complete the development and commercialization of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#8482; (</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">bevacizumab-gamma) outside of the European Union (the &#8220;EU&#8221;) and United Kingdom (the &#8220;UK&#8221;) and support our operations until we are able to generate sufficient revenue from the sales of ONS-5010/LYTENAVA in the EU and UK. This additional funding may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital, including modifications to our existing convertible securities, may cause dilution to our securityholders, restrict our operations or require us to relinquish rights to our technologies or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on the success of ONS-5010/LYTENAVA, our only product that has been approved in the EU and UK. If ONS-5010/LYTENAVA does not receive regulatory approval outside the EU and UK, or is not successfully commercialized, our business may be harmed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need to enter into alliances with other companies that can provide capabilities and funds for the development and commercialization of product candidates. If we are unsuccessful in forming or maintaining these alliances on favorable terms, our business could be harmed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Due to our limited resources and access to capital, we have, and will continue to need to, prioritize development of certain product candidates, and these decisions may prove to have been wrong and may harm our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical drug development is a lengthy and expensive process and we may encounter substantial delays in our clinical trials or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates, and our existing insurance coverage may not be sufficient to satisfy any liability that may arise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The development and commercialization of pharmaceutical products is subject to extensive regulation, and we may not obtain regulatory approvals for ONS-5010/LYTENAVA outside of the EU and UK or in any other indications for which we plan to develop the product, or any future product candidates, on a timely basis or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced or more effective than ours. Other products may be approved and successfully commercialized before ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently have no marketing and sales organization. If we are unable to establish and maintain sales and marketing capabilities in jurisdictions for which we choose to retain commercialization rights, we may be unable to generate any revenue and will depend on the efforts of our licensing partners, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to manufacture and test ONS-5010/LYTENAVA, conduct our preclinical and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for ONS-5010/LYTENAVA outside the EU and UK, or for any other of </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates, or commercialize ONS-5010/LYTENAVA or any other of our product candidates and our business could be harmed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently engage single source suppliers for clinical trial services and multiple source suppliers for future drug substance manufacturing, fill-finish manufacturing and product testing of ONS-5010/LYTENAVA. The loss of any of these suppliers, or any future single source suppliers, could harm our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may become involved in lawsuits to protect or enforce any future patents, which could be expensive, time-consuming and unsuccessful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain effective patent rights for ONS-5010/LYTENAVA or our other &#160;product candidates or any future product candidates, we may not be able to prevent competitors from using technologies we consider important in the development and commercialization of ONS-5010/LYTENAVA or any future product candidates, resulting in loss of any potential competitive advantage our patents may have otherwise afforded us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to maintain effective proprietary rights for ONS-5010/LYTENAVA or any future product candidates, we may not be able to compete effectively in our markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on the services of our key executives and personnel, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We and certain of our officers have been named as defendants in a pending securities class action lawsuit. Certain of our officers and directors have also been named as defendants in a pending shareholder derivative action. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in its outcome;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences, which may adversely affect our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The trading price of our securities is likely to be volatile, and purchasers of our securities could incur substantial losses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GMS Ventures and Investments, or GMS Ventures, beneficially owns a significant percentage of our common stock and has the right to designate members of our board of directors and is able to exert significant control over matters subject to stockholder approval, preventing new investors from influencing significant corporate decisions. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iv</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_91781bf1_704c_44d6_aa1e_490a0b2148fb"></a><a id="PARTI_75115"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I</p><a id="Item1Business_522452"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are a biopharmaceutical company that is the first to receive marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA<span style="background:#ffffff;">&#8482; (</span>bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, or EU, and United Kingdom, or UK. We are developing ONS-5010/LYTENAVA to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. We are also working to receive approval and launch ONS-0510/LYTENAVA in the United States. Our initial goal is to launch directly in the EU and the UK, and in the United States, if approved, as the first and only approved ophthalmic bevacizumab for the treatment of retina conditions, including wet age-related macular degeneration, or wet AMD. Our plans also include seeking approval and launching the product in Japan and other markets, either directly or through a strategic partner, if approved. We have entered into a collaboration agreement with Cencora (formerly AmerisourceBergen Corporation) to support the commercial launch of ONS-5010/LYTENAVA in Europe and the United States<span style="font-size:12pt;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody, or mAb, that inhibits VEGF and associated angiogenic activity. In October 2022, we submitted a Marketing Authorization Application, or MAA, for ONS-5010/LYTENAVA with the European Medicines Agency (EMA). On May 27, 2024, we received a marketing authorization from the European Commission for ONS-5010/LYTENAVA for the treatment of wet AMD, which is valid throughout the European Economic Area, or EEA. The marketing authorization in the EEA provides eight years of data exclusivity and 10 years of market exclusivity. On July 8, 2024, we also received approval from the Medicine and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. Additionally, on December 4, 2024, the UK National Institute for Health and Care Excellence (NICE) recommended LYTENAVA&#8482; (bevacizumab gamma), as an option for the treatment of wet AMD. &#160;We anticipate commencing our initial commercial launches in the EEA and UK in the first half of calendar 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Separately, in March 2022, we submitted a BLA with the U.S. Food and Drug Association, or the FDA, for ONS-5010/LYTENAVA&#8482;. In May 2022, we voluntarily withdrew our BLA to provide additional information requested by the FDA. We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA. On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. At subsequent Type A meetings with the FDA, we learned that the FDA requires the completion of an additional adequate and well-controlled clinical trial demonstrating the effectiveness of ONS-5010/LYTENAVA in the treatment of nAMD, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We agreed to conduct an additional adequate and well-controlled clinical trial following discussions with the FDA in support of our BLA for ONS-5010/LYTENAVA. In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this trial (NORSE EIGHT) seeking confirmation that, if successful, it would address the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA. In January 2024, we received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA, and in September 2024, we successfully completed enrollment in the NORSE EIGHT trial. As agreed to with the FDA in the SPA, NORSE EIGHT is a randomized, controlled, parallel-group, masked, non-inferiority study of approximately 400 newly diagnosed, wet AMD subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010/LYTENAVA or 0.5 mg ranibizumab intravitreal injections. Subjects received injections at Day 0 (randomization), Week 4, and Week 8 visits, with a final follow-up visit at Week 12. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2024, we reported that &#160;ONS-5010/LYTENAVA &#160;did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pre-specified non-inferiority endpoint at week 8 set forth in the SPA with the FDA was measured by mean change in best corrected visual acuity (BCVA) from baseline to week 8. The difference in the means between the ONS-5010/LYTENAVA and ranibizumab in the NORSE EIGHT trial was -2.257 BCVA letters with a 95% confidence interval of (-4.044, -0.470) while the lower bound of the pre-specified non-inferiority margin in the SPA was -3.5 at a 95% confidence interval; the hypothesis of noninferiority was not met (p&gt;0.025).&#160;In the intent-to-treat (ITT) primary dataset, NORSE EIGHT demonstrated a mean +4.2 letter improvement in BCVA in the ONS-5010/LYTENAVA arm and +6.3 letter improvement in BCVA in the ranibizumab arm.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:92.45%;background:#ffffff;"><tr style="height:22.9pt;"><td style="vertical-align:middle;width:36.72%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:36.5%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mean change in BCVA at week 8</p></td><td style="vertical-align:middle;width:26.76%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Non-Inferiority</p></td></tr><tr style="height:23.75pt;"><td style="vertical-align:middle;width:36.72%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ONS-5010/LYTENAVA 1.25 mg</p></td><td style="vertical-align:middle;width:36.5%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">+4.2 letters</p></td><td rowspan="2" style="vertical-align:middle;width:26.76%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">95%CI: (-4.044, -0.470)<br/>P-value: 0.0863</p></td></tr><tr style="height:22.9pt;"><td style="vertical-align:middle;width:36.72%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Ranibizumab 0.5mg</p></td><td style="vertical-align:middle;width:36.5%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt -0.5pt 0pt 7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">+6.3 letters</p></td><td style="display:none;vertical-align:middle;width:26.76%;background:#ffffff;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/>At the week 8 timepoint of NORSE EIGHT, ONS-5010/LYTENAVA was generally well-tolerated with overall ocular adverse event rates comparable to ranibizumab. The safety results demonstrated in NORSE EIGHT are consistent with previously reported safety results from the NORSE ONE, NORSE TWO, and NORSE THREE clinical trials, with no cases of retinal vasculitis reported in either study arm.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Analysis of the data is ongoing as the week 12 data from NORSE EIGHT is being collected, which is expected to be available in January 2025. Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025. Previously, through a Type A meeting and additional interactions with the FDA in a series fo Type C and Type D meetings, we identified the approaches needed to resolve the CMC comments in the CRL and believe that we have resolved these comments. If the BLA for ONS-5010/LYTENAVA is approved, we expect to receive 12 years of regulatory exclusivity in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our BLA and MAA submissions for ONS-5010/LYTENAVA in wet AMD involved three clinical trials, which we refer to as NORSE ONE, NORSE TWO and NORSE THREE. The study design for our clinical program to evaluate ONS-5010/LYTENAVA as an ophthalmic formulation of bevacizumab was reviewed at an end of Phase 2 meeting with the FDA in April 2018, and we filed our investigational new drug application, or IND, with the FDA in the first quarter of calendar 2019. In August 2020, we reported achieving the anticipated safety and efficacy proof-of-concept results from NORSE ONE, a clinical experience study. NORSE TWO was our pivotal Phase 3 clinical trial comparing ONS-5010/LYTENAVA to ranibizumab (LUCENTIS). The topline results reported from NORSE TWO in August 2021 showed that ONS-5010/LYTENAVA met the primary and key secondary endpoints for efficacy with clinically impactful change observed for treated patients. The NORSE TWO primary endpoint difference in proportion of subjects gaining at least 15 letters in Best Corrected Visual Acuity, or BCVA, score was met and was both highly statistically significant and clinically relevant. For a discussion of NORSE TWO, please see &#8220;Our Product Candidate Portfolio&#8212;<i style="font-style:italic;">ONS-5010/LYTENAVA &#8212; Bevacizumab for Ophthalmic Use&#8212;Clinical Development Status</i>&#8212;NORSE TWO&#8221;. In the intent to treat, or ITT, primary dataset, the percentage of patients who gained at least 15 letters who were treated with ONS-5010/LYTENAVA, was 41.7%, and the percentage of patients who gained at least 15 letters who were treated with ranibizumab was 23.1% (p = 0.0052). The primary endpoint was also statistically significant and clinically relevant in the secondary per protocol, or PP, dataset (p = 0.04) where the percentages were almost identical, at 41.0% with ONS-5010/LYTENAVA, and 24.7% with ranibizumab. The key secondary endpoint, BCVA score change from baseline to month 11, in the primary ITT dataset was also highly statistically significant and clinically relevant (p = 0.0035). A mean change of 11.2 letters in BCVA score was observed with ONS-5010/LYTENAVA, and with ranibizumab the mean change was 5.8 letters. The results were also statistically significant in the secondary PP dataset (p = 0.01) with a mean change with ONS-5010/LYTENAVA of 11.1 letters versus 7.0 letters with ranibizumab. Additionally, the majority of ONS-5010/LYTENAVA subjects maintained or gained BCVA during the study (defined as change from baseline in BCVA &#8805; 0), with at least 80% of ONS-5010/LYTENAVA subjects maintaining BCVA each month. Results were also positive for the remaining NORSE TWO secondary endpoints with 56.5% (p = 0.0016) of ONS-5010/LYTENAVA subjects gaining &#8805; 10 letters of vision and 68.5% (p = 0.0116) of ONS-5010/LYTENAVA subjects gaining &#8805; 5 letters of vision. NORSE THREE was an open-label safety study we conducted to ensure the adequate number of safety exposures to ONS-5010/LYTENAVA were available for the initial ONS-5010/LYTENAVA BLA submission with the FDA. In March 2021, we reported that the results from NORSE </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">THREE showed a positive safety profile for ONS-5010/LYTENAVA. The NORSE BLA registration program was also used to support our successful MAA submissions in the EU and UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, in November 2021, we began enrolling patients in our NORSE SEVEN clinical trial. The study compares the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including exudative age-related macular degeneration, DME, or BRVO. Subjects will be treated for three months, and the enrollment of subjects in the arm of the study receiving ONS-5010/LYTENAVA in vials has been completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have also received agreement from the FDA on three SPAs for three additional registration clinical trials for our ongoing Phase 3 program for ONS-5010/LYTENAVA. The agreements reached with the FDA on these SPAs cover the protocols for NORSE FOUR, a registration clinical trial evaluating ONS-5010/LYTENAVA to treat BRVO, and NORSE FIVE and NORSE SIX, two registration clinical trials evaluating ONS-5010/LYTENAVA to treat DME. The timing for initiating these studies has not been determined pending initial FDA approval for wet AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because there are no approved bevacizumab products for the treatment of retinal diseases in the United States, we submitted a standard BLA, and are not using the biosimilar drug development pathway that would be required if there were an approved bevacizumab drug for the targeted diseases. If approved in the United States, we believe ONS-5010/LYTENAVA has potential to mitigate risks associated with off-label use of repackaged bevacizumab. In the United States, 66.3% of retina physicians state off-label repackaged bevacizumab is their most commonly used first-line anti-VEGF (ASRS 2022 Membership Survey Presented at ASRS NY 2022).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Our goal is to launch ONS-5010/LYTENAVA as the first, and only, approved bevacizumab for ophthalmic use in the EU, UK, United States and other markets. We plan to do this directly in the United States and either directly or through a strategic partner in the EU and UK and in other markets. In order to achieve this goal, we have adopted a streamlined clinical and regulatory strategy, the key elements of which include:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Leveraging the ophthalmic drug development and commercialization expertise of our leadership team. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Members of our executive team have extensive expertise in developing and commercializing treatments for retinal diseases, such as wet AMD, DME and BRVO. We intend to leverage their collective experience to further the development of, and execute an optimal commercial strategy for, ONS-5010/LYTENAVA, including licensing commercial rights to ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to a strategic partner outside the United States.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Engaging with regulatory authorities to establish clear guidelines for potential approval of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">outside the EU and UK. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have continued our approach of working closely with regulatory authorities to develop and conduct clinical trials that we believe will appropriately support approval of ONS-5010/LYTENAVA outside the EU and UK.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Leveraging the expertise of large partners in the biopharma industry to support launch of ONS-5010/LYTENAVA in the EU and UK, and outside of these countries if the product is approved in other territories. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have entered into a strategic commercialization agreement for the distribution of ONS-5010/LYTENAVA, which is intended to provide us with the leverage and capabilities of a large biopharmaceutical company. We use the same approach for leveraging the expertise of experienced third party biologic manufacturers for the production of our drug substance and finished product.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Reducing and managing costs to minimize additional investment to complete our development programs and plan for a potential commercial launch.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We have made the strategic decision to outsource the commercial manufacturing and future clinical trial supply manufacturing for ONS-5010/LYTENAVA and other product candidates. We believe this will significantly reduce future overhead costs not directly related to our ONS-5010/LYTENAVA program.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">ONS-5010/LYTENAVA &#8212; Bevacizumab for Ophthalmic Use</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have one product, ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab, approved in the EU and UK. On May 27, 2024, the European Commission granted a marketing authorization for ONS-5010/LYTENAVA<span style="background:#ffffff;"> for the treatment of wet AMD. This authorization is valid throughout the EEA. On July 8, 2024, the MHRA also granted a marketing authorization </span>for ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the UK for the treatment of wet AMD.</span> <span style="background:#ffffff;">ONS-5010/LYTENAVA is currently authorized for supply in vials. We also plan, however, to seek a variation to the current authorization to permit approval of supply of the product in pre-filled syringes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">We are actively working towards obtaining FDA approval of </span>ONS-5010/LYTENAVA<span style="background:#ffffff;"> for the treatment of wet AMD and anticipate resubmitting a BLA in the first calendar quarter of 2025. We are also planning to develop</span><span style="color:#231f20;"> </span>ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span><span style="color:#231f20;">for use in the treatment of other retina diseases such as DME and BRVO. We continue to hold the developed market commercialization rights for two legacy biosimilar product candidates, but currently have no plans to further develop these assets</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Bevacizumab is a full-length, humanized anti-VEGF recombinant mAb that inhibits VEGF and associated angiogenic (the growth of new blood vessels) activity. With wet AMD, abnormally high levels of VEGF are secreted in the eye. VEGF is a protein that promotes the growth of new abnormal blood vessels. Anti-VEGF injection therapy blocks this growth. Since the advent of anti-VEGF therapy, it has become the standard of care treatment option within the retina community, globally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:none;">Market Opportunity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">Age-related macular degeneration, or AMD, is a common eye condition and a leading cause of vision loss among people age 50 and older. Wet AMD is a form of &#8220;late stage&#8221; AMD and is also called neovascular AMD. In wet AMD, abnormal blood vessels grow underneath the retina. These vessels can leak fluid and blood, which may lead to swelling and damage of the macula causing vision loss. With wet AMD, abnormally high levels of VEGF are secreted in the eyes. VEGF is a protein that promotes the growth of new abnormal blood vessels. Anti-VEGF injection therapy blocks this growth. Since the advent of anti-VEGF therapy, it has become the standard of care treatment option within the retina community, globally. Wet AMD is a significant disease worldwide, with an estimated prevalence of over 2.9 million patients diagnosed in the United States, European countries and Japan alone in 2020 (GlobalData). Although bevacizumab is not currently FDA-approved for use in treating wet AMD, in the United States, approximately 66.3% of new patient starts are off-label repackaged bevacizumab (ASRS 2022 Membership Survey Presented at ASRS NY 2022). </span><span style="text-decoration-color:#000000;text-decoration-line:none;">Similarly, prior to the marketing authorization of ONS-5010/LYTENAVA</span><span style="text-decoration-color:#000000;text-decoration-line:none;background:#ffffff;"> in the EU and UK</span><span style="text-decoration-color:#000000;text-decoration-line:none;">, bevacizumab has been commonly utilized off-label in the treatment of wet AMD in many European countries. There is variability across European countries but in some markets it is believed that up to 80% of all wet AMD intravitreal injections are with bevacizumab. We believe ONS-5010/LYTENAVA has potential to mitigate risks associated with off-label repackaging of bevacizumab including, but not limited to, variability in potency, safety and sterility adverse events and syringe-related </span><span style="text-decoration-color:#000000;text-decoration-line:none;">adverse events</span><span style="text-decoration-color:#000000;text-decoration-line:none;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">DME is caused by a complication of diabetes called diabetic retinopathy. Diabetic retinopathy is the most common diabetic eye disease and the leading cause of irreversible blindness in working age Americans. Diabetic retinopathy usually affects both eyes and is caused by ongoing damage to the small blood vessels of the retina. The leakage of fluid into the retina may lead to swelling of the surrounding tissue, including the macula. DME is the most common cause of vision loss in people with diabetic retinopathy. DME can occur at any stage of diabetic retinopathy, although it is more likely to occur in later stages of the disease. There were approximately 8.6 million patients with DME in the United States, European countries and Japan alone in 2020 (GlobalData).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">In BRVO, retinal vein occlusions occur when there is a blockage of veins carrying blood with needed oxygen and nutrients away from the nerve cells in the retina. A blockage in the main vein of the retina is referred to as a central retinal vein occlusion, or CRVO, while a blockage in a smaller vein is called BRVO. Per the American Academy of Ophthalmology, retinal vein occlusions are the second most common retinal vascular disorder after diabetic retinopathy. There were an estimated 0.3 million patients with BRVO in the United States, European countries and Japan alone in 2020 (Triangulation </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">of Global Data, Market Scope and Investor Forecasts (2020)).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Annual revenue (worldwide) for anti-VEGF therapies was estimated to be $13.1 billion in 2020 (GlobalData). The United States accounted for approximately 50% of this market and Europe accounted for approximately 25% in 2020 (Global Data).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Clinical Development Status</i><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">The study design for our Phase 3 clinical program to evaluate ONS-5010/LYTENAVA as an ophthalmic formulation of bevacizumab was reviewed with the FDA at an end of Phase 2 meeting in April 2018, and we filed our IND with the FDA in the first quarter of calendar 2019. Our registration plan for wet AMD, the initial indication planned for ONS-5010/LYTENAVA, consisted of three clinical trials which we refer to as NORSE ONE, NORSE TWO and NORSE THREE. All three clinical trials have been completed. We reported achieving the anticipated safety and efficacy and positive proof-of-concept topline results from NORSE ONE, a clinical experience study, in August 2020. NORSE TWO was our pivotal Phase 3 clinical trial comparing ONS-5010/LYTENAVA to ranibizumab (LUCENTIS) that reported highly statistically significant topline results in August 2021. NORSE THREE was an open-label safety study conducted to ensure the adequate number of safety exposures to ONS-5010/LYTENAVA were available for the ONS-5010/LYTENAVA BLA submission with the FDA. After reviewing our BLA for ONS-5010/LYTENAVA, the FDA issued a CRL indicating that it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. We have agreed to conduct an additional clinical trial (NORSE EIGHT) to support approval of ONS-5010/LYTENAVA for the treatment of wet AMD in the United States. The FDA agreed with our SPA for NORSE EIGHT, and we successfully completed enrollment in the trial in September 2024. NORSE EIGHT is designed as a randomized, controlled non-inferiority clinical trial to assess the safety and efficacy of intravitreal injections of ONS-5010/LYTENAVA compared with ranibizumab (Lucentis) intravitreal injections, in subjects with neovascular age-related macular degeneration (nAMD). In November 2024, we reported that ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in SPA with the FDA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA, as described in greater detail above under &#8220;&#8212;Overview&#8221;. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025. Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025 (see &#8220;-Overview&#8221;)</span><span style="text-decoration-color:#000000;text-decoration-line:none;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">We have received agreements from the FDA on three SPAs for three additional registration clinical trials for our ongoing Phase 3 program for ONS-5010</span><span style="text-decoration-color:#000000;text-decoration-line:none;">/LYTENAVA</span><span style="text-decoration-color:#000000;text-decoration-line:none;">. The agreements reached with the FDA on these SPAs cover the protocols for NORSE FOUR, a registration clinical trial evaluating ONS-5010/LYTENAVA to treat BRVO, and NORSE FIVE and NORSE SIX, two registration clinical trials evaluating ONS-5010/LYTENAVA to treat DME. We intend to initiate these studies following the anticipated FDA approval of our BLA for wet AMD.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2021, we began enrolling patients in our NORSE SEVEN clinical trial. The study compares the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including exudative age-related macular degeneration, DME, or BRVO. Subjects will be treated for three months, and the enrollment of subjects in the arm of the study receiving ONS-5010/LYTENAVA in vials has been completed.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NORSE ONE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">NORSE ONE was designed as a randomized, masked clinical experience trial to support our BLA submission with the FDA for ONS-5010/LYTENAVA for the treatment of wet AMD. A total of 61 treatment na&#239;ve and previously treated patients were enrolled in the study at nine sites in Australia and randomized onto treatment arms of ONS-5010/LYTENAVA or ranibizumab. The primary endpoint for the study was the difference in proportion of subjects gaining 15 letters of BCVA at Day 330 for ONS-5010/LYTENAVA dosed on a monthly basis compared to ranibizumab dosed using the PIER alternative dosing regimen of three monthly doses followed by quarterly dosing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">In August 2020, we reported positive proof-of-concept topline results for ONS-5010/LYTENAVA as it achieved anticipated safety and efficacy expectations. In the analysis of treatment na&#239;ve patients who had a baseline visual acuity of &lt; 67 letters (20/50 or worse) at study entry, 2 of 4 (50%) patients in the ONS-5010/LYTENAVA arm and 4 of 9 (44%) patients in the ranibizumab arm achieved &gt; 15 letters at Day 330. This subgroup was the relevant patient population for our pivotal clinical trial of ONS-5010/LYTENAVA (NORSE TWO). Additionally, in a key secondary endpoint for the relevant patient population, the ONS-5010/LYTENAVA patients achieved a mean improvement in BCVA of 8.3 letters</span><span style="text-decoration-color:#000000;text-decoration-line:none;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NORSE TWO</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">NORSE TWO was a masked, randomized, pivotal Phase 3 clinical trial evaluating ONS-5010/LYTENAVA against ranibizumab for wet AMD. A total of 227 primarily treatment na&#239;ve patients were enrolled at 39 clinical trial sites in the United States. Patients enrolled in the study were randomized to either ONS-5010/LYTENAVA or ranibizumab arms and were treated for 11 months. The primary endpoint for the study was the difference in proportion of subjects gaining 15 letters of BCVA at Day 330 for ONS-5010/LYTENAVA dosed on a monthly basis compared to ranibizumab dosed using the PIER alternative dosing regimen. We reported topline results for NORSE TWO in August 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:none;">The topline results reported from NORSE TWO in August 2021 showed that ONS-5010/LYTENAVA met the primary and key secondary endpoint for efficacy with clinically impactful change observed for treated patients. The NORSE TWO primary endpoint difference in proportion of subjects gaining at least 15 letters in BCVA score was met and was both highly statistically significant and clinically relevant. In the intent-to-treat, or ITT, primary dataset, the percentage of patients who gained at least 15 letters who were treated with ONS-5010/LYTENAVA, was 41.7%, and the percentage of patients who gained at least 15 letters who were treated with ranibizumab was 23.1% (p = 0.0052). The primary endpoint was also statistically significant and clinically relevant in the secondary per-protocol, or PP dataset (p = 0.04) where the percentages were almost identical, at 41.0% with ONS-5010/LYTENAVA, and 24.7% with ranibizumab. The key secondary endpoint BCVA score change from baseline to month 11 in the primary ITT dataset was also highly statistically significant and clinically relevant (p = 0.0035). A mean change of 11.2 letters in BCVA score was observed with ONS-5010/LYTENAVA, and with ranibizumab the mean change was 5.8 letters. The results were also statistically significant in the secondary PP dataset (p = 0.01) with a mean change with ONS-5010/LYTENAVA of 11.1 letters versus 7.0 letters with ranibizumab. Results were also positive for the remaining NORSE TWO secondary endpoints with 56.5% (p = 0.0016) of ONS-5010/LYTENAVA subjects gaining &#8805; 10 letters of vision and 68.5% (p = 0.0116) of ONS-5010/LYTENAVA subjects gaining &#8805; 5 letters of vision</span><span style="text-decoration-color:#000000;text-decoration-line:none;">. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:219.65pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="otlk-20240930x10k006.jpg" alt="Graphic" style="display:inline-block;height:219.45pt;width:465.59pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="otlk-20240930x10k007.jpg" alt="Graphic" style="display:inline-block;height:219.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:456.83pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NORSE THREE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">NORSE THREE was an open-label safety study we conducted to ensure the adequate number of safety exposures to ONS-5010/LYTENAVA were available for the initial ONS-5010/LYTENAVA BLA submission with the FDA. In March 2021 we reported that the results from NORSE THREE provided a positive safety profile for ONS-5010/LYTENAVA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NORSE SEVEN</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">NORSE SEVEN was initiated to support our ongoing development program for delivering ONS-5010/LYTENAVA using a pre-filled syringe. It is a three month study designed to compare the safety of ophthalmic bevacizumab in vials versus </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including exudative AMD, DME, or BRVO. A total of 120 patients are expected to be enrolled in the study with 60 patients receiving ONS-5010/LYTENAVA packaged in vials and 60 patients receiving ONS packaged in a pre-filled syringe. Subjects will be treated for three months and the enrollment of subjects in the arm of the study receiving ONS-5010/LYTENAVA in vials has been completed. If successful, this study will support the submission of a supplemental BLA to the FDA after ONS-5010/LYTENAVA is approved for wet AMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NORSE EIGHT</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">NORSE EIGHT is a randomized, controlled, parallel-group, masked non-inferiority study of neovascular age-related macular degeneration subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010/LYTENAVA or 0.5 mg ranibizumab intravitreal injections. The primary endpoint is the mean change in BCVA from baseline to Week 8. Subjects received injections at Day 0 (randomization), Week 4, and Week 8 visits. In January 2024, we received confirmation from the FDA that, if successful, this study will address the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to support the resubmission of the ONS-5010/LYTENAVA BLA for wet AMD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A total of 400 patients were enrolled in the study. We successfully completed enrollment in September 2024 and in November 2024 we reported that &#160;ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA with the FDA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010. The difference in the means between the ONS-5010/LYTENAVA and ranibizumab in the NORSE EIGHT trial was -2.257 BCVA letters with a 95% confidence interval of (-4.044, -0.470) while the lower bound of the pre-specified non-inferiority margin in the SPA was -3.5 at a 95% confidence interval; the hypothesis of noninferiority was not met (p&gt;0.025). In the intent-to-treat (ITT) primary dataset, NORSE EIGHT demonstrated a mean +4.2 letter improvement in BCVA in the ONS-5010/LYTENAVA arm and +6.3 letter improvement in BCVA in the ranibizumab arm. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Commercialization, Sales and Marketing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">Our commercialization strategy is to provide a safe, effective, and affordable on-label bevacizumab for the retina community while maximizing revenue and patient access to ONS-5010/LYTENAVA. As part of our multi-year commercial planning process, we entered into a strategic collaboration agreement with Cencora to support the commercial launch of ONS-5010/LYTENAVA globally. Cencora will provide comprehensive launch support in the EU and UK, including pharmacovigilance, regulatory affairs, quality management, market access support, importation, third-party logistics distribution and field solutions. The collaboration and integrated approach is designed to support market access and efficient distribution of ONS-5010/LYTENAVA in the EU and UK, as well as other regions outside the United States. If approved by the FDA, we currently intend to launch and market ONS-5010/LYTENAVA ourselves in the United States. We currently own all of the development and commercialization rights to ONS-5010/LYTENAVA and have licensed rights only to our joint venture in the People&#8217;s Republic of China, or PRC, for the greater China market (see &#8220;-Collaboration and License Agreements-Syntone-Private Placement and PRC Joint Venture&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">The marketing authorization for ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EEA</span> provides eight years of data exclusivity and 10 years of market exclusivity. If approved by the FDA, we believe that ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>will be entitled to 12 years of regulatory exclusivity granted in the United States against biosimilar competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For many years, anti-VEGF therapy has been the standard of care for many ophthalmic diseases, including wet AMD, DME and BRVO. However, although multiple branded drugs have been approved for these indications (e.g., LUCENTIS, EYLEA, EYLEA HD, BEOVU, SUSVIMO and VABYSMO), they are very expensive. The recently approved biosimilar versions of LUCENTIS and EYLEA are also expensive, although they are available at a discount to the reference drug. Doctors who wish to treat their retinal patients with a less expensive anti-VEGF drug, with minimal reimbursement hurdles, often use off-label bevacizumab. However, because there is no FDA approved ophthalmic formulation of bevacizumab in the United States, and there was previously no approved ophthalmic formulation of bevacizumab in the EU or UK until the marketing authorizations of ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EU and UK</span>, doctors have used repackaged bevacizumab (Avastin) provided by compounding pharmacists that is not required to meet the standards for ophthalmic </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">use necessary for an approved product. Despite clinicians&#8217; widespread acceptance and use of bevacizumab to treat ophthalmic diseases such as wet AMD, DME and BRVO, no manufacturer has previously sought approval of bevacizumab for these diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The repackaged bevacizumab that is provided by compounding pharmacies is not required to meet ophthalmic drug standards and can carry known risks of contamination (including silicone oil droplet contamination from syringes) and inconsistent potency, with potentially severe consequences, as leading retinal societies have reported. For these reasons, the retina community and payors have shown interest in the development of an ophthalmic formulation of bevacizumab that could be an on-label alternative to repackaged bevacizumab from compounding pharmacists. Of 152 U.S. and European retina physicians surveyed in 2019, nearly 84% indicated they had an interest or high interest in an approved ophthalmic formulation of bevacizumab. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To meet this retinal market need, we are developing ONS-5010/LYTENAVA as an investigational ophthalmic formulation of bevacizumab in the United States. ONS-5010/LYTENAVA has been approved for the treatment of wet AMD in the EU and UK and provides a viable treatment option across the spectrum of anti-VEGF ophthalmic drugs that treat wet AMD, avoiding the safety, sterility, potency, availability, and syringe drawbacks that can occur with repackaged bevacizumab from compounding pharmacies. If approved in other indications, ONS-5010/LYTENAVA may also provide a viable alternative for the treatment of DME and BRVO<span style="background:#ffffff;">.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, we expect that ONS-5010/LYTENAVA will be able to help mitigate the high cost of treatment for retinal diseases in the EU and UK, and also in the United States if the product is approved there. Both in the United States and globally, the high cost of treating retinal diseases such as wet AMD, DME and BRVO can result in patients receiving an insufficient number of treatments, or potentially no treatment at all. We believe in the value of having an affordable, FDA and European Commission-approved option for patients that is safe, effective, and manufactured under proper guidance. Our commercial strategy for ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>includes providing an on-label bevacizumab as a first line option for treating retinal diseases. In addition, our approach to responsible price determination is being crafted with the retina community (patients, payors, and providers) to support patient access, maintain physician choice, and accelerate time to treatment. We are committed to keeping the patient at the core of what we do to ensure we provide an affordable option that offers streamlined access to compliant patient support services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ONS-5010/LYTENAVA has the potential to become the anti-VEGF cornerstone of care for retinal diseases in the EU and UK, and also in the United States if the product is approved there. It may also provide synergies with future long-acting agents and adjunct therapies for advanced treatment of wet AMD, DME and BRVO. ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>has the potential to help lower the aggregate costs of treating retinal diseases for the overall healthcare system in the EU and UK, and in the United States if the product is approved and commercialized there.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration and License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We enter into collaboration and license agreements in the ordinary course of our business. We have in-licensed certain technology from Selexis SA, or Selexis, that we used to research and develop our product candidates. For product candidates developed using the Selexis technology, we enter into commercial license agreements with Selexis that give us rights to commercialize, file investigational new drugs, or INDs and enter into collaborative arrangements with third parties for the further development and commercialization of such biosimilar product candidates. Although we are no longer working on our biosimilar development program, we have licensed rights to these biosimilar product candidates (ONS-3010, ONS-1045 and ONS-1050) in other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Syntone &#8211; Private Placement and PRC Joint Venture</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In May 2020, we entered into a stock purchase agreement with Syntone Ventures LLC, or Syntone, pursuant to which we sold and issued, in a private placement in June 2020, 800,000 shares of our common stock at a purchase price of $20.00 per share, for aggregate gross proceeds of $16.0 million. In connection with the entry into the stock purchase agreement, we entered into a joint venture agreement with Syntone&#8217;s PRC-based affiliate, pursuant to which we agreed to form a PRC joint venture that is 80% owned by Syntone&#8217;s PRC-affiliate and 20% owned by us. Upon formation of the PRC joint venture in April 2021, we entered into a royalty-free license with the PRC joint venture for the development, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We used approximately $0.9 million of the proceeds from the May 2020 private placement to Syntone to fund our initial capital contribution to the PRC joint venture, and are committed to make additional capital contributions to the PRC joint venture up to approximately $2.1 million which will be made within four years after the establishment date (April 2021) upon approval of the development plan contemplated in the license agreement or on such other terms as may be determined within such four-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Selexis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In October 2011, Selexis granted us a non-transferrable option to obtain a perpetual, non-exclusive, worldwide commercial license under the Selexis Technology to manufacture, or have manufactured, a recombinant protein produced by a cell line developed using the Selexis Technology for clinical testing and commercial sale. We exercised this option in April 2013 and entered into three commercial license agreements with Selexis for ONS-1045 (which covers ONS-5010/LYTENAVA), and two of our biosimilar product candidates, ONS-3010 and ONS-1050 (which are no longer in active clinical development). We paid an upfront licensing fee to Selexis for each commercial license and also agreed to pay a fixed milestone payment for each licensed product. In addition, we are required to pay a single-digit royalty on a final product-by-final product and country-by-country basis, based on worldwide net sales of such final products by us or any of our affiliates or sub-licensees during the royalty term. At any time during the term, we have the right to terminate our royalty payment obligation by providing written notice to Selexis and paying Selexis a royalty termination fee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Commercial License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 11, 2013, following the exercise of our option to enter a commercial license under the Selexis research license, we entered into commercial license agreements with Selexis for each of ONS-1045, ONS-3010 and ONS-1050. Under the terms of each commercial license agreement, we acquired a non-exclusive worldwide license under the Selexis Technology to use the cell lines developed under the research license and related materials, to manufacture and commercialize licensed and final products, with a limited right to sublicense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were required to pay an upfront licensing fee of CHF 65,000 (approximately $0.1 million) to Selexis for each commercial license and also agreed to pay up to CHF 365,000 (approximately $0.4 million) in milestone payments for each licensed product. In addition, we are required to pay a single-digit royalty on a final product-by-final product and country-by-country basis, based on worldwide net sales of such final products by us or any of our affiliates or sublicensees during the royalty term. The royalty term for each final product in each country is the period commencing from the first commercial sale of the applicable final product in the applicable country and ending on the expiration of the specified patent coverage. At any time during the term, we have the right to terminate our royalty payment obligation by providing written notice to Selexis and paying Selexis a royalty termination fee of CHF 1,750,000 (approximately $1.8 million). The initiation of our Phase 3 clinical program for ONS-5010/LYTENAVA in fiscal 2019 triggered a CHF 65,000 (approximately $0.1 million) milestone payment to Selexis under the commercial license agreement, which we paid in November 2019. As of September 30, 2024, we have paid Selexis an aggregate of approximately $0.4 million under the commercial license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of our commercial agreements with Selexis will expire in its entirety upon the expiration of all applicable Selexis patent rights. The licensed patent rights consist of two patent families. The first patent family relates to methods of transferring cells, and is filed in the United States, Australia, Canada, Europe, Japan and Singapore. This patent family began to expire worldwide in 2022. The second patent family claims DNA compositions of matter useful for having protein production increasing activity. This patent family is filed in the United States, Australia, Canada, China, Europe, Hong Kong, Israel, India, Japan, South Korea, Russia, Singapore and South Africa. This patent family will begin to expire worldwide in 2025. Either party may terminate the related agreement in the event of an uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, winding up or similar circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Either party may also terminate the related agreement under designated circumstances if the Selexis Technology infringes third-party intellectual property rights. In addition, we have the right to terminate each of the commercial agreements at </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any time for our convenience; however, with respect to the agreements relating to ONS-3010 and ONS-1045, this right is subject to the consent of Laboratories Liomont, S.A. de C.V., or Liomont (a licensing partner in Mexico for ONS-3010 and ONS-1045) pursuant to a corresponding letter we executed in conjunction with the standby agreement entered into between Selexis and Liomont on November 11, 2014. The standby agreement permits Liomont to assume the license under the applicable commercial agreement for Mexico upon specified triggering events involving our bankruptcy, insolvency or similar circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are working with FujiFilm Diosynth Biotechnologies, or Fuji, and Ajinomoto Bio-pharma Services, or AjiBio, to provide product manufacturing in current Good Manufacturing Practices, or cGMP, manufacturing facilities. We have also executed a supply agreement for a best-in-class pre-filled ophthalmic syringe, which we believe will provide both ease-of-use for clinicians and add to ONS-5010/LYTENAVA&#8217;s safety profile over the current unapproved therapies that have caused problems related to syringe malfunction and contamination. We will screen other contract manufacturers to meet our clinical, commercial and regulatory supply requirements as needed. For a discussion of risks related to our sources and availability of supplies, please see &#8220;Risk Factors.&#8221; Previously, we manufactured bulk drug substance for preclinical and clinical supplies of our product candidates in our in-house facility. Our business could be harmed if our current contract manufacturer is unable to manufacture our product candidates at the necessary quantity or quality levels, We currently engage single source suppliers for clinical trial services and multiple source suppliers for future drug substance manufacturing, fill-finish manufacturing and product testing of ONS-5010/LYTENAVA. The loss of any of these suppliers, or any future single source suppliers, could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition in the area of pharmaceutical research and development is extensive and significantly depends upon multiple scientific and technological factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize technological developments and the ability to obtain regulatory approval for testing, manufacturing and marketing. Our competitors include major pharmaceutical and specialized biotechnology companies, many of which have financial, technical and marketing resources significantly greater than ours, as well as compounding pharmacies that repackage bevacizumab to treat retinal diseases. In addition, many biotechnology companies have formed collaborations with large, established companies to support research, development and commercialization of products that may be competitive with ours, and we may also compete against other biotechnology companies in our efforts to find a potential strategic partner for ONS-5010/LYTENAVA. Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize products on their own or through joint ventures. We are aware of certain other products manufactured or under development by competitors that are used for the treatment of the health conditions that we have targeted for product development. We can provide no assurance that developments by others will not render our technology obsolete, noncompetitive or harm our development strategy, that we will be able to keep pace with new technological developments, that our technology will be able to supplant established products and methodologies in the therapeutic areas that are targeted by us or that we will be able to enter into a strategic partnership arrangement for ONS-5010/LYTENAVA. The foregoing factors could have a material adverse effect on our business, prospects, financial condition and results of operations. These companies, as well as academic institutions, governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will encounter competition from existing firms that offer competitive solutions in ocular diseases. These competitive companies could develop products that are superior to, or have greater market acceptance than the product candidates being developed by us. We will have to compete against other biotechnology and pharmaceutical companies with greater market recognition and greater financial, marketing and other resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Wet-AMD Market </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">AMD is a medical condition that usually affects older adults and generally results in a loss of vision. AMD occurs in &#8220;dry&#8221; (non-exudative) and &#8220;wet&#8221; (exudative) forms. Wet AMD is the advanced form of macular degeneration that involves the formation of abnormal and leaky blood vessels in the back of the eye behind the retina, through a process known as </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">choroidal neovascularization. While the wet form accounts for approximately 15% of all AMD cases, according to the National Eye Institute, it is responsible for 90% of severe vision loss associated with AMD. The National Eye Institute also estimates that the prevalence of wet AMD among adults 40 years or older in the United States is approximately 1.75 million people. In addition, more than 200,000 new cases are diagnosed annually in North America. Similary, it is estimated that the prevalence of wet AMD in Europe is approximately 1.7 million people. Globally, the incidence and prevalence of wet AMD is projected to increase significantly in the future due to an aging population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Competitive Landscape</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"><span style="font-style:normal;">In the United States, approximately 66.3% of new patient starts are off-label repackaged bevacizumab (ASRS 2022 Membership Survey Presented at ASRS NY 2022). Off-label repackaged bevacizumab is also commonly utilized in the treatment of wet AMD in Europe. The current FDA approved market leaders for the treatment of wet AMD are VEGF inhibitors, including EYLEA, EYLEA HD, BEOVU, LUCENTIS, SUSVIMO and VABYSMO. Recently, BYOOVIZ and CIMERLI were approved and launched, both ranibizumab biosimilars, as well as PAVBLU, an aflibercept biosimilar. Annual revenue (worldwide) for anti-VEGF therapies was estimated to be $13.1 billion in 2020 (Triangulation of Global Data, Market Scope and Investor Forecasts (2020)). We expect to strategically price ONS-5010/LYTENAVA to make it a lower cost alternative to biosimilars and premium branded products, while higher than off-label compounds. The initial recently approved biosimilar versions of LUCENTIS and EYLEA are also expensive, although they are available at a discount to the reference drug. Bevacizumab, BYOOVIZ, CIMERLI, PAVBLU, EYLEA, EYLEA HD, BEOVU, LUCENTIS and VABYSMO are all administered via intravitreal injections directly into the eye. SUSVIMO is an implantable refillable port delivery system that delivers anti-VEGF for 4-6 months, upon which the device is refilled. In addition to the other treatments used in patients with wet AMD, there are various other companies with product candidates in Phase 1, 2 and 3 clinical trials, or FDA review, for the treatment of wet AMD. Programs currently in Phase 2 or Phase 3 clinical trials or FDA review include, but are not limited to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bevacizumab (HLX04-O) under development by Shanghai Henlius Biotech, Inc. and Essex Bio-Technology Ltd;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ranibizumab biosimilar developed by STADA Arzneimittel AG and Xbrane Biopharma AB;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Aflibercept biosimilars developed by Bioeq/Formycon (FB-203), Mylan (M-710) and Samsung/Biogen (SB-15) among others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Small molecule receptor tyrosine kinase inhibitor sunitinib malate (Graybug, GB-102); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adeno-associated virus (AAV) carrying aflibercept coding sequence (Adverum, ADVM-022).</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that ONS-5010/LYTENAVA has potential competitive advantages due to the familiarity of physicians in using off-label Avastin. We also believe that an affordable, FDA and European Commission-approved ophthalmic bevacizumab option, that is safe, effective, and manufactured under proper guidance will garner strong market uptake and patient access to therapy. Furthermore, we have reduced the risk in our clinical program by leveraging our prior work in developing a biosmilar drug product candidate for Avastin as a treatment for cancer. However, clinical trial data from other clinical programs may negatively impact our ability to garner future financing or business collaborations, combinations or transactions with other pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our commercial success depends in part on our ability to avoid infringing the proprietary rights of third parties, our ability to obtain and maintain proprietary protection for our technologies where applicable and to prevent others from infringing our proprietary rights. We seek to protect our proprietary technologies by, among other methods, evaluating relevant patents, establishing defensive positions, monitoring EU oppositions and pending intellectual property rights, preparing litigation strategies in view of the U.S. legislative framework and filing U.S. and international patent applications on technologies, inventions and improvements that are important to our business. As of September 30, 2024, we own three U.S. patents, eighteen foreign patents, and two pending international applications that were nationalized from six Patent Cooperation Treaty, or PCT, applications, which relate to formulations developed for our legacy biosimilar program ONS-3010 and ONS-5010/ONS-1045, methods of antibody purification, methods for purifying antibodies to separate isoforms, methods of use, methods of reducing high molecular weight species, and modulating afucosylated species as well as efficiently determining the amino acid sequence of antibodies. Our first PCT application was nationalized in April 2016 in Australia, Canada, China, Europe, Hong Kong, India, Japan, Mexico and the United States. If granted, patents issuing </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from these nine applications are expected to expire in 2034, absent any adjustments or extensions. Our second PCT application was nationalized in July 2017 in Europe and the United States. If granted, patents issuing from these two applications are expected to expire in 2036, absent any adjustments or extensions. Our third PCT application was nationalized in June 2018 in Australia, Canada, China, Europe, India, Japan, Mexico and the United States. If granted, patents issuing from these eight applications are expected to expire in 2036, absent any adjustments or extensions. Our fourth PCT application was nationalized in July 2018 in Australia, Canada, China, Europe, India, Japan, Mexico and the United States. If granted, patents issuing from these eight applications are expected to expire in 2037, absent any adjustments or extensions. Our fifth PCT application was nationalized in August 2018 in Australia, Canada, China, Europe, India, Japan, Mexico and the United States. If granted, patents issuing from these eight applications are expected to expire in 2037, absent any adjustments or extensions. Our sixth PCT application was nationalized in August 2018 in Australia, Canada, China, Europe, India, Japan, Mexico and the United States. If granted, patents issuing from these eight applications are expected to expire in 2037, absent any adjustments or extensions. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term of the patents in countries in which they are obtained. In most countries, including the United States, the patent term is generally 20 years from the earliest date of filing a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in examining and granting a patent or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation and Product Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 &#8212; The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2 &#8212; The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3 &#8212; The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once a BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the marketplace. The FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars and Reference Product Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Other U.S. Healthcare Laws and Compliance Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we currently do not have any products on the market, our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors expose us to broadly applicable healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in cash or in kind, either to induce or award the referral of an individual, for an item or service or the purchasing, recommending or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on, in certain cases, sham consulting and other financial arrangements with physicians. Further, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, amends the intent requirement of the federal Anti-Kickback Statute and the criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or federal civil monetary penalties statute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, the federal false claims and civil monetary penalties laws, including the civil False Claims Act prohibit, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government has used the civil False Claims Act, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other illegal sales and marketing practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes requirements regarding the privacy and security of individually identifiable health information, including mandatory contractual terms, for covered entities, or certain healthcare providers, health plans, and healthcare clearinghouses, their business associates that provide services to the covered entity that involve individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, via the Physician Payments Sunshine Act, imposes annual reporting requirements on certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, for payments made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care providers (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain states also impose restrictions on pharmaceutical manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians. Certain states and local governments require the registration of pharmaceutical sales representatives. Additionally, analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. State laws may also apply that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers or other potential referral sources. In addition, certain states require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing. In addition, state and local laws may require the registration of pharmaceutical sales representatives. We may also be subject to state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The shifting commercial compliance environment and the need to build and maintain robust systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In the United States and some foreign jurisdictions there have been, and we expect there will continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system to contain costs, improve quality, and expand access to care. For example, in March 2010, President Obama signed into law the Affordable Care Act, which among other things, expanded coverage for the uninsured while at the same time containing overall healthcare costs, expanded and increased industry rebates for drugs covered under Medicaid programs, and made changes to the coverage requirements under the Medicare prescription drug benefit. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">There have been judicial, Congressional and executive branch challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, there have been a number of health reform initiatives by the Biden administration that have impacted the Affordable Care Act. For example, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. Accordingly, we continue to evaluate the effect that the Affordable Care Act has on our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011 led to automatic reductions of Medicare payments to providers of up to 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments will remain in effect until 2032 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Additionally, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon reimbursement prices of the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. HHS will select up to fifteen additional drugs covered under Part D for negotiation in 2025. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare and Medicaid Services Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. In the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We cannot predict what healthcare reform initiatives may be adopted in the future, particularly in light of the U.S. presidential and Congressional elections. &#160;The Affordable Care Act, the IRA, as well as other federal, state and foreign healthcare reform measures that have been and may be adopted in the future, could harm our future revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">International Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, foreign regulations also govern clinical trials, commercial sales and distribution of product candidates within their jurisdiction. The regulatory approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Clinical Trials in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">Similarly to the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls. In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20, or CTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal", the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. For clinical trials in relation to which an application for approval was made on the basis of the CTD before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:0.05pt;"> </span>cases,<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials<span style="letter-spacing:0.05pt;"> </span>must<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>conducted<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>accordance<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:0.05pt;"> </span>GCP<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:0.1pt;"> </span>requirements and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>ethical<span style="letter-spacing:0.1pt;"> </span>principles<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:0.05pt;"> </span>origin<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>Declaration<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Helsinki.<span style="letter-spacing:0.05pt;"> </span>Medicines<span style="letter-spacing:0.1pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:0.1pt;"> </span>trials, including<span style="letter-spacing:0.05pt;"> </span>ATMPs, must be manufactured<span style="letter-spacing:0.1pt;"> </span>in accordance<span style="letter-spacing:0.1pt;"> </span>with the guidelines<span style="letter-spacing:0.1pt;"> </span>on cGMP and in a GMP licensed facility,<span style="letter-spacing:0.1pt;"> </span>which can be subject<span style="letter-spacing:0.05pt;"> </span>to GMP inspections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">EU Review and approval process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the EU, medicinal products can only be commercialized after a related marketing authorization, or MA, has been granted. To obtain an MA for a product in the EU, an applicant must submit a Marketing Authorization Application, or MAA, either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">procedures administered by the competent authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The centralized procedure provides for the grant of a single MA by the European Commission that is valid throughout the EEA (which is comprised of the 27 EU Member States plus Iceland, Liechtenstein and Norway). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs, and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. The maximum timeframe for the evaluation of an MAA under the centralized procedure is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfils an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the MA will cease to be renewed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><i style="color:#231f20;font-style:italic;">Pediatric</i><i style="color:#231f20;font-style:italic;letter-spacing:0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Development in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.75pt 0pt 0pt;"><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Regulation</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">(EC) No 1901/2006</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">provides</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">all</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MAAs for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">new medicinal</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">have</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">include the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">results</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">conducted</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">population,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">compliance</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">investigation</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">plan,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or PIP, agreed with the EMA&#8217;s Pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Committee,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or PDCO.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">The PIP sets out the timing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">proposed to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generate</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">support</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">indication</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">being</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sought.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">The PDCO</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">can</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">grant</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">deferral</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obligation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">implement</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">some</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">all</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">provided</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">PIP</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">until there</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sufficient</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">demonstrate</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">efficacy</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adults.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Further,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obligation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to provide</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trial</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">can</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">waived</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">PDCO</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">when</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">these</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">needed</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">appropriate</span> <span style="color:#231f20;">because</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">likely</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ineffective</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">unsafe</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">children,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">disease</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">condition</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">which</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">intended</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">occurs</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">only</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adult</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">populations,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">when</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">does</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">not</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">represent</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">significant</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">therapeutic benefit</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">over</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">existing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">treatments</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">pediatric</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">patients.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Once</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obtained</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">all</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">States</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and study</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">results</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">included</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">information,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">even</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">when</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">negative,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eligible</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">six-month extension</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Supplementary</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Protection</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Certificate,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">SPC,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">if</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">any</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">effect</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">at</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">time</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">authorization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">or, in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">case</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">orphan</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">two-year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">extension</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">orphan</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Manufacturing Regulation in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.15pt 0pt 0pt;"><span style="color:#231f20;">In addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products in the EU requires a manufacturing authorization and import of medicinal products into the EU requires a manufacturing authorization allowing for import. The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of EU Member States. Marketing authorization holders and/or manufacturing and import authorization, or MA holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><span style="color:#231f20;font-style:italic;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><i style="color:#231f20;font-style:italic;">Data and Market</i><i style="color:#231f20;font-style:italic;letter-spacing:0.05pt;"> </i><i style="color:#231f20;font-style:italic;">Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.15pt 0pt 0pt;"><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">provides</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">opportunities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">market</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">related</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MAs.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Upon receiving</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA, innovative</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generally</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">entitled</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">receive</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eight</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">10</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">exclusivity.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">Data exclusivity,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">if</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">granted,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">prevents</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">referencing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the innovator&#8217;s</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">assess</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">generic</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">application</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">biosimilar</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">application</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eight</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">date</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of authorization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of the innovative</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product, after</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">which a generic</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or biosimilar</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">MAA can be submitted,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and the innovator&#8217;s</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">data</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be referenced.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">The market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">exclusivity</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">period</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">prevents</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">a successful</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">generic</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or biosimilar applicant</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">commercializing</span><span style="color:#231f20;letter-spacing:0.2pt;"> </span><span style="color:#231f20;">its</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">until</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">10 years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">have</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">elapsed</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">initial</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the reference</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">overall</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ten-year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">period</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">may,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">occasionally,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">be</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">extended</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">further</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">year</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a maximum</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">11</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">if,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">during</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">first</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">eight</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">those</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">ten</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">years,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA holder</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obtains</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">authorization for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">one</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">more</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">new</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">therapeutic</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">indications</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">which,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">during</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">scientific</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">evaluation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">prior</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">their</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">authorization, are</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">held</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">bring</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">significant</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">benefit</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">comparison</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">existing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">therapies.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">However,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">there</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">no guarantee</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">that a product will be considered</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">by the EU&#8217;s regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.15pt 0pt 0pt;"><span style="color:#231f20;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.15pt 0pt 0pt;"><span style="color:#231f20;">[In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.]</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -1pt 0pt 0pt;"><i style="color:#231f20;font-style:italic;">Post-authorization</i><i style="color:#231f20;font-style:italic;letter-spacing:0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Requirements in the EU</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.15pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 5.15pt 0pt 0pt;"><span style="color:#231f20;">Where</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">granted</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">relation</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">holder</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">required</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">comply with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">range</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">applicable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">manufacturing,</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">marketing,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">sale</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Similar</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">United</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">States,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">both</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">holders</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">manufacturers</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">are subject</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">comprehensive</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">oversight</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EMA,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">European</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Commission</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and/or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">competent regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">individual</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">States.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">The holder</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of an MA must</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">establish</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">and maintain</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">a pharmacovigilance</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">system</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and appoint an individual</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">qualified</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">person for pharmacovigilance</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">who is responsible for</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">oversight</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">system.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Key</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obligations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">include</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">expedited</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reporting</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">suspected</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">serious</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">adverse</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reactions and submission</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of periodic</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">update</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">reports,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or PSURs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.35pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.35pt 0pt 0pt;"><span style="color:#231f20;">All</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">new MAAs must</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">include</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">risk</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">management</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">plan,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">RMP, describing</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">risk</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">management</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">system</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the company</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">will</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">put</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">place</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">documenting</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">prevent</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">minimize</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">risks</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">associated</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the product.</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">The regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorities</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">also</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">impose</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">specific</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">obligations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">as a condition</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">MA. Such risk- minimization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">measures</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or post-authorization</span><span style="color:#231f20;letter-spacing:0.2pt;"> </span><span style="color:#231f20;">obligations</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">may</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">include</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">additional</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">monitoring,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">more</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">frequent submission</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">PSURs,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">conduct</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">additional</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">trials</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">or</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">post-authorization</span><span style="color:#231f20;letter-spacing:0.2pt;"> </span><span style="color:#231f20;">safety</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.4pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.4pt 0pt 0pt;"><span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">EU,</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">advertising</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:-1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">subject</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">both</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">Member</span><span style="color:#231f20;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;">States&#8217;</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">laws governing</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">products,</span><span style="color:#231f20;letter-spacing:-0.85pt;"> </span><span style="color:#231f20;">interactions</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">physicians</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">other</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">healthcare</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span><span style="color:#231f20;">professionals, </span><span style="color:#231f20;">misleading</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">comparative</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">advertising</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">unfair</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">commercial</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">practices.</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span>General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 2.4pt 0pt 0pt;">However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="color:#231f20;font-style:italic;">United Kingdom </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">The UK&#8217;s withdrawal</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the EU on January 31, 2020, commonly</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">referred</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">to as Brexit, has</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">changed the</span><span style="color:#231f20;letter-spacing:0.05pt;"> regulatory </span><span style="color:#231f20;">relationship</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">between</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">UK</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Medicines and Healthcare</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Regulatory</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Agency, orMHRA,</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">now the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">UK&#8217;s standalone</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulator for medicinal products and medical devices. </span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;</span><span style="color:#231f20;">Great</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Britain</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">(England,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Scotland</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Wales)</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:0.05pt;"> now </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">third country to the EU.</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Northern</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Ireland</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">will,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regard</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulations,</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">continue</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">follow</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">rules until the implementation of the Windsor Framework.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;letter-spacing:0.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The UK regulatory framework in relation to clinical trials is governed by the <span style="color:#040c28;">Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is </span>derived from the CTD, as implemented into UK national law through secondary legislation. <span style="letter-spacing:-0.25pt;">On </span>January 17, 2022, the MHRA<span style="letter-spacing:-0.25pt;"> </span>launched<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>eight-week<span style="letter-spacing:-0.2pt;"> </span>consultation<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.2pt;"> </span>reframing<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>UK<span style="letter-spacing:-0.2pt;"> </span>legislation<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable<span style="letter-spacing:-0.25pt;"> </span>greater<span style="letter-spacing:-0.2pt;"> </span>risk<span style="letter-spacing:-0.2pt;"> </span>proportionality,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>promote<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>public<span style="letter-spacing:-0.2pt;"> </span>involvement<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Marketing authorizations in the UK are governed by the </span><span style="color:#333333;">Human Medicines Regulations (SI 2012/1916), as amended. </span><span style="color:#231f20;">Since January 1, 2021, an applicant</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">for the EU centralized</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">procedure</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">marketing</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">authorization</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">can no longer</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">be established</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">UK.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> As a result, s</span><span style="color:#231f20;">ince</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">this</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">date,</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">companies established</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">UK</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">cannot</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">use</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> EU </span><span style="color:#231f20;">centralized</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">procedure</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">instead</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">must</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">follow</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">one</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">UK</span><span style="color:#231f20;letter-spacing:-0.05pt;"> </span><span style="color:#231f20;">national authorization</span><span style="color:#231f20;letter-spacing:0.15pt;"> </span><span style="color:#231f20;">procedures</span> or one of the remaining post-Brexit international cooperation procedures<span style="color:#231f20;"> to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">obtain</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">marketing authorization</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">market</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">UK.</span><span style="color:#231f20;letter-spacing:-0.05pt;"> A</span>ll existing EU marketing authorizations for centrally authorized products were automatically converted<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.4pt;"> </span>grandfathered<span style="letter-spacing:-0.4pt;"> </span>into<span style="letter-spacing:-0.4pt;"> </span>UK<span style="letter-spacing:-0.4pt;"> </span>marketing authorization, effective<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.4pt;"> </span>Great Britain<span style="letter-spacing:-0.4pt;"> </span>only,<span style="letter-spacing:-0.4pt;"> </span>free<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.4pt;"> </span>charge<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:-0.4pt;"> </span>January 1,<span style="letter-spacing:-0.4pt;"> </span>2021,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.2pt;">unless </span>the marketing authorization holder opted-out of this possibility. Northern Ireland will remain within the scope of EU authorizations in relation to centrally authorized medicinal products until <span style="color:#231f20;">the implementation of the Windsor Framework. </span>Accordingly, from when<span style="color:#0b0c0c;"> the Windsor Framework is implemented in Northern Ireland </span>(currently anticipated to be <span style="color:#0b0c0c;">January 1, 2025</span>)<span style="color:#0b0c0c;">, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain. </span>To be used, sold, or supplied in Great Britain, a medicinal product must have been granted a marketing authorization that is effective in Great Britain. Applications are governed by the Human Medicines Regulations (SI 2012/1916) and are made electronically through the MHRA Submissions Portal. Following Brexit, the MHRA has also introduced changes to national marketing authorization procedures. There are two national routes to approval, the 150-day assessment procedure (subject to clock-stops) and a rolling review procedure. The rolling-review procedure permits the separate or joint submission of quality, non-clinical, and clinical data to the MHRA which can be reviewed on a rolling basis.&#160; After an application under the rolling-review procedure has been validated, the decision should be received within 100 days (subject to clock-stops).&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, since January 1, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of marketing authorization applications. Pursuant to the IRP, the MHRA will take into account the expertise and decision-making of trusted regulatory partners (e.g. the regulatory in Australia, Canada, Switzerland, Singapore, Japan, the U.S.A. and the EU). The MHRA will conduct a targeted assessment of IRP applications but retain the authority to reject applications if the evidence provided is considered insufficiently robust. &#160;The IRP allows medicinal products approved by such trusted regulatory partners that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK or Great Britain.&#160; Applications should be decided within a maximum of 60 days if there are no major objections identified that cannot be resolved within such 60 day period and the approval from the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">trusted regulatory partner selected has been granted within the previous 2 years or if there are such major objections identified or such approval hasn&#8217;t been granted within the previous 2 years within 110 days. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In the UK, the initial duration of an MA is five years and following renewal will be valid for an unlimited period unless the MHRA decides on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal.&#160; Any authorization which is not followed by the actual placing of the drug on the market in the UK (or Great Britain, if the MA is only valid in Great Britain) within three (3) years shall ease to be in force.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The UK has an initiative known as the Innovative Licensing and Access Pathway, orILAP which has similar aims to the EU PRIME scheme but significant differences.&#160; ILAP can be entered into earlier, notably during non-clinical development. The MHRA and, notably, the National Institute for Health and Care Excellence (the body responsible for assessing which medicines should be funded by the NHS in England and Wales) will assist with the development of a target development profile for medications accepted into ILAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Pharmaceutical Coverage, Pricing and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and the adequacy of reimbursement from third-party payors, including government health administrative authorities, managed care organizations, private health insurers and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of drug products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly drug products. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, there is no uniform policy for coverage and reimbursement in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As such, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to realize an appropriate return on our investment in product development. Obtaining and maintaining adequate reimbursement for our product candidates, once approved, may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement compared to existing approved biologics and other therapies. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs in the United States, and coverage may be more limited than the indications for which the product is approved by the FDA or similar regulatory authorities outside the United States. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our net revenue and results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician utilization of our products and have a material adverse effect on our sales, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Europe, pricing and reimbursement schemes vary widely from country to country. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. In addition, the EU provides options for its Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product, may adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. In addition, some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment, or HTA, process is the procedure according to which the assessment of the public health impact, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Privacy Laws </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In the ordinary course of our business, we may process personal or sensitive data, including data related to our clinical trials. &#160;Accordingly, we are, or may become, subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy, security, and protection. &#160;Such obligations may include, without limitation, the California Consumer Privacy Act of 2018, or the CCPA, as amended, the EU&#8217;s General Data Protection Regulation 2016/679, or the EU GDPR, the EU GDPR as it forms part of UK law by virtue of section 3 of the European Union (Withdrawal) Act 2018, or the UK GDPR, collectively the GDPR. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The CCPA and GDPR are examples of the increasingly stringent and evolving regulatory frameworks related to personal data processing that may increase our compliance obligations and exposure for any noncompliance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="white-space:pre-wrap;"> </span>These laws impose significant and complex compliance obligations on entities that are subject to those laws. As one example, the EU GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. These obligations may include limiting personal data processing to only what is necessary for specified, explicit, and legitimate purposes; requiring a legal basis for personal data processing; requiring the appointment of a data protection officer in certain circumstances; increasing transparency obligations to data subjects; requiring data protection impact assessments in certain circumstances; limiting the collection and retention of personal data; increasing rights for data subjects; formalizing a heightened and codified standard of data subject consents; requiring the implementation and maintenance of technical and organizational safeguards for personal data; mandating notice of certain personal data breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the UK and/or the EU in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees and Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2024, we had 23 full-time employees, seven of whom were primarily engaged in research and development activities and five of whom have a Ph.D. degree. None of our employees are represented by a labor union or covered by a collective bargaining agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We initially incorporated in January 2010 in New Jersey as Oncobiologics, Inc., and in October 2015, we reincorporated in Delaware by merging with and into a Delaware corporation. In November 2018, we changed our name to Outlook Therapeutics, Inc. Our headquarters are located at 111 S. Wood Avenue, Unit #100, Iselin, New Jersey, 08830, and our telephone number at that location is (609) 619-3990. Our website address is www.outlooktherapeutics.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into this Annual Report on Form 10-K.</p><a id="_545e774f_b973_4e4c_8a17_e2efec641791"></a><a id="Item1ARiskFactors_454488"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item 1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be adversely affected. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition, results of operations and/or prospects.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Condition and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses and negative cash flows from operations since our inception and expect to continue to incur significant losses and negative cash flows from operations for at least the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred net losses in each year since our inception in January 5, 2010, including net losses of $75.4 million and $59.0 million for the years ended September 30, 2024 and 2023, respectively. We have not generated material revenue from the sales of any product. Our success as a company is substantially dependent on our ability to generate revenue from the sales of ONS-5010/LYTENAVA, which has been approved for the treatment of wet AMD in the EU and UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have devoted substantially all of our financial resources to identify, develop and manufacture our product candidates, including conducting, among other things, analytical characterization, process development and manufacture, formulation and clinical trials, regulatory filing and communication activities and providing general and administrative support for these operations. To date, only one of our product candidates, ONS-5010/LYTENAVA<span style="background:#ffffff;">,</span> has been approved for sale in the EU and UK, and we have financed our operations primarily through the sale of equity securities and debt financings, as well as to a limited degree, payments under our co-development and license agreements. The amount of our future net losses will depend, in part, on our ability to generate revenue from product sales, the rate of our future expenditures and our ability to obtain funding through equity or debt financing or our ability to enter into and receive funding under strategic licensing or co-development collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant expenses and operating losses for at least the next 12 months. We anticipate that our expenses may increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prepare to launch and market ONS-5010/LYTENAVA in the EU and UK, and in other countries if the product is approved in these territories;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the clinical development of ONS-5010/LYTENAVA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance ONS-5010/LYTENAVA into additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change or add contract manufacturing providers, clinical research service providers, testing laboratories, device suppliers, legal service providers or other vendors or suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory and marketing approvals for ONS-5010/LYTENAVA in the United States and other markets if we successfully complete clinical trials;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval and for which we retain such rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify, assess, acquire or develop other product candidates that may be complementary to ONS-5010/LYTENAVA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make upfront, milestone, royalty or other payments under any license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to create, maintain, protect and expand our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in litigation, including the pending securities class action lawsuit, as well as any other potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to attract and retain skilled personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">create additional infrastructure to support our operations as a public company and any future commercialization efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience any delays or encounter issues with any of the above, including but not limited to failed clinical trials, conflicting results, safety issues or regulatory challenges that may require longer follow-up of existing studies, additional major studies or additional supportive studies in order to pursue marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in our value could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never generated any revenue from product sales and may never be profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have one product, ONS-5010/LYTENAVA<span style="background:#ffffff;">,</span> approved for commercialization in the EU and UK and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>for the treatment of wet AMD, and our other targeted indications, and as appropriate, any of our other product candidates. We currently estimate that we could potentially begin generating revenue from product sales in Europe as early as the first half of calendar 2025, but this depends heavily on our success in many areas, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Securing capital sufficient to fund our commercialization efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching and commercializing ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and any other product candidates for which we or our partners obtain regulatory and marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining and obtaining regulatory and marketing approvals for ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and any other product candidates for which we or our partners complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retaining our manufacturing partner for ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and any approved product candidates to support clinical development, regulatory requirements and the market demand for any such approved product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining third-party coverage and adequate reimbursements of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> and any other product candidates, if approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining market acceptance of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and any other product candidates for which we obtain regulatory and marketing approval as viable treatment options;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing or demonstrating in the medical community the safety and efficacy of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> and its potential advantages over and side effects compared to existing products used to treat wet AMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing clinical development of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for the treatment of wet AMD in the United States and the other targeted indications, and any other product candidates we may develop in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate incurring significant costs to commercialize ONS-5010/LYTENAVA and any of our other product candidates that may be approved for commercialization in the future. Our expenses could increase beyond our expectations if we are required by the FDA, or other regulatory authorities, supranational, domestic or foreign, or by any unfavorable outcomes in intellectual property litigation filed against us, to change our manufacturing processes or assays or to perform clinical, preclinical or other types of studies in addition to those that we currently anticipate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from the sales of ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EU, UK or in any other country where the product is approved, or in relation to any other product candidate that may be approved, </span>will be dependent, in part, upon:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to execute our sales and marketing strategy for ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> in the EU and UK;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain and manage the necessary sales, marketing and other capabilities and infrastructure that are required to successfully commercialize ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> in the EU and UK;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the markets in the territories for which we gain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of competitors in such markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market acceptance of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> and any other product candidate that may be approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accepted price for the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain coverage and adequate reimbursement for ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> and any other product candidate that may be approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality and performance of ONS-5010/LYTENAVA</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> and any other product candidate that may be approved</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, including the relative safety and efficacy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we own, or have partnered, the commercial rights for that territory.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If the market for ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>or any other product candidates we may develop in the future, or our share of that market, is not as large as we expect, the number of indications approved by regulatory authorities is narrower than we expect or the target population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products to become profitable. If we are unable to successfully complete development and obtain regulatory approval for ONS-5010/LYTENAVA<span style="background:#ffffff;"> outside the EU and UK</span>, our business will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is substantial doubt about our ability to continue as a going concern. We will need to raise substantial additional funding to complete the development of ONS-5010/LYTENAVA <span style="background:#ffffff;">outside the EU and UK </span>and support our operations until we are able to generate sufficient revenue from the sales of ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EU and UK</span>. This additional funding may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Developing product candidates is an expensive, risky and lengthy process. We have received a marketing authorization from the European Commission and the MHRA for ONS-5010/LYTENAVA<span style="background:#ffffff;"> for the treatment of wet AMD in the EU and UK, respectively. </span>We are currently advancing ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>through additional clinical development and the regulatory approval process in the United States. Our expenses may increase in connection with our ongoing activities, particularly as we continue the research and development of, continue and initiate clinical trials of, and seek marketing approval for, ONS-5010/LYTENAVA<span style="background:#ffffff;"> outside the EU and UK</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024, our cash and cash equivalents balance was $14.9 million. We do not believe that our existing cash and cash equivalents as of September 30, 2024, together with $1.7 million in net proceeds from the sale of shares of common stock under an at-the-market sales program since September 30, 2024, are sufficient to fund our operations through one year from the Form 10-K filing date. On December 22, 2022, we entered into a Securities Purchase Agreement and issued an unsecured convertible promissory note with a face amount of $31.8 million, or the December 2022 Note, to Streeterville Capital, LLC, or the Lender. In March 2024, the Lender agreed to extend the maturity of the December 2022 Note from April 1, 2024 until July 1, 2025 to provide us time to negotiate the terms to further extend the maturity of the December 2022 Note. See <i style="font-style:italic;">&#8220;Raising additional capital, including modifications to our existing convertible securities, may cause dilution to our securityholders, restrict our operations or require us to relinquish rights to our technologies and product candidates&#8221;</i> for additional information on the effects of an event of default under the terms of the December 2022 Note. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Because our cash and cash equivalents will not be adequate to fund our currently planned operations through at least the next 12 months from the date the consolidated financial statements in this Annual Report on Form 10-K are issued, there is substantial doubt about our ability to continue as a going concern. We will require substantial additional capital to continue to operate as a going concern. Although we continue to pursue discussions with additional potential strategic partners for ONS-5010/LYTENAVA outside of the United States, there is no guarantee that we will be successful in reaching any such agreement, nor that such agreement, if successful, will cover the anticipated commercialization costs for ONS-5010/LYTENAVA. Our operating plan may also change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as through other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. On December 10, 2024, our board of directors approved a reduction of our workforce to reduce operating expenses and preserve capital. On December 13, 2024, we reduced our workforce by five people, or approximately 23% of our existing headcount. At a minimum, all employees affected by the workforce reduction are eligible to receive severance payments and paid COBRA premiums for a specified time period post-termination, subject to execution of a general release of claims against us. We estimate that we will incur approximately $0.3 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and related costs. While we expect that the majority of the cash payments related to the workforce reduction will be substantially complete by the end of the third calendar quarter of 2025, we may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the workforce reduction. Additionally, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. For example, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">our ability to raise additional capital may be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as has been experienced recently due in part to, among other things, the impacts of inflation, ongoing overseas conflict, and disruptions in access to bank deposits and lending commitments due to bank failure. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our business and our ability to develop our technology and products candidates. Moreover, the terms of any financing may negatively impact the holdings or the rights of our stockholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our securities to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, in order to obtain necessary funding, any of which may harm our business, operating results and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or for specific strategic considerations. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our development programs or the commercialization of ONS-5010/LYTENAVA or any product candidates, if approved. We may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Raising additional capital, including modifications to our existing convertible securities, may cause dilution to our securityholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Until such time, if ever, as we can generate sufficient product revenues, we expect to finance our cash needs through a combination of equity and debt financings, as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not currently have any committed external source of funding. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a securityholder. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In December 2022, we issued the December 2022 Note to the Lender. Under the December 2022 Note, upon the occurrence of certain events described therein, including, among others, the Company&#8217;s failure to pay amounts due and payable under the December 2022 Note, events of insolvency or bankruptcy, failure to observe covenants contained in the Securities Purchase Agreement and the December 2022 Note, breaches of representations and warranties in the Securities Purchase Agreement, and the occurrence of certain transactions without the Lender&#8217;s consent (each such event, a Trigger Event), the Lender shall have the right, subject to certain exceptions, to increase the balance of the December 2022 Note by 10% for a Major Trigger Event (as defined in the December 2022 Note) and 5% for a Minor Trigger Event (as defined in the December 2022 Note). If a Trigger Event is not cured within ten (10) trading days of written notice thereof from the Lender, it will result in an event of default (such event, an &#8220;Event of Default&#8221;). Following an Event of Default, the Lender may accelerate the December 2022 Note such that all amounts thereunder become immediately due and payable, and interest shall accrue at a rate of 22% annually until paid. Prior to April 1, 2024, under the December 2022 Note, &#8220;Conversion Price&#8221; meant, prior to a Major Trigger Event, $40.00 per share (subject to adjustment for stock splits and stock combinations), and following a Major Trigger Event, the lesser of (i) $40.00 per share (subject to adjustment for stock splits and stock combinations), and (ii) 90% multiplied by the lowest closing bid price of the Company&#8217;s common stock in the three trading days prior to the date on which the conversion notice is delivered. If the Conversion Price is below $3.51 per share, we will be required to satisfy a conversion notice from the Lender in cash. Subject to certain exceptions, while the December 2022 Note is outstanding, the Lender will have a consent right on any future variable rate transactions or any debt and a 10% participation right in any future debt or equity financings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On January 22, 2024, we entered into an amendment to the December 2022 Note with the Lender, which became effective on April 1, 2024 after satisfaction of certain conditions, including various required stockholder approvals and the closing of the private placement on March 18, 2024.</span> <span style="font-style:normal;font-weight:normal;">The maturity of the December 2022 Note was extended to July 1, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may be secured by all or a portion of our assets. If we secure development funds for ONS-5010/LYTENAVA or any future product candidate through entering into collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish additional valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts, including for ONS-5010/LYTENAVA<span style="background:#ffffff;">, </span>or grant rights to develop and market ONS-5010/LYTENAVA<span style="background:#ffffff;"> or other </span>product candidates that we would otherwise prefer to develop and market ourselves, terminate product development or future commercialization efforts, including for ONS-5010/LYTENAVA<span style="background:#ffffff;">,</span> or to cease operations altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Discovery and Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the success of ONS-5010/LYTENAVA, our only product that has been approved in the EU and UK. If ONS-5010/LYTENAVA does not receive regulatory approval outside the EU and UK, or is not successfully commercialized, our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have one product, ONS-5010/LYTENAVA<span style="background:#ffffff;">,</span><span style="font-style:italic;font-weight:bold;background:#ffffff;"> </span>that is approved for commercial sale in the EU and UK. We may never be able to obtain regulatory approval for ONS-5010/LYTENAVA<span style="background:#ffffff;"> outside the EU or UK, commercialize </span>ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EU</span> or UK, or develop other marketable products. We expect that a substantial portion of our efforts and expenditures in the foreseeable future will be devoted to the advancement of ONS-5010/LYTENAVA, our only approved product and only product candidate in active development. &#160;We also expect that we will need to devote significant effort to the commercialization of ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EU, UK, and other markets </span>following regulatory approval, if received. We cannot assure you that we will be able to successfully obtain regulatory approval of ONS-5010/LYTENAVA<span style="background:#ffffff;"> outside of the EU and UK </span>and develop sufficient commercial capabilities for ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>if and when necessary. Accordingly, our business currently depends heavily on the successful regulatory approval of ONS-5010/LYTENAVA<span style="background:#ffffff;"> outside the EU and UK, </span>and commercialization of ONS-5010/LYTENAVA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot be certain that ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>will receive regulatory approval outside of the EU or UK, or be successfully commercialized even in the EU or UK, or any other targeted market in which we receive regulatory approval. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of products are, and will remain, subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries that each have differing regulations. We are not permitted to market ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>in the United States until we receive approval from the FDA, or in any foreign country until we receive the requisite approvals from the appropriate authorities in such countries for marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining approval from the FDA or similar regulatory approval is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or other foreign regulatory authorities may delay, limit or deny approval of ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to demonstrate that ONS-5010/LYTENAVA is effective as a treatment for any of our currently targeted indications to the satisfaction of the FDA or other relevant regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relevant regulatory authorities may require additional pre-approval studies or clinical trials, which would increase our costs and prolong our development timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or other relevant regulatory authorities for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other relevant regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other relevant regulatory authorities may not find the data from nonclinical studies or clinical trials sufficient to demonstrate that the clinical and other benefits of these products outweigh their safety risks;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other relevant regulatory authorities may disagree with our interpretation of data or significance of results from the nonclinical studies and clinical trials of ONS-5010/LYTENAVA and any future product candidate, or may require that we conduct additional trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other relevant regulatory authorities may require development of a risk evaluation and mitigation strategy, or REMS, or its equivalent, as a condition of approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other relevant regulatory authorities may require additional post-marketing studies, which would be costly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other relevant regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturers; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other relevant regulatory authorities may change their approval policies or adopt new regulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that our BLA or MAAs of ONS-5010/LYTENAVA for wet AMD, or planned future, clinical trials for other retina indications, will ultimately meet the requirements sufficient for us to receive regulatory approval outside of the EU and UK. For example, in May 2022, we voluntarily withdrew our BLA to provide additional information requested by the FDA. We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022. On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. At subsequent Type A meetings with the FDA, we learned that the FDA requires the successful completion of an additional adequate and well-controlled clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD. We received agreement from FDA under the SPA for the NORSE EIGHT trial protocol and completed enrollment in the trial in September 2024. &#160;In November 2024, we reported that &#160;ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025. Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025. There can be no assurance that we will address the deficiencies identified in the CRL to the satisfaction of the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to our limited resources and access to capital, we have, and will continue to need to, prioritize development of certain product candidates; and these decisions may prove to have been wrong and may harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. We are currently focusing only on one active development program, ONS-5010/LYTENAVA, and are no longer actively developing ONS-3010, ONS-1045 or the other biosimilar product candidates in our pipeline. We currently do not intend to actively develop such biosimilar product candidates. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect to certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the pharmaceutical industry, our business, financial condition and results of operations could be harmed.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical drug development is a lengthy and expensive process and we may encounter substantial delays in our clinical trials or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">ONS-5010/LYTENAVA, our only product that has been approved for the treatment of wet AMD in the EU and UK, and our only product candidate in active development, required an additional adequate and well-controlled clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL, in advance of our resubmission of a BLA for approval of ONS-5010/LYTENAVA to treat wet AMD in the United States and extensive additional clinical testing before we are prepared to submit an application for regulatory approval for other indications. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we and any collaboration partners must conduct clinical trials to demonstrate the safety and efficacy of the product candidates in humans</span><span style="font-style:normal;font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any future clinical trials will be conducted as planned or completed on schedule, if at all. For example, enrollment in the NORSE ONE and NORSE TWO studies was delayed from our original expectations. We could experience similar enrollment delays in the remaining NORSE trials (FOUR, FIVE, SIX, and SEVEN) once they are initiated. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely completion of clinical development include but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory authorities on study design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining required IRB approval at each clinical trial site, or positive Ethics Committees opinions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities, after review of an IND, application or amendment or equivalent filing, or an inspection of our clinical trial operations or trial sites, or as a result of adverse events reported during a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further delays in recruiting suitable patients to participate in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty collaborating with patient groups and investigators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by our CROs, other third parties or us to adhere to clinical trial requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to perform in accordance with the FDA&#8217;s good clinical practice, or GCP, requirements or applicable regulatory guidelines in other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in having subjects complete participation in a study or return for post-treatment follow-up, or subjects dropping out of a study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our product candidates being greater than we anticipate;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates producing negative or inconclusive results, which may result in us deciding or regulators requiring us to conduct additional clinical trials or abandon product development programs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in manufacturing, testing, releasing, validating or importing/exporting and/or distributing sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any inability to successfully complete preclinical studies and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional clinical trials to bridge our modified product candidates to earlier versions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA, EMA and the European Commission or other comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. We will be required to demonstrate with substantial evidence through well controlled clinical trials that our product candidates are as safe and effective for use in a specific patient population before we can seek regulatory approvals for their commercial sale. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate equivalent safety and efficacy to the satisfaction of the FDA, EMA and European Commission and other comparable foreign regulatory authorities despite having progressed through initial clinical trials. Product candidates that have shown promising results in early clinical trials may still fail in subsequent confirmatory clinical trials. Similarly, the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical industry, including those with greater resources and experience than we have, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. In some instances, there can be significant variability in safety or efficacy results between different trials of the same product candidate due to numerous factors, including but not limited to changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and the rate of dropout among clinical trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or registration trials. The FDA, EMA or European Commission and other comparable foreign regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change the requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a Phase 3 clinical trial that has the potential to result in FDA or other authorities&#8217; approval. For example, in May 2022, we voluntarily withdrew our BLA to provide additional information requested by the FDA. We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022. On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. At subsequent Type A meetings with the FDA, we learned that the FDA requires the successful completion of an additional adequate and well-controlled clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD. Although in January 2024 we reached agreement on a SPA with FDA, this agreement only indicates concurrence with critical trial design concepts; it does not imply that FDA has reviewed, or concurs with, protocol details that do not affect approvability. Moreover, the presence of a SPA agreement does not guarantee that a marketing application will be filed or approved, even if the trial is conducted in accordance with the protocol. In November 2024, we reported that ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have received marketing authorization for ONS-5010/LYTENAVA<span style="background:#ffffff;"> for the treatment of wet AMD in the EU and UK. </span>We also intend to seek approval for ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>for the treatment of wet AMD outside the EU and UK. Any of the regulatory authorities may approve a product candidate for fewer indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ONS-5010/LYTENAVA and any future product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As with most pharmaceutical products, use of ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>and any future product candidates could be associated with side effects or adverse events, which can vary in severity and frequency. Side effects or adverse events associated with the use of ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>and any future product candidates may be observed at any time, including in clinical trials or when a product is commercialized. Undesirable side effects caused by ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>and any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other foreign authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects, toxicity or other safety issues, and could require us to perform additional studies or halt development or sale of ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>or any future product candidates or expose us to product liability lawsuits that will harm our business. In such an event, we may be required by regulatory authorities to conduct additional animal or human studies regarding the safety and efficacy of ONS-5010/LYTENAVA or any future product candidates that we have not planned or anticipated or our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw approval of ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>or any future product candidates for any or all targeted indications. There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any other regulatory authority in a timely manner, if ever, which could harm our business, prospects and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, product quality characteristics have been shown to be sensitive to changes in process conditions, manufacturing techniques, equipment or sites and other related considerations, and as such, any manufacturing process changes we implement prior to or after regulatory approval could impact product safety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, such as ONS-5010/LYTENAVA, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw, vary, or suspend approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use, or foreign equivalent strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of ONS-5010/LYTENAVA<span style="background:#ffffff;"> or any other </span>future product candidate that may be approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are required by the FDA, MHRA, EEA authorities and other comparable foreign regulatory authorities to report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, MHRA, the national competent authorities of EEA countries or other foreign regulatory authorities could take action including but not limited to criminal prosecution, the imposition of civil monetary penalties, seizure of our products, withdrawal, variation or suspension of our approvals or delay in approval or clearance of future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates, and our existing insurance coverage may not be sufficient to satisfy any liability that may arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Drug-related side effects could affect patient recruitment for clinical trials, the ability of enrolled patients to complete our studies or result in potential product liability claims. We currently carry product liability insurance in the amount of $10.0 million per product candidate and we are required to maintain product liability insurance pursuant to certain of our license agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could negatively impact our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize ONS-5010/LYTENAVA<span style="background:#ffffff;"> or </span>any other product candidate and decreased demand for ONS-5010/LYTENAVA<span style="background:#ffffff;"> or </span>any other product candidate, if approved for commercial sale. Furthermore, we may also not be able to take advantage of limitations on product liability lawsuits that apply to generic drug products, which could increase our exposure to liability for products deemed to be dangerous or defective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to obtain regulatory approval in any targeted jurisdiction would prevent us from marketing our products to a larger patient population and reduce our commercial opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to market our products in Europe, the United States and other jurisdictions, we and any collaboration partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. We have received a marketing authorization from the European Commission and from the MHRA for ONS-5010/LYTENAVA<span style="background:#ffffff;"> for the treatment of wet AMD in the EU and UK, respectively. The EU marketing authorization is </span>valid in all EU countries, as well as in Iceland, Liechtenstein and Norway. The time required to obtain approval in other countries may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval, and we may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the European Commission, MHRA or the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. We or any collaboration partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products within other European countries, the United States or in other jurisdictions. Failure to obtain these approvals would harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ONS-5010/LYTENAVA, or any other product candidates we may pursue that are approved, will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including requirements imposed by the EU, other EEA countries and the UK, as well as federal and state requirements in the United States and requirements of other comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturers and manufacturing facilities are required to comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, our current and future manufacturing partners will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any non-disclosure agreement, marketing authorization, BLA or marketing authorization application. Accordingly, we and our collaborators and suppliers must </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we or any collaboration partners receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval or may contain requirements for potentially costly additional clinical trials and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization or increased costs to assure compliance. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we are not allowed to promote our products for indications or uses for which they do not have approval. We must submit new or supplemental applications and obtain approval for certain changes to the marketing authorizations that have been granted for ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EU and UK, or for any other </span>approved products, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal, suspension, or variation of marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If a regulatory authority discovers previously unknown problems with an approved product, such as adverse events of unanticipated severity or frequency or problems with our manufacturing facilities or disagrees with the promotion, marketing or labeling of a product, such regulatory authority may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory authority or enforcement authority may, among other things:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue untitled and warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend, vary or withdraw regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of our ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications submitted by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">total or partial suspension of production, distribution or manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on our operations, including closing our manufacturing facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of licenses; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products or require a product recall.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, suspended or varied, the value of our company and our operating results will be negatively impacted.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The development and commercialization of pharmaceutical products is subject to extensive regulation, and we may not obtain regulatory approvals for ONS-5010/LYTENAVA outside of the EU or UK or in any other indications for which we plan to develop the product, or any future product candidates, on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other possible activities relating to ONS-5010/LYTENAVA, as well as any other product candidate that we may develop in the future, are subject to extensive regulation. Marketing approval of biologics in the United States requires the submission of a BLA to the FDA and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the BLA for that product. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FDA approval of a BLA is not guaranteed, and the review and approval process is an expensive and uncertain process that may take several years. The FDA also has substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for BLA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to treat and the regulations applicable to any particular product candidate. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage. The results of preclinical and early clinical trials of ONS-5010/LYTENAVA or any future product candidates may not be predictive of the results of our later-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits, and failure in clinical trials can occur at any stage. Companies in the biopharmaceutical industry frequently suffer setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA could delay, limit or deny approval of a product candidate for many reasons, or request additional information, including because they:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not deem our product candidate to be adequately safe and effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not agree that the data collected from clinical trials are acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval, and may impose requirements for additional preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may determine that adverse events experienced by participants in our clinical trials represents an unacceptable level of risk;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may determine that population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may disagree regarding the formulation, labeling and/or the specifications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not approve the manufacturing processes or facilities associated with our product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may change approval policies or adopt new regulations; or</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, in May 2022, we voluntarily withdrew our BLA to provide additional information requested by the FDA. We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022. On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. At subsequent Type A meetings with the FDA, we learned that the FDA requires the successful completion of an additional adequate and well-controlled trial clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD. In response to FDA&#8217;s CRL, we are conducting the NORSE EIGHT clinical trial and completed enrollment in September 2024. In November 2024, we reported that &#160;ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025. Generally, public concern regarding the safety of pharmaceutical products could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs. We have not obtained FDA approval for any product. This lack of experience may impede our ability to obtain FDA approval in a timely manner, if at all, for ONS-5010/LYTENAVA. We may not receive approval from the FDA at the conclusion of its review of the BLA that we intend to resubmit following the completion of NORSE EIGHT, in which case our business, financial condition and results of operations would be further harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If we experience additional delays in obtaining approval or if we fail to obtain approval of ONS-5010/LYTENAVA<span style="background:#ffffff;"> outside the EU and UK</span>, our commercial prospects will be harmed and our ability to generate revenues will be materially impaired which would adversely affect our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. Before we can initiate clinical trials in the United States in any distinct indication, we must submit the results of preclinical and/or other studies to the FDA along with other information, including information about chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory filing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Before obtaining marketing approval from the FDA for the sale of a product candidate in any indication, we must conduct extensive clinical studies to demonstrate its safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we expect to rely in part on preclinical, clinical and quality data generated by CROs, and other third parties for regulatory submissions for ONS-5010/LYTENAVA. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may require us to conduct additional studies for a product candidate before it allows us to initiate clinical trials under any IND, which could lead to additional delays and increase the costs of our development programs. Any such delays in the commencement or completion of our planned or future clinical trials could significantly affect our product development costs. We do not know whether planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining FDA authorizations to commence a trial or reaching a consensus with the FDA on trial design;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining approval from one or more IRBs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to clinical trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination therapies for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects choosing an alternative treatment, or participating in competing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects experiencing severe or unexpected drug-related adverse effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or permanently shut down due to violations of cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our manufacturing process that may be necessary or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party contractors not performing data collection or analysis in a timely or accurate manner; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or supranational or comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs or Ethics Committees for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues which may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we experience delays or difficulties in enrolling patients in our planned clinical trials, our receipt of necessary regulatory approvals of ONS-5010/LYTENAVA outside the EU and UK could be delayed or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to initiate or continue our planned clinical trials if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. Some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as ONS-5010/LYTENAVA or any future product candidates we may develop, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is also affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators of appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">invasive procedures required to obtain evidence of the product candidate&#8217;s performance during the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved medications for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eligibility criteria defined in the protocol for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reluctance of physicians to encourage patient participation in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These factors can be exacerbated by other situations. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs, which would cause the value of our company to decline and limit our ability to obtain additional financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Adverse side effects or other safety risks associated with ONS-5010/LYTENAVA or any future product candidate could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with a product candidate in planned clinical trials. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by a product candidate could result in the delay, suspension or termination of clinical trials by us or the FDA or supranational or comparable foreign regulatory authorities for a number of reasons, or could result in a delay of FDA or comparable foreign regulatory authority approval, similar to our withdrawal of our BLA in May 2022 to provide additional information requested by the FDA. If we elect or are required to delay, suspend or terminate any clinical trial, the commercial prospects of ONS-5010/LYTENAVA or any future product candidate will be harmed and our ability to generate product revenues from this product candidate will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of ONS-5010/LYTENAVA or any future product candidate. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, if ONS-5010/LYTENAVA or any future product candidate is associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon or limit its development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many biologics that initially showed promise in early stage testing have later been found to cause side effects that prevented further development. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">It is possible that as we test a product candidate in larger, longer and more extensive clinical trials including for additional indications, or as the use of ONS-5010/LYTENAVA or any future product candidate becomes more widespread following regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, if, following the marketing authorizations of ONS-5010/LYTENAVA in the EU and UK, or if ONS-5010/LYTENAVA receives FDA approval, or if any future product candidate receives marketing approval, and we or others later identify undesirable side effects, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw, suspend, or vary approval of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a REMS, or create a medication guide outlining the risks of such side effects for distribution to patients, or comparable foreign strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such product could become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of ONS-5010/LYTENAVA or any future product candidate that may be approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interim, &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim, top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary, top-line or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory authorities may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular development program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed meaningful by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced or more effective than ours. Other products may be approved and successfully commercialized before ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to enter highly competitive pharmaceutical markets. Successful competitors in the pharmaceutical markets have demonstrated the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as an ability to effectively commercialize, market and promote approved products. Numerous companies, universities and other research institutions are engaged in developing, patenting, manufacturing and marketing of products competitive with those that we are developing. Many of these potential competitors are large, experienced pharmaceutical companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources. These companies also have greater brand recognition and more experience in conducting preclinical testing and clinical trials of product candidates and obtaining FDA and other regulatory approvals of products.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. Some of the pharmaceutical and biotechnology companies we expect to compete with include, for example, Novartis, which currently markets LUCENTIS and BEOVU, Regeneron, with its product EYLEA, Genentech, the marketer of VABYSMO, both Biogen and Coherus with their biosimilar formulations of LUCENTIS and Amgen with their biosimilar formulation of EYLEA, all of which have been approved for use in patients with wet AMD. Furthermore, the cancer drug Avastin, sold by Roche, is used off-label in wet AMD patients although it has not been approved for use in these patients. ONS-5010/LYTENAVA is an approved alternative to the use of off-label Avastin as well as the much more expensive approved therapies in the EU and UK, and is being developed for the same purposes in other markets. In addition, these companies and other, smaller, biotechnology and pharmaceutical companies are also developing new treatments for wet AMD and are at various stages of pre-clinical and clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval in countries where we have not yet received approval for ONS-5010/LYTENAVA more rapidly than we are able to and may be more effective in selling and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies, and we also compete against such companies for resources from and in securing partnering arrangements with, such large, established companies. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop; they may also obtain patent protection that could block our products; and they may obtain regulatory approval in countries where we have not yet received approval for ONS-5010/LYTENAVA, product commercialization and market penetration earlier than we do. Product candidates developed by our competitors may render ONS-5010/LYTENAVA and any of our other potential product candidates uneconomical, less desirable or obsolete, and we may not be successful in marketing our product candidates against competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect additional companies to seek approval to manufacture and market anti-VEGF therapies for ophthalmic indications. If other anti-VEGF therapies are approved in countries where we have not yet received approval for ONS-5010/LYTENAVA and successfully commercialized before ONS-5010/LYTENAVA, we may never achieve significant market share for this product, our revenue would be reduced and, as a result, our business, prospects and financial condition could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even with the requisite approvals from the FDA, European Commission, MHRA and comparable foreign regulatory authorities, the commercial success of ONS-5010/LYTENAVA<span style="background:#ffffff;"> </span>or any other product candidates we may pursue will depend in part on the medical community, patients and third-party payors accepting ONS-5010/LYTENAVA<span style="background:#ffffff;"> or </span>our product candidates as medically useful, cost-effective and safe. Even though we expect that ONS-5010/LYTENAVA will be priced responsibly, there is no guarantee that ONS-5010/LYTENAVA or any other product that we bring to the market directly or through a strategic partner will gain market acceptance by physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of ONS-5010/LYTENAVA<span style="background:#ffffff;"> or </span>any of our product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy of the product in clinical trials, and potential advantages over competing treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the publication of unfavorable safety or efficacy data concerning our product by third-parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which approval is granted;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recognition and acceptance of our product candidates over our competitors&#8217; products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevalence of the disease or condition for which the product is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment, particularly in relation to competing treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try our therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which the product is approved for inclusion on formularies of hospitals and managed care organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning our products or competing products and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which third-party payors provide coverage and adequate reimbursement for ONS-5010/LYTENAVA, or any other product candidates we may pursue that may be approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain compliance with regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling or naming imposed by FDA or other regulatory authorities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if ONS-5010/LYTENAVA or any other product candidate we may develop in the future displays an equivalent or more favorable efficacy and safety profile in preclinical and clinical trials, market acceptance of ONS-5010/LYTENAVA<span style="background:#ffffff;"> or any other </span>product candidate will not be fully known until after it is launched and may be negatively affected by a potential poor safety experience and the track record of other product candidates. Our efforts, or those of any strategic licensing partner, to educate the medical community and third-party payors on the benefits of ONS-5010/LYTENAVA<span style="background:#ffffff;"> or</span> our other future product candidates may require significant resources, may be under-resourced compared to large well-funded pharmaceutical entities and may never be successful. If ONS-5010/LYTENAVA or any other product candidates we may develop in the future that are approved fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community, we will not be able to generate sufficient revenue to become or remain profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although ONS-5010/LYTENAVA is approved in the EU and the UK, off-label repackaging of Avastin at compounding pharmacies may continue, which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the United States, approximately 66.3% of new patient starts are off-label repackaged bevacizumab (ASRS 2022 Membership Survey Presented at ASRS NY 2022), notwithstanding that such use is off-label and requires repackaging at a compounding pharmacy. Although ONS-5010/LYTENAVA is approved for use as a treatment for wet AMD in the EU and the UK, ONS-5010/LYTENAVA<span style="background:#ffffff;"> has not yet been approved in the United States. Even though </span>ONS-5010/LYTENAVA<span style="background:#ffffff;"> is approved </span>for use as a treatment for wet AMD in the EU and UK, or even if it is approved in the United States or other countries for the same use, there is no guarantee that we will be effective in reducing the off-label use of Avastin and other drugs in the EU, UK, United States or other major markets where we plan to seek regulatory approval and commercialize ONS-5010/LYTENAVA, directly or through a strategic partner, if approved. If we are not successful in reducing off-label use of Avastin or other drugs with ONS-5010/LYTENAVA, our business and financial condition could be adversely affected.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no marketing and sales organization. If we are unable to establish and maintain sales and marketing capabilities in jurisdictions for which we choose to retain commercialization rights, we may be unable to generate any revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We currently have no internal marketing or sales organization. We have one product, ONS-5010/LYTENAVA, for which we received a marketing authorization in the EU and the UK. We, as a company, have no experience selling and marketing </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">any pharmaceutical products. To successfully commercialize ONS-5010/LYTENAVA or any other products for which we receive approvals, we will need to develop these capabilities, either on our own or with others. If we are not able to secure a strategic licensing partner who will commercialize ONS-5010/LYTENAVA or any other product for which we receive approval, we may need to establish our own sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize ONS-5010/LYTENAVA or any other product candidates that are approved in major markets where we may choose to retain commercialization rights. Doing so will be expensive, difficult and time-consuming. We have entered into a strategic collaboration agreement with Cencora to support the commercial launch of ONS-5010/LYTENAVA globally, with a current focus on the EU, UK, as well as other regions outside of the US, if approved, pursuant to which Cencora would provide third-party logistics services and distribution, as well as medical information and pharmacovigilance services in the EEA and UK, as well as other regions outside the United States. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products. Further, given our lack of prior experience in marketing and selling our products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such, we may be required to hire substantially more sales representatives and medical support liaisons to adequately support the commercialization of ONS-5010/LYTENAVA or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaboration partners do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. If we are unable to establish sales and marketing capabilities for any approved product, whether on our own or through collaborations, including through the strategic collaboration agreement with Cencora, our results of operations will be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may need to enter into alliances with other companies that can provide capabilities and funds for the development and commercialization of product candidates. If we are unsuccessful in forming or maintaining these alliances on favorable terms, our business could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we have been a pre-commercial biopharmaceutical company, we have found it necessary to enter into alliances with other companies. For example, we entered into a strategic partnership agreement for consulting services for ONS-5010/LYTENAVA, pursuant to which we paid a monthly fee prior to terminating such arrangement. We have also entered into service agreements for clinical trials, and co-development and license agreements for our biosimilar product candidates, and are potentially pursuing strategic partners for ONS-5010/LYTENAVA. In the future, we may also find it necessary to form other alliances or joint ventures with major pharmaceutical companies to jointly develop and/or commercialize the inactive biosimilar product candidates in our pipeline and any other product candidates that we may develop. In such alliances, we would expect our collaboration partners to provide substantial capabilities in regulatory affairs, as well as sales and marketing. We may not be successful in entering into any such alliances, including reaching agreement with a potential partner for ONS-5010/LYTENAVA. Even if we do succeed in securing such alliances, we may not be able to maintain them if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. We may also have disagreements from time to time with our collaboration partners regarding our rights and obligations under such arrangements. If we are not able to successfully resolve disagreements with our contract partners, it could negatively impact our business or reputation. Further, if we are unable to secure or maintain such alliances, we may not have the capabilities necessary to continue or complete development of our product candidates and bring them to market, which may have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to commercialization capabilities, we may depend on our alliances with other companies to provide substantial additional funding for development and potential commercialization of our product candidates. We may not be able to obtain funding on favorable terms from these alliances, and even if so, we may underestimate our development costs, and such fund may not be sufficient to develop a particular product candidate internally or to bring it to market. Failure to bring ONS-5010/LYTENAVA, or any other product candidates we may develop in the future, to market will prevent us from generating sales revenue and this will substantially harm our business. Furthermore, any delay in entering into these alliances could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. As a result, our business and operating results may be harmed.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The third-party coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pricing, coverage and reimbursement of ONS-5010/LYTENAVA, or any other product candidates we may develop in the future that may be approved, may not be adequate to support our commercial infrastructure. Our per-patient prices may not be sufficient to recover our development costs and potentially achieve profitability. The availability of coverage and adequacy of reimbursement by governmental and private payors are essential for most patients to be able to afford expensive treatments such as ours, if approved. Accordingly, sales of ONS-5010/LYTENAVA or any other of our product candidates that may be approved, will depend substantially, both domestically and abroad, on the extent to which the costs of ONS-5010/LYTENAVA and any of our other product candidates that may be approved, will be paid for by third-party payors such as health maintenance, managed care organizations, pharmacy benefit and similar healthcare management organizations, private health insurers and other third-party payors. If coverage and reimbursement are not available, or are available only at insufficient levels, we may not be able to successfully commercialize ONS-5010/LYTENAVA or any other of our product candidates that may be approved. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Even if coverage is provided, the approved reimbursement amount may not be adequate to allow us to realize a return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare program covers certain individuals aged 65 or older or those who are disabled or suffering from end-stage renal disease. The Medicaid program, which varies from state to state, covers certain individuals and families who have limited financial means and/or certain disabilities. The Medicare and Medicaid programs increasingly are used as models for how third-party payors develop their coverage and reimbursement policies for drugs and biologics. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our biosimilar product candidates, if approved. In addition, in the United States, no uniform policy of coverage and reimbursement for biologics exists among third-party payors. Therefore, coverage and reimbursement for biologics can differ significantly from payor to payor. As a result, the process for seeking favorable coverage determinations often is time-consuming and costly and may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Our inability to promptly obtain coverage and profitable reimbursement rates from third-party payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outside the United States, pharmaceutical businesses are generally subject to extensive governmental price controls and other market regulations. Reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. The EU provides options for EU Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe the increasing emphasis on cost-containment initiatives in the EU, Canada and other countries has and will continue to put pressure on the pricing and usage of our product candidates. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to control healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for ONS-5010/LYTENAVA, or any other product candidates we may develop in the future that may be approved. We expect to experience pricing pressures in connection with the sale of ONS-5010/LYTENAVA, or any other product candidates we may develop in the future, if approved, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Off-label use or misuse of our products may harm our reputation in the marketplace, result in injuries that lead to costly product liability suits, and/or subject us to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may only promote or market ONS-5010/LYTENAVA<span style="background:#ffffff;"> in the EEA and the UK,</span> or any other of our product candidates that may be approved, for their specifically approved indications. We will train our marketing and sales force against promoting ONS-5010/LYTENAVA or any other of our product candidates for uses outside of the approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our products off-label, when in the physician&#8217;s independent professional medical judgment he or she deems it appropriate. Furthermore, the use of our products for indications other than those approved by the FDA or comparable foreign regulatory authorities may not effectively treat such conditions. Any such off-label use of ONS-5010/LYTENAVA or our future product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our products for these uses for which they are not approved, which could lead to product liability suits that that might require significant financial and management resources and that could harm our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the U.S. Federal Trade Commission, the Department of Justice, or the DOJ, the Office of Inspector General of the U.S. Department of Health and Human Services, or HHS, state attorneys general, members of the U.S. Congress, and the public. Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States will be heavily scrutinized by comparable foreign entities and stakeholders. <span style="color:#231f20;">In</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">EEA,</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">advertising</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:-1pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">subject</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">both</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">EU</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> EEA countries&#8217;</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">laws governing</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span><span style="color:#231f20;">promotion</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">medicinal</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">products,</span><span style="color:#231f20;letter-spacing:-0.85pt;"> </span><span style="color:#231f20;">interactions</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">physicians</span><span style="color:#231f20;letter-spacing:-0.95pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">other</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">healthcare</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span><span style="color:#231f20;">professionals, </span><span style="color:#231f20;">misleading</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">comparative</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">advertising</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;">unfair</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">commercial</span><span style="color:#231f20;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;">practices.</span><span style="color:#231f20;letter-spacing:-0.9pt;"> </span>General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual <span style="color:#231f20;letter-spacing:-0.35pt;">EEA countries </span>and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU. Violations, including actual or alleged promotion of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries, and investigations, and civil and criminal sanctions by the FDA, DOJ, or comparable foreign authorities. Any actual or alleged failure to comply with labeling and promotion requirements may result in fines, warning letters, mandates to corrective information to healthcare practitioners, injunctions, or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The affected populations for ONS-5010/LYTENAVA or any of our other future product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are estimates based on our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">knowledge and understanding of these diseases. These estimates may prove to be incorrect and new studies may further reduce the estimated incidence or prevalence of this disease. The number of patients in the United States, the EEA, the UK and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our product candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects. Further, even if we obtain approval for our product candidates, the FDA or other regulators may limit their approved indications to more narrow uses or subpopulations within the populations for which we are targeting development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process we have used in developing an estimated incidence and prevalence range for the indications we are targeting has involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included in this Annual Report on Form 10-K or our other filings with the Securities and Exchange Commission, or the SEC, should be viewed with caution. Further, the data and statistical information used in this Annual Report on Form 10-K or our other filings with the SEC, including estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the launch of ONS-5010/LYTENAVA or any of our other future product candidates is further delayed or unsuccessful, or if sales of our marketed products do not meet the levels currently expected, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If our product candidates are discontinued or their clinical development is further delayed, if the launch of new indications for our marketed products or new product candidates is delayed or does not occur, or if such products are launched and the launch is unsuccessful or the product is subsequently recalled or marketing approval is rescinded, we may have to absorb one hundred percent of related overhead costs and inefficiencies, as well as similar costs of third-party contract manufacturers performing services for us. For example, in May 2022, we voluntarily withdrew our BLA to provide additional information requested by the FDA. We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022. On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence. At subsequent Type A meetings with the FDA, we learned that the FDA requires the successful completion of an additional adequate and well-controlled clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD. In response to this, we conducted an additional clinical trial, NORSE EIGHT. In November 2024, we reported that ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025. Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025. In addition, if we or our future collaborators experience excess inventory, it may be necessary to write down or write off such excess inventory or incur an impairment charge with respect to the facility where such product is manufactured, which could adversely affect our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our preclinical and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for ONS-5010/LYTENAVA outside the EU and UK, or for any other of our product candidates, or commercialize ONS-5010/LYTENAVA or any other of our product candidates and our business could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have relied upon and plan to continue to rely upon CROs to monitor and manage data for our ongoing clinical development programs. We rely on these parties for execution of our preclinical and clinical trials and we can only control certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific requirements and standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with cGMP, GCP, and GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of EEA countries and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites and other contractors. If we, any of our CROs, service providers or investigators fail to comply with applicable regulations or GCPs, the data generated in our preclinical and clinical trials may be deemed unreliable and the FDA, MHRA, EMA, European Commission, or comparable foreign regulatory authorities may require us to perform additional preclinical and clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Failure to comply by any of the participating parties or ourselves with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if our CROs or any other participating parties violate supranational, national, federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of our relationships with any of these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going preclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changing or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can negatively impact our ability to meet our desired clinical development timelines. We may encounter challenges or delays in the future and these delays or challenges may have an adverse effect on our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we may rely on third parties, some of which are or may be sole source vendors for manufacturing and supply of our drug candidates for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality. Our business could be harmed if our current contract manufacturer is unable to manufacture our product candidates at the necessary quantity or quality levels for preclinical, clinical and commercial supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We currently rely on third-party contract manufacturers for our current and future clinical trial product materials and supplies and do not have the infrastructure or capability internally to manufacture supplies of ONS-5010/LYTENAVA, or any other product candidate, for use in clinical development, and we lack the resources and the capability to manufacture ONS-5010/LYTENAVA or any product candidates on a clinical or commercial scale. If we are unable to manufacture or have manufactured sufficient supplies of ONS-5010/LYTENAVA or any other product candidates, our development </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">efforts would be delayed, which would adversely affect our business and prospects. We have selected FUJIFILM Diosynth Biotechnologies, or FUJIFILM to manufacture and supply us with our product candidates for future clinical development, as well as to establish commercial supplies of ONS-5010/LYTENAVA and our product candidates. If our need for contract manufacturing services increases during a period of industry-wide production capacity shortage, we may not be able to produce ONS-5010/LYTENAVA or our product candidates on a timely basis or on commercially viable terms. Establishing additional or replacement vendors, including FUJIFILM, if required, may not be accomplished quickly. Any delays resulting from manufacturing or supply interruptions associated with our reliance on third-party manufacturing and supply partners could impede, delay, limit or prevent our drug development and commercialization efforts. Any significant delay or discontinuation in the supply of a product candidate for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates, which could harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Reliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third-party manufacturers may not be able to comply with cGMP or similar regulatory requirements outside the United States. Our failure or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of ONS-5010/LYTENAVA or any other product candidates that we may develop. Any failure or refusal to supply the components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected products or product candidates could be delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may need to enter into agreements with another third party for contract manufacturing of ONS-5010/LYTENAVA, or any other product candidates that may be approved, in order to produce the quantities necessary to meet anticipated market demand. If we are unable to build and stock ONS-5010/LYTENAVA or any other of our product candidates that may be approved, in sufficient quantities to meet the requirements for the launch of ONS-5010/LYTENAVA or these product candidates or to meet future demand, our revenue and gross margins could be adversely affected. Although we believe that we will not have any material supply issues, we cannot be certain that we will be able to obtain long-term supply arrangements for ONS-5010/LYTENAVA or our product candidates or materials used to produce them on acceptable terms, if at all. If we are unable to arrange for third-party manufacturing, or to do so on commercially reasonable terms, we may not be able to complete development or market ONS-5010/LYTENAVA or any other of our product candidates that may be approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any adverse developments affecting the manufacture of ONS-5010/LYTENAVA could substantially increase our costs and limit supply for such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process of manufacturing our ONS-5010/LYTENAVA and our other monoclonal antibody product candidates is complex, highly regulated and subject to several risks, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to establish contracts with CMOs, and device vendors where applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product loss due to contamination, equipment failure or improper installation or operation of equipment or vendor or operator error;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringing intellectual property rights of third parties relating to manufacturing and quality testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to achieve or maintain compliance with MHRA, EEA authorities&#8217; or FDA&#8217;s requirements for acceptance of the applicable manufacturing facilities; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labor shortages, natural disasters and power failures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even minor deviations from normal manufacturing processes for ONS-5010/LYTENAVA or any of our product candidates could result in reduced production yields, product defects and other supply disruptions. In addition, if we require a change in CMO, this will add time along with financial and personnel resources to change manufacturing sites. If microbial, viral or other contaminations are discovered in ONS-5010/LYTENAVA or our product candidates or in our manufacturing facilities, our facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any adverse developments affecting manufacturing operations for ONS-5010/LYTENAVA or our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions in the supply of ONS-5010/LYTENAVA or our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for ONS-5010/LYTENAVA or product candidates that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on third parties for the commercialization of ONS-5010/LYTENAVA in the EU and UK, and may depend on third parties for the commercialization of ONS-5010/LYTENAVA in the United States, if approved. Failure to commercialize in the relevant markets could harm our business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We continue to pursue discussions for the licensing and/or co-development rights to ONS-5010/LYTENAVA outside of the U.S. We may not be successful in reaching agreements with such parties on terms that are as favorable to our company as we would anticipate. We do not have in place any licensing agreements for commercialization of ONS-5010/LYTENAVA and have only licensed ONS-5010/LYTENAVA to our PRC-joint venture, for commercialization in greater China. Our current arrangements are for our inactive biosimilar product candidates, and aside from one U.S. arrangement for ONS-3010, are for smaller ex-U.S. markets where we would not otherwise intend to commercialize our biosimilar product candidates, such as China and India, among others. If any entity with whom we enter into a commercialization arrangement fails to exercise commercially reasonable efforts to market and sell our approved products in their respective licensed jurisdictions or are otherwise ineffective in doing so, our business will be harmed and we may not be able to adequately remedy the harm through negotiation, litigation, arbitration or termination of the license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have also entered into a strategic relationship with Cencora in preparation for the anticipated commercial launch of ONS-5010/LYTENAVA in the EEA, UK, and in the United States, if approved by the FDA, pursuant to which Cencora would provide comprehensive launch support in the EEA and the UK including pharmacovigilance, regulatory affairs, quality management, market access support, importation, field solutions, third-party logistics services and distribution, andmedical information, as well as other regions outside the United States. If Cencora is unable to provide services pursuant to the strategic relationship, or otherwise breaches the terms of our agreement with them, our commercialization efforts in the EEA and UK could be delayed or adversely impacted, and our business, financial condition and prospects may be adversely effected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Moreover, any disputes with the third parties on which we rely concerning the adequacy of their commercialization efforts will substantially divert the attention of our senior management from other business activities and will require us to incur substantial legal costs to fund litigation or arbitration proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event that any of our license agreements or our strategic relationship with Cencora terminates, we may need to find another partner in those markets to commercialize and in certain instances, manufacture any product candidates. Further, upon any such termination, our contract counterparties may still have the right to commercialize these product candidates in such markets, which may affect our ability to commercialize in the same markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Because we rely, and continue to expect to rely on third parties to manufacture our current and any future product candidates, and we expect to continue to collaborate with third parties on the development of our current and any future </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, CROs, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our or our licensors&#8217; intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently engage single source suppliers for clinical trial services and multiple source suppliers for future drug substance manufacturing, fill-finish manufacturing and product testing of ONS-5010/LYTENAVA. The loss of any of these suppliers, or any future single source suppliers, could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ONS-5010/LYTENAVA is fill-finished by Ajinomoto Bio-Pharma Services, Inc., or Ajinomoto. As such, we are heavily dependent on Ajinomoto for supplying us with sufficient supply of ONS-5010/LYTENAVA. Additionally, we selected FUJIFILM Diosynth Biotechnologies to conduct all future manufacturing of ONS-5010/LYTENAVA bulk drug substance. Although we believe that there are alternate sources for these services, we cannot assure you that identifying and establishing new relationships would not result in significant delay in the development of ONS-5010/LYTENAVA. Additionally, we may not be able to enter into arrangements with alternative vendors on commercially reasonable terms, or at all. A delay in the development of ONS-5010/LYTENAVA or having to enter into a new agreement with a different third party on less favorable terms than we have with our current suppliers could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in large part on avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the pharmaceutical industry, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. We have conducted patent searches for third-party patents with respect to our lead product candidate, and are not aware of third-party patent families with claims that, if valid and enforceable, could be construed to cover such product candidates or their respective methods of manufacture or use. We cannot guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents covering our product candidates. The existence of any patent with valid and enforceable claims covering one or more of our product candidates could cause substantial delays in our ability to introduce a candidate into the U.S. market if the term of such patent extends beyond our desired product launch date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There may also be patent applications that have been filed but not published and if such applications issue as patents, they could be asserted against us. For example, in most cases, a patent filed today would not become known to industry participants for at least 18 months given patent rules applicable in most jurisdictions that do not require publication of patent applications until 18 months after filing. Moreover, we may face claims from non-practicing third-party entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. In addition, the scope of patent claims is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the asserted patent claims or that the claims are invalid and/or unenforceable, and we may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Proving that a patent is invalid or unenforceable is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. In proceedings before courts in the EU, the burden of proving invalidity of a patent also usually rests on the party alleging invalidity. Even if we are successful in litigation, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted, which could harm our business. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial monetary damages. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. If a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on commercially acceptable terms or at all. If, as a result of patent infringement claims or to avoid potential claims, we choose or are required to seek licenses from third parties, these licenses may not be available on acceptable terms or at all. Even if we are able to obtain a license, the license may obligate us to pay substantial license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would likely involve substantial litigation expense and would likely be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may, in addition to being blocked from the market, have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">foreign countries, regarding intellectual property rights with respect to our current or future products. An unfavorable outcome in any such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Third parties may submit applications for patent term extensions in the United States or other jurisdictions where similar extensions are available and/or Supplementary Protection Certificates in the EU states (including Switzerland) seeking to extend certain patent protection that, if approved, may interfere with or delay the launch of one or more of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Patent litigation and other proceedings may fail, and even if successful, may result in substantial costs and distract our management and other employees. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">So called &#8220;submarine&#8221; patents may be granted to our competitors that may significantly alter our launch timing expectations, reduce our projected market size, cause us to modify our product or process or block us from the market altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The term &#8220;submarine&#8221; patent has been used in the pharmaceutical industry and in other industries to denote a patent issuing from a U.S. application with an effective filing date prior to June 8, 1995 that was not published, publicly known or available prior to its grant. Submarine patents add substantial risk and uncertainty to our business. Submarine patents may be issued to our competitors covering our product candidates and thereby cause significant market entry delay, defeat our ability to market our product candidates or cause us to abandon development and/or commercialization of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The issuance of one or more submarine patents may harm our business by causing substantial delays in our ability to introduce a candidate into the U.S. market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which might adversely affect our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete and thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products or pipeline candidates. We may incorrectly determine that our products are not covered by a third party patent. Further, we may conclude that a well-informed court or other tribunal would find the claims of a relevant third-party patent to be invalid based on prior art, enablement, written description, or other ground, and that conclusion may be incorrect, which may negatively impact our ability to market our products or pipeline molecules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many patents may cover a marketed product, including but not limited to the composition of the product, methods of use, formulations, cell line constructs, vectors, growth media, production processes and purification processes. The identification of all patents and their expiration dates relevant to the production and sale of a reference product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. We may not identify all relevant patents, or incorrectly determine their expiration dates, which may negatively impact our ability to develop and market our products.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop, market and commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce any future patents, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have issued patents and when and if we do obtain additional issued patents, we may discover that competitors are infringing these patents. Expensive and time-consuming litigation may be required to enforce our patents. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including but not limited to lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone involved in the prosecution of the patent withheld relevant or material information related to the patentability of the invention from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly and decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during any litigation we initiate to enforce our patents. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a negative impact on the market price of our securities. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We employ individuals and retain independent contractors and consultants and members on our board of directors who were previously employed at universities or other pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us and we are not currently subject to any claims that they have done so, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us asserting ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain effective patent rights for ONS-5010/LYTENAVA or any future product candidates, we may not be able to prevent competitors from using technologies we consider important in the development and commercialization of ONS-5010/LYTENAVA or any future product candidates, resulting in loss of any potential competitive advantage our patents may have otherwise afforded us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While our principal focus in matters relating to intellectual property is to avoid infringing the valid and enforceable rights of third parties, we also rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our own intellectual property related to our product candidates and development programs. Our ability to enjoy any competitive advantages afforded by our own intellectual property depends in large part on our ability to obtain and maintain patents and other intellectual property protection in the United States and in other countries with respect to various proprietary elements of our product candidates, such as, for example, our product formulations and processes for manufacturing our products and our ability to maintain and control the confidentiality of our trade secrets and confidential information critical to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no guarantee that any patent application we file will result in an issued patent having claims that protect our products; and, as a result, we may not be able to effectively prevent others from commercializing competitive products. Additionally, while the basic requirements for patentability are similar across jurisdictions, each jurisdiction has its own specific requirements for patentability. We cannot guarantee that we will obtain identical or similar patent protection covering our products in all jurisdictions where we file patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent positions of biopharmaceutical companies generally are highly uncertain and involve complex legal and factual questions for which legal principles remain unresolved. As a result, the patent applications that we own or license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries for many reasons. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, considered or cited during patent prosecution, which can be used to invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patent claims being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competitors from using the technologies claimed in any patents issued to us, which may have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to prevent third parties from using the same technologies that we use in our product candidates. In addition, recent changes to the patent laws of the United States provide additional procedures for third parties to challenge the validity of issued patents based on patent applications filed after March 15, 2013. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is challenged, then it could threaten our ability to prevent competitive products from using our proprietary technology. Further, because patent applications in the United States and most other countries are confidential for a period of time, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">typically for 18 months after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013 or patents issuing from such applications, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. If third parties have filed such applications after March 15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to our issued patents, we have patent applications in the United States and other jurisdictions, which are currently pending, directed to various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will be issued, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened or infringed by third parties. Any successful actions by third parties to challenge the validity or enforceability of any patents that may be issued to us could deprive us of the ability to prevent others from using the technologies claimed in such issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. We are currently experiencing delays in our anticipated timeline for FDA approval of ONS-5010/LYTENAVA due to the FDA requirement to successfully complete an additional adequate and well-controlled trial for ONS-5010/LYTENAVA, which could result in a reduced period of time during which we could market ONS-5010/LYTENAVA under patent protection if ultimately approved by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have filed patent applications directed to our own proprietary formulations and processes for our product candidates when we have believed securing such patents may afford a competitive advantage. For example, the companies that originated Humira and Avastin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>(AbbVie and Genentech, respectively) own patents directed to formulations for these products. Rather than wait for the expiration of these formulation patents, we have developed our own proprietary formulations for these products that we believe are not covered by valid claims of third-party patents, including AbbVie or Genentech&#8217;s formulation patents; and we have filed patent applications directed to our formulations. We cannot guarantee that our proprietary formulations will avoid infringement of third-party patents. Moreover, because competitors may be able to develop their own proprietary product formulations, it is uncertain whether issuance of any of our pending patent applications directed to formulations of adalimumab (Humira) and bevacizumab (Avastin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) would cover the formulations of any competitors. For example, we are aware that Sandoz is developing biosimilar versions of adalimumab (Humira) and has filed patent applications directed to formulations of adalimumab (Humira). We are also aware that Boehringer is developing a biosimilar version of adalimumab (Humira) and has filed a patent application directed to formulations of adalimumab (Humira). We have patents and patent applications directed to aspects of our downstream manufacturing processes for various biosimilars, including ONS-3010. In contrast to our patent applications directed to formulations of ONS-3010, the proprietary technologies embodied in our process-related patent filings, while directed to inventions we believe may provide us with competitive advantage, were not developed by us to avoid third-party patents. As in the case of our formulation patent filings, it is highly uncertain and we cannot predict whether our patent filings on process enhancements will afford us a competitive advantage against third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural requirements, document submissions, fee payment and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting, defending and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Further, licensing partners may choose not to file patent applications in certain jurisdictions in which we may obtain commercial rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or importing products made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but the ability to enforce our patents is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not being approved, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Governments of some foreign countries may force us to license our patents to third parties on terms that are not commercially reasonable or acceptable to us. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation, including the Leahy-Smith America Invents Act, or the America Invents Act, signed into law on September 16, 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications claiming the same invention are filed by different parties. A third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to &#8220;first-to-file&#8221; from &#8220;first-to-invent&#8221; is one of the changes to the patent laws of the United States resulting from the America Invents Act. Among some of the other significant changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO via procedures including post-grant and inter partes review. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a patent invalidated in a Patent Office post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we or our licensors or collaborators will be successful in defending the patent, which would result in a loss of the challenged patent right. It is not yet clear what, if any, impact the America Invents Act will have on the operation of our business. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">our patent applications and the enforcement or defense of any issued patents, all of which could harm our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, recent court rulings in cases such as Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad I); BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig., (Myriad II); and Promega Corp. v. Life Technologies Corp. have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on future actions by the United States Congress, the Federal Courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to maintain effective proprietary rights for ONS-5010/LYTENAVA or our product candidates or any future product candidates, we may not be able to compete effectively in our markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While we have filed patent applications to protect certain aspects of our own proprietary formulation and process developments, we also rely on trade secret protection and confidentiality agreements to protect proprietary scientific, business and technical information and know-how that is not or may not be patentable or that we elect not to patent. However, confidential information and trade secrets can be difficult to protect. Moreover, the information embodied in our trade secrets and confidential information may be independently and legitimately developed or discovered by third parties without any improper use of or reference to information or trade secrets. We seek to protect the scientific, technical and business information supporting our operations, as well as the confidential information relating specifically to our product candidates by entering into confidentiality agreements with parties to whom we need to disclose our confidential information, such as, our employees, consultants, board members, contractors, potential collaborators and financial investors. However, we cannot be certain that such agreements have been entered into with all relevant parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. Our confidential information and trade secrets thus may become known by our competitors in ways we cannot prove or remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may harm our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secret. We cannot guarantee that our employees, former employees or consultants will not file patent applications claiming our inventions. Because of the &#8220;first-to-file&#8221; laws in the United States, such unauthorized patent application filings may defeat our attempts to obtain patents on our own inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship of our patent filings and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patent applications or patents we may be granted or other intellectual property as an inventor or co-inventor. For example, we may have inventorship or ownership disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Such an outcome could harm our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are party to a non-exclusive worldwide commercial license agreements with Selexis, pertaining to clinical testing and sale of its cell line expression technology and we may enter into additional license agreements in the future. Our commercial license agreements with Selexis impose, and we expect that future license agreements will impose, various milestone payments, royalty payments and other obligations on us. If we fail to comply with our obligations under these agreements or if we are subject to a bankruptcy, we may be required to make certain payments to the licensor of our license or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event we breach any of our obligations under these agreements, we may incur significant liability to our licensing partners. Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patents and other rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be successful in obtaining or maintaining necessary rights to ONS-5010/LYTENAVA or our product candidates through acquisitions and in-licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have rights to certain intellectual property through licenses from third parties, including Selexis, to develop ONS-5010/LYTENAVA/ONS-1045 and ONS-3010. Because we may find that our programs require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disease outbreaks, epidemics and pandemics, in regions where we have concentrations of clinical trial sites and other business operations, could adversely affect our business, including by causing significant disruptions in our operations and/or in the operations of manufacturers and CROs upon whom we rely. Disease outbreaks, epidemics and pandemics may have negative impacts on our ability to initiate new clinical trial sites, enroll new patients and to maintain existing patients who are participating in clinical trials, which may result in increased clinical trial costs, longer timelines and delay in our ability to obtain regulatory approvals of our product candidates, if at all. For example, patient enrollment and recruitment of NORSE TWO was delayed due to local clinical trial site protocols designed to protect staff and patients from COVID-19 infection. Additionally, general supply chain issues may be exacerbated during disease outbreaks, epidemics or pandemics and may also impact the ability of our clinical trial sites to obtain basic medical supplies used in our trials in a timely fashion, if at all. Moreover, the extent to which disease outbreaks, epidemics and pandemics may impact our business, results of operations and financial position will depend on future developments, which are highly uncertain and cannot be predicted with confidence. New health epidemics or pandemics may emerge that result in similar or more severe disruptions to our business. To the extent any future disease outbreak, epidemic or pandemic adversely affects our business, financial condition, results of operations and growth prospects, it could also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our results of operations could be adversely affected by general conditions in the global economy, the global financial markets and the global political conditions. The United States and global economies are facing growing inflation, higher interest rates and potential recession. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the United States dollar would make those clinical trials more costly to operate. Furthermore, a severe or prolonged economic downturn, including a recession or depression resulting from epidemics, pandemics or ongoing overseas conflict could result in a variety of risks to our business, including weakened demand for ONS-5010/LYTENAVA or any other of</span> <span style="font-style:normal;font-weight:normal;">our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption, including any international trade disputes, could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could seriously harm our business, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could seriously harm our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be successful in our efforts to identify, develop or commercialize additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although a substantial amount of our current effort is focused on the potential approval of ONS-5010/LYTENAVA outside the EU and UK, and commercialization of ONS-5010/LYTENAVA, the long-term success of our business also depends upon our ability to identify, develop and commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our development efforts may fail to yield additional product candidates suitable for clinical development and commercialization for a number of reasons, including but not limited to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be successful in identifying potential product candidates that pass our strict screening criteria;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to overcome technological hurdles to development or a product candidate may not be capable of producing commercial quantities at an acceptable cost, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may not succeed in preclinical or clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render our product candidates obsolete or less attractive or the market for a product candidate may change such that a product candidate may not justify further development.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs or we may not be able to identify, develop or commercialize additional product candidates, which would harm our business and could potentially cause us to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the services of our key executives and personnel, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the principal members of our management and scientific and technical staff. The loss of service of any of our management or key scientific and technical staff could harm our business and our prospects in the continued development and commercialization of ONS-5010/LYTENAVA and any future product candidates we may develop. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow our product offering beyond ONS-5010/LYTENAVA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 10, 2024, our board of directors approved a reduction of our workforce to reduce operating expenses and preserve capital. On December 13, 2024, we reduced our workforce by five people, or approximately 23% of our existing headcount. Our focus on the development of ONS-5010/LYTENAVA and other potential future drug candidates will require adequate staffing. We may need to hire and retain new employees to execute our future clinical development and manufacturing plans. We cannot provide assurance that we will be able to hire or retain adequate staffing levels to develop our current and potential future drug candidates or to run our operations or to accomplish all of our objectives. We may experience delays or other difficulties effectuating the transition of certain responsibilities that were previously performed by employees impacted by the workforce reduction, which could result in significant disruptions to our business and delays in our development efforts and timelines. In addition, our workforce reduction could yield unanticipated consequences, such as reputational risk, litigation risk and expense, attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and loss of institutional knowledge and expertise. The workforce reduction could also harm our ability to attract and retain qualified personnel who are critical to our operations. In addition, we may need to undertake additional workforce reductions or restructuring activities in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our future performance will also depend, in part, on our ability to successfully integrate new executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of ONS-5010/LYTENAVA or any other of our product candidates, harming future regulatory approvals, sales of ONS-5010/LYTENAVA or any other of our product candidates that may be approved, and our results of operations. Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We and certain of our officers have been named as defendants in a pending securities class action lawsuit. </span><span style="font-style:italic;font-weight:bold;">Certain of our officers and directors have also been named as defendants in a pending shareholder derivative action.</span> <span style="font-style:italic;font-weight:bold;">These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in its outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Securities-related class action lawsuits and/or derivative lawsuits have often been brought against companies, including biotechnology and biopharmaceutical companies, that experience volatility in the market price of their securities. This risk is especially relevant for us because we often experience significant stock price volatility in connection with our product development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 3, 2023, a securities class action lawsuit was filed against us and certain of our officers in the United States District Court for the District of New Jersey. The class action complaint alleges violations of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in connection with allegedly false and misleading statements made by us related to our BLA during the period from December 29, 2022 through August 29, 2023. The complaint alleges, among other things, that we violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by failing to disclose that there was an alleged lack of evidence supporting ONS-5010/LYTENAVA as a treatment for wet AMD and that we and/or our manufacturing partner had deficient CMC controls for ONS-5010/LYTENAVA, which remained unresolved at the time our BLA was re-submitted to the FDA and, as a result, the FDA was unlikely to approve our BLA, and that our stock price dropped when such information was disclosed. The plaintiffs in the class action complaint seek damages and interest, and an award of reasonable costs, including attorneys&#8217; fees. Defendants&#8217; motion to dismiss is currently pending before the court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2024, certain of the company&#8217;s officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware. &#160;The derivative complaint alleges that defendants breached their fiduciary duties by causing and/or allowing the company to violate federal securities laws based on the same alleged misstatements as the securities class action. &#160;The derivative complaint also alleges defendants violated Section 14(a) of the Exchange Act, as well as claims for contribution, unjust enrichment, and waste of corporate assets. &#160;The derivative complaint seeks unspecified damages, corporate governance reforms, restitution, contribution, attorneys&#8217; fees, and other costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">It is possible that additional lawsuits will be filed, or allegations received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of the pending lawsuits and any additional lawsuits, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with such lawsuits. We currently are not able to estimate the possible cost to us from this matter, as the pending lawsuits are currently at an early stage, and we cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that we may be required to pay. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in the settlement or defense of the pending lawsuits and any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not established any reserve for any potential liability relating to the pending lawsuits or any potential future lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests in the pending lawsuits, or in similar or related litigation, could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our business, our stock price, cash flow, results of operations and financial condition.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare legislative reform measures and other regulatory reforms may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In the United States, there have been and continue to be a number of legislative initiatives to improve the access to and quality of healthcare, and to contain healthcare costs. For example, in March 2010, the Affordable Care Act, was passed, which substantially changes the way health care is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act, among other things, imposed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, added a provision to increase the Medicaid rebate for line extensions or reformulated drugs, established annual fees on manufacturers and importers of certain branded prescription drugs and biologic agents, and promoted a new Medicare Part D coverage gap discount program. The Affordable Care Act also expanded eligibility for Medicaid programs and introduced a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">There have been judicial, Congressional and executive branch challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, there have been a number of health reform initiatives by the Biden administration that have impacted the Affordable Care Act. For example, on August 16, 2022, President Biden signed the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and any additional healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business. Accordingly, we continue to evaluate the potential impact of the Affordable Care Act and its possible repeal or replacement on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, led to aggregate reductions of Medicare payments to providers up to 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments will stay in effect until 2032 unless additional Congressional action is taken. Additionally, on January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which among other things, further reduced Medicare payments to certain providers, including physicians, hospitals and cancer treatment centers. Further, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-style:normal;font-weight:normal;">In addition, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Additionally, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon reimbursement prices of the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. HHS will select up to fifteen additional drugs covered under Part D for negotiation in 2025. HHS has and will continue to issue and update guidance as these programs are implemented. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. On December 7, 2023, the Biden administration also announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that the Affordable Care Act, the IRA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and additional downward pressure on the price that we receive for any approved product, particularly in light of the U.S. presidential and Congressional elections. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms could result in reduced demand for our product candidates or additional pricing pressures, and may prevent us from being able to generate revenue, attain profitability or commercialize our drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2021, Regulation No 2021/2282 on Health Technology Assessment was adopted in the EU. This Regulation, which entered into force in January 2022 will apply from January 2025. It is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation and on 10 April 2024, the Parliament adopted its related position. <span style="color:#0070c0;">I</span>f adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject, directly and indirectly, to foreign, federal, and state healthcare laws and regulations, including fraud and abuse, false claims, physician payment transparency and health information privacy and security laws. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our operations are directly and indirectly through our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject to various foreign, federal, and state fraud and abuse laws, including without limitation, the federal Anti-Kickback Statute, the civil False Claims Act and physician sunshine laws and regulations. These laws may impact, among other things, our clinical research, proposed sales, marketing, charitable donations and grants, education programs and patient assistance. In addition, we may be subject to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">patient data privacy and security regulation by both the federal government and the states in which we conduct our business. The healthcare laws that may affect our ability to operate include but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce, reward, or in return for either the referral of an individual for, or the purchase, recommendation, order or furnishing of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, which can be enforced by private individuals through civil whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented claims for payment from Medicare, Medicaid or other government health programs that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements, including mandatory contractual terms, relating to the privacy, security and transmission of individually identifiable health information on health plans, certain healthcare providers, and healthcare clearinghouses, known as covered entities, and their business associates that provide services to the covered entity that involve individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal legislation commonly referred to as the Physician Payments Sunshine Act under the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value made by such manufacturers to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare providers (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state, foreign and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these laws. For example, the Affordable Care Act, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. Moreover, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from participation in government healthcare programs, such as Medicare and Medicaid or comparable foreign programs, individual imprisonment, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The international aspects of our business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have limited international operations of our own and have several international collaborations. Doing business internationally involves a number of risks, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us or our collaboration partners to obtain and maintain regulatory approvals for the use of our products in various countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations by us or our collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems by our collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our or our collaboration partners&#8217; ability to penetrate international markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions, or comparable foreign requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our third-party suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our suppliers are subject to laws and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research, development and manufacturing efforts and business operations, and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our suppliers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue strategic alliances, joint ventures or investments in complementary businesses. Any of these transactions could be material to our financial condition and operating results and expose us to many risks, including: </p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption in our relationships with existing strategic partners or suppliers as a result of such a transaction; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated liabilities related to acquired companies or joint ventures; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties integrating acquired personnel, technologies and operations into our existing business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retention of key employees; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increases in our expenses and reductions in our cash available for operations and other uses; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible write-offs or impairment charges relating to acquired businesses.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic transactions related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may pursue the development of our product candidates in combination with other approved therapeutics. If the FDA </span><span style="font-style:italic;font-weight:bold;">or a comparable foreign regulatory authority </span><span style="font-style:italic;font-weight:bold;">revokes approval of any such therapeutic, or if safety, efficacy, manufacturing or supply issues arise with any therapeutic that we use in combination with one of our product candidates in the future, we may be unable to further develop and/or market our product candidate or we may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may pursue the development of our product candidates in combination with other approved therapeutics, and we may commence clinical trials of our product candidates in combination with other approved therapeutics, in the future. In such a case, we will not have developed or obtained regulatory approval for, nor will we manufacture or sell, any of these approved therapeutics. In addition, the combinations will likely not have been previously tested and may, among other things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, may exacerbate adverse events associated with one of our product candidates when used as monotherapy or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the FDA or a comparable foreign regulatory authority revokes its approval of any combination therapeutic, we would not be able to continue clinical development of or market any product candidate in combination with such revoked therapeutic. If safety or efficacy issues were to arise with therapeutics that we seek to combine with, we could experience significant regulatory delays, and the FDA or a comparable foreign regulatory authority could require us to redesign or terminate the applicable clinical trials. In addition, we may need, for supply, data referencing or other purposes, to collaborate or otherwise engage with the companies who market these approved therapeutics. If we are unable to do so on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate or indication, reduce or delay its development program, delay its potential commercialization or reduce the scope of any sales or marketing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data, and comparable foreign regulations. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid or comparable foreign programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business activities will be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As we expand our business activities outside of the United States, including our clinical trial efforts, we will be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-United States government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-United States governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers will be subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. &#160;Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, data we collect about trial participants in connection with clinical trials, intellectual property, sensitive third-party data, business plans, transactions, and financial information (collectively, sensitive data).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). &#160;For example, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or the CPRA, collectively, the CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. The CCPA and other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts and increase legal risk and compliance costs for us and the third parties with whom we work. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. &#160;For example, the European Union&#8217;s General Data Protection Regulation, or the EU GDPR, the United Kingdom&#8217;s GDPR, or the UK GDPR, collectively, the GDPR, Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or the LGPD) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law, or thePIPL impose strict requirements for processing personal data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">For example, under the GDPR, in the event of any non-compliance, companies subject to the laws may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. The Swiss Federal Act on Data Protection, or the FADP, also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. &#160;Governments have passed and are likely to pass additional laws regulating generative AI. &#160;Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. &#160;If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. &#160;Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. &#160;In particular, the European Economic Area, or the EEA, and the United Kingdom, or the UK, have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. &#160;Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. &#160;Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. &#160;If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.<i style="font-style:italic;"> &#160;</i>Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. &#160;Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In addition to data privacy and security laws, we are contractually subject to certain industry standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to data privacy and security. Our efforts to comply with such contractual obligations may not be successful which may lead to claims against us. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We publish privacy policies, marketing materials, and other statements regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. &#160;Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. &#160;Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations. &#160;If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. &#160;Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. &#160;Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, our clinical trials); inability to process personal data or to operate in certain jurisdictions; limited expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations, including our clinical trials. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In the ordinary course of our business, we and the third parties with whom we work process sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats that could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. &#160;Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. &#160;During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We and the third parties with whom we work are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods, and other similar threats. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="color:#231f20;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. &#160;Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. &#160;Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations.<span style="font-style:italic;font-weight:bold;"> </span>We rely on third-party service providers and technologies to operate critical business systems to process sensitive data (including data related to our clinical trials) in a variety of contexts, including, without limitation, contract research organizations, employee email, content delivery to customers, and other functions. &#160;Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place.<span style="color:#231f20;"> &#160;If the third parties with whom we work experience a security incident or other interruption, we could experience adverse consequences. &#160;While we may be entitled to damages if these third parties fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span><span style="font-style:italic;font-weight:bold;"> &#160;</span><span style="color:#231f20;">In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. &#160;We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. &#160;Further, we may experience delays in deploying remedial measures or patches designed to address identified vulnerabilities. &#160;Vulnerabilities could be exploited and result in a security incident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work. &#160;A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to operate our business, including conducting our clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. &#160;Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. &#160;Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Material security incidents (whether actual or perceived and whether experienced by us or a third party with whom we work) could cause material adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data or data related to our clinical trials); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. &#160;Security incidents and attendant consequences may negatively impact our ability to grow and operate our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. &#160;We cannot be sure that our insurance coverage, if any, will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company could be leaked, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Ownership of Our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The trading price of our securities is likely to be volatile, and purchasers of our securities could incur substantial losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market price of our securities has been and will likely continue to be volatile. The stock market in general and the market in which we operate have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their securities at a profit. The market price of our securities could be subject to wide fluctuations in response to a variety of factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive services, products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in preclinical or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any inability to obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in filing an IND, BLA or other regulatory submission for ONS-5010/LYTENAVA, or any of our product candidates when planned, and any adverse development or perceived adverse development with respect to the applicable regulatory agency&#8217;s review of that IND, BLA or other regulatory submission;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception of limited market sizes or pricing for ONS-5010/LYTENAVA or any of our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully develop and commercialize ONS-5010/LYTENAVA or any of our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">post-marketing safety issues relating to our product candidates generally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to maintain our existing strategic collaborations or enter into new collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or regulations applicable to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products, services or technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial projections we may provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the financial projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including stockholder litigation and litigation filed by us or filed against us pertaining to patent infringement or other violations of intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcomes of any citizens petitions filed by parties seeking to restrict or limit the approval of ONS-5010/LYTENAVA in the EU or UK, or any of our product candidates that may be approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts do not publish research or reports about our business or if they issue an adverse or misleading opinion regarding our stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry or market conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our securities by us or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance of patents to third parties that could prevent our ability to commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of one or more employees constituting our leadership team;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements that could make it more difficult for us to develop our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As further discussed in the Risk Factor above entitled <i style="font-style:italic;">&#8220;We and certain of our officers have been named as defendants in a pending securities class action lawsuit. Certain of our officers and directors have also been named as defendants in a pending shareholder derivative action.</i> <i style="font-style:italic;">These lawsuits and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in its outcome&#8221;,</i> we and two of our officers have been named as defendants a class action lawsuit filed in the United States District Court for the District of New Jersey and certain of our officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware. Such lawsuits have often been instituted against companies, including us, whose securities have experienced periods of volatility in market price. The pending lawsuits and any lawsuits brought against us in the future could result in substantial costs, which would hurt our financial condition and results of operations and divert management&#8217;s attention and resources, which could preclude or delay commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our securities, regardless of our actual operating performance.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GMS Ventures beneficially owns a significant percentage of our common stock and has the right to designate members to our board of directors and is able to exert significant control over matters subject to stockholder approval, which could prevent new investors from influencing significant corporate decisions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2024, GMS Ventures owned 5,808,074 shares of common stock and a warrant to acquire an additional &#160;3,458,571 shares of common stock. Accordingly, GMS Ventures beneficially owned approximately 33.9% of our common stock as of such date. Under an amended and restated investor rights agreement with GMS Ventures, GMS Ventures also currently has the power to designate members of our board of directors proportionate to the aggregate holdings of GMS Ventures (including any of its affiliates), and two of our ten board members were designated by GMS Ventures. GMS Ventures&#8217; interests may not coincide with the interests of other securityholders. GMS Ventures has the ability to influence our company through its ownership position and its representation on our board of directors, both of which may prevent or discourage unsolicited acquisition proposals or offers for our capital stock that you may believe are in your best interest as one of our securityholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our quarterly operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are out of our control and may be difficult to predict, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully develop, market and sell ONS-5010/LYTENAVA and any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical development for ONS-5010/LYTENAVA and any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials of our product candidates or those of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or clinical development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, manufacture, acquire or in-license additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our quarterly operating results fall below the expectations of investors or securities analysts, the market price of our securities could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our securities to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research, or publish unfavorable research, about our business, the market price of our securities and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The trading market for our securities depends in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors. We do not have any control over these analysts. If any analysts who cover us downgrade our securities or change their opinion of our securities, the market price of our securities would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the market price of our securities or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a &#8220;smaller reporting company&#8221; and, because we have opted to use the reduced reporting requirements available to us, certain investors may find investing in our securities less attractive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We are a &#8220;smaller reporting company&#8221; under the SEC&#8217;s disclosure rules, meaning that we have either: (i) a public float of less than $250 million; or (ii) annual revenues of less than $100 million during the most recently completed fiscal year; and no public float; or a public float of less than $700 million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared to other issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company, the scaled-back disclosure in our SEC filings will result in less information about our company being available than for other public companies. If investors consider our common shares less attractive as a result of our election to use the scaled-back disclosure permitted for smaller reporting companies, there may be a less active trading market for our common shares and our share price may be more volatile. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also a non-accelerated filer under the Exchange Act, and we are not required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. Therefore, our internal controls over financial reporting will not receive the level of review provided by the process relating to the auditor attestation included in annual reports of issuers that are subject to the auditor attestation requirements. In addition, we cannot predict if investors will find our common shares less attractive because we are not required to comply with the auditor attestation requirements. We cannot predict if investors will find our securities less attractive because we rely on these available exemptions. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the market price of our securities may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have and will continue to incur significant costs and demands upon management as a result of complying with the laws and regulations affecting public companies in the United States, which may harm our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a public company listed in the United States, we have and will continue to incur significant additional legal, accounting and other expenses. The Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, and The Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on public companies. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and Nasdaq, or as a result of stockholder activism, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report, on the effectiveness of our internal control over financial reporting by Section 404 of the Sarbanes-Oxley Act, or Section 404. Our testing may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses. Our compliance with Section 404 requires us to incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group and rely on independent contractors for control monitoring and for the preparation and review of our consolidated financial statements. If we are not able to comply with the requirements of Section 404 in a timely manner or if we identify or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which would require additional financial and management resources. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, failure to comply with these laws, regulations and standards might also make it more difficult for us to obtain certain types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future sales and issuances of our common stock or rights to purchase securities, including pursuant to our equity incentive plans or exercise of warrants, could result in additional dilution of the percentage ownership of our stockholders and could cause the market price of our securities to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need additional capital in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the 2024 Equity Incentive Plan, or the 2024 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. Under the 2024 Plan, the number of shares of our common stock reserved for future issuance as of September 30, 2024 was 4,680,755 shares. In addition, we have reserved shares for issuance under our 2016 Employee Stock Purchase Plan, or the ESPP, which similarly provides for an annual &#8220;evergreen&#8221; increase unless determined otherwise by our board of directors. If our board of directors does not elect to reduce the annual increases in the number of shares available for future grant under the 2024 Plan or the ESPP, our stockholders may experience additional dilution, which could cause the market price of our securities to fall. We also currently have issued and outstanding a number of warrants to purchase an aggregate of 14,207,622 shares of our common stock, at prices ranging from $7.70 to $240.00 per share. Additionally, in December 2022, we issued the December 2022 Note to the Lender. The December 2022 Note is convertible into shares of common stock at the option of the Lender or the Company under certain conditions described in more detail under &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;Description of Indebtedness.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Unused federal net operating losses, or NOLs, for taxable years beginning before January 1, 2018 may be carried forward to offset future taxable income, if any, until such unused NOLs expire. Under current law, federal NOLs incurred in taxable years beginning after December 31, 2017, can be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the federal tax laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of subsequent shifts in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The enactment of proposed or future tax legislation may adversely impact our financial condition and results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. The issuance of additional guidance related to existing or future tax laws, or changes to tax laws or regulations proposed or implemented by the current or a future U.S. presidential administration, Congress, or taxing authorities in other jurisdictions could materially affect our tax obligations. For example, beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures in the year incurred and instead requires taxpayers to capitalize and subsequently amortize such expenditures over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. In addition, U.S. federal, state and local tax laws are extremely complex and subject to various interpretations. Although we believe that our tax estimates and positions are reasonable, there can be no assurance that our tax positions will not be challenged by relevant tax authorities. If the relevant tax authorities assess additional taxes on us, this could result in adjustments to, or impact the timing or amount of, taxable income, deductions or other tax allocations, which may adversely affect our results of operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our international operations may subject us to greater than anticipated tax liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The amount of taxes we may pay in different jurisdictions depends on the application of the tax laws of various jurisdictions, including the United States, to our international business activities, changes in tax rates, new or revised tax laws or interpretations of existing tax laws and policies, and our ability to operate our business in a manner consistent with our corporate structure and intercompany arrangements. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for pricing intercompany transactions pursuant to any future intercompany arrangement or disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a challenge or disagreement were to occur, and our position was not sustained, we could be required to pay additional taxes, interest and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. Our financial statements could fail to reflect adequate reserves to cover such a contingency. Similarly, a taxing authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not intend to pay dividends on our capital stock, and as such any returns will be limited to the value of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our capital stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to securityholders will therefore be limited to the appreciation of their securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our securityholders or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation, as amended, amended and restated bylaws, as amended and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our charter documents also contain other provisions that could have an anti-takeover effect, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing a classified board of directors so that not all members of our board of directors are elected at one time;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permitting the board of directors to establish the number of directors and fill any vacancies and newly created directorships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing that directors may only be removed for cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibiting cumulative voting for directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring super-majority voting to amend some provisions in our amended and restated certificate of incorporation and amended and restated bylaws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorizing the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eliminating the ability of stockholders to call special meetings of stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibiting stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These provisions, alone or together, could delay, deter or prevent hostile takeovers and changes in control or changes in our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any provision of our amended and restated certificate of incorporation or amended and restated bylaws, each as amended, or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our securityholders to receive a premium for their securities and could also affect the price that some investors are willing to pay for our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws, each as amended, provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws, each as amended, provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, each as amended, or any action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. If a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation or in our amended and restated bylaws, as amended, to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business and financial condition.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales of substantial amounts of our outstanding common stock in the public market could cause our common stock price to fall. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, in the future, we may issue shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance, including pursuant to any at-the-market agreements, could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.</p><a id="_9bb06099_f612_489f_80f1_1e433e9e105c"></a><a id="Item1BUnresolvedStaffComments_222284"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_3baa261a_7e3c_48fe_811a_f259ffd2712d"></a><a id="Cybersecurity"></a><a id="Item_1C_Cyber"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item 1C. Cybersecuri</b><b style="font-weight:bold;">ty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk management and strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:0pt 0pt 6pt 0pt;">We depend on the functioning, availability and security of our information systems, including financial, data processing, communications and operating systems. Several information systems, such as software applications and cloud platforms, are provided by third parties. Our cybersecurirty risk framework is designed to allow us to identify, assess and manage the cybersecurity risks we face in relation to, our systems and the information we process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">As part of our framework, we maintain certain processes defined to assess, identify and manage risks. &#160;For example, we have an incident management and response process under which we communicate the details of certain threats and incidents to management and the board as may be appropriate; use manual and automated processes that are designed to monitor relevant information systems for vulnerabilities, threats and incidents; manage and take certain actions designed to address incidents that may occur; and take actions designed to remediate certain vulnerabilities identified in relevant enviornements. We employ an array of data security technologies, processes, and methods across our infrastructure designed to protect our systems and sensitive information from unauthorized access. We work with &#160;information technology consultants who provide advice and expertise on monitoring evolving industry practices. Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. For example, certain management executives, including our Executive VP and Chief Financial Officer evaluates material risks from cybersecurity threats in &#160;connection with our overall business objectives and reports such evaluations to the audit committee of the board of directors as appropriate, which then evaluates our overall enterprise risks. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the third parties above, we use additional third-party service providers to perform a variety of functions throughout our business, such as enterprise and employee management platforms, labs, contract research organizations, contract manufacturing organizations, and supply chain resources. Depending on the nature of the services provided, the sensitivity of the information systems and data at issue, and the identity of the provider, we take steps designed to address cybersecurity risks that such service providers may present to us, such as conducting diligence into such service providers&#8217; cybersecurity practices and risk profiles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part I. Item 1A. Risk Factors in this Annual Report on Form 10-K, including <span style="font-style:italic;font-weight:bold;">If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain management, including our Director of Information Technology, who has more than two decades of information technology and information technology leadership experience. Our Director of Information Technology, under the supervision of our Executive VP and Chief Financial Officer, manages and monitors our cybersecurity risk (including that presented by our information technology service providers). Our Director of Information Technology is responsible for informing our Executive VP and Chief Financial Officer of relevant cybersecurity risks including, as relevant, the prevent, detection, mitigation and remediation of cybersecurity incidents. Our Executive VP and Chief Financial Officer has over two decades of management experience, including oversight over information technology and cybersecurity matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our Board of Directors, with the assistance of the Audit Committee, has oversight for the cybersecurity risks facing us and for our processes designed to identify, prioritize, assess, manage, and mitigate those risks. As part of its oversight responsibilities, the Audit Committee receives periodic updates on cybersecurity and information technology matters and related risk exposures (including, as relevant, those stemming from certain cybersecurity incidents) from our Executive VP and Chief Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_333f233f_6cf0_4ae5_81cf_e2f3e80c64d9"></a><a id="Item2Properties_440075"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our headquarters are located in Iselin, New Jersey where we occupy approximately 3,726 square feet of office space under a lease that expires in April 30, 2029. In March 2021, we entered into a three-year term corporate office lease for our former corporate headquarters in Iselin, New Jersey that ended on April 30, 2024.</p><a id="_84deb58c_b64e_4574_9da2_d2f9f42ee1d0"></a><a id="Item3LegalProceedings_843298"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On November 3, 2023, a securities class action lawsuit was filed against us and certain of our officers in the United States District Court for the District of New Jersey. The class action complaint alleges violations of the Exchange Act in connection with allegedly false and misleading statements made by us related to our BLA during the period from August 3, 2021 through August 29, 2023. The complaint alleges, among other things, that we violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by failing to disclose that there was an alleged lack of evidence supporting ONS-5010/LYTENAVA as a treatment for wet AMD and that we and/or our manufacturing partner had deficient CMC controls for ONS-5010/LYTENAVA, which remained unresolved at the time our BLA was re-submitted to the FDA and, as a result, the FDA was unlikely to approve our BLA, and that our stock price dropped when such information was disclosed. The plaintiffs in the class action complaint seek damages and interest, and an award of reasonable costs, including attorneys&#8217; fees. Defendants&#8217; motion to dismiss is currently pending before the court.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2024, certain of the company&#8217;s officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware. &#160;The derivative complaint alleges that defendants breached their fiduciary duties by causing and/or allowing the company to violate federal securities laws based on the same alleged misstatements as the securities class action. &#160;The derivative complaint also alleges defendants violated Section 14(a) of the Exchange Act, as well as claims for contribution, unjust enrichment, and waste of corporate assets. &#160;The derivative complaint seeks unspecified damages, corporate governance reforms, restitution, contribution, attorneys&#8217; fees, and other costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The pending lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of the pending lawsuits and any additional lawsuits, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with such lawsuits. We currently are not able to estimate the possible cost to us from these matters, as the pending lawsuits are currently at an early stage, and we cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that we may be required to pay. Such amounts could be material to our financial statements if we do not prevail in the defense of the pending lawsuits and any other related lawsuits, or even if </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">we do prevail. We have not established any reserve for any potential liability relating to the pending lawsuits and any other related lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may also become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no additional claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows.</p><a id="_7bcbf48c_43f3_4405_8dae_8823779b736d"></a><a id="Item4MineSafetyDisclosures_479866"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_46519b7b_f67a_494c_ae02_1dd9fe54e584"></a><a id="PARTII_830844"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is traded on The Nasdaq Capital Market under the symbol &#8220;OTLK&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 14, 2024, there were approximately 78 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in Item 12 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not repurchase any of our equity securities during fiscal year ended September 30, 2024.</p><a id="Item6SelectedFinancialData_822305"></a><a id="_7cf3e91c_9e71_4522_86fc_d734aae5a2d6"></a><a id="Item_6_Reserved"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 6. Reserved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a5d745c2_b4bc_44f7_a571_4a27dd61851a"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K. This Annual Report on Form 10-K, including the following sections, contains forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see Item 1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. See also &#8220;Cautionary Note Regarding Forward-Looking Statements and Industry Data.&#8221; We caution the reader not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis only as of the date of this Form 10-K. We undertake no obligation to update forward-looking statements, which reflect events or circumstances occurring after the date of this Form 10-K</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We are a biopharmaceutical company working to launch the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union (EU), the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) and the U.S. Food and Drug Administration (FDA), for use in retinal indications. Our initial goal is to launch directly or with a partner in the EU and UK, and, if approved, to launch directly in the United States as the first and only approved ophthalmic bevacizumab for the treatment of retina conditions, including wet age-related macular degeneration, or wet AMD. Our plans also include seeking approval and launching the product in Japan and other markets. On May 27, 2024, we received a marketing authorization from the European Commission for ONS-5010/LYTENAVA for the treatment of wet AMD. The authorization is valid throughout the European Economic Area, or the EEA, and provides eight years of data exclusivity and 10 years of market exclusivity. On July 8, 2024, we also received marketing authorization for ONS-5010/LYTENAVA for the treatment of wet AMD in the UK, followed by a recommendation by the UK National Institute for Health and Care Excellence (NICE) for LYTENAVA&#8482; (bevacizumab gamma), as an option for the treatment of wet AMD on December 4, 2024. Outside of the United States, we are currently assessing options to commercialize either directly or through a strategic partner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody, or mAb, that inhibits VEGF and associated angiogenic activity. In October 2022 we submitted a Marketing Authorization Application, or MAA, for ONS-5010/LYTENAVA with the European Medicines Agency (EMA). The MAA was submitted as a &#8216;full-mixed marketing authorization application&#8217; based on Article 8.3 of Directive 2001/83/EC. On March 22, 2024, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA (bevacizumab gamma), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) in the EU. In May 2024, the European Commission granted the Marketing Authorization for ONS-5010/LYTENAVA for the treatment of wet AMD in the EU. The decision applied automatically in all 27 EU Member States, and, within 30 days, also to Iceland, Norway and Liechtenstein. Additionally, in April 2024, we submitted a MAA to the MHRA in the UK seeking approval of ONS-5010/LYTENAVA (bevacizumab gamma) for the treatment of wet AMD. The submission was completed under the new International Recognition Procedure (IRP), which allows the MHRA to rely on an authorization received for the same product from one of MHRA&#8217;s specified Reference Regulators (RRs) when considering an application for marketing authorization in the UK. These RRs include a positive opinion by the EMA&#8217;s CHMP concerning an application for grant of marketing authorization for the same product in the EU. In July 2024, the MHRA granted marketing authorization for ONS-5010/LYTENAVA for the treatment of wet AMD in the UK. ONS-5010/LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;">Separately, in March 2022, we submitted a BLA with the FDA for ONS-5010/LYTENAVA, an investigational ophthalmic formulation of bevacizumab, which we have developed to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. In May 2022, we voluntarily withdrew our BLA to provide additional information requested by the FDA. We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA. On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">of substantial evidence. At subsequent Type A meetings with the FDA, we learned that the FDA requires the completion of an additional adequate and well-controlled clinical trial evaluating ONS-5010/LYTENAVA, as well as additional requested CMC data indicated in the CRL to approve ONS-5010/LYTENAVA for use in wet AMD.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We agreed to conduct an additional adequate, and well-controlled clinical trial following discussions with the FDA in support of our BLA for ONS-5010/LYTENAVA. In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA. In January 2024, we received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA. If the NORSE EIGHT trial is successful, it would satisfy the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the CRL. In addition, through a Type A meeting and additional interactions with the FDA, we have identified the approaches needed to resolve the CMC comments in the CRL. We are working to address the open CMC items and have concluded a series of Type C and Type D meetings with the FDA to help to resolve these comments prior to reporting top line results from NORSE EIGHT in the fourth quarter of calendar 2024. We completed enrollment of the NORSE EIGHT trial in September 2024</span><span style="font-weight:normal;">. In November 2024, we reported that ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025. Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our BLA and MAA submissions for ONS-5010/LYTENAVA in wet AMD involved three clinical trials, which we refer to as NORSE ONE, NORSE TWO and NORSE THREE. The study design for our clinical program to evaluate ONS-5010/LYTENAVA as an ophthalmic formulation of bevacizumab was reviewed at an end of Phase 2 meeting with the FDA in April 2018, and we filed our investigational new drug application, or IND, with the FDA in the first quarter of calendar 2019. In August 2020, we reported achieving the anticipated safety and efficacy proof-of-concept results from NORSE ONE, a clinical experience study. NORSE TWO was our pivotal Phase 3 clinical trial comparing ONS-5010/LYTENAVA to ranibizumab (LUCENTIS). The topline results reported from NORSE TWO in August 2021 showed that ONS-5010/LYTENAVA met the primary and key secondary endpoints for efficacy with clinically impactful change observed for treated patients. In March 2021, we reported that the results from NORSE THREE showed a positive safety profile for ONS-5010/LYTENAVA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As agreed to with the FDA in the SPA, NORSE EIGHT is a randomized, controlled, parallel-group, masked, non-inferiority study of approximately 400 newly diagnosed, wet AMD subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010/LYTENAVA or 0.5 mg ranibizumab intravitreal injections. Subjects received injections at Day 0 (randomization), Week 4, and Week 8 visits. The primary endpoint is the mean change in BCVA from baseline to week 8. In November 2024, we reported that &#160;ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025. Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025. If approved, we expect to receive 12 years of regulatory exclusivity in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Additionally, in November 2021, we began enrolling patients in our NORSE SEVEN clinical trial. The study compares the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including exudative age-related macular degeneration, DME, or BRVO. Subjects will be treated for three months, and the enrollment of subjects in the arm of the study receiving ONS-5010/LYTENAVA in vials has been completed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;">We have also received agreement from the FDA on three SPAs for three additional registration clinical trials for our ongoing Phase 3 program for ONS-5010/LYTENAVA. The agreements reached with the FDA on these SPAs cover the </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">protocols for NORSE FOUR, a registration clinical trial evaluating ONS-5010/LYTENAVA to treat BRVO, and NORSE FIVE and NORSE SIX, two registration clinical trials evaluating ONS-5010/LYTENAVA to treat DME. The timing for initiating these studies has not been determined pending initial FDA approval for wet AMD.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Because there are no approved bevacizumab products for the treatment of retinal diseases in the United States and other major markets, we submitted a standard BLA, and are not using the biosimilar drug development pathway that would be required if Avastin were an approved drug for the targeted diseases. If approved in the United States, we believe ONS-5010/LYTENAVA has potential to mitigate risks associated with off-label use of unapproved bevacizumab. In the United States, 66.3% of retina physicians state off-label repackaged bevacizumab is their most commonly used first-line anti-VEGF (ASRS 2022 Membership Survey Presented at ASRS NY 2022).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 10, 2024, our board of directors approved a reduction of our workforce to reduce operating expenses and preserve capital. On December 13, 2024, we reduced our workforce by five people, or approximately 23% of our existing headcount. At a minimum, all employees affected by the workforce reduction are eligible to receive severance payments and paid COBRA premiums for a specified time period post-termination, subject to execution of a general release of claims against us. We estimate that we will incur approximately $0.3 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and related costs. While we expect that the majority of the cash payments related to the workforce reduction will be substantially complete by the end of the third calendar quarter of 2025, we may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the workforce reduction. Additionally, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern Consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through September 30, 2024, we have funded substantially all of our operations with&#8201;$530.9 million in proceeds from the sale and issuance of our equity and debt securities. We have also received $29.0 million pursuant to our collaboration and licensing agreements through such date. Our net loss for the year ended September 30, 2024 was $75.4 million. We also had a net loss of $59.0 million for the year ended September 30, 2023. We have not generated any revenue from product sales. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of ONS-5010/LYTENAVA or any other product candidate we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">On May 16, 2023, we entered into an At-the-Market Sales Agreement with BTIG, LLC (&#8220;BTIG&#8221;), as sales agent (the &#8220;BTIG ATM Agreement&#8221; or the &#8220;BTIG ATM Offering&#8221;), under which we may issue and sell shares of our common stock having an aggregate offering price of up to $100.0 million from time to time through BTIG. We incurred financing costs of $0.4 million, which were capitalized and are being reclassified to additional paid in capital on a pro rata basis when we sell common stock under the BTIG ATM Offering. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Under the BTIG ATM Agreement, the Company pays BTIG a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the BTIG ATM Agreement. The offering of common stock pursuant to the BTIG ATM Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the BTIG ATM Agreement or (ii) termination of the BTIG ATM Agreement in accordance with its terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">In November 2024 and December 2024, we sold 1,000,000 shares of common stock under the BTIG ATM Agreement generated $1.7 million in net proceeds after paying fees to BTIG and other issuance costs of $0.1 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern. We do not believe our current cash resources of&#8201;$14.9 million as of September 30, 2024, together with $1.7 million in net proceeds from the sale of shares of common stock under the BTIG ATM Offering since September 30, 2024, are sufficient to fund our operations through one year from the Form 10-K filing date. These factors raise substantial doubt about our ability to continue as a going concern. We will need to raise substantial additional capital to fund our planned future operations, receive approval for and commercialize ONS-5010/LYTENAVA, commence and continue clinical trials, or develop other product candidates. We plan to finance our future operations with </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a combination of proceeds from potential licensing and/or marketing arrangements with pharmaceutical companies, the issuance of equity securities and the issuance of additional debt, potential collaborations and revenues from potential future product sales, if any. There are no assurances that we will be successful in obtaining an adequate level of financing for the development and commercialization of ONS-5010/LYTENAVA or any other current or future product candidates. If we are unable to secure adequate additional funding, our business, operating results, financial condition and cash flows may be materially and adversely affected. Our consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration and License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we enter into collaboration and license agreements for the research and development, manufacture and/or commercialization of our products and/or product candidates. These agreements generally provide for non-refundable upfront license fees, development and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. We have also licensed rights to our legacy biosimilar product candidates (ONS-3010, ONS-1045 and ONS-1050) in other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Syntone &#8211; Private Placement and PRC Joint Venture</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, we entered into a stock purchase agreement with Syntone, pursuant to which we sold and issued in a private placement in June 2020, 800,000 shares of our common stock at a purchase price of $20.00 per share, for aggregate gross proceeds of $16.0 million. In connection with the entry into the stock purchase agreement, we entered into a joint venture agreement with Syntone&#8217;s People&#8217;s Republic of China, or PRC, based-affiliate, pursuant to which we agreed to form a PRC joint venture that is 80% owned by Syntone&#8217;s PRC-affiliate and 20% owned by us. Upon formation of the PRC joint venture in April 2021, we entered into a royalty-free license with the PRC joint venture for the development, commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Selexis SA</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2011, we entered into a research license agreement with Selexis whereby we acquired a non-exclusive license to conduct research internally or in collaboration with third parties to develop recombinant proteins from cell lines created in mammalian cells using the Selexis expression technology, or the Selexis Technology. See Note 8 in the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K for additional detail. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reverse stock split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Effective on March 14, 2024, we amended our amended and restated certificate of incorporation to implement a one-for-twenty reverse stock split of our common stock. The disclosure of our results of operations reflect the reverse stock split for all periods presented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with contract research organizations, or CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred by us directly, as well as under agreements with contract manufacturing organizations, or CMOs, for manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials and commercial materials, including manufacturing validation batches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outsourced professional scientific development services;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, which include salaries, benefits and stock-based compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments made under a third-party assignment agreement, under which we acquired intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses relating to regulatory activities, including filing fees paid to regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laboratory materials and supplies used to support our research activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allocated expenses, utilities and other facility-related costs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any of our other product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of clinical sites included in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll suitable patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that ultimately participate in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses patients receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the establishment of commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt of marketing approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commercialization of product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our biosimilar product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Full product commercialization will take several years and millions of dollars in additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size, complexity and duration of later-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses. Other general and administrative expenses include facility related costs, patent filing and prosecution costs and professional fees for business development, legal, auditing and tax services and insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase if and when we believe a regulatory approval of a product candidate appears likely, and we anticipate an increase in payroll and expense as a result of our preparation for commercial operations, particularly as it relates to the sales and marketing of our product.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss on equity method investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Loss on equity method investment represents our proportionate share for the period of the net loss of our investee to which the equity method of accounting is applied. We account for equity investments where we own a non-controlling interest, but have the ability to exercise significant influence, under the equity method of accounting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest income is earned from short term investments primarily money market investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest expense consists of cash paid and non-cash interest expense related to our December 2022 Note. The interest expense was associated with the fees incurred for extending the debt and original issue discount and debt issuance costs that were written off upon election to fair value and accounted for as interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss on Extinguishment of Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognized a $0.6 million loss on extinguishment related to the prepayment and cancellation our November 2021 Note (as defined below) during the year ended September 30, 2023 that was accounted for as an extinguishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of Promissory Notes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The change in fair value relates to convertible promissory notes that we elected to account for at fair value. As permitted under ASC 825, we elected the fair value option to account for our convertible promissory notes. We recorded the convertible promissory note at fair value with changes in fair value recorded in the consolidated statements of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrant Related Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The warrant related expense relates to the excess of the fair value of the warrants upon issuance over the proceeds of the private placements that closed on March 18, 2024 and April 15, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> Change in Fair Value of Warrant Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We issued warrants to purchase our common stock in conjunction with convertible senior secured notes issued pursuant to a certain Note and Warrant Purchase Agreement dated December 22, 2017, which are classified as liabilities and recorded at fair value. The warrants are subject to re-measurement at each balance sheet date and we recognize any change in fair value in our statements of operations as other (income) expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since inception, we have not recorded any U.S. federal or state income tax benefits (excluding the sale of New Jersey state NOLs and research and development, or R&amp;D, tax credits) for the net losses we have incurred in each year or on our earned R&amp;D tax credits, due to our uncertainty of realizing a benefit from those items. As of September 30, 2024, we had federal and state NOL carryforwards of $406.7 million and $242.5 million, respectively, that will begin to expire in 2030 and 2039, respectively. As of September 30, 2024, we had federal foreign tax credit carryforwards of $0.3 million available to reduce future tax liabilities, which begin to expire starting in 2023. As of September 30, 2024, we also had federal and state R&amp;D tax credit carryforwards of $13.0 million and $0.8 million, respectively, that will begin to expire in 2032 and 2033, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In general, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its NOLs to offset future taxable income. We have not completed a study to assess whether an ownership change has occurred in the past. Our existing NOLs may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change in connection with or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">after our Initial Public Offering, or IPO, our ability to utilize NOLs could be further limited by Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. Our NOLs are also subject to international regulations, which could restrict our ability to utilize our NOLs. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Comparison of Years Ended September 30, 2024 and 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,763,047</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,452,942</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,310,105</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,940,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,673,440</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,266,748</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (71,703,235)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53,126,382)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,576,853)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on equity method investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100,742</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,998</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,744</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (906,150)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (971,480)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,330</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,156,964</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,531,228</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 625,736</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 577,659</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (577,659)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of promissory notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,457,153</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,756,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,298,847)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,490,012</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,490,012</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (38,638,042)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (50,919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (38,587,123)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (75,363,914)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (58,979,868)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,384,046)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (75,366,714)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (58,982,668)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,384,046)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our research and development expenses by functional area for the years ended September 30, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ONS-5010/LYTENAVA development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,355,884</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,718,140</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,507,635</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,126,772</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 800,956</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 986,598</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,098,572</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,378,568)</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,763,047</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,452,942</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the year ended September 30, 2024 increased by $15.3 million compared to the year ended September 30, 2023. The increase was primarily due to an $8.6 million rise in development costs associated with ONS-5010/LYTENAVA related to the commencement and subsequent completion of enrollment in the NORSE EIGHT clinical trial, combined with the effects of a $6.2 million refund for BLA submission fees from the FDA received in the prior period.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our general and administrative expenses by type for the years ended September 30, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,866,128</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,522,528</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,301,200</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,366,447</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,584,168</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,560,421</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Europe prelaunch expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,010,687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facilities, fees and other related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,178,005</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,224,044</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,940,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,673,440</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the year ended September 30, 2024 increased by $3.3 million compared to the year ended September 30, 2023. During the year ending September 30, 2024, we incurred pre-launch expenses in Europe amounting to $5.0 million, along with a $1.9 million increase in compensation and benefits primarily attributed to severance-related costs and adjustments in headcount. These increases were offset by a $4.7 million decrease in professional fees, which resulted from the discontinuation of U.S. commercial launch activities following the receipt of the CRL in August 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Loss on Equity Method Investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Loss on equity method investment represents our share of the loss from Beijing Syntone Biopharma Ltd, or Syntone JV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest income for the year ended September 30, 2024 and 2023 was earned from short term investments, primarily consisting of money market investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest expense for the year ended September 30, 2024 increased by $0.6 million compared to prior year. This increase was primarily attributable to convertible promissory note maturity extension fees of $3.2 million associated with the December 2022 Note incurred during the year, in contrast to $2.5 million incurred in the prior year primarily related to the recognition of the original issue discount as interest expense on the December 2022 Note, as result of our adoption the fair value option for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Loss on Extinguishment of Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognized a $0.6 million loss on extinguishment related to the prepayment and cancellation of our November 2021 Note (as defined below) during the year ended September 30, 2023 that was accounted for as an extinguishment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of Promissory Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The change in fair value relates to the convertible promissory notes that we elected to account for at fair value. As permitted under ASC 825, we elected the fair value option to account for our convertible promissory notes. We record the convertible promissory notes at fair value with changes in fair value recorded in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Related Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2024, we recognized charges associated with warrants issued during the period, which were categorized as liabilities. The warrant related charges amounted to the difference between the fair value of the warrants and the net proceeds received from private placements that closed on March 18, 2024 and April 15, 2024.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of Warrant Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognized income related to the decrease in the fair value of our common stock warrant liability in both fiscal years 2024 and 2023. This income was attributed to a decline in the price of our common stock during those periods. In fiscal year 2024, we recorded income of $38.6 million, compared to $0.1 million in fiscal year 2023. We issued warrants to purchase our common stock in conjunction with convertible senior secured notes issued pursuant to a certain Note and Warrant Purchase Agreement dated December 22, 2017. Additionally, we issued warrants in connection with private placements that closed on March 18, 2024 and April 15, 2024. These warrants are categorized as liabilities and recorded at fair value. The warrants are subject to re-measurement at each balance sheet date, and we recognize any change in fair value in our statements of operations. The gain recorded during the period was primarily due to the reduction in our stock price per share of common stock during the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not generated any revenue from product sales. Since inception, we have incurred net losses and negative cash flows from our operations. Through September 30, 2024, we have funded substantially all of our operations with $530.9 million in net proceeds from the sale and issuance of our equity securities, debt securities and borrowings under debt facilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of ONS-5010/LYTENAVA or any other product candidate we may develop. We will need substantial additional financing to fund our operations and to commercially launch ONS-5010/LYTENAVA or any other product candidate we may develop. Management is currently evaluating various strategic opportunities to obtain the required funding for future operations. These strategies may include but are not limited to payments from potential strategic research and development, licensing and/or marketing arrangements with pharmaceutical companies, private placements and/or public offerings of equity and/or debt securities. Alternatively, we will be required to, among other things, make reductions in our workforce, scale back our plans and place certain activities on hold, discontinue our development programs, liquidate all or a portion of our assets, and/or seek protection under the provisions of the U.S. Bankruptcy Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2021, we received $10.0 million in net proceeds from the issuance of an unsecured promissory note (the &#8220;November 2021 Note&#8221;), with a face amount of $10.2 million. The November 2021 Note bore interest at a rate of 9.5% per annum, was due to mature January 1, 2023 and included an original issue discount of $0.2 million. We could prepay all or a portion of the note at any time by paying 105% of the outstanding balance elected for prepayment. On December 28, 2022, we prepaid the November 2021 Note in full by paying 105% of the outstanding balance. The total payment was $11.9 million, which included interest of $1.2 million and a prepayment fee of $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, we sold 44,769 shares of common stock under our prior at-the-market offering program for $1.1 million in net proceeds, and the fees paid to the sales agent were immaterial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2023, we entered into the BTIG ATM Agreement, under which we may issue and sell shares of common stock having an aggregate offering price of up to $100.0 million from time to time through BTIG. Under the BTIG ATM Agreement, we pay BTIG a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the BTIG ATM Agreement. The offering of common stock pursuant to the BTIG ATM Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the BTIG ATM Agreement or (ii) termination of the BTIG ATM Agreement in accordance with its terms. No shares of common stock were sold under the BTIG ATM Offering during the year ended September 30, 2024. During the year ended September 30, 2023, we sold 178,911 shares of common stock pursuant to the BTIG ATM Offering, generating $6.1 million in net proceeds after we paid fees to BTIG of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2022, in a registered direct equity offering to certain institutional and accredited investors, including GMS Ventures, our largest stockholder, we issued 1,423,041 shares of common stock at a purchase price per share of $17.568 for $23.2 million in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of 711,520 shares of common stock in the registered direct equity offering. In connection with the registered direct equity offering, we issued to M.S. Howells &amp; Co., as placement agent for certain accredited investors in the offering, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">warrants to purchase up to an aggregate of 25,787 shares of common stock, which will be exercisable commencing on the one-year anniversary of the closing of the offering at an exercise price of $21.00 per share, which warrants have a three-year term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 22, 2022, we entered into a Securities Purchase Agreement and issued an unsecured convertible promissory note with a face amount of $31.8 million, or the December 2022 Note, to Streeterville Capital, LLC, or the Lender, the holder of our November 2021 Note. The December 2022 Note has an original issue discount of $1.8 million. A portion of the proceeds from the December 2022 Note were used to repay in full the remaining outstanding principal and accrued interest on the November 2021 Note, which was cancelled upon repayment. We received net proceeds of $18.1 million upon the closing on December 28, 2022, after deducting the Lender&#8217;s transaction costs in connection with the issuance and November 2021 Note repayment. In December 2023, the Company extended the maturity of the December 2022 Note from January 1, 2024 to April 1, 2024. The Company incurred a $475,000 extension fee. The December 2022 Note bore interest at 9.5% per annum through April 1, 2024. On January 22, 2024, the Company entered into an amendment to the December 2022 Note (the &#8220;January 2024 Note Amendment&#8221;) with the Lender, which became effective on April 1, 2024 after satisfaction of certain closing conditions, including various required stockholder approvals and the closing of the private placement that closed on March 18, 2024. &#160;The maturity of the December 2022 Note was extended to July 1, 2025. An extension fee of $2.7 million (calculated as 7.5% of the outstanding balance of the December 2022 Note) was added to the outstanding balance on March 18, 2024. Under the January 2024 Note Amendment, the initial conversion price with respect to $15.0 million in aggregate principal amount of the December 2022 Note was changed to $7.00, the price per share in the private placement that closed on March 18, 2024 and the remaining aggregate principal amount has a conversion price of $40.00 per share. Effective April 1 2024, the December 2022 Note bears interest at the prime rate (as published in the Wall Street Journal) plus 3% (subject to a floor of 9.5%) and the Company has an obligation to repay at least $3.0 million of the outstanding balance of the December 2022 Note for each calendar quarter beginning with the second calendar quarter of 2024 (subject to adjustment for conversions by the Lender and to payment of an exit fee as set forth in the December 2022 Note) and continuing until the December 2022 Note is repaid in full. The December 2022 Note contains customary covenants, including a restriction on our ability to pledge certain ofour assets, subject to certain exceptions, without the Lender&#8217;s consent. The principal amount and conversion price of the December 2022 Note are subject to adjustment upon certain triggering events. See &#8220;Description of Indebtedness&#8221; and Note 7 in the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K for additional detail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2024, an aggregate of principal and accrued interest totaling $11.3 million of the December 2022 Note was converted into 1,607,093 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2024, in a private placement pursuant to a securities purchase agreement entered into in January 2024 with certain institutional and accredited investors, including GMS Ventures, our largest stockholder, we issued an aggregate of 8,571,423 shares of common stock and warrants to purchase an aggregate of 12,857,133 shares of common stock at a purchase price per share of $7.00 per share and accompanying warrant to purchase one and one-half shares of common stock for $55.5 million in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of 2,305,714 shares of common stock and warrants to purchase an aggregate of 3,458,571 shares of common stock in the private placement. The warrants have an exercise price of $7.70 per share of common stock and will expire on March 18, 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 15, 2024, in a private placement with Syntone Ventures, LLC pursuant to a securities purchase agreement entered into in January 2024, we issued 714,286 shares of common stock and accompanying warrants to purchase 1,071,429 shares of common stock for $4.8 million in gross proceeds on substantially the same terms as those in the private placement closed in March 2024. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2024 and December 2024, we sold 1,000,000 shares of common stock under the BTIG ATM Agreement generated $1.7 million in net proceeds after paying fees to BTIG and other issuance costs of $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern. As of September 30, 2024, we had an accumulated deficit of&#8201;$543.3 million and $31.4 million of principal, accrued interest and exit fees due on the December 2022 Note. We do not believe our current </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cash resources of $14.9 million, together with $1.7 million in net proceeds from the sale of shares of common stock under the BTIG ATM Offering since September 30, 2024, are sufficient to fund our operations through one year from the Form 10-K filing date as a result of the costs associated with the NORSE EIGHT clinical trial and the July 1, 2025 maturity date of the December 2022 Note, as amended in January 2024. These factors raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of ONS-5010/LYTENAVA or any other product candidate we may develop. We will need substantial additional financing to fund our operations and to commercially develop ONS-5010/LYTENAVA or any other product candidate we may develop. Management is currently evaluating various strategic opportunities to obtain the required funding for future operations. These strategies may include but are not limited to payments from potential strategic research and development, licensing and/or marketing arrangements with pharmaceutical companies, private placements and/or public offerings of equity and/or debt securities. There can be no assurance that these future funding efforts will be successful. Alternatively, we will be required to, among other things, make reductions in our workforce, scale back our plans and place certain activities on hold, discontinue our development programs, liquidate all or a portion of our assets, and/or seek protection under the provisions of the U.S. Bankruptcy Code<span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing discussed above, (ii) our ability to complete revenue-generating partnerships with pharmaceutical companies, (iii) the success of our research and development, (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v) regulatory approval and market acceptance of our proposed future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While we expect that the majority of the cash payments related to the workforce reduction will be substantially complete by the third calendar quarter of 2025, we may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the workforce reduction. Additionally, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our cash flows for each of the years presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.26%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.26%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (68,793,858)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,973,398)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,329,414</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 48,968,568</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,464,444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5,995,170 </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2024, we used $68.8 million of cash in operating activities resulting primarily from our net loss of $75.4 million. This use of cash was partially offset by $9.6 million of non-cash items such as stock-based compensation, non-cash interest expense, change in fair value of promissory notes, warrant related expense, change in fair value of warrant liability, loss on equity method investment and depreciation and amortization expense. The net cash outflow of $3.0 million from changes in our operating assets and liabilities was primarily due to an increase in prepaid expenses of $4.9 million for timing of payments associated with ONS-5010/LYTENAVA development costs relating to clinical trial and drug development costs partially offset by an increase in accounts payable and accrued expenses of $1.9 million due to professional fees associated with our EU launch activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the year ended September 30, 2023, we used $43.0 million of cash in operating activities resulting primarily from our net loss of $59.0 million. This use of cash was partially offset by $12.4 million of non-cash items such as stock-based compensation, non-cash interest expense, change in fair value of promissory notes, change in fair value of warrant liability, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">loss on extinguishment of debt, loss on equity method investment and depreciation and amortization expense. We also paid interest on debt of $1.2 million during the period. The net cash inflow of $4.8 million from changes in our operating assets and liabilities was primarily due to a net increase in accounts payable and accrued expenses of $2.4 million and a decrease in prepaid expenses of $2.6 million related to timing of payments associated with ONS-5010/LYTENAVA development costs, partially offset by an increase in other assets of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2024, net cash provided by financing activities was $60.3 million, primarily attributable to $60.3 million in net proceeds from private placements in March 2024 and April 2024 of an aggregate of &#160;9,285,709 shares of our common stock and warrants to purchase an aggregate of 13,928,562 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, net cash provided by financing activities was $49.0 million, primarily attributable to $23.2 million in net proceeds from a registered direct equity offering in December 2022 of an aggregate of 1,423,041 shares of our common stock, $7.2 million in net proceeds from the sale of common stock under our prior at-the-market offering program and BTIG ATM Offering and $30.0 million in net proceeds from the issuance of the December 2022 Note with a face amount of $31.8 million in December 2022. We also made $10.2 million in debt and finance lease obligation payments and a $0.8 million payment of financing costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Description of Indebtedness</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The December 2022 Note contains customary covenants, including a restriction on the Company&#8217;s ability to pledge certain of the Company&#8217;s assets, subject to certain exceptions, without the Lender&#8217;s consent. Since April 1, 2023, the Lender has the right to convert the December 2022 Note at the Conversion Price (as defined below). The principal amount and Conversion Price of the December 2022 Note were subject to adjustment upon certain triggering events. In addition, the Company has the right to convert all or any portion of the outstanding balance under the December 2022 Note into shares of common stock at the Conversion Price if certain conditions have been met at the time of conversion, including if at any time after the six-month anniversary of the closing date, the daily volume-weighted average price of the common stock on Nasdaq equals or exceeds $50.00 per share (subject to adjustments for stock splits and stock combinations) for a period of 30 consecutive trading days. Payments may be made by the Company (i) in cash, (ii) in shares of common stock, with the number of shares being equal to the portion of the applicable payment amount divided by the Conversion Price (as defined below), or (iii) a combination of cash and shares of common stock. Any payments made by the Company in cash, including prepayments or repayment at maturity, will be subject to an additional fee of 7.5%. Upon the occurrence of certain events described in the December 2022 Note, including, among others, the Company&#8217;s failure to pay amounts due and payable under the December 2022 Note, events of insolvency or bankruptcy, failure to observe covenants contained in the Securities Purchase Agreement and the December 2022 Note, breaches of representations and warranties in the Securities Purchase Agreement, and the occurrence of certain transactions without the Lender&#8217;s consent (each such event, a &#8220;Trigger Event&#8221;), the Lender shall have the right, subject to certain exceptions, to increase the balance of the December 2022 Note by 10% for a Major Trigger Event (as defined in the December 2022 Note) and 5% for a Minor Trigger Event (as defined in the December 2022 Note). If a Trigger Event is not cured within ten (10) trading days of written notice thereof from the Lender, it will result in an event of default (such event, an &#8220;Event of Default&#8221;). Following an Event of Default, the Lender may accelerate the December 2022 Note such that all amounts thereunder become immediately due and payable, and interest shall accrue at a rate of 22% annually until paid. Prior to April 1, 2024, under the December 2022 Note, &#8220;Conversion Price&#8221; meant, prior to a Major Trigger Event, $40.00 per share (subject to adjustment for stock splits and stock combinations), and following a Major Trigger Event, the lesser of (i) $40.00 per share (subject to adjustment for stock splits and stock combinations), and (ii) 90% multiplied by the lowest closing bid price of the Company&#8217;s common stock in the three trading days prior to the date on which the conversion notice is delivered. The maturity date of the December 2022 Note was extended from January 1, 2024 to April 1, 2024 in December 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;">On January 22, 2024, the Company entered into the January 2024 Note Amendment with the Lender, which became effective on April 1, 2024 after satisfaction of certain closing conditions, including various required stockholder approvals and the closing of the private placement that closed on March 18, 2024. &#160;The maturity of the December 2022 Note was extended to July 1, 2025. An extension fee of $2.7 million (calculated as 7.5% of the outstanding balance of the December 2022 Note) was added to the outstanding balance on March 18, 2024. Under the January 2024 Note Amendment, the initial </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">conversion price with respect to $15.0 million in aggregate principal amount of the December 2022 Note was changed to $7.00, the price per share in the private placement that closed on March 18, 2024 and the remaining aggregate principal amount is converted at a price ofhas a conversion price of $40.00 per share. Effective April 1 2024, the December 2022 Note bears interest at the prime rate (as published in the Wall Street Journal) plus 3% (subject to a floor of 9.5%) and the Company has an obligation to repay at least $3.0 million of the outstanding balance of the December 2022 Note for each calendar quarter beginning with the second calendar quarter of 2024 (subject to adjustment for conversions by the Lender and to payment of an exit fee as set forth in the December 2022 Note) and continuing until the December 2022 Note is repaid in full. If the Conversion Price is below $3.51 per share, the Company will be required to satisfy a conversion notice from the Lender in cash. Subject to certain exceptions, while the December 2022 Note is outstanding, the Lender will have a consent right on any future variable rate transactions or any debt and a 10% participation right in any future debt or equity financings</span><span style="font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We plan to focus in the near term on supporting the review of our BLA submission for ONS-5010/LYTENAVA with the FDA and to prepare for the potential launch of ONS-5010/LYTENAVA</span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-style:normal;font-weight:normal;">to support the generation of commercial revenues. We anticipate we will incur net losses and negative cash flow from operations for the foreseeable future. We may not be able to initiate commercialization of ONS-5010/LYTENAVA if, among other things, the FDA does not approve our BLA when we expect, or at all, or if we are not able to secure sufficient funding of our expected post-launch commercial costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, manufacturing and facility costs, external research and development services, laboratory and related supplies, legal and other regulatory expenses, and administrative and overhead costs. Our future funding requirements will be heavily determined by the resources needed to support the marketing and development of our lead product candidate and any other product candidates we may choose to pursue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not believe our existing cash and cash equivalents of $14.9 million as of September 30, 2024, together with $1.7 million in net proceeds from the sale of shares of common stock under the BTIG ATM Offering since September 30, 2024, are sufficient to fund our operations through one year from the Form 10-K filing date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We will need to raise substantial additional capital in order to complete our planned ONS-5010/LYTENAVA development program. We plan to finance our future operations with a combination of proceeds from potential strategic collaborations, sale of the development and commercial rights to our drug product candidates, the issuance of equity securities, the issuance of additional debt, and revenues from potential future product sales, if any. If we raise additional capital through the sale of equity or convertible debt securities, your ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Further, due to current market volatility, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. There are no assurances that we will be successful in obtaining an adequate level of financing for the commercialization of ONS-5010/LYTENAVA or the development of any other current or future product candidates. Alternatively, we will be required to, among other things, modify our clinical trial plans for ONS-5010/LYTENAVA in additional indications, make reductions in our workforce, scale back our plans and place certain activities on hold, discontinue our development programs, liquidate all or a portion of our assets, and/or seek protection under the provisions of the U.S. Bankruptcy Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of the product candidates we pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing our product candidates and any drugs we successfully commercialize;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with the pending securities class action lawsuit, as well as other potential litigation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">See Item 1A &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Significant Judgments and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our prepaid and accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers require advance payments; however, some invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met. We make estimates of our prepaid expenses and accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated prepaid and accrued research and development expenses include fees paid to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors in connection with preclinical development activities</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CMOs for the production of preclinical and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs in connection with clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In many instances payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In recognizing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of prepaid and accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. We are currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. We are currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures.</p><a id="_2ff22dda_9f65_4e11_b20c_fdd164a944c0"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a &#8220;Smaller Reporting Company&#8221;, this Item and the related disclosure is not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d5e066c8_640f_44b7_a29d_2e4a240d23a4"></a><a id="Item8ConsolidatedFinancialStatementsandS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 8. Consolidated Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">OUTLOOK THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNUAL REPORT ON FORM 10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">INDEX TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:94.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a><span style="white-space:pre-wrap;">  (PCAOB ID </span><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:AuditorFirmId" id="Narr_LdsNAI-HPkeOhJcmHuIwBw">185</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">103</span></p></td></tr><tr><td style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_938368"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">105</span></p></td></tr><tr><td style="vertical-align:bottom;width:94.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations_98519"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:bottom;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">106</span></p></td></tr><tr><td style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofConvertiblePrefe"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity </span></a>(Deficit)</p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">107</span></p></td></tr><tr><td style="vertical-align:bottom;width:94.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_508882"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">108</span></p></td></tr><tr><td style="vertical-align:bottom;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a1OrganizationandOperations_100881"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">109</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_32cae6a3_91d7_42d6_92d9_36dbf19d5539"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Outlook Therapeutics, Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Opinion on the Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Outlook Therapeutics, Inc. and subsidiaries (the Company) as of September 30, 2024 and 2023, the related consolidated statements of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred recurring losses from operations and negative cash flows from operations and has an accumulated deficit, that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Critical Audit Matter </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Evaluation of prepaid and accrued research and development expenses </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">As discussed in Note 3 to the consolidated financial statements, research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, as well as regulatory compliance costs. At the end of each reporting period, the Company compares the payments made to third-party service providers to the estimated progress towards completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense related to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">We identified the evaluation of prepaid and accrued research and development expenses for contract manufacturing organizations (CMOs) used by the Company for supply and manufacturing of pre-clinical and clinical trial materials and commercial materials, including manufacturing validation batches, as a critical audit matter. Specifically, evaluating the sufficiency of audit evidence obtained over associated costs incurred for the services provided by the CMOs required especially subjective auditor judgment due to the nature of evidence available regarding progress towards completion of underlying phases within the statements of work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The following are the primary procedures we performed to address this critical audit matter. We examined a sample of (1) statements of work, (2) payments, and (3) communications received from the CMOs related to the status of underlying phases within the statements of work, and compared them to the Company's schedules of costs incurred as of year-end. We also confirmed the status of underlying phases within the statements of work directly with the CMOs. We assessed the sufficiency of audit evidence obtained related to prepaid and accrued research and development expenses related to statements of work with the CMOs by evaluating the cumulative results of the audit procedures. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:AuditorName" id="Narr_k0llEx39AkOJ-BUJUfh1sA">KPMG LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="dei:AuditorLocation" id="Narr_EYDeJYl610uREyrB6UMI_A">Philadelphia, Pennsylvania</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">December 27, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9c90a3d2_3de1_4661_bfff_88d8bd07648d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Outlook Therapeutics,&#160;Inc.</p><a id="ConsolidatedBalanceSheets_938368"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Consolidated Balance Sheets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_09db87e9_df94_415c_93b1_b38f8bd419fa"></a><a id="Tc_D0PuS_7nL0myGzF5I64Ylg_1_2"></a><a id="Tc_9IQ0a9M3qkiRS0Pw3BcX_g_2_2"></a><a id="Tc_PAPvQ8h06Eey9UCquV5d3Q_2_5"></a><a id="Tc_aWJifTv4VEe7aZbevikyPQ_4_0"></a><a id="Tc_sJglXZ9L3UWS765B715Yjg_5_0"></a><a id="Tc_xZPlCT5K1kCCIPSNbNdrpQ_6_0"></a><a id="Tc_9nkvuPv_eUqDUCOwl8v8LA_6_2"></a><a id="Tc_IxY4Rut7hkCKvjRsdUyCyQ_6_5"></a><a id="Tc_8_TnRU0WZEeGnQLpgLzGCg_7_0"></a><a id="Tc_eYzNmSPbu06eNnLA8NFXBw_8_0"></a><a id="Tc_usCx6RdtsUuaSzFI8yWH0Q_10_0"></a><a id="Tc_9hBCEo_5vEyJeypkhD2rcg_11_0"></a><a id="Tc_cwDbpCrz6US7lZ_s-LQ1aw_12_0"></a><a id="Tc_8pKjHAwS3U-m-Yp8FTkNeA_13_0"></a><a id="Tc_9fweFP4eo0G2k3B1muILfw_13_2"></a><a id="Tc_3MlkanS4N0ydQmbs8puqnw_13_5"></a><a id="Tc_J6Laft7XDkCIsj2rVbhrWA_15_0"></a><a id="Tc_dpRVkYwjnEaIte9JB-nv9w_17_0"></a><a id="Tc_TntXfQb5U0Ov7cq1uxGMqg_18_0"></a><a id="Tc_N1de1A3Tnki1f_nbXdbTYg_18_2"></a><a id="Tc_TJdi4k-oYkiFe7LK8wjMdg_18_5"></a><a id="Tc_gP2xnPLcQUabGT94nol1xg_19_0"></a><a id="Tc_wKksdzQbj0SonGxwKn8zDQ_19_3"></a><a id="Tc_xKzuKIsgYkePiqZ2pmzJNQ_20_0"></a><a id="Tc_W9Eh1XN1VkGLVjjLGIYEqA_20_6"></a><a id="Tc_BmB4-NkTZ0OptV8JkEpJCw_21_0"></a><a id="Tc_FXYqi59ANEmXISZt06L-eQ_22_0"></a><a id="Tc_9Hu3bZXNm02JDJ3jML-_2w_23_0"></a><a id="Tc_NH8OctjWBkKNdG8cKQROMg_24_0"></a><a id="Tc_oNWCWxxlk0WT7_X08Jfi7w_26_0"></a><a id="Tc_gXnRJdcqPkKmUrhWMfIw6g_26_6"></a><a id="Tc_Bkjj70H7HkWQIXeJJoHOxQ_27_0"></a><a id="Tc_7CsaOlrSXUuBZPi-xsC8hw_28_0"></a><a id="Tc_xPMnkzJDdE2Km3UzwkSGcA_30_0"></a><a id="Tc_mlzWTkllwEKHOVKURExDqw_32_0"></a><a id="Tc_ZC73Vjc1y0ON_osU_Cktkg_33_0"></a><a id="_8615e570_82c2_4fe8_84c2_0370e0510deb"></a><a id="_8615e570_82c2_4fe8_84c2_0370e0510deb_2"></a><a id="_8615e570_82c2_4fe8_84c2_0370e0510deb_3"></a><a id="Tc_7YUTge55Ak2F-Tg7eKCFOQ_34_0"></a><a id="Tc_VsISTQ9qb0a8-sRe8I79SQ_35_0"></a><a id="Tc_S_bp0J1FX0Sxi_7RdXZDIA_36_0"></a><a id="Tc_esgriBID0EqzqQYFjJNW8g_37_0"></a><a id="Tc_N8JEf9R3FEu1ChDmc8RaPw_38_0"></a><a id="Tc_YJ2up36gIEStwRRJ2a_NQA_38_2"></a><a id="Tc_ckNjXvOZLUi_b6zhbLBJQw_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_t26dnrivYE-PHLR7ZL7rQQ_6_3">14,927,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_NM6xd6rHuUGNheoZm7bGyg_6_6">23,391,982</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_gMsLhczZrUmB7TxFF7xslA_7_3">12,488,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_gSPucFsrc0-43zoDVxWd4w_7_6">7,587,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_mjGNvgg4MUW3RlIdhb_COQ_8_3">27,416,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_m2ZtFiiqBU6YUF8MIGyQZw_8_6">30,979,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Operating lease right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_6Y7FmaCsdUqsieqEd7JqtA_10_3">274,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_6JsbaYoWJkaewLj61E5TBA_10_6">26,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Equity method investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" id="Tc_6DuoPC09GUepBDiUH5wjWQ_11_3">693,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" id="Tc_mlkpSsBsmECmktH7UwghNg_11_6">793,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_Ko2M1NJBdUWqNndbDrOiIw_12_3">439,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_JwBWhHiVEE23PlsX9OgDzw_12_6">501,299</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_FcWNM1FBwku8CLcUD_kp7w_13_3">28,823,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_zMVAqaN_fkGMnOCO1wzBAg_13_6">32,300,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Unsecured convertible promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansPayableCurrent" scale="0" id="Tc_i1sZYw39I0KL-SdBehFg_A_18_3">29,440,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansPayableCurrent" scale="0" id="Tc_0v30su1Cxk2xuz6NAKpAYg_18_6">35,551,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="0" id="Tc_HgRDv7ym5Eq39vdFF94W7g_19_6">4,267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_OgjKUSFlm0GWhPCjTzft3A_20_3">50,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_Yn9RwdBh3E-1LDmVLH5NgQ_21_3">7,968,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_goSLm1IPwU6xNCze322Qwg_21_6">6,574,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_v_TFnylnaU6npTV6wMJeXw_22_3">3,237,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_kTjxF694JEWRG7Vg9_Zu_g_22_6">2,745,740</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" id="Tc_oY5yoIDdHUWuoRrVca2CDg_23_3">1,856,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" id="Tc_skL0GKyNwEOFB6K0Ptog2A_23_6">1,856,629</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_VihIFBl4ykqaz2ABq5_lMQ_24_3">42,553,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_WzGzop8PVESoTNphFuLagg_24_6">46,732,159</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_2lf3NpCQKEWGz5NMWtgs_g_26_3">246,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Tc_0QRiuZO4skeEEsq3uEdzEw_27_3">59,099,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Tc_ii3ThtF-a06i9C2DP3r_Yg_27_6">6,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_usaBEQGcAUKYp4mUTdofBg_28_3">101,899,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_zs9ALj8UjkW8A9F8d1zLqQ_28_6">46,738,378</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Commitments and contingencies (Note 8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Uojy3gPTSUWIgh2oA1ub3Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr__GQD4RsT6Uqlm_TPhYr6dQ">0.01</ix:nonFraction></ix:nonFraction> per share: <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_ckYmvGMXy0Kqgj-UWukytw"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_-FUH5ecJDEKnSlIumQhqrQ">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_k3skrFukHEG49YnQBjnevQ"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_RPJvFPywSEKPphEomZuMbg">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_iF2dUt8Qkkehhy_NkHzsNg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_y3Ew4CJ85UmmLIFLRTmQzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:top;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;">Common stock, par value </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_cMVL-Ge7WEilfnZUFwQ-ag"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_fSaOe6tGrUev9kIfJScpoA">0.01</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ZO2DNgvY3U2t-M4CX7kcEg"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_AgiHiUInh0u9FcJ5yyHTfw">60,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_VLWjxtsrlkSk8UhDos6kXQ">23,905,635</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_x-QdmUz9JkGJIrEgnwR-Lw">13,012,833</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_XPEQyVvjd0uleb7M0shZcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_N4pkjJobP0maC3w1WPuLFw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> at September&#160;30,&#160;2024 and September&#160;30,&#160;2023, respectively</span></p></td><td style="vertical-align:top;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_N-8UAnfo3EqHbqZuLxIMDw_34_3">239,057</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_PXsz6yMVMka1hoTTqw02YQ_34_6">130,128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="Tc_wcXTTktfxEuNFCd3WkgIdQ_35_3">469,969,333</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="Tc_-HOZfOxl9kuoP60CQzXFnA_35_6">453,350,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_M3zd9jJAiUWpioeLDxTNXA_36_3">543,284,900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_u5cxtzIZk0WgCezW0bBMGw_36_6">467,918,186</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total stockholders' deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_V90n8go7OEq1AK7S42uq0Q_37_3">73,076,510</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Fn4vo9I4LU-83B3yLPbw4w_37_6">14,437,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders' deficit</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_iNNUjZp3PkOhk8Mz41Y6Eg_38_3">28,823,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_1FGum5ithkyXLca4ryhWDg_38_6">32,300,601</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ac261882_2e99_4697_beb8_cc6d5ba92076"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Outlook Therapeutics,&#160;Inc.</p><a id="ConsolidatedStatementsofOperations_98519"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Consolidated Statements of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_644b7193_8412_4afa_b8cb_c2a750c85684"></a><a id="Tc_phVxcbU3LUe73pnOaZclrw_1_2"></a><a id="Tc_CSLU5WCcxkiMkfWJUsh7-A_2_2"></a><a id="Tc_vdAvsBHjtUWbQvxxDWJg9g_2_5"></a><a id="Tc_0xRyP1d1xkCWxAv8kC-iOA_3_0"></a><a id="Tc_8XZIiJ9y3UeLnve3AuvISQ_4_0"></a><a id="Tc_vZlZ0t2qDUO7MAbw8nHqKA_4_2"></a><a id="Tc_D65aDbzk7U-fsqMYO9jq_Q_4_5"></a><a id="Tc_sYBhamQbt0CCuq8RcL8GIw_5_0"></a><a id="Tc_tgqZLCUkJk2V8g9kwdG1Kg_6_0"></a><a id="Tc_t05Uqtcpyk-2CcEnG-cLBA_7_0"></a><a id="Tc_VKUYH7G7fkaZMLhBi262MQ_8_0"></a><a id="Tc_aiZT5zLQl0-YJKzcQLz7OQ_9_0"></a><a id="Tc_C3LbvHWkuUK-uta1ipualw_10_0"></a><a id="Tc_ZbgbzzEyCk6cGeH-yH9axg_10_3"></a><a id="Tc_0617eZU6406Tby8XLPeHag_11_0"></a><a id="Tc_7gdmHNR5WU24_URiz7TUHg_12_0"></a><a id="Tc_HQdxq4mS3EuDCDhgwgtm7A_12_6"></a><a id="Tc_LQJAkRzQBkedOYJ-Pke-3Q_13_0"></a><a id="Tc_Sk2W4Ws4X0STenBDlgkKdg_14_0"></a><a id="Tc_J3aF2o9B6kGc4OlKvhKNbw_15_0"></a><a id="Tc_DX6WTbDGBUyznyNr0SvSyQ_16_0"></a><a id="Tc_UR9pjeCPeUS6xYyUq6w5fQ_16_2"></a><a id="Tc_bmF9oLPFJEWKclhQ9SpOQw_16_5"></a><a id="Tc_1-zyioamQkqgnIJI83uvag_18_0"></a><a id="Tc_ys8ImOYBRkevVRd2ADLV3Q_19_0"></a><a id="Tc_XzQo_8_VD0u6C3uqTkpBnA_19_2"></a><a id="Tc_Aa3h3Jv7UEa6j4jZaCwwXg_19_5"></a><a id="Tc_27sPu4SasUerV6or1mM1zg_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_RLVmjJ1j4EGlJ9zYhr8Djw_4_3">41,763,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_YA1Uz6ylkESZ76J-PvJVwQ_4_6">26,452,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_MsCbzLipdUaMWSH9aFPGvA_5_3">29,940,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_IcC6WFuOrECxoRlNRW2fxg_5_6">26,673,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_dx6LAKuzkUq1YMxFO6qinA_6_3">71,703,235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_6hc3wjinYkWbD9Gx-9Ytxw_6_6">53,126,382</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Loss on equity method investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="0" id="Tc_4CAU7yh35kahLq0RJ94xSA_7_3">100,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="0" id="Tc_ZVrcT7cG_kSJAhe5rCM0hg_7_6">10,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_Etl8rRZeg0-qnVAHBcYcVw_8_3">906,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_4kZJyg0ZjEmhX4kCZL7Phw_8_6">971,480</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Interest expense </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Tc_MrpTSgsQnkiLma5-feUoaQ_9_3">3,156,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Tc_3WlZwBLo9UavaMO5SHJASg_9_6">2,531,228</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="0" id="Tc_gmMANjhLj0mgizuuz4CdLA_10_6">577,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Change in fair value of promissory notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="otlk:ChangeInFairValueOfRedemptionFeature" scale="0" id="Tc_DxYsFuJktU2BEWwFgdqyaA_11_3">2,457,153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="otlk:ChangeInFairValueOfRedemptionFeature" scale="0" id="Tc_bYAoPov80k2Mp-de2gLgmA_11_6">3,756,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Warrant related expenses (Note 9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="otlk:WarrantRelatedExpenses" scale="0" id="Tc_NRTHsOTc_kGn_e_KL6uz1Q_12_3">37,490,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_Hlj_eFW8JU2v7Wh6tDSKug_13_3">38,638,042</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_lImBzmqAZUuRa0XZ_A6wzg_13_6">50,919</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_P3rMUPM4b0GJVt63dgiHwg_14_3">75,363,914</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_Itd6CcnEhkq9XlZRLWlF7g_14_6">58,979,868</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_uQpQhiBK_kOrMtY5bSIkzg_15_3">2,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_fjq5LHO8ykaG9F4FwGPJUQ_15_6">2,800</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_veMVHoavDUWug-BDmdOGVQ_16_3">75,366,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_Z6KrS1WOwkCXaR2OAgBF7g_16_6">58,982,668</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Per share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net loss per share of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_fqXj6TcqSUqne6X_aWYCMA_19_3">4.06</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_9DkMDpDdUkiivJSPynRyqw_19_6">4.72</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Weighted average shares outstanding, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_1onzAclBv0yX_CbOAi-dRQ_20_3">18,548,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6sQffL0gXk-OtvPYocPQkA_20_6">12,508,817</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:3.45%;padding-right:3.45%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_df884927_305f_4551_9b88_8ed76876c3e4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;text-align:center;margin:0pt;">Outlook Therapeutics,&#160;Inc.</p><a id="ConsolidatedStatementsofConvertiblePrefe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;text-align:center;margin:0pt;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4c6c85f5_c6f5_4230_8310_b8cee19f8dac"></a><a id="Tc_8kBxs80ZWEeXwvW6p0oYxQ_1_2"></a><a id="Tc_nI4omXdh3Uy1OOTjbXGwzQ_2_2"></a><a id="Tc_85ynxxM9AUCGaeJ5o9xmjA_2_7"></a><a id="Tc_d8gXoEebi0myPKg8lAaGzA_2_10"></a><a id="Tc_akfUAsOZI0mKxueWyWYD3A_2_13"></a><a id="Tc_xjgt6rfdKkqQKtKH_yQPaw_3_2"></a><a id="Tc_UaF5d2-HPUaOkuPF5w-S3w_3_4"></a><a id="Tc_bTwsOj6XrkGgIFkRd6F_sw_3_7"></a><a id="Tc_xj0r-kTmVUusMWwClVCZyg_3_10"></a><a id="Tc_XTlCvFF0X0eIW6pt2Ws9Wg_3_13"></a><a id="Tc_DO_YjGlKUkufT2yYMlZ6dg_4_0"></a><a id="Tc_e7L2BTlB60KLiLNHOsSpWA_5_0"></a><a id="Tc_PH9lfMBfT0K_dO_G2VXadw_5_11"></a><a id="Tc_Z7oaRhgVFE6IPcEFwNmlcw_6_0"></a><a id="Tc_MuHuXxrls06oiPBuVs89Pw_6_11"></a><a id="Tc_zEnF8_yDsUadGS-4lXlWbA_7_0"></a><a id="Tc_JBCR5cBhCk29bByfuiuwVw_7_2"></a><a id="Tc_3vMaRBrNcEajUbttedPwCA_7_5"></a><a id="Tc_hzbVVQL_tE6s6O4x9FCQPQ_7_11"></a><a id="Tc_BprEsyVVZE-WEqMhlgJHmQ_8_0"></a><a id="Tc_rYx1otk1_kqU9rvQCO_LnQ_8_2"></a><a id="Tc_2jERCDlqDE6f8PEovEsJAw_8_5"></a><a id="Tc_jF1e2CLRBUekWKN2VBZo9g_8_8"></a><a id="Tc_DfBi6tDNB0WUGR1rN4k3ag_9_0"></a><a id="Tc_Cc5962RY80K_Vqoip1Ve3A_10_0"></a><a id="Tc_zjVEKLGdBEGujNrd-Fy20A_10_11"></a><a id="Tc_cbeSyD_Lf0ePum3Jbg3sTg_11_0"></a><a id="Tc_UnBfgURTO02XEj4h63KQug_11_8"></a><a id="Tc_7n9tWykTrEKSidNFgo3wqw_11_11"></a><a id="Tc_9cQIUS9HVUeh0Ave4kedpw_12_0"></a><a id="Tc_pTNr3oZHf0WBISAbt3Iwzg_12_2"></a><a id="Tc_kK4Yp5nvx02oOEbn6_RVSw_12_5"></a><a id="Tc_tnuXF1xjDEyMWxbZtgdfsw_12_11"></a><a id="Tc_UqscmqaYR0qGSrBin-j5vw_13_0"></a><a id="Tc_c1Sq4bS3q06BnW4LJW7iFw_13_2"></a><a id="Tc_0rN4DbYgPE6F4i_9CV736Q_13_5"></a><a id="Tc_BZme8z_jmUyHuucfg4yZ2g_13_8"></a><a id="Tc_XaawaVoVWkqXSb0nPrXBTQ_14_0"></a><a id="Tc_CfvPwbGHi0mNJwqlN9bWmA_14_4"></a><a id="Tc_cTCkTxJoxU22XRb3hLsTUQ_14_7"></a><a id="Tc_WdQgWc4CrkCN0clFXyAh4Q_14_10"></a><a id="Tc_b9uSrNaLl02n3S0kiVZIdg_14_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:52.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;&#160;Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Balance at October 1, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xyLJUczsLEWjWNfFeX2L9A_4_2">11,365,486</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Uu24kukzd0m0VvlFBu4J7A_4_5">113,655</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nab82IT-Gki9oEVbHZmkcQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_j2d1aWghQ066peTCK8wfVw_4_8">417,558,434</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0N8PxP9kEu7Rni9SApcXQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_FChBY2LO8U-XkiGqE-hAEA_4_11">408,935,518</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_JAk9DE6R-UmhHk9RvOIKkg_4_14">8,736,571</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Issuance of common stock in connection with conversion of convertible promissory note</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_MtZxorPnEUK0eE6Si0WaaA_5_2">625</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_ZHoba5AJAESisz33mMzvQw_5_5">6</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_u48aZnCjckaxoAQL79mm_A_5_8">24,994</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_dZ4rzgeMf0uc0g3n29mo-Q_5_14">25,000</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Sale of common stock, net of issuance costs  (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_MjjLjHTdc0Sg4GQVpw8mGA_6_2">1,646,722</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_UKeJdF42w0iJn7ox-N-TFA_6_5">16,467</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_xr8nsNXmGU2i7Q7q616tng_6_8">30,219,834</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_mhpPshBy5EaEGGt4Ohvvfg_6_14">30,236,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_gMvYC28xQU2_49AWDz4n8g_7_8">5,547,019</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_s8qQpS08A0aFhfRV7IAmKg_7_14">5,547,019</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DOx7DSkcUUK1qwvbqatS0w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ArMWz5CteUKcKig1N1ksiA_8_11">58,982,668</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_LgTVb363dUqVOSfBiSUhng_8_14">58,982,668</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Balance at September&#160;30,&#160;2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tVVfsw2X4ku21-b-wI1Fsw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_u_UVADY__UiVCwzXt1-F5A_9_2">13,012,833</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tVVfsw2X4ku21-b-wI1Fsw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_uIr93YOFTUWXSHOFhuBDvA_9_5">130,128</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eLtmRbHPMk-R2-bot8_N2A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_qBjGSb0PkU2gAd4IpMKXtw_9_8">453,350,281</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UoWGYXeAcUmQc5T0sAOkNA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Bu6NE50Nd0K5UbWu1JSqkQ_9_11">467,918,186</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_nBITLumU-kqaBe07i2_hnw_9_14">14,437,777</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Issuance of common stock in connection with conversion of convertible promissory note</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_siplt-OoUkaevPM4NRfw_w_10_2">1,607,093</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_T7lz0vY2I028GRLLEzBnjg_10_5">16,072</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5GDfve-pQk2XYOfwNALJmA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_IIJDWfJhKUCbHD6xn-iZfw_10_8">11,233,928</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_EUP5CsDxaku7FBcfytD_XA_10_14">11,250,000</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Sale of common stock, net of issuance costs (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_BVHqvo2jx0KHhfu8t5HvAw_11_2">9,285,709</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_gIWQ_X2eCEG6Mz2AW4MdsA_11_5">92,857</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_n2oR53jC9EKsbNI7JWLxNw_11_14">92,857</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5GDfve-pQk2XYOfwNALJmA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_IO4-Wikn4k2zsmYzf8boFg_12_8">5,385,124</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_ETO-3j3ZrEqXhl-EFz9JRg_12_14">5,385,124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5I3oWKzZqkyIrUS7CKXITQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_v_C9zp_Y5UyntYj4oUjvog_13_11">75,366,714</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_9o4KfS1s-k2FfjgrNofFlQ_13_14">75,366,714</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Balance at September&#160;30,&#160;2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6NrSVQ0gRUCQVI56arDZNQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_3ZKhf06FnkSMCBTuOSar1w_14_2">23,905,635</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6NrSVQ0gRUCQVI56arDZNQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_T39hkl6xL0Czf3-UKl-Ktg_14_5">239,057</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_keL3bo7nE0CNPVnUOmT-gg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_4wyT_fk_VE68GSsBni2PEg_14_8">469,969,333</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aqpTcTgcvEKqWIkMkLyvSQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_7PC6rU-6okGitEO30XKQkg_14_11">543,284,900</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_6U809a0NoE2_CjpJiMH_Dg_14_14">73,076,510</ix:nonFraction>)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:93.09%;border:0;margin:30pt 3.45% 30pt 3.45%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cea94998_0c93_4c8f_9491_2a604dd17d74"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Outlook Therapeutics,&#160;Inc.</p><a id="ConsolidatedStatementsofCashFlows_508882"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Consolidated Statements of Cash Flows</p><a id="_360696cc_e7de_4900_8c01_d2d7213923a9"></a><a id="Tc_g3TPV9F_HECeY2TJDXuPPA_1_2"></a><a id="Tc_jwFSrFU42US0EHoOtrXqHw_2_2"></a><a id="Tc_j1aslUJ7rkSn1sSClCqdow_2_5"></a><a id="Tc_5vhmFTROFEmAifuhpzxaUA_3_0"></a><a id="Tc_sCGPV7Xwukyv62iJJFVjDA_4_0"></a><a id="Tc_rv-MdmaQ6Em4LibOfBL3bA_4_2"></a><a id="Tc_aft9gCw5MEm0De9MQT4iwQ_4_5"></a><a id="Tc_Ev4IDXViV0qNp-EIV3S2Uw_5_0"></a><a id="Tc_EFdZ2tJL3UyrlfsV83WkBw_6_0"></a><a id="Tc_V9LXngHk302CtnPtOnfrCQ_7_0"></a><a id="Tc_ClrEWqaqg06qbB-Bu0h51A_7_3"></a><a id="Tc_91eqYy9T5E6ttnGf_kh_Qg_8_0"></a><a id="Tc_nRYsVPsN90GJHqBLCS0wtw_9_0"></a><a id="Tc_cyDZk3r-KUycGCUbDPokDA_10_0"></a><a id="Tc_B49v2Zk5zU-C-YFizWi_6Q_11_0"></a><a id="Tc_2_wZcNHQ1Ey_fOic2Mp20g_11_6"></a><a id="Tc_cLCdBmTYmU-TpHDcSwAH6w_12_0"></a><a id="Tc_JnmsODYJ3U6o-NjQv7FR_Q_13_0"></a><a id="Tc_C7BXNEgMyUWpL6oQFls_GA_14_0"></a><a id="Tc_IOCWyA653kaiHkVD6Vzdzg_14_3"></a><a id="Tc_3BMMzsTpBEeOVsTBnuEMyw_15_0"></a><a id="Tc_tSlHz6_yT0yto-k9CBjzoA_16_0"></a><a id="Tc_55EGvHyJmk-Zm9Tj_2OdyQ_17_0"></a><a id="Tc_mz4rWbuJNUGbZ7i70OaZ3A_18_0"></a><a id="Tc_MWk7s6dYLkqz1Fa7R1ZUzg_19_0"></a><a id="Tc_jrcD3vdTr0CpMY3MvhlF-Q_20_0"></a><a id="Tc_ih5N38Zmk0isL4koJso1Pg_21_0"></a><a id="Tc_hGzqgh-z70azcfBaiQJlBw_23_0"></a><a id="Tc_Swi04J7iBEKnK0LYDkiPDQ_24_0"></a><a id="Tc_8jkiF9xof0SW3o7mzaF0IA_25_0"></a><a id="Tc_IBA6VZtjhUq32C9otBCnXQ_25_3"></a><a id="Tc_vPLWJvLprkyQbU0jvqRz_w_26_0"></a><a id="Tc_pEjyDu7olUKMYzatvPv5LA_27_0"></a><a id="Tc_oLLAZ554BE2RvvWG4egP1A_27_3"></a><a id="Tc_ofLGH1XehUmg-Kjyc1h86Q_28_0"></a><a id="Tc_mI3EoHms2UOQCDzqQDKjOg_28_3"></a><a id="Tc_SVOKgO5J_kCHC859LflBzQ_29_0"></a><a id="Tc_5rN_XPj6DU64bEY50MIyTQ_30_0"></a><a id="Tc_8SvdgHbqAkmny_ixXN8u-A_31_0"></a><a id="Tc_H9GIyS43WE-6VNzJkMea0A_32_0"></a><a id="Tc_Uvk0RyppiUaubjq-NCzm0A_32_2"></a><a id="Tc_eSkauX4j4U6evHkGAv8TBw_32_5"></a><a id="Tc_BJVBTRvkFkW5zaz7FDhrdw_33_0"></a><a id="Tc_ZxMs9YXJNkyZELEUmWvhHw_34_0"></a><a id="Tc_ElvcM4wiSk2yOZXrK9XNZw_34_2"></a><a id="Tc_QFRKzdhSvEuVVHKja2gWyg_34_5"></a><a id="Tc_7Qwg1CL-f0WVu4I5f8CSVQ_35_0"></a><a id="Tc_h7R3ThivP0aDWwvnxJ0h1w_36_0"></a><a id="Tc_QaAUfhMLIEewzRG6zpds3A_36_2"></a><a id="Tc_440c0Xbmkkm9XVXH_Pyqag_36_5"></a><a id="Tc_z9wVQJNjGkmGBNf9BQzghg_37_0"></a><a id="Tc_dQCF1sAYwEGqcvk6uFed6Q_37_2"></a><a id="Tc_kM7pr_u_B0e5D3H_mRttnw_37_5"></a><a id="Tc_euWoG5K6nU-yX4jRgaHDuw_37_6"></a><a id="Tc_Nujld8ZBDEWFHpqWVWNH-A_38_0"></a><a id="Tc_aE7rG4M74UGeFuM6-c58_w_38_2"></a><a id="Tc_8wHuWzfn1UqbG_o9pgpWaw_38_3"></a><a id="Tc_-BnHRBgs7kOJNhMJUUBang_38_5"></a><a id="Tc_rJ941yN3A06Wu7YZuJHbvQ_39_0"></a><a id="Tc_RZMaELE5mUK5Tch6O3UQuQ_39_2"></a><a id="Tc_ZHv8kildb0KVG1VjHgxU7w_39_5"></a><a id="Tc_VaGPHGcxL0Whc5X_-8sCxg_39_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_hDNEbkMPNkeUY1I-0Ld9eg_4_3">75,366,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Fg_FmnAV1kOtDmn6ecTVzA_4_6">58,982,668</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="Tc_qAmAYcWXNkCCyPfrBjGeOA_6_3">113,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="Tc_W2FXpVczak2UJx7v8kSGEA_6_6">44,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="0" id="Tc_MpHJwHjOCEqhrzXuMp-ePw_7_6">577,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaidInKindInterest" scale="0" id="Tc_z-p-H3hu4EGmVVzKzZXWDw_8_3">2,681,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaidInKindInterest" scale="0" id="Tc_14m09uxqkke7j4oMtX9v3A_8_6">2,529,830</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_v-NKQFe4AUej2NxG5GenQQ_9_3">5,385,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_zy4pQNNZrESLalQVu9QnJw_9_6">5,547,019</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Change in fair value of promissory notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="otlk:ChangeInFairValueOfRedemptionFeature" scale="0" id="Tc_E2hvBjVj6kOSbV7mCgeEMQ_10_3">2,457,153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="otlk:ChangeInFairValueOfRedemptionFeature" scale="0" id="Tc_599hbwVn-UWzXhAYpIu_4Q_10_6">3,756,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Warrant related expenses (Note 9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="otlk:WarrantRelatedExpenses" scale="0" id="Tc_v7szLJ4W5EaYD7jIk5eTEQ_11_3">37,490,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_JaU5U07USU-XykGenSNIBA_12_3">38,638,042</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_-PVCecac402CW4XORpoB-w_12_6">50,919</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Loss on equity method investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="0" id="Tc_rrHqkp5wKEG6H5D7NwvSFQ_13_3">100,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="0" id="Tc_xazjJjSQZ0KXdmOKkIlVqQ_13_6">10,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid on debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaid" scale="0" id="Tc_9uGj78jGMkakpt8kU4AC3g_14_6">1,158,609</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_0waC805L9kaYCSH6-hA3VA_16_3">4,901,282</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_VBdfOL3Mck6gRete1wdvTg_16_6">2,616,925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_KUkAbdraT0-3R18x7Q9Gag_17_3">5,900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_XCqAtqjZpUqxVLjehIP2dQ_17_6">208,203</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" id="Tc_lqAlrbNlREyblpHoNL0hZw_18_3">3,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc_SdowLSf1BU62SCMFtlQclA_18_6">26,995</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_wPxBz_NLAkOgsdwGUFZPgg_19_3">1,394,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_JoOdyWtru0eoMqVxlL2pFg_19_6">3,083,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_9xk8G_m0HEKcc6Pb2mjUmQ_20_3">491,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_pyLvwVniX02_V8dTehMgrg_20_6">711,661</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_E7xv7oznhkCVgowE6VYC1Q_21_3">68,793,858</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_TXVkA2ruyUuoAeY4a4CzaA_21_6">42,973,398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_VseG25c4bkmzRiFyIhiL4Q_24_3">60,333,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_hch24BlazEiKOD-EWfcwzQ_24_6">30,024,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Tc_zxgMsSQQqUG9BZQzeS5AIA_25_6">30,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Payments of finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" id="Tc_7OSEWuCXQ0ubDdw2-wdRiw_26_3">4,267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" id="Tc_JQkFmh7u2kGSdI3hCvt2jQ_26_6">11,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Repayment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_-R6bBw8NF0uKdwuNVL_7Jg_27_6">10,220,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Payment of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="Tc_gwV7lhG8gEWVCJPrGTzwww_28_6">823,894</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_fq3jEm7m2UGZ_DOXMBO46g_29_3">60,329,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_IKmZf604D02FVheb1oovDQ_29_6">48,968,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_fJw9Nh57hES4EKCFsrAc0Q_30_3">8,464,444</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_GdV7O8FBX0-mSlsU93znlA_30_6">5,995,170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_VbELQYIQ10Ck2d5sbpkawA_31_3">23,391,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Bgg7aDNJmEed0wnmrtvfnQ_31_6">17,396,812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_1EP-_S1S4kKTcPOJa7TiJw_32_3">14,927,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_dW4uVf-GK0e73dy0Huc_cQ_32_6">23,391,982</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_mMUIXjYqnUClzHkHGPZX7g_34_3">475,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_0sdOVLCgIk6RoVanJ1zRNw_34_6">1,160,008</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental schedule of non-cash financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Convertible promissory note converted into common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Tc_vXLSor6o10SWw-1wiRXLkg_36_3">11,250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Tc_Jzd_XSNNLUOAZ-umn_bf1Q_36_6">25,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Recognition of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="otlk:WarrantLiabilityIncurredButNotYetPaid" scale="0" id="Tc_bdaj59BC0k2_KT9oZrHjcA_37_3">97,730,836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Deferred offering costs amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="0" id="Tc_jKLYlTQa40O4EgK41JRS5Q_38_6">141,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset and lease liability recognized for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="Tc_HGqUAr_hbE6Zq6lYvIkSOA_39_3">294,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a1OrganizationandOperations_100881"></a><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:NatureOfOperations" id="Tb_ZVke3geZOUyGBQIqHUwFcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;Organization and Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outlook Therapeutics, Inc. (&#8220;Outlook&#8221; or the &#8220;Company&#8221;) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to &#8220;Outlook Therapeutics, Inc.&#8221; in November 2018. The Company is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA<span style="background:#ffffff;">&#8482; (</span>bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2024, the Company received Marketing Authorization from the European Commission for ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (&#8220;AMD&#8221;) in the European Union (&#8220;EU&#8221;). &#160;Additionally, in July 2024 the Company also received marketing authorization for ONS-5010/LYTENAVA in the United Kingdom (&#8220;UK&#8221;) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). ONS-5010/LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of calendar 2023, the Company agreed to conduct an additional adequate and well-controlled clinical trial following discussions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in support of the Company&#8217;s Biologics License Application (&#8220;BLA&#8221;) for ONS-5010/LYTENAVA. In December 2023, the Company submitted a Special Protocol Assessment (&#8220;SPA&#8221;) to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010/LYTENAVA BLA. In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter (&#8220;CRL&#8221;). In addition, through a Type A meeting and additional interactions, the Company has identified the approaches needed to resolve the chemistry, manufacturing and controls (&#8220;CMC&#8221;) comments in the CRL. In November 2024, the Company reported that &#160;ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="Tb_BE2UltUFTEyXT-T5yTEJiQ" continuedAt="Tb_BE2UltUFTEyXT-T5yTEJiQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since its inception and has an accumulated deficit of $ <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Narr_-2oGEEHjAkaX2_USoOnP4w">543,284,900</ix:nonFraction> as of September 30, 2024. As of September 30, 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="0" id="Narr_i9C3S-eX10qNTlrOxgk0hg">31,352,857</ix:nonFraction> of principal, accrued interest and exit fees due under an unsecured convertible promissory note issued in December 2022 (the &#8220;December 2022 Note&#8221;), maturing on July 1, 2025, as amended. &#160;As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2024 and December 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_UBcSaeWKtU27QaE35aSKWg">1,000,000</ix:nonFraction> shares of common stock under the BTIG ATM Offering and generated $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_8hgzxyDEOkaKEna1a7NmmA">1,742,343</ix:nonFraction> in net proceeds after paying fees to BTIG and other issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_oG0g3Ju0x06-3B7duugbfA">53,918</ix:nonFraction>. Refer to Note 9 for further details on the BTIG ATM Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that the Company&#8217;s existing cash and cash equivalents as of September 30, 2024, together with $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_B5BJaTy-nkCS0Cp3aQ3lRQ">1,742,343</ix:nonFraction> in net proceeds from the sale of shares of common stock under the BTIG ATM Offering since September 30, 2024, are sufficient to fund the Company&#8217;s operations through one year from the Form 10-K filing date. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern and additional financing will be </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_BE2UltUFTEyXT-T5yTEJiQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">needed by the Company to fund its operations in the future and to commercially develop ONS-5010/LYTENAVA and to develop any other product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations, including but not limited to, the exercise of outstanding warrants to purchase shares of the Company&#8217;s common stock (subject to meeting the requirements for calling such warrants), proceeds from potential licensing and/or marketing arrangements or collaborations with pharmaceutical or other companies, sale of the development and commercial rights to the Company&#8217;s drug product candidates in regions outside of the U.S., the issuance of additional debt, the issuance of equity securities, including accessing capital through at-the-market offering agreements (refer to Note 9 for further details), and revenues from potential future product sales, if any. There can be no assurance that these future funding efforts will be successful. The Company&#8217;s consolidated financial statements do not include any adjustments that might be necessary if it is unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing discussed above; (ii) the Company&#8217;s ability to successfully begin marketing of its product candidates or complete revenue-generating partnerships with other companies; (iii) the success of its research and development; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies; and, ultimately, (v) regulatory approval and market acceptance of the Company&#8217;s proposed future products.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_0cuEvmVP1EWfS_yVMUlGwA" continuedAt="Tb_0cuEvmVP1EWfS_yVMUlGwA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;Basis of Presentation and Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_Za3yzU8Kh06zzwruVjnhrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The accompanying consolidated financial statements have been prepared in conformity with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying consolidated financial statements include the accounts of the Company and Outlook Therapeutics Pty Ltd, its wholly-owned subsidiary incorporated in Australia (the &#8220;Subsidiary&#8221;). All intercompany accounts and transactions have been eliminated in consolidation.</span> <span style="background:#ffffff;">The Company has determined the functional currency of the Subsidiary to be the U.S. dollar. The Company translates assets and liabilities of its foreign operations at exchange rates in effect at the balance sheet date. The Company records remeasurement gains and losses on monetary assets and liabilities, such as incentive and tax receivables and accounts payables, which are not in the functional currency of the operation. These remeasurement gains and losses are recorded in the consolidated statements of operations as they occur.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="otlk:ReverseStockSplitPolicyTextBlock" id="Tb_I_CjvTvF_k6uU0wJJz9j4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reverse stock split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective on March 14, 2024, the Company amended its amended and restated certificate of incorporation to implement a <span style="-sec-ix-hidden:Hidden_35bPP_NyTECQ2xx8ssQR0g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-twenty</span></span> reverse stock split of its common stock. As a result of the reverse stock split, the Company made corresponding adjustments to the share amounts under its employee incentive plans, outstanding options, and common stock warrant agreements with third parties. The disclosure of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_vhXxTC6l80-K7wKH7kt8pg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash and cash equivalents include cash-on-hand and demand deposits with financial institutions and other short-term investments with maturities of less than three months when acquired and convertible to known cash amounts. At September 30, 2024 and 2023, the Company&#8217;s cash equivalents consist of a money market account.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:EquityMethodInvestmentsPolicy" id="Tb_k9Ry6sH0H0i38piN2Xp03g" continuedAt="Tb_k9Ry6sH0H0i38piN2Xp03g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity method investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company&#8217;s share of equity in the earnings or loss of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance </span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_0cuEvmVP1EWfS_yVMUlGwA_cont1" continuedAt="Tb_0cuEvmVP1EWfS_yVMUlGwA_cont2"><ix:continuation id="Tb_k9Ry6sH0H0i38piN2Xp03g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. The Company has not elected the fair value option. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:UseOfEstimates" id="Tb_xXTehD1xGUyu67lbfy9QUw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_QaRrCdkKI0mfXj_x-dKVcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The asset&#8217;s or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At September 30, 2024 and 2023, the Company&#8217;s financial instruments included cash and cash equivalents, accounts payable, accrued expenses, unsecured convertible promissory note and warrant liabilities. The carrying amount of accounts payable, and accrued expenses approximates fair value due to the short-term maturities of these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Option</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company elected the fair value option to account for the December 2022 Note. Refer to Note 7 for further details on the December 2022 Note.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_OLl4_uAvxEKKUCVPiWCGuA" continuedAt="Tb_OLl4_uAvxEKKUCVPiWCGuA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_0cuEvmVP1EWfS_yVMUlGwA_cont2" continuedAt="Tb_0cuEvmVP1EWfS_yVMUlGwA_cont3"><ix:continuation id="Tb_OLl4_uAvxEKKUCVPiWCGuA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#8220;Short-Term Leases&#8221;). For Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the consolidated balance sheet. The Company had no Short-Term Leases as of September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the re-measured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received, and any initial direct costs incurred are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</p></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_xgzldccriU6rz0tiTPVB7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures equity classified stock-based awards based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of stock option awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model, which is described more fully in Note&#160;11. The fair value of each restricted stock award is measured as the fair value per share of the Company&#8217;s common stock on the date of grant.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_kXQi00iKkUuoTVbLtYvIUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upfront milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_5xq9NBeOK0SsHXM9KIkw8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_14h4HhEoy0mA5DhwLlAnQQ" continuedAt="Tb_14h4HhEoy0mA5DhwLlAnQQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted net loss per common share, the denominator includes both the weighted average common shares outstanding and the number of </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8fd0af2e_53ed_43c2_a0f8_f2df013fd451"></a><a id="Tc_6gxO4yUtEkuKDgJHZJDsWQ_1_2"></a><a id="Tc_9oWjZVdsDkqEg6707ZxVvg_2_2"></a><a id="Tc_tKLE3VXhZUSnalumb34moQ_2_4"></a><a id="Tc_1xY4cRFp_UyNBwv3wk01Ig_3_0"></a><a id="Tc_5QuSjHNYgEWOn9UlES326w_3_2"></a><a id="Tc_ZkdfjQE-GkOReWugHOHDFA_4_0"></a><a id="Tc_S_u-Qx2bE0Oyw8rNN2sa0A_5_0"></a><a id="Tc_R6LbnKDnG0u-mcjNkXNlbQ_6_0"></a><a id="Tc_oqyxkYZQQ0SW-poiGExS4A_7_0"></a><a id="Tc_ouxCi77NnESHvfP0KRHZhA_7_3"></a><a id="Tc_O9hlBYtJ8kWG9szBBdJD7g_7_5"></a><ix:continuation id="Tb_0cuEvmVP1EWfS_yVMUlGwA_cont3"><ix:continuation id="Tb_14h4HhEoy0mA5DhwLlAnQQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include convertible debt, warrants, performance-based stock options and units, and stock options the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company&#8217;s losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September&#160;30, 2024 and 2023, as they would be antidilutive:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_1Qw3UZLRFU-1tug-PjiUgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.68%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;white-space:nowrap;width:29.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_9aSINsKIFUCWW7CgnYrY4Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_-3eMEXUZ8UqXxY4A5vvfiQ_3_4">123</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_JP8U0OONT0eXTY4nRn7zlw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_uF1HwD_CuUa0zvL4uZDrTg_4_2">666,500</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_MSrK39kxQUu7ngOH5FFwIQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GE03VEJ-jECu83ydSdWnMA_4_4">35,000</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NSNiPG1XOE-noQA60o5JOA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_0EEVO6GVIEue252kUJN40g_5_2">1,946,646</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MSv0WissdE66_EmEuqeCpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_A4tyDiOCoEyTw7KfguwY3w_5_4">1,197,774</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_feX5121kQ0qodVdS2YmgWA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Os68JzhT0ECoiqip0JA79Q_6_2">14,207,622</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_o0ezSlIIp02ostECr3h3Zw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Lqk-87NSD0ufXFCcCIMKLQ_6_4">366,427</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible debt</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_CGyuX5E2Lk6tYUEmOYyhpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2k96Y919vkqfBS_sn71L8g_7_2">1,171,100</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(i)</sup></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_H3wdezVmCkeyQmMuA4qHQQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_khYhlUrLK0i6cy-2Ldg16w_7_4">854,962</ix:nonFraction></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(ii)</sup></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The calculation for potentially dilutive securities pertaining to convertible debt is as follows: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_9E7IaktkjkmxEa7PB2T1Zw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_I66hZpKaRUC2N3t6jB-1rA">3,750,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of outstanding principal and accrued interest as of September 30, 2024, is converted at a rate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_9E7IaktkjkmxEa7PB2T1Zw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_kFLH9WhKZ0iq0bXaLcAPFA">7.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and the remaining amount is converted based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_Q4I_32NkR0GngeV1BKZ52Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_McLUE3T2YkKSKalcQcyZ7g">40.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_md536lyF-ESJilyGxz3vZw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_QDWrKu-wYU6sYQn7nbcUNw">40.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_d747MmsodEi_ScxU-SSWYw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. &#160;</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0af36445_744c_487f_b5f8_82bf253f0e98"></a><a id="Tc_wGy6MUmb0kabOYHx8gAFCw_1_2"></a><a id="Tc_DN85JqbvQkWV51RWDyXmlQ_2_2"></a><a id="Tc_JwohAEnAkkCb823d2ngU-g_2_5"></a><a id="Tc_203wKpR-jkygp-HSNYvJ3g_2_8"></a><a id="Tc_2P5-YctLf02na6GwVpINDw_3_0"></a><a id="Tc_unipgIXfxUir7lo0QxZx9w_4_0"></a><a id="Tc_4-T45z-8cUKp3CS8AshKBQ_4_2"></a><a id="Tc_uvw3-0Gcx0eirtYYFRm6AQ_4_3"></a><a id="Tc_s7Dhthr70Umhm7jjuqowcw_4_5"></a><a id="Tc_CLT9-G0fBUmc8dEP9ao54Q_4_6"></a><a id="Tc_jjMLo73BNkee1avJujo2Yg_4_8"></a><a id="Tc_7EYjyBb8fUyhHxSIodFlBQ_5_3"></a><a id="Tc_Z3XVDPfZXkWe7GYWljtEig_5_6"></a><a id="Tc_lYcIkuPvIkGCAjEH0ruMbg_6_0"></a><a id="Tc_OfCBCZfa9Ui2yXUVhXgeKw_6_2"></a><a id="Tc_Mvnz9BwdF0-GRWuywEkNSg_6_3"></a><a id="Tc_xZNuggkxD0eQ1zQWgdzizA_6_5"></a><a id="Tc_rfWJ0mBCDUS1Mg9UDxmIsw_6_6"></a><a id="Tc_P0B47yO1B02tgR46tQYJzQ_6_8"></a><a id="Tc_iexUOtaep02-7vrM3rWg7Q_8_2"></a><a id="Tc_5QNlpnaWeUeqUHLZTlfJuQ_9_2"></a><a id="Tc_C8xtefuIJkq9eWBRREqfeA_9_5"></a><a id="Tc_4c09X9Ot602u8N-foM4sZA_9_8"></a><a id="Tc_Ficcf25C0kqos3rfMA_AhA_10_0"></a><a id="Tc_ehYQxgsv5EqqMYyRgBuXvA_11_0"></a><a id="Tc_YR6Ufu2cpk-450JbeefiRA_11_2"></a><a id="Tc_PKe-b6l1k0eY3n9fxWo5Nw_11_3"></a><a id="Tc_rLANPGkjvkSrLh3AsGpPLg_11_5"></a><a id="Tc_LtVwY1g5XEumwrbWu_PIyA_11_6"></a><a id="Tc_lnThd-SrN0GFmNZBH1eofA_11_8"></a><a id="Tc_eznzornNR0K5xf_ml1asPg_12_3"></a><a id="Tc_6P-bJQeTLU2Xx7HOzyFhLw_12_6"></a><a id="Tc_wsN0EE42IEyXAafwUeriLw_13_0"></a><a id="Tc_iFaMwsQ5oEybUxyQvD2Llg_13_2"></a><a id="Tc_n7JlOvmmuka1YBgiksNNFg_13_3"></a><a id="Tc_7HfQtado4Ue2iT1aeBUT-Q_13_5"></a><a id="Tc_qxD6ryVNwUyN81JkqEqALA_13_6"></a><a id="Tc_Kb1xpQnwhE29KmJZSTUIxA_13_8"></a><a id="Tc_MnFT8nhTOk2W8mgWiH50WA_1_2"></a><a id="Tc_jaeLwkwh5UKthvQDLL7YiA_2_2"></a><a id="Tc_bBOuw09Z0EyTmlJCKDmPbw_2_5"></a><a id="Tc_3Pf39IMrwEq8tdUBDCRW3Q_3_0"></a><a id="Tc_wzTdLwhWe0GotBuhBEqhfg_3_2"></a><a id="Tc_w39xP9N9ZUC4VyYgfH2G8g_3_3"></a><a id="Tc_rcdWsPazpEyI8LPRv3PH7g_3_5"></a><a id="Tc_iozAOmIre0CsdXQN93xZmg_4_0"></a><a id="Tc_N6v7gmUuNECY_WxXy8hLKQ_4_6"></a><a id="Tc_YFLHL0m9vUmuuxDmCpo1KQ_5_0"></a><a id="Tc_k3T3cE1RSkaw68q_fw0xXQ_5_6"></a><a id="Tc_IiWcll2By0-IKaqjN_vhpQ_6_0"></a><a id="Tc_r8A4b9O4qkqAPdkU9Ze1lA_7_0"></a><a id="Tc_liffVtlAakangeGz40hxAw_8_0"></a><a id="Tc_3xZn7G3b80SDR_0qlug5Fw_8_3"></a><a id="Tc_vLZsFuwOSUiV7sHtRmU5XQ_9_0"></a><a id="Tc_2Bu_us4i20e2olNK0q8rwg_9_6"></a><a id="Tc_frIKYHp8yUiIyxJU-leydg_10_0"></a><a id="Tc_7pi6fHcTGkWpQzXBwZVTTQ_10_6"></a><a id="Tc_UvjN6K-w2EiDuakMemaQiQ_12_0"></a><a id="Tc_G6csf5bDm0inWy9V95pJIA_12_2"></a><a id="Tc_ZbA72CTXKk2gqNAaDsSLjQ_12_5"></a><a id="Tc_F_ZdbRjRekacy8vnJLP9LQ_1_2"></a><a id="Tc_rAiXEfQnqUiCenf48ZRxIg_2_2"></a><a id="Tc_ESnFUZV5zEWTR4gyyk18AQ_2_6"></a><a id="Tc_j_mEdD2pwEGSjAL0ppFrhA_3_0"></a><a id="Tc_KKNwqyvtf0iZiL32xclJtQ_4_0"></a><a id="Tc_xwMNAuy52kiGfR9sDEbkcA_4_4"></a><a id="Tc_m0zFwd32IkuSiODS1XKktg_4_8"></a><a id="Tc_9GcQCcwR7E20ivfcu5iVdQ_5_0"></a><a id="Tc_KGR2JoQ0F0iBYUQ_UITJUg_5_4"></a><a id="Tc_x66tNozHxEGX_YJIatVJRQ_5_8"></a><a id="Tc_Lk3f0zhsnEOLLOzAwyq0AA_6_0"></a><a id="Tc_Cy_lqOBnJEyF_EDufliVSQ_6_4"></a><a id="Tc_lBroN8SQ_0mhJPkCnp1LDw_6_8"></a><a id="Tc_mD7Nfuor30y0SdvVmTBIAw_7_0"></a><a id="Tc_erWQXf6D10Sz8Te5aOVyaw_7_4"></a><a id="Tc_gCtdOh1QyEyoArFr38tBDQ_7_8"></a><a id="Tc_MrOinQ7uT0GmcMSMFWF6eQ_8_0"></a><a id="Tc_FGLSNDYBxUW54gTFUDC0Ww_8_2"></a><a id="Tc_BcwD6xv3DEq_FOdj10ccUQ_8_6"></a><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_47UxO6W_WEK4K3MZDbu3sA" continuedAt="Tb_47UxO6W_WEK4K3MZDbu3sA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the Company&#8217;s liabilities that are measured at fair value on a recurring basis:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_Bu0QMHd9l0qNTO6JlXoI1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="0" id="Tc_0sASjAaVGkSqx79EHS2uhQ_4_9">29,440,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nriUGTcej0qNzzfpnoD1Jg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="0" id="Tc_7rlrqpsFtUCQrG5Ul0vFyg_5_9">59,099,013</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_upm0xUGrLEmcgrbcGtWsng_6_9">88,539,013</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="0" id="Tc_Wu0buAVZE0S94lQCTKAtVA_11_9">35,551,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_7BYTPZDFbEyyt_JlN9COqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="0" id="Tc_DNJAgG4zPkiXYtzyCnSecA_12_9">6,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_bw7cTbbKBUOdh15EHpSvSQ_13_9">35,557,219</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the warrant liability and the December 2022 Note for the&#160;years ended September&#160;30, 2024 and 2023:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_SwsNiiSa30qEB9_p9D8CjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unsecured Convertible</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Promissory Note</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at October 1, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_jrGO66RARkOJ5xdVUtPWcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_quPodp76xkioI4bMj-za1w_3_6">57,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at issuance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="0" id="Tc_Ix04Vwxdb0SVORpgvXJU6g_4_3">31,820,000</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest converted to common stock</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" sign="-" scale="0" id="Tc_rALQHll9AEOVIXInBg34-g_5_3">25,000</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="0" id="Tc_Qb1LYAcgika9eERaY3r1sQ_6_3">3,756,000</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_2gdPZ9SMLEuQPHawoXcHxQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_t7dkWl_4FkSylyG83zDbRg_6_6">50,919</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2023</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_DIM-yieXZEii39hWIo3zyQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_Mx8_2Ty3FESf03imami8jg_7_3">35,551,000</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_SE9TpsNiB0SZh02vDR962A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_OQdZXtTv6U2rPj9AYiV6jA_7_6">6,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issued in connection with sale of common stock</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="0" id="Tc_1udGIFm4l0W_C-rSzABzAw_8_6">97,730,836</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Promissory note maturity extension fee added to outstanding balance</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw" decimals="0" format="ixt:num-dot-decimal" name="otlk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" scale="0" id="Tc_xboAKg2b-UOpw4RPrBn5Xw_9_3">2,681,847</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal and accrued interest converted to common stock</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" sign="-" scale="0" id="Tc_cJRx9Rp7AE-hpmgq5XLAbg_10_3">11,250,000</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_n00HlfZxbEWQPFKyyKwVxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="0" id="Tc_r6stCpsdp0SzNVOWGscjeg_11_3">2,457,153</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="0" id="Tc_itg81tGgwESyESURGxWQMQ_11_6">38,638,042</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_7Nz6MTqRk06UkjKgAzcXCA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_149Gd-EAEU-0EJaO5P2qqg_12_3">29,440,000</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_Sk5RTQxSUkKzLC9zG8VQXQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="Tc_r4k2nT8qO0Kjb45tLrw04g_12_6">59,099,013</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As further described in Note 7, the Company elected the fair value option to account for the December 2022 Note. The fair value of the December 2022 Note is estimated using a binomial lattice model, which evaluates the payouts under hold, convert or call decisions. Significant estimates in the binomial lattice model include the Company&#8217;s stock price, volatility, risk-free rate of return, and credit-adjusted discount rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair values of the December 2022 Note as of September 30, 2024 and 2023 were estimated using a binomial lattice model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_lP3m7TNM90absnspWDq2Wg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Xsc6whjgVESfBgOVzsMmJA_3_3">0.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qJ_fPZFQk0y4wnAgsqRsTA" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_erbQbaIJFEG6pCLzcH2Qrg_3_7">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_0FNNd0MQSEGbVAxJkUYUBQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_vXZoNR7aRE6llWD3tGsoSg_4_3">91.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7-lVNsEf202TYs18lInWUw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_9mPY43KpH0un4ktH4vKJww_4_7">71.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3IXjRjrvOUmxyOEeUsHZtw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_Wwg2cDaKlEKwa9Ls6jA54w_5_3">4.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kUMWn2QlUkGH1AcNmJxH4A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_pTMUx__310ijonSneED_nA_5_7">5.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_9bYKF4TI30O9lev1VzvfWg" decimals="2" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_ETxeCa1k30CYi0EgH3uZ8Q_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_7lqaz_2bqEqu4ykwZdkCvg" decimals="2" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_XGFx-4KXLkqu071GKVuF3w_6_7">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credit-adjusted discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_tRV5Gx6Jz0y-S8KiNciwMw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_odBrQTxbWkCfgdNjSo6U2Q_7_3">20.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bEUH4cZ0TUOwGFyu8Z-8Ag" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_shniUkW9LkarPSyTGSQBcg_7_7">22.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U7MnAhTIHkej02WiFwj3Lw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_GwH0En33nEK3A7klii2IZQ_8_3">5.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qZPC37xTWUe1Gonx3VN-Hw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_sR6INJhvHkOFAb8G8eKssg_8_7">4.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a56f6bc2_1b32_48ff_acd2_790c724a8c50"></a><a id="Tc_vvABwa_c_kCwrz9SdWzekA_1_2"></a><a id="Tc_zI0ryrI4xkSMB92kC_AGqg_2_2"></a><a id="Tc_ZvYfodf0vka1fMfj-Rzl-w_2_6"></a><a id="Tc_dzpvXQjXLk-5sR5mOXiFBg_3_0"></a><a id="Tc_g2h09zfgyUWsizQKYLKyFA_3_4"></a><a id="Tc_uwGfRlDRFUCn_LtEx_3itg_3_8"></a><a id="Tc_mtPGqzTwREWTRW1aoXH-Hg_4_0"></a><a id="Tc_LQKVt76UMUCZtO_66F-iWQ_5_0"></a><a id="Tc_bd-kjRka_US2C6LTHAufDQ_5_4"></a><a id="Tc_i6A6JvJA1EiMLm040ZRBxA_5_8"></a><a id="Tc_IUyaagHHbEuiyJCH5PhcFA_6_0"></a><a id="Tc_MGGc_M8DkUCGytqkZpGusg_6_4"></a><a id="Tc_hOt5WNkTFUOWkuMPJ8IMlQ_6_8"></a><a id="Tc_lRSYYyeYjke0na8yCKxN6Q_7_0"></a><a id="Tc_lleyP590v0qEKsJwTz0zRw_7_2"></a><a id="Tc_VL6qYPIZKUq15aTOsQPYfQ_7_6"></a><ix:continuation id="Tb_47UxO6W_WEK4K3MZDbu3sA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The warrants related to the Note and Warrant Purchase Agreement dated December 22, 2017 are classified as liabilities as the warrants include cash settlement features at the option of the holders under certain circumstances. The warrants issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 are classified as liabilities as the Company assessed that they are not indexed to the Company&#8217;s own stock and must be classified as liabilities. For further details on the evaluation refer to Note 9. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The above warrant liabilities are revalued each reporting period with the change in fair values recorded in the accompanying consolidated statements of operations until the warrants are exercised or expire. The fair values of the warrant liabilities are estimated using the Black-Scholes option pricing model using the following weighted average assumptions:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_9Yv0uFFQ4Eq0PEB7nRvmzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:22.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3IXjRjrvOUmxyOEeUsHZtw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_sicfwLAEgke9gjdiuKJM2A_3_3">3.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kUMWn2QlUkGH1AcNmJxH4A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_ASWFv4YZ8kWP_xpUEff13Q_3_7">5.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remaining contractual term of warrants (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_zZgEe-bt9Ea5Tl_R5ZMmTw_4_3">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qJ_fPZFQk0y4wnAgsqRsTA" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_O_8UisVKCkWYTz2fPwYbJQ_4_7">1.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_0FNNd0MQSEGbVAxJkUYUBQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_MA0DvRbu_EKqenxbVqBf_Q_5_3">125.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7-lVNsEf202TYs18lInWUw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_ppnFijkmeEC7-bShCY4eQw_5_7">158.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Annual dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_9bYKF4TI30O9lev1VzvfWg" decimals="2" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_6yT-g8blL0qzaXN-juZz-Q_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_7lqaz_2bqEqu4ykwZdkCvg" decimals="2" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_PmWjf0ayG06wlHWBPAkC0A_6_7">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of common stock (per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U7MnAhTIHkej02WiFwj3Lw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_LO330uZ0gkeuTDdePaxPyQ_7_3">5.34</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qZPC37xTWUe1Gonx3VN-Hw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_5D4Nri4rP0CPkv9d1EC8bA_7_7">4.40</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="Tb_TeDYNskLWkS3_a_rs70qQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">5. &#160;&#160;&#160;&#160;&#160;Equity Method Investment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the execution of a stock purchase agreement with Syntone Ventures LLC (&#8220;Syntone Ventures&#8221;), the U.S. based affiliate of Syntone Technologies Group Co. Ltd. (&#8220;Syntone PRC&#8221;) on May 22, 2020, the Company and Syntone PRC entered into a joint venture agreement pursuant to which they agreed to form a People&#8217;s Republic of China (&#8220;PRC&#8221;) joint venture, Beijing Syntone Biopharma Ltd (&#8220;Syntone JV&#8221;), that is <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_5_22_2020_dei_LegalEntityAxis_otlk_PRCJointVentureMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_gJdyvVXshEuX-08Mf6ndHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr__I31htUrDUKGfxF0nmf9fg">80</ix:nonFraction>% owned by Syntone PRC and <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_dFqRCua5mUCQBzlFx5wdtA">20</ix:nonFraction>% owned by the Company. As the Company can exert significant influence over, but does not control, Syntone JV&#8217;s operations through voting rights or representation on Syntone JV&#8217;s board of directors, the Company accounts for this investment using the equity method of accounting. Upon formation of Syntone JV in April 2021, the Company entered into a royalty-free license with Syntone JV for the development, commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company made the initial investment of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_6_1_2020_To_6_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_P56yKUXSbkSeAJyaiAzVzA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" id="Narr_Xofyi92cgEuCV5B-3l5gRw">900,000</ix:nonFraction> in June 2020 and is committed to making capital contributions to Syntone JV of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="0" id="Narr_J6G8j3rfvEGcpfplp5biQA">2,100,000</ix:nonFraction>, based upon the development plan contemplated in the license agreement. The maximum exposure to a loss as a result of the Company&#8217;s involvement in Syntone JV is limited to the initial investment and the future capital contributions totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="0" id="Narr_xL6bHMSSyk2WH1dXcqx4_A">2,100,000</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_O4aYeNQm9U2wcbmvnYNqxA_1_2"></a><a id="Tc_1OqvZEgbB0eF35ytEMSi7A_2_2"></a><a id="Tc_LT-sI6TGNEukiXPq70j5DA_2_5"></a><a id="Tc_Fm9gi-zWTkWXUuhADCcHUw_3_0"></a><a id="Tc_ybljKFqE5kSF5HnNv63I2A_3_2"></a><a id="Tc_BZmkc7w3uU6rR5xnD4N5JA_3_5"></a><a id="Tc_XWPDgeaZekueRTwtnPgXzg_4_0"></a><a id="Tc_LZUOcxwxykabMEbufuvclA_5_0"></a><a id="Tc_RELQXpRsdEqnSXRVOBAqaw_6_0"></a><a id="Tc_vKKZVIfJY0WpoMwCmQ9tSQ_7_2"></a><a id="Tc_u9pYqGgTw0WWJ2BgKMjc7w_7_5"></a><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_1zeXI7nunkemLnsvjbXf1g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">6</span>.&#160;&#160;&#160;&#160;&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses consists of:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_jA3VgMLtuEW1uAEhFeGgXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:middle;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_x5W0xv-XM0KNsA8gb2LUbw_3_3">1,012,962</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_7HAJxnFGmkqJvnx-li3plg_3_6">919,970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_Ft9a20nwPUiV9d1JkQ7agA_4_3">1,798,767</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_KVQ8hs3qiEeflonmThYUzw_4_6">165,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="otlk:AccruedResearchAndDevelopmentExpensesCurrent" scale="0" id="Tc_RF3KqjpfOky7Dy0lZFzv_g_5_3">41,373</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="otlk:AccruedResearchAndDevelopmentExpensesCurrent" scale="0" id="Tc_fBldgqHcPkuzgh0MSoVcLw_5_6">1,234,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_Z-ei7isJHEuEbc257gv-vw_6_3">384,366</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_PV5PAiK0uUGpYlRhllC3pQ_6_6">426,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_JklChQwBqUiBrPV-l2jiRA_7_3">3,237,468</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_rwxWTl-CE0m37e76TiHw1w_7_6">2,745,740</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;"> </b><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_8qUc_lSBG0meP0R7nI7AaQ_1_2"></a><a id="Tc_rbas8VFmUkyM1VjlT7lDpw_2_2"></a><a id="Tc_QVG-Ox_qC0ODIwAaTYzzhQ_2_5"></a><a id="Tc_nCZc7uvjOkWoH2a7mSl-MQ_3_0"></a><a id="Tc_tXM5mGQkakC9jN6ei_fw7A_3_2"></a><a id="Tc_Y_397n4K30a-UvqhJtSCiw_3_5"></a><a id="Tc_W8AprBwTIUeEXdC0tXXRqQ_4_0"></a><a id="Tc_q7_nc3A-pU-v7erMzE99ww_5_0"></a><a id="Tc_7w8SCuawLkuBuqxn_cWs3w_5_2"></a><a id="Tc_QJeMscb-D0qOtq_NaNsTaw_5_3"></a><a id="Tc_ECen_gwRSkKlnsJ5FTyBBg_5_5"></a><a id="Tc_KnjDg3Wx4UqbnTGPGPibgg_5_6"></a><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:DebtDisclosureTextBlock" id="Tb_h9CBDzYiFUOjEH34i7X4LA" continuedAt="Tb_h9CBDzYiFUOjEH34i7X4LA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Debt consists of:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_D7hGoQdRYk2Rhx2sLzc9Dg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:middle;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note (measured at fair value)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Afa1M1WaS0SR2fyB14IoaQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="Tc_G0sSdKACWUGQ_PeS7Z4I1w_3_3">29,440,000</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_SCSz0Z-7s0WGtX-bZHuMVg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="Tc_GQYvJPJjLE-0xssbbUn8Lw_3_6">35,551,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:middle;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansPayableCurrent" scale="0" id="Tc_Jvl1DEFEPkCxUhRnuttzEg_4_3">29,440,000</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansPayableCurrent" scale="0" id="Tc_eSC51lU2jE2StsVJMRS3eQ_4_6">35,551,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:middle;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">December 2022 Note</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On December 22, 2022, the Company entered into a Securities Purchase Agreement and issued the December 2022 Note with a face amount of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ninrKLLlD0a6ZBI-j6EB3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_2cxmf7V8S06UHtzK05y1_w">31,820,000</ix:nonFraction> to Streeterville Capital, LLC (the &#8220;Lender&#8221;), the holder of the Company&#8217;s unsecured promissory note issued in November 2021 (the &#8220;November 2021 Note&#8221;). The December 2022 Note has an original issue discount of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_IIixdt1PWEmEeVdgsm6k4w">1,820,000</ix:nonFraction>. The Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Narr_TrW93v9CuEC8dNR_FOcoTA">18,052,461</ix:nonFraction> upon the closing on December 28, 2022 after deducting the Lender&#8217;s transaction costs in connection with the issuance and a full payment of the remaining outstanding principal and accrued interest on the November 2021 Note. The November 2021 Note was cancelled upon repayment. See below for additional disclosures relating to the November 2021 Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In December 2023, the Company extended the maturity of the December 2022 Note from January 1, 2024 to April 1, 2024. The Company incurred a $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_MHzt-sxje0CSeW0EsqpjLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_aZAqpAOPTEij1W_uNLzG9w">475,000</ix:nonFraction> extension fee. The December 2022 Note bore interest at <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_VI7IUXbs602kl6vuqYnf0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_08vaMNV6s0q1ZDAKbcS3RA">9.5</ix:nonFraction>% per annum through April 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The December 2022 Note contains customary covenants, including a restriction on the Company&#8217;s ability to pledge certain of the Company&#8217;s assets, subject to certain exceptions, without the Lender&#8217;s consent. Beginning on April 1, 2023, the Lender had the right to convert the December 2022 Note at the Conversion Price (as defined below). The principal amount and conversion price of the December 2022 Note were subject to adjustment upon certain triggering events. In addition, the Company had the right to convert all or any portion of the outstanding balance under the December 2022 Note into shares of common stock at the Conversion Price if certain conditions have been met at the time of conversion, including if at any time after the six-month anniversary of the closing date, the daily volume-weighted average price of the common stock on Nasdaq equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="Narr_nDZ5g6kVlEe0NAjFp5VM1Q">50.00</ix:nonFraction> per share (subject to adjustments for stock splits and stock combinations) for a period of <ix:nonFraction unitRef="Unit_Standard_D_HK570P66lU6uxT7voueYkg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="Narr_IE9wrWJtbkCYFb2ljx3BXg">30</ix:nonFraction> consecutive trading days. Payments may be made by the Company (i) in cash, (ii) in shares of common stock, with the number of shares being equal to the portion of the applicable payment amount divided by the Conversion Price (as defined below), or (iii) a combination of cash and shares of common stock. Any payments made by the Company in cash, including prepayments or repayment at maturity, will be subject to an additional fee of <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="otlk:DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" scale="-2" id="Narr_GxzsG5nCVkqHnHGc4cHICA">7.5</ix:nonFraction>%. Upon the occurrence of certain events described in the December 2022 Note, including, among others, the Company&#8217;s failure to pay amounts due and payable under the December 2022 Note, events of insolvency or bankruptcy, failure to observe covenants contained in the Securities Purchase Agreement and the December 2022 Note, breaches of representations and warranties in the Securities Purchase Agreement, and the occurrence of certain transactions without the Lender&#8217;s consent (each such event, a &#8220;Trigger Event&#8221;), the Lender shall have the right, subject to certain exceptions, to increase the balance of the December 2022 Note by <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="otlk:DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" scale="-2" id="Narr_mDP7YtPADUSa_b4UEiy-fA">10</ix:nonFraction>% for a Major Trigger Event (as defined in the December 2022 Note) and <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="otlk:DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" scale="-2" id="Narr_TiE22ZP0jUqThh88FDbp-Q">5</ix:nonFraction>% for a Minor Trigger Event (as defined in the December 2022 Note). If a Trigger Event is not cured within <span style="-sec-ix-hidden:Hidden_nFi_I78LHEio1BmDRkU8nQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) trading days of written notice thereof from the Lender, it will result in an event of default (such event, an &#8220;Event of Default&#8221;). Following an Event of Default, the Lender may accelerate the December 2022 Note such that all amounts thereunder become immediately due and payable, and interest shall accrue at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="otlk:DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" scale="-2" id="Narr_P7Ot9aVEX0Ko2LEJ-akpoA">22</ix:nonFraction>% annually until paid. Prior to April 1, 2024, under the December 2022 Note, &#8220;Conversion Price&#8221; meant, prior to a Major Trigger Event, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ninrKLLlD0a6ZBI-j6EB3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_XQoPdy_gn0m2be-Aqsz-UQ">40.00</ix:nonFraction> per share (subject to adjustment for stock splits and stock combinations), and following a Major Trigger Event, the lesser of (i) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_RQ1gGyRoQE2vajTWGBJEqg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_p68WAEh2MkKPJNrvLCDzWw">40.00</ix:nonFraction> per share (subject to adjustment for stock splits and stock combinations), and (ii) <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_22_2022_To_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_9HupkBCxL0i0_z-wbjRQoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="Narr_FEuJU4xH7EqILmGfwaHzSQ">90</ix:nonFraction>% multiplied by the lowest closing bid price of the Company&#8217;s common stock in the <ix:nonFraction unitRef="Unit_Standard_D_HK570P66lU6uxT7voueYkg" contextRef="Duration_12_22_2022_To_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_9HupkBCxL0i0_z-wbjRQoQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="Narr_4AwL0JZs1EuoM0Uazu_YRQ">three</ix:nonFraction> trading days prior to the date on which the conversion notice is delivered. If the Conversion Price is below $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="otlk:DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" scale="0" id="Narr_ilbS6x2kXkGTkkhJNaz6LQ">3.51</ix:nonFraction> per share, the Company will be required to satisfy a conversion notice from the Lender in cash. Subject to certain exceptions, while the December 2022 Note is outstanding, the Lender will have a consent right on any future variable rate transactions or any debt and a <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="INF" format="ixt:num-dot-decimal" name="otlk:DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" scale="-2" id="Narr_qRfGNZnkAUijU4wt0Jkv7g">10</ix:nonFraction>% participation right in any future debt or equity financings.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_h9CBDzYiFUOjEH34i7X4LA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On January 22, 2024, the Company entered into an amendment to the December 2022 Note (the &#8220;January 2024 Note Amendment&#8221;) with the Lender, which became effective on April 1, 2024 after satisfaction of certain conditions, including various required stockholder approvals and the closing of the private placement on March 18, 2024. The maturity of the December 2022 Note was extended to July 1, 2025. An extension fee of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_EautLaMCKE-dCXo8OpRpjQ">2,681,847</ix:nonFraction> (calculated as <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw" decimals="INF" format="ixt:num-dot-decimal" name="otlk:DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" scale="-2" id="Narr_Baqrf_XcOkKx4k8fdYEoOw">7.5</ix:nonFraction>% of the outstanding balance of the December 2022 Note) was added to the outstanding balance on March 18, 2024. The extension fee was included in interest expense in the consolidated statement of operations for the year ended September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the January 2024 Note Amendment, the initial conversion price with respect to $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Vnv1HvGas0WeOr-RGPMVOw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_4Ymn1fKqGkGRKrkR3zVGSQ">15,000,000</ix:nonFraction> in aggregate principal amount of the December 2022 Note was changed to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Vnv1HvGas0WeOr-RGPMVOw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_D5PRs6baakaa8yF8-TXRaA">7.00</ix:nonFraction>, the price per share in the private placement that closed on March 18, 2024 and the remaining aggregate principal amount has a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ynXa_bg7OkmqRB_LUbXGyQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_T8HhGk6rtEy_UoJcqPkGEg">40.00</ix:nonFraction> per share. Effective April 1, 2024, the December 2022 Note bears interest at the <span style="-sec-ix-hidden:Hidden_-FJYa8lNSUetfvJA523X1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prime rate</span></span> (as published in the Wall Street Journal) plus <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_HEIymDu_nkqjVbdvauJNhw">3</ix:nonFraction>% (subject to a floor of <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_1_22_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_bGKy_9nKJ0yCir38nGdxBA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="Narr_UYwx2F6ntUuLzp4oQ0QG2w">9.5</ix:nonFraction>%) and the Company has an obligation to repay at least $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_z0Wf1cuLukuR71jlKjSUSA">3,000,000</ix:nonFraction> of the outstanding balance of the December 2022 Note for each calendar quarter beginning with the second calendar quarter of 2024 (subject to adjustment for conversions by the Lender and to payment of an exit fee as set forth in the January 2024 Note Amendment) and continuing until the December 2022 Note is repaid in full. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended September 30, 2024, an aggregate of principal and accrued interest totaling $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" id="Narr_IGXTmT7DsUKD4WRXp743Gg">11,250,000</ix:nonFraction> of the December 2022 Note was converted into <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_DafWg9wJgkCk4kBKGZW8xg">1,607,093</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company elected to account for the December 2022 Note at fair value (Note 4) and was not required to bifurcate the conversion option as a derivative and as a result the original issue discount of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_6qP7lToo5ki-9mO8Xmwc1A">1,820,000</ix:nonFraction> and debt issuance costs were written off upon election to fair value and accounted for as interest. During the year ended September 30, 2024, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Narr_pSv_0N9QZk-9eUpJt9P3ug">3,156,847</ix:nonFraction> of interest expense related to extension fees. During the year ended September 30, 2023, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Narr_DNQ2TLtSFUSJgIWYewHQGg">2,074,964</ix:nonFraction> of interest expense related to original issue discount of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_GCbV41JW2Ea3Q1NydJZdhQ">1,820,000</ix:nonFraction> and other third party debt issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="Narr_gNU-G18h00SE_pfhs4LfVw">254,964</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">November 2021 Note</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2021, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Narr_4t1RGiGd_ECAeEVF5UHs0w">10,000,000</ix:nonFraction> in net proceeds from the issuance of the November 2021 Note with a face amount of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_tRxOTTUeTkW37kzoC2c6jg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr__nwwSyKfvkGVzIbuPpkcNA">10,220,000</ix:nonFraction>. Debt issuance costs totaling $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_EWdibXn1kU--gjkAY3Bjxw">820,000</ix:nonFraction> were recorded as debt discount and were deducted from the principal in the accompanying consolidated balance sheets. The debt discount was amortized as a component of interest expense over the term of the underlying debt using the effective interest method. The note bore interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_tRxOTTUeTkW37kzoC2c6jg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_GQ3Y7gyFwk-fAPbTx6HBoA">9.5</ix:nonFraction>% per annum compounding daily and was set to mature on January 1, 2023. The Company could prepay all or a portion of the note at any time by paying <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="Narr_3Zfv25h0sUGkhjzst0WHtQ">105</ix:nonFraction>% of the outstanding balance elected for prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the November 2021 Note was cancelled using proceeds from the December 2022 Note issued to the same lender. The total repayment was $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="0" id="Narr_q3xGDZeKFEqPLbZ9Q1uSSA">11,947,539</ix:nonFraction>, which represented <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="Narr_EJA_QHYZ7U2Xia1ZskbgtA">105</ix:nonFraction>% of the outstanding balance and included $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaid" scale="0" id="Narr_JJAUo7_pTU6o0N_GcPNaqw">1,158,609</ix:nonFraction> of interest expense. The transaction has been accounted for as an extinguishment of the November 2021 Note. As a result, the Company recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="0" id="Narr_XX_nKS4A40-PmkIvHxNZ5A">577,659</ix:nonFraction>, which included $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" id="Narr_lqhaG0DSSUKq26BQVWHBHQ">8,729</ix:nonFraction> of unamortized debt discount, and prepayment fees of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" id="Narr_ShKl5XeOJEWGfJEkaSlilw">568,930</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_sI6h_SoIjUqmJoYH1Yzl-Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" id="Narr_rxpCPVQGoEuaXVfmA3Ev-A">454,866</ix:nonFraction> of interest expense related to the unsecured promissory note, of which $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_sI6h_SoIjUqmJoYH1Yzl-Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" id="Narr_lVaUfCbgb0yFfTm3xr_Ugg">190,775</ix:nonFraction> was related to the amortization of debt discount. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_1BjdEIbM-UWLDCjijJM6XA" continuedAt="Tb_1BjdEIbM-UWLDCjijJM6XA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Selexis Commercial License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In April&#160;2013, the Company entered into commercial license agreements with Selexis for each of the ONS-3010, ONS-1045 and ONS-1050 biosimilar product candidates (which agreements were subsequently amended on May&#160;21, 2014). Under the terms of each commercial license agreement, the Company acquired a non-exclusive worldwide license under the Selexis Technology to use the applicable Selexis expression technology along with the resulting Selexis </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_1BjdEIbM-UWLDCjijJM6XA_cont1" continuedAt="Tb_1BjdEIbM-UWLDCjijJM6XA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">materials/cell lines, each developed under the research license, to manufacture and commercialize licensed and final products, with a limited right to sublicense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company paid an upfront licensing fee to Selexis for each commercial license and also agreed to pay a fixed milestone payment for each licensed product. In addition, the Company is required to pay a low single-digit royalty on a final product-by-final product and country-by-country basis, based on worldwide net sales of such final products by the Company or any of the Company&#8217;s affiliates or sublicensees during the royalty term. The royalty term for each final product in each country is the period commencing from the first commercial sale of the applicable final product in the applicable country and ending on the expiration of the specified patent coverage. At any time during the term, the Company has the right to terminate its royalty payment obligation by providing written notice to Selexis and paying Selexis a royalty termination fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of the Company&#8217;s commercial agreements with Selexis will expire upon the expiration of all applicable Selexis patent rights. Either party may terminate the related agreement in the event of an uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, winding up or similar circumstances. Either party may also terminate the related agreement under designated circumstances if the Selexis Technology infringes third-party intellectual property rights. In addition, the Company has the right to terminate each of the commercial agreements at any time at its convenience; however, with respect to the agreements relating to ONS-3010 and ONS-1045, this right is subject to the licensee&#8217;s consent pursuant to a corresponding letter the Company executed in conjunction with the standby agreement entered into between Selexis and Laboratories Liomont, S.A. de C.V. (&#8220;Liomont&#8221;) in November&#160;2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The standby agreement permits Liomont to assume the license under the applicable commercial agreement for Mexico upon specified triggering events involving the Company&#8217;s bankruptcy, insolvency or similar circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Technology License</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into a technology license agreement with Selexis that will require milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_otlk_SelexisMember_H9U6x4CDa0-Y6bDTtuTUEQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractualObligation" scale="0" id="Narr_X_0sT8gRHEi-P2injdcw-w">332,779</ix:nonFraction> (based on an exchange rate on September&#160;30, 2024 for converting Swiss Francs to U.S. dollars) to the licensor by the Company upon achievement of certain clinical milestones and pay a single digit royalty on net sales by the Company utilizing such technology. The Company also has the contractual right to buy out the royalty payments at a future date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On November 3, 2023, a securities class action lawsuit was filed against the Company and certain of its officers in the United States District Court for the District of New Jersey. The class action complaint alleges violations of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in connection with allegedly false and misleading statements made by the Company related to the Company&#8217;s BLA during the period from August 3, 2021 through August 29, 2023. The complaint alleges, among other things, that the Company violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by failing to disclose that there was an alleged lack of evidence supporting ONS-5010/LYTENAVA as a treatment for wet AMD and that the Company and/or their manufacturing partner had deficient CMC controls for ONS-5010/LYTENAVA, which remained unresolved at the time the Company&#8217;s BLA was re-submitted to the FDA and, as a result, the FDA was unlikely to approve the Company&#8217;s BLA, and that the Company&#8217;s stock price dropped when such information was disclosed. The plaintiffs in the class action complaint seek damages and interest, and an award of reasonable costs, including attorneys&#8217; fees. Defendants&#8217; motion to dismiss is currently pending before the court.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2024, certain of the company&#8217;s officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware. &#160;The derivative complaint alleges that defendants breached their fiduciary duties by causing and/or allowing the Company to violate federal securities laws based on the same alleged misstatements as the securities class action. &#160;The derivative complaint also alleges defendants violated Section 14(a) of the Exchange Act, as well as claims for contribution, unjust enrichment, and waste of corporate assets. &#160;The derivative complaint seeks unspecified damages, corporate governance reforms, restitution, contribution, attorneys&#8217; fees, and other costs.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fd04e829_8f0d_41f3_a1d3_1f80998cbb88"></a><a id="Tc_pM65opqLok2RhzbUiAhXzw_1_2"></a><a id="Tc_6BTX7nYMEEuywL_u-Mij-A_2_2"></a><a id="Tc_t40FxwFI6kyAyzfHlJXi0Q_2_5"></a><a id="Tc_BwHkMatjfEux7xEwy4FQ9A_3_0"></a><a id="Tc_oXj7EplIT0acThBRq8FY_Q_4_0"></a><a id="Tc_RS2eyR2xIkWtVGd_40loQQ_4_2"></a><a id="Tc_AITS1MbSFUytEJ_6YbkrVA_4_5"></a><a id="Tc_N4JyazQNm06M21IFoSxy4w_5_0"></a><a id="Tc_HqN4pyPF20iQPGl3OlR7Nw_6_0"></a><a id="Tc_DRfnpK1mBEqHqOV2bJjEvg_7_0"></a><a id="Tc_qzvTksx0wUiJxlSuJX76CA_7_2"></a><a id="Tc_59R2N-GyikShi3hgSrT5tA_7_5"></a><ix:continuation id="Tb_1BjdEIbM-UWLDCjijJM6XA_cont2" continuedAt="Tb_1BjdEIbM-UWLDCjijJM6XA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pending lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain. The Company could be forced to expend significant resources in the defense of the pending lawsuits and any additional lawsuits, and the Company may not prevail. In addition, the Company may incur substantial legal fees and costs in connection with such lawsuits. The Company currently is not able to estimate the possible cost to it from these matters, as the pending lawsuits are currently at an early stage, and the Company cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that the Company may be required to pay. Such amounts could be material to the Company&#8217;s financial statements if it does not prevail in the defense of the pending lawsuits and any other related lawsuits, or even if it does prevail. The Company has not established any reserve for any potential liability relating to the pending lawsuits and any other related lawsuits. It is possible that the Company could, in the future, incur judgments or enter into settlements of claims for monetary damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Corporate office </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company entered into a <ix:nonNumeric contextRef="As_Of_3_31_2021_Wd5dAA2oOEitqaUmu8NEFg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_gWuGjYkt40ejdp5M4RFUxA">three-year</ix:nonNumeric> term corporate office lease in Iselin, New Jersey that ended on April 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2024, the Company entered into a <ix:nonNumeric contextRef="As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_ekAVabpKiEyveqeP_tfQBQ">five-year</ix:nonNumeric> term corporate office lease for its new corporate headquarters in Iselin, New Jersey that commenced on May 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Equipment leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2024, all equipment leases had expired. The Company had equipment leases with terms between <ix:nonNumeric contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_Q7ljKxKDCE6cUaMIlRBFDw" format="ixt-sec:durmonth" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Narr_IxRVBVEy1U-g0cB1Rj0JxQ">12</ix:nonNumeric> and <ix:nonNumeric contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MaximumMember_jnZ5DzV7xUyhrtJAXYQ3mA" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Narr_Psm92n-OJk2YMwTDuZ5YFg">36 months</ix:nonNumeric> and had recorded those leases as finance leases. The equipment leases bore interest between <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_Q7ljKxKDCE6cUaMIlRBFDw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="Narr_QOkm1v7BS0K-GoamNzJ9bA">4.0</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MaximumMember_jnZ5DzV7xUyhrtJAXYQ3mA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="Narr_UTrWuKpAR0Gni7XwRb7jUA">13.0</ix:nonFraction>% per annum. Payments due under the lease contracts included minimum payments that the Company was obligated to make under the non-cancelable initial terms of the leases as the renewal terms were at the Company&#8217;s option. Lease expense was recorded as research and development or general and administrative based on the use of the leased asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:LeaseCostTableTextBlock" id="Tb_Z0TQqVzX80y-mu63Kv2KlQ" continuedAt="Tb_Z0TQqVzX80y-mu63Kv2KlQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The components of lease cost for the years ended September 30, 2024 and 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:47.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="0" id="Tc_qiHalihVv0iQTtriAzJKrw_4_3">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="0" id="Tc_WhNmQjkMZ0OOqLyresPNxA_4_6">1,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="otlk:FinanceLeaseCost" scale="0" id="Tc_jDBXp7MfGkuOGkD9dMLUFw_5_3">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="otlk:FinanceLeaseCost" scale="0" id="Tc_wCUU7fu1_kS0slhrgF4N-g_5_6">1,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_RWZs5W3xSEWuBMRrjiumpg_6_3">57,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_YtX6bkHGT0azS7ibJmkt_Q_6_6">44,867</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="Tc_nnktmdJQOUi_nmwalV1_nQ_7_3">58,089</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="Tc_NkfhNIcA8EiE4EiRyB3p_Q_7_6">46,266</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_725062c2_8f08_41e2_ba3b_584c11cec8f0"></a><a id="Tc_5ZbQbirgekmqGFdi-uH5Ug_1_2"></a><a id="Tc_-ivVRGzTVEuyXbzpBYuxEg_2_2"></a><a id="Tc_iBISj2qQn0mlOAYDyBNCdw_2_5"></a><a id="Tc_Ew-ARx6kB0WaQlC7gmlEsw_3_0"></a><a id="Tc_816ZtlZyrUmQibMA8Cg0tw_4_0"></a><a id="Tc_7a_f13OO_EyojUK36VAibQ_4_2"></a><a id="Tc_E9Eyjv6QwUe_mOshfDPy8Q_4_5"></a><a id="Tc_TYpvFoWme0Ow8F0QjC3m5A_5_0"></a><a id="Tc_5_InG0PdUk-Qe0JSR3lvCg_5_6"></a><a id="Tc_gwZavmcKzEqeSZpEykQNyA_6_0"></a><a id="Tc_Xs3hD45P8U-NRZwApiuCLw_7_0"></a><a id="Tc_tXeWrBABtkmpLavFnFBhKA_7_2"></a><a id="Tc_YaMFm62iwU2TIxfy1FQsnA_7_3"></a><a id="Tc_8hz8goYKHU25Wzux0KuS_A_7_5"></a><a id="Tc_r9fTsET8EUe591teJFIisA_7_6"></a><a id="Tc_VBiixum3Dkec2nmkGiD74A_8_0"></a><a id="Tc_eCjWpkplXEWOk6w3z7_R_w_8_3"></a><a id="Tc_VhEBPyL6kUGdiXGks-ooGw_9_0"></a><a id="Tc_VEnquGSQl0y3Sej7M6XpkA_10_0"></a><a id="Tc_8BLifbo4_0arbBKIF2_d8A_11_0"></a><a id="Tc_i0j_BOIF1kG2H4T4mniflg_11_3"></a><a id="Tc_oHbSFXwBFEOnTtPeo5JLgQ_12_0"></a><a id="Tc_V1Lrtx7UiEawVnKHqfEoXg_13_0"></a><a id="Tc_tAYlXoqQzEeHEf7nMuwZBw_14_0"></a><a id="Tc_OO7SmMofKECNVWH1Fx02xw_14_3"></a><a id="_61a31d63_e481_4025_999f_3c41b028fa79"></a><a id="Tc_HhUx7P-lCU-vM6b2Nx2z6w_1_2"></a><a id="Tc_9jNDk5sPN0WoEKVyQBnf7Q_2_2"></a><a id="Tc_z7Xq4wg5C0mrpPjcCcG7wg_2_5"></a><a id="Tc_ThHGNjF2AkyD2qTzrYGNpg_3_0"></a><a id="Tc_3ZZMG9RtBkq0-fsMJAVHUA_4_0"></a><a id="Tc_bfyg4TlGgkKNzk4rSCCanQ_4_2"></a><a id="Tc_3qK2wet2_0SdbZ-9slg1wA_4_5"></a><a id="Tc_5RXBq3GVqkithVe8mUJZ7w_5_0"></a><a id="Tc_bU4VtVXMhUmOiWHo1mxMgg_6_0"></a><a id="Tc_5t80tVgyXEmcij4qRHGpWQ_7_0"></a><a id="Tc_3SodDKnwRkOlWN9DCGG3nQ_8_0"></a><a id="Tc_uuXNdR4w3k2oqlK4OlHztA_8_2"></a><a id="Tc_DiQStUP_GkaaDLpLELuSOw_8_5"></a><a id="Tc_YuyL1yLaEEyYzwOD3lYZoQ_8_6"></a><a id="Tc_9QKoe3MzrkG3Sae2KNTPaw_1_5"></a><a id="Tc_1IpLssNdPUqqboqUmqZrew_2_0"></a><a id="Tc_KAaUHjWuR02LVBrSEYHr9Q_2_5"></a><a id="Tc_FzSvUQanW0ePy_Siidg7zA_3_0"></a><a id="Tc_iuLU-GNYgE-KOhSt_4smVw_4_0"></a><a id="Tc_qneo6HBE2U67RJE5OSVQgw_5_0"></a><a id="Tc_3TfzWmVUY02G-XyATnWapw_6_0"></a><a id="Tc_gKpl8EhGlEqDOPRVN5voQg_7_0"></a><a id="Tc_P_PWvbTtP0aT6R4txBaFvg_8_0"></a><a id="Tc_qRDtNMRlZUiuMY1I_F6tDw_9_0"></a><a id="Tc_6yt0wEbhE0-VNMQu_NRGrA_9_5"></a><ix:continuation id="Tb_1BjdEIbM-UWLDCjijJM6XA_cont3"><ix:continuation id="Tb_Z0TQqVzX80y-mu63Kv2KlQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:middle;width:37.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_JexQinfdQEiGq0gmsiz0wQ_4_3">274,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_0LOj6sgAFE6JWgQPYtLOrg_4_6">26,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_b1MC4RfiOE-KDmFeixl3JA_5_3">297,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="Tc_TxQDUjJaz06V_dK4hUmx8Q_8_6">4,267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term (years):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_kFy5RT3eAUiPuRdalIc6tQ_10_3"> 4.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_Myv9H_cNv0amSEWb0xQY5A_10_6"> 0.6</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_C2qDDy5LP0mYWiHcXHdWgQ_11_6"> 0.3</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average discount rate:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_vdyiUe03ZUanOdgnjEY1cQ_13_3">9.9</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_blcq1GGXA0msMvq0WIpGVQ_13_6">7.5</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_COOx1LcaC0OtgIYyBpzzQg_14_6">13.0</ix:nonFraction>%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other information related to leases for the years ended September 30, 2024 and 2023 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:87.9%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease obligations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="0" id="Tc_S9LYdyTF1E6Q9RzVo8eomQ_4_3">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="0" id="Tc_syOJAbPq9EGkW57xKZvweA_4_6">1,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_n1LqRAopuEyj2wr89lsexA_5_3">14,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_zgAKz_l3qEeId38wCaU1cg_5_6">27,675</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" id="Tc_7cF2-R7AXkSb6Zg4dAeHxg_6_3">4,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="0" id="Tc_4NHUMseGh0CR1QDcroso9Q_6_6">11,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets obtained in exchange for lease obligations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="Tc_yFaPYG9GUEOF9iuE8vrjKw_8_3">294,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under noncancelable leases at September&#160;30, 2024 are as follows for the&#160;years ending September&#160;30:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_kXLh-i0RTUWEaqT-WoHL-A" escape="true"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb_N8Szvjj1SUa36DcmJuNT9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating leases</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_R0bfEL3Ot0iLgpfb_jO1cg_2_6">78,091</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_zhr9r25RdkWwv2uNGTD7hg_3_6">79,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="Tc_ET3fV8E1hkStUHSf22g4mQ_4_6">81,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="Tc_fSzo47tYhUaZS_WkYlqtgA_5_6">83,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="Tc_WS9uVjbH40-anBl8lMe5OQ_6_6">49,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_hmpGpoWC8UuiNiIj6FEo2g_7_6">372,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_f95mxds67UeaKJaZRmcXnQ_8_6">75,160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_Lnr8aWrKk0G6lV3UgTXV7g_9_6">297,829</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company maintains a defined contribution 401(k)&#160;plan (the &#8220;Plan&#8221;) in which employees may contribute up to <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_lmPXGKGL2U6QZFBP99Pprw">100</ix:nonFraction>% of their salary and bonus, subject to statutory maximum contribution amounts. The Company matches <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_QVN1LybTfkGecwya9Y5vXA">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_iuJT_S7W2EyPCy0AmDdCOg">3</ix:nonFraction>% of employee contributions. The Company assumes all administrative costs of the Plan. For the&#160;years ended September&#160;30, 2024 and 2023, the expense relating to the matching contribution was $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_NtQp7SZlG0q17Sxs-87DZQ">177,309</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_l05dg9jV8kOH5e0oKVs3Zw">136,914</ix:nonFraction>, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_w5coq2t7mUGH_jQ5zop-_w" continuedAt="Tb_w5coq2t7mUGH_jQ5zop-_w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On March 7, 2024, following receipt of stockholder approval at the Company&#8217;s 2024 annual meeting of stockholders, the number of authorized shares of common stock under the Company&#8217;s Certificate of Incorporation was increased from </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_3_6_2024_pDZUs5e-AkWbZ0eR564CBQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Xvx3G3GzuEq79kAGuWRfPQ">21,250,000</ix:nonFraction></span><span style="font-weight:normal;"> shares to </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_3_7_2024_lLMZhv4wdEyjXYMfzCMdRA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_c2CFq4FjmEubXIYrOV9hKg">60,000,000</ix:nonFraction></span><span style="font-weight:normal;"> shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 18, 2024, in a private placement (the &#8220;Private Placement&#8221;) pursuant to a securities purchase agreement entered in January 2024 with certain institutional and accredited investors, including GMS Ventures and Investments (&#8220;GMS Ventures&#8221;), the Company&#8217;s largest stockholder, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_3_18_2024_To_3_18_2024_T3YCPqRoGE2MDvlAJH7KjQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_WopA9EXk70iNi2MtU2GT2g">8,571,423</ix:nonFraction> shares of common stock and warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_OcV4V5B9J0KDIZdpGVW_bg">12,857,133</ix:nonFraction> shares of common stock at a purchase price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_CLpR9WxER0ymz7VuhpdaGQ">7.00</ix:nonFraction> per share and accompanying warrant to purchase one and <span style="-sec-ix-hidden:Hidden_DkBDMcGwhUOfLjYffyDfaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-half shares of common stock for $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_3_18_2024_To_3_18_2024_T3YCPqRoGE2MDvlAJH7KjQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_utc_NSBm9USUqY7ReoIl2w">55,498,311</ix:nonFraction> in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_3_18_2024_To_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_3Dv-BLq7jECeFMzClAG8Nw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_L54uZgdthE-8jiFMvJrEDw">2,305,714</ix:nonFraction> shares of common stock and warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_tR_1C3dSWUSlzc9QqxzIbQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_T7PzcCsE10CKsHfEIp8C1w">3,458,571</ix:nonFraction> shares of common stock in the Private Placement. The Warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_iFIFdveCWk-Ii1giegZ4Qw">7.70</ix:nonFraction> per share of common stock and will expire on March 18, 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 15, 2024, in a private placement with Syntone pursuant to a securities purchase agreement entered into in January &#160;2024 (the &#8220;Syntone Private Placement&#8221;), the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_4_15_2024_To_4_15_2024_PCVHwACz-E-GaHioJ0Mb4Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nxqnRRhIq0K3zPWDV3T8wQ">714,286</ix:nonFraction> shares of common stock and accompanying warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_4_15_2024_ktUhxMsOBk6ial5Q3nMCKA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_qXJu2oi1YEGSDxYyp-D81g">1,071,429</ix:nonFraction> shares of common stock for $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_4_15_2024_To_4_15_2024_PCVHwACz-E-GaHioJ0Mb4Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_A5VZTRbJW0SZ605Fi0sNfg">4,835,371</ix:nonFraction> in net proceeds on substantially the same terms as those in the Private Placement. The warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_4_15_2024_ktUhxMsOBk6ial5Q3nMCKA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_s5pjUc_MZ0mu5DERhFCxbg">7.70</ix:nonFraction> per share of common stock and will expire on April 15, 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#212529;">The Company evaluated the equity classification for the common stock warrants and considered the conditions as prescribed within ASC 815-40,&#160;</span><i style="color:#212529;font-style:italic;">Derivatives and Hedging, Contracts in an Entity&#8217;s own Equity</i><span style="color:#212529;">&#160;(&#8220;ASC 815-40&#8221;). The Company determined that the warrants did not meet the &#8220;fixed for fixed&#8221; settlement provision set forth in Step 2 of the indexation guidance and as a result they are not indexed to the Company&#8217;s own stock and must be classified as liabilities. The warrants were measured at fair value at issuance and recorded as a liability and will be remeasured to fair value at each subsequent reporting date, with changes in fair value recorded in current earnings. The net proceeds from the Private Placement were allocated first to the warrants at fair value, with the residual amount recorded as common stock at par value. The Company will continue to classify such warrants as liabilities until they are exercised, expire, or are no longer required to be classified as liabilities</span><span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In December 2022, in a registered direct equity offering to certain institutional and accredited investors, including GMS Ventures, the Company issued </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_6SGXL8bLrEG6_8cW5MPZcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_jVCcfBnR3Eu72H6xaecOOQ">1,423,041</ix:nonFraction></span><span style="font-weight:normal;"> shares of common stock at a purchase price per share of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_t3JCYhRKO0qAD5NVNkzh_w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_oUHV2-OIfEmSugXjGsb74w">17.568</ix:nonFraction></span><span style="font-weight:normal;"> for </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_6SGXL8bLrEG6_8cW5MPZcg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_4OSaVURwa0iKb-P7l_xCKw">23,208,679</ix:nonFraction></span><span style="font-weight:normal;"> in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_12_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_tMGVlJe9F0SPML1If6N2Lw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_9mcwaEt8-kymGqxYm01V6A">711,520</ix:nonFraction></span><span style="font-weight:normal;"> shares of common stock in the registered direct equity offering. In connection with the registered direct equity offering, the Company issued to M.S. Howells &amp; Co., the placement agent, warrants to purchase up to an aggregate of </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ZYcBnKUvwEek4lFXQ6H0rQ">25,787</ix:nonFraction></span><span style="font-weight:normal;"> shares of common stock at an exercise price of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_yGTg4fY6l0yUvYmurUvJcw">21.00</ix:nonFraction></span><span style="font-weight:normal;"> per share, which warrants have a </span><ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_C9WpZsk41kSJIrIrhSbGrg"><span style="font-weight:normal;">three-year</span></ix:nonNumeric><span style="font-weight:normal;"> term.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each share of common stock entitles the holder to <ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:CommonStockVotingRights" id="Narr_gKwikTpzyEq0Dk-G-tsTCA">one</ix:nonNumeric> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#8217;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="0" id="Narr_fDIULpkn5UeLrESZnPt4XQ">No</ix:nonFraction> dividends had been declared through September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">H.C. Wainwright &amp; Co. At-the-Market Offering Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 26, 2021, the Company entered into an At-the-Market Offering Agreement with H.C. Wainwright &amp; Co., as sales agent (&#8220;Wainwright&#8221;), (the &#8220;Wainwright ATM Agreement&#8221; or the &#8220;Wainwright ATM Offering&#8221;), under which the Company may issue and sell shares of its common stock from time to time through Wainwright as sales agent. The Company filed a prospectus supplement, dated March 26, 2021, with the Securities and Exchange Commission pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to up to $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_KmQM4eVrbkSrlJCBAuGuLg" decimals="0" format="ixt:num-dot-decimal" name="otlk:AggregateOfferingPriceAuthorized" scale="0" id="Narr_FS53WSW5f0ieufczKtaMVA">40,000,000</ix:nonFraction> from time to time through Wainwright. The Company incurred financing costs of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_Wo2tL6zH10-t08OvobXAMA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_QawwIP1b9UC6NuBd_eY2og">197,654</ix:nonFraction> which were </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e4d8283e_6e53_43b3_967d_715f04f9a997"></a><a id="_f60fcc3d_7493_48c7_95a2_9c5599a03793"></a><a id="Tc_k38ONolvUU6LOmUvOWLp9Q_1_2"></a><a id="Tc_L9SQ6DiutEG9rwfodIIwlQ_2_2"></a><a id="Tc_kUqpkaZaAUalAA-PKKsciQ_3_2"></a><a id="Tc_i49MN6sFtU2tsySuc8TXHA_4_2"></a><a id="Tc_n8Lw4pgvIUazx6VVeUjrHQ_4_4"></a><a id="Tc_U0L5DyUXbEuxRHRTTFixvg_5_0"></a><a id="Tc_HRUr-woaFkCbPfjp0EXu5A_5_2"></a><a id="Tc_6c_rP2eZMEWyivr3x1qI4w_5_4"></a><a id="Tc_DaH1H7-TAEa12zwW8Nkz1g_6_0"></a><a id="Tc_b3OLd80joUirSrdw6u6JLQ_6_1"></a><a id="Tc_ZhHby3U100ClOC3Ql2izhQ_6_4"></a><a id="Tc_-7MYr1365Eel_EqfqXwOqA_7_0"></a><a id="Tc_wuR3udtF60aldoctSs9UBQ_7_4"></a><a id="Tc_x--5YjMHO0CfRFV2ccVMGw_8_0"></a><a id="Tc_2LgOOJHbykes5t5uTMyqbg_8_1"></a><a id="Tc_MUqeTNGU2Uuuz3D7XjCPaw_8_4"></a><a id="Tc_s1P68yYlO061PZ_is8ghAA_9_0"></a><a id="Tc_VZ1p_v7hG02DV8CgTkrtVw_9_1"></a><a id="Tc_KYQmjvq42UeXD0ax7_cbYQ_9_4"></a><a id="Tc_Vaw_XLif4E27vbEQy1tNcw_10_0"></a><a id="Tc_cv0gUriBXEqt_jFBDUfq9w_10_4"></a><a id="Tc_yjCWhvOkME2MNzFw8QNOrg_11_0"></a><a id="Tc_SWeGX2SF9UOCN3AsthO_2w_11_4"></a><a id="Tc_MbFyeVCqpUOgETjVcAj1_w_12_0"></a><a id="Tc_sKYnJjQuTUWqjhCHW37ZYg_12_4"></a><a id="Tc_k4XUelUY5keKk7eCO9tJxg_13_0"></a><a id="Tc_l8JN9h1ZCkG7Oim-qJ5V0A_13_4"></a><a id="Tc_kte_Cf5T10eUS7iOZxYaBA_14_0"></a><a id="Tc_6SV5zfNjX0OZBMmNjyVsYw_14_4"></a><a id="Tc_zdx4_QZQ3kC5fVDt9U1rDQ_15_0"></a><a id="Tc_MAmjxOJ4nkqAM0FxrtycvA_15_1"></a><a id="Tc_c-1Tf-8-60qt6nh9pfzL7Q_15_4"></a><a id="Tc_dWqgvY78qEO2--ltK2gOiw_16_0"></a><a id="Tc_Gmkbj8meC0GvlHwNZ5RhgQ_16_1"></a><a id="Tc_AUsZtfCofk6ZSSsicUcxVQ_16_4"></a><ix:continuation id="Tb_w5coq2t7mUGH_jQ5zop-_w_cont1" continuedAt="Tb_w5coq2t7mUGH_jQ5zop-_w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">capitalized and were being reclassified to additional paid in capital on a pro rata basis when the Company sold common stock under the Wainwright ATM Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Wainwright ATM Offering, the Company paid Wainwright a commission equal to <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_Wo2tL6zH10-t08OvobXAMA" decimals="3" format="ixt:num-dot-decimal" name="otlk:PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" scale="-2" id="Narr_c2X1l5fyhkWbFkqqeOiiHQ">3.0</ix:nonFraction>% of the aggregate gross proceeds of any sales of common stock under the Wainwright ATM Agreement. The Company terminated the Wainwright ATM Agreement effective May 15, 2023. As a result, the Company wrote off unamortized deferred costs under the Wainwright ATM Agreement. During the year ended September 30, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_AzYfGm-DQUeiUzR3Ala9dg">44,769</ix:nonFraction> shares of common stock under the Wainwright ATM Offering and generated $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_fvKWlKfb6k-lHz4vVstHQg">1,089,105</ix:nonFraction> in net proceeds after paying fees to Wainwright of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_yvP2Xkcc10eKM8A_9zUDhw">38,799</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTIG, LLC At-the-Market Offering Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On May 16, 2023, the Company entered into an At-the-Market Sales Agreement with BTIG, LLC (&#8220;BTIG&#8221;), as sales agent (the &#8220;BTIG ATM Agreement&#8221; or the &#8220;BTIG ATM Offering&#8221;), under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_A1DDuw-oSUK__0BNs8JxRw" decimals="0" format="ixt:num-dot-decimal" name="otlk:AggregateOfferingPriceAuthorized" scale="0" id="Narr_T13G7iEQYkiAnrQaKJsNrA">100,000,000</ix:nonFraction> from time to time through BTIG. The Company incurred financing costs of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_ecX5SQhuQUOy_xktLgPaqg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_fcp7HqvOl0G-4yflqfwxtw">353,688</ix:nonFraction>, which were capitalized and are being reclassified to additional paid in capital on a pro rata basis when the Company sells common stock under the BTIG ATM Offering. As of September 30, 2024, $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_iTKqGJl7VU6tkLMN2O_qZA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCosts" scale="0" id="Narr_RCWMK2U7Sk2Pj_eoco0LQg">331,512</ix:nonFraction> of such deferred costs are included in other assets on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the BTIG ATM Agreement, the Company pays BTIG a commission equal to <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_ecX5SQhuQUOy_xktLgPaqg" decimals="3" format="ixt:num-dot-decimal" name="otlk:PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" scale="-2" id="Narr_n9dqHjCP2UWyC-4hNnZpRQ">3.0</ix:nonFraction>% of the aggregate gross proceeds of any sales of common stock under the BTIG ATM Agreement. The offering of common stock pursuant to the BTIG ATM Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the BTIG ATM Agreement or (ii) termination of the BTIG ATM Agreement in accordance with its terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended September 30, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_9gDHf8RsIEKIozNakQyBHA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_WLhaXY_Gdkmrh8i45ODJHA">no</ix:nonFraction> shares of common stock were sold under the BTIG ATM Offering. During the year ended September 30, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_E5JR6dFzSkSs2N2mels11g">178,911</ix:nonFraction> shares of common stock under the BTIG ATM Offering and generated $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_KyEp-fSCbEGUWe9dAU5rBQ">6,080,088</ix:nonFraction> in net proceeds after paying fees to BTIG and other issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_4sMoVEWeTESuQ9EDRpJCKg">188,044</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common stock warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September&#160;30, 2024, the Company had the following warrants outstanding to acquire shares of its common stock:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_9_Sf7UephkmaZbBXC-cbvw" continuedAt="Tb_9_Sf7UephkmaZbBXC-cbvw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">issuable upon</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 22, 2024</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_5wnuAFtnzkWYbs_N6ZIXsQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_s12FDT5KyEW3z3oPBBuoaw_6_2">13,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_5wnuAFtnzkWYbs_N6ZIXsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_j8Qwy8yI1USniUlwiODU7A_6_5">240.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 24, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_VvsudmHpd0ulTJVNbJMjYQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_ilMQp46UjEiGwQl_Vs5tJw_7_2">8,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_VvsudmHpd0ulTJVNbJMjYQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_KkTwEjTQQk2-s_qnMRJa2g_7_5">25.40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 13, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirteenAprilTwoThousandTwentyFiveMember_UmZHRjMnC0qFpaKeOWRUqw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_4LMCrR1dGU6xINi9zOcP1Q_8_2">7,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirteenAprilTwoThousandTwentyFiveMember_UmZHRjMnC0qFpaKeOWRUqw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_2GDx7S_efECbQvMKMcp5dw_8_5">240.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 31, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_7YfxW7oNqECNDRvtIT0roQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_nW2fKW3xzEyYNS4LGP6Htw_9_2">3,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_7YfxW7oNqECNDRvtIT0roQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_razAAv8q4UWwxIyQrs-6rg_9_5">240.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 22, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentySecondJuneTwoThousandTwentyFiveMember_ZSTbnrDNxUGsk02iJzVFvA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_VxkagzBAKkygkZLD6n6Srg_10_2">9,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentySecondJuneTwoThousandTwentyFiveMember_ZSTbnrDNxUGsk02iJzVFvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_QoZ8SCJ5tUe5fGG30ys8fA_10_5">30.38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 28, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_tHeUnkmGn0e6bXwpNgxn8w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_BjzXLw-Yg0eE7qKpqHNCqA_11_2">25,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_tHeUnkmGn0e6bXwpNgxn8w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_EpydL18cwkSkU0Y0XyQ7iQ_11_5">21.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 28, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_z4Qp_byL30eF_-1LyvR3aQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_4TZSXeaJxU-tLVOqU_4a2g_12_2">12,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_z4Qp_byL30eF_-1LyvR3aQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_gOevLIV3aEatVvJMYsKxtQ_12_5">25.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 2, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_WarrantExpirationDateFebruary22026Member_zdlkKXee3EeGESp4jsin-Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_yRHpddohgEeBCoe-8wJJPA_13_2">93,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_WarrantExpirationDateFebruary22026Member_zdlkKXee3EeGESp4jsin-Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_AiK0TlKDMkKuIjlAlmlfjQ_13_5">25.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 23, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyThirdNovemberTwoThousandTwentySixMember_EB2rl2TAN0CnXGRhH5XKvQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_Yasj6GVOE0-9QJQAe8Xzvg_14_2">104,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyThirdNovemberTwoThousandTwentySixMember_EB2rl2TAN0CnXGRhH5XKvQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_Q4YHl593RkuT5SISDzT8fA_14_5">31.25</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2029</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_EighteenMarchTwoThousandTwentyNineMember_0ANP-WX04kCa7auIEgQwfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_L2CtAwjmfUW0Nwx0R9sa6Q_15_2">12,857,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_EighteenMarchTwoThousandTwentyNineMember_0ANP-WX04kCa7auIEgQwfQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_oz7gISmqx0yCE1JoZWwfcQ_15_5">7.70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 15, 2029</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_FifteenthAprilTwoThousandTwentyNineMember_laMN9AKa2kC-sX-fpIwEWw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_w7606cjiKEOja-KV2qwEIQ_16_2">1,071,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_FifteenthAprilTwoThousandTwentyNineMember_laMN9AKa2kC-sX-fpIwEWw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_plYVGIloOEO2XIsPC6G_Tg_16_5">7.70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_j0eXJBSBM06qGYoCr_kw7Q_17_2">14,207,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The warrants were issued in connection with the convertible senior secured notes originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017 and are classified as liabilities on the accompanying consolidated balance sheets, as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_w5coq2t7mUGH_jQ5zop-_w_cont2"><ix:continuation id="Tb_9_Sf7UephkmaZbBXC-cbvw_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The warrants were issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 and are exercisable only for cash, except in limited circumstances, at any time after the date of issuance. The Company evaluated the warrants under ASC 815-40 guidance and determined that the warrants did not meet Step 2 of the indexation. As a result they are not indexed to the Company&#8217;s own stock and must be classified as liabilities. Refer to the disclosure above under the header &#8220;&#8212;Common stock&#8221; for further details.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;">A holder of warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than a specified percentage of the outstanding common stock (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="4" format="ixt:num-dot-decimal" name="otlk:BeneficialOwnershipOneForHolderToNotExerciseWarrant" scale="-2" id="Narr_Af6dCgWpPUuI9hMBVTrPdA">4.99</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="4" format="ixt:num-dot-decimal" name="otlk:BeneficialOwnershipTwoForHolderToNotExerciseWarrant" scale="-2" id="Narr_TcWo3YEKwkOLqkjV4rH_yg">9.99</ix:nonFraction>% or <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="4" format="ixt:num-dot-decimal" name="otlk:BeneficialOwnershipThreeForHolderToNotExerciseWarrant" scale="-2" id="Narr_AdIhFon2H0KFs1WSwtALIQ">19.99</ix:nonFraction>%, as applicable), immediately after giving effect to such exercise, which may be increased or decreased at the holders&#8217; option (not to exceed <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="4" format="ixt:num-dot-decimal" name="otlk:BeneficialOwnershipThreeForHolderToNotExerciseWarrant" scale="-2" id="Narr_-u5JZ-dLbkyp99VaKAjQ_g">19.99</ix:nonFraction>%), effective 61 days after written notice to the Company. In addition, the Company may require the holders to cash exercise the warrants under certain circumstances as follows: (i) if the daily volume weighted average price (the &#8220;VWAP&#8221;) of the common stock equals or exceeds $20.00 per share (subject to adjustment in the event of stock splits, combinations or similar events, such as the reverse stock split implemented prior to closing) for 30 consecutive days (the &#8220;Stock Price Condition&#8221;) at any time after the Company publicly announces topline data from its NORSE EIGHT clinical trial evidencing satisfaction of the trial&#8217;s primary endpoints (the &#8220;NORSE EIGHT Announcement&#8221;), upon the consent of a majority of the members of the Company&#8217;s board of directors, the Company may require the holders to exercise up to <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="4" format="ixt:num-dot-decimal" name="otlk:PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" scale="-2" id="Narr_-uyCpU-7Tkmc8ZKTJ4qUaQ">20</ix:nonFraction>% of the aggregate number of warrants issued to such holder on the issue date; and (ii) the Company may require up to the remainder of the warrants be exercised (A) if the Stock Price Condition is satisfied at any time after the Company publicly announces approval from the FDA of its BLA for ONS-5010/LYTENAVA, upon the consent of a majority of the members of the board of directors or (B) if the Stock Price Condition is satisfied at any time after the NORSE EIGHT Announcement, upon the unanimous consent of the members of the Company&#8217;s Board of Directors present at a duly called meeting.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:PreferredStockTextBlock" id="Tb_0TrG-4B-mESfJ7zTxjDrdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 13, 2024, the Company filed a Certificate of Elimination to its Certificate of Incorporation, as then amended, with the Secretary of State of the State of Delaware to eliminate from the Certificate of Incorporation all matters set forth in the Certificates of Designation filed with the Secretary of State of the State of Delaware on September 8, 2017 (with respect to its Series A Convertible Preferred Stock and the Series B Convertible Preferred Stock) and July 18, 2018, as amended on March 19, 2020 (with respect to its Series A-1 Convertible Preferred Stock) and returning each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series A-1 Convertible Preferred Stock to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series. There were <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_5_13_2024_CMktv_oZdUe5aaSem6VwXg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_0gX0VFb1xka4lmJ1YTW2BQ">no</ix:nonFraction> outstanding shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock or Series A-1 Convertible Preferred Stock as of May 13, 2024. Immediately following the filing of the Certificate of Elimination, the Company filed a Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, which restates and integrates but does not further amend the Company&#8217;s Certificate of Incorporation, as then amended. The number of authorized shares of preferred stock under the Company&#8217;s Certificate of Incorporation is <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_sjbcPMMhoE-F-CimOjVRhQ">10,000,000</ix:nonFraction> shares.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_mK4dgQoBEkami-BAxemitA" continuedAt="Tb_mK4dgQoBEkami-BAxemitA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2011 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2011 Equity Compensation Plan (the &#8220;2011 Plan&#8221;) provided for the Company to sell or issue restricted common stock, restricted stock units (&#8220;RSUs&#8221;), performance-based awards (&#8220;PSUs&#8221;), cash-based awards or to grant stock options for the purchase of common stock to officers, employees, consultants and directors of the Company. The 2011 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board. As of September 30, 2024, there were no equity awards outstanding under the 2011 Plan. In light of the December&#160;2015 adoption of the 2015 Equity Incentive Plan, (the &#8220;2015 Plan&#8221;) no future awards under the 2011 Plan will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2024 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December&#160;2015, the Company adopted the 2015 Plan. The 2015 Plan provided for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1e786964_0034_4e06_b262_36474caae035"></a><a id="Tc_3XNfKusxlkOaEGgOWx-kHw_1_2"></a><a id="Tc_iEvy8npoXE2nsZQFX3arPw_2_2"></a><a id="Tc_tO3uTacorEC3AdHDt5BJdQ_2_5"></a><a id="Tc_5DGQy3s9IU6nZlERBUWN9Q_3_0"></a><a id="Tc_1UC7WpKZTUeeZ7upp45mYw_3_2"></a><a id="Tc_-EmzcAH3xkuH_0nC_1rifA_3_5"></a><a id="Tc_p9weTTCahESHoUvh3HocCA_4_0"></a><a id="Tc_iDmNemXALUq3CnniK_WbMQ_5_2"></a><a id="Tc_0YiOQeE1NEm4OSqJ0yFTgw_5_5"></a><a id="Tc_jxIbq1PE6EmF0ptfcJpvkA_1_7"></a><a id="Tc_QWfdTexDB0eklFXiTDDYCQ_2_7"></a><a id="Tc_p5vnsJKgR0WOBrh8ZsKgNQ_3_4"></a><a id="Tc_7Pky2uJrpU6-he7pm0q_nQ_3_7"></a><a id="Tc__VQub1KjUUGuMu3sxn56pg_4_2"></a><a id="Tc_R5b1iZfYlUa6qDhEhZXIEQ_4_4"></a><a id="Tc_AhDta8t-J0eccD5UsQeKcQ_4_7"></a><a id="Tc_KUsiJ6KFakWLs9uaLGwvLA_4_9"></a><a id="Tc_D6z_CXOtcEGD9bA3s_Yt4A_5_2"></a><a id="Tc_FVgxBgCruUGkdgYnBS-Fpg_5_4"></a><a id="Tc_KIsniwZvLkyKq9se30y2DQ_5_7"></a><a id="Tc_MVfGo-smR0SUsBnKyzvdAQ_5_9"></a><a id="Tc_ugGbcP21LUi_kIgzuB7qCA_6_0"></a><a id="Tc_to3sm6IVB0qgOdmBsXZGVA_6_4"></a><a id="Tc_hIrHPRUauUCUS87JDJMRlw_7_0"></a><a id="Tc_DlzqitL2rU-5kFdtk0ts9w_8_0"></a><a id="Tc_MV3_JMNQFEexX5fNtHS9ow_9_0"></a><a id="Tc_HBoedrHVQE-rmO1BVqKX7A_10_0"></a><a id="Tc_DBAoKfUXCEykhC40Hpt-Sw_10_4"></a><a id="Tc_2eDRgtKFqEmjH78eHZf9eA_10_9"></a><a id="Tc_iRIjG7ZxGUKPCknuKgmo0g_11_0"></a><a id="Tc_h9cjaaedpE293t0OvzGS1A_11_4"></a><a id="Tc_8EqpBsy2WEyCeFoHpCSOSg_11_9"></a><ix:continuation id="Tb_mK4dgQoBEkami-BAxemitA_cont1" continuedAt="Tb_mK4dgQoBEkami-BAxemitA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">compensation to Company employees, directors and consultants. In August 2024, the Company&#8217;s stockholders approved the amendment and restatement of the 2015 Plan and, in connection with amending and restating the 2015 Plan, the name of the 2015 Plan was updated to the Outlook Therapeutics, Inc. 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;). The 2024 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity compensation to Company employees, directors and consultants. The aggregate number of shares of common stock authorized for issuance pursuant to the Company&#8217;s 2024 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_8_31_2024_Z5sSwB3u8UeB-gHP0Yk07Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_L9ekvSpDgkyYntLcTMvjXw">7,293,901</ix:nonFraction>. As of September 30, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_4HO4o6Fu4EGVt7Rau9w1sg">4,680,755</ix:nonFraction> shares remained available for grant under the 2024 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Stock options and RSUs granted under the Company's 2024 Plan generally vest over a period of <span style="-sec-ix-hidden:Hidden_bxPvBnUfBkO5HfmvqqI1rg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MaximumMember_HtgYYVJwm0iJl8VrJguejw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Rg2pWsQ7UE6UxOrPLujbuQ">four years</ix:nonNumeric> from the date of grant and, in the case of stock options, have a term of <ix:nonNumeric contextRef="Duration_8_1_2024_To_8_31_2024_Xa-tuAfcY0uN_xgNYumOzA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_ed3yyXgILkOWqqYeGD5prQ">10 years</ix:nonNumeric>. The Company recognizes the grant date fair value of each option and share of RSU over its vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the years ended September 30, 2024 and 2023:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_9UnFvFbYukyj3tDxG0lPUw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:46.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.12%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rYTA6Gi8qkKqslIZHJezrg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_kB6oOsQ5wUCte4S3LULOPg_3_3">800,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jYVe9FMFeUqI7idUL2hGsQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_CJvKwgkOGUGfh3pfwI3xZw_3_6">986,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OOq4Je4wC0aStmP-fhnlkw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_1160IBX6bESWRzHjoeuqWA_4_3">4,584,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3_uEMNY46EulPN5v_asqtw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_GFIcbu5pxEqOWT-WCy5fIw_4_6">4,560,421</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_d_UI10dn2E-HWXolhClVYg_5_3">5,385,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_Rm48gu_MS0utEPDSGDIurQ_5_6">5,547,019</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Stock options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes all of the Company&#8217;s stock option activity for the&#160;years ended September&#160;30, 2024:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_eYOR7h830EeDSPaCBWN-cQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Eds8gmT6BESQIrdG8MwAiQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_OWPiDge0A0GfsLHtgFI1sw_6_2">1,197,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Eds8gmT6BESQIrdG8MwAiQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Q7RB74ePlkurtiK5fJqTrQ_6_5">28.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_RGW452GvekWJs2wWjEeN1g_7_2">817,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_YRaIVnnc00KKV68lgajFWA_7_5">6.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_3D3HShkMDEOtehuE2XqHWA_8_2">59,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ug13uxfMCkmF0avuaQdlIg_8_5">26.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_j55qaOi7e0GkjGnGqjP9OA_9_2">9,645</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7G9jWjU7dEy8LoP2aIeUEQ_9_5">34.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_0GBGSdyVM0CutjNMEV2p_A_10_2">1,946,646</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_YYBbRajJCUKgFFeK16iq_Q_10_5">19.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_6oAjZgj8RU-p66ekNP0j9A_10_7"> 7.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_-g-wYqjNwkKrEhNMz4qq-A_10_10">53,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_NEI23IPLVUSCpD2NgoLB9Q_11_2">1,006,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_pZkpfNfkZUacmsYRNZeG7g_11_5">26.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_wyOg2mYoP0Wp4r1mcbjLMQ_11_7"> 6.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" id="Tc_3T_QqIw4u06y5NTZYP36Tw_11_10">53,985</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value represents the total amount by which the fair market value of the common stock subject to options exceeds the exercise price of the related options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model, wherein expected volatility is based on a weighted average of the Company&#8217;s historical volatility and the volatilities of similar entities within the Company&#8217;s industry which are commensurate with the expected term assumption. The expected term calculation is based on the &#8220;simplified&#8221; method described in Staff Accounting Bulletin (&#8220;SAB&#8221;) No.&#160;107, <i style="font-style:italic;">Share-Based Payment</i>, and SAB No.&#160;110, <i style="font-style:italic;">Share-Based Payment</i>, since the simplified method provides a reasonable estimate in comparison to actual experience. The risk-free interest rate is based on the U.S. Treasury yield at the date of grant for an instrument with a maturity that is commensurate with the expected term of the stock options. The dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_5rwPqNp1GEWO9fYcAtnr1Q">zero</ix:nonFraction> since the Company has never paid cash dividends on its common stock and has no present intention to pay cash dividends. Options granted under the 2024 Plan generally vest over <span style="-sec-ix-hidden:Hidden_aurQEKRsiUKUgtUDwMQVZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_urH4VPBGPEWtUdqeC7Beig" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_widPNIyONkOGT3ve6_VZyQ">four years</ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_b20xk0-ndEiwyo36kVe2Kw">10 years</ix:nonNumeric>.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e6374f2e_106c_4db2_9b5b_6116aae9a0e0"></a><a id="Tc_PQClM_U7gUKf9Dw97_rxdw_1_2"></a><a id="Tc_0C9FQyOYekWBNyCLwvuGBw_2_2"></a><a id="Tc_uVB-yBSPDkeD1Jq8nhHzMQ_2_4"></a><a id="Tc_5jnm5RbouUGHHIdVsY6meg_3_0"></a><a id="Tc_YvlFkAAfR0yc08R0Xq8piQ_3_3"></a><a id="Tc_whGRkl0DdkG5v4xaz7K5NA_3_5"></a><a id="Tc_cjMW4Gk9QkikqpBWH4YiGA_4_0"></a><a id="Tc_Sj6Q2yHgF0yp-NMrCa-vAw_5_0"></a><a id="Tc_nPRb7_Rdok2wMadxCc3Eog_5_3"></a><a id="Tc_v1t_iDAdx0yWy_gobFfUwA_5_5"></a><a id="Tc_LkrJkUDvOEydjkwLnaBJgw_6_0"></a><a id="Tc_Ziqe8D99c0uHFDfQaXfiRA_6_2"></a><a id="Tc_YYwIvOi96Ea2o7626PvqSw_6_4"></a><a id="Tc_51uVOz-nKEi_nhKEB45V8g_1_7"></a><a id="Tc_RHTlZETktUCtGbAWqXiVHg_2_7"></a><a id="Tc_c-g1qNP9rkelS16xE-VbgQ_3_4"></a><a id="Tc_K0Gwgtfa5kGwU9K9bcml-g_3_7"></a><a id="Tc_Ks8URYWLsUKn-QW0C0Nk9g_4_2"></a><a id="Tc_arXAvCAZBEGajcpE0AyCMg_4_4"></a><a id="Tc_CsSob8uSPEelt6kH2oPEIA_4_7"></a><a id="Tc_vmdWXOQwTkK_Xx7fiRki1w_4_9"></a><a id="Tc_wjbaU93xrUGIrZIXxsG3gA_5_2"></a><a id="Tc_fTL0ch2gyU2Rafsmbudqqw_5_4"></a><a id="Tc_mtatvqn2P0KKrQldZNCsYA_5_7"></a><a id="Tc_Upisf5nkDEClTbV6ioBb3w_5_9"></a><a id="Tc_BLL0-9CuLkGBAsTK4IqZLA_6_0"></a><a id="Tc_fKBzdiiaVUStw1HP_5pCJw_6_4"></a><a id="Tc_Zogh4gFfQUacToADzfcGwQ_7_0"></a><a id="Tc_dRa6Gt3-U06S6EoF_OjfMg_8_0"></a><a id="Tc_5qqfcmjvCkGnTomNIKojeA_9_0"></a><a id="Tc_gm4NsgBq2k-e5Z9nSmydrg_9_4"></a><a id="Tc_3AfbUfFebkeidEj6u7KcrQ_9_9"></a><a id="Tc_SQn66XjYekWH3mRLzrcbRw_9_10"></a><a id="Tc_uF7j9xpCAUWtkkg6Lk8aBA_10_0"></a><a id="Tc_hsHsh9HdB0i2JQiDaWkaUw_10_4"></a><a id="Tc_9qoSYnOy6kuLnu67PIAgFA_10_9"></a><a id="Tc_qnvkxnMO70yusIAk4wPsng_10_10"></a><a id="Tc_aBNWTz6lS0qfOuzNAsf-7w_1_2"></a><a id="Tc_Kud2E_6IPEeV8xDaBtrP3A_2_2"></a><a id="Tc_snZTgn3mpUejBr_CgjMzPw_2_4"></a><a id="Tc_9EYkNo2sR0mdr7vGJB9FSQ_3_0"></a><a id="Tc_08ZkqHdgo0OW-tU7lYKwfg_3_3"></a><a id="Tc_W_kJI6v_8kS5PNZ11BoqtQ_3_5"></a><a id="Tc_KEkE_2PTk0GIfUVS1yCuuA_4_0"></a><a id="Tc_3Fn8lJxNOEKyzvtLy2mTdA_5_0"></a><a id="Tc_5_C_lksGRE-6RuL1n7QqOQ_5_3"></a><a id="Tc_EGI_k0ZBKEe3JqDx83jGhA_5_5"></a><a id="Tc_u4CLW9jBuEWhicpNLBKR1A_6_0"></a><a id="Tc_gdb31lOQkUiUjiXzrULcjQ_6_2"></a><a id="Tc_32OxWDVpHEeT-wanqpD7-Q_6_4"></a><ix:continuation id="Tb_mK4dgQoBEkami-BAxemitA_cont2" continuedAt="Tb_mK4dgQoBEkami-BAxemitA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The weighted average grant date fair value of the options awarded to employees and directors for the&#160;years ended September&#160;30, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_q8eLQBW9a0icy4p9E3z9Zw">6.04</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_7uHsGXGVpk-TQ4T9LalHtw">19.40</ix:nonFraction> per option, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_4EcWMQ8wek-8G2DzhPtNjw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_ZnAk24c3CEqaM1Kw3trNmA_3_2">4.3</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_OF_8NUU1tUK0ns1auQHtdw_3_4">3.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_ex-cmMJ9c0Gm6cS2k52MuQ_4_2"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_riB_UWgkE0C4pxMPFTHo9g_4_4"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_rHqF-CUoTkaUschULIs3Tw_5_2">131.4</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_dSrSeIcdeUm4eL8Lh4Eihg_5_4">111.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024, there was $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_HacWQURGQEuXX1oC-6EP-A">7,508,106</ix:nonFraction> of unrecognized compensation expense that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_irvpxI6zDU6IC7aoVO9HKQ">1.3</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Performance-based stock options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company granted certain officers of the Company option awards where vesting was contingent upon meeting certain company-wide performance goals. The performance stock options were granted &#8220;at-the-money&#8221; and have a term of <ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_el-qtTKfE0K2pK5bBnG9fQ">10 years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of each option grant under the performance share option plan was estimated on the date of grant using the same option valuation model used for non-statutory options above. Compensation expense for performance-based stock options is only recognized when management determines it is probable that the awards will vest. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The following table summarizes all of the Company&#8217;s performance-based stock option activity for the years ended September 30, 2024.</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_qeY_CQ-p3Ey2Mf84i2bYxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_pJJcoDJ6gU6lV4j5MOa6zA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_GaQfIpZVK0y28HwOYz5QnQ_6_2">35,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_pJJcoDJ6gU6lV4j5MOa6zA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_LcCWCVMWTUK2mMG9pegoKw_6_5">28.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_beTBNn91g02MpRcKc-0oZQ_7_2">634,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_d-ti5wq22kqfUsw1oAdXgQ_7_5">6.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_gJhpRp05lECNS4m2k-8bEQ_8_2">2,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_dPWMMEss80GWexPnjM55dw_8_5">6.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_T_3gWRVQFke2_vNg3whqEw_9_2">666,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_oe87xDv9wEq6o533d8uc0Q_9_5">7.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_JNo5kCZU0Eu-sA-R8j4Ijw_9_7"> 9.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_IVXlhgcMcU6PDbJ0vnbSkw_10_2">35,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_WRloIBxrD0y-222U7BhrVw_10_5">28.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_8GMVtJD8UkaR0EZ0_5fLiA_10_7"> 6.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The weighted average grant date fair value of the performance stock options awarded for the years ended September 30, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_OIFD_-8aYkm7YoUKqinhsQ">6.52</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_wZlXakRD2UGgtlbtxJnb5Q">18.20</ix:nonFraction> per option, respectively. During the year ended September 30, 2024, <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_0Fmy9LwzYk6ETEyEqDYRSA">no</ix:nonFraction> expense was recognized because the performance conditions were not considered probable of achievement. As of September 30, 2024, the Company assessed that the performance conditions related to the performance options granted were not probable of achievement. The assessment was based on the relevant facts and circumstances and therefore no compensation costs were recognized. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_e26ii-rdQ0KyDR26MwZKwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_PJuJj6_mYEOJ17R7IxjTYQ_3_2">4.3</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_cPNQrYgn3kGNOAGuz-qLfw_3_4">3.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_U_D6VM0V40iIFD2ao_YpgA_4_2"> 10.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_8n7D2uRcvkmu14M3x59WGQ_4_4"> 10.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_Q7vkEjE2nEiiiqnG1aP4Hw_5_2">125.6</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ayc6YCFlnE6BepaBoBNZhQ_5_4">91.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6d2772d1_7732_49a7_974c_0399bae635ff"></a><a id="Tc_uKQHqDM5nUmBe3OP8BeXcw_1_7"></a><a id="Tc_iXSmD3oNcU6HSsbCGkY0Tw_2_7"></a><a id="Tc_KBVkOiJyHUaBIDAKe1AO4A_3_2"></a><a id="Tc_3rXc3eOKTkuwEuhDIYvs9w_3_4"></a><a id="Tc_ednggm37_0SaLwDz74DOhw_3_7"></a><a id="Tc_OT_pg8fgmkmGFiv5vICCyA_4_2"></a><a id="Tc_wn97pwzqYUSuz0_T5Fz3vg_4_4"></a><a id="Tc_SFhyO4-EwkaCcXy1vqGv3w_4_7"></a><a id="Tc_WteGTZi-Q0yJETircv3zKg_4_9"></a><a id="Tc_X5OHtYlFlEqLMHiTS_8-Jg_5_2"></a><a id="Tc_Nvk1w5L68EmKgXm-uIj2aw_5_4"></a><a id="Tc_tXp4wAE8EkSNBA8b2bH_Pg_5_7"></a><a id="Tc_ssQsYOFt20elC09Ov-K9nQ_5_9"></a><a id="Tc_5mQkFlVVoE2VSfzPcikUlQ_6_0"></a><a id="Tc_28v4U27LMkauMmys8fWl-Q_6_4"></a><a id="Tc_23zhlzVjd0GTxEIDsDBthw_7_0"></a><a id="Tc_Be7YbCX8MkWIata_6Hse8Q_8_0"></a><a id="Tc_eEa_E6e3f0aCwwvMffQ3Nw_8_2"></a><a id="Tc_EkGqKRCmvk69QS2jYwK9yA_8_4"></a><a id="Tc_4rKjUdy5i0mt_nexa3eftQ_8_5"></a><a id="Tc_uME-Pngp-0SLkS68rMexnA_8_7"></a><a id="Tc_rB9CTDIzMUukO2Pi6VA5mg_8_9"></a><a id="Tc_7HpclplKbEiNpyS0NGlcFw_8_10"></a><a id="Tc_s8xDZfAR6EuDHlVwI6SxmQ_9_0"></a><a id="Tc_AUdJnK1TK0q0BoI6FMCbYA_9_2"></a><a id="Tc_DXeT4f83ykSjG0HIu7yzDQ_9_4"></a><a id="Tc_FtzcF5yLrkWUgl2-uHmJZg_9_5"></a><a id="Tc_dOBQIwFDC0m81Dltrn5sWw_9_7"></a><a id="Tc_AUraznbEJ0uf5g8vPil_UA_9_9"></a><a id="Tc_J6LCIKjWPUaxXUrerrQzVA_9_10"></a><ix:continuation id="Tb_mK4dgQoBEkami-BAxemitA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Performance-based stock units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has issued PSUs, which generally have a <ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_xdhX_MHiDkifyUvaXm5JpQ">ten-year</ix:nonNumeric> life from the date of grant. Upon exercise, the PSU holder receives common stock or cash at the Company&#8217;s discretion. The following table summarizes the activity related to PSUs during the&#160;years ended September&#160;30, 2024:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="Tb_SvVy9amd2kGnS_qqq2VLTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per PSU</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_rZA90vXOikO3jdT2EdMy6Q_6_2">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_zilKqq4P8USZhKiv789s1A_6_5">999.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA" decimals="INF" format="ixt:num-dot-decimal" name="otlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" sign="-" scale="0" id="Tc___6K2-OB0Ei1TTvNOuFebQ_7_2">123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw" contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA" decimals="2" format="ixt:num-dot-decimal" name="otlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" scale="0" id="Tc_P0z4xq4FQ0KGa2ElYl45Gw_7_5">999.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="otlk:CollaborationArrangementsTextBlock" id="Tb_ncCIiD5GWU2bxLvycQUsTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Collaboration Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Syntone Strategic Partnership and PRC Joint Venture</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with a stock purchase agreement entered in May 2020 between the Company and Syntone, the Company and Syntone entered into a joint venture agreement pursuant to which they agreed to form a PRC joint venture that will be <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_5_22_2020_dei_LegalEntityAxis_otlk_PRCJointVentureMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_gJdyvVXshEuX-08Mf6ndHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_76rrhv2OH0alJoC4Qcbbvg">80</ix:nonFraction>% owned by Syntone and <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_K8vLKrXgSEWZnKrHbLvWFQ">20</ix:nonFraction>% owned by the Company. Upon formation of the PRC joint venture in April 2021, the Company entered into a royalty-free license with the PRC joint venture for the development, commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company made the initial investment of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_6_1_2020_To_6_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_P56yKUXSbkSeAJyaiAzVzA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" id="Narr_7Mq3cv9XbUC-nA1vi8AeYg">900,000</ix:nonFraction> in June 2020. The Company is committed to making up to $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="0" id="Narr_UdeNXYb5m0mZFkOZFMM7Iw">2,100,000</ix:nonFraction> in additional capital contributions to the PRC joint venture, based upon the development plan contemplated in the license agreement or on such other terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a6c3e55e_6718_47a9_a183_3f1ac3e2756e"></a><a id="Tc_6L1txZSFY0-nIyneYZqt_w_1_2"></a><a id="Tc_WaHlE4N-J0KmLv9qs_25SQ_2_2"></a><a id="Tc_dmKUMIuQ_02GorFymLd_IA_2_5"></a><a id="Tc_oG83At9-LU6sR6C9_Ow6QQ_3_0"></a><a id="Tc_g-OuqnKKfkKAbAunz6dPIw_3_2"></a><a id="Tc_SMQY8UKgSEy26Rr_ZevJBw_3_5"></a><a id="_46db183b_5794_405e_b750_e942b96dc3ed"></a><a id="Tc_FIfTL2a3-kaHl1btW6JnrA_1_2"></a><a id="Tc_SYauygIfW0K1l08C1IGaGA_2_2"></a><a id="Tc_8O2xRjY8V0Sa2bwDGOdh-A_2_4"></a><a id="Tc_5U_TdEb5h0OZb9ZXw_Btxg_3_0"></a><a id="Tc_bBs2cTtMaEiI_Bx_cEjFCg_3_3"></a><a id="Tc_hTcqSEsi5ECi6PyG1YEOKQ_3_5"></a><a id="Tc_aL1JVUy3C0-cMXWXVaXX7w_4_0"></a><a id="Tc_kTALTboN10egV1QM6N46ZQ_5_0"></a><a id="Tc_Bz3_wOe_xEeLyAVS5v3jSQ_6_0"></a><a id="Tc_YQEWRGwtuEmVCtOSMp5NsA_7_0"></a><a id="Tc_zuluN3vmJki3pXouFGw7ZA_8_0"></a><a id="Tc_rOOLuZoDVkqKvgrby-e7Lg_9_0"></a><a id="Tc_J-nFZe-HA0mKI9c52puCDg_10_0"></a><a id="Tc_ZGmthG9UhESkkgKPNzS1vw_11_0"></a><a id="Tc_YvBcAvzLc02f9TgVhutIsg_11_3"></a><a id="Tc_SFFNuPBuEkyWAyZEGEh1GA_11_5"></a><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_ibFFjlQeL0is6VnQfTatcw" continuedAt="Tb_ibFFjlQeL0is6VnQfTatcw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">13.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax benefit for the&#160;years ended September&#160;30, 2024 and 2023 consists of the following:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_VBqwtcoX8k61mEQH5tpQag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.27%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">State tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="Tc_3NyhiT4AWkyoXMtcmVdIlg_3_3">2,800</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="Tc_i4jzk2FIbES-kHhvkOGxTQ_3_6">2,800</ix:nonFraction></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_463YxcLAJkS8mepYj6udhw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">U.S. federal statutory rate</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_EWE-Lgy6lky7OVjRgJ54Pg_3_2">21.0</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_8w0YtfS-uEalT-9GyoqWnA_3_4">21.0</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">State taxes, net of federal benefit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_tZBewbsAr0ewyCu31OLSUQ_4_2">6.2</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_qjG4G0zLAkqZ0qah7MsCYQ_4_4">7.3</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Deferred true-up</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="otlk:EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" sign="-" scale="-2" id="Tc_51ezZWvA0EWNKJXa0z41yg_5_2">0.2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="otlk:EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" sign="-" scale="-2" id="Tc_45I20nF5ykW0hnj11SWO-w_5_4">0.1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Permanent differences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_6vFboXsZ90uySMkaAsM9bA_6_2">2.5</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="Tc_kVL0_96Hk06PT91qSGciGQ_6_4">0.7</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Foreign tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="Tc_Ng6jY5PNoEuG2JHSsYSxIg_7_2">1.7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" scale="-2" id="Tc_zCtzjS98kE6_a5PZ6QCOgg_7_4">1.3</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Research and development credit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_M9-WrBcjyk6e0eCICzpJ5A_8_2">2.4</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_8yzVpPI-NEyMzOrCepKA1A_8_4">1.3</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Change in valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_j-dr263rWESwZs35NyUaoA_9_2">25.3</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_PVAmnz7XqU6ViOsTAKTNSQ_9_4">29.0</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_UqRkB2-LAEO1yIV20_zjsw_10_2">0.1</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_HVjb3cWKNU6gdPhUgQxnWQ_10_4">0.1</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_N5_eIwCD_0aoNl3i3gE6Ig_11_2">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_7xLofhPdmEKabwF0dkZRAA_11_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3eee1721_ac51_4a62_ba2c_a92f5187c25d"></a><a id="Tc_5YKNaNRmKkiUUeKT4-s9Hw_1_2"></a><a id="Tc_wF1B0b48e021sTHGDz5s_w_2_2"></a><a id="Tc_Ax56AiJeC0aa2mfIgZ2kHA_2_5"></a><a id="Tc_FjCi45mcWk6lwIu-qTc3mw_3_0"></a><a id="Tc_YMe62BD-bUC57-sLSEcc3A_4_0"></a><a id="Tc_HuMx_A-1EkCUH68djkdadg_4_2"></a><a id="Tc_fKyzJuCFbUiBne0sZOn7Uw_4_5"></a><a id="Tc_HCF5UIxBDUuJm4TVVhNruQ_5_0"></a><a id="Tc_cm_fRuMNUkuBE-siY1mjfg_6_0"></a><a id="Tc_FkFAT2DDB0mzGBID8C20qQ_7_0"></a><a id="Tc_WNIqTr4vnk2A_X334TKTYQ_7_6"></a><a id="Tc_45ueyDXh70aZSAuauGCIWA_8_0"></a><a id="Tc_cu7BsSE4dkyU4ft-mRlkIQ_9_0"></a><a id="Tc_olUz-y-AAkqQw1LsuhtvZA_10_0"></a><a id="Tc_ZdxrcSZ4nkui8qp8FBcqGA_11_0"></a><a id="Tc_l3tD_GaEIUuWIu4PpXIVXA_12_0"></a><a id="Tc_WOv0QT_ebEi0MTpy9uiDPw_14_0"></a><a id="Tc_bnR231O0IUqLHrmFxLFkIg_15_0"></a><a id="Tc_3PZTsscljE-CxCLXsOaQyg_15_3"></a><a id="Tc_Mr6Ecr7yUkKw_O3kgRwAjg_15_6"></a><a id="Tc_VGCuYETIPUKaBtJut2eFSQ_16_0"></a><a id="Tc_tt2JEYhkR0a3-cIe0QHwSg_17_0"></a><a id="Tc_Zy9KDVJ95U207WOZiOuOGg_17_2"></a><a id="Tc_CdD01kv2CE6Ou_YdegX_Yg_17_3"></a><a id="Tc_UUxbVSgRfEOcX5YuZLFARQ_17_5"></a><a id="Tc_3zzL_Z3vrU2n4QFGhwKQQw_17_6"></a><a id="_d9c679ec_6dfd_4971_9657_6252afdb741a"></a><a id="Tc_57Zt-2GW9E2D0oLlDrFKCA_1_2"></a><a id="Tc_6sF9QKiEjkur_7ZjcR8R0g_2_2"></a><a id="Tc_b0mv9HAdNkG986QIm9FP7g_2_5"></a><a id="Tc_irk5bBoFcEG0VYLoJR7Rmw_3_0"></a><a id="Tc_YQp8GalAfkSGaKAebOt5qw_3_2"></a><a id="Tc_BH4yqCYZdkaxEXZGPaXu0A_3_5"></a><a id="Tc_GKQ7g6A78UO6ffuIuPvVBw_4_0"></a><a id="Tc_i6l_4O9f-U6CJkVh9FqDKg_5_0"></a><a id="Tc_8KLJqI9Ld0KlsZuYR0kuDQ_5_2"></a><a id="Tc_xn7L2d3EEUmnHOc3d-CoCQ_5_5"></a><ix:continuation id="Tb_ibFFjlQeL0is6VnQfTatcw_cont1" continuedAt="Tb_ibFFjlQeL0is6VnQfTatcw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The tax effects of the temporary differences that gave rise to deferred taxes were as follows:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_UyCHAerVBkC8LtnjVReHRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_dQl3v3mp6E6IKo6ypR-lhw_4_3">102,906,140</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_O0Zj7giZSkOybifEemxMRQ_4_6">92,961,718</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Capitalized research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_9-SxwEgGjkireON3xgCYOA_5_3">15,200,918</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_iixQiZIUKEu8GxU9tvUOvg_5_6">6,531,508</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_uKg4hWmgA0CTbsPnUnlwDg_6_3">6,463,068</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_drKfaCd5PEyPaeDD3DmJRA_6_6">5,066,375</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="otlk:DeferredTaxAssetsLeaseLiability" scale="0" id="Tc_KTUPt-FaUE6Ky5jkm6_BZA_7_3">83,720</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Research and development credit carryforward</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_ugH6fa1E30aM4nXaD7R4WA_8_3">13,748,600</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_zrVKNQ6FhkS_qA1iPntfmA_8_6">11,953,956</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Foreign tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" scale="0" id="Tc_-J5OFFilf0W3z6kSpzmr6g_9_3">290,188</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" scale="0" id="Tc_D1tfRQ--c0KbJNmQvmcxwA_9_6">1,562,639</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Accruals and others</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" id="Tc_sKoV-iLD2EuxgUbjE0UYYA_10_3">144,079</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" id="Tc_7N_BXObaD0uLC-8ttdfHUQ_10_6">1,656,239</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Gross deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_ISSrvGaxwUGuGDjSupkKsA_11_3">138,836,713</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_iAmwGCllhEyAppPH5FUzmw_11_6">119,732,435</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Less: valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_ST-Kb8Ltz0KX5e7_J9GQ2g_12_3">138,759,510</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_EYJyLzqLx0afMecb96M9ow_12_6">119,725,078</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_gyf4ezea4U6pZRCwBcl2dA_13_3">77,203</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_Vg_JWXX_j0C8kITWNqllnQ_13_6">7,357</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" id="Tc_RN5-44KOM0-bbH4xLgRjqg_16_3">77,203</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" id="Tc_a-xQMg9Ii0qsdxAnz_9MiQ_16_6">7,357</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2024, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LKsDtuAd_kibOfWHNXl-Xg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_aK8Taf1KtEialAbH7XF6SQ">406.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_xm5rwmnSsUqyr_jq4s9uow" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_3r26FFHcS0qfuZNczgHLew">242.5</ix:nonFraction> million of U.S. federal and New Jersey NOLs that will begin to expire in 2030 and 2039, respectively. As of September 30, 2024, the Company had federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LKsDtuAd_kibOfWHNXl-Xg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_nH_i_YRVEkqdzFZM2BS9Tg">13.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_xm5rwmnSsUqyr_jq4s9uow" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_uN4Y7vZjkUWMiPwM11VLfg">0.8</ix:nonFraction> million, respectively, available to reduce future tax liabilities which will begin to expire in 2032 and 2033, respectively. As of September 30, 2024, the Company has federal foreign tax credit (&#8220;FTC&#8221;) carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3nC_oDhzvUyW3kv-c_voPw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_55OUToU4KkGpc-7a0l1kOA">0.3</ix:nonFraction> million available to reduce future tax liabilities which began to expire starting in 2023, of which $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3nC_oDhzvUyW3kv-c_voPw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_EZvOMbtStUKsWzqGM7jJfw">0.3</ix:nonFraction> million of the FTC carryforward is included in the balance of unrecognized tax benefits. Realization of the deferred tax asset is contingent on future taxable income and based upon the level of historical losses, management has concluded that the deferred tax asset does not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance continues to be recorded against the Company&#8217;s deferred tax assets as of September 30, 2024 and 2023. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="Narr_JQai6B1FyUiMnsjkjB574A">19.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="Narr_EZhlNo5Wt02eRwpy2pgAYA">17.1</ix:nonFraction> million during the year ended September 30, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely-than-not be realized. The determination as to whether the tax benefit will more-likely-than-not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes interest and penalties accrued on any unrecognized tax benefits within the provision for income taxes in its consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_5nBa67hjs0aUWv8DN7UTcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Balance at beginning of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_PaQwsUlNwkOFB6Rb1KZuVQ_3_3">1,856,629</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_gkhEkiGlA0CdINxwaheBuA_3_6">1,856,629</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Changes based on tax positions related to the current year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" decimals="0" format="ixt:fixed-zero" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="0" id="Tc_8xBhUsUCt0yK9bJOHr_Llg_4_3">&#8212;</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug" decimals="0" format="ixt:fixed-zero" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="0" id="Tc_-wTkUBI0bk62wOKFOMP0jQ_4_6">&#8212;</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Balance at end of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_3bXSF7U8H0GzjpWI7uRhqw_5_3">1,856,629</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Tc_KVjw9uSqKUi1ZVaq4l-xqw_5_6">1,856,629</ix:nonFraction></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company does not anticipate material change in the unrecognized tax benefits in the next 12&#160;months. These unrecognized tax benefits, if recognized, would affect the annual effective tax rate. The Company&#8217;s income tax returns for the&#160;years from 2011 through 2023 remain open for examination by the Internal Revenue Service as well as various states and municipalities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Due to the change in ownership provisions of the Code, the availability of the Company&#8217;s NOL carryforwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ibFFjlQeL0is6VnQfTatcw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on beneficial ownership and therefore no determination has been made whether the net operating loss carry forward is subject to any Code Section&#160;382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax assets with an offsetting reduction in the valuation allowance.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A" name="us-gaap:SubsequentEventsTextBlock" id="Tb_0Ys8T-g3GUqBd0gMI0L0Ug" continuedAt="Tb_0Ys8T-g3GUqBd0gMI0L0Ug_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">14.&#160;&#160;&#160;Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Departure of Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 3, 2024, C. Russell Trenary III stepped down as the President and Chief Executive Officer the Company and as a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;), effective immediately (the &#8220;Effective Date&#8221;). The Board has resolved to reduce its size to nine directors immediately upon Mr. Trenary&#8217;s resignation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr. Trenary&#8217;s departure constituted a termination of employment without &#8220;cause&#8221; for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Trenary is a party or otherwise participates, including that certain executive employment agreement, dated as of July 6, 2021, by and between Mr. Trenary and the Company (the &#8220;Employment Agreement&#8221;). Accordingly, subject to Mr. Trenary&#8217;s execution and non-revocation of a separation agreement containing a release of claims against the Company, Mr. Trenary is entitled to continued payment of his base salary for 12 months following the termination, 100% of his target bonus for the calendar year of termination paid in a lump sum, employee benefit coverage for up to 12 months, full vesting of 50% of his then unvested equity awards, and reimbursement of expenses owed to him through the date of his termination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 3, 2024, Lawrence A. Kenyon, the Company&#8217;s Chief Financial Officer, was appointed Interim Chief Executive Officer of the Company, effective as of the Effective Date, to serve while the Board conducts a formal search process to identify and appoint a permanent Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reduction in Workforce </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 10, 2024, the Board approved a reduction of the Company&#8217;s workforce in connection with its plans to reduce operating expenses and preserve capital. On December 13, 2024, the Company reduced its workforce by <ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_YaRjv0sVtUmmIVPNNkR7Tw">five</ix:nonFraction> people, or approximately <ix:nonFraction unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg" contextRef="Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_CBKAshr_hkaHAuMS7bRILg">23</ix:nonFraction>% of its existing headcount. At a minimum, all employees affected by the workforce reduction are eligible to receive severance payments and paid COBRA premiums for a specified time period post-termination, subject to execution of a general release of claims against the Company. The Company estimates that it will incur approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg" contextRef="As_Of_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RHl_XSAP6E2hmGDCfAw-ng" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="0" id="Narr_-n9CrXjCbES_R4cm7FaCHw">336,000</ix:nonFraction> in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and related costs.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_0Ys8T-g3GUqBd0gMI0L0Ug_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_23b27e82_8197_418e_8ef5_19520587054a"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_d7c495d9_dae1_4070_8f74_085cb2769be2"></a><a id="Item9AControlsandProcedures_432274"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, has evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) prior to the filing of this Annual Report on Form 10-K. Based on that evaluation, our Interim Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were, in design and operation, effective as of September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting, based on criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control-Integrated Framework. Based on our evaluation, we concluded that our internal control over financial reporting was effective as of September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a smaller reporting company, our independent registered accounting firm is not required to issue an attestation report on our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inherent Limitation on the Effectiveness of Internal Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.</p><a id="_03124355_457c_4702_9616_1235c1d4d8c3"></a><a id="Item9BOtherInformation_380541"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the fiscal year covered by this Annual Report, none of our directors or Section 16 officers <ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_oPfo8suufUi2rUr6rSuwAA">adopted</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_tMjkZ2e5EEa5qtTnh0B4Jg">or</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_tK3y0mkWP0mine0-oKNh6g">terminated</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_JqsaAydKpk-MJSAD3tb-pg">any</ix:nonNumeric> contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">defense conditions of Rule 10b5-1(c) under the Exchange Act or any &#8220;non-Rule 10b5-1 trading arrangement&#8221; as such term is defined in Item 408(a) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><a id="_69649949_32d8_493b_aa65_80ee0c48963d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Not applicable.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_418ac37f_d218_4f38_959d_3d21306949d9"></a><a id="PARTIII_435170"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART III</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain information required by Part III is omitted from this Report on Form 10-K because we intend to file our definitive Proxy Statement for our next Annual Meeting of the Stockholders, pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, or the 2025 Proxy Statement, no later than January 28, 2025, and certain information to be included in the 2025 Proxy Statement is incorporated herein by reference.</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 10. Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item is to be included in our 2025 Proxy Statement as follows: </p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information relating to our directors and nominees for director is to be included in the section entitled &#8220;Election of Directors&#8221;; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information relating to our executive officers is to be included in the section entitled &#8220;Executive Officers of the Company&#8221;; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If required, the information regarding compliance with Section 16(a) of the Exchange Act is to be included in the section entitled &#8220;Delinquent Section 16(a) Reports&#8221;; &#160;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information regarding family relationships is to be included in the section entitled &#8220;Election of Directors &#8211; Family Relationships&#8221;; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information relating to our audit committee and audit committee financial expert is to be included in the section entitled &#8220;Information Regarding the Board of Directors and Corporate Governance &#8211; Audit Committee&#8221;.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have adopted a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The Code of Business Conduct and Ethics is publicly available on our website under the Investors &amp; Media section at ir.outlooktherapeutics.com. This website address is intended to be an inactive, textual reference only; none of the material on this website is part of this Annual Report on Form 10-K. We intend to promptly disclose on our website or in a Current Report on Form 8-K in the future (i) the date and nature of any amendment (other than technical, administrative or other non-substantive amendments) to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and relates to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K and (ii) the nature of any waiver, including an implicit waiver, from a provision of the Code of Conduct that is granted to one of these specified individuals that relates to one or more of the elements of the code of ethics definition enumerated in Item 406(b) of Regulation S-K, the name of such person who is granted the waiver and the date of the waiver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have adopted an Insider Trading Policy governing the purchase, sale and/or other dispositions of our securities by our directors, officers and employees and by us. A copy of the Insider Trading Policy is filed as an exhibit to this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_00601020_b1f4_4060_905a_c87a9fddf2e1"></a><a id="Item11ExecutiveCompensation_986273"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this item is to be included in our 2025 Proxy Statement under the section entitled &#8220;Executive Compensation&#8221; and is incorporated herein by reference, provided that if the 2025 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2bbcd1af_da5c_47eb_8dfb_dc2cd3fc49bc"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The information required with respect to equity compensation plans is to be included in our 2025 Proxy Statement under the section entitled &#8220;Equity Compensation Plan Information&#8221; and the information required by this item with respect to security ownership of certain beneficial owners and management is to be included in our 2025 Proxy Statement under the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and is incorporated herein by reference, provided that if the 2025 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span> </p><a id="_367c202a_adee_4f8f_9a5b_baa5415bb9ea"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item is to be included in our 2025 Proxy Statement under the sections entitled &#8220;Transactions with Related Persons&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance &#8211; Independence of the Board of Directors&#8221; and is incorporated herein by reference, provided that if the 2025 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</p><a id="_bc3dac8d_1a01_4b83_aefb_e84110d8c2d5"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 14. Principal Accounting Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this item is to be included in our 2025 Proxy Statement under the section entitled &#8220;Ratification of Selection of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference, provided that if the 2025 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c37795e7_2b42_4e66_9d4a_82486f5db569"></a><a id="PARTIV_613503"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;(1)&#160;&#160;&#160;The financial statements required by Item 15(a) are filed in Item 8 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">(2)&#160;&#160;&#160;The financial statement schedules required by Item 15(a) are omitted because they are not applicable, not required or the required information is included in the financial statements or notes thereto as filed in Item 8 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBITS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000155837024008318/otlk-20240331xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s quarterly report on Form 10-Q filed with the SEC on May 15, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465921042442/tm2110800d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on March 26, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="otlk-20240930xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s securities.</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.1#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000157104916010787/t1600032_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2011 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s registration statement on Form S-1 (File No. 333-209011) filed with the SEC on January 15, 2016)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.2#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000157104916014288/t1600655_ex10-29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Performance Stock Unit Agreement for 2011 Stock Incentive Plan (incorporated by reference to Exhibit 10.29 to the Registrant&#8217;s registration statement on Form S-1 (File No. 333-209011) filed with the SEC on April 27, 2016)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.3#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465920106584/tm2031308d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2015 Equity Incentive Plan, as amended and restated (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on September 18, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.4#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000157104916010787/t1600032_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Forms of agreements and award grant notices for 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s registration statement on Form S-1 (File No. 333-209011) filed with the SEC on January 15, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.5#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000155837024012234/otlk-20240630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Registrant&#8217;s quarterly report on Form 10-Q filed with the SEC on August 14, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.6#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000155837024012234/otlk-20240630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to Registrant&#8217;s quarterly report on Form 10-Q filed with the SEC on August 14, 2024)</span></a>. </p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.7#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000157104916011706/t1603170_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s registration statement on Form S-1 (File No. 333-209011) filed with the SEC on February 12, 2016)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.8#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/tm2121712d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement by and between C. Russell Trenary III and Outlook Therapeutics, Inc, dated July 6, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on July 9, 2021)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.9#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465922068944/tm2217693d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Executive Employment Agreement by and between Lawrence Kenyon and Outlook Therapeutics, Inc, dated June 2, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on June 7, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.10#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465921153209/tm2136248d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement by and between Jeff Evanson and Outlook Therapeutics, Inc, dated December 21, 2021 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on December 23, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.11#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="otlk-20240930xex10d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Outlook Therapeutics, Inc. Non-Employee Director Compensation Policy, as amended and restated, effective as of October 1, 2024</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.12#</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000157104916010787/t1600032_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnity Agreement, by and between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s registration statement on Form S-1 (File No. 333-209011) filed with the SEC on January 15, 2016)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.13&#8224;</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000157104916010787/t1600032_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ONS-1045 Commercial License Agreement by and between the Registrant and Selexis SA effective as of April 11, 2013, as amended effective as of May 21, 2014 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s registration statement on Form S-1 (File No. 333-209011) filed with the SEC on January 15, 2016)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465922048921/tm2213216d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Investor Rights Agreement by and between the Registrant and GMS Ventures and Investments, dated April 21, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on April 22, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465920024322/tm2010761d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on February 24, 2020)</span></a>. &#160;</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465920024322/tm2010761d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of GMS Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on February 24, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.17</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465920024322/tm2010761d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on February 24, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465920067132/tm2021184d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stock Purchase Agreement dated May 22, 2020, by and between the Registrant and Syntone Ventures LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on May 28, 2020).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465920076104/tm2023202d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on June 23, 2020)</span></a>. </p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465921011018/tm214858d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of underwriter warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on February 2, 2021)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.21**</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/tm2233327d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement, dated as of December 22, 2022, by and between the Company and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on December 22, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/tm2233327d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on December 22, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000155837023001286/otlk-20221231xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment, dated February 10, 2023, to the Convertible Promissory Note, dated December 22, 2022, by and between the Company and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s quarterly report on Form 10-Q </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">filed with the SEC on February 14, 2023</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000155837023020000/otlk-20230930xex10d30.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment, dated December 21, 2023, to the Convertible Promissory Note, dated December 22, 2022, by and between the Company and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.30 to Registrant&#8217;s annual report on Form 10-K filed with the SEC on December 22, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/tm243921d1_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment, dated January 22, 2024, to the Convertible Promissory Note, dated December 22, 2022, by and between the Company and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on January 24, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465922129882/tm2233312d2_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on December 23, 2022)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.27</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465923061113/tm2315915d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At-the-market Sales Agreement between the Company and BTIG, LLC dated May 16, 2023 (incorporated by reference to Exhibit 10.1 to the </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registrant&#8217;s</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> current report on Form 8-K filed with the SEC on May 16, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.28</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/tm243921d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement, dated January 22, 2024, between the Company and the investors party thereto (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on January 24, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.29</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/tm243921d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated January 22, 2024, between the Company and Syntone (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on January 24, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.30</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/tm243921d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on January 24, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.31</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465924006019/tm243921d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Syntone Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on January 24, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.32</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000110465924046752/tm2411708d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment, dated April 12, 2024, to Sales Agreement, dated May 16, 2023, by and between the Company and BTIG (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed with the SEC on April 12, 2024)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">19.1</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="otlk-20240930xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading Policy, as amended and restated.</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="otlk-20240930xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="otlk-20240930xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of independent registered public accounting firm.</span></a></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="otlk-20240930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="otlk-20240930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">97</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1649989/000155837023020000/otlk-20230930xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Incentive Compensation Recoupment Policy (incorporated by reference to Exhibit 97 to the Registrant&#8217;s annual report on Form 10-K filed with the SEC on December 22, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.SCH </p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.CAL </p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.DEF </p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.LAB </p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">101.PRE </p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">104</p></td><td style="vertical-align:top;width:3.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Confidential treatment has been granted for certain information contained in this document pursuant to an order of the SEC. Such information (indicated by asterisks) has been omitted and been filed separately with the SEC.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">&#165;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are not material.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><a id="_f486b0b3_9129_44e3_9ac5_23a48e058b36"></a><a id="Item16Form10KSummary_624675"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 16. Form 10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a13149d3_3a03_4370_a4a2_7f50bcc80139"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Date:</span> December 27, 2024</p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">By: </span></p></td><td style="vertical-align:top;width:44.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">/s/ Lawrence A. Kenyon</span></p></td></tr><tr><td style="vertical-align:top;width:49.74%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Name:</span></p></td><td style="vertical-align:top;width:44.75%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Lawrence A. Kenyon</span></p></td></tr><tr><td style="vertical-align:top;width:49.74%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Title:</span></p></td><td style="vertical-align:top;width:44.75%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Chief Financial Officer and Interim Chief Executive Officer</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">/s/ Ralph H. Thurman</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Executive Chairman</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Ralph H. Thurman</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Chief Financial Officer,</span> <span style="font-size:10pt;">Interim Chief Executive Officer,</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">/s/ Lawrence A. Kenyon</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Treasurer, Secretary and Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Lawrence A. Kenyon</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><i style="font-size:10pt;font-style:italic;">(Principal Executive, Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">/s/ Yezan Haddadin</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Yezan Haddadin</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">/s/ Kurt J. Hilzinger</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Kurt J. Hilzinger</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">/s/ Julia A. Haller</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Julia A. Haller</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">/s/ Faisal G. Sukhtian</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Faisal G. Sukhtian</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">/s/ Julian Gangolli</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Julian Gangolli</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">/s/ Gerd Auffarth</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Gerd Auffarth</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">/s/ Andong Huang</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="font-size:10pt;">Director</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;">December 27, 2024</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">Andong Huang</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:22.36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:49.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.28%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>otlk-20240930xex4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 12/27/2024 04:49:23 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 4.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Description of Registrant&#8217;s Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following is a description of the capital stock of Outlook Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;). The following summary description is based on the provisions of our Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), our Amended and Restated Bylaws, (the &#8220;Bylaws&#8221;), and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). This information may not be complete in all respects and is qualified entirely by reference to the provisions of our Certificate of Incorporation, our Bylaws and the DGCL. Our Certificate of Incorporation and our Bylaws are filed as exhibits to our Annual Report on Form 10-K to which this description is filed as Exhibit 4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our authorized capital stock consists of 60,000,000 shares of common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), and 10,000,000 shares of preferred stock, par value $0.01 per share (the &#8220;Preferred Stock&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Voting Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote of holders of 66 2&#8725;3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our Certificate of Incorporation, including provisions relating to amending our Bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose on a non-cumulative basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Liquidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Rights and Preferences</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the number, rights, preferences, privileges and restrictions thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control or other corporate action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Stockholder Registration Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain holders of our securities, including certain holders of 5% of our capital stock who are affiliated with certain of our directors, are entitled to certain rights with respect to registration of such securities under the Securities Act of 1933, as amended. These securities are referred to as registrable securities. The holders of these registrable securities possess registration rights pursuant to the terms of registration rights agreements. In general, the registration of shares of our common stock pursuant to the exercise of registration rights enables the holders to trade such shares without restriction under the Securities Act when the applicable registration statement is declared effective. We generally have agreed to pay the registration expenses for such registration statements, other than underwriting discounts, </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">selling commissions and stock transfer taxes, of the shares registered. Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to limit the number of shares the holders may include. We must use commercially reasonable efforts to keep the registration statement effective until the earlier of the date on which all registrable securities covered by such registration statement have been sold, or at such time that the holders of the registrable securities can sell their shares under Rule 144 of the Securities Act during any three-month period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Provisions of Delaware Law and Our Charter Documents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Section 203 of the DGCL</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are subject to Section 203 of the DCGL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; and</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:4.8pt;"><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2&#8725;3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In general, Section 203 defines a &#8220;business combination&#8221; to include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger or consolidation involving the corporation and the interested stockholder; any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation; and</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as Amended</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Among other things, our Certificate of Incorporation and Bylaws:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.7%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.94%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.63%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.93%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.82%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that our board of directors is classified into three classes of directors;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least a majority of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:98.44%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:10.4pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or president or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:99.88%;margin:0pt;padding:0pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font></div></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The amendment of any of these provisions requires approval by the holders of at least 66 2&#8725;3% of the voting power of all of our then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The combination of these provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Choice of Forum</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our Certificate of Incorporation and our Bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty to us or our stockholders; any action asserting a claim against us arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;OTLK&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The transfer agent and registrar for our common stock is Equinti Trust Company, LLC. Its address is 48 Wall Street, Floor 23, New York, NY 10005.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>otlk-20240930xex10d11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 12/27/2024 04:49:22 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OUTLOOK THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">AS AMENDED AND RESTATED EFFECTIVE OCTOBER 1, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Each member of the Board of Directors (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Board</font><font style="font-size:12pt;">&#8221;) who is not also serving as an employee of Outlook Therapeutics, Inc. (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221;) or any of its subsidiaries (each such member, an &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Eligible Director</font><font style="font-size:12pt;">&#8221;) will receive the compensation described in this Non-Employee Director Compensation Policy (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-size:12pt;">&#8221;) for his or her Board service with respect to the Company&#8217;s fiscal year beginning on October 1 (each, a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Fiscal Year</font><font style="font-size:12pt;">&#8221;). This Non-Employee Director Compensation Policy, as amended and restated hereby, will be effective as of October 1, 2024 (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:12pt;">&#8221;). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be. &#160;This policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-size:12pt;">&#8221;). &#160;The terms and conditions of this Policy shall supersede any prior Non-Employee Director Compensation Policy of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Annual Cash Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Eligible Directors are eligible to receive the following annual cash compensation in the amounts and subject to the terms and conditions as set forth below. &#160;If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. &#160;In addition, each Eligible Director may elect to receive all of the annual cash compensation set forth below that the Eligible Director is eligible to earn beginning with the Fiscal Year commencing on October 1, 2024 and each subsequent Fiscal Year in the form of stock options granted pursuant to the Company&#8217;s 2024 Equity Incentive Plan, as amended (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-size:12pt;">&#8221;) subject to the terms and conditions as set forth below.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Board Service Retainers</u><font style="font-size:12pt;">:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><font style="font-size:12pt;">All Eligible Directors: $50,000</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Chairman of the Board Service Retainer (in addition to Annual Board Service Retainer): $30,000</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">c.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Executive Chairman of the Board Service Retainer (in addition to Annual Board Service Retainer): $120,000</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Committee Member Service Retainer</u><font style="font-size:12pt;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><font style="font-size:12pt;">Member of the Audit Committee: $12,500</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b.</font></font><font style="font-size:12pt;">Member of the Compensation Committee: $10,000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">c.</font></font><font style="font-size:12pt;">Member of the Nominating and Corporate Governance Committee: $5,000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">d.</font></font><font style="font-size:12pt;">Member of the Executive Committee: $30,000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Committee Chair Service Retainer (in lieu of Annual Committee Member Service Retainer)</u><font style="font-size:12pt;">:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><font style="font-size:12pt;">Chairman of the Audit Committee: $25,000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b.</font></font><font style="font-size:12pt;">Chairman of the Compensation Committee: $20,000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">c.</font></font><font style="font-size:12pt;">Chairman of the Nominating and Corporate Governance Committee: $10,000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Timing of Elections Regarding Annual Cash Compensation; Time and Form of Payment</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><i style="font-size:12pt;font-style:italic;">Current Eligible Directors</i><font style="font-size:12pt;">: If an Eligible Director&#8217;s service as an Eligible Director commences prior to the beginning of a Fiscal Year, then the Eligible Director must make an election, prior to the beginning of such Fiscal Year, to receive the Eligible Director&#8217;s (i) Annual Board Service Retainer(s) for such Fiscal Year and (ii) any Annual Committee Member Service Retainer(s) or Annual Committee Chair Service Retainer(s) that is or may become payable for such Fiscal Year (each, a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Retainer</font><font style="font-size:12pt;">&#8221;) in the form of either cash or stock options. &#160;The Retainer(s) will be paid or granted as follows:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">Cash</i><font style="font-size:12pt;">: If the Eligible Director elects to receive all or a portion of the Retainers in cash, (i) such portion of the Retainers that is payable in the form of cash, other than the Executive Chairman of the Board Service Retainer, will be paid in arrears in substantially equal installments over the applicable number of fiscal quarters during such Fiscal Year, with payment occurring on the last day of the applicable fiscal quarter (i.e., December 31</font><sup style="font-size:9pt;vertical-align:top;">st</sup><font style="font-size:12pt;">, March 31</font><sup style="font-size:9pt;vertical-align:top;">st</sup><font style="font-size:12pt;">, June 30</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> or September 30</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">), and (ii) the Executive Chairman of the Board Service Retainer will be paid in the form of cash in arrears in equal monthly installments on the last day of each month.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">Stock Options</i><font style="font-size:12pt;">: If the Eligible Director elects to receive all or a portion of the Retainers in the form of stock options, such portion of the Retainers that is payable in the form of stock options will automatically, and without further action by the Board or Committee of the Board, be granted on the third business day in October of such Fiscal Year. &#160;Any such award will vest as follows: (i) 25% will vest on the last day of the first fiscal quarter during such Fiscal Year; and (ii) 25% will vest on the last day of each subsequent fiscal quarter during such Fiscal Year, provided that the Eligible Director is in service as a Director on the first day of the fiscal quarter of the applicable scheduled vesting date. &#160;Notwithstanding the foregoing, if the Eligible Director becomes a chairperson of a Committee, Chairman of the Board or Executive Chairman of the Board after the third business day in October of such Fiscal Year, then the portion (if any) of his or her Annual Committee Chair Service Retainer, Chairman of the Board Service Retainer or Executive Chairman of the Board Service Retainer, as applicable, that is to be granted in the form of stock options will automatically, and without further action by the Board or Committee of the Board, &#160;be granted on the third business day after the date that the Eligible Director becomes a chairperson of a Committee, Chairman of the Board or Executive Chairman of the Board, as applicable. &#160;Any such award will vest in equal installments as follows: (i) the first installment will vest on the last day of the fiscal quarter of the date of grant; and (ii) any remaining installment(s) will vest on the last day of any subsequent fiscal quarter(s) during such Fiscal Year,</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-size:12pt;">provided that the Eligible Director is in service as a Director on the first day of the fiscal quarter of the applicable scheduled vesting date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><i style="font-size:12pt;font-style:italic;">New Eligible Directors</i><font style="font-size:12pt;">: If an Eligible Director&#8217;s service as an Eligible Director commences on or after the beginning of a Fiscal Year, then the Eligible Director must make an election, within 30 days following the commencement of such service, with respect to his or her Retainers that are or may become payable for such Fiscal Year; provided, however, that (a) such election will be applicable only to the portion of the applicable Retainer payable for any fiscal quarter during such Fiscal Year that begins after the date of such election, and (b) no such election may be made if such service commences during the final fiscal quarter of such Fiscal Year. &#160;Each such Retainer will be paid or granted as follows:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">Cash</i><font style="font-size:12pt;">: &#160;If the Eligible Director elects to receive all or a portion of the Retainers in cash, (i) any portion of the Retainers that is payable in the form of cash, other than the Executive Chairman of the Board Service Retainer, with respect to any fiscal quarter during such &#160;Fiscal Year that begins after the date of such election will be paid in substantially equal installments over the applicable number of fiscal quarters during such Fiscal Year, with payment occurring on the last day of the applicable fiscal quarter, and (ii) the Executive Chairman of the Board Service Retainer with respect to the remaining portion of the Fiscal Year that begins after the date of such election will be paid in the form of cash in arrears in equal monthly installments on the last day of each month.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">Stock Options</i><font style="font-size:12pt;">: &#160;If the Eligible Director elects to receive all or a portion of the Retainers in the form of stock options, with respect to any fiscal quarter (or month with respect to the Executive Chairman of the Board Service Retainer) during such Fiscal Year that begins after the date of such election, such stock options will automatically, and without further action by the Board or Committee of the Board, be granted on the first business day of the first fiscal quarter that begins after the date of such election. &#160;Any such award will vest in equal installments as follows: (i) the first installment will vest on the last day of the fiscal quarter of the date of grant; and (ii) any remaining installment(s) will vest on the last day of any subsequent fiscal quarter(s) during such Fiscal Year, provided that the Eligible Director is in service as a Director on the first day of the fiscal quarter of the applicable scheduled vesting date. &#160;Notwithstanding the foregoing, if the Eligible Director becomes a chairperson of a Committee, Chairman of the Board or Executive Chairman of the Board after the first business day of the first fiscal quarter that begins after the date of such election, then the portion (if any) of his or her Annual Committee Chair Service Retainer, Chairman of the Board Service Retainer or Executive Chairman of the Board Service Retainer, as applicable, that is to be granted in the form of stock options, will automatically, and without further action by the Board or Committee of the Board, be granted on the third business day after the date that the Eligible Director becomes a chairperson of a Committee, Chairman of the Board or Executive Chairman of the Board, as applicable. &#160;Any such award will vest in equal installments as follows: (i) the first installment will vest on the last day of the fiscal quarter of the date of grant; and (ii) any remaining installment(s) will vest on the last day of any subsequent fiscal quarter(s) during such Fiscal Year, provided that the</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-size:12pt;">Eligible Director is in service as a Director on the first day of the fiscal quarter of the applicable scheduled vesting date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Terms of Elections Regarding Annual Cash Compensation:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Once an election is submitted for a Fiscal Year, it will be irrevocable with respect to such Fiscal Year.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">An Eligible Director must submit a new election for each Fiscal Year.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Elections with respect to an Eligible Director&#8217;s Retainers must be allocated in either cash or stock options as follows: (i) 0% in cash and 100% in stock options; (ii) 50% in cash and 50% in stock options; and (iii) 100% in cash and 0% in stock options. &#160;To the extent that an Eligible Director elects to receive such Eligible Director&#8217;s Retainers partially in cash and partially in stock options, the election will apply proportionally, in accordance with the elected amounts of cash and stock options, with respect to each installment of the Retainers during the applicable period. An Eligible Director may not make an election to receive cash or stock options with respect to an individual Retainer.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Terms of Stock Options Granted Pursuant to Elections</font><font style="font-size:12pt;">:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Any stock options granted pursuant to an Eligible Director&#8217;s election will be granted under the Plan and will be subject to the terms and conditions of (i) this Policy, (ii) the Plan and (iii) the form stock option grant notices and agreements approved by the Board for the grant of such awards to Non-Employee Directors (as defined in the Plan).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The actual number of shares subject to any stock options granted pursuant to this Policy and an Eligible Director&#8217;s election to receive all or a portion of the Retainers in the form of stock options will be determined by dividing the Retainers by the &#8220;fair value&#8221; of a share of the Company&#8217;s common stock (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-size:12pt;">&#8221;) on the third business day in October of the Fiscal Year in which the stock option is granted, determined using a Black-Scholes or binominal valuation model regularly used by the Company.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The shares subject to any stock options granted pursuant to an Eligible Director&#8217;s election will vest in installments subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) through such vesting dates on the terms specified above; provided, however, that all unvested shares subject to such stock options will accelerate and vest in full upon a Change in Control (as defined in the Plan), subject in each case to the Eligible Director&#8217;s Continuous Service as of immediately prior to the Change in Control.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Any stock options granted pursuant to this Policy will be nonqualified stock options, will have an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the Common Stock on the date of grant and will have a term of ten years from the date of grant (subject to earlier termination in connection with the Eligible Director&#8217;s termination of service or certain corporate transactions and in accordance with the terms of the Plan). &#160;Any such stock option will become exercisable when vested and the vested portion of any such stock option</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 18pt;"><font style="font-size:12pt;">will remain exercisable in accordance with the stock option grant notice and agreement governing the stock option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Equity Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The equity compensation set forth below will be granted under the Plan, and will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Grant</u><font style="font-size:12pt;">: On the date of the Eligible Director&#8217;s initial election to the Board, for each Eligible Director who is first elected to the Board following the Effective Date (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase shares of Common Stock with an aggregate &#8220;fair value&#8221; of $245,000, determined using a Black-Scholes or binominal valuation model regularly used by the Company. &#160;The shares subject to each such stock option will vest in three equal installments on the first, second and third anniversary of the date of grant (with the first two tranches rounded down and the third tranche rounded up to the nearest share) such that the stock option will be fully vested as of the third anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service through such vesting dates, provided, however, that all unvested shares subject to such stock options will accelerate and vest in full upon a Change in Control, subject in each case to the Eligible Director&#8217;s Continuous Service as of immediately prior to the Change in Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Grant</u><font style="font-size:12pt;">: On the first day of each fiscal year of the Company commencing with the 2025 fiscal year (i.e., beginning on the Effective Date), each Eligible Director who is then serving as a non-employee member of the Board will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase Common Stock with an aggregate &#8220;fair value&#8221; of $265,000 as of such date, determined using a Black-Scholes or binominal valuation model regularly used by the Company. &#160;The shares subject to each such stock option will vest on the first anniversary of the date of grant, subject in each case to the Eligible Director&#8217;s Continuous Service through such vesting date, provided, however, that all unvested shares subject to such stock options will accelerate and vest in full upon a Change in Control, subject in each case to the Eligible Director&#8217;s Continuous Service as of immediately prior to the Change in Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Non-Employee Director Compensation Limit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Notwithstanding anything herein to the contrary, the aggregate value of all compensation granted or paid, as applicable, to an Eligible Director shall in no event exceed the limits set forth in Section 3(d) of the Plan.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>otlk-20240930xex19d1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 12/27/2024 04:49:23 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 19.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">OUTLOOK THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INSIDER TRADING POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Initially Adopted by the Board - January 28, 2016</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Amended and Restated by the Board &#8211; June 21, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">As Amended and Restated by the Board &#8211; December 10, 2024</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:12pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">I. &#160;INTRODUCTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This policy determines acceptable transactions in the securities of Outlook Therapeutics, Inc. (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:11pt;">&#8221; or &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Outlook</font><font style="font-size:11pt;">&#8221;) by our employees, directors, consultants and contractors. During the course of your relationship with the Company, you may receive important information that is not yet publicly available (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">inside information</font><font style="font-size:11pt;">&#8221;), about the Company or about other publicly traded companies with which the Company has business dealings. &#160;Because of your access to this inside information, you may be in a position to profit financially by buying or selling, or in some other way dealing, in the Company&#8217;s stock, or stock of another publicly traded company, or to disclose such information to a third party who does so profit (a &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">tippee</font><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The prohibition against insider trading is absolute. It applies </font><font style="font-size:11pt;font-style:italic;font-weight:bold;">even if</font><font style="font-size:11pt;"> the decision to trade is not based on such material nonpublic information. It also applies to transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) and also to very small transactions and bona fide gifts. All that matters is whether you are aware of </font><b style="font-size:11pt;font-weight:bold;">any</b><font style="font-size:11pt;"> material nonpublic information relating to the Company at the time of the transaction. The U.S. federal securities laws do not recognize any mitigating circumstances to insider trading. In addition, even the appearance of an improper transaction must be avoided to preserve the Company&#8217;s reputation for adhering to the highest standards of conduct.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">II. INSIDER TRADING POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;white-space:pre-wrap;">A.  Securities Transactions</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Use of inside information by someone for personal gain, or to pass on, or &#8220;tip,&#8221; the inside information to someone who uses it for personal gain, is illegal, regardless of the quantity of shares, and is therefore prohibited. &#160;You can be held liable both for your own transactions and for transactions effected by a tippee, or even a tippee of a tippee. &#160;Furthermore, it is important that the appearance of insider trading in securities be avoided. &#160;There are no exceptions to this policy, except as specifically noted below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">B. Inside Information</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">As a practical matter, it is sometimes difficult to determine whether you possess inside information. &#160;The key to determining whether nonpublic information you possess about a public company is inside information is whether dissemination of the information would likely affect the market price of the company&#8217;s stock or would likely be considered important, or &#8220;material,&#8221; by investors who are considering trading in that company&#8217;s stock. &#160;Certainly, if the information makes you want to trade, it would probably have the same effect on others. &#160;Remember, both positive and negative information can be material. &#160;If you possess inside information, you may not trade in a company&#8217;s stock, advise anyone else to do so or communicate the information to anyone else until you know that the information has been publicly disseminated. This policy also applies to all family members and other household members of</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">1</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">those covered by this policy and all companies controlled by those covered by this policy. You may never recommend to another person that he or she buy, hold, sell or otherwise acquire or dispose of our securities. This means that in some circumstances, you may have to forego a proposed transaction in a company&#8217;s securities even if you planned to execute the transaction prior to learning of the inside information and even though you believe you may suffer an economic loss or sacrifice an anticipated profit by waiting. &#160;For purposes of this policy, the terms &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">trade</font><font style="font-size:11pt;">,&#8221; &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">trading</font><font style="font-size:11pt;">&#8221; and &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">transactions</font><font style="font-size:11pt;">&#8221; include not only purchases and sales of the Company&#8217;s common stock in the public market but also any other purchases, sales, transfers, gifts or other acquisitions and dispositions of common or preferred equity, options, warrants and other securities (including debt securities) and other arrangements or transactions that affect economic exposure to changes in the prices of these securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">You may not participate in &#8220;chat rooms&#8221; or other electronic discussion groups or contribute to blogs, bulletin boards or social media forums on the Internet concerning the activities of the Company or other companies with which the Company does business, even if you do so anonymously, unless doing so is part of your job responsibilities and you have explicit authorization from the Compliance Officer (the Chief Financial Officer of the Company).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Although by no means an all-inclusive list, information about the following items may be considered to be inside information until it is publicly disseminated:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(a)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">financial results or forecasts;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(b)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">major new products or processes;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(c)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">communications with government agencies, such as the FDA;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(d)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">strategic plans;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(e)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">discovery and development of new product candidates and new technology;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(f)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">details, including timelines, or results of clinical trials of the Company&#39;s product candidates;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(g)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">significant changes or developments in suppliers;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(h)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">major new drugs, processes or services, or many developments related to the same;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(i)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">acquisitions or dispositions of assets, divisions, companies, etc.;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(j)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">pending public or private sales of debt or equity securities;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(k)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">declaration of stock splits, dividends or changes in dividend policy;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(l)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">major contract awards or cancellations;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(m)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">scientific, clinical. legislative or regulatory results or developments;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(n)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">key management or control changes;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(o)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">possible tender offers or proxy fights;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">2</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(p)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">employee layoffs;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(q)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">financial restatements or significant writeoffs;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(r)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the establishment of a repurchase program with respect to the Company&#8217;s securities;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(s)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">actual or threatened significant litigation, or the resolution of such litigation;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(t)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">impending bankruptcy of the Company or its key collaborators or partners;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(u)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">gain or loss of a significant license agreement or other contracts with customers or suppliers;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(v)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">pricing changes or discount policies;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(w)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">a disruption in the Company&#8217;s operations or breach or unauthorized access of its property or assets, including its facilities and information technology infrastructure;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(x)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">establishment of or developments related to corporate partner relationships, strategic partnerships, joint ventures or other collaborations; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(y)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">notice of issuance or denial of patents.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For information to be considered publicly disseminated, it must be widely disclosed through a press release or U.S. Securities and Exchange Commission (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">SEC</font><font style="font-size:11pt;">&#8221;) filing, and a sufficient amount of time must have passed to allow the information to be fully disclosed. &#160;Generally speaking, information will be considered publicly disseminated after two full trading days have elapsed since the date of public disclosure of the information. &#160;For example, if an announcement of inside information of which you were aware was made prior to trading on Wednesday, then you may execute a transaction in the Company&#8217;s securities on Friday.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">III. STOCK TRADING BY OFFICERS, DIRECTORS AND OTHER EMPLOYEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Because the officers and directors and certain members of management of the Company are the most visible to the public and are most likely, in the view of the public, to possess inside information about the Company, we require them to do more than refrain from insider trading. &#160;We require that they limit their transactions in the Company&#8217;s stock to defined time periods following public dissemination of quarterly and annual financial results and notify, and receive approval from the Compliance Officer prior to engaging in transactions in the Company&#8217;s stock and observe other restrictions designed to minimize the risk of apparent or actual insider trading. We also require that employees limit their transactions in the Company&#8217;s stock to defined time periods following public dissemination of quarterly and annual financial results.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">A. Covered Insiders</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The provisions outlined in this stock trading policy apply to all officers, directors, employees and consultants of the Company. Generally, any entities or immediate family members or others whose trading activities are controlled by any of such persons should be considered to be subject to the same restrictions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">3</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">B. Window Period</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Generally, except as set forth in this policy, officers, directors and employees may buy or sell securities of the Company only during an open &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">window period</font><font style="font-size:11pt;">&#8221; that opens after two full trading days have elapsed after the public dissemination of the Company&#8217;s annual or quarterly financial results and closes after the close of the trading on the last trading day of the quarter or year, as applicable. This window period may be closed and may not reopen if, in the judgment of the Company&#8217;s Chief Executive Officer or Chief Financial Officer, there exists undisclosed information that would make trades inappropriate. This closing of the window period/prohibition on trading is commonly called, and referred to in this policy, as a &#8220;trading blackout.&#8221; A trading blackout may be implemented, for example, if there is some information or development with or relating to the Company&#8217;s business that merits a suspension of trading. &#160;It is important to note that the fact that a trading blackout has been imposed and/or that the window period has not reopened should be considered inside information. &#160;If a trading blackout has been imposed due to the existence of material nonpublic information, generally the window period will not re-open until the third trading day (</font><i style="font-size:11pt;font-style:italic;">e.g.</i><font style="font-size:11pt;">, two full trading days have elapsed) after the Company&#8217;s public dissemination of the material nonpublic information, or until such time a determination is made that it is no longer material nonpublic information. &#160;An officer, director or other employee who believes that special circumstances require him or her to trade outside the window period (</font><i style="font-size:11pt;font-style:italic;">e.g.</i><font style="font-size:11pt;">, during any trading blackout period) should consult with the Compliance Officer who will consult with the Company&#8217;s counsel. &#160;Permission to trade outside the window period (during any trading blackout period) will be granted only where the circumstances are extenuating and there appears to be no significant risk that the trade may subsequently be questioned.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">C. Exceptions to Window Period/Trading Blackout</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><i style="font-size:11pt;font-style:italic;">ESPP/Option Exercises. &#160;</i><font style="font-size:11pt;">Officers and other employees who are eligible to do so may purchase stock under the Company&#8217;s Employee Stock Purchase Plan (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">ESPP</font><font style="font-size:11pt;">&#8221;) on periodic designated dates in accordance with the ESPP without restriction to any particular period. &#160;Directors and officers and other members of management may exercise options for cash granted under the Company&#8217;s stock option plans without restriction to any particular period. &#160;However, the subsequent sale of the stock (including sales of stock in a cashless exercise) acquired upon the exercise of options or pursuant to the ESPP is subject to all provisions of this policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><i style="font-size:11pt;font-style:italic;">Tax Withholding Transactions</i><font style="font-size:11pt;">. This policy does not apply to the surrender of shares directly to the Company to satisfy tax withholding obligations as a result of the issuance of shares upon vesting or exercise of restricted stock units, options or other equity awards granted under the Company&#8217;s equity compensation plans. Of course, any market sale of the stock received upon exercise or vesting of any such equity awards remains subject to all provisions of this policy whether or not for the purpose of generating the cash needed to pay the exercise price or pay taxes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><i style="font-size:11pt;font-style:italic;">10b5-1 Automatic Trading Programs. &#160;</i><font style="font-size:11pt;">In addition, purchases or sales of the Company&#8217;s securities made pursuant to, and in compliance with, a written plan established by a director, officer or other employee that meets the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-size:11pt;">&#8221;) (a &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Trading Plan</font><font style="font-size:11pt;">&#8221;) may be made without restriction to any particular period provided that (i) the Trading Plan was established in good faith, in compliance with the requirements of Rule 10b5-1 of the Exchange Act, at the time when such individual was not in possession of inside information about the Company and the Company had not imposed any trading blackout period, (ii) the Trading Plan was reviewed and pre-approved by the Company prior to establishment to confirm compliance with this policy, any 10b5-1 trading plan or other applicable guidelines of the Company as may be in effect from time to time, and applicable securities laws and (iii) the Trading Plan allows for the cancellation of a transaction and/or suspension of the such Trading Plan upon notice and request by the Company to the individual if any proposed trade (a) fails to comply with applicable laws (e.g. exceeding the number of shares that may be sold under Rule 144) or (b) would create material adverse consequences</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">4</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">for the Company. &#160;The Company must be notified of the establishment of any such Trading Plan, any amendments to such Trading Plan and the termination of such Trading Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><i style="font-size:11pt;font-style:italic;">Domestic Relations Order. </i><font style="font-size:11pt;">This policy does not apply to the acquisition or disposition of Outlook&#8217;s securities pursuant to a domestic relations order, as defined in the Internal Revenue Code of 1986, as amended, or Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">D. Pre-Clearance and Advance Notice of Transactions</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">In addition to the requirements listed above, officers and directors and certain other employees and designated consultants of the Company who have been notified of their designation may not engage in any transaction in the Company&#8217;s securities, including any purchase or sale in the open market, loan, gift, pledge, hedge or other transfer of beneficial ownership without first obtaining pre-clearance of the transaction from the Company&#8217;s Chief Financial Officer (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Clearing Officer</font><font style="font-size:11pt;">&#8221;) at least two business days in advance of the proposed transaction. This includes even proposed bona fide gifts involving the Company&#8217;s common stock or transfers for tax planning purposes in which the beneficial ownership and pecuniary interest in the transferred securities do not change. This requirement does not apply to transactions that are specifically exempted from this policy, including purchases or sales of the Company&#8217;s securities made pursuant to a Trading Plan that complies with this policy. &#160;The Clearing Officer will then determine whether the transaction may proceed and, if so, will direct the Compliance Coordinator (as identified in the Company&#8217;s Section 16 Compliance Program) to assist in complying with the reporting requirements under Section 16(a) of the Exchange Act, if any. &#160;Pre-cleared transactions not completed within three business days shall require new pre-clearance under the provisions of this paragraph. &#160;The Company may, at its discretion, shorten such period of time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Persons subject to pre-clearance must also give advance notice of an intent to exercise an outstanding stock option to the Clearing Officer. &#160;To the extent possible, advance notice of upcoming transactions to be effected pursuant to an established Trading Plan shall also be given to the Clearing Officer. &#160;Upon completion of any transaction, the officer or director or other member of management must immediately notify the Compliance Coordinator and any other individuals identified in Section 3 of the Company&#8217;s Section 16 Compliance Program so that the Company may assist in any Section 16 reporting obligations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">E. &#160;Prohibition of Speculative or Short-term Trading. </font><font style="font-size:11pt;">No officer, director, employee or consultant to the Company may engage in short sales, transactions in put or call options, hedging transactions, margin accounts, pledges, or other inherently speculative transactions with respect to the Company&#8217;s securities at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">1. </font><i style="font-size:11pt;font-style:italic;">Hedging Transactions</i><font style="font-size:11pt;">. Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit an employee, director or consultant of the Company to continue to own the Company&#8217;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the employee, director or consultant may no longer have the same objectives as the Company&#8217;s other shareholders. Therefore, employees, directors and consultants of the Company are prohibited from engaging in any such transactions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2. </font><i style="font-size:11pt;font-style:italic;">Margin Accounts and Pledged Securities</i><font style="font-size:11pt;">. Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&#8217;s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">5</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in the Company&#8217;s securities, employees, directors and consultants of the Company are prohibited from holding Company securities in a margin account or otherwise pledging the Company&#8217;s securities as collateral for a loan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">3</font><i style="font-size:11pt;font-style:italic;">. &#160;Standing and Limit Orders</i><font style="font-size:11pt;">. Standing and limit orders (except standing and limit orders under approved Trading Plans, as discussed above) create heightened risks for insider trading violations similar to the use of margin accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when an employee, director or consultant of the Company is in possession of material nonpublic information. The Company therefore discourages placing standing or limit orders on the Company&#8217;s securities. If a person subject to this policy determines that they must use a standing order or limit order (other than under an approved Trading Plan as discussed above), the order should be limited to short duration and the person using such standing order or limit order is required to cancel such instructions immediately in the event restrictions are imposed on their ability to trade pursuant to the provisions herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">F. Short-Swing Trading/Control Stock/Section 16 Reports</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Officers and directors subject to the reporting obligations under Section 16 of the Exchange Act should take care not to violate the prohibition on short-swing trading (within the meaning of Section 16(b) of the Exchange Act) and the restrictions on sales by control persons (Rule&#160;144 under the Securities Act of 1933, as amended), and should file all appropriate Section 16(a) reports (Forms&#160;3, 4 and 5), which are enumerated and described in the Company&#8217;s Section 16 Compliance Program, and any notices of sale required by Rule 144.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">IV. DURATION OF POLICY&#8217;S APPLICABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This policy continues to apply to your transactions in the Company&#8217;s securities or the securities of other public companies engaged in business transactions with the Company even after your employment, directorship or consultancy with the Company has terminated. &#160;If you are in possession of inside information when your relationship with the Company concludes, you may not trade in the Company&#8217;s securities or the securities of such other company until the information has been publicly disseminated or is no longer material. Further, if you leave the Company during a trading blackout period, then you may not trade in the Company&#8217;s securities or securities of other applicable companies until the trading blackout period has ended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">V. PENALTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Anyone who effects transactions in the Company&#8217;s securities or the securities of other public companies engaged in business transactions with the Company (or provides information to enable others to do so) on the basis of inside information is subject to both civil liability and criminal penalties, as well as disciplinary action by the Company. &#160;An employee, director or consultant who has questions about this policy should contact his or her own attorney or the Compliance Officer &#160;Please also see Frequently Asked Questions attached hereto as </font><b style="font-size:11pt;font-weight:bold;">EXHIBIT A</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">6</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">FREQUENTLY ASKED QUESTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">1.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What is insider trading?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Insider trading is the buying or selling of stocks, bonds, futures, or other securities by someone in who possesses or is otherwise aware of material nonpublic information about the securities or the issuer of the securities. Insider trading also includes trading in options (puts and calls) the price of which is linked to the underlying price of a company&#8217;s securities. It does not matter how many securities you buy or sell, or whether it has an effect on the price &#8211; if you have or become aware of material nonpublic information and you trade, you have broken the law and violated our insider trading policy. In addition, our insider trading policy provides that if in the course of your relationship with the Company, you learn of confidential information that is material to another publicly trading company with which the Company does business, including a customer, supplier, partner or collaborator of the Company, you may not trade in that other company&#8217;s securities until the information becomes public or is no longer material to that other company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">2.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Why is insider trading illegal?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">If company insiders are able to use their confidential knowledge to their financial advantage, other investors would not have confidence in the fairness and integrity of the marketplace. &#160;Requiring those who have such information to disclose (the information to the public) or abstain (from trading) ensures an even playing field.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">3.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What is material, nonpublic information?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Information is material if it would influence a reasonable investor to buy or sell a stock, bond future or other security. &#160;This could mean many things &#8211; financial, regulatory or clinical trial results, potential acquisitions or mergers, major contracts, etc. Information is nonpublic if it has not yet been released and disseminated to the public.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">4.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Who can be guilty of insider trading?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Anyone who engages in a transaction of securities while aware of or in possession of material, nonpublic information. &#160;It does not matter if you are not an executive officer or director, or even if you do not work at the Company &#8211; if you know something material about the value of a security that not everyone else does, regardless of who you are, you can be found guilty of insider trading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">5.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Does the Company have an insider trading policy?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Yes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">6.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I work in a foreign office?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">There is no difference. &#160;The policy and law applies to you. Because our securities trade on a U.S. securities exchange, the insider trading laws of the United States apply. &#160;The SEC (a U.S. government agency in charge of investor protection) and the Financial Industry Regulatory Authority (also known as &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">FINRA</font><font style="font-size:11pt;">&#8221;) (a private regulator that oversees U.S. securities exchanges) routinely investigate trading in a company&#8217;s securities conducted by internationally-based individuals and firms. In</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">7</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">addition, as an Outlook employee, contractor or consultant, our policies apply to you no matter where in the world you work.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I don&#8217;t buy or sell anything, but I tell someone else the information and they buy or sell?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">That is called &#8220;tipping.&#8221; You are the &#8220;tipper&#8221; and the other person is called the &#8220;tippee.&#8221; &#160;If the tippee buys or sells based on that material nonpublic information, both you and the &#8220;tippee&#8221; might still be guilty of insider trading. In fact, if you tell family members who tell others and those people then trade on the information, those family members and the &#8220;tippee&#8221; might be guilty of insider trading too. As a result, you may not discuss material nonpublic information about the Company with anyone outside Outlook, including spouses, family members, friends, or business associates. This includes anonymous discussion on the Internet about the Company or companies with which the Company does business.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I don&#8217;t tell them the information itself, I just tell them whether they should buy or sell?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">That is still tipping, and you can still be found guilty of insider trading. &#160;According to our policies, you may never recommend to another person that they buy, hold or sell our securities or any derivative security related to our securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">9.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What are the penalties if I trade on inside information, or tip off someone else?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">In addition to disciplinary action by the Company, which may include termination of employment, anyone found liable in a civil case for trading on inside information may need to pay the U.S. government an amount equal to any profit made or any loss avoided and may also face a penalty of up to three times this amount. &#160;Persons found liable for tipping inside information, even if they did not trade themselves, may face a penalty of up to three times the amount of any profit gained or loss avoided by everyone in the chain of tippees. In addition, anyone convicted of criminal insider trading can face prison terms and additional fines.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">10.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What is &#8220;loss avoided&#8221;?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">If you sell common stock or a related derivative security before the negative news is publicly announced, and as a result of the announcement the stock price declines, you have avoided the loss caused by the negative news.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Am I restricted from trading securities of any companies other than the Company (for example a customer or competitor of the Company)?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Yes. U.S. insider trading laws restrict everyone from trading in a company&#8217;s securities based on material nonpublic information about that company, regardless of whether the person is directly connected with that company. &#160;Therefore, if you obtain material nonpublic information about another company, you should not trade in that company&#8217;s securities. &#160;You should be particularly conscious of this restriction if, through your position at the Company, you sometimes obtain sensitive, material information about other companies and their business dealings with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">8</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">So if I do not trade Outlook securities when I have material nonpublic information, and I don&#8217;t &#8220;tip&#8221; other people, I am in the clear, right?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Not necessarily. &#160;Even if you do not violate U.S. law, you may still violate our policies. &#160;Our policies are stricter than the law requires so that we and our employees, contractors and consultants can avoid even the appearance of wrongdoing. Therefore, please review the entire policy carefully.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">13.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">So when can I buy or sell my Outlook securities?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">According to our policies, if you have material nonpublic information, you may not buy or sell our securities until the third trading day after that information is released or announced to the public. &#160;At that point, the information is considered public. &#160;</font><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Even if you do not have material, nonpublic information</b><b style="font-size:11pt;font-weight:bold;">, you may not trade in our securities during any trading &#8220;blackout&#8221; period</b><font style="font-size:11pt;">. &#160;And finally, directors, officers, and certain other employees and designated consultants of the Company who have been notified of their designation must pre-clear any purchases or sales of stock with the Clearing Officer two business days in advance of the proposed transaction.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">If I have an open order to buy or sell Outlook securities on the date a trading blackout is imposed, my broker will cancel the open order and won&#8217;t execute the trade, right?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">No. &#160;If you have any open orders at the time a trading blackout is imposed, it is your responsibility to cancel these orders with your broker. &#160;If you have an open order and it executes after the trading window closes, it is a violation of our insider trading policy and may also be a violation of the insider trading laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">15.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Am I allowed to trade derivative securities of the Company? Or short the Company&#8217;s common stock?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">No. &#160;Under our policies, you may not trade in derivative securities related to our securities, which includes, but is not limited to publicly traded call and put options. &#160;In addition, under our policies, you may not engage in short selling of our securities at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Derivative securities</font><font style="font-size:11pt;">&#8221; are securities other than common stock that are speculative in nature because they permit a person to leverage his or her investment using a relatively small amount of money. Examples of derivative securities include (but are not limited to) &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">put options</font><font style="font-size:11pt;">&#8221; and &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">call options</font><font style="font-size:11pt;">.&#8221; &#160;These are different from employee stock options, which are not derivative securities</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Short selling</font><font style="font-size:11pt;">&#8221; is profiting when you expect the price of the stock to decline, and includes transactions in which you borrow stock from a broker, sell it, and eventually buy it back on the market to return the borrowed shares to the broker. Profit is made through the expectation that the stock price will decrease during the period of borrowing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">16.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Why does the Company prohibit trading in derivative securities and short selling?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Many companies with volatile stock prices have adopted such policies because of the temptation it represents to try to benefit from a relatively low cost method of trading on short-term swings in stock prices (without actually holding the underlying common stock) and encourages speculative trading. &#160;For this reason, we have decided to prohibit employees from such trading. &#160;As we are dedicated to building stockholder value, short selling our securities is adverse to our stated values and would not be received well by our stockholders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">9</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">17.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I purchase Outlook securities on margin or hold them in a margin account?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Under our policies, you may not purchase our securities on margin or hold them in a margin account at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Purchasing on margin</font><font style="font-size:11pt;">&#8221; is the use of borrowed money from a brokerage firm to purchase our securities. &#160;Holding our securities in a margin account includes holding the securities in an account in which the securities can be sold to pay a loan to the brokerage firm.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">18.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Why does the Company prohibit me from purchasing Outlook securities on margin or holding them in a margin account?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Margin loans are subject to a margin call whether or not you possess insider information at the time of the call. &#160;If your margin call were called at a time when you had insider information and you could not or did not supply other collateral, you and the Company could be subject to litigation based on your insider trading activities: the sale of the securities (through the margin call) when you possessed material nonpublic information. &#160;The sale would be attributed to you even though the lender made the ultimate determination to sell. &#160;The SEC takes the view that you made the determination to not supply the additional collateral and you are therefore responsible for the sale.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">19.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I hedge my ownership position in the Company?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A:</b><font style="font-size:11pt;"> &#160;Hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds are prohibited by our insider trading policy. Since such hedging transactions allow you to continue to own the Company&#8217;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership, you may no longer have the same objectives as the Company&#8217;s other shareholders. Therefore, our insider trading policy prohibits you from engaging in any such transactions.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">20.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I exercise stock options during a trading blackout period or when I possess material nonpublic information?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Yes. &#160;You may exercise the option and receive shares, but you may not sell the shares (even to pay the exercise price or any taxes due) or otherwise settle the option during a trading blackout period or any time that you have material nonpublic information. &#160;Also note that if you choose to exercise and hold the shares, you will be responsible at that time for any taxes due.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">21.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Am I subject to the trading blackout period if I am no longer an employee of the Company?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">It depends. &#160;If your employment with the Company ends on a day when the window period is closed, you will be subject to the trading blackout period then in effect. &#160;If your employment with the Company ends on a day when the window period is open, you will not be subject to the next trading blackout. &#160;However, even if you are not subject to our trading blackout after you leave the Company, you should not trade in Outlook securities if you possess material nonpublic information. &#160;That restriction stays with you as long as the information you possess is material and not released by the Company.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">22.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I gift securities while I possess material nonpublic information or during a trading blackout period?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">No. A gift of stock could subject you to insider trading liability if you are aware of material nonpublic information at the time of the gift and knew or were reckless in not knowing that the recipient would sell the securities prior to the disclosure of such information. Therefore, gifts may only be made</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">10</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">when you are not in possession of material nonpublic information and not subject to a trading blackout period.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">23.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">What if I purchased publicly traded options or other derivative securities before I became an Outlook employee (or contractor or consultant)?</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">The same rules apply as for employee stock options. &#160;You may exercise the publicly traded options at any time, but you may not sell such securities during a trading blackout period or at any time that you have material nonpublic information. &#160;When you become an Outlook employee, you must report to our Compliance Officer that you hold such publicly traded options or other derivative securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">24.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">May I own shares of a mutual fund that invests in the Company?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Yes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">25.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Are mutual fund shares holding Outlook securities subject to the trading blackout periods?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">No. &#160;You may trade in mutual funds holding our securities at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">26.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">May I use a &#8220;routine trading program&#8221; or &#8220;10b5-1 plan&#8221;?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Yes, subject to the requirements discussed in our Insider Trading Policy, any 10b5-1 trading plan guidelines that may be in effect from time to time and applicable securities laws. &#160;A routine trading program, also known as a 10b5-1 plan, allows you to set up a highly structured program with your stock broker through which you specify ahead of time the date, price, and amount of securities to be traded. If you wish to create a 10b5-1 plan, you must contact the Compliance Officer for approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">27.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">What happens if I violate our insider trading policy?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">Violation of our policies may result in severe personnel action, including a memo to your personnel file and up to and including termination of your employment or other relationship with the Company. &#160;In addition, you may be subject to criminal and civil enforcement actions by the government.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">28.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Can I pledge my Company securities as collateral for a personal loan?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">A: No. Pledging your shares as collateral for a personal loan could cause the pledgee to transfer your shares during a trading blackout period or when you are otherwise aware of material nonpublic information. As a result, you may not pledge your shares as collateral for a loan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">29.</b></font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Who should I contact if I have questions about our insider trading policy?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">A: &#160;</b><font style="font-size:11pt;">You should contact the Compliance Officer.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:11pt;">11</font><font style="font-size:11pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>otlk-20240930xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 12/27/2024 04:49:23 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Subsidiaries of the Registrant</b></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">d</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Name of Subsidiary</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 72pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">State or Other Jurisdiction</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Outlook Therapeutics Pty Ltd</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Australia</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Outlook Therapeutics Limited (dormant subsidiary)</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">England and Wales</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Outlook Therapeutics Limited</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Republic of Ireland</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This list does not include joint ventures in which the Company has an ownership interest.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>otlk-20240930xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 12/27/2024 04:49:35 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the registration statements (Nos. 333-211362, 333-216081, 333-223064, 333-229685, 333-234024, 333-236471, 333-238318, 333-254777, 333-262731, 333-269770, 333-278343 and 333-281549) on Form S-8 and (Nos. 333-222387, 333-223063, 333-273979, 333-278209, 333-278340 and 333-278959) on Form S-3 of our report dated December 27, 2024, with respect to the consolidated financial statements of Outlook Therapeutics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ KPMG LLP</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Philadelphia, Pennsylvania</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">December 27, 2024</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>otlk-20240930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 12/27/2024 04:49:35 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;text-indent:36pt;margin:0pt 0pt 12pt 360pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">I, Lawrence A. Kenyon, certify that:</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">1.</font><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Outlook Therapeutics, Inc. (the &#8220;registrant&#8221;); and</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">3.</font><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">4.</font><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><font style="color:#231f20;display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">5.</font><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:12pt;"></div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Date: </font><font style="font-family:'Times New Roman','Times','serif';">December 27, 2024</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">/s/ Lawrence A. Kenyon</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Lawrence A. Kenyon</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Chief Financial Officer and Interim Chief Executive Officer</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">(Principal Executive, Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>otlk-20240930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 12/27/2024 04:49:35 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;"> AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">I, Lawrence A. Kenyon, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, certify that the Annual Report of Outlook Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-K for the year ended September 30, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that information contained in the Report fairly presents in all material respects the financial condition and results of operations of the Registrant.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:54.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:39.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Date:</font><font style="font-family:'Times New Roman','Times','serif';"> December 27, 2024</font></p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">By: </font></p></td><td style="vertical-align:top;width:54.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">/s/ Lawrence A. Kenyon</font></p></td></tr><tr><td style="vertical-align:top;width:39.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Name:</font></p></td><td style="vertical-align:top;width:54.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> </font><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Lawrence A. Kenyon</font></p></td></tr><tr><td style="vertical-align:top;width:39.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Title:</font></p></td><td style="vertical-align:top;width:54.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#231f20;font-family:'Times New Roman','Times','serif';">Chief Financial Officer and Interim Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:top;width:39.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:54.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;">(Principal Executive, Financial and Accounting Officer)</i></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;">A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-style:italic;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>otlk-20240930x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 otlk-20240930x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &D WL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M3?\ @H#XA&G^'_!^D7_Q:/PG\.:K=7":G<V]E=7-U>QJJ$1QBWC9@!N;<&=%
M.X9W=*\M^ _Q/_8I_9^2&YT/Q0-2\0*/GU[5M%U">[+=RA^S;8O^  >Y-?<7
MC#X=>$_B'!;0^*O#&C>)H;9B\$>L:?%=K$Q !*B13M) &<>E<O\ \,S?!_\
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MQ(0 T\3AU3)Z;P&3/;?SQ7L%G9V^G6D%I:01VMK!&L44$*!$C11A551P
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M)W VR,$A13%(L:[ A4[ 'SN+<Y/?_P#!,V*PA\??&E=)^U?V3_83FR-\ )S
M9&,1DV\;BFTG'&>G%?I/XD^$_@CQCJT.JZ_X-\/ZYJ<./*O=2TN"XF3&,;7=
M"PQ@=#VJYI/P_P#"^@ZOJ.JZ9X;TC3M4U)0E[>VEC%%/=*.@E=5#.!Z,35U,
MQA.BZ:BU=+JK*W;0B&!E&HIN2T;]7?N?FE^PO_R97^TQ_P!@B^_]-LU?07_!
M*3_DV"Z_[&&[_P#14%?4>@?"_P &^%-'U'2=$\):%H^E:D&%[8V&FPP0709=
MK"5$4*^5.#N!R.*O^%?!OA_P+I7]F>&M#TWP]IOF&7['I5I';0[SC+;(P!DX
M&3CM6&(QL:\:B2MS-/[E8VHX5TG!M_"FOO9^57[%O@W5_B)^R/\ M&^'=%66
M?4KF"S>VMXF^:5T$LA1?=Q'M]\@5YK\#_!G[,FM>"&;XK>,?&?A+QG;32QW%
MG8PA[>8!CL\L+:2E3C"D.P^8$\ \?LOX1^'OA;X?Q747A?PUH_AN*Z<27":1
M816JS,. SB-1N/)Y-9>N_!3X>>*=7;5M:\!>&-7U1F#F^O\ 1[>><L.AWLA;
M/ YS75_:B<YNS2DT]'KM;L<_U!J,-4VE;5:;W/SZ\>^'OASH7_!-KQA+\+[G
MQ%>>&K[Q-#-Y_B4Q_:))EF@B9E$:JH0B-<9 ;KGT'UE^RAJUCX=_8D\':IJ-
MNUUIUCX=ENKFWCC$C2Q)YC.H4X#$@$8/!S7M>J>!O#>N>&SX=U+P_I6H>'R%
M!TJZLHY;7"G<H\IE*\$ CC@\U>T?0M-\/:1;:5I6GVNF:7;1^5!96<"Q01)_
M=5% 51[ 5PU<6JM/D:?Q7W\K'73P[ISY[_9L?CG\6O$_P7\%11^//V>?B)XH
M\)>+YKE6?PL+>>-(T).X"7:%"C/W"\H()'2OUH^#.M^(/$OPE\':MXJM?L?B
M2]TFVN-0@,?EE9VC4OE/X3DY*]LX[5'9_ [X<:=K2ZQ:?#_PM:ZNK;Q?PZ+;
M).&]?,";L\#G/:NVIXO%0KPC&*>G5ZOTV%A\/*C)R;6O1;>I^=?Q5#^!_P#@
MK'X"U:=-D.L6T B>3E6\VUGL^.G\0Q]?RKZ^^+W[4WPO^ VLV6E>.O% T/4+
MVW^U00_8+JX+Q;BN[,,3@<J1@D'BO'/V\_V<O&/Q3NO 'CGX:V"7WCCPIJ"N
MD!N8[=I(=ZRHP>1E7,<D8(&0<2-UP*^AM>^%W@_XF1:=J/C3P'H&L:HELJ[-
M9TZWOI+7/S-$LCJW 8G[O!/-75G1J0HSGK96:35]-B:<*D)5(PZNZ;VUW/BO
M]A7]HGX/_ ;X7Q> ]9^)>F:IKE]K4D\!TO2]4,+>:(D12TMI'@Y7G(P,CFOT
M'KSJU_9Q^$UC=0W-M\+_  9;W$+B2*:+P_:*Z,#D,I$>001D$5Z+7+BJM.M/
MVD$[O>]OT1T8>G.E#DG;3:USXG\4?MN_L_?$O3M?\*?&'0)=)OM+N;FTETK5
M]+EO,LCE=T$L:%HV8*#DB,@]^ 3X=_P3^\,WO_%_?$NA65_9?#BXT:\M-/\
MMK<R-EVA4GH[QQ;@Q'0O[U^CGBCX0^!/'&HKJ'B/P5X=\07Z@!;K5-*@N91C
MIAG0GL*Z&TTBPT_3$TVULK>VTY(_*6TAB5(E3^Z$ P![8KJ6,ITZ4J=*+7-:
M]W=*W8Y_JTYU%.I):=EK\S\C?V#_ (D?L_>!O"GBF#XRVF@7.I3WL3Z>=8\.
MOJ;"(1D-M98)-@W=LC-?HOX:^+/PW\2?L[^)?$?PXGLCX+T73KY%2RL'L+>
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M=\):'X1T5-'T+1M/T72(]VS3].M8[>W7<26Q&@"C)))XYS5PS!4[M1^WS?\
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M0:'FOQ5U77/B%XF\$ZKX;T?QW?\ @_2FU#_A(=.TMKOP]>3[H$^S;5GDM'F
M<,?D8]".IP>;L?B/8_%[QI\&-"\-ZQXALOA_K6E:EJDB?VK=0:A=2P9B$,UT
MLOGGRWWD@2D,5&2RA:^A?&7PYT/QZL0U>*]#Q1O$)=/U*YL)&C?&^-GMY$9D
M. 2C$KD XR*Q[WX$>!KS2/#6FIHATZW\-!QH\FE7EQ8SV0="D@2:"1)!O!._
MYOG/+9/- 'R*_CSXC:I\$/AAX@N?'FK0Q6OC&W\/RPV_[F;4D2ZEC$MQ<*0\
MH\M0A3HQ!9][<CU?XMZQK'BWXP?$+P\^OZQHVF>&_ LFIZ;#HVHSV)^V2%C]
MI=H75I2FQ5".60<_+DFO5=9_9O\ A]KVA:%HESH]W%H^AK&-.T^RU>]M((&C
M)*2[(IE5I068^:P+DDDL:L^)O@'X)\826LNK:=?7-S!IC:,;M=8O8KBXLF(+
M6]Q*DP>XC)&2LI<$DGN<@$OP#\7:IX]^"_@SQ#K9#ZMJ.F0SW,BQB,2.5Y?:
M  -WWL  <\<5WU0V5E;Z;9P6EI!%:VEO&L4,$*!$C11A551P    !TQ4U 'R
M_P"-OVT-:L-)UJW\.? CXM7>OPQRQV$E[X3?["\XR$9V24L8\X/RC)'3&<CB
M?@=^V_\ $*X\&N_Q'^"?Q%U35S<O]GO/"?A*5[:2# P&\R1?G#!P=O&,=P2?
MM:BNY5J*CR^R_%G(Z55RYO:?@>+_  Q_:8_X6;XN@T'_ (53\3O"GG1O)_:?
MB?PY]CLDVKG:TOF-@GH!CDUPOP\_:/\ &/BCX/Z;XUUS4/"NAMK>IG2M.M8-
M(O[V8.DCJS+!#(TER[&,@0ILVCYS(<;#]15YQ%^SQX M_!VD>%X-#DM='TB]
M;4-/6VU"ZBGM;AF9C)'<+()5)+MT?O["N6<HR=XJQT04DO>=SQF#]J_Q9=?"
MK1M:@TS2&UV?Q[_PAMP;BTN+>"1"S[9A S^;"V/+RCLQ!#9 SA<*U^,^I>*_
MVG? OAGQ+HN@ZEK?A_Q%K&EQZS:PW5N$C^Q1L)(H3<,JLP+*WF&4# *[3S7T
M%9_L[?#ZQT"ST6'06&G6FM+XBBB>_N78:@O2<NTA9CZJQ*GJ0:EM_P!G[P#:
M^/4\:1:#M\3)>RZ@M]]LN#B>6,1R/L\S9R@ QMP.H /-9EGR_P#LJ_$_Q-\.
M/AG\)K.2/2KWPKXG\0WVC"!()1?02--*RS>;OV%=X8%/+X !W<D+H?#GXP>(
M/!_[+G@C4/!%AX9TG5-4UBYTG3_##V%W=+>7$EZX!25KP/&JC>[LWF#H!M&!
M7T/X3_9M^'/@C4M+OM&\/&VETMY);&.6_N9X;>5QAY4BDD9!(1@&3;NP!SP*
MK1_LO_#BWL?#UI;:->V,7AY[B32VL=;O[>2T:=MTS+)'.K98]22>.!QQ0!PG
MC']HCQ;X27XY0FTT6XNO .FZ1<V3BWF"7$US"7F\P>;DJ&'RA2I ZENM</#^
MUQ\1)O#^I>($T_PPUC8>,8_"QLFMKA99Q(,K+YOG$(5RH(V-NR?NXP?>O%/[
M-?P[\:WMU=ZUH<]_/>6<5C=L^J7:B\BB4B+SPLH$SIG(D<,X(!#9 (DB_9Q^
M'<.CW6E)X>Q87.L)KTL7VVX^:^3&V7/F9&,#Y0=OM0!PVB?M"ZQ::+\5(/$M
MUX?M-5\&:G%IZ:J+:YALYEF">6YMU::5G!+8B1R9#M4%,[AXA\7?C+XA^)EA
M::'>Q63ZKX:^)6@Q6=Z=*N]*2X6:&5T\VTN&::,JZMG)Y4@@#J?K/4O@-X$U
MB#Q3%>:"LZ>)[F*\U7-U,&FFBQY<BD/F)EP,&/;63+^R[\-+JWO8;KP_/?"]
MOH-2N9;W5;R>6:YA1TBE>1YBQ95E<<GG(SD@8 &_!7XGZYXR\2_$#PQXDCT^
M35?">I1VAOM+@D@@NHI8]Z-Y;O(48<@C>PZ?CZO7->!_AQX>^'-K?0Z!8O;&
M_N&N[RXN+F6ZN+F8]7DFF9Y'/'\3'':NEH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_\ B:/[1B_N3_\ @/)_\30!:HJK_:,7]R?_ ,!Y/_B:/[1B_N3_ /@/)_\
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M)_\ P'D_^)H_M&+^Y/\ ^ \G_P 30!:HJK_:,7]R?_P'D_\ B:/[1B_N3_\
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M)_\ $T 6J*J_VC%_<G_\!Y/_ (FC^T8O[D__ (#R?_$T 6J*J_VC%_<G_P#
M>3_XFC^T8O[D_P#X#R?_ !- %JBJO]HQ?W)__ >3_P")H_M&+^Y/_P" \G_Q
M- %JBJO]HQ?W)_\ P'D_^)H_M&+^Y/\ ^ \G_P 30!:HJK_:,7]R?_P'D_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MUG5!EF"C(&2<<DX%$C%$9@I<@$A5QD^PSQ7SI\9_C]";!-&T_3]3TW5[:^AG
MF2^B6/"QN' &&;.65?;BO0P6!JXZJJ=)>OEYGBYKFV&RB@ZV(?HN[[(^C:*X
M;X>?%O3_ (E/)_9>EZI%!$O[RZN8D6%6_NA@Y)/T'Y5W-<U:C4P\W3JJS70]
M##8JCC*2K8>7-%[,****P.H*\E_:<2XC^&:WUC#K#ZGIVHVU]9SZ)I@U&6VF
MC?<LKVY(WQCD-@Y .1R*]:KRC]IF_O++X7R)IVH:_9:C=7MO:VT?AATCO[J1
MWVB&.1P1'G.2_P#"%)YZ4 >9_L:G3=2EO[R7X@VGBS7;*R6P72K?3WL&TVW,
MSRMYD4@$C,TC\L1@8 &<YKZCKYT_9?\ #FC^$O$?B#3KWP-K7@_QVUM%<7=U
MKNKC59M1MBQ"NMRK%#M9<,H P2O7/'T70 4UW6)&=V"(HR68X 'J:=5;45C?
M3[I9O,\HQ,'\I"[XP<[5 ))]  3[4 <QIGQD\ :U:W]SI_CCPW?VVGQ>?>36
MVKV\B6T><;Y"KD(N>,G K>\/>)=(\6Z5%J>AZK9:UILI81WFGW"3PN5)# .A
M(.""#SU%?%7B#PGXP@T_3_"GA&W\8>)/A+X:.CWTL/B'0&M;S?%?;I(+>,VT
M$MRGDC>P*.047#?-BOH']G#1M4M9_B1K=W8WNEZ7X@\4W.H:9:ZA;/;3M#LC
MC,S0N \>]HV(#JK$ ,1AAD ]FHI",@C./<=JK?9)?^?V?_OF/_XF@"U157[)
M+_S^S_\ ?,?_ ,31]DE_Y_9_^^8__B: +5%5?LDO_/[/_P!\Q_\ Q-'V27_G
M]G_[YC_^)H M455^R2_\_L__ 'S'_P#$T?9)?^?V?_OF/_XF@"U157[)+_S^
MS_\ ?,?_ ,31]DE_Y_9_^^8__B: +5%5?LDO_/[/_P!\Q_\ Q-'V27_G]G_[
MYC_^)H M455^R2_\_L__ 'S'_P#$T?9)?^?V?_OF/_XF@"U157[)+_S^S_\
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M_P#$T?9)?^?V?_OF/_XF@"U157[)+_S^S_\ ?,?_ ,31]DE_Y_9_^^8__B:
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M?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\
MWS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V
M?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\
MWS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V
M?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\
MWS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V
M?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\
MWS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V
M?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\
MWS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V
M?_OF/_XFC[)+_P _L_\ WS'_ /$T 6J*J_9)?^?V?_OF/_XFC[)+_P _L_\
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M,[G 4#J2>PK/T3Q-H_B:*671]5L=5CB8+(]C<I,$/8$J3@T :=%%% !1110
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MJ?[M2G4](V7_ (%/E3^39Z-=WEO80-/<SQV\*_>DE<*H^I-</JWQR\':;/\
M9H-3.L7G1;;2HFN6;Z%1M_6J]I\!O#+3K<ZR^H>)KL<^=K%X\O/^Z,#'L0:[
MC2M"TW0H/)TVPMM/A_N6T*QC\@!1;!T]W*;^45_[<_P07S.OLH4EYWF_N7*E
M]\C@?^$_\;^(>- \"RV,+=+OQ!<"#'UA7YOR-<O\#_A9>_#WXAZ[_:-_%<W1
MTR"5DMMYC_?32]VY)7[.>2/X_P _=*Y73_\ DJ6O_P#8&T[_ -'WU4\?*-*=
M&C%0C+>UVWZMM_A8S644ZE>GBL54E4G3NXWLDK[V44OQN=51117F'OA1110
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MT5ZIN+_5?@5]1Q-+^!B9>DDI+\E+_P F.2T;XL^#M? ^Q>(]/9FZ)-,(7/\
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MR_Y^X/\ OZO^-']J67_/W!_W]7_&K5% %7^U++_G[@_[^K_C1_:EE_S]P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV(KU^O$?C/\ &K4_A3XS,1TW6M3TR[T&5[./2])>[07XD(4R,BY4;<<9Q[4
M6OV?_@[XD^$1U&UU'4?#,NDW"AH[7P_H2:<1-NY>1E)W\9 STKV2O!?V=]/\
M:^&_$%YI?B3Q9J?C*VO-%L]7FGU2W\MM/NY2^ZW0]-I49V?P[!P-W/O5 !11
M10 45RME\5O!.HV^K7%IXQT"Z@T@;M1EAU2!ULADC,Q#8C&5(^;'0^E;'A[Q
M+I'BW2HM3T/5;+6M-E+".\T^X2>%RI(8!T)!P00>>HH TJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH S-;\3:/X9BBEUC5;'2HY6*QO?7*0ASW +$9-6[#4+75;.*[LKF&\M)E
MW1SV\@>-QZAAP1]*\^_:$\60>$OA;KTMW>:/8VUW97%HTNKZD+/+/$P58LHP
MDD)X"97)P,UW^F37-QI]O)=Q0P7+H"\=M,9HP?\ 9<JI8>^T4[.UQ76Q:HHH
MI#"BFNZQHSNP55&2Q. !ZUP>M_&SPWIMV;#3Y)_$FJ<@66C1&X;/NP^4<]>>
M/2MZ5"K7=J46_P"NO8Y,3B\/A(\U>:C?:[W]%NWY([ZJ&L:[IWAZT:ZU.^M]
M/MQ_RTN90@^@SU/M7GK3_$GQ@I;%AX"TQOXY2+N\*_3[B\>O(J&Q\ > -$NQ
M?^(-:M]?U0<F[U_4$EP?9&(4#TX.*[%AJ5+^-4U[1]Y_?\/W-^AYOU[$XC_=
M*+2_FG[J^4?C?S4?4M2?&@Z_(T'@OP_?^)Y 2OVPK]FLU/3F5QS],<XZUY/\
M/OAUXYT_X@:WI]_J.K:9<W$<$]W?:;+;RB2.1I0CNSR!AS'(!M1FZ\ 8S[G-
M\7_A]I,8CF\:^&;.-!@*^JV\84>F"_%>2_ C]JWX??'CXW>,=,\+W]P]S::9
M:PQ&[B$:WJPS7)DE@^8ED'GQ]0IY)QCFNJ&*JT:<XX6ERQ=KMKF?E>ZM]R1Q
MU,JIXNK3J9A6<Y1ORJ+Y(JZULD^;[Y/\6>A+\ _#UVP?6[W6?$CYR3JFHR.,
M_1=M=-H_PW\*Z!M-AX?TZW=>D@MU9_\ OH@G]:Z2BO.J8W$U5RSJ.W:^GW;'
MJT<KP-"7-3HQ3[V5_O>OXB !0 !@#H!2T45QGJ!1110 57U"^CTVSENIEF>.
M)=S+;P/-(1[(@+,?8 U8HH Y+X3NX^&WAJWEM[JTN+33K>UFAO+:2"1)$B56
M&UU!(!!Y'![$UUM%% !1110 4444 %%%% !1110 4444 %%%% !1110 R:(3
M1/&Q8*ZE248J<'T(Y!]Q65X;\*:=X2MIK?31=+%-*TSK<WLUS\[,69@978@L
MS%CCJ22>:V** "BBB@ HHHH *Q_$'@[0_%47EZOI-IJ Q@-/$&9?HW4?@:V*
M*N$Y4WS0=GY&=2E"M%PJ133Z-71YFWP4&B$OX1\2ZMX8;JML)?M-J/\ ME)U
M_.N!\3:I\5=*^(WAFQN[:UUN&"X:2REAA$%O<RF"56WN?NN(VE.W('&0#BOH
MJN5\9?\ (P>!O^PS)_Z;[RO3IYC43?MX1J:?:5W]^_XG@5LDHM)86I.C9I^Y
M)I:=.5WBODO6ZT.=_P"$=^)?B3G4O$NG>&K=NL&C6IFDQZ&23H?=:EM?@/X;
MDG6YUN74O%%VO/FZO>/* ?91@8]B#7H]%9/'UUI3:@O[J2_%:OYLZ5D^$D[U
MTZC_ +[<OP?NKY)%#2=!TW08/)TW3[73X?[EM"L8_05?HHK@E)R=Y.[/7C",
M(J,%9(****DL**** .:\+^'-4T75]=O+[4[.]BU2Y%UY5O8O T3"*.(#<97W
M#9$O8<DGI@#I:** "BBB@ HHHH **** ,?Q+XKT[PE:PW&I&Z6&6585:VLIK
MGYV8*JD1(Q!9F"C/4D <UH6%]'J5G%=0K,D<J[E6X@>&0#W1P&4^Q KB?B]X
MIT71-,T73]1U>PL+_4=:TQ+*UNKE(Y;IEOH&81JQ!<@ DA<X S7?4[-:BN%%
M%%(84444 %%%% !1110 4444 %%%% !7C'QSL/B_>>*O"L7PZUZWT71+HR6^
MISR:=#=M;28+1RLKD'8<%3MY!(.#GCV>O*/C_P#&:^^%.DZ5:>'='7Q+XQUF
M=TT[1RY7S(HD,MQ*2!G:B+^;+UYH R/A1X*^)WA[XIWU[X\\40^+;.311#;W
M=I8)9Q12>?DH44_,V.<XZ<5[=7G/@/XPVGQ$US1ETA(Y=%U3PZFN0W!)\Q6:
M;RS&1T&WD'N""*]&H *AO0K6<X:W-VIC8&W 4F48^[\Q YZ<D#GFIJ* /A'X
M@^ ?$FN>/9M7T+0O$OB#PQ8PZ++J$^L:"UE=Q1V^H;CIUM;)%"EQ$D8,A\N%
M^40"1L@5]$?LX:-JEK/\2-;N[&]TO2_$'BFYU#3+74+9[:=H=D<9F:%P'CWM
M&Q =58@!B,,,^S44 (<X.#@]LU6\N]_Y^(/^_#?_ !=6J* *OEWO_/Q!_P!^
M&_\ BZ/+O?\ GX@_[\-_\75JB@"KY=[_ ,_$'_?AO_BZ/+O?^?B#_OPW_P 7
M5JB@"KY=[_S\0?\ ?AO_ (NCR[W_ )^(/^_#?_%U:HH J^7>_P#/Q!_WX;_X
MNCR[W_GX@_[\-_\ %U:HH J^7>_\_$'_ 'X;_P"+H\N]_P"?B#_OPW_Q=6J*
M *OEWO\ S\0?]^&_^+H\N]_Y^(/^_#?_ !=6J* *OEWO_/Q!_P!^&_\ BZ/+
MO?\ GX@_[\-_\75JB@"KY=[_ ,_$'_?AO_BZ/+O?^?B#_OPW_P 75JB@"KY=
M[_S\0?\ ?AO_ (NCR[W_ )^(/^_#?_%U:HH J^7>_P#/Q!_WX;_XNCR[W_GX
M@_[\-_\ %U:HH J^7>_\_$'_ 'X;_P"+H\N]_P"?B#_OPW_Q=6J* *OEWO\
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M"%!]Z]TCC2&-8XU5(T 5548  Z "G45S3JSJN\W<WA"--6BK!1116984444
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MD'_?I?\ "K5% %7^R[+_ )](/^_2_P"%5]0T*WO+.6&$"QD=<+<V\,1DC/J
MZ,N?JIK2HH Y_P *^"K'PIH-GI*.^HPVD:PQ2WL<1D"* %4E$4'  Y(R>Y-:
MW]EV7_/I!_WZ7_"K5% %7^R[+_GT@_[]+_A1_9=E_P ^D'_?I?\ "K5% %7^
MR[+_ )](/^_2_P"%']EV7_/I!_WZ7_"K5% %7^R[+_GT@_[]+_A1_9=E_P ^
MD'_?I?\ "K5% %7^R[+_ )](/^_2_P"%']EV7_/I!_WZ7_"K5% %7^R[+_GT
M@_[]+_A1_9=E_P ^D'_?I?\ "K5% %7^R[+_ )](/^_2_P"%']EV7_/I!_WZ
M7_"K5% %7^R[+_GT@_[]+_A1_9=E_P ^D'_?I?\ "K5% %7^R[+_ )](/^_2
M_P"%']EV7_/I!_WZ7_"K5% %7^R[+_GT@_[]+_A1_9=E_P ^D'_?I?\ "K5%
M %7^R[+_ )](/^_2_P"%']EV7_/I!_WZ7_"K5% %7^R[+_GT@_[]+_A1_9=E
M_P ^D'_?I?\ "K5% %7^R[+_ )](/^_2_P"%8GB#X<Z!XGN+6>^M9Q+:DM";
M2]GM0A((+8B=1G#,,GG!(Z&NEHH I1:-8PQ)&MI$510H+J&.!ZD\D^YI_P#9
M=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR
M_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_
MWZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^
M_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_P
MJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\
MA1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5
M_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\
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M[G=Y .< 8 &<U]GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQQW,<D@93<1Y<HK;6VDAMI#*1D=UYE[_ ,^\'_?]O_B*/,O?^?>#_O\ M_\
M$5Q5*DZLW.;NV=M.G"E%0@K)$EHNVUA&R2/"*-DK[W7CHS9.3ZG)^IJ:JOF7
MO_/O!_W_ &_^(H\R]_Y]X/\ O^W_ ,169H6J*J^9>_\ /O!_W_;_ .(H\R]_
MY]X/^_[?_$4 6J*J^9>_\^\'_?\ ;_XBCS+W_GW@_P"_[?\ Q% %JBJOF7O_
M #[P?]_V_P#B*/,O?^?>#_O^W_Q% %JBJOF7O_/O!_W_ &_^(H\R]_Y]X/\
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MW_;_ .(H\R]_Y]X/^_[?_$4 6J*J^9>_\^\'_?\ ;_XBCS+W_GW@_P"_[?\
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M74/WC>'U8&RMYRV6E@3&8MV3N13L)P0 >O:444 %%%% !1110 4444 %%%%
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M<E2I*K)SF[MG9"$:<5""LD%%%%9EA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%>7_&^Y\7>'O#]SKWAW7DLK:UC!N+.:")@1G&Y&*DYY'!/TKIPU!XFK
M&DI)-Z:WM^"9PX[%K X>>(E!R45=J-KVZO5K8[KPUXDL_%5A+=V3[XH[F:V/
M^]'(R$_0XR/8BM&ZNH;&UFN;B188(4,DDCG 50,DGV KY)_9UU'QAK6JW.B:
M-KZZ7IJ$WMT9(8Y7.2JDH'4\GCVKZD\3PZ>_A;4H=8G*Z:]J\=U.W!"%<,W
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MES'#<RZ[XIU63[5KGB2^^:ZU&X.2S,Q)(0$G:N3C))R22?5JJ_V=%_?G_P#
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M)/\ XJC^SHO[\_\ X$2?_%4 6J*J_P!G1?WY_P#P(D_^*H_LZ+^_/_X$2?\
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M,K%4GC\N23 R,%7VL-PRM=7X[\+1^.? _B'PW-.;:+6-.N-.>=5W&-98FC+
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MI&I\3?V6M,\1^&OAOX.\-:=IFE^#O#GB :M=P7,TKS"'=([PPE@^1(\K%@S
M  8Z #TO5/@]X3UKQ=!XEO=.GN=3@O(]017O[C[+]JCC$4=P;;S/),JH%42%
M"P"KSP, ':4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>otlk-20240930x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 otlk-20240930x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &K W@# 2(  A$! Q$!_\0
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MSQ/I-MJNC:C::MIETN^"]L9UFAE7.,HZDJPR#R#3L[7Z"NKV+]%%%(84444
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MWQ LO"5G)K>E7=],MM9WNJV:16MQ*QPB!ED9E+$@#>JC) KP/]M;0-.\4_\
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M:?(^"Q-S"?\ 5L3PV-C YRI.07@*T:2DI75[)22O;_AQ8RG*HXM6=KZ-VO\
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M6EKIV_X+NCZW^&7[=/PS^+WQ<MOA[X8;5;[4[BW>=+_[,@LB4C,CQ[_,W%@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5G.?M)/7N*-.,(\B6A\8WG_!*#X+W6IFZBO_ !99P;L_8H=1A,('IEX&?'_
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M<SS;;R!D7:LBR(%P^"<\;3W4CBO8**%7J122EL[_ #&Z5-MMK=6^1\?>%?\
M@EE\&/#.OV^J27'B;61!,LR6>H:A$(<JV0#Y4*,1_P "K[!HHHJUZM=IU)7L
M%.E3I:05@HHHK U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\YG^,_D321_\ ""^-9-C%=Z:1E6P>H._I7HU%=%&=.%_:0YOG
M8XL32KU;>PJ\G?1._P!YX=X4^,_C"/5=4;Q%X&\0R:>[[K%=/TB3S(QD_*^X
M@'C'/KGMT[31OBU_;&JVME_PAGBZQ\^0)]IO-+\N&//=VWG ]Z[VBNRMB</5
M;:H*+\FSS<-@,;ATHRQ;DD^L5=ZWM?\ +L?&_AO4]9^*'P ^)7Q0U+QAXBTG
MQ/97&I3Z>EAJ\]K:Z8MIEH8/LJ.L3@[ &\U69@YR<\UQ:_'+XB0?$?1/']QJ
M&I3Z1I'A71M6\0>'(YW6TEMKE&2YN5A!VAU9TE7 S@8)P.?K/5OV=?A_K6H:
MK=76BSA-6NUOM1L+?4[N"PO9P5/F3VB2K!*Q**6WH=Q&6R2:WX_A;X5A\1:G
MKB:/$-1U/3DTF[?>_ER6B9"Q>5G8% )'"@XXKRSWSY2\/:G\2_B#\+K76_#=
M_K'B_2;+QMJCZII^GZ])9WU[8*Y\E(+K>&$:#)\M&&[*@>WL_@#XTZ#XL^&%
MA!X9;QE>W5_;3V]C-J6D7EQ-!-YDD:QW%VD;1(Z,NTM)+D*%9V.2QZ/1OV;O
MA]X<\/Z=HVCZ3>Z/9:=--/:MINLWUM<1-,%\T">.82[6V)E"VT[5..!77^&_
M OA_PAX/M?"ND:1:V7AVVMS:QZ<J;HC&<[@P;.\MEBQ;)8LQ8DDF@#YE\ ^.
M;[X3>%;[0_%%IXQL?BW;>#;W5A-X@UR74["^>%69FB47<T2L&C'5$;;D=&P<
MSP5JGC*T\1_!BUT?QOJ[WWQ"\(7MWJ=[JL\NIP6]Y]F6=+B.WDDV1E'DVA$V
M*0 "#TKZ1T#X)>#O#FMW&L0:9<7^J3V?]G-=ZSJ-SJ4BVV23"AN9)-D9+'*K
M@'/(-4O#G[/7@3PDTK:1I=Y92-9OI\4JZO>M):6[-N:.V8S$VREN?W)3MZ4
M?..@_%#QAX2_9 ^,&O1>(]3U77]'\27NGV>J:G.;B>*/SX(002,#:KLP  4'
MH!7I_P ,;G5/!O[36M> X-=U?7/#+>$K76%;6-0FOG2Z\_R2RRRN[*'&6*@[
M<C@#%=]X>_9W\!>&-%US1[+2+J32=;60:A87VK7EY!<-(07D,<TKJ)"0"9
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M!([8KE=%_9O^'GA[7M,UBPT.>"[TN[FO=/0ZG=O;V<TVXRM# TIBC#;CE54
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M^W_Q%6J* *OF7O\ S[P?]_V_^(H\R]_Y]X/^_P"W_P 15JB@"KYE[_S[P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^W_Q%'F7O_/O!_W_ &_^(H M455\R]_Y]X/^_P"W_P 11YE[_P ^\'_?]O\
MXB@"U157S+W_ )]X/^_[?_$4>9>_\^\'_?\ ;_XB@"U157S+W_GW@_[_ +?_
M !%'F7O_ #[P?]_V_P#B* +5%5?,O?\ GW@_[_M_\11YE[_S[P?]_P!O_B*
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M #[P?]_V_P#B*/,O?^?>#_O^W_Q% %JBJOF7O_/O!_W_ &_^(H\R]_Y]X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH S->\.:?XGMX+;4H!=6L4RS^0_W'9<[=P_B )S@\9
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M^W_Q%6J* *OF7O\ S[P?]_V_^(H\R]_Y]X/^_P"W_P 15JB@"KYE[_S[P?\
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M*M44 5?,O?\ GW@_[_M_\11YE[_S[P?]_P!O_B*M44 5?,O?^?>#_O\ M_\
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M #[P?]_V_P#B*/,O?^?>#_O^W_Q% %JBJOF7O_/O!_W_ &_^(H\R]_Y]X/\
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MF5G&0O<CYB01C*UZ]X]T33O#OP<\4Z=I5A:Z9I]OHEXD-I9PK#%&/(?A44
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M^PUS0M1M]5TB^B$UM>6KAXY4/<'\P1U!!!Y%:E<333LSJ3OJ@HHHI#"BBB@
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M[1/Q$^.U_HMAX>\3>%_AY8ZMJ2Z:]E9RC4=>MU:.5R\D;A4C&(]N0,AFZ\4
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MWD)/19(SAXV]F -=?7%*+B[25F=::DKIA1114C"BBB@ HHHH **** "BBB@
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M5\T?\*L_:0\!\^&/B[H7CFU3E+#QMHOD,!_=-Q;'>Q]SBC_AH'XV>!_E\;_
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M)8BM-6E-V]2HT:4=5%%*);FWB6.*TMHXU&%1)B !Z ;*?YE[_P ^\'_?]O\
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MW_;_ .(H\R]_Y]X/^_[?_$5:HH J^9>_\^\'_?\ ;_XBCS+W_GW@_P"_[?\
MQ%6J* *OF7O_ #[P?]_V_P#B*/,O?^?>#_O^W_Q%6J* /%_CW^SK:_&B&QU:
MSF'A3Q]HY\W1O%>G2D7-HXZ(^%'F1')RA/0G&,G/-?"K]H_Q!IWC:W^%OQ>T
MNS\.?$$H/[/U*.4IIOB%!QYEL^W D/&8C@Y/ !^4?1M<3\7/@YX4^-_A.3P_
MXLTU;VUW>9;W$9V7%I*!\LL,@Y1QZC@]"""175"JG'V=75=.Z]/+R.>=-I\]
M/1_@_P"NYUGF7O\ S[P?]_V_^(K TOQ[;ZQKDVD6]M<+?PH))([BSNX%5"6
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MHJR*OF7O_/O!_P!_V_\ B*/,O?\ GW@_[_M_\15JBI&5?,O?^?>#_O\ M_\
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MS3G*;YI.[-XQ4%:*LCD8_"&HQ>+;C7DUB\$EPD<,EGYD'D-%&79(_P#CVW@
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M_#&<JM2E\<>;S7^7_#GWGXA\2:'X#\/S:GK6HV6A:-91_O+F[E6&&)0.!DX
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M_B*/,O?^?>#_ +_M_P#$4 6J*J^9>_\ /O!_W_;_ .(H\R]_Y]X/^_[?_$4
M6J*J^9>_\^\'_?\ ;_XBCS+W_GW@_P"_[?\ Q% %JBJOF7O_ #[P?]_V_P#B
M*/,O?^?>#_O^W_Q% %JBJOF7O_/O!_W_ &_^(H\R]_Y]X/\ O^W_ ,10!:HJ
MKYE[_P ^\'_?]O\ XBCS+W_GW@_[_M_\10!:HJKYE[_S[P?]_P!O_B*/,O?^
M?>#_ +_M_P#$4 6J*J^9>_\ /O!_W_;_ .(H\R]_Y]X/^_[?_$4 6J*J^9>_
M\^\'_?\ ;_XBCS+W_GW@_P"_[?\ Q% %JBJOF7O_ #[P?]_V_P#B*/,O?^?>
M#_O^W_Q% %JBJOF7O_/O!_W_ &_^(H\R]_Y]X/\ O^W_ ,10!:HJKYE[_P ^
M\'_?]O\ XBCS+W_GW@_[_M_\10!:HJKYE[_S[P?]_P!O_B*/,O?^?>#_ +_M
M_P#$4 6J*J^9>_\ /O!_W_;_ .(H\R]_Y]X/^_[?_$4 6J*J^9>_\^\'_?\
M;_XBCS+W_GW@_P"_[?\ Q% %JBJOF7O_ #[P?]_V_P#B*/,O?^?>#_O^W_Q%
M %JBJOF7O_/O!_W_ &_^(H\R]_Y]X/\ O^W_ ,10!:HJKYE[_P ^\'_?]O\
MXBCS+W_GW@_[_M_\10!:HJKYE[_S[P?]_P!O_B*/,O?^?>#_ +_M_P#$4 6J
M*J^9>_\ /O!_W_;_ .(H\R]_Y]X/^_[?_$4 6J*J^9>_\^\'_?\ ;_XBCS+W
M_GW@_P"_[?\ Q% %JBJOF7O_ #[P?]_V_P#B*/,O?^?>#_O^W_Q% %JBJOF7
MO_/O!_W_ &_^(H\R]_Y]X/\ O^W_ ,10!:KE?&7_ ",'@;_L,R?^F^\KH/,O
M?^?>#_O^W_Q%9&M^$M-\32Q2ZQX<T;59(E*QO?1K,4'H"T9P* .AHJE$+FWB
M2**TMHXT4*J),0% Z #9P*?YE[_S[P?]_P!O_B* +5%5?,O?^?>#_O\ M_\
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MO?\ GW@_[_M_\11YE[_S[P?]_P!O_B* +5%5?,O?^?>#_O\ M_\ $4>9>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M45Y4I.3<GNSVTE%604445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Y;XIZ;:ZK\./$D%YHL'B*%;"68:5=)OC
MNGC4ND;#OEU6OEO5]'_9YM/@1)KUFG@&Z\2)I N(<6]NTMQ>! ?*^S [LM(-
MFP#<,]<C-?9M<!!\ /AM;>+1XGA\$:'%KJR><MXED@*R9SY@7&T/GG=C.><Y
MH [72\?V9:8M_L8\E/\ 1_\ GE\H^3\.GX5:HHH *^4_@9JG@7Q?^TAK/B+P
M9JVCZ5IL&F2Z,NGQ7\9U#7[D3>;-?31EC*ZK@@22 N^2V=O7ZLHH *KR/=!R
M$AA9>Q:8@G\-IJQ10!5\R]_Y]X/^_P"W_P 11YE[_P ^\'_?]O\ XBK5% %7
MS+W_ )]X/^_[?_$4>9>_\^\'_?\ ;_XBK5% %7S+W_GW@_[_ +?_ !%'F7O_
M #[P?]_V_P#B*M5Y/^T]\;K;X"?"35?$)'GZM*!9Z59J-SW%T_$:A1R<'DX]
M*UI4I5IJG#=F-:K&A3=2>R_K\>AX%\?KJ_\ VJ_V@=(^"FF$?\(GX>9=5\73
MP3,$95(VV^_;PS$A<8R,L>0#7V+9P3:?:06MK8VEO;0(L44,4I5$0# 50$P
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M_P#$5:HH J^9>_\ /O!_W_;_ .(H\R]_Y]X/^_[?_$5:HH J^9>_\^\'_?\
M;_XBCS+W_GW@_P"_[?\ Q%6J* *OF7O_ #[P?]_V_P#B*/,O?^?>#_O^W_Q%
M6J* *OF7O_/O!_W_ &_^(H\R]_Y]X/\ O^W_ ,15JB@"KYE[_P ^\'_?]O\
MXBCS+W_GW@_[_M_\15JB@"KYE[_S[P?]_P!O_B*/,O?^?>#_ +_M_P#$5:HH
M J^9>_\ /O!_W_;_ .(H\R]_Y]X/^_[?_$5:HH J^9>_\^\'_?\ ;_XBCS+W
M_GW@_P"_[?\ Q%6J* *OF7O_ #[P?]_V_P#B*/,O?^?>#_O^W_Q%6J* *OF7
MO_/O!_W_ &_^(H\R]_Y]X/\ O^W_ ,15JB@"KYE[_P ^\'_?]O\ XBCS+W_G
MW@_[_M_\15JB@"KYE[_S[P?]_P!O_B*/,O?^?>#_ +_M_P#$5:HH J^9>_\
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M^SP[E56)\\XP20/X/]DT 7J*J^9>_P#/O!_W_;_XBCS+W_GW@_[_ +?_ !%
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M^W7MW;-##;K&/F(8]3GH!UQ6;\4)M4U;5->M%TMK2:WU*)H(+31B[W$89?\
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M\/G1+G4I6MX](%LV(S:EO+W(JQR&7;O+.6+'<* /M:BBB@ I,#)..3QFEHH
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M:%H.LP0Z;+J-[)>RQ"2V1Y8?.E9G8*YZ,Q(W8KVN@ I" 2,C..E+10 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@?[6&K:E:3_"73++
M5M2TJUUCQK8V%_\ V7?36<D]NZR!XS)$RN%.>@8<@'J!CWRN6\?_  R\.?$^
MSTVV\164UTNFWJ:C9R6UY/:36]P@8+(DL+HX(#'OUP>H& #P*7XF:A\%/BQ\
M1?"X\2M=^&;/0[/6+*7Q1=7-\=,N99Q"8O, >XF#!@ZPEBS$*JLFYF%&V_:S
M\6Z==:W)J=CIEUHGAKQ+I^FZSJ)T>\TR5=/O(P%G^S7$A>%XY>#O)#*ZX ZM
M[A_PSYX!?P[K6BS:";NTUJ>.YU&>[O;B>\N98R#&[W3R&8E,?*=_R\XQDYYC
MQ]^SAI;_  L^(.A>";&"'7O%MND5S=Z]J5W<K-(IPLLDDC2ON168@@'+!<^H
M /-KK]JCQY<:+;^*[?2M+T_X?7NIZJD'B9]'O-0BMK&V^2W>X2"7>OG2*X,H
M4JGR_*W-?5.DWZ:KI=G>QO%)'<PI,KP2>9&P9005; W+SP<#(["O-[/]G/PA
M/\//#7A75K*>YM](TI=*8V>H7-F+B(JOFI+Y,B>:CLNXJ^1DDXY->FVEI!86
ML-K:PQVUM"BQQ0Q*%2- ,!5 X     H FHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>otlk-20240930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/27/2024 4:49:40 PM-->
<!--Modified on: 12/27/2024 4:49:40 PM-->
<xsd:schema targetNamespace="http://www.outlooktherapeutics.com/20240930" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:otlk="http://www.outlooktherapeutics.com/20240930" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>99940401 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940601 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" id="DisclosureCommitmentsAndContingenciesLeaseCostDetails">
        <link:definition>99940802 - Disclosure - Commitments and Contingencies - Lease cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2" id="DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2">
        <link:definition>40804 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details) calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" id="DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails">
        <link:definition>99940805 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>99941302 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails" id="DisclosureIncomeTaxesDeferredDetails">
        <link:definition>99941303 - Disclosure - Income Taxes - Deferred (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals" id="StatementConsolidatedBalanceSheetsParentheticals">
        <link:definition>995200105 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>995200300 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99930403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99931103 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails" id="DisclosureLiquidityDetails">
        <link:definition>99940201 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails" id="DisclosureFairValueMeasurementsFairValueChangesDetails">
        <link:definition>99940402 - Disclosure - Fair Value Measurements - Fair value changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails" id="DisclosureFairValueMeasurementsAssumptionsDetails">
        <link:definition>99940403 - Disclosure - Fair Value Measurements - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails" id="DisclosureEquityMethodInvestmentSyntoneDetails">
        <link:definition>99940501 - Disclosure - Equity Method Investment - Syntone (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails" id="DisclosureDebtSummaryDetails">
        <link:definition>99940701 - Disclosure - Debt - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails" id="DisclosureDebtInformationDetails">
        <link:definition>99940702 - Disclosure - Debt - Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99940801 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails" id="DisclosureStockholdersEquityCommonStockDetails">
        <link:definition>99940901 - Disclosure - Stockholders' Equity - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails" id="DisclosureStockholdersEquityWarrantsDetails">
        <link:definition>99940902 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosurePreferredStockDetails" id="DisclosurePreferredStockDetails">
        <link:definition>99941001 - Disclosure - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails" id="DisclosureStockBasedCompensationInformationDetails">
        <link:definition>99941101 - Disclosure - Stock-Based Compensation - Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationExpenseDetails">
        <link:definition>99941102 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails" id="DisclosureStockBasedCompensationOptionActivityDetails">
        <link:definition>99941103 - Disclosure - Stock-Based Compensation - Option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails" id="DisclosureStockBasedCompensationOptionAssumptionsDetails">
        <link:definition>99941104 - Disclosure - Stock-Based Compensation - Option Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" id="DisclosureStockBasedCompensationNonOptionsDetails">
        <link:definition>99941105 - Disclosure - Stock-Based Compensation - Non-options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails" id="DisclosureCollaborationArrangementsDetails">
        <link:definition>99941201 - Disclosure - Collaboration Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" id="DisclosureIncomeTaxesCarryforwardsDetails">
        <link:definition>99941304 - Disclosure - Income Taxes - Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>995210101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureLiquidity" id="DisclosureLiquidity">
        <link:definition>995210201 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995210301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995210401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestment" id="DisclosureEquityMethodInvestment">
        <link:definition>995210501 - Disclosure - Equity Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210601 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>995210701 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995210801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995210901 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosurePreferredStock" id="DisclosurePreferredStock">
        <link:definition>995211001 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995211101 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangements" id="DisclosureCollaborationArrangements">
        <link:definition>995211201 - Disclosure - Collaboration Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>99930303 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930603 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>99930703 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>99930803 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>99930903 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931303 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails" id="DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails">
        <link:definition>99940803 - Disclosure - Commitments and Contingencies - Lease balance sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails" id="DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails">
        <link:definition>99940804 - Disclosure - Commitments and Contingencies - Lease cash flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails" id="DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails">
        <link:definition>99940806 - Disclosure - Commitments and Contingencies - Employee Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>99941301 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails" id="DisclosureIncomeTaxesUnrecognizedBenefitsDetails">
        <link:definition>99941305 - Disclosure - Income Taxes - Unrecognized benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="otlk-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="otlk-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="otlk-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="otlk-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:element name="OrganizationAndDescriptionOfBusinessAbstract" id="otlk_OrganizationAndDescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityAbstract" id="otlk_LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentExpensesCurrent" id="otlk_AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ExpirationDateAxis" id="otlk_ExpirationDateAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpirationDateDomain" id="otlk_ExpirationDateDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneAxis" id="otlk_MilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneDomain" id="otlk_MilestoneDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ThirtyFirstMayTwoThousandTwentyFiveMember" id="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ThirteenAprilTwoThousandTwentyFiveMember" id="otlk_ThirteenAprilTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinanceLeaseCost" id="otlk_FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ChangeInFairValueOfRedemptionFeature" id="otlk_ChangeInFairValueOfRedemptionFeature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DirectRegisteredOfferingMember" id="otlk_DirectRegisteredOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SyntoneMember" id="otlk_SyntoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PRCJointVentureMember" id="otlk_PRCJointVentureMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="otlk_GmsVenturesInvestmentsMember" name="GmsVenturesInvestmentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="otlk_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="otlk_AggregateOfferingPriceAuthorized" name="AggregateOfferingPriceAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" name="PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="PerformanceBasedShareOptionsMember" id="otlk_PerformanceBasedShareOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnsecuredPromissoryNotesMember" id="otlk_UnsecuredPromissoryNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnsecuredPromissoryNote2021Member" id="otlk_UnsecuredPromissoryNote2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" id="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarketOfferingBtigMember" id="otlk_AtMarketOfferingBtigMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationArrangementsAbstract" id="otlk_CollaborationArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationArrangementsTextBlock" id="otlk_CollaborationArrangementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SelexisMember" id="otlk_SelexisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="otlk_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="TwentyTwoDecemberTwoThousandTwentyFourMember" id="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwentySecondJuneTwoThousandTwentyFiveMember" id="otlk_TwentySecondJuneTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwentyEighthDecemberTwoThousandTwentyFiveMember" id="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwentyEighthJanuaryTwoThousandTwentySixMember" id="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwentyThirdNovemberTwoThousandTwentySixMember" id="otlk_TwentyThirdNovemberTwoThousandTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwentyFourFebruaryTwoThousandTwentyFiveMember" id="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" id="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" id="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" id="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" id="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" id="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentFollowingToMajorTriggerEventMember" id="otlk_DebtInstrumentFollowingToMajorTriggerEventMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" id="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" id="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" id="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BeneficialOwnershipOneForHolderToNotExerciseWarrant" id="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BeneficialOwnershipTwoForHolderToNotExerciseWarrant" id="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BeneficialOwnershipThreeForHolderToNotExerciseWarrant" id="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" id="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" id="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReverseStockSplitPolicyTextBlock" id="otlk_ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" id="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantRelatedExpenses" id="otlk_WarrantRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WarrantLiabilityIncurredButNotYetPaid" id="otlk_WarrantLiabilityIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EighteenMarchTwoThousandTwentyNineMember" id="otlk_EighteenMarchTwoThousandTwentyNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantExpirationDateFebruary22026Member" id="otlk_WarrantExpirationDateFebruary22026Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" id="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" id="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FifteenthAprilTwoThousandTwentyNineMember" id="otlk_FifteenthAprilTwoThousandTwentyNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScenarioOneMember" id="otlk_ScenarioOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScenarioTwoMember" id="otlk_ScenarioTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>otlk-20240930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/27/2024 4:49:40 PM-->
<!--Modified on: 12/27/2024 4:49:40 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesLeaseCostDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesDeferredDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails" />
  <link:roleRef roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails" xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureDebtInformationDetails" />
  <link:roleRef roleURI="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestment" xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureEquityMethodInvestment" />
  <link:roleRef roleURI="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails" xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureEquityMethodInvestmentSyntoneDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638709149788289055" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638709149788289055" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638709149788299058" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638709149788289055" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638709149788299058" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638709149788299058" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638709149788289055" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638709149788299058" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638709149788299058" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638709149788299058" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_638709149788299058" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_EquityMethodInvestments_638709149788299058" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638709149788299058" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638709149788299058" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638709149788299058" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638709149788299058" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638709149788299058" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638709149788299058" xlink:to="us-gaap_LiabilitiesCurrent_638709149788299058" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638709149788309061" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638709149788299058" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638709149788309061" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="us-gaap_NotesAndLoansPayableCurrent_638709149788309061" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638709149788299058" xlink:to="us-gaap_NotesAndLoansPayableCurrent_638709149788309061" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638709149788309061" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638709149788299058" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638709149788309061" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638709149788309061" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638709149788299058" xlink:to="us-gaap_AccountsPayableCurrent_638709149788309061" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638709149788309061" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638709149788299058" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638709149788309061" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638709149788309061" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638709149788299058" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638709149788309061" order="6" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638709149788309061" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638709149788299058" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638709149788309061" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638709149788319062" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638709149788299058" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638709149788319062" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638709149788319062" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638709149788319062" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638709149788319062" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638709149788319062" xlink:to="us-gaap_PreferredStockValue_638709149788319062" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638709149788319062" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638709149788319062" xlink:to="us-gaap_CommonStockValue_638709149788319062" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638709149788319062" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638709149788319062" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638709149788319062" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638709149788319062" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638709149788319062" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638709149788319062" order="4" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638709149788329064" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638709149788329064" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638709149788329064" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638709149788329064" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantRelatedExpenses" xlink:label="otlk_WarrantRelatedExpenses_638709149788329064" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="otlk_WarrantRelatedExpenses_638709149788329064" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ChangeInFairValueOfRedemptionFeature" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature_638709149788329064" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="otlk_ChangeInFairValueOfRedemptionFeature_638709149788329064" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149788329064" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149788329064" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638709149788529039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="us-gaap_InvestmentIncomeInterest_638709149788529039" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638709149788529039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="us-gaap_InterestExpenseNonoperating_638709149788529039" order="6" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_638709149788529039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_638709149788529039" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638709149788529039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149788329064" xlink:to="us-gaap_OperatingIncomeLoss_638709149788529039" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638709149788529039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638709149788529039" xlink:to="us-gaap_OperatingExpenses_638709149788529039" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638709149788529039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638709149788529039" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638709149788529039" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638709149788539065" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638709149788529039" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638709149788539065" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638709149788539065" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_NetIncomeLoss_638709149788539065" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638709149788539065" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_DepreciationAndAmortization_638709149788539065" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149788539065" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149788539065" order="3" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_638709149788539065" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_638709149788539065" order="4" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_638709149788549071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_InterestPaid_638709149788549071" order="5" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638709149788549071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_PaidInKindInterest_638709149788549071" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantRelatedExpenses" xlink:label="otlk_WarrantRelatedExpenses_638709149788549071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="otlk_WarrantRelatedExpenses_638709149788549071" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638709149788549071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_ShareBasedCompensation_638709149788549071" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638709149788549071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638709149788549071" order="9" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ChangeInFairValueOfRedemptionFeature" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature_638709149788549071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="otlk_ChangeInFairValueOfRedemptionFeature_638709149788549071" order="10" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638709149788549071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638709149788549071" order="11" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638709149788559069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638709149788559069" order="12" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638709149788559069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638709149788559069" order="13" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638709149788559069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638709149788559069" order="14" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638709149788559069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149788539065" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638709149788559069" order="15" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149788559069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149788559069" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149788559069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149788559069" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149788559069" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638709149788559069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149788559069" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638709149788559069" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638709149788569069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149788559069" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638709149788569069" order="3" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638709149788569069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149788559069" xlink:to="us-gaap_PaymentsOfFinancingCosts_638709149788569069" order="4" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638709149788569069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149788559069" xlink:to="us-gaap_RepaymentsOfDebt_638709149788569069" order="5" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638709149788569069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638709149788569069" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_638709149788569069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities_638709149788569069" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Accrued Expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638709149788579069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638709149788579069" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="otlk_AccruedResearchAndDevelopmentExpensesCurrent_638709149788579069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="otlk_AccruedResearchAndDevelopmentExpensesCurrent_638709149788579069" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638709149788579069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638709149788579069" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638709149788579069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638709149788579069" order="4" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Commitments and Contingencies - Lease cost (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FinanceLeaseCost" xlink:label="otlk_FinanceLeaseCost_638709149788579069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="otlk_FinanceLeaseCost_638709149788579069" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638709149788579069" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="otlk_FinanceLeaseCost_638709149788579069" xlink:to="us-gaap_FinanceLeaseInterestExpense_638709149788579069" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638709149788589136" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638709149788589136" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="40804 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details) calc 2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638709149788589136" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_FinanceLeaseLiability_638709149788589136" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638709149788589136" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638709149788589136" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638709149788589136" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xlink:to="us-gaap_OperatingLeaseLiability_638709149788589136" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638709149788599084" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638709149788599084" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638709149788599084" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638709149788599084" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638709149788599084" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638709149788599084" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638709149788599084" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638709149788599084" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638709149788599084" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638709149788599084" order="5" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - Income Taxes - Reconciliation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638709149788599084" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638709149788599084" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638709149788599084" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638709149788599084" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" xlink:label="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_638709149788609071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_638709149788609071" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638709149788609071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638709149788609071" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_638709149788609071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_638709149788609071" order="5" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638709149788609071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638709149788609071" order="6" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638709149788609071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638709149788609071" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638709149788609071" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638709149788609071" order="8" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails" xlink:type="extended" xlink:title="99941303 - Disclosure - Income Taxes - Deferred (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638709149788619079" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638709149788619079" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638709149788619079" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsGross_638709149788619079" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638709149788619079" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638709149788619079" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DeferredTaxAssetsLeaseLiability" xlink:label="otlk_DeferredTaxAssetsLeaseLiability_638709149788619079" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638709149788619079" xlink:to="otlk_DeferredTaxAssetsLeaseLiability_638709149788619079" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638709149788619079" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638709149788619079" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638709149788619079" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638709149788619079" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638709149788619079" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638709149788619079" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_638709149788629068" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_638709149788629068" order="6" use="optional" weight="1" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638709149788629068" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638709149788629068" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638709149788629068" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638709149788619079" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638709149788629068" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638709149788629068" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638709149788629068" order="2" use="optional" weight="-1" priority="2" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>otlk-20240930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/27/2024 4:49:40 PM-->
<!--Modified on: 12/27/2024 4:49:40 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureLiquidityDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsFairValueChangesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsAssumptionsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureEquityMethodInvestmentSyntoneDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureDebtSummaryDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureDebtInformationDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesLeaseCostDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationInformationDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationOptionActivityDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationOptionAssumptionsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCollaborationArrangementsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesCarryforwardsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.outlooktherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="otlk-20240930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_FairValueAdjustmentOfWarrants" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ChangeInFairValueOfRedemptionFeature" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature" xlink:title="otlk_ChangeInFairValueOfRedemptionFeature" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="otlk_ChangeInFairValueOfRedemptionFeature" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To otlk_ChangeInFairValueOfRedemptionFeature" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_1" xlink:title="us-gaap_WarrantsAndRightsOutstanding_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_WarrantsAndRightsOutstanding_1" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:title="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_1" xlink:title="us-gaap_ProjectMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:to="us-gaap_ProjectMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1 To us-gaap_ProjectMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_MilestoneAxis" xlink:label="otlk_MilestoneAxis_1" xlink:title="otlk_MilestoneAxis_1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_MilestoneDomain" xlink:label="otlk_MilestoneDomain_1" xlink:title="otlk_MilestoneDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="otlk_MilestoneAxis_1" xlink:to="otlk_MilestoneDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:otlk_MilestoneAxis_1 To otlk_MilestoneDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ExpirationDateAxis" xlink:label="otlk_ExpirationDateAxis_1" xlink:title="otlk_ExpirationDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ExpirationDateDomain" xlink:label="otlk_ExpirationDateDomain_1" xlink:title="otlk_ExpirationDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="otlk_ExpirationDateAxis_1" xlink:to="otlk_ExpirationDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:otlk_ExpirationDateAxis_1 To otlk_ExpirationDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_2" xlink:title="srt_CounterpartyNameAxis_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_2" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_2 To srt_RepurchaseAgreementCounterpartyNameDomain_2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Fair Value Measurements (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Stock-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="otlk_PerformanceBasedShareOptionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Liquidity (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingBtigMember" xlink:label="otlk_AtMarketOfferingBtigMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="otlk_AtMarketOfferingBtigMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="otlk_PerformanceBasedShareOptionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioOneMember" xlink:label="otlk_ScenarioOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="otlk_ScenarioOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioTwoMember" xlink:label="otlk_ScenarioTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="otlk_ScenarioTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - Fair Value Measurements - Fair value changes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" xlink:label="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - Fair Value Measurements - Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Equity Method Investment - Syntone (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PRCJointVentureMember" xlink:label="otlk_PRCJointVentureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="otlk_PRCJointVentureMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SyntoneMember" xlink:label="otlk_SyntoneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="otlk_SyntoneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Debt - Summary (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="us-gaap_NotesAndLoansPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesAndLoansPayableCurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Debt - Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_UnsecuredPromissoryNotesMember" xlink:label="otlk_UnsecuredPromissoryNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="otlk_UnsecuredPromissoryNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="otlk_UnsecuredPromissoryNotesMember" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_UnsecuredPromissoryNote2021Member" xlink:label="otlk_UnsecuredPromissoryNote2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="otlk_UnsecuredPromissoryNotesMember" xlink:to="otlk_UnsecuredPromissoryNote2021Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentFollowingToMajorTriggerEventMember" xlink:label="otlk_DebtInstrumentFollowingToMajorTriggerEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="otlk_DebtInstrumentFollowingToMajorTriggerEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioOneMember" xlink:label="otlk_ScenarioOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="otlk_ScenarioOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioTwoMember" xlink:label="otlk_ScenarioTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="otlk_ScenarioTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" xlink:label="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" xlink:label="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" xlink:label="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" xlink:label="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" xlink:label="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" xlink:label="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="us-gaap_DebtWeightedAverageInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtWeightedAverageInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaid" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SelexisMember" xlink:label="otlk_SelexisMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="otlk_SelexisMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligation" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Commitments and Contingencies - Lease cost (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCostAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FinanceLeaseCost" xlink:label="otlk_FinanceLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="otlk_FinanceLeaseCost" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Stockholders' Equity - Common Stock (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DirectRegisteredOfferingMember" xlink:label="otlk_DirectRegisteredOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="otlk_DirectRegisteredOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingMember" xlink:label="otlk_AtMarketOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="otlk_AtMarketOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingBtigMember" xlink:label="otlk_AtMarketOfferingBtigMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="otlk_AtMarketOfferingBtigMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_GmsVenturesInvestmentsMember" xlink:label="otlk_GmsVenturesInvestmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="otlk_GmsVenturesInvestmentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AggregateOfferingPriceAuthorized" xlink:label="otlk_AggregateOfferingPriceAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="otlk_AggregateOfferingPriceAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DeferredCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" xlink:label="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantRelatedExpenses" xlink:label="otlk_WarrantRelatedExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="otlk_WarrantRelatedExpenses" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Stockholders' Equity - Warrants (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" xlink:label="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" xlink:label="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ThirteenAprilTwoThousandTwentyFiveMember" xlink:label="otlk_ThirteenAprilTwoThousandTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_ThirteenAprilTwoThousandTwentyFiveMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" xlink:label="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentySecondJuneTwoThousandTwentyFiveMember" xlink:label="otlk_TwentySecondJuneTwoThousandTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_TwentySecondJuneTwoThousandTwentyFiveMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" xlink:label="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantExpirationDateFebruary22026Member" xlink:label="otlk_WarrantExpirationDateFebruary22026Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_WarrantExpirationDateFebruary22026Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" xlink:label="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyThirdNovemberTwoThousandTwentySixMember" xlink:label="otlk_TwentyThirdNovemberTwoThousandTwentySixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_TwentyThirdNovemberTwoThousandTwentySixMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_EighteenMarchTwoThousandTwentyNineMember" xlink:label="otlk_EighteenMarchTwoThousandTwentyNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_EighteenMarchTwoThousandTwentyNineMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FifteenthAprilTwoThousandTwentyNineMember" xlink:label="otlk_FifteenthAprilTwoThousandTwentyNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="otlk_FifteenthAprilTwoThousandTwentyNineMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" xlink:label="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock-Based Compensation - Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="otlk_PerformanceBasedShareOptionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock-Based Compensation - Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Stock-Based Compensation - Option activity (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="otlk_PerformanceBasedShareOptionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Stock-Based Compensation - Option Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="otlk_PerformanceBasedShareOptionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - Stock-Based Compensation - Non-options (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Collaboration Arrangements (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PRCJointVentureMember" xlink:label="otlk_PRCJointVentureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="otlk_PRCJointVentureMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SyntoneMember" xlink:label="otlk_SyntoneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="otlk_SyntoneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" xlink:type="extended" xlink:title="99941304 - Disclosure - Income Taxes - Carryforwards (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Subsequent Events (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>otlk-20240930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/27/2024 4:49:40 PM-->
<!--Modified on: 12/27/2024 4:49:40 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases, Right-of-use asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity method investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders' deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="us-gaap_NotesAndLoansPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayableCurrent" xlink:to="us-gaap_NotesAndLoansPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayableCurrent_lbl" xml:lang="en-US">Notes and Loans Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NotesAndLoansPayableCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansPayableCurrent_lbl" xml:lang="en-US">Unsecured convertible promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' deficit:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, par value $0.01 per share: 10,000,000 shares authorized, no shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.01 per share; 60,000,000 shares authorized; 23,905,635 and 13,012,833 shares issued and outstanding at September 30, 2024 and September 30, 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance, ending</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance, beginning</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value per share (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value per share (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ChangeInFairValueOfRedemptionFeature" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ChangeInFairValueOfRedemptionFeature" xlink:to="otlk_ChangeInFairValueOfRedemptionFeature_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature_lbl" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of redemption feature.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature_lbl" xml:lang="en-US">Change In Fair Value Of Redemption Feature</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature_lbl" xml:lang="en-US">Change in fair value of promissory notes</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantRelatedExpenses" xlink:label="otlk_WarrantRelatedExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_WarrantRelatedExpenses" xlink:to="otlk_WarrantRelatedExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_WarrantRelatedExpenses_lbl" xml:lang="en-US">The amount of expenses related to warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_WarrantRelatedExpenses_lbl" xml:lang="en-US">Warrant Related Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_WarrantRelatedExpenses_lbl" xml:lang="en-US">Warrant related expenses (Note 9)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="otlk_WarrantRelatedExpenses_lbl" xml:lang="en-US">Warrants related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Per share information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net income (loss) per share of common stock, basic (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share of common stock, diluted (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders Equity (Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock in connection with conversion of convertible promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock in connection with conversion of convertible promissory note (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid on debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from loan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments of finance lease obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of financing costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of lender fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental schedule of non-cash financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Convertible promissory note converted into common stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Carrying value of notes exchanged</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantLiabilityIncurredButNotYetPaid" xlink:label="otlk_WarrantLiabilityIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_WarrantLiabilityIncurredButNotYetPaid" xlink:to="otlk_WarrantLiabilityIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_WarrantLiabilityIncurredButNotYetPaid_lbl" xml:lang="en-US">The amount of warrant liability incurred but not yet paid.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_WarrantLiabilityIncurredButNotYetPaid_lbl" xml:lang="en-US">Warrant Liability Incurred but Not Yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_WarrantLiabilityIncurredButNotYetPaid_lbl" xml:lang="en-US">Recognition of warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Deferred offering costs amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset and lease liability recognized for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="otlk_OrganizationAndDescriptionOfBusinessAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="otlk_OrganizationAndDescriptionOfBusinessAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_OrganizationAndDescriptionOfBusinessAbstract_lbl" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_LiquidityAbstract" xlink:label="otlk_LiquidityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_LiquidityAbstract" xlink:to="otlk_LiquidityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_LiquidityAbstract_lbl" xml:lang="en-US">Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" xml:lang="en-US">Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Preferred Stock.</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_CollaborationArrangementsAbstract" xlink:label="otlk_CollaborationArrangementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_CollaborationArrangementsAbstract" xlink:to="otlk_CollaborationArrangementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_CollaborationArrangementsAbstract_lbl" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_CollaborationArrangementsTextBlock" xlink:label="otlk_CollaborationArrangementsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_CollaborationArrangementsTextBlock" xlink:to="otlk_CollaborationArrangementsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_CollaborationArrangementsTextBlock_lbl" xml:lang="en-US">The entire disclosure for a collaboration arrangements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_CollaborationArrangementsTextBlock_lbl" xml:lang="en-US">Collaboration Arrangements [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_CollaborationArrangementsTextBlock_lbl" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ReverseStockSplitPolicyTextBlock" xlink:label="otlk_ReverseStockSplitPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ReverseStockSplitPolicyTextBlock" xlink:to="otlk_ReverseStockSplitPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for Reverse stock-split</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse stock split</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Equity method investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net loss per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_lbl" xml:lang="en-US">Related to the unsecured promissory note issued in December 2022, originally maturing January 1, 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_lbl" xml:lang="en-US">Securities Purchase Agreement Unsecured Promissory Note [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_lbl" xml:lang="en-US">December 2022 Note</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_lbl" xml:lang="en-US">Unsecured convertible promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Common stock warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of assets and liabilities measured at fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of changes in the fair value of Level 3 liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value inputs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease future minimum payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of finance lease future minimum payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_PerformanceBasedShareOptionsMember" xlink:to="otlk_PerformanceBasedShareOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_PerformanceBasedShareOptionsMember_lbl" xml:lang="en-US">Represents information relating to performance based share options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_PerformanceBasedShareOptionsMember_lbl" xml:lang="en-US">Performance Based Stock Options [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_PerformanceBasedShareOptionsMember_lbl" xml:lang="en-US">Performance-based stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of option assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of performance-based stock units activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of tax expense reconciliation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of unrecognized tax benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingBtigMember" xlink:label="otlk_AtMarketOfferingBtigMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_AtMarketOfferingBtigMember" xlink:to="otlk_AtMarketOfferingBtigMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_AtMarketOfferingBtigMember_lbl" xml:lang="en-US">Represents information pertaining to at the market offering with BTIG, LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_AtMarketOfferingBtigMember_lbl" xml:lang="en-US">At Market Offering BTIG [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_AtMarketOfferingBtigMember_lbl" xml:lang="en-US">BTIG ATM</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Debt, interest, fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of fees to sales agent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance-based stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioOneMember" xlink:label="otlk_ScenarioOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ScenarioOneMember" xlink:to="otlk_ScenarioOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ScenarioOneMember_lbl" xml:lang="en-US">Represents the information pertaining to the first scenario.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ScenarioOneMember_lbl" xml:lang="en-US">Scenario One [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_ScenarioOneMember_lbl" xml:lang="en-US">Scenario one</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioTwoMember" xlink:label="otlk_ScenarioTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ScenarioTwoMember" xlink:to="otlk_ScenarioTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ScenarioTwoMember_lbl" xml:lang="en-US">Represents the information pertaining to the second scenario.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ScenarioTwoMember_lbl" xml:lang="en-US">Scenario Two [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_ScenarioTwoMember_lbl" xml:lang="en-US">Scenario two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stock split ratio</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Original principal amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt conversion rate (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Unsecured convertible promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US">Liabilities fair value changes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance, ending</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance, beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Fair value at issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" xlink:label="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" xlink:to="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees_lbl" xml:lang="en-US">Amount of capitalized extension fees of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Capitalized Extension Fees</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees_lbl" xml:lang="en-US">Promissory note maturity extension fee added to outstanding balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US">Converted to common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Change in fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk-free rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Credit-adjusted discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Stock price (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair value inputs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt inputs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrant inputs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">All Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PRCJointVentureMember" xlink:label="otlk_PRCJointVentureMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_PRCJointVentureMember" xlink:to="otlk_PRCJointVentureMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_PRCJointVentureMember_lbl" xml:lang="en-US">Represents information pertaining to Syntone PRC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_PRCJointVentureMember_lbl" xml:lang="en-US">PRC Joint Venture [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_PRCJointVentureMember_lbl" xml:lang="en-US">Syntone PRC</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SyntoneMember" xlink:label="otlk_SyntoneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_SyntoneMember" xlink:to="otlk_SyntoneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_SyntoneMember_lbl" xml:lang="en-US">Represents information pertaining to Syntone joint venture.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_SyntoneMember_lbl" xml:lang="en-US">Syntone [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_SyntoneMember_lbl" xml:lang="en-US">Syntone</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xml:lang="en-US">Investment in joint venture</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Expected future investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="otlk_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="otlk_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Represents accrued research and development expenses.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued Research And Development Expenses Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="otlk_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Total debt</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_UnsecuredPromissoryNotesMember" xlink:label="otlk_UnsecuredPromissoryNotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_UnsecuredPromissoryNotesMember" xlink:to="otlk_UnsecuredPromissoryNotesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_UnsecuredPromissoryNotesMember_lbl" xml:lang="en-US">Represents the debt obligation related to the aggregate unsecured promissory notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_UnsecuredPromissoryNotesMember_lbl" xml:lang="en-US">Unsecured promissory notes-aggregate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_UnsecuredPromissoryNotesMember_lbl" xml:lang="en-US">Unsecured promissory notes-aggregate</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_UnsecuredPromissoryNote2021Member" xlink:label="otlk_UnsecuredPromissoryNote2021Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_UnsecuredPromissoryNote2021Member" xlink:to="otlk_UnsecuredPromissoryNote2021Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_UnsecuredPromissoryNote2021Member_lbl" xml:lang="en-US">Related to the unsecured promissory note issued in November 2021.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_UnsecuredPromissoryNote2021Member_lbl" xml:lang="en-US">Unsecured Promissory Note 2021 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_UnsecuredPromissoryNote2021Member_lbl" xml:lang="en-US">November 2021 Note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentFollowingToMajorTriggerEventMember" xlink:label="otlk_DebtInstrumentFollowingToMajorTriggerEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentFollowingToMajorTriggerEventMember" xlink:to="otlk_DebtInstrumentFollowingToMajorTriggerEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentFollowingToMajorTriggerEventMember_lbl" xml:lang="en-US">Represents the information pertaining to following to major trigger event of debt instrument.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentFollowingToMajorTriggerEventMember_lbl" xml:lang="en-US">Debt Instrument, Following to Major Trigger Event [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentFollowingToMajorTriggerEventMember_lbl" xml:lang="en-US">Major Trigger Event</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Debt issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl" xml:lang="en-US">Stock trigger price (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Trading day threshold</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" xlink:label="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" xlink:to="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash_lbl" xml:lang="en-US">Percentage of additional fee on payments made by the Company in cash, including prepayments or repayment at maturity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash_lbl" xml:lang="en-US">Debt Instrument, Percentage of Additional Fee on Payments in Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash_lbl" xml:lang="en-US">Additional fee cash payments (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Stock price trigger threshold (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" xlink:to="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent_lbl" xml:lang="en-US">Percentage of increase in debt balance by Lender for a Minor Trigger Event.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent_lbl" xml:lang="en-US">Debt Instrument, Percentage of Increase in Debt Balance by Lender for a Major Trigger Event</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent_lbl" xml:lang="en-US">Increase in debt balance for a Major Trigger Event (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" xlink:to="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent_lbl" xml:lang="en-US">Percentage of increase in debt balance by Lender for a Minor Trigger Event.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent_lbl" xml:lang="en-US">Debt Instrument, Percentage of Increase in Debt Balance by Lender for a Minor Trigger Event</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent_lbl" xml:lang="en-US">Increase in debt balance for a Minor Trigger Event (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" xlink:label="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" xlink:to="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent_lbl" xml:lang="en-US">Represents the threshold trading days of written notice from Lender for cure of Trigger Event.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent_lbl" xml:lang="en-US">Debt Instrument, Threshold Trading days of Written Notice from Lender for Cure of Trigger Event</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent_lbl" xml:lang="en-US">Threshold trading days for Trigger Event cure</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" xlink:label="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" xlink:to="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable_lbl" xml:lang="en-US">Represents the interest rate annually  until paid for the immediately due and payable amounts in case of debt default.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable_lbl" xml:lang="en-US">Debt Instrument, Debt Default, Accelerated Interest Rate On Immediate Due and Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable_lbl" xml:lang="en-US">Default interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" xlink:label="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" xlink:to="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender_lbl" xml:lang="en-US">Debt instrument, convertible, conversion price, required to satisfy conversion notice from the lender in cash.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Conversion Price, Required to Satisfy Conversion Notice from the Lender</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender_lbl" xml:lang="en-US">Conversion notice threshold (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" xlink:label="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" xlink:to="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing_lbl" xml:lang="en-US">Percentage of participation right to Lender in future debt or equity financing in the debt instrument.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing_lbl" xml:lang="en-US">Debt Instrument, Percentage of Participation Right to Lender in Future Debt or Equity Financing</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing_lbl" xml:lang="en-US">Participation right in future financing (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" xlink:label="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" xlink:to="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance_lbl" xml:lang="en-US">Represents the extension fee as percentage of the outstanding balance upon amendment of debt.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance_lbl" xml:lang="en-US">Debt Modification, Extension Fee As Percentage Of The Outstanding Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance_lbl" xml:lang="en-US">Extension fee based on balance (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Variable rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xml:lang="en-US">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="us-gaap_DebtWeightedAverageInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Total interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Quarterly payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Shares converted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xml:lang="en-US">Repayments of unsecured debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US">Prepayment fee</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SelexisMember" xlink:label="otlk_SelexisMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_SelexisMember" xlink:to="otlk_SelexisMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_SelexisMember_lbl" xml:lang="en-US">Information related to Selexis SA.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_SelexisMember_lbl" xml:lang="en-US">Selexis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Remaining future financial obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Operating lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US">Finance lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Finance lease interest (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Remaining future minimum lease payments for finance lease</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FinanceLeaseCost" xlink:label="otlk_FinanceLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_FinanceLeaseCost" xlink:to="otlk_FinanceLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_FinanceLeaseCost_lbl" xml:lang="en-US">Total amount of lease cost recognized by lessee for finance lease contract.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_FinanceLeaseCost_lbl" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="otlk_FinanceLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases, Weighted-average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance leases, Weighted-average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases, Weighted-average discount rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance leases, Weighted-average discount rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Maximum employee annual contributions (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Maximum employer annual contributions (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Maximum employer match (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Expense related to matching contribution</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DirectRegisteredOfferingMember" xlink:label="otlk_DirectRegisteredOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DirectRegisteredOfferingMember" xlink:to="otlk_DirectRegisteredOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DirectRegisteredOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to registered direct offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DirectRegisteredOfferingMember_lbl" xml:lang="en-US">Direct registered offering [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DirectRegisteredOfferingMember_lbl" xml:lang="en-US">Direct registered offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Underwriter</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingMember" xlink:label="otlk_AtMarketOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_AtMarketOfferingMember" xlink:to="otlk_AtMarketOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_AtMarketOfferingMember_lbl" xml:lang="en-US">Represents information pertaining to at the market offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_AtMarketOfferingMember_lbl" xml:lang="en-US">At Market Offering [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_AtMarketOfferingMember_lbl" xml:lang="en-US">Wainwright ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_GmsVenturesInvestmentsMember" xlink:label="otlk_GmsVenturesInvestmentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_GmsVenturesInvestmentsMember" xlink:to="otlk_GmsVenturesInvestmentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_GmsVenturesInvestmentsMember_lbl" xml:lang="en-US">Represents information pertaining to GMS Ventures &amp; Investments an affiliate of BioLexis Pte. Ltd.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_GmsVenturesInvestmentsMember_lbl" xml:lang="en-US">GMS Ventures Investments [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_GmsVenturesInvestmentsMember_lbl" xml:lang="en-US">GMS Ventures &amp; Investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Common Stock and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Common stock issuable on exercise of warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Common stock issuable by each warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants exercise term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common Stock, Voting Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting rights</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AggregateOfferingPriceAuthorized" xlink:label="otlk_AggregateOfferingPriceAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_AggregateOfferingPriceAuthorized" xlink:to="otlk_AggregateOfferingPriceAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_AggregateOfferingPriceAuthorized_lbl" xml:lang="en-US">The authorized amount of aggregate offering price under the agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_AggregateOfferingPriceAuthorized_lbl" xml:lang="en-US">Aggregate Offering Price, Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_AggregateOfferingPriceAuthorized_lbl" xml:lang="en-US">Aggregate maximum offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Amount reclassified on additional paid in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred Costs, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred costs</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" xlink:label="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" xlink:to="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission_lbl" xml:lang="en-US">The percentage of aggregate gross proceeds from sale of common stock to be paid as commission under the agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission_lbl" xml:lang="en-US">Percentage Of Gross Proceeds From Sale Of Common Stock To Be Paid As Commission</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission_lbl" xml:lang="en-US">Common stock sale commission (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" xlink:label="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" xlink:to="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of December 22, 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_lbl" xml:lang="en-US">Twenty Two December Two Thousand Twenty Four [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_lbl" xml:lang="en-US">December 22, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" xlink:label="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" xlink:to="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of February 24, 2025.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Twenty Four February Two Thousand Twenty Five [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">February 24, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ThirteenAprilTwoThousandTwentyFiveMember" xlink:label="otlk_ThirteenAprilTwoThousandTwentyFiveMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ThirteenAprilTwoThousandTwentyFiveMember" xlink:to="otlk_ThirteenAprilTwoThousandTwentyFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ThirteenAprilTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of April 13, 2025.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ThirteenAprilTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">April 13, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" xlink:label="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" xlink:to="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of
May 31, 2025.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">May 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentySecondJuneTwoThousandTwentyFiveMember" xlink:label="otlk_TwentySecondJuneTwoThousandTwentyFiveMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_TwentySecondJuneTwoThousandTwentyFiveMember" xlink:to="otlk_TwentySecondJuneTwoThousandTwentyFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_TwentySecondJuneTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of June 22, 2025.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_TwentySecondJuneTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Twenty Second June Two Thousand Twenty Five [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_TwentySecondJuneTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">June 22, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" xlink:label="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" xlink:to="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of December 28, 2025.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Twenty Eighth December Two thousand Twenty Five [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">December 28, 2025</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" xlink:label="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" xlink:to="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of January 28, 2026.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_lbl" xml:lang="en-US">Twenty Eighth January Two Thousand Twenty Six [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_lbl" xml:lang="en-US">January 28, 2026</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantExpirationDateFebruary22026Member" xlink:label="otlk_WarrantExpirationDateFebruary22026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_WarrantExpirationDateFebruary22026Member" xlink:to="otlk_WarrantExpirationDateFebruary22026Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_WarrantExpirationDateFebruary22026Member_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of February 2, 2026.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_WarrantExpirationDateFebruary22026Member_lbl" xml:lang="en-US">Warrant Expiration Date, February 2 2026 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_WarrantExpirationDateFebruary22026Member_lbl" xml:lang="en-US">February 2, 2026</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyThirdNovemberTwoThousandTwentySixMember" xlink:label="otlk_TwentyThirdNovemberTwoThousandTwentySixMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_TwentyThirdNovemberTwoThousandTwentySixMember" xlink:to="otlk_TwentyThirdNovemberTwoThousandTwentySixMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_TwentyThirdNovemberTwoThousandTwentySixMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of November 23, 2026.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_TwentyThirdNovemberTwoThousandTwentySixMember_lbl" xml:lang="en-US">Twenty Third November Two Thousand Twenty-Six [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_TwentyThirdNovemberTwoThousandTwentySixMember_lbl" xml:lang="en-US">November 23, 2026</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_EighteenMarchTwoThousandTwentyNineMember" xlink:label="otlk_EighteenMarchTwoThousandTwentyNineMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_EighteenMarchTwoThousandTwentyNineMember" xlink:to="otlk_EighteenMarchTwoThousandTwentyNineMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_EighteenMarchTwoThousandTwentyNineMember_lbl" xml:lang="en-US">Represents the information related to March 18, 2029.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_EighteenMarchTwoThousandTwentyNineMember_lbl" xml:lang="en-US">March 18, 2029</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FifteenthAprilTwoThousandTwentyNineMember" xlink:label="otlk_FifteenthAprilTwoThousandTwentyNineMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_FifteenthAprilTwoThousandTwentyNineMember" xlink:to="otlk_FifteenthAprilTwoThousandTwentyNineMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_FifteenthAprilTwoThousandTwentyNineMember_lbl" xml:lang="en-US">Represents common stock warrants with expiration date of April 15, 2029.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_FifteenthAprilTwoThousandTwentyNineMember_lbl" xml:lang="en-US">Fifteenth April Two Thousand Twenty Nine [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_FifteenthAprilTwoThousandTwentyNineMember_lbl" xml:lang="en-US">April 15, 2029</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" xlink:to="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Represents the first beneficial ownership restriction for the warrant holder to not exercise.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Beneficial Ownership One For The Holder To Not Exercise Warrant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Beneficial ownership exercise restriction, one (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" xlink:to="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Represents the second beneficial ownership restriction for the warrant holder to not exercise.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Beneficial Ownership Two For The Holder To Not Exercise Warrant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Beneficial ownership exercise restriction, two (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" xlink:to="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Represents the third beneficial ownership restriction for the warrant holder to not exercise.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Beneficial Ownership Three For The Holder To Not Exercise Warrant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant_lbl" xml:lang="en-US">Beneficial ownership exercise restriction, three (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" xlink:label="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" xlink:to="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions_lbl" xml:lang="en-US">Represents the percentage of aggregate number of Warrants the entity may require holders to exercise upon satisfaction of certain conditions.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions_lbl" xml:lang="en-US">Percentage Of Aggregate Number Of Warrants The Holders May Require To Exercise Upon Satisfaction Of Certain Conditions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions_lbl" xml:lang="en-US">Warrant holders exercise under certain conditions (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based stock authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based stock available for grant (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Balance, Ending (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Balance, Beginning (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance, Ending (in dollars per share)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance, Beginning (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Balance-Remaining contractual term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and exercisable -Remaining contractual term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Vested and exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value of options (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation exercise period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of PSUs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Balance, Ending</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Balance, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:to="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_lbl" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expirations in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Average Base Price Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Balance, Ending</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Balance, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:to="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the expiration.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expirations, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative arrangements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State tax</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Reconciliation of income taxes (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" xlink:label="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" xlink:to="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_lbl" xml:lang="en-US">Percentage of the difference between reported income true expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the deferred true-up.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred True-up, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_lbl" xml:lang="en-US">Deferred true-up</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent differences</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xml:lang="en-US">Foreign tax credits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DeferredTaxAssetsLeaseLiability" xlink:label="otlk_DeferredTaxAssetsLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="otlk_DeferredTaxAssetsLeaseLiability" xlink:to="otlk_DeferredTaxAssetsLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="otlk_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Represents information pertaining to deferred tax assets lease liability.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="otlk_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="otlk_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Foreign</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xml:lang="en-US">Foreign tax credits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Accruals and others</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets net of valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">NOL carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Changes based on tax positions related to the current year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US">Positions eliminated</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Positions eliminated (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xml:lang="en-US">Estimated restructuring charges</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>otlk-20240930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/27/2024 4:49:40 PM-->
<!--Modified on: 12/27/2024 4:49:40 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedBalanceSheetsParentheticals" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.outlooktherapeutics.com/role/DisclosureOrganizationAndDescriptionOfBusiness" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureLiquidity" roleURI="http://www.outlooktherapeutics.com/role/DisclosureLiquidity" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurements" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurements" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureEquityMethodInvestment" roleURI="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestment" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureAccruedExpenses" roleURI="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpenses" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureDebt" roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebt" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockholdersEquity" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosurePreferredStock" roleURI="http://www.outlooktherapeutics.com/role/DisclosurePreferredStock" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensation" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCollaborationArrangements" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangements" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxes" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxes" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureSubsequentEvents" roleURI="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureDebtTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureLiquidityDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsFairValueChangesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureFairValueMeasurementsAssumptionsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureEquityMethodInvestmentSyntoneDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureDebtSummaryDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureDebtInformationDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesLeaseCostDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosurePreferredStockDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosurePreferredStockDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationInformationDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationOptionActivityDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationOptionAssumptionsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureCollaborationArrangementsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesDeferredDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesCarryforwardsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureIncomeTaxesUnrecognizedBenefitsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="otlk-20240930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document And Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638709149789319077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638709149789319077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638709149789319077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638709149789319077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638709149789319077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638709149789319077" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638709149789319077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638709149789319077" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638709149789319077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638709149789319077" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638709149789319077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638709149789319077" order="6" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638709149789329079" order="7" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638709149789329079" order="8" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638709149789329079" order="9" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638709149789329079" order="10" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638709149789329079" order="11" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638709149789329079" order="12" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638709149789329079" order="13" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638709149789329079" order="14" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638709149789329079" order="15" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638709149789329079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638709149789329079" order="16" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638709149789339084" order="17" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638709149789339084" order="18" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638709149789339084" order="19" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638709149789339084" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638709149789339084" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638709149789339084" order="22" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638709149789339084" order="23" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638709149789339084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638709149789339084" order="24" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638709149789349087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638709149789349087" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638709149789349087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638709149789349087" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638709149789349087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638709149789349087" order="27" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638709149789349087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638709149789349087" order="28" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638709149789349087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638709149789349087" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638709149789349087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638709149789349087" order="30" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638709149789349087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638709149789349087" order="31" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638709149789359079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638709149789359079" order="32" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638709149789359079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638709149789359079" order="33" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638709149789359079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638709149789359079" order="34" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638709149789359079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638709149789359079" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638709149789359079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638709149789359079" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638709149789359079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638709149789359079" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638709149789369076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638709149789369076" xlink:to="us-gaap_AssetsCurrentAbstract_638709149789369076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638709149789369076" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638709149789369076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638709149789369076" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638709149789369076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638709149789369076" xlink:to="us-gaap_AssetsCurrent_638709149789369076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638709149789369076" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638709149789369076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638709149789369076" xlink:to="us-gaap_EquityMethodInvestments_638709149789369076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638709149789369076" xlink:to="us-gaap_OtherAssetsNoncurrent_638709149789369076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638709149789369076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638709149789369076" xlink:to="us-gaap_Assets_638709149789369076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="us-gaap_NotesAndLoansPayableCurrent_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" xlink:to="us-gaap_NotesAndLoansPayableCurrent_638709149789379085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638709149789379085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638709149789379085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" xlink:to="us-gaap_AccountsPayableCurrent_638709149789379085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638709149789379085" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638709149789379085" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638709149789379085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638709149789379085" xlink:to="us-gaap_LiabilitiesCurrent_638709149789379085" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638709149789389079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638709149789389079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" xlink:to="us-gaap_Liabilities_638709149789389079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" xlink:to="us-gaap_CommitmentsAndContingencies_638709149789389079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" xlink:to="us-gaap_StockholdersEquityAbstract_638709149789389079" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638709149789389079" xlink:to="us-gaap_PreferredStockValue_638709149789389079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638709149789389079" xlink:to="us-gaap_CommonStockValue_638709149789389079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638709149789389079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638709149789389079" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638709149789389079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638709149789399080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638709149789389079" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638709149789399080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638709149789399080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638709149789389079" xlink:to="us-gaap_StockholdersEquity_638709149789399080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638709149789399080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638709149789379085" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638709149789399080" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parentheticals)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638709149789399080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638709149789399080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638709149789399080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638709149789399080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638709149789399080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638709149789399080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638709149789399080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638709149789399080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638709149789409076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638709149789409076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638709149789409076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638709149789409076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638709149789409076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638709149789409076" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638709149789409076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638709149789409076" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638709149789409076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638709149789409076" xlink:to="us-gaap_OperatingExpenses_638709149789409076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638709149789409076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638709149789409076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_638709149789419080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest_638709149789419080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating_638709149789419080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149789419080" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ChangeInFairValueOfRedemptionFeature" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="otlk_ChangeInFairValueOfRedemptionFeature_638709149789419080" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantRelatedExpenses" xlink:label="otlk_WarrantRelatedExpenses_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="otlk_WarrantRelatedExpenses_638709149789419080" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638709149789419080" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638709149789419080" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638709149789419080" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638709149789419080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638709149789419080" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638709149789429085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638709149789429085" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638709149789429085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638709149789429085" xlink:to="us-gaap_EarningsPerShareBasic_638709149789429085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638709149789429085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638709149789429085" xlink:to="us-gaap_EarningsPerShareDiluted_638709149789429085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638709149789429085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638709149789429085" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638709149789429085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638709149789429085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638709149789429085" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638709149789429085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638709149789429085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638709149789429085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638709149789429085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638709149789429085" xlink:to="us-gaap_StatementEquityComponentsAxis_638709149789429085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638709149789429085" xlink:to="us-gaap_CommonStockMember_638709149789439089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638709149789429085" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638709149789439089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638709149789429085" xlink:to="us-gaap_RetainedEarningsMember_638709149789439089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638709149789429085" xlink:to="us-gaap_EquityComponentDomain_638709149789439089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638709149789429085" xlink:to="us-gaap_StatementLineItems_638709149789439089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638709149789439089" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_StockholdersEquity_638709149789439089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_SharesOutstanding_638709149789439089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638709149789439089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638709149789439089" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638709149789439089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638709149789439089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638709149789439089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638709149789449083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638709149789439089" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638709149789449083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638709149789449083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638709149789449083" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638709149789449083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_NetIncomeLoss_638709149789449083" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638709149789449083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_StockholdersEquity_638709149789449083" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638709149789449083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638709149789439089" xlink:to="us-gaap_SharesOutstanding_638709149789449083" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638709149789449083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638709149789449083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638709149789449083" xlink:to="us-gaap_NetIncomeLoss_638709149789459085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638709149789449083" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_DepreciationAndAmortization_638709149789459085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149789459085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_PaidInKindInterest_638709149789459085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_ShareBasedCompensation_638709149789459085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ChangeInFairValueOfRedemptionFeature" xlink:label="otlk_ChangeInFairValueOfRedemptionFeature_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="otlk_ChangeInFairValueOfRedemptionFeature_638709149789459085" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantRelatedExpenses" xlink:label="otlk_WarrantRelatedExpenses_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="otlk_WarrantRelatedExpenses_638709149789459085" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638709149789459085" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_638709149789459085" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_638709149789459085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_InterestPaid_638709149789459085" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638709149789459085" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638709149789469092" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638709149789469092" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638709149789469092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638709149789469092" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638709149789469092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638709149789469092" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638709149789469092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638709149789469092" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638709149789469092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638709149789469092" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638709149789469092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638709149789449083" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638709149789469092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149789469092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149789469092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638709149789479085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638709149789479085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638709149789479085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638709149789479085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638709149789479085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" xlink:to="us-gaap_RepaymentsOfDebt_638709149789479085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638709149789479085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" xlink:to="us-gaap_PaymentsOfFinancingCosts_638709149789479085" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149789479085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638709149789469092" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638709149789479085" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638709149789479085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638709149789479085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638709149789479085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638709149789479085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638709149789489087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638709149789489087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638709149789489087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638709149789489087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638709149789489087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638709149789489087" xlink:to="us-gaap_InterestPaidNet_638709149789489087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638709149789489087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638709149789489087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_638709149789489087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638709149789489087" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_638709149789489087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantLiabilityIncurredButNotYetPaid" xlink:label="otlk_WarrantLiabilityIncurredButNotYetPaid_638709149789489087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638709149789489087" xlink:to="otlk_WarrantLiabilityIncurredButNotYetPaid_638709149789489087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_638709149789489087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638709149789489087" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_638709149789489087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638709149789499085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638709149789489087" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638709149789499085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Organization and Description of Business">
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="OrganizationAndDescriptionOfBusinessAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638709149789499085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationAndDescriptionOfBusinessAbstract" xlink:to="us-gaap_NatureOfOperations_638709149789499085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureLiquidity" xlink:type="extended" xlink:title="995210201 - Disclosure - Liquidity">
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_LiquidityAbstract" xlink:label="LiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638709149789499085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638709149789499085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638709149789509080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638709149789509080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995210401 - Disclosure - Fair Value Measurements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638709149789509080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638709149789509080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestment" xlink:type="extended" xlink:title="995210501 - Disclosure - Equity Method Investment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="OtherAssetsNoncurrentDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_638709149789509080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_638709149789509080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210601 - Disclosure - Accrued Expenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638709149789509080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638709149789509080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureDebt" xlink:type="extended" xlink:title="995210701 - Disclosure - Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638709149789519082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638709149789519082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995210801 - Disclosure - Commitments and Contingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638709149789519082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638709149789519082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="995210901 - Disclosure - Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638709149789519082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638709149789519082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosurePreferredStock" xlink:type="extended" xlink:title="995211001 - Disclosure - Preferred Stock">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_638709149789529084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_PreferredStockTextBlock_638709149789529084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995211101 - Disclosure - Stock-Based Compensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638709149789529084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638709149789529084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangements" xlink:type="extended" xlink:title="995211201 - Disclosure - Collaboration Arrangements">
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_CollaborationArrangementsAbstract" xlink:label="CollaborationArrangementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_CollaborationArrangementsTextBlock" xlink:label="otlk_CollaborationArrangementsTextBlock_638709149789529084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationArrangementsAbstract" xlink:to="otlk_CollaborationArrangementsTextBlock_638709149789529084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211301 - Disclosure - Income Taxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638709149789529084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638709149789529084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211401 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638709149789539081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638709149789539081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638709149789539081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638709149789539081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ReverseStockSplitPolicyTextBlock" xlink:label="otlk_ReverseStockSplitPolicyTextBlock_638709149789539081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="otlk_ReverseStockSplitPolicyTextBlock_638709149789539081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638709149789539081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638709149789539081" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_638709149789539081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_638709149789539081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638709149789539081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638709149789539081" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638709149789549083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638709149789549083" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638709149789549083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638709149789549083" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638709149789549083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638709149789549083" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638709149789549083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638709149789549083" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638709149789549083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638709149789549083" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638709149789549083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638709149789549083" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638709149789549083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638709149789549083" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638709149789559084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Fair Value Measurements (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789559084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789559084" xlink:to="us-gaap_FinancialInstrumentAxis_638709149789559084" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638709149789559084" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789559084" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789559084" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789559084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789559084" xlink:to="us-gaap_WarrantMember_638709149789559084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789559084" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789559084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789559084" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638709149789559084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789559084" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638709149789559084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638709149789559084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789559084" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638709149789559084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Accrued Expenses (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638709149789569083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638709149789569083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Debt (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638709149789569083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638709149789569083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Commitments and Contingencies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638709149789569083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638709149789569083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638709149789579084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638709149789579084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638709149789579084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638709149789579084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Stockholders' Equity (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638709149789579084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638709149789579084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Stock-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789579084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789579084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638709149789579084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789579084" xlink:to="us-gaap_AwardTypeAxis_638709149789579084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789579084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638709149789579084" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789579084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638709149789579084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789579084" xlink:to="us-gaap_EmployeeStockOptionMember_638709149789579084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789579084" xlink:to="otlk_PerformanceBasedShareOptionsMember_638709149789589099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789579084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789589099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789589099" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638709149789589099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789589099" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638709149789589099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789589099" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638709149789589099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789589099" xlink:to="us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_638709149789589099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931303 - Disclosure - Income Taxes (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638709149789589099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638709149789589099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638709149789589099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638709149789599084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638709149789599084" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Liquidity (Details)">
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_LiquidityAbstract" xlink:label="otlk_LiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="otlk_LiquidityAbstract" xlink:to="us-gaap_StatementTable_638709149789599084" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638709149789599084" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638709149789599084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638709149789599084" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789599084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingBtigMember" xlink:label="otlk_AtMarketOfferingBtigMember_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789599084" xlink:to="otlk_AtMarketOfferingBtigMember_638709149789599084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638709149789599084" xlink:to="us-gaap_SubsequentEventTypeAxis_638709149789599084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638709149789599084" xlink:to="us-gaap_SubsequentEventTypeDomain_638709149789599084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638709149789599084" xlink:to="us-gaap_SubsequentEventMember_638709149789599084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638709149789599084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638709149789599084" xlink:to="us-gaap_StatementLineItems_638709149789599084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638709149789599084" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638709149789609079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638709149789599084" xlink:to="us-gaap_DebtInstrumentFairValue_638709149789609079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638709149789599084" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638709149789609079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638709149789599084" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149789609079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638709149789599084" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638709149789609079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638709149789609079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638709149789609079" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638709149789609079" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638709149789609079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638709149789609079" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638709149789609079" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638709149789609079" xlink:to="us-gaap_PerformanceSharesMember_638709149789619086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638709149789609079" xlink:to="otlk_PerformanceBasedShareOptionsMember_638709149789619086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638709149789609079" xlink:to="us-gaap_EmployeeStockOptionMember_638709149789619086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638709149789609079" xlink:to="us-gaap_WarrantMember_638709149789619086" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638709149789609079" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_638709149789619086" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638709149789609079" xlink:to="srt_StatementScenarioAxis_638709149789619086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638709149789619086" xlink:to="srt_ScenarioUnspecifiedDomain_638709149789619086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioOneMember" xlink:label="otlk_ScenarioOneMember_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638709149789619086" xlink:to="otlk_ScenarioOneMember_638709149789619086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioTwoMember" xlink:label="otlk_ScenarioTwoMember_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638709149789619086" xlink:to="otlk_ScenarioTwoMember_638709149789619086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638709149789619086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638709149789609079" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638709149789619086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638709149789619086" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638709149789629082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638709149789619086" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638709149789629082" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638709149789619086" xlink:to="us-gaap_DebtInstrumentFaceAmount_638709149789629082" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638709149789619086" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638709149789629082" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Fair Value Measurements (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789629082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789629082" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638709149789629082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638709149789629082" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638709149789629082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638709149789629082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638709149789629082" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638709149789629082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789629082" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638709149789639084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638709149789639084" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638709149789639084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638709149789639084" xlink:to="us-gaap_FairValueInputsLevel3Member_638709149789639084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789629082" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789639084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789639084" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638709149789639084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638709149789639084" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638709149789639084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638709149789639084" xlink:to="us-gaap_DerivativeLiabilities_638709149789639084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilities_638709149789639084" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_638709149789639084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_638709149789639084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638709149789639084" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_638709149789639084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - Fair Value Measurements - Fair value changes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789649083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789649083" xlink:to="us-gaap_FinancialInstrumentAxis_638709149789649083" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638709149789649083" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789649083" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789649083" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789649083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638709149789649083" xlink:to="us-gaap_WarrantMember_638709149789649083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638709149789649083" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789649083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638709149789649083" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638709149789649083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638709149789649083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees" xlink:label="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees_638709149789649083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" xlink:to="otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees_638709149789649083" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638709149789659081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638709149789659081" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638709149789659081" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638709149789659081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638709149789649083" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638709149789659081" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - Fair Value Measurements - Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638709149789659081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638709149789659081" xlink:to="us-gaap_MeasurementInputTypeAxis_638709149789659081" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638709149789659081" xlink:to="us-gaap_MeasurementInputTypeDomain_638709149789659081" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638709149789659081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638709149789659081" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638709149789659081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638709149789659081" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638709149789669078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638709149789659081" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638709149789669078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638709149789659081" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638709149789669078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638709149789659081" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638709149789669078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638709149789659081" xlink:to="us-gaap_MeasurementInputSharePriceMember_638709149789669078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638709149789659081" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638709149789669078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638709149789669078" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638709149789669078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638709149789669078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638709149789669078" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638709149789669078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Equity Method Investment - Syntone (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:label="OtherAssetsNoncurrentDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638709149789679080" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638709149789679080" xlink:to="dei_LegalEntityAxis_638709149789679080" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638709149789679080" xlink:to="dei_EntityDomain_638709149789679080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PRCJointVentureMember" xlink:label="otlk_PRCJointVentureMember_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638709149789679080" xlink:to="otlk_PRCJointVentureMember_638709149789679080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638709149789679080" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638709149789679080" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638709149789679080" xlink:to="srt_EquityMethodInvesteeNameDomain_638709149789679080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SyntoneMember" xlink:label="otlk_SyntoneMember_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638709149789679080" xlink:to="otlk_SyntoneMember_638709149789679080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_638709149789679080" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638709149789679080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638709149789679080" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_638709149789679080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638709149789679080" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_638709149789679080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_638709149789679080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_638709149789679080" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_638709149789679080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Accrued Expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638709149789689089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638709149789689089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638709149789689089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638709149789689089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="otlk_AccruedResearchAndDevelopmentExpensesCurrent_638709149789689089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="otlk_AccruedResearchAndDevelopmentExpensesCurrent_638709149789689089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638709149789689089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638709149789689089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638709149789689089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638709149789689089" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Debt - Summary (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638709149789689089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638709149789689089" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638709149789689089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638709149789689089" xlink:to="us-gaap_DebtInstrumentAxis_638709149789689089" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638709149789689089" xlink:to="us-gaap_DebtInstrumentNameDomain_638709149789699087" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638709149789699087" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789699087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638709149789689089" xlink:to="us-gaap_DebtInstrumentLineItems_638709149789699087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789699087" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638709149789699087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="us-gaap_NotesAndLoansPayableCurrent_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789699087" xlink:to="us-gaap_NotesAndLoansPayableCurrent_638709149789699087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Debt - Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638709149789699087" order="1" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638709149789699087" xlink:to="us-gaap_DebtInstrumentAxis_638709149789699087" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638709149789699087" xlink:to="us-gaap_DebtInstrumentNameDomain_638709149789699087" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_UnsecuredPromissoryNotesMember" xlink:label="otlk_UnsecuredPromissoryNotesMember_638709149789699087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638709149789699087" xlink:to="otlk_UnsecuredPromissoryNotesMember_638709149789699087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember" xlink:label="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789709080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="otlk_UnsecuredPromissoryNotesMember_638709149789699087" xlink:to="otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_638709149789709080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_UnsecuredPromissoryNote2021Member" xlink:label="otlk_UnsecuredPromissoryNote2021Member_638709149789769083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="otlk_UnsecuredPromissoryNotesMember_638709149789699087" xlink:to="otlk_UnsecuredPromissoryNote2021Member_638709149789769083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638709149789769083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638709149789699087" xlink:to="srt_RangeAxis_638709149789769083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638709149789769083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638709149789769083" xlink:to="srt_RangeMember_638709149789769083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638709149789769083" xlink:to="srt_MinimumMember_638709149789779079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638709149789699087" xlink:to="srt_StatementScenarioAxis_638709149789779079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638709149789779079" xlink:to="srt_ScenarioUnspecifiedDomain_638709149789779079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentFollowingToMajorTriggerEventMember" xlink:label="otlk_DebtInstrumentFollowingToMajorTriggerEventMember_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638709149789779079" xlink:to="otlk_DebtInstrumentFollowingToMajorTriggerEventMember_638709149789779079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioOneMember" xlink:label="otlk_ScenarioOneMember_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638709149789779079" xlink:to="otlk_ScenarioOneMember_638709149789779079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ScenarioTwoMember" xlink:label="otlk_ScenarioTwoMember_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638709149789779079" xlink:to="otlk_ScenarioTwoMember_638709149789779079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638709149789699087" xlink:to="us-gaap_DebtInstrumentLineItems_638709149789779079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentFaceAmount_638709149789779079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638709149789779079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638709149789779079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638709149789779079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638709149789789083" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_638709149789789083" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_638709149789789083" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash" xlink:label="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash_638709149789789083" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_638709149789789083" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent_638709149789789083" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent" xlink:label="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent_638709149789789083" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent" xlink:label="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent_638709149789789083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent_638709149789789083" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable" xlink:label="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable_638709149789799077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable_638709149789799077" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638709149789799077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638709149789799077" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender" xlink:label="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender_638709149789799077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender_638709149789799077" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing" xlink:label="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing_638709149789799077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing_638709149789799077" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance" xlink:label="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance_638709149789799077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance_638709149789799077" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638709149789799077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638709149789799077" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638709149789799077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638709149789799077" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638709149789799077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="us-gaap_DebtWeightedAverageInterestRate_638709149789809095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtWeightedAverageInterestRate_638709149789809095" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638709149789809095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638709149789809095" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_638709149789809095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_638709149789809095" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638709149789809095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638709149789809095" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638709149789809095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_InterestExpenseNonoperating_638709149789809095" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638709149789809095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_PaymentsOfFinancingCosts_638709149789809095" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_638709149789819082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_638709149789819082" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_638709149789819082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt_638709149789819082" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_638709149789819082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_InterestPaid_638709149789819082" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149789819082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638709149789819082" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638709149789819082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638709149789819082" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_638709149789819082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638709149789779079" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_638709149789819082" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Commitments and Contingencies (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638709149789829086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638709149789829086" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638709149789829086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638709149789829086" xlink:to="us-gaap_TypeOfArrangementAxis_638709149789829086" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638709149789829086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638709149789829086" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638709149789829086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SelexisMember" xlink:label="otlk_SelexisMember_638709149789829086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638709149789829086" xlink:to="otlk_SelexisMember_638709149789829086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638709149789829086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638709149789829086" xlink:to="us-gaap_OtherCommitmentsLineItems_638709149789829086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_638709149789829086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638709149789829086" xlink:to="us-gaap_ContractualObligation_638709149789829086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Commitments and Contingencies - Lease cost (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638709149789839087" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638709149789839087" xlink:to="srt_RangeAxis_638709149789839087" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638709149789839087" xlink:to="srt_RangeMember_638709149789839087" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638709149789839087" xlink:to="srt_MinimumMember_638709149789839087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638709149789839087" xlink:to="srt_MaximumMember_638709149789839087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638709149789839087" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638709149789839087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638709149789839087" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638709149789839087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638709149789839087" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_638709149789839087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_638709149789839087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638709149789839087" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_638709149789839087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638709149789849091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638709149789839087" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638709149789849091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638709149789849091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638709149789839087" xlink:to="us-gaap_LeaseCostAbstract_638709149789849091" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638709149789849091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638709149789849091" xlink:to="us-gaap_FinanceLeaseInterestExpense_638709149789849091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FinanceLeaseCost" xlink:label="otlk_FinanceLeaseCost_638709149789849091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638709149789849091" xlink:to="otlk_FinanceLeaseCost_638709149789849091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638709149789849091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638709149789849091" xlink:to="us-gaap_OperatingLeaseCost_638709149789849091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638709149789849091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638709149789849091" xlink:to="us-gaap_LeaseCost_638709149789849091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Commitments and Contingencies - Lease balance sheet (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeasesAbstract_638709149789859090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789859090" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638709149789859090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789859090" xlink:to="us-gaap_OperatingLeaseLiability_638709149789859090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789859090" xlink:to="us-gaap_FinanceLeaseLiability_638709149789859090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789859090" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638709149789859090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789859090" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638709149789859090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789859090" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638709149789859090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638709149789859090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789859090" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638709149789859090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Commitments and Contingencies - Lease cash flow (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeasesAbstract_638709149789869085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789869085" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_638709149789869085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789869085" xlink:to="us-gaap_OperatingLeasePayments_638709149789869085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789869085" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638709149789869085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_638709149789869085" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638709149789869085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638709149789869085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638709149789869085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638709149789869085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638709149789869085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638709149789879081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638709149789879081" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638709149789879081" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638709149789879081" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638709149789869085" xlink:to="us-gaap_OperatingLeaseLiability_638709149789879081" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638709149789879081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638709149789879081" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638709149789879081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638709149789879081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638709149789879081" xlink:to="us-gaap_FinanceLeaseLiability_638709149789879081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails" xlink:type="extended" xlink:title="99940806 - Disclosure - Commitments and Contingencies - Employee Benefit (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638709149789889083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638709149789889083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638709149789889083" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638709149789889083" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Stockholders' Equity - Common Stock (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638709149789889083" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638709149789889083" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638709149789889083" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638709149789889083" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789889083" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DirectRegisteredOfferingMember" xlink:label="otlk_DirectRegisteredOfferingMember_638709149789889083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789889083" xlink:to="otlk_DirectRegisteredOfferingMember_638709149789889083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789889083" xlink:to="us-gaap_OverAllotmentOptionMember_638709149789899097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingMember" xlink:label="otlk_AtMarketOfferingMember_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789889083" xlink:to="otlk_AtMarketOfferingMember_638709149789899097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AtMarketOfferingBtigMember" xlink:label="otlk_AtMarketOfferingBtigMember_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638709149789889083" xlink:to="otlk_AtMarketOfferingBtigMember_638709149789899097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638709149789889083" xlink:to="srt_CounterpartyNameAxis_638709149789899097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638709149789899097" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638709149789899097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_GmsVenturesInvestmentsMember" xlink:label="otlk_GmsVenturesInvestmentsMember_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638709149789899097" xlink:to="otlk_GmsVenturesInvestmentsMember_638709149789899097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638709149789889083" xlink:to="us-gaap_ClassOfStockLineItems_638709149789899097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_CommonStockSharesAuthorized_638709149789899097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638709149789899097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638709149789899097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638709149789899097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_SharesIssuedPricePerShare_638709149789899097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638709149789909113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638709149789909113" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638709149789909113" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638709149789909113" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_CommonStockVotingRights_638709149789909113" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_DividendsCommonStock_638709149789909113" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_AggregateOfferingPriceAuthorized" xlink:label="otlk_AggregateOfferingPriceAuthorized_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="otlk_AggregateOfferingPriceAuthorized_638709149789909113" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638709149789909113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638709149789909113" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638709149789919095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638709149789919095" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts_638709149789919095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="us-gaap_DeferredCosts_638709149789919095" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission" xlink:label="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission_638709149789919095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission_638709149789919095" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantRelatedExpenses" xlink:label="otlk_WarrantRelatedExpenses_638709149789919095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789899097" xlink:to="otlk_WarrantRelatedExpenses_638709149789919095" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Stockholders' Equity - Warrants (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638709149789919095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638709149789919095" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638709149789919095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638709149789919095" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638709149789919095" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638709149789919095" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyTwoDecemberTwoThousandTwentyFourMember" xlink:label="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_638709149789929087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember" xlink:label="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_638709149789929087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ThirteenAprilTwoThousandTwentyFiveMember" xlink:label="otlk_ThirteenAprilTwoThousandTwentyFiveMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_ThirteenAprilTwoThousandTwentyFiveMember_638709149789929087" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ThirtyFirstMayTwoThousandTwentyFiveMember" xlink:label="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_638709149789929087" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentySecondJuneTwoThousandTwentyFiveMember" xlink:label="otlk_TwentySecondJuneTwoThousandTwentyFiveMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_TwentySecondJuneTwoThousandTwentyFiveMember_638709149789929087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember" xlink:label="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_638709149789929087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyEighthJanuaryTwoThousandTwentySixMember" xlink:label="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_638709149789929087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_WarrantExpirationDateFebruary22026Member" xlink:label="otlk_WarrantExpirationDateFebruary22026Member_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_WarrantExpirationDateFebruary22026Member_638709149789929087" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_TwentyThirdNovemberTwoThousandTwentySixMember" xlink:label="otlk_TwentyThirdNovemberTwoThousandTwentySixMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_TwentyThirdNovemberTwoThousandTwentySixMember_638709149789929087" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_EighteenMarchTwoThousandTwentyNineMember" xlink:label="otlk_EighteenMarchTwoThousandTwentyNineMember_638709149789929087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_EighteenMarchTwoThousandTwentyNineMember_638709149789929087" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_FifteenthAprilTwoThousandTwentyNineMember" xlink:label="otlk_FifteenthAprilTwoThousandTwentyNineMember_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638709149789929087" xlink:to="otlk_FifteenthAprilTwoThousandTwentyNineMember_638709149789939087" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638709149789919095" xlink:to="us-gaap_ClassOfStockLineItems_638709149789939087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789939087" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638709149789939087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789939087" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638709149789939087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789939087" xlink:to="otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant_638709149789939087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789939087" xlink:to="otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant_638709149789939087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant" xlink:label="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789939087" xlink:to="otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant_638709149789939087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions" xlink:label="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions_638709149789939087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638709149789939087" xlink:to="otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions_638709149789939087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosurePreferredStockDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Preferred Stock (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638709149789949091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638709149789949091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock-Based Compensation - Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789949091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789949091" xlink:to="us-gaap_AwardTypeAxis_638709149789949091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638709149789949091" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789949091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789949091" xlink:to="us-gaap_EmployeeStockOptionMember_638709149789949091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789949091" xlink:to="otlk_PerformanceBasedShareOptionsMember_638709149789949091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638709149789949091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789949091" xlink:to="us-gaap_PerformanceSharesMember_638709149789949091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789949091" xlink:to="srt_RangeAxis_638709149789959085" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638709149789959085" xlink:to="srt_RangeMember_638709149789959085" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638709149789959085" xlink:to="srt_MinimumMember_638709149789959085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638709149789959085" xlink:to="srt_MaximumMember_638709149789959085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789949091" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789959085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789959085" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638709149789959085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789959085" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638709149789959085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789959085" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638709149789959085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638709149789959085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789959085" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638709149789959085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock-Based Compensation - Expense (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789969092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789969092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638709149789969092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789969092" xlink:to="us-gaap_IncomeStatementLocationAxis_638709149789969092" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638709149789969092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638709149789969092" xlink:to="us-gaap_IncomeStatementLocationDomain_638709149789969092" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638709149789969092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638709149789969092" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638709149789969092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638709149789969092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638709149789969092" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638709149789969092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789969092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789969092" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789969092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638709149789969092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789969092" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638709149789969092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Stock-Based Compensation - Option activity (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789979095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789979095" xlink:to="us-gaap_AwardTypeAxis_638709149789979095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789979095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789979095" xlink:to="us-gaap_EmployeeStockOptionMember_638709149789979095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149789979095" xlink:to="otlk_PerformanceBasedShareOptionsMember_638709149789979095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789979095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638709149789979095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638709149789979095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638709149789979095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638709149789979095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638709149789979095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638709149789989090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638709149789989090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638709149789989090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638709149789989090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638709149789989090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638709149789989090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638709149789989090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638709149789989090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638709149789989090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638709149789989090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638709149789989090" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638709149789989090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387091497899890901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387091497899890901" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638709149789989090" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638709149789999088" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638709149789999088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638709149789999088" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638709149789999088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638709149789999088" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638709149789999088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638709149789999088" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638709149789999088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638709149789999088" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638709149789999088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789979095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638709149789999088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638709149789999088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149789979095" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638709149789999088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Stock-Based Compensation - Option Assumptions (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790009103" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790009103" xlink:to="us-gaap_AwardTypeAxis_638709149790009103" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638709149790009103" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149790009103" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149790009103" xlink:to="us-gaap_EmployeeStockOptionMember_638709149790009103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PerformanceBasedShareOptionsMember" xlink:label="otlk_PerformanceBasedShareOptionsMember_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149790009103" xlink:to="otlk_PerformanceBasedShareOptionsMember_638709149790009103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790009103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638709149790009103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638709149790009103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638709149790009103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638709149790019092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638709149790019092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638709149790019092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638709149790019092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638709149790019092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638709149790019092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638709149790019092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790009103" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638709149790019092" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="99941105 - Disclosure - Stock-Based Compensation - Non-options (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790019092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790019092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638709149790019092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790019092" xlink:to="us-gaap_AwardTypeAxis_638709149790019092" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149790019092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638709149790019092" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149790019092" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638709149790019092" xlink:to="us-gaap_PerformanceSharesMember_638709149790029084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638709149790019092" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790029084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790029084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638709149790029084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638709149790029084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638709149790029084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638709149790029084" xlink:to="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_638709149790029084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387091497900290841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638709149790029084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387091497900290841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638709149790029084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638709149790029084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638709149790029084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638709149790029084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue" xlink:label="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_638709149790029084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638709149790029084" xlink:to="otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue_638709149790029084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387091497900290841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638709149790029084" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6387091497900290841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Collaboration Arrangements (Details)">
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_CollaborationArrangementsAbstract" xlink:label="CollaborationArrangementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638709149790039086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638709149790039086" xlink:to="dei_LegalEntityAxis_638709149790039086" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638709149790039086" xlink:to="dei_EntityDomain_638709149790039086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_PRCJointVentureMember" xlink:label="otlk_PRCJointVentureMember_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638709149790039086" xlink:to="otlk_PRCJointVentureMember_638709149790039086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638709149790039086" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638709149790039086" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638709149790039086" xlink:to="srt_EquityMethodInvesteeNameDomain_638709149790039086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_SyntoneMember" xlink:label="otlk_SyntoneMember_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638709149790039086" xlink:to="otlk_SyntoneMember_638709149790039086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638709149790039086" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638709149790039086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_638709149790039086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638709149790039086" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_638709149790039086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_638709149790049087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638709149790039086" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_638709149790049087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_638709149790049087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638709149790039086" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_638709149790049087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Income Taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638709149790049087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638709149790049087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - Income Taxes - Reconciliation (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638709149790049087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638709149790049087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638709149790059087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent" xlink:label="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent_638709149790059087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638709149790059087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_638709149790059087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638709149790059087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638709149790059087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638709149790059087" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638709149790049087" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638709149790059087" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails" xlink:type="extended" xlink:title="99941303 - Disclosure - Income Taxes - Deferred (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638709149790069086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638709149790069086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638709149790069086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="otlk-20240930.xsd#otlk_DeferredTaxAssetsLeaseLiability" xlink:label="otlk_DeferredTaxAssetsLeaseLiability_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="otlk_DeferredTaxAssetsLeaseLiability_638709149790069086" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638709149790069086" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_638709149790069086" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638709149790069086" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsGross_638709149790069086" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638709149790069086" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638709149790059087" xlink:to="us-gaap_DeferredTaxAssetsNet_638709149790069086" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638709149790069086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638709149790069086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638709149790069086" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638709149790079088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638709149790079088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" xlink:type="extended" xlink:title="99941304 - Disclosure - Income Taxes - Carryforwards (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638709149790079088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638709149790079088" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638709149790079088" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638709149790079088" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638709149790079088" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638709149790079088" xlink:to="us-gaap_DomesticCountryMember_638709149790079088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638709149790079088" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638709149790079088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638709149790079088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638709149790079088" xlink:to="us-gaap_ForeignCountryMember_638709149790079088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638709149790089080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638709149790079088" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638709149790089080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638709149790089080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638709149790089080" xlink:to="us-gaap_OperatingLossCarryforwards_638709149790089080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638709149790089080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638709149790089080" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638709149790089080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638709149790089080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638709149790089080" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638709149790089080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638709149790089080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638709149790089080" xlink:to="us-gaap_UnrecognizedTaxBenefits_638709149790089080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails" xlink:type="extended" xlink:title="99941305 - Disclosure - Income Taxes - Unrecognized benefits (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638709149790089080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638709149790089080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638709149790089080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638709149790089080" xlink:to="us-gaap_UnrecognizedTaxBenefits_638709149790089080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638709149790089080" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_638709149790099093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638709149790089080" xlink:to="us-gaap_UnrecognizedTaxBenefits_638709149790099093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Subsequent Events (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638709149790099093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638709149790099093" xlink:to="us-gaap_SubsequentEventTypeAxis_638709149790099093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638709149790099093" xlink:to="us-gaap_SubsequentEventTypeDomain_638709149790099093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638709149790099093" xlink:to="us-gaap_SubsequentEventMember_638709149790099093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638709149790099093" xlink:to="us-gaap_SubsequentEventLineItems_638709149790099093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638709149790099093" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638709149790099093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638709149790099093" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638709149790099093" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638709149790099093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_638709149790109088" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638709149790099093" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_638709149790109088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957253293440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 24, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-37759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OUTLOOK THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3982704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">111 S. Wood Avenue, Unit #100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Iselin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">619-3990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OTLK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,905,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001649989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252127120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,927,538<span></span>
</td>
<td class="nump">$ 23,391,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,488,498<span></span>
</td>
<td class="nump">7,587,216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">27,416,036<span></span>
</td>
<td class="nump">30,979,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">274,645<span></span>
</td>
<td class="nump">26,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">693,190<span></span>
</td>
<td class="nump">793,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">439,283<span></span>
</td>
<td class="nump">501,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,823,154<span></span>
</td>
<td class="nump">32,300,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayableCurrent', window );">Unsecured convertible promissory note</a></td>
<td class="nump">29,440,000<span></span>
</td>
<td class="nump">35,551,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">50,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,968,725<span></span>
</td>
<td class="nump">6,574,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,237,468<span></span>
</td>
<td class="nump">2,745,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,856,629<span></span>
</td>
<td class="nump">1,856,629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,553,729<span></span>
</td>
<td class="nump">46,732,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">246,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">59,099,013<span></span>
</td>
<td class="nump">6,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">101,899,664<span></span>
</td>
<td class="nump">46,738,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.01 per share: 10,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.01 per share; 60,000,000 shares authorized; 23,905,635 and 13,012,833 shares issued and outstanding at September 30, 2024 and September 30, 2023, respectively</a></td>
<td class="nump">239,057<span></span>
</td>
<td class="nump">130,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">469,969,333<span></span>
</td>
<td class="nump">453,350,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(543,284,900)<span></span>
</td>
<td class="num">(467,918,186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(73,076,510)<span></span>
</td>
<td class="num">(14,437,777)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 28,823,154<span></span>
</td>
<td class="nump">$ 32,300,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251738880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">23,905,635<span></span>
</td>
<td class="nump">13,012,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">23,905,635<span></span>
</td>
<td class="nump">13,012,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250074384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 41,763,047<span></span>
</td>
<td class="nump">$ 26,452,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,940,188<span></span>
</td>
<td class="nump">26,673,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(71,703,235)<span></span>
</td>
<td class="num">(53,126,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">100,742<span></span>
</td>
<td class="nump">10,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(906,150)<span></span>
</td>
<td class="num">(971,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">3,156,964<span></span>
</td>
<td class="nump">2,531,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_ChangeInFairValueOfRedemptionFeature', window );">Change in fair value of promissory notes</a></td>
<td class="nump">2,457,153<span></span>
</td>
<td class="nump">3,756,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_WarrantRelatedExpenses', window );">Warrant related expenses (Note 9)</a></td>
<td class="nump">37,490,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(38,638,042)<span></span>
</td>
<td class="num">(50,919)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(75,363,914)<span></span>
</td>
<td class="num">(58,979,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss)</a></td>
<td class="num">$ (75,366,714)<span></span>
</td>
<td class="num">$ (58,982,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share of common stock, basic (in dollars per share)</a></td>
<td class="num">$ (4.06)<span></span>
</td>
<td class="num">$ (4.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (4.06)<span></span>
</td>
<td class="num">$ (4.72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">18,548,813<span></span>
</td>
<td class="nump">12,508,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">18,548,813<span></span>
</td>
<td class="nump">12,508,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_ChangeInFairValueOfRedemptionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of redemption feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_ChangeInFairValueOfRedemptionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_WarrantRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses related to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_WarrantRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250251824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Sep. 30, 2022</a></td>
<td class="nump">$ 113,655<span></span>
</td>
<td class="nump">$ 417,558,434<span></span>
</td>
<td class="num">$ (408,935,518)<span></span>
</td>
<td class="nump">$ 8,736,571<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning (in shares) at Sep. 30, 2022</a></td>
<td class="nump">11,365,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 16,467<span></span>
</td>
<td class="nump">30,219,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,236,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">1,646,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with conversion of convertible promissory note</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">24,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with conversion of convertible promissory note (in shares)</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,547,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,547,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,982,668)<span></span>
</td>
<td class="num">(58,982,668)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2023</a></td>
<td class="nump">$ 130,128<span></span>
</td>
<td class="nump">453,350,281<span></span>
</td>
<td class="num">(467,918,186)<span></span>
</td>
<td class="num">(14,437,777)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2023</a></td>
<td class="nump">13,012,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 92,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">9,285,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with conversion of convertible promissory note</a></td>
<td class="nump">$ 16,072<span></span>
</td>
<td class="nump">11,233,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in connection with conversion of convertible promissory note (in shares)</a></td>
<td class="nump">1,607,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,385,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,385,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,366,714)<span></span>
</td>
<td class="num">(75,366,714)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2024</a></td>
<td class="nump">$ 239,057<span></span>
</td>
<td class="nump">$ 469,969,333<span></span>
</td>
<td class="num">$ (543,284,900)<span></span>
</td>
<td class="num">$ (73,076,510)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2024</a></td>
<td class="nump">23,905,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251625264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (75,366,714)<span></span>
</td>
<td class="num">$ (58,982,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">113,859<span></span>
</td>
<td class="nump">44,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">2,681,847<span></span>
</td>
<td class="nump">2,529,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,385,124<span></span>
</td>
<td class="nump">5,547,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_ChangeInFairValueOfRedemptionFeature', window );">Change in fair value of promissory notes</a></td>
<td class="nump">2,457,153<span></span>
</td>
<td class="nump">3,756,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_WarrantRelatedExpenses', window );">Warrant related expenses (Note 9)</a></td>
<td class="nump">37,490,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(38,638,042)<span></span>
</td>
<td class="num">(50,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">100,742<span></span>
</td>
<td class="nump">10,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,158,609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,901,282)<span></span>
</td>
<td class="nump">2,616,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(5,900)<span></span>
</td>
<td class="num">(208,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">3,413<span></span>
</td>
<td class="num">(26,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,394,202<span></span>
</td>
<td class="nump">3,083,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">491,728<span></span>
</td>
<td class="num">(711,661)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,793,858)<span></span>
</td>
<td class="num">(42,973,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs</a></td>
<td class="nump">60,333,681<span></span>
</td>
<td class="nump">30,024,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease obligations</a></td>
<td class="num">(4,267)<span></span>
</td>
<td class="num">(11,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,220,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(823,894)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">60,329,414<span></span>
</td>
<td class="nump">48,968,568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(8,464,444)<span></span>
</td>
<td class="nump">5,995,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">23,391,982<span></span>
</td>
<td class="nump">17,396,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">14,927,538<span></span>
</td>
<td class="nump">23,391,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">1,160,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Convertible promissory note converted into common stock</a></td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_WarrantLiabilityIncurredButNotYetPaid', window );">Recognition of warrant liability</a></td>
<td class="nump">97,730,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability recognized for new operating lease liabilities</a></td>
<td class="nump">$ 294,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_ChangeInFairValueOfRedemptionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of redemption feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_ChangeInFairValueOfRedemptionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_WarrantLiabilityIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liability incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_WarrantLiabilityIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_WarrantRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses related to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_WarrantRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251813696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_OrganizationAndDescriptionOfBusinessAbstract', window );"><strong>Organization and Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;Organization and Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outlook Therapeutics, Inc. (&#8220;Outlook&#8221; or the &#8220;Company&#8221;) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to &#8220;Outlook Therapeutics, Inc.&#8221; in November 2018. The Company is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA<span style="background:#ffffff;">&#8482; (</span>bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2024, the Company received Marketing Authorization from the European Commission for ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (&#8220;AMD&#8221;) in the European Union (&#8220;EU&#8221;). &#160;Additionally, in July 2024 the Company also received marketing authorization for ONS-5010/LYTENAVA in the United Kingdom (&#8220;UK&#8221;) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). ONS-5010/LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of calendar 2023, the Company agreed to conduct an additional adequate and well-controlled clinical trial following discussions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in support of the Company&#8217;s Biologics License Application (&#8220;BLA&#8221;) for ONS-5010/LYTENAVA. In December 2023, the Company submitted a Special Protocol Assessment (&#8220;SPA&#8221;) to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010/LYTENAVA BLA. In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA&#8217;s requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter (&#8220;CRL&#8221;). In addition, through a Type A meeting and additional interactions, the Company has identified the approaches needed to resolve the chemistry, manufacturing and controls (&#8220;CMC&#8221;) comments in the CRL. In November 2024, the Company reported that &#160;ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_OrganizationAndDescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_OrganizationAndDescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252923088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since its inception and has an accumulated deficit of $ 543,284,900 as of September 30, 2024. As of September 30, 2024, the Company had $31,352,857 of principal, accrued interest and exit fees due under an unsecured convertible promissory note issued in December 2022 (the &#8220;December 2022 Note&#8221;), maturing on July 1, 2025, as amended. &#160;As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2024 and December 2024, the Company sold 1,000,000 shares of common stock under the BTIG ATM Offering and generated $1,742,343 in net proceeds after paying fees to BTIG and other issuance costs of $53,918. Refer to Note 9 for further details on the BTIG ATM Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that the Company&#8217;s existing cash and cash equivalents as of September 30, 2024, together with $1,742,343 in net proceeds from the sale of shares of common stock under the BTIG ATM Offering since September 30, 2024, are sufficient to fund the Company&#8217;s operations through one year from the Form 10-K filing date. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern and additional financing will be </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">needed by the Company to fund its operations in the future and to commercially develop ONS-5010/LYTENAVA and to develop any other product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations, including but not limited to, the exercise of outstanding warrants to purchase shares of the Company&#8217;s common stock (subject to meeting the requirements for calling such warrants), proceeds from potential licensing and/or marketing arrangements or collaborations with pharmaceutical or other companies, sale of the development and commercial rights to the Company&#8217;s drug product candidates in regions outside of the U.S., the issuance of additional debt, the issuance of equity securities, including accessing capital through at-the-market offering agreements (refer to Note 9 for further details), and revenues from potential future product sales, if any. There can be no assurance that these future funding efforts will be successful. The Company&#8217;s consolidated financial statements do not include any adjustments that might be necessary if it is unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing discussed above; (ii) the Company&#8217;s ability to successfully begin marketing of its product candidates or complete revenue-generating partnerships with other companies; (iii) the success of its research and development; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies; and, ultimately, (v) regulatory approval and market acceptance of the Company&#8217;s proposed future products.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252929504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;Basis of Presentation and Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The accompanying consolidated financial statements have been prepared in conformity with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying consolidated financial statements include the accounts of the Company and Outlook Therapeutics Pty Ltd, its wholly-owned subsidiary incorporated in Australia (the &#8220;Subsidiary&#8221;). All intercompany accounts and transactions have been eliminated in consolidation.</span> <span style="background:#ffffff;">The Company has determined the functional currency of the Subsidiary to be the U.S. dollar. The Company translates assets and liabilities of its foreign operations at exchange rates in effect at the balance sheet date. The Company records remeasurement gains and losses on monetary assets and liabilities, such as incentive and tax receivables and accounts payables, which are not in the functional currency of the operation. These remeasurement gains and losses are recorded in the consolidated statements of operations as they occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reverse stock split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective on March 14, 2024, the Company amended its amended and restated certificate of incorporation to implement a <span style="-sec-ix-hidden:Hidden_35bPP_NyTECQ2xx8ssQR0g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-twenty</span></span> reverse stock split of its common stock. As a result of the reverse stock split, the Company made corresponding adjustments to the share amounts under its employee incentive plans, outstanding options, and common stock warrant agreements with third parties. The disclosure of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash and cash equivalents include cash-on-hand and demand deposits with financial institutions and other short-term investments with maturities of less than three months when acquired and convertible to known cash amounts. At September 30, 2024 and 2023, the Company&#8217;s cash equivalents consist of a money market account.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity method investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company&#8217;s share of equity in the earnings or loss of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. The Company has not elected the fair value option. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The asset&#8217;s or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At September 30, 2024 and 2023, the Company&#8217;s financial instruments included cash and cash equivalents, accounts payable, accrued expenses, unsecured convertible promissory note and warrant liabilities. The carrying amount of accounts payable, and accrued expenses approximates fair value due to the short-term maturities of these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Option</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company elected the fair value option to account for the December 2022 Note. Refer to Note 7 for further details on the December 2022 Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#8220;Short-Term Leases&#8221;). For Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the consolidated balance sheet. The Company had no Short-Term Leases as of September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the re-measured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received, and any initial direct costs incurred are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures equity classified stock-based awards based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of stock option awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model, which is described more fully in Note&#160;11. The fair value of each restricted stock award is measured as the fair value per share of the Company&#8217;s common stock on the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upfront milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted net loss per common share, the denominator includes both the weighted average common shares outstanding and the number of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include convertible debt, warrants, performance-based stock options and units, and stock options the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company&#8217;s losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September&#160;30, 2024 and 2023, as they would be antidilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.68%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;white-space:nowrap;width:29.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 123</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 666,500</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,000</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,946,646</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,197,774</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,207,622</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 366,427</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible debt</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,171,100</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(i)</sup></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 854,962</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(ii)</sup></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The calculation for potentially dilutive securities pertaining to convertible debt is as follows: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3,750,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of outstanding principal and accrued interest as of September 30, 2024, is converted at a rate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and the remaining amount is converted based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252926224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the Company&#8217;s liabilities that are measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,440,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nriUGTcej0qNzzfpnoD1Jg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,099,013</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,539,013</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,551,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_7BYTPZDFbEyyt_JlN9COqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,219</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,557,219</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table presented below is a summary of changes in the fair value of the Company&#8217;s Level 3 valuation for the warrant liability and the December 2022 Note for the&#160;years ended September&#160;30, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unsecured Convertible</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Promissory Note</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at October 1, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,138</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at issuance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,820,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest converted to common stock</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,000)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,756,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,919)</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2023</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,551,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,219</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issued in connection with sale of common stock</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 97,730,836</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Promissory note maturity extension fee added to outstanding balance</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,681,847</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal and accrued interest converted to common stock</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,250,000)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_n00HlfZxbEWQPFKyyKwVxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,457,153</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38,638,042)</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,440,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,099,013</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As further described in Note 7, the Company elected the fair value option to account for the December 2022 Note. The fair value of the December 2022 Note is estimated using a binomial lattice model, which evaluates the payouts under hold, convert or call decisions. Significant estimates in the binomial lattice model include the Company&#8217;s stock price, volatility, risk-free rate of return, and credit-adjusted discount rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair values of the December 2022 Note as of September 30, 2024 and 2023 were estimated using a binomial lattice model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 71.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credit-adjusted discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The warrants related to the Note and Warrant Purchase Agreement dated December 22, 2017 are classified as liabilities as the warrants include cash settlement features at the option of the holders under certain circumstances. The warrants issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 are classified as liabilities as the Company assessed that they are not indexed to the Company&#8217;s own stock and must be classified as liabilities. For further details on the evaluation refer to Note 9. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The above warrant liabilities are revalued each reporting period with the change in fair values recorded in the accompanying consolidated statements of operations until the warrants are exercised or expire. The fair values of the warrant liabilities are estimated using the Black-Scholes option pricing model using the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:22.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remaining contractual term of warrants (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 125.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 158.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Annual dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of common stock (per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252931728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">5. &#160;&#160;&#160;&#160;&#160;Equity Method Investment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the execution of a stock purchase agreement with Syntone Ventures LLC (&#8220;Syntone Ventures&#8221;), the U.S. based affiliate of Syntone Technologies Group Co. Ltd. (&#8220;Syntone PRC&#8221;) on May 22, 2020, the Company and Syntone PRC entered into a joint venture agreement pursuant to which they agreed to form a People&#8217;s Republic of China (&#8220;PRC&#8221;) joint venture, Beijing Syntone Biopharma Ltd (&#8220;Syntone JV&#8221;), that is 80% owned by Syntone PRC and 20% owned by the Company. As the Company can exert significant influence over, but does not control, Syntone JV&#8217;s operations through voting rights or representation on Syntone JV&#8217;s board of directors, the Company accounts for this investment using the equity method of accounting. Upon formation of Syntone JV in April 2021, the Company entered into a royalty-free license with Syntone JV for the development, commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company made the initial investment of $900,000 in June 2020 and is committed to making capital contributions to Syntone JV of approximately $2,100,000, based upon the development plan contemplated in the license agreement. The maximum exposure to a loss as a result of the Company&#8217;s involvement in Syntone JV is limited to the initial investment and the future capital contributions totaling approximately $2,100,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252711456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">6</span>.&#160;&#160;&#160;&#160;&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses consists of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:middle;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,012,962</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 919,970</p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,798,767</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 165,192</p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,373</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,234,192</p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 384,366</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 426,386</p></td></tr><tr><td style="vertical-align:middle;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,237,468</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,745,740</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251820480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">7.&#160;&#160;&#160;&#160;&#160;Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Debt consists of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:middle;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note (measured at fair value)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,440,000</p></td><td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,551,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:middle;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,440,000)</p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,551,000)</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:middle;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">December 2022 Note</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On December 22, 2022, the Company entered into a Securities Purchase Agreement and issued the December 2022 Note with a face amount of $31,820,000 to Streeterville Capital, LLC (the &#8220;Lender&#8221;), the holder of the Company&#8217;s unsecured promissory note issued in November 2021 (the &#8220;November 2021 Note&#8221;). The December 2022 Note has an original issue discount of $1,820,000. The Company received net proceeds of $18,052,461 upon the closing on December 28, 2022 after deducting the Lender&#8217;s transaction costs in connection with the issuance and a full payment of the remaining outstanding principal and accrued interest on the November 2021 Note. The November 2021 Note was cancelled upon repayment. See below for additional disclosures relating to the November 2021 Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In December 2023, the Company extended the maturity of the December 2022 Note from January 1, 2024 to April 1, 2024. The Company incurred a $475,000 extension fee. The December 2022 Note bore interest at 9.5% per annum through April 1, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The December 2022 Note contains customary covenants, including a restriction on the Company&#8217;s ability to pledge certain of the Company&#8217;s assets, subject to certain exceptions, without the Lender&#8217;s consent. Beginning on April 1, 2023, the Lender had the right to convert the December 2022 Note at the Conversion Price (as defined below). The principal amount and conversion price of the December 2022 Note were subject to adjustment upon certain triggering events. In addition, the Company had the right to convert all or any portion of the outstanding balance under the December 2022 Note into shares of common stock at the Conversion Price if certain conditions have been met at the time of conversion, including if at any time after the six-month anniversary of the closing date, the daily volume-weighted average price of the common stock on Nasdaq equals or exceeds $50.00 per share (subject to adjustments for stock splits and stock combinations) for a period of 30 consecutive trading days. Payments may be made by the Company (i) in cash, (ii) in shares of common stock, with the number of shares being equal to the portion of the applicable payment amount divided by the Conversion Price (as defined below), or (iii) a combination of cash and shares of common stock. Any payments made by the Company in cash, including prepayments or repayment at maturity, will be subject to an additional fee of 7.5%. Upon the occurrence of certain events described in the December 2022 Note, including, among others, the Company&#8217;s failure to pay amounts due and payable under the December 2022 Note, events of insolvency or bankruptcy, failure to observe covenants contained in the Securities Purchase Agreement and the December 2022 Note, breaches of representations and warranties in the Securities Purchase Agreement, and the occurrence of certain transactions without the Lender&#8217;s consent (each such event, a &#8220;Trigger Event&#8221;), the Lender shall have the right, subject to certain exceptions, to increase the balance of the December 2022 Note by 10% for a Major Trigger Event (as defined in the December 2022 Note) and 5% for a Minor Trigger Event (as defined in the December 2022 Note). If a Trigger Event is not cured within <span style="-sec-ix-hidden:Hidden_nFi_I78LHEio1BmDRkU8nQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) trading days of written notice thereof from the Lender, it will result in an event of default (such event, an &#8220;Event of Default&#8221;). Following an Event of Default, the Lender may accelerate the December 2022 Note such that all amounts thereunder become immediately due and payable, and interest shall accrue at a rate of 22% annually until paid. Prior to April 1, 2024, under the December 2022 Note, &#8220;Conversion Price&#8221; meant, prior to a Major Trigger Event, $40.00 per share (subject to adjustment for stock splits and stock combinations), and following a Major Trigger Event, the lesser of (i) $40.00 per share (subject to adjustment for stock splits and stock combinations), and (ii) 90% multiplied by the lowest closing bid price of the Company&#8217;s common stock in the three trading days prior to the date on which the conversion notice is delivered. If the Conversion Price is below $3.51 per share, the Company will be required to satisfy a conversion notice from the Lender in cash. Subject to certain exceptions, while the December 2022 Note is outstanding, the Lender will have a consent right on any future variable rate transactions or any debt and a 10% participation right in any future debt or equity financings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On January 22, 2024, the Company entered into an amendment to the December 2022 Note (the &#8220;January 2024 Note Amendment&#8221;) with the Lender, which became effective on April 1, 2024 after satisfaction of certain conditions, including various required stockholder approvals and the closing of the private placement on March 18, 2024. The maturity of the December 2022 Note was extended to July 1, 2025. An extension fee of $2,681,847 (calculated as 7.5% of the outstanding balance of the December 2022 Note) was added to the outstanding balance on March 18, 2024. The extension fee was included in interest expense in the consolidated statement of operations for the year ended September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the January 2024 Note Amendment, the initial conversion price with respect to $15,000,000 in aggregate principal amount of the December 2022 Note was changed to $7.00, the price per share in the private placement that closed on March 18, 2024 and the remaining aggregate principal amount has a conversion price of $40.00 per share. Effective April 1, 2024, the December 2022 Note bears interest at the <span style="-sec-ix-hidden:Hidden_-FJYa8lNSUetfvJA523X1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prime rate</span></span> (as published in the Wall Street Journal) plus 3% (subject to a floor of 9.5%) and the Company has an obligation to repay at least $3,000,000 of the outstanding balance of the December 2022 Note for each calendar quarter beginning with the second calendar quarter of 2024 (subject to adjustment for conversions by the Lender and to payment of an exit fee as set forth in the January 2024 Note Amendment) and continuing until the December 2022 Note is repaid in full. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended September 30, 2024, an aggregate of principal and accrued interest totaling $11,250,000 of the December 2022 Note was converted into 1,607,093 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company elected to account for the December 2022 Note at fair value (Note 4) and was not required to bifurcate the conversion option as a derivative and as a result the original issue discount of $1,820,000 and debt issuance costs were written off upon election to fair value and accounted for as interest. During the year ended September 30, 2024, the Company recognized $3,156,847 of interest expense related to extension fees. During the year ended September 30, 2023, the Company recognized $2,074,964 of interest expense related to original issue discount of $1,820,000 and other third party debt issuance costs of $254,964.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">November 2021 Note</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2021, the Company received $10,000,000 in net proceeds from the issuance of the November 2021 Note with a face amount of $10,220,000. Debt issuance costs totaling $820,000 were recorded as debt discount and were deducted from the principal in the accompanying consolidated balance sheets. The debt discount was amortized as a component of interest expense over the term of the underlying debt using the effective interest method. The note bore interest at a rate of 9.5% per annum compounding daily and was set to mature on January 1, 2023. The Company could prepay all or a portion of the note at any time by paying 105% of the outstanding balance elected for prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the November 2021 Note was cancelled using proceeds from the December 2022 Note issued to the same lender. The total repayment was $11,947,539, which represented 105% of the outstanding balance and included $1,158,609 of interest expense. The transaction has been accounted for as an extinguishment of the November 2021 Note. As a result, the Company recorded a loss on debt extinguishment of $577,659, which included $8,729 of unamortized debt discount, and prepayment fees of $568,930.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, the Company recognized $454,866 of interest expense related to the unsecured promissory note, of which $190,775 was related to the amortization of debt discount. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251660464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Selexis Commercial License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In April&#160;2013, the Company entered into commercial license agreements with Selexis for each of the ONS-3010, ONS-1045 and ONS-1050 biosimilar product candidates (which agreements were subsequently amended on May&#160;21, 2014). Under the terms of each commercial license agreement, the Company acquired a non-exclusive worldwide license under the Selexis Technology to use the applicable Selexis expression technology along with the resulting Selexis </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">materials/cell lines, each developed under the research license, to manufacture and commercialize licensed and final products, with a limited right to sublicense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company paid an upfront licensing fee to Selexis for each commercial license and also agreed to pay a fixed milestone payment for each licensed product. In addition, the Company is required to pay a low single-digit royalty on a final product-by-final product and country-by-country basis, based on worldwide net sales of such final products by the Company or any of the Company&#8217;s affiliates or sublicensees during the royalty term. The royalty term for each final product in each country is the period commencing from the first commercial sale of the applicable final product in the applicable country and ending on the expiration of the specified patent coverage. At any time during the term, the Company has the right to terminate its royalty payment obligation by providing written notice to Selexis and paying Selexis a royalty termination fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of the Company&#8217;s commercial agreements with Selexis will expire upon the expiration of all applicable Selexis patent rights. Either party may terminate the related agreement in the event of an uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, winding up or similar circumstances. Either party may also terminate the related agreement under designated circumstances if the Selexis Technology infringes third-party intellectual property rights. In addition, the Company has the right to terminate each of the commercial agreements at any time at its convenience; however, with respect to the agreements relating to ONS-3010 and ONS-1045, this right is subject to the licensee&#8217;s consent pursuant to a corresponding letter the Company executed in conjunction with the standby agreement entered into between Selexis and Laboratories Liomont, S.A. de C.V. (&#8220;Liomont&#8221;) in November&#160;2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The standby agreement permits Liomont to assume the license under the applicable commercial agreement for Mexico upon specified triggering events involving the Company&#8217;s bankruptcy, insolvency or similar circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Technology License</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into a technology license agreement with Selexis that will require milestone payments of $332,779 (based on an exchange rate on September&#160;30, 2024 for converting Swiss Francs to U.S. dollars) to the licensor by the Company upon achievement of certain clinical milestones and pay a single digit royalty on net sales by the Company utilizing such technology. The Company also has the contractual right to buy out the royalty payments at a future date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On November 3, 2023, a securities class action lawsuit was filed against the Company and certain of its officers in the United States District Court for the District of New Jersey. The class action complaint alleges violations of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in connection with allegedly false and misleading statements made by the Company related to the Company&#8217;s BLA during the period from August 3, 2021 through August 29, 2023. The complaint alleges, among other things, that the Company violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by failing to disclose that there was an alleged lack of evidence supporting ONS-5010/LYTENAVA as a treatment for wet AMD and that the Company and/or their manufacturing partner had deficient CMC controls for ONS-5010/LYTENAVA, which remained unresolved at the time the Company&#8217;s BLA was re-submitted to the FDA and, as a result, the FDA was unlikely to approve the Company&#8217;s BLA, and that the Company&#8217;s stock price dropped when such information was disclosed. The plaintiffs in the class action complaint seek damages and interest, and an award of reasonable costs, including attorneys&#8217; fees. Defendants&#8217; motion to dismiss is currently pending before the court.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2024, certain of the company&#8217;s officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware. &#160;The derivative complaint alleges that defendants breached their fiduciary duties by causing and/or allowing the Company to violate federal securities laws based on the same alleged misstatements as the securities class action. &#160;The derivative complaint also alleges defendants violated Section 14(a) of the Exchange Act, as well as claims for contribution, unjust enrichment, and waste of corporate assets. &#160;The derivative complaint seeks unspecified damages, corporate governance reforms, restitution, contribution, attorneys&#8217; fees, and other costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pending lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain. The Company could be forced to expend significant resources in the defense of the pending lawsuits and any additional lawsuits, and the Company may not prevail. In addition, the Company may incur substantial legal fees and costs in connection with such lawsuits. The Company currently is not able to estimate the possible cost to it from these matters, as the pending lawsuits are currently at an early stage, and the Company cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that the Company may be required to pay. Such amounts could be material to the Company&#8217;s financial statements if it does not prevail in the defense of the pending lawsuits and any other related lawsuits, or even if it does prevail. The Company has not established any reserve for any potential liability relating to the pending lawsuits and any other related lawsuits. It is possible that the Company could, in the future, incur judgments or enter into settlements of claims for monetary damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Corporate office </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company entered into a three-year term corporate office lease in Iselin, New Jersey that ended on April 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2024, the Company entered into a five-year term corporate office lease for its new corporate headquarters in Iselin, New Jersey that commenced on May 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Equipment leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2024, all equipment leases had expired. The Company had equipment leases with terms between 12 and 36 months and had recorded those leases as finance leases. The equipment leases bore interest between 4.0% and 13.0% per annum. Payments due under the lease contracts included minimum payments that the Company was obligated to make under the non-cancelable initial terms of the leases as the renewal terms were at the Company&#8217;s option. Lease expense was recorded as research and development or general and administrative based on the use of the leased asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The components of lease cost for the years ended September 30, 2024 and 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:47.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 57,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 44,867</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 58,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,266</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:middle;width:37.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 274,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,172</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 297,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,267</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term (years):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average discount rate:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.9%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.5%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">13.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other information related to leases for the years ended September 30, 2024 and 2023 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:87.9%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease obligations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27,675</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,751</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets obtained in exchange for lease obligations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 294,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under noncancelable leases at September&#160;30, 2024 are as follows for the&#160;years ending September&#160;30:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating leases</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 78,091</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79,954</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,817</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,680</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,447</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 372,989</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75,160</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 297,829</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company maintains a defined contribution 401(k)&#160;plan (the &#8220;Plan&#8221;) in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum contribution amounts. The Company matches 100% of the first 3% of employee contributions. The Company assumes all administrative costs of the Plan. For the&#160;years ended September&#160;30, 2024 and 2023, the expense relating to the matching contribution was $177,309 and $136,914, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252698928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On March 7, 2024, following receipt of stockholder approval at the Company&#8217;s 2024 annual meeting of stockholders, the number of authorized shares of common stock under the Company&#8217;s Certificate of Incorporation was increased from </span><span style="font-weight:normal;">21,250,000</span><span style="font-weight:normal;"> shares to </span><span style="font-weight:normal;">60,000,000</span><span style="font-weight:normal;"> shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 18, 2024, in a private placement (the &#8220;Private Placement&#8221;) pursuant to a securities purchase agreement entered in January 2024 with certain institutional and accredited investors, including GMS Ventures and Investments (&#8220;GMS Ventures&#8221;), the Company&#8217;s largest stockholder, the Company issued an aggregate of 8,571,423 shares of common stock and warrants to purchase an aggregate of 12,857,133 shares of common stock at a purchase price per share of $7.00 per share and accompanying warrant to purchase one and <span style="-sec-ix-hidden:Hidden_DkBDMcGwhUOfLjYffyDfaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-half shares of common stock for $55,498,311 in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of 2,305,714 shares of common stock and warrants to purchase an aggregate of 3,458,571 shares of common stock in the Private Placement. The Warrants have an exercise price of $7.70 per share of common stock and will expire on March 18, 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 15, 2024, in a private placement with Syntone pursuant to a securities purchase agreement entered into in January &#160;2024 (the &#8220;Syntone Private Placement&#8221;), the Company issued 714,286 shares of common stock and accompanying warrants to purchase 1,071,429 shares of common stock for $4,835,371 in net proceeds on substantially the same terms as those in the Private Placement. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#212529;">The Company evaluated the equity classification for the common stock warrants and considered the conditions as prescribed within ASC 815-40,&#160;</span><i style="color:#212529;font-style:italic;">Derivatives and Hedging, Contracts in an Entity&#8217;s own Equity</i><span style="color:#212529;">&#160;(&#8220;ASC 815-40&#8221;). The Company determined that the warrants did not meet the &#8220;fixed for fixed&#8221; settlement provision set forth in Step 2 of the indexation guidance and as a result they are not indexed to the Company&#8217;s own stock and must be classified as liabilities. The warrants were measured at fair value at issuance and recorded as a liability and will be remeasured to fair value at each subsequent reporting date, with changes in fair value recorded in current earnings. The net proceeds from the Private Placement were allocated first to the warrants at fair value, with the residual amount recorded as common stock at par value. The Company will continue to classify such warrants as liabilities until they are exercised, expire, or are no longer required to be classified as liabilities</span><span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In December 2022, in a registered direct equity offering to certain institutional and accredited investors, including GMS Ventures, the Company issued </span><span style="font-weight:normal;">1,423,041</span><span style="font-weight:normal;"> shares of common stock at a purchase price per share of </span><span style="font-weight:normal;">$17.568</span><span style="font-weight:normal;"> for </span><span style="font-weight:normal;">$23,208,679</span><span style="font-weight:normal;"> in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of </span><span style="font-weight:normal;">711,520</span><span style="font-weight:normal;"> shares of common stock in the registered direct equity offering. In connection with the registered direct equity offering, the Company issued to M.S. Howells &amp; Co., the placement agent, warrants to purchase up to an aggregate of </span><span style="font-weight:normal;">25,787</span><span style="font-weight:normal;"> shares of common stock at an exercise price of </span><span style="font-weight:normal;">$21.00</span><span style="font-weight:normal;"> per share, which warrants have a </span><span style="font-weight:normal;">three-year</span><span style="font-weight:normal;"> term.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#8217;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. No dividends had been declared through September&#160;30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">H.C. Wainwright &amp; Co. At-the-Market Offering Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 26, 2021, the Company entered into an At-the-Market Offering Agreement with H.C. Wainwright &amp; Co., as sales agent (&#8220;Wainwright&#8221;), (the &#8220;Wainwright ATM Agreement&#8221; or the &#8220;Wainwright ATM Offering&#8221;), under which the Company may issue and sell shares of its common stock from time to time through Wainwright as sales agent. The Company filed a prospectus supplement, dated March 26, 2021, with the Securities and Exchange Commission pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to up to $40,000,000 from time to time through Wainwright. The Company incurred financing costs of $197,654 which were </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">capitalized and were being reclassified to additional paid in capital on a pro rata basis when the Company sold common stock under the Wainwright ATM Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Wainwright ATM Offering, the Company paid Wainwright a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the Wainwright ATM Agreement. The Company terminated the Wainwright ATM Agreement effective May 15, 2023. As a result, the Company wrote off unamortized deferred costs under the Wainwright ATM Agreement. During the year ended September 30, 2023, the Company sold 44,769 shares of common stock under the Wainwright ATM Offering and generated $1,089,105 in net proceeds after paying fees to Wainwright of $38,799. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTIG, LLC At-the-Market Offering Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On May 16, 2023, the Company entered into an At-the-Market Sales Agreement with BTIG, LLC (&#8220;BTIG&#8221;), as sales agent (the &#8220;BTIG ATM Agreement&#8221; or the &#8220;BTIG ATM Offering&#8221;), under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100,000,000 from time to time through BTIG. The Company incurred financing costs of $353,688, which were capitalized and are being reclassified to additional paid in capital on a pro rata basis when the Company sells common stock under the BTIG ATM Offering. As of September 30, 2024, $331,512 of such deferred costs are included in other assets on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the BTIG ATM Agreement, the Company pays BTIG a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the BTIG ATM Agreement. The offering of common stock pursuant to the BTIG ATM Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the BTIG ATM Agreement or (ii) termination of the BTIG ATM Agreement in accordance with its terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended September 30, 2024, no shares of common stock were sold under the BTIG ATM Offering. During the year ended September 30, 2023, the Company sold 178,911 shares of common stock under the BTIG ATM Offering and generated $6,080,088 in net proceeds after paying fees to BTIG and other issuance costs of $188,044.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common stock warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September&#160;30, 2024, the Company had the following warrants outstanding to acquire shares of its common stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">issuable upon</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 22, 2024</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 240.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 24, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25.40</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 13, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 240.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 31, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 240.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 22, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30.38</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 28, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 28, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 2, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 23, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 104,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31.25</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2029</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,857,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.70</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 15, 2029</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,071,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.70</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,207,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The warrants were issued in connection with the convertible senior secured notes originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017 and are classified as liabilities on the accompanying consolidated balance sheets, as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The warrants were issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 and are exercisable only for cash, except in limited circumstances, at any time after the date of issuance. The Company evaluated the warrants under ASC 815-40 guidance and determined that the warrants did not meet Step 2 of the indexation. As a result they are not indexed to the Company&#8217;s own stock and must be classified as liabilities. Refer to the disclosure above under the header &#8220;&#8212;Common stock&#8221; for further details.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;">A holder of warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than a specified percentage of the outstanding common stock (4.99%, 9.99% or 19.99%, as applicable), immediately after giving effect to such exercise, which may be increased or decreased at the holders&#8217; option (not to exceed 19.99%), effective 61 days after written notice to the Company. In addition, the Company may require the holders to cash exercise the warrants under certain circumstances as follows: (i) if the daily volume weighted average price (the &#8220;VWAP&#8221;) of the common stock equals or exceeds $20.00 per share (subject to adjustment in the event of stock splits, combinations or similar events, such as the reverse stock split implemented prior to closing) for 30 consecutive days (the &#8220;Stock Price Condition&#8221;) at any time after the Company publicly announces topline data from its NORSE EIGHT clinical trial evidencing satisfaction of the trial&#8217;s primary endpoints (the &#8220;NORSE EIGHT Announcement&#8221;), upon the consent of a majority of the members of the Company&#8217;s board of directors, the Company may require the holders to exercise up to 20% of the aggregate number of warrants issued to such holder on the issue date; and (ii) the Company may require up to the remainder of the warrants be exercised (A) if the Stock Price Condition is satisfied at any time after the Company publicly announces approval from the FDA of its BLA for ONS-5010/LYTENAVA, upon the consent of a majority of the members of the board of directors or (B) if the Stock Price Condition is satisfied at any time after the NORSE EIGHT Announcement, upon the unanimous consent of the members of the Company&#8217;s Board of Directors present at a duly called meeting.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957344548608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Preferred Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 13, 2024, the Company filed a Certificate of Elimination to its Certificate of Incorporation, as then amended, with the Secretary of State of the State of Delaware to eliminate from the Certificate of Incorporation all matters set forth in the Certificates of Designation filed with the Secretary of State of the State of Delaware on September 8, 2017 (with respect to its Series A Convertible Preferred Stock and the Series B Convertible Preferred Stock) and July 18, 2018, as amended on March 19, 2020 (with respect to its Series A-1 Convertible Preferred Stock) and returning each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series A-1 Convertible Preferred Stock to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series. There were no outstanding shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock or Series A-1 Convertible Preferred Stock as of May 13, 2024. Immediately following the filing of the Certificate of Elimination, the Company filed a Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, which restates and integrates but does not further amend the Company&#8217;s Certificate of Incorporation, as then amended. The number of authorized shares of preferred stock under the Company&#8217;s Certificate of Incorporation is 10,000,000 shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252690992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2011 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2011 Equity Compensation Plan (the &#8220;2011 Plan&#8221;) provided for the Company to sell or issue restricted common stock, restricted stock units (&#8220;RSUs&#8221;), performance-based awards (&#8220;PSUs&#8221;), cash-based awards or to grant stock options for the purchase of common stock to officers, employees, consultants and directors of the Company. The 2011 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board. As of September 30, 2024, there were no equity awards outstanding under the 2011 Plan. In light of the December&#160;2015 adoption of the 2015 Equity Incentive Plan, (the &#8220;2015 Plan&#8221;) no future awards under the 2011 Plan will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2024 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December&#160;2015, the Company adopted the 2015 Plan. The 2015 Plan provided for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">compensation to Company employees, directors and consultants. In August 2024, the Company&#8217;s stockholders approved the amendment and restatement of the 2015 Plan and, in connection with amending and restating the 2015 Plan, the name of the 2015 Plan was updated to the Outlook Therapeutics, Inc. 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;). The 2024 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity compensation to Company employees, directors and consultants. The aggregate number of shares of common stock authorized for issuance pursuant to the Company&#8217;s 2024 Plan is 7,293,901. As of September 30, 2024, 4,680,755 shares remained available for grant under the 2024 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Stock options and RSUs granted under the Company's 2024 Plan generally vest over a period of <span style="-sec-ix-hidden:Hidden_bxPvBnUfBkO5HfmvqqI1rg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four years from the date of grant and, in the case of stock options, have a term of 10 years. The Company recognizes the grant date fair value of each option and share of RSU over its vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the years ended September 30, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:46.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.12%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 800,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 986,598</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,584,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,560,421</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,385,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,547,019</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Stock options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes all of the Company&#8217;s stock option activity for the&#160;years ended September&#160;30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,197,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 817,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,946,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,985</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,006,079</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,985</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value represents the total amount by which the fair market value of the common stock subject to options exceeds the exercise price of the related options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model, wherein expected volatility is based on a weighted average of the Company&#8217;s historical volatility and the volatilities of similar entities within the Company&#8217;s industry which are commensurate with the expected term assumption. The expected term calculation is based on the &#8220;simplified&#8221; method described in Staff Accounting Bulletin (&#8220;SAB&#8221;) No.&#160;107, <i style="font-style:italic;">Share-Based Payment</i>, and SAB No.&#160;110, <i style="font-style:italic;">Share-Based Payment</i>, since the simplified method provides a reasonable estimate in comparison to actual experience. The risk-free interest rate is based on the U.S. Treasury yield at the date of grant for an instrument with a maturity that is commensurate with the expected term of the stock options. The dividend yield is zero since the Company has never paid cash dividends on its common stock and has no present intention to pay cash dividends. Options granted under the 2024 Plan generally vest over <span style="-sec-ix-hidden:Hidden_aurQEKRsiUKUgtUDwMQVZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four years and have a term of 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The weighted average grant date fair value of the options awarded to employees and directors for the&#160;years ended September&#160;30, 2024 and 2023 was $6.04 and $19.40 per option, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131.4</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 111.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September&#160;30, 2024, there was $7,508,106 of unrecognized compensation expense that is expected to be recognized over a weighted-average period of 1.3 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Performance-based stock options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company granted certain officers of the Company option awards where vesting was contingent upon meeting certain company-wide performance goals. The performance stock options were granted &#8220;at-the-money&#8221; and have a term of 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of each option grant under the performance share option plan was estimated on the date of grant using the same option valuation model used for non-statutory options above. Compensation expense for performance-based stock options is only recognized when management determines it is probable that the awards will vest. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The following table summarizes all of the Company&#8217;s performance-based stock option activity for the years ended September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 634,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 666,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The weighted average grant date fair value of the performance stock options awarded for the years ended September 30, 2024 and 2023 was $6.52 and $18.20 per option, respectively. During the year ended September 30, 2024, no expense was recognized because the performance conditions were not considered probable of achievement. As of September 30, 2024, the Company assessed that the performance conditions related to the performance options granted were not probable of achievement. The assessment was based on the relevant facts and circumstances and therefore no compensation costs were recognized. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 125.6</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Performance-based stock units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has issued PSUs, which generally have a ten-year life from the date of grant. Upon exercise, the PSU holder receives common stock or cash at the Company&#8217;s discretion. The following table summarizes the activity related to PSUs during the&#160;years ended September&#160;30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per PSU</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 999.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 999.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252988048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_CollaborationArrangementsAbstract', window );"><strong>Collaboration Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_CollaborationArrangementsTextBlock', window );">Collaboration Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Collaboration Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Syntone Strategic Partnership and PRC Joint Venture</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with a stock purchase agreement entered in May 2020 between the Company and Syntone, the Company and Syntone entered into a joint venture agreement pursuant to which they agreed to form a PRC joint venture that will be 80% owned by Syntone and 20% owned by the Company. Upon formation of the PRC joint venture in April 2021, the Company entered into a royalty-free license with the PRC joint venture for the development, commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company made the initial investment of $900,000 in June 2020. The Company is committed to making up to $2,100,000 in additional capital contributions to the PRC joint venture, based upon the development plan contemplated in the license agreement or on such other terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_CollaborationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_CollaborationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_CollaborationArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a collaboration arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_CollaborationArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252902640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">13.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax benefit for the&#160;years ended September&#160;30, 2024 and 2023 consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.27%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">State tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 2,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 2,800</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">U.S. federal statutory rate</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (21.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (21.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">State taxes, net of federal benefit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (6.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (7.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Deferred true-up</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 0.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 0.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Permanent differences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 2.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (0.7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Foreign tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Research and development credit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (2.4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (1.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Change in valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 25.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 29.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (0.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (0.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The tax effects of the temporary differences that gave rise to deferred taxes were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 102,906,140</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 92,961,718</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Capitalized research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 15,200,918</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 6,531,508</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 6,463,068</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 5,066,375</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 83,720</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Research and development credit carryforward</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 13,748,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 11,953,956</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Foreign tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 290,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,562,639</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Accruals and others</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 144,079</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,656,239</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Gross deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 138,836,713</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 119,732,435</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Less: valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (138,759,510)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (119,725,078)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 77,203</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 7,357</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (77,203)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (7,357)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2024, the Company had approximately $406.7 million and $242.5 million of U.S. federal and New Jersey NOLs that will begin to expire in 2030 and 2039, respectively. As of September 30, 2024, the Company had federal and state research and development tax credit carryforwards of $13.0 million and $0.8 million, respectively, available to reduce future tax liabilities which will begin to expire in 2032 and 2033, respectively. As of September 30, 2024, the Company has federal foreign tax credit (&#8220;FTC&#8221;) carryforwards of $0.3 million available to reduce future tax liabilities which began to expire starting in 2023, of which $0.3 million of the FTC carryforward is included in the balance of unrecognized tax benefits. Realization of the deferred tax asset is contingent on future taxable income and based upon the level of historical losses, management has concluded that the deferred tax asset does not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance continues to be recorded against the Company&#8217;s deferred tax assets as of September 30, 2024 and 2023. The valuation allowance increased by $19.0 million and $17.1 million during the year ended September 30, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely-than-not be realized. The determination as to whether the tax benefit will more-likely-than-not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes interest and penalties accrued on any unrecognized tax benefits within the provision for income taxes in its consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Balance at beginning of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Changes based on tax positions related to the current year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Balance at end of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company does not anticipate material change in the unrecognized tax benefits in the next 12&#160;months. These unrecognized tax benefits, if recognized, would affect the annual effective tax rate. The Company&#8217;s income tax returns for the&#160;years from 2011 through 2023 remain open for examination by the Internal Revenue Service as well as various states and municipalities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Due to the change in ownership provisions of the Code, the availability of the Company&#8217;s NOL carryforwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on beneficial ownership and therefore no determination has been made whether the net operating loss carry forward is subject to any Code Section&#160;382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax assets with an offsetting reduction in the valuation allowance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957253014336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">14.&#160;&#160;&#160;Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Departure of Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 3, 2024, C. Russell Trenary III stepped down as the President and Chief Executive Officer the Company and as a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;), effective immediately (the &#8220;Effective Date&#8221;). The Board has resolved to reduce its size to nine directors immediately upon Mr. Trenary&#8217;s resignation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr. Trenary&#8217;s departure constituted a termination of employment without &#8220;cause&#8221; for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Trenary is a party or otherwise participates, including that certain executive employment agreement, dated as of July 6, 2021, by and between Mr. Trenary and the Company (the &#8220;Employment Agreement&#8221;). Accordingly, subject to Mr. Trenary&#8217;s execution and non-revocation of a separation agreement containing a release of claims against the Company, Mr. Trenary is entitled to continued payment of his base salary for 12 months following the termination, 100% of his target bonus for the calendar year of termination paid in a lump sum, employee benefit coverage for up to 12 months, full vesting of 50% of his then unvested equity awards, and reimbursement of expenses owed to him through the date of his termination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 3, 2024, Lawrence A. Kenyon, the Company&#8217;s Chief Financial Officer, was appointed Interim Chief Executive Officer of the Company, effective as of the Effective Date, to serve while the Board conducts a formal search process to identify and appoint a permanent Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reduction in Workforce </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 10, 2024, the Board approved a reduction of the Company&#8217;s workforce in connection with its plans to reduce operating expenses and preserve capital. On December 13, 2024, the Company reduced its workforce by five people, or approximately 23% of its existing headcount. At a minimum, all employees affected by the workforce reduction are eligible to receive severance payments and paid COBRA premiums for a specified time period post-termination, subject to execution of a general release of claims against the Company. The Company estimates that it will incur approximately $336,000 in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957249916928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (75,366,714)<span></span>
</td>
<td class="num">$ (58,982,668)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252490304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250905696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The accompanying consolidated financial statements have been prepared in conformity with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The accompanying consolidated financial statements include the accounts of the Company and Outlook Therapeutics Pty Ltd, its wholly-owned subsidiary incorporated in Australia (the &#8220;Subsidiary&#8221;). All intercompany accounts and transactions have been eliminated in consolidation.</span> <span style="background:#ffffff;">The Company has determined the functional currency of the Subsidiary to be the U.S. dollar. The Company translates assets and liabilities of its foreign operations at exchange rates in effect at the balance sheet date. The Company records remeasurement gains and losses on monetary assets and liabilities, such as incentive and tax receivables and accounts payables, which are not in the functional currency of the operation. These remeasurement gains and losses are recorded in the consolidated statements of operations as they occur.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_ReverseStockSplitPolicyTextBlock', window );">Reverse stock split</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reverse stock split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective on March 14, 2024, the Company amended its amended and restated certificate of incorporation to implement a <span style="-sec-ix-hidden:Hidden_35bPP_NyTECQ2xx8ssQR0g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-twenty</span></span> reverse stock split of its common stock. As a result of the reverse stock split, the Company made corresponding adjustments to the share amounts under its employee incentive plans, outstanding options, and common stock warrant agreements with third parties. The disclosure of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash and cash equivalents include cash-on-hand and demand deposits with financial institutions and other short-term investments with maturities of less than three months when acquired and convertible to known cash amounts. At September 30, 2024 and 2023, the Company&#8217;s cash equivalents consist of a money market account.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity method investment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity method investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company&#8217;s share of equity in the earnings or loss of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. The Company has not elected the fair value option. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The asset&#8217;s or liability&#8217;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At September 30, 2024 and 2023, the Company&#8217;s financial instruments included cash and cash equivalents, accounts payable, accrued expenses, unsecured convertible promissory note and warrant liabilities. The carrying amount of accounts payable, and accrued expenses approximates fair value due to the short-term maturities of these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair Value Option</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company elected the fair value option to account for the December 2022 Note. Refer to Note 7 for further details on the December 2022 Note.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#8220;Short-Term Leases&#8221;). For Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the consolidated balance sheet. The Company had no Short-Term Leases as of September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the re-measured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received, and any initial direct costs incurred are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company measures equity classified stock-based awards based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of stock option awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model, which is described more fully in Note&#160;11. The fair value of each restricted stock award is measured as the fair value per share of the Company&#8217;s common stock on the date of grant.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upfront milestone payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted net loss per common share, the denominator includes both the weighted average common shares outstanding and the number of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include convertible debt, warrants, performance-based stock options and units, and stock options the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company&#8217;s losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September&#160;30, 2024 and 2023, as they would be antidilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.68%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;white-space:nowrap;width:29.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 123</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 666,500</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,000</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,946,646</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,197,774</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,207,622</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 366,427</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible debt</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,171,100</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(i)</sup></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 854,962</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(ii)</sup></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The calculation for potentially dilutive securities pertaining to convertible debt is as follows: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3,750,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of outstanding principal and accrued interest as of September 30, 2024, is converted at a rate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and the remaining amount is converted based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Reverse stock-split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252671712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.68%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;white-space:nowrap;width:29.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 123</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Performance-based stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 666,500</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,000</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,946,646</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,197,774</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,207,622</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 366,427</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible debt</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,171,100</p></td><td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(i)</sup></p></td><td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 854,962</p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;">(ii)</sup></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The calculation for potentially dilutive securities pertaining to convertible debt is as follows: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3,750,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of outstanding principal and accrued interest as of September 30, 2024, is converted at a rate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and the remaining amount is converted based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share, which is subject to change as described in Note 7.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250308384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,440,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nriUGTcej0qNzzfpnoD1Jg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,099,013</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,539,013</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,551,000</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_7BYTPZDFbEyyt_JlN9COqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrant liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,219</p></td></tr><tr><td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,557,219</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in the fair value of Level 3 liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unsecured Convertible</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Promissory Note</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at October 1, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,138</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at issuance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,820,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest converted to common stock</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,000)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,756,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,919)</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2023</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,551,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,219</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issued in connection with sale of common stock</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 97,730,836</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Promissory note maturity extension fee added to outstanding balance</p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,681,847</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal and accrued interest converted to common stock</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,250,000)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_n00HlfZxbEWQPFKyyKwVxA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value</span></span></p></td><td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,457,153</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38,638,042)</p></td></tr><tr><td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,440,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 59,099,013</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">December 2022 Note</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 71.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credit-adjusted discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 20.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:22.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remaining contractual term of warrants (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 125.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 158.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Annual dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value of common stock (per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252623744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:middle;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,012,962</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 919,970</p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,798,767</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 165,192</p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,373</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,234,192</p></td></tr><tr><td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 384,366</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 426,386</p></td></tr><tr><td style="vertical-align:middle;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,237,468</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,745,740</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957254257536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:middle;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unsecured convertible promissory note (measured at fair value)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,440,000</p></td><td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,551,000</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:middle;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,440,000)</p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (35,551,000)</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:middle;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957249682128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The components of lease cost for the years ended September 30, 2024 and 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:47.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 57,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 44,867</p></td></tr><tr><td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 58,089</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,266</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amounts reported in the consolidated balance sheets for leases where the Company is the lessee were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:middle;width:37.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 274,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,172</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 297,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,267</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term (years):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average discount rate:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9.9%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7.5%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">13.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other information related to leases for the years ended September 30, 2024 and 2023 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:87.9%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease obligations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,399</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27,675</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing cash flows from finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,751</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets obtained in exchange for lease obligations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 294,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating lease future minimum payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating leases</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 78,091</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79,954</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,817</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,680</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,447</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 372,989</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75,160</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 297,829</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of finance lease future minimum payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating leases</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 78,091</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79,954</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81,817</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,680</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,447</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 372,989</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75,160</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 297,829</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957254128432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">issuable upon</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.22%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 22, 2024</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 240.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 24, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25.40</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 13, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 240.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 31, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(i)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 240.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 22, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30.38</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 28, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 28, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 2, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 93,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25.00</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 23, 2026</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 104,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31.25</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2029</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,857,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.70</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 15, 2029</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ii)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,071,429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.70</p></td></tr><tr><td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,207,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The warrants were issued in connection with the convertible senior secured notes originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017 and are classified as liabilities on the accompanying consolidated balance sheets, as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The warrants were issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 and are exercisable only for cash, except in limited circumstances, at any time after the date of issuance. The Company evaluated the warrants under ASC 815-40 guidance and determined that the warrants did not meet Step 2 of the indexation. As a result they are not indexed to the Company&#8217;s own stock and must be classified as liabilities. Refer to the disclosure above under the header &#8220;&#8212;Common stock&#8221; for further details.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;">A holder of warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than a specified percentage of the outstanding common stock (4.99%, 9.99% or 19.99%, as applicable), immediately after giving effect to such exercise, which may be increased or decreased at the holders&#8217; option (not to exceed 19.99%), effective 61 days after written notice to the Company. In addition, the Company may require the holders to cash exercise the warrants under certain circumstances as follows: (i) if the daily volume weighted average price (the &#8220;VWAP&#8221;) of the common stock equals or exceeds $20.00 per share (subject to adjustment in the event of stock splits, combinations or similar events, such as the reverse stock split implemented prior to closing) for 30 consecutive days (the &#8220;Stock Price Condition&#8221;) at any time after the Company publicly announces topline data from its NORSE EIGHT clinical trial evidencing satisfaction of the trial&#8217;s primary endpoints (the &#8220;NORSE EIGHT Announcement&#8221;), upon the consent of a majority of the members of the Company&#8217;s board of directors, the Company may require the holders to exercise up to 20% of the aggregate number of warrants issued to such holder on the issue date; and (ii) the Company may require up to the remainder of the warrants be exercised (A) if the Stock Price Condition is satisfied at any time after the Company publicly announces approval from the FDA of its BLA for ONS-5010/LYTENAVA, upon the consent of a majority of the members of the board of directors or (B) if the Stock Price Condition is satisfied at any time after the NORSE EIGHT Announcement, upon the unanimous consent of the members of the Company&#8217;s Board of Directors present at a duly called meeting.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957249723472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:46.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.12%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 800,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 986,598</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,584,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,560,421</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,385,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,547,019</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of performance-based stock units activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per PSU</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 999.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 999.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,197,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 817,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (59,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,645)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,946,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,985</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,006,079</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,985</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131.4</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 111.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at October 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 634,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 666,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and exercisable at September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 125.6</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252676944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.27%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">State tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 2,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 2,800</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of tax expense reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">U.S. federal statutory rate</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (21.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (21.0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">State taxes, net of federal benefit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (6.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (7.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Deferred true-up</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 0.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 0.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Permanent differences</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 2.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (0.7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Foreign tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Research and development credit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (2.4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (1.3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Change in valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 25.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 29.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (0.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (0.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;">&#160;&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 102,906,140</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 92,961,718</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Capitalized research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 15,200,918</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 6,531,508</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 6,463,068</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 5,066,375</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 83,720</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Research and development credit carryforward</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 13,748,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 11,953,956</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Foreign tax credits</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 290,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,562,639</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Accruals and others</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 144,079</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,656,239</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Gross deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 138,836,713</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 119,732,435</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Less: valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (138,759,510)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (119,725,078)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 77,203</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 7,357</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (77,203)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (7,357)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of reconciliation of unrecognized tax benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Balance at beginning of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Changes based on tax positions related to the current year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Balance at end of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 1,856,629</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252014224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 15, 2024</div></th>
<th class="th"><div>Mar. 18, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 543,284,900<span></span>
</td>
<td class="nump">$ 467,918,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt, interest, fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,352,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">8,571,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">$ 4,835,371<span></span>
</td>
<td class="nump">$ 55,498,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,333,681<span></span>
</td>
<td class="nump">$ 30,024,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of fees to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingBtigMember', window );">BTIG ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,080,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of fees to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingBtigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingBtigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957253258192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=otlk_PerformanceBasedShareOptionsMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,500<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,946,646<span></span>
</td>
<td class="nump">1,197,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,207,622<span></span>
</td>
<td class="nump">366,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,171,100<span></span>
</td>
<td class="nump">854,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt | Scenario one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt | Scenario two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=otlk_PerformanceBasedShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=otlk_PerformanceBasedShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=otlk_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=otlk_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=otlk_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=otlk_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957253083808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Warrants and Rights Outstanding<span></span>
</td>
<td class="text">Warrants and Rights Outstanding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Unsecured convertible promissory note</a></td>
<td class="nump">$ 29,440,000<span></span>
</td>
<td class="nump">$ 35,551,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">59,099,013<span></span>
</td>
<td class="nump">6,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 88,539,013<span></span>
</td>
<td class="nump">$ 35,557,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957249708128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair value changes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">Unsecured convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities fair value changes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning</a></td>
<td class="nump">$ 35,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,820,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees', window );">Promissory note maturity extension fee added to outstanding balance</a></td>
<td class="nump">2,681,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Converted to common stock</a></td>
<td class="num">(11,250,000)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 2,457,153<span></span>
</td>
<td class="nump">$ 3,756,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change In Fair Value Of Redemption Feature<span></span>
</td>
<td class="text">Change In Fair Value Of Redemption Feature<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, ending</a></td>
<td class="nump">$ 29,440,000<span></span>
</td>
<td class="nump">$ 35,551,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities fair value changes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning</a></td>
<td class="nump">6,219<span></span>
</td>
<td class="nump">57,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value at issuance</a></td>
<td class="nump">97,730,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">$ (38,638,042)<span></span>
</td>
<td class="num">$ (50,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, ending</a></td>
<td class="nump">$ 59,099,013<span></span>
</td>
<td class="nump">$ 6,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized extension fees of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250312992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assumptions (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>Y</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt inputs | Y</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant inputs | Y</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt inputs</a></td>
<td class="nump">0.91<span></span>
</td>
<td class="nump">0.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant inputs</a></td>
<td class="nump">1.25<span></span>
</td>
<td class="nump">1.583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt inputs</a></td>
<td class="nump">0.042<span></span>
</td>
<td class="nump">0.055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant inputs</a></td>
<td class="nump">0.0358<span></span>
</td>
<td class="nump">0.053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt inputs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant inputs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Credit-adjusted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt inputs</a></td>
<td class="nump">0.204<span></span>
</td>
<td class="nump">0.228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt inputs | $ / shares</a></td>
<td class="nump">5.34<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant inputs | $ / shares</a></td>
<td class="nump">5.34<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957253262128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment - Syntone (Details) - Syntone - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 22, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Expected future investment</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=otlk_PRCJointVentureMember', window );">Syntone PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=otlk_SyntoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=otlk_SyntoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=otlk_PRCJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=otlk_PRCJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957254009312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 1,012,962<span></span>
</td>
<td class="nump">$ 919,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,798,767<span></span>
</td>
<td class="nump">165,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development</a></td>
<td class="nump">41,373<span></span>
</td>
<td class="nump">1,234,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">384,366<span></span>
</td>
<td class="nump">426,386<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 3,237,468<span></span>
</td>
<td class="nump">$ 2,745,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250449344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayableCurrent', window );">Less: current portion</a></td>
<td class="num">$ (29,440,000)<span></span>
</td>
<td class="num">$ (35,551,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">Unsecured convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 29,440,000<span></span>
</td>
<td class="nump">$ 35,551,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957246035632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 22, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 22, 2022 </div>
<div>USD ($) </div>
<div>D </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Carrying value of notes exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,250,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,156,964<span></span>
</td>
<td class="nump">2,531,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of lender fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(577,659)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">December 2022 Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,681,847<span></span>
</td>
<td class="nump">1,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,820,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,052,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Stock trigger price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading day threshold | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash', window );">Additional fee cash payments (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent', window );">Increase in debt balance for a Major Trigger Event (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent', window );">Increase in debt balance for a Minor Trigger Event (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent', window );">Threshold trading days for Trigger Event cure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable', window );">Default interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender', window );">Conversion notice threshold (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing', window );">Participation right in future financing (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance', window );">Extension fee based on balance (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">us-gaap:PrimeRateMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Quarterly payment</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Carrying value of notes exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,156,847<span></span>
</td>
<td class="nump">2,074,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of lender fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">December 2022 Note | Major Trigger Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading day threshold | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Stock price trigger threshold (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">December 2022 Note | Scenario one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion rate (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">December 2022 Note | Scenario two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion rate (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember', window );">December 2022 Note | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Total interest rate (as a percent)</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=otlk_UnsecuredPromissoryNote2021Member', window );">November 2021 Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,947,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(577,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, convertible, conversion price, required to satisfy conversion notice from the lender in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the interest rate annually  until paid for the immediately due and payable amounts in case of debt default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional fee on payments made by the Company in cash, including prepayments or repayment at maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in debt balance by Lender for a Minor Trigger Event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in debt balance by Lender for a Minor Trigger Event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of participation right to Lender in future debt or equity financing in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold trading days of written notice from Lender for cure of Trigger Event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the extension fee as percentage of the outstanding balance upon amendment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=otlk_DebtInstrumentFollowingToMajorTriggerEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=otlk_DebtInstrumentFollowingToMajorTriggerEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=otlk_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=otlk_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=otlk_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=otlk_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=otlk_UnsecuredPromissoryNote2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=otlk_UnsecuredPromissoryNote2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957246078912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=otlk_SelexisMember', window );">Selexis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Remaining future financial obligations</a></td>
<td class="nump">$ 332,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=otlk_SelexisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=otlk_SelexisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251960096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease cost (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">57,973<span></span>
</td>
<td class="nump">44,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 58,089<span></span>
</td>
<td class="nump">$ 46,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance lease interest (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance lease interest (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of lease cost recognized by lessee for finance lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251669952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease balance sheet (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases, Right-of-use asset</a></td>
<td class="nump">$ 274,645<span></span>
</td>
<td class="nump">$ 26,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 297,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, Weighted-average remaining lease term</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, Weighted-average discount rate (as a percent)</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, Weighted-average discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250278912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease cash flow (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 1,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">14,514<span></span>
</td>
<td class="nump">27,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">4,267<span></span>
</td>
<td class="nump">$ 11,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 294,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957249913536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Minimum lease payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 78,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">79,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">81,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">83,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">49,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">372,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">75,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">$ 297,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251625920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Employee Benefit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee annual contributions (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum employer annual contributions (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Maximum employer match (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense related to matching contribution</a></td>
<td class="nump">$ 177,309<span></span>
</td>
<td class="nump">$ 136,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957245104592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 15, 2024</div></th>
<th class="th"><div>Mar. 18, 2024</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">21,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">8,571,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">1,071,429<span></span>
</td>
<td class="nump">12,857,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,207,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock issuable by each warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">$ 4,835,371<span></span>
</td>
<td class="nump">$ 55,498,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,333,681<span></span>
</td>
<td class="nump">$ 30,024,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_WarrantRelatedExpenses', window );">Warrants related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,490,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=otlk_GmsVenturesInvestmentsMember', window );">GMS Ventures &amp; Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,305,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,458,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_DirectRegisteredOfferingMember', window );">Direct registered offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,423,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,208,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_DirectRegisteredOfferingMember', window );">Direct registered offering | GMS Ventures &amp; Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingMember', window );">Wainwright ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,089,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_AggregateOfferingPriceAuthorized', window );">Aggregate maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Amount reclassified on additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of fees to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission', window );">Common stock sale commission (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingBtigMember', window );">BTIG ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,080,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_AggregateOfferingPriceAuthorized', window );">Aggregate maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Amount reclassified on additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 353,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of fees to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission', window );">Common stock sale commission (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_AggregateOfferingPriceAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The authorized amount of aggregate offering price under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_AggregateOfferingPriceAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of aggregate gross proceeds from sale of common stock to be paid as commission under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_WarrantRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses related to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_WarrantRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=otlk_GmsVenturesInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=otlk_GmsVenturesInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_DirectRegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=otlk_DirectRegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingBtigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=otlk_AtMarketOfferingBtigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957254349712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Apr. 15, 2024</div></th>
<th class="th"><div>Mar. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">14,207,622<span></span>
</td>
<td class="nump">1,071,429<span></span>
</td>
<td class="nump">12,857,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant', window );">Beneficial ownership exercise restriction, one (as a percent)</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant', window );">Beneficial ownership exercise restriction, two (as a percent)</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant', window );">Beneficial ownership exercise restriction, three (as a percent)</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions', window );">Warrant holders exercise under certain conditions (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyTwoDecemberTwoThousandTwentyFourMember', window );">December 22, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">13,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember', window );">February 24, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">8,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_ThirteenAprilTwoThousandTwentyFiveMember', window );">April 13, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">7,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_ThirtyFirstMayTwoThousandTwentyFiveMember', window );">May 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">3,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentySecondJuneTwoThousandTwentyFiveMember', window );">June 22, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">9,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 30.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember', window );">December 28, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">25,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyEighthJanuaryTwoThousandTwentySixMember', window );">January 28, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">12,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_WarrantExpirationDateFebruary22026Member', window );">February 2, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">93,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyThirdNovemberTwoThousandTwentySixMember', window );">November 23, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">104,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_EighteenMarchTwoThousandTwentyNineMember', window );">March 18, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">12,857,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_FifteenthAprilTwoThousandTwentyNineMember', window );">April 15, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock and Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable on exercise of warrants (in shares)</a></td>
<td class="nump">1,071,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the first beneficial ownership restriction for the warrant holder to not exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the third beneficial ownership restriction for the warrant holder to not exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the second beneficial ownership restriction for the warrant holder to not exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate number of Warrants the entity may require holders to exercise upon satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyTwoDecemberTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyTwoDecemberTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_ThirteenAprilTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_ThirteenAprilTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_ThirtyFirstMayTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_ThirtyFirstMayTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentySecondJuneTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentySecondJuneTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyEighthJanuaryTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyEighthJanuaryTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_WarrantExpirationDateFebruary22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_WarrantExpirationDateFebruary22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyThirdNovemberTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_TwentyThirdNovemberTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_EighteenMarchTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_EighteenMarchTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=otlk_FifteenthAprilTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=otlk_FifteenthAprilTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251900768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>May 13, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Preferred Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957249642864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based stock authorized (in shares)</a></td>
<td class="nump">7,293,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,680,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250997360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,385,124<span></span>
</td>
<td class="nump">$ 5,547,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">800,956<span></span>
</td>
<td class="nump">986,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,584,168<span></span>
</td>
<td class="nump">$ 4,560,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957245636688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,385,124<span></span>
</td>
<td class="nump">$ 5,547,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, Beginning (in shares)</a></td>
<td class="nump">1,197,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">817,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(59,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(9,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, Ending (in shares)</a></td>
<td class="nump">1,946,646<span></span>
</td>
<td class="nump">1,197,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">1,006,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, Beginning (in dollars per share)</a></td>
<td class="nump">$ 28.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">26.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, Ending (in dollars per share)</a></td>
<td class="nump">19.51<span></span>
</td>
<td class="nump">$ 28.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 26.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance-Remaining contractual term</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable -Remaining contractual term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 53,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and exercisable</a></td>
<td class="nump">$ 53,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of options (in dollars per share)</a></td>
<td class="nump">$ 6.04<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, Beginning (in shares)</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, Ending (in shares)</a></td>
<td class="nump">666,500<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, Beginning (in dollars per share)</a></td>
<td class="nump">$ 28.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">6.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, Ending (in dollars per share)</a></td>
<td class="nump">7.94<span></span>
</td>
<td class="nump">$ 28.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 28.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance-Remaining contractual term</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable -Remaining contractual term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of options (in dollars per share)</a></td>
<td class="nump">$ 6.52<span></span>
</td>
<td class="nump">$ 18.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957250273776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Assumptions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">131.40%<span></span>
</td>
<td class="nump">111.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 7,508,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation exercise period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">125.60%<span></span>
</td>
<td class="nump">91.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=otlk_PerformanceBasedShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251105072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Non-options (Details) - Performance-based stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of PSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, Beginning | shares</a></td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod', window );">Expired | shares</a></td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Base Price Per Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, Beginning | $ / shares</a></td>
<td class="nump">$ 999.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue', window );">Expired | $ / shares</a></td>
<td class="nump">$ 999.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957254729984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Arrangements (Details) - Syntone - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 22, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Expected future investment</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=otlk_PRCJointVentureMember', window );">Syntone PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=otlk_SyntoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=otlk_SyntoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=otlk_PRCJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=otlk_PRCJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251045376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State tax</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957253069280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income taxes (as a percent)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent', window );">Deferred true-up</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Foreign tax credits</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">25.30%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income true expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the deferred true-up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957251223504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 102,906,140<span></span>
</td>
<td class="nump">$ 92,961,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">15,200,918<span></span>
</td>
<td class="nump">6,531,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,463,068<span></span>
</td>
<td class="nump">5,066,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_otlk_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">83,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">13,748,600<span></span>
</td>
<td class="nump">11,953,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Foreign tax credits</a></td>
<td class="nump">290,188<span></span>
</td>
<td class="nump">1,562,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and others</a></td>
<td class="nump">144,079<span></span>
</td>
<td class="nump">1,656,239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">138,836,713<span></span>
</td>
<td class="nump">119,732,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(138,759,510)<span></span>
</td>
<td class="num">(119,725,078)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets net of valuation allowance</a></td>
<td class="nump">77,203<span></span>
</td>
<td class="nump">7,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">$ (77,203)<span></span>
</td>
<td class="num">$ (7,357)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_otlk_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">otlk_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>otlk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957253089648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,856,629<span></span>
</td>
<td class="nump">$ 1,856,629<span></span>
</td>
<td class="nump">$ 1,856,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">406,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">242,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252996336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 1,856,629<span></span>
</td>
<td class="nump">$ 1,856,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Changes based on tax positions related to the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 1,856,629<span></span>
</td>
<td class="nump">$ 1,856,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45957252512432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Events<br></strong></div></th>
<th class="th">
<div>Dec. 10, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Positions eliminated</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Positions eliminated (as a percent)</a></td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated restructuring charges</a></td>
<td class="nump">$ 336,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M!#"*9 /X_HESN5U(=I"]!'+^'U!+ P04    " #+@YM90-0-5_H%  "3&
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MRUHL["K*P<)Y$;\HO3;>CK83B9.!B%KBQ">8LTG"2NE:8JHU4IW">2I,ZMG
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M@=&0U>FCZFA1E!OX@]#F.% V,W-B VD#S/V%$'K;L6>"Y@P8_P=02P,$%
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M+:I#D-9-=2;SA<E-"KOYC*_!);X, 9:LCCFJ&RUVY4G!4F@M\O)RRUG"I3&
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MB#AS@/B" VH<4,\!!1<<<.. ^PZ70O(:!^_:D$CC4 _=.8Z])FY-)5TN*GX
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MS](1-DONPMF_6%6Y2]Z%LE85[G$-'(F8%N#\4B&--"^T07OK?_474$L#!!0
M   ( ,N#FUFE"'3#I@0  ),*   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;*U6;6_;-A#^*P>W*S; M64E:;/&-I!XZ=HNZ8*\#?M(2R>+#46J)&7'
M^_6[(VU%3I,  _;%IDC><\_=/4=RO#+VSI6('NXKI=VD5WI??Q@.759B)=S
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M-LHL),'^;DU3P\P,X,SG@Q\\7%S.MN! Q,_%&M(TR">)SF:FJH5>@] Y=(R
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MQM,C)@Q+>C6BY0VT7ACCMQ_LH'V'3O\%4$L#!!0    ( ,N#FUG@K1 >CP(
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M$Y&3H8$'KMANE2%[%=R%69ABNLF(83@?M%DBS2F/<*9I8;5F_1Q?RXQK0\4
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MUYD%%Y=8D!8K<1K++*XPKU.?M5P5CXT@![4X8S509KT.!^G'K1QJ2)P\T#Y
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MP;[WZ2C"UK6FWW<,/#4G54I4@,)24LP16\I@;!#)/#>H1#!$LM.OG7-J5NG
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MI)UK(F,/(A59I1Q838UL0-TZVX3CGX*)AW*/1E6X"?KK(P#*GL] >](#OP/
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M[T1E90I&@*BX,TSZ40EDW:BL \(_K@/"_/\%!.K)-QLM-F!25E:4-JC7EH/
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MFO3?GD5@N[>JF["IP_NP-"RO31@6\KR3]0:ROS*&#Q,?X/@/P_0[4$L#!!0
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MW3F0"3,0%7.:&Y$[#KH\>VBCH0TXKWZ[1R?7RLORL-:+U3C*GC^BQ<B'^SA
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M=S098R3:5M!.%*]M-6VXTK5IAX7NGB!,@/Z^Y5P=)V:#OA^GOP%02P,$%
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MV8)5@YD3L+JZ?A>08EV:W/FI(9ZUR:9/<1.X3B>^C^R<A/#6XD_<__[J^NW
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MV+X-R5S(">)1 USB W0=19,KMVD9#521[R/$>!BP"Y3Y.(J-7$Y/ZS$I//\
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M/MVBF*O;QDJAYZAS<6Q7Q^0_!9)DO>,0,-;'V;A]1O ]=\*@HQW2=FD64\B
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M^A:"HY]J!/KO@;\G"$I<?=Y74\N8IBG024HUQC6[Z I[)>M+<"_[3\W*69Y
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M&FZ(VI.-!@/2TA K69%M2).[V_*#Y'O.J+3DEC'52<OE@6R4X(R#(6^_T)T
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M7K=H3^-YV_ 6A-/#J[5%;UIK@^1O1E(Y\U;4)*7'(T@*0?D-'4U>O\"A\V[
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M;SF<>$A&B;C*4-_VT"OD0>Q>J?,%W^DPB=2)>=\D9K_G_9D*[,0\E8W5#2M
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M3Z""SL#4L:-@A'ASW]]4)*OU'?L5DY*5NKB@)*-<#8#^&6.RK:@)NG]=)O\
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M965T,S4N>&ULU5C?;^(X$/Y7K-SIU$JTB1,"H0=(A;9[E;:ZJJB[#Z=[,,D
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M@K(.N+Z66(.M87ML=Z5F?P%02P,$%     @ RX.;60=L$_C^"P  LH   !D
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MS)5W]"(Z.67UM4VX:/_E9,&U+8Y;(Z=O<I&P  D+D3"*A+%11P%CVQE/7+T
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M%&_K^9I#]5:*QGAL]WB@$4,HC4)I#$5392)=4]OLFMY)A:196;DCLO_[5K5
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M;\IL4^_/_IB59;:N7ZYX-.=Y=8#X_2++RM<W58#G+/]>G_;T?U!+ P04
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M,D!K!FCG#M"; ?JY XQF@''N +,98'8'F*\,L)H!5G> ]<J 63-@=NXNV<T
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MTGU9?!/R/2V*=%=_N>7ABF?5!N7/UVE:O'Q33?"49C_JW5[\#U!+ P04
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M*=V*/"OA@2&^+0K"_LXAI_N981F'A<=LDPJU8$;3BFQ@">*I>F!R9K8H259
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MQH2N: )Y@C84TL1F9PF$@V8 '-C8NM>9$7];,[EM9?*2<XC9/*?_*39Q,UO
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M3:Y!_YQJ1M7-MC:,+%V#6TE#[=)-,WJ?4-D-]'\MI=D;EJ!]\>+?4$L#!!0
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MYAHC%1H\!$:VOD<6TMB.\\O:SD10KL#N+Z4T^\ =T$_9X@]02P,$%     @
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M,U=8DYEFB64S"!V WPO.U:FC)Q@+\?1?4$L#!!0    ( ,N#FUG%$)G)QP,
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MI$#!W0T!&2VS_[4C^%9HY\I?JRL9+Z]MISZ1Z\D.DO](=(2#\CYQGH_+;GA
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MP.5J[ V\S<(C*RNT"WZ:-+2$&>!3\Z#,S.]1<E:#T$P*HJ 8>]>#JVELXUW
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MORR_=LYNP@7G!+\3/?X%4$L#!!0    ( ,N#FUG63,"2X $  .,C   3
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M[;EZ!U!+ 0(4 Q0    ( ,N#FUD'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ RX.;6>SD30OM
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ RX.;69E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #+@YM92)2/':,'   0,@  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ RX.;64#4#5?Z!0  DQ@  !@              ("!Y0\  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,N#FUG;D#]]T0(   \*
M   8              " @146  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #+@YM9?T;#/O@$  !X$@  &               @($<&0
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ RX.;6:C89>R+
M!0  3"   !@              ("!2AX  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( ,N#FUG2V[N:N <  $@A   8              "
M@0LD  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #+@YM9
MAU*\3;\&   &$   &               @('Y*P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ RX.;64F."L1R!P  .Q(  !@
M     ("![C(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M ,N#FUDDD=T38A(  $$W   8              " @98Z  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #+@YM91<X(LR('   !&   &0
M            @($N30  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( ,N#FUFE"'3#I@0  ),*   9              " @8=4  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ RX.;6>"M$!Z/ @
M3@8  !D              ("!9%D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #+@YM9ZE;M] 4+   M(   &0              @($J
M7   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,N#FUF?
M5FD)Z0\  (\N   9              " @69G  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ RX.;6='V=:B:#@  (RT  !D
M     ("!AG<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,N#FUFSWD@4%08  &,.   9              "
M@92B  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ RX.;
M6;IQK9!% @  FP4  !D              ("!X*@  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #+@YM9 'J/JT,"  "*!@  &0
M        @(%<JP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( ,N#FUD@,1^'%!,  -@\   9              " @=:M  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ RX.;68QQ#620 P  Z@@
M !D              ("!(<$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #+@YM98V.[J"@%   F%0  &0              @('HQ
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,N#FUF'MCU4
MF0(  $,&   9              " @4?*  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ RX.;6<\/OB9U @  RP4  !D
M ("!%\T  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #+
M@YM9[112M;P$  !)$@  &0              @('#SP  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,N#FUEZ:J1:H0<  /H2   9
M          " @;;4  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#
M%     @ RX.;69=ONX=)!0  @1D  !D              ("!CMP  'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #+@YM93DE'#NL$  !,
M#@  &0              @($.X@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+ 0(4 Q0    ( ,N#FUEX"2%66 0  +89   9              " @3#G
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ RX.;67+,
M"K@2!0  Q2(  !D              ("!O^L  'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"% ,4    " #+@YM9C'=/@.D"  !!"0  &0
M    @($(\0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M ,N#FUDHWW2*C@0  ($2   9              " @2CT  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ RX.;66R:C<$1!   FA4  !D
M             ("![?@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #+@YM9L'&[&= "  #N"0  &0              @($U_0  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,N#FUF1*'$ZF@(
M '@'   9              " @3P  0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ RX.;64VH.;Q= @  7@<  !D              ("!
M#0,! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #+@YM9
M!VP3^/X+  "R@   &0              @(&A!0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,N#FUE2 _RW"P(  *X$   9
M      " @=81 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ RX.;60YJ).\O!   1QH  !D              ("!&!0! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #+@YM9A!S*'P #  !["@
M&0              @(%^& $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( ,N#FUE$E5ADT0(  !H(   9              " @;4; 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ RX.;69ZQU[P2
M P  / P  !D              ("!O1X! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #+@YM9S] &(;T"  !S"   &0
M@($&(@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,N#
MFUDE_=MF: L  $&.   9              " @?HD 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ RX.;6<V&ZFHX!P   4,  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( ,N#FUG>15[]JP,  .D.   9
M  " @:5( 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MRX.;60#($I:@ @  _08  !D              ("!ATP! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " #+@YM9)0^;W]4"   $"@  &0
M            @(%>3P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( ,N#FUD+$?LT+ (  '$%   9              " @6I2 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ RX.;69P9''=O P
ME L  !D              ("!S50! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " #+@YM9Q1"9R<<#   $#0  &0              @(%S
M6 $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,N#FUDA
MCV:XR ,  (@5   9              " @7%< 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ RX.;6091@NZ= @  &0<  !D
M     ("!<& ! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,N#FUGU29+, 0(  %XD   :
M          "  2=O 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( ,N#FUG63,"2X $  .,C   3              "  6!Q 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !% $4 VA(  '%S 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>143</ContextCount>
  <ElementCount>313</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureLiquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosurePreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Collaboration Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangements</Role>
      <ShortName>Collaboration Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99920302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureDebt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureLiquidity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940402 - Disclosure - Fair Value Measurements - Fair value changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails</Role>
      <ShortName>Fair Value Measurements - Fair value changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940403 - Disclosure - Fair Value Measurements - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Equity Method Investment - Syntone (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails</Role>
      <ShortName>Equity Method Investment - Syntone (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Debt - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails</Role>
      <ShortName>Debt - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - Debt - Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails</Role>
      <ShortName>Debt - Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Commitments and Contingencies - Lease cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Lease cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Commitments and Contingencies - Lease balance sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Lease balance sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - Commitments and Contingencies - Lease cash flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails</Role>
      <ShortName>Commitments and Contingencies - Lease cash flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940805 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940806 - Disclosure - Commitments and Contingencies - Employee Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails</Role>
      <ShortName>Commitments and Contingencies - Employee Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Stockholders' Equity - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosurePreferredStockDetails</Role>
      <ShortName>Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosurePreferredStock</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Stock-Based Compensation - Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99941103 - Disclosure - Stock-Based Compensation - Option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99941104 - Disclosure - Stock-Based Compensation - Option Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99941105 - Disclosure - Stock-Based Compensation - Non-options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Non-options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Collaboration Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails</Role>
      <ShortName>Collaboration Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangements</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941302 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941303 - Disclosure - Income Taxes - Deferred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails</Role>
      <ShortName>Income Taxes - Deferred (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99941304 - Disclosure - Income Taxes - Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99941305 - Disclosure - Income Taxes - Unrecognized benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="otlk-20240930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.outlooktherapeutics.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>otlk-20240930.xsd</File>
    <File>otlk-20240930_cal.xml</File>
    <File>otlk-20240930_def.xml</File>
    <File>otlk-20240930_lab.xml</File>
    <File>otlk-20240930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="otlk-20240930x10k.htm">otlk-20240930x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>otlk-20240930x10k006.jpg</File>
    <File>otlk-20240930x10k007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="573">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "otlk-20240930x10k.htm": {
   "nsprefix": "otlk",
   "nsuri": "http://www.outlooktherapeutics.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "otlk-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "otlk-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "otlk-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "otlk-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "otlk-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "otlk-20240930x10k.htm"
     ]
    }
   },
   "keyStandard": 287,
   "keyCustom": 26,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 24,
   "hidden": {
    "total": 33,
    "http://fasb.org/us-gaap/2024": 27,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://www.outlooktherapeutics.com/20240930": 1
   },
   "contextCount": 143,
   "entityCount": 1,
   "segmentCount": 53,
   "elementCount": 578,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 573,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals",
     "longName": "995200105 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
     "longName": "995200300 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "longName": "995210101 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureLiquidity",
     "longName": "995210201 - Disclosure - Liquidity",
     "shortName": "Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995210301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurements",
     "longName": "995210401 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestment",
     "longName": "995210501 - Disclosure - Equity Method Investment",
     "shortName": "Equity Method Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpenses",
     "longName": "995210601 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureDebt",
     "longName": "995210701 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995210801 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquity",
     "longName": "995210901 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosurePreferredStock",
     "longName": "995211001 - Disclosure - Preferred Stock",
     "shortName": "Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensation",
     "longName": "995211101 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangements",
     "longName": "995211201 - Disclosure - Collaboration Arrangements",
     "shortName": "Collaboration Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "otlk:CollaborationArrangementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "otlk:CollaborationArrangementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxes",
     "longName": "995211301 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEvents",
     "longName": "995211401 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "99930303 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99930403 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930603 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureDebtTables",
     "longName": "99930703 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "99930803 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityTables",
     "longName": "99930903 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99931103 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931303 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
     "longName": "99940201 - Disclosure - Liquidity (Details)",
     "shortName": "Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_9aSINsKIFUCWW7CgnYrY4Q",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_9aSINsKIFUCWW7CgnYrY4Q",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails",
     "longName": "99940401 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails",
     "longName": "99940402 - Disclosure - Fair Value Measurements - Fair value changes (Details)",
     "shortName": "Fair Value Measurements - Fair value changes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_DIM-yieXZEii39hWIo3zyQ",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails",
     "longName": "99940403 - Disclosure - Fair Value Measurements - Assumptions (Details)",
     "shortName": "Fair Value Measurements - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails",
     "longName": "99940501 - Disclosure - Equity Method Investment - Syntone (Details)",
     "shortName": "Equity Method Investment - Syntone (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940601 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails",
     "longName": "99940701 - Disclosure - Debt - Summary (Details)",
     "shortName": "Debt - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:NotesAndLoansPayableCurrent",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Afa1M1WaS0SR2fyB14IoaQ",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
     "longName": "99940702 - Disclosure - Debt - Information (Details)",
     "shortName": "Debt - Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ninrKLLlD0a6ZBI-j6EB3Q",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99940801 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_otlk_SelexisMember_H9U6x4CDa0-Y6bDTtuTUEQ",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_otlk_SelexisMember_H9U6x4CDa0-Y6bDTtuTUEQ",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails",
     "longName": "99940802 - Disclosure - Commitments and Contingencies - Lease cost (Details)",
     "shortName": "Commitments and Contingencies - Lease cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails",
     "longName": "99940803 - Disclosure - Commitments and Contingencies - Lease balance sheet (Details)",
     "shortName": "Commitments and Contingencies - Lease balance sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails",
     "longName": "99940804 - Disclosure - Commitments and Contingencies - Lease cash flow (Details)",
     "shortName": "Commitments and Contingencies - Lease cash flow (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails",
     "longName": "99940805 - Disclosure - Commitments and Contingencies - Minimum lease payments (Details)",
     "shortName": "Commitments and Contingencies - Minimum lease payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails",
     "longName": "99940806 - Disclosure - Commitments and Contingencies - Employee Benefit (Details)",
     "shortName": "Commitments and Contingencies - Employee Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
     "longName": "99940901 - Disclosure - Stockholders' Equity - Common Stock (Details)",
     "shortName": "Stockholders' Equity - Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_7_2024_lLMZhv4wdEyjXYMfzCMdRA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails",
     "longName": "99940902 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "otlk:BeneficialOwnershipOneForHolderToNotExerciseWarrant",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosurePreferredStockDetails",
     "longName": "99941001 - Disclosure - Preferred Stock (Details)",
     "shortName": "Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_5_13_2024_CMktv_oZdUe5aaSem6VwXg",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_13_2024_CMktv_oZdUe5aaSem6VwXg",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
     "longName": "99941101 - Disclosure - Stock-Based Compensation - Information (Details)",
     "shortName": "Stock-Based Compensation - Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_8_31_2024_Z5sSwB3u8UeB-gHP0Yk07Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_31_2024_Z5sSwB3u8UeB-gHP0Yk07Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
     "longName": "99941102 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rYTA6Gi8qkKqslIZHJezrg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails",
     "longName": "99941103 - Disclosure - Stock-Based Compensation - Option activity (Details)",
     "shortName": "Stock-Based Compensation - Option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails",
     "longName": "99941104 - Disclosure - Stock-Based Compensation - Option Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Option Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
     "longName": "99941105 - Disclosure - Stock-Based Compensation - Non-options (Details)",
     "shortName": "Stock-Based Compensation - Non-options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
     "longName": "99941201 - Disclosure - Collaboration Arrangements (Details)",
     "shortName": "Collaboration Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDetails",
     "longName": "99941301 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "longName": "99941302 - Disclosure - Income Taxes - Reconciliation (Details)",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails",
     "longName": "99941303 - Disclosure - Income Taxes - Deferred (Details)",
     "shortName": "Income Taxes - Deferred (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails",
     "longName": "99941304 - Disclosure - Income Taxes - Carryforwards (Details)",
     "shortName": "Income Taxes - Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails",
     "longName": "99941305 - Disclosure - Income Taxes - Unrecognized benefits (Details)",
     "shortName": "Income Taxes - Unrecognized benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A",
      "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941401 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "otlk-20240930x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r48",
      "r818"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r655"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r84"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "otlk_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses Current",
        "verboseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r791",
      "r792",
      "r793",
      "r795",
      "r832",
      "r861"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Amount reclassified on additional paid in capital",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r75"
     ]
    },
    "otlk_AggregateOfferingPriceAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "AggregateOfferingPriceAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The authorized amount of aggregate offering price under the agreement.",
        "label": "Aggregate Offering Price, Authorized",
        "terseLabel": "Aggregate maximum offering price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r732"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r692",
      "r702",
      "r735"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r727",
      "r736",
      "r740",
      "r748"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r347"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r631",
      "r632",
      "r782",
      "r843"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r132",
      "r164",
      "r167",
      "r173",
      "r174",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r394",
      "r396",
      "r433",
      "r506",
      "r568",
      "r624",
      "r625",
      "r655",
      "r668",
      "r813",
      "r814",
      "r849"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r113",
      "r132",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r394",
      "r396",
      "r433",
      "r655",
      "r813",
      "r814",
      "r849"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_AtMarketOfferingBtigMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "AtMarketOfferingBtigMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to at the market offering with BTIG, LLC.",
        "label": "At Market Offering BTIG [Member]",
        "terseLabel": "BTIG ATM"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to at the market offering.",
        "label": "At Market Offering [Member]",
        "terseLabel": "Wainwright ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r685"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r685"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r685"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "otlk_BeneficialOwnershipOneForHolderToNotExerciseWarrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "BeneficialOwnershipOneForHolderToNotExerciseWarrant",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first beneficial ownership restriction for the warrant holder to not exercise.",
        "label": "Beneficial Ownership One For The Holder To Not Exercise Warrant",
        "terseLabel": "Beneficial ownership exercise restriction, one (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_BeneficialOwnershipThreeForHolderToNotExerciseWarrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "BeneficialOwnershipThreeForHolderToNotExerciseWarrant",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the third beneficial ownership restriction for the warrant holder to not exercise.",
        "label": "Beneficial Ownership Three For The Holder To Not Exercise Warrant",
        "terseLabel": "Beneficial ownership exercise restriction, three (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_BeneficialOwnershipTwoForHolderToNotExerciseWarrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "BeneficialOwnershipTwoForHolderToNotExerciseWarrant",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second beneficial ownership restriction for the warrant holder to not exercise.",
        "label": "Beneficial Ownership Two For The Holder To Not Exercise Warrant",
        "terseLabel": "Beneficial ownership exercise restriction, two (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r107",
      "r617"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r63",
      "r129"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r63"
     ]
    },
    "otlk_ChangeInFairValueOfRedemptionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ChangeInFairValueOfRedemptionFeature",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of redemption feature.",
        "label": "Change In Fair Value Of Redemption Feature",
        "terseLabel": "Change in fair value of promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Common Stock and Stockholders' Equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r166",
      "r278",
      "r279",
      "r280",
      "r282",
      "r285",
      "r290",
      "r292",
      "r531",
      "r532",
      "r533",
      "r534",
      "r633",
      "r759",
      "r784"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "positiveLabel": "Exercise price per share",
        "terseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Common stock issuable by each warrants (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Common stock issuable on exercise of warrants (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "otlk_CollaborationArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "CollaborationArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_CollaborationArrangementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "CollaborationArrangementsTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a collaboration arrangements.",
        "label": "Collaboration Arrangements [Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative arrangements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r86",
      "r507",
      "r555"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r232",
      "r233",
      "r613",
      "r807",
      "r812"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r791",
      "r792",
      "r795",
      "r832",
      "r859",
      "r861"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r556"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r556",
      "r574",
      "r861",
      "r862"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.01 per share; 60,000,000 shares authorized; 23,905,635 and 13,012,833 shares issued and outstanding at September 30, 2024 and September 30, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r509",
      "r655"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Remaining future financial obligations",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Unsecured convertible promissory note",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible debt",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r253",
      "r280",
      "r463",
      "r483",
      "r505",
      "r618",
      "r620"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State tax",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r787",
      "r827"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares converted",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r20"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Amount",
        "netLabel": "Convertible promissory note converted into common stock",
        "terseLabel": "Carrying value of notes exchanged",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r20"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r130",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r238",
      "r239",
      "r249",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r272",
      "r273",
      "r275",
      "r441"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43",
      "r44",
      "r83",
      "r85",
      "r136",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r785",
      "r808",
      "r809",
      "r810",
      "r842",
      "r844"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total debt",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r85",
      "r276"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt conversion rate (in dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r252"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "terseLabel": "Stock trigger price (in dollars per share)",
        "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective."
       }
      }
     },
     "auth_ref": []
    },
    "otlk_DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, convertible, conversion price, required to satisfy conversion notice from the lender in cash.",
        "label": "Debt Instrument, Convertible, Threshold Conversion Price, Required to Satisfy Conversion Notice from the Lender",
        "terseLabel": "Conversion notice threshold (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Stock price trigger threshold (as a percent)",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Trading day threshold",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "otlk_DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the interest rate annually  until paid for the immediately due and payable amounts in case of debt default.",
        "label": "Debt Instrument, Debt Default, Accelerated Interest Rate On Immediate Due and Payable",
        "terseLabel": "Default interest rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Original principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r441",
      "r442",
      "r629",
      "r630",
      "r653"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt, interest, fees",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r432",
      "r629",
      "r630",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "otlk_DebtInstrumentFollowingToMajorTriggerEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentFollowingToMajorTriggerEventMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to following to major trigger event of debt instrument.",
        "label": "Debt Instrument, Following to Major Trigger Event [Member]",
        "terseLabel": "Major Trigger Event"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r251"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r785",
      "r842",
      "r844"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Debt inputs",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r136",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r785",
      "r808",
      "r809",
      "r810",
      "r842",
      "r844"
     ]
    },
    "otlk_DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional fee on payments made by the Company in cash, including prepayments or repayment at maturity.",
        "label": "Debt Instrument, Percentage of Additional Fee on Payments in Cash",
        "terseLabel": "Additional fee cash payments (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in debt balance by Lender for a Minor Trigger Event.",
        "label": "Debt Instrument, Percentage of Increase in Debt Balance by Lender for a Major Trigger Event",
        "terseLabel": "Increase in debt balance for a Major Trigger Event (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in debt balance by Lender for a Minor Trigger Event.",
        "label": "Debt Instrument, Percentage of Increase in Debt Balance by Lender for a Minor Trigger Event",
        "terseLabel": "Increase in debt balance for a Minor Trigger Event (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of participation right to Lender in future debt or equity financing in the debt instrument.",
        "label": "Debt Instrument, Percentage of Participation Right to Lender in Future Debt or Equity Financing",
        "terseLabel": "Participation right in future financing (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Quarterly payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r40"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage",
        "verboseLabel": "Redemption price (as a percent)",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r31",
      "r34",
      "r39",
      "r73",
      "r74",
      "r136",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r653",
      "r785",
      "r842",
      "r844"
     ]
    },
    "otlk_DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold trading days of written notice from Lender for cure of Trigger Event.",
        "label": "Debt Instrument, Threshold Trading days of Written Notice from Lender for Cure of Trigger Event",
        "terseLabel": "Threshold trading days for Trigger Event cure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Deferred offering costs amortization",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "otlk_DebtModificationExtensionFeeAsPercentageOfOutstandingBalance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DebtModificationExtensionFeeAsPercentageOfOutstandingBalance",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the extension fee as percentage of the outstanding balance upon amendment of debt.",
        "label": "Debt Modification, Extension Fee As Percentage Of The Outstanding Balance",
        "terseLabel": "Extension fee based on balance (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Total interest rate (as a percent)",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r775"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized research and development costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "otlk_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to deferred tax assets lease liability.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign",
        "verboseLabel": "Foreign tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development credit carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "verboseLabel": "Accruals and others",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesDeferredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "verboseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense related to matching contribution",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Maximum employer annual contributions (as a percent)",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Maximum employer match (as a percent)",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesEmployeeBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum employee annual contributions (as a percent)",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "verboseLabel": "Warrant liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r411",
      "r412",
      "r424",
      "r432",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r569",
      "r571",
      "r572",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r620",
      "r836",
      "r837",
      "r838",
      "r860"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "otlk_DirectRegisteredOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "DirectRegisteredOfferingMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to registered direct offering.",
        "label": "Direct registered offering [Member]",
        "terseLabel": "Direct registered offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r308",
      "r339",
      "r340",
      "r342",
      "r638"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r75"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r685"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r685",
      "r728"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Per share information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income (loss) per share of common stock, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r155",
      "r158",
      "r159",
      "r160",
      "r163",
      "r389",
      "r392",
      "r408",
      "r409",
      "r502",
      "r517",
      "r621"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share of common stock, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r155",
      "r158",
      "r159",
      "r160",
      "r163",
      "r389",
      "r392",
      "r408",
      "r409",
      "r502",
      "r517",
      "r621"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r162"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r642"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of income taxes (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "U.S. federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r356",
      "r379",
      "r642"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r642",
      "r788",
      "r819"
     ]
    },
    "otlk_EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income true expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the deferred true-up.",
        "label": "Effective Income Tax Rate Reconciliation, Deferred True-up, Percent",
        "negatedLabel": "Deferred true-up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedLabel": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r788",
      "r819"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r788",
      "r819",
      "r820"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r642",
      "r788",
      "r819"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "terseLabel": "Foreign tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r819",
      "r821"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "verboseLabel": "Research and development credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r788",
      "r819",
      "r821"
     ]
    },
    "otlk_EighteenMarchTwoThousandTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "EighteenMarchTwoThousandTwentyNineMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to March 18, 2029.",
        "label": "March 18, 2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation exercise period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r103",
      "r119",
      "r120",
      "r121",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r165",
      "r213",
      "r214",
      "r223",
      "r294",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r443",
      "r444",
      "r462",
      "r515",
      "r523",
      "r524",
      "r525",
      "r537",
      "r594"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r210",
      "r385",
      "r761",
      "r762",
      "r763",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership (as a percent)",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investment",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r172",
      "r174",
      "r206",
      "r774",
      "r805"
     ]
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investment",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r209",
      "r212",
      "r763"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity method investment",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r38",
      "r208"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r732"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r729"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "verboseLabel": "Change in fair value of warrant liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r424",
      "r643"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r424",
      "r643"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair value inputs",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r646"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r646"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value inputs",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r646"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r423",
      "r424",
      "r426",
      "r470",
      "r471",
      "r472",
      "r629",
      "r630",
      "r634",
      "r635",
      "r636",
      "r643",
      "r646"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r415",
      "r643",
      "r837",
      "r840"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r501",
      "r643",
      "r647"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r412",
      "r413",
      "r414",
      "r415",
      "r424",
      "r472",
      "r629",
      "r630",
      "r634",
      "r635",
      "r636",
      "r643",
      "r646"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Liabilities fair value changes",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in the fair value of Level 3 liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r420",
      "r425"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r415",
      "r643",
      "r837",
      "r840"
     ]
    },
    "otlk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capitalized extension fees of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Capitalized Extension Fees",
        "terseLabel": "Promissory note maturity extension fee added to outstanding balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r425"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Fair value at issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r425"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "verboseLabel": "Converted to common stock",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r425"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r425"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r423",
      "r424",
      "r426",
      "r470",
      "r471",
      "r472",
      "r629",
      "r630",
      "r634",
      "r635",
      "r636",
      "r643",
      "r646"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r840"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r425"
     ]
    },
    "otlk_FifteenthAprilTwoThousandTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "FifteenthAprilTwoThousandTwentyNineMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of April 15, 2029.",
        "label": "Fifteenth April Two Thousand Twenty Nine [Member]",
        "terseLabel": "April 15, 2029"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of lease cost recognized by lessee for finance lease contract.",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r454",
      "r654"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r456"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing lease liabilities",
        "verboseLabel": "Total lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r460"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of finance lease future minimum payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "terseLabel": "Remaining future minimum lease payments for finance lease",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments of finance lease obligations",
        "terseLabel": "Financing cash flows from finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r456"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases, Weighted-average discount rate (as a percent)",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r654"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases, Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r654"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r274",
      "r290",
      "r405",
      "r431",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r516",
      "r627",
      "r643",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r801",
      "r802",
      "r803",
      "r804",
      "r833",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "terseLabel": "Foreign",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r736"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r736"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r736"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r736"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r736"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r28"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r578"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "otlk_GmsVenturesInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "GmsVenturesInvestmentsMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to GMS Ventures &amp; Investments an affiliate of BioLexis Pte. Ltd.",
        "label": "GMS Ventures Investments [Member]",
        "terseLabel": "GMS Ventures &amp; Investments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r685"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r89",
      "r92",
      "r503",
      "r513",
      "r623",
      "r624",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss on equity method investment",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r59",
      "r88",
      "r164",
      "r170",
      "r174",
      "r206",
      "r512"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r230",
      "r231",
      "r417",
      "r420",
      "r425",
      "r520",
      "r522",
      "r579",
      "r616",
      "r645",
      "r858"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r417",
      "r420",
      "r425",
      "r520",
      "r522",
      "r579",
      "r616",
      "r645",
      "r858"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r356",
      "r357",
      "r366",
      "r374",
      "r642",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r356",
      "r357",
      "r366",
      "r374",
      "r642",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r351",
      "r356",
      "r363",
      "r364",
      "r365",
      "r368",
      "r373",
      "r380",
      "r382",
      "r383",
      "r384",
      "r536",
      "r642"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r100",
      "r149",
      "r150",
      "r164",
      "r171",
      "r174",
      "r355",
      "r356",
      "r381",
      "r518",
      "r642"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r353",
      "r354",
      "r368",
      "r369",
      "r372",
      "r376",
      "r530"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "verboseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r642",
      "r819"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r781"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r727",
      "r736",
      "r740",
      "r748"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r752"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r752"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r752"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "terseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r778"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "negatedLabel": "Interest paid on debt",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126",
      "r127"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r168",
      "r174",
      "r624",
      "r777"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r654"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Discount Rate",
        "terseLabel": "Finance lease interest (as a percent)",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease term",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r461"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r461"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of operating lease future minimum payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43",
      "r44",
      "r45",
      "r47",
      "r48",
      "r49",
      "r50",
      "r132",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r395",
      "r396",
      "r397",
      "r433",
      "r554",
      "r622",
      "r668",
      "r813",
      "r849",
      "r850"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r87",
      "r511",
      "r655",
      "r786",
      "r806",
      "r841"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r106",
      "r132",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r395",
      "r396",
      "r397",
      "r433",
      "r655",
      "r813",
      "r849",
      "r850"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r834"
     ]
    },
    "otlk_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "LiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Expected future investment",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r303",
      "r348",
      "r415",
      "r499",
      "r519",
      "r521",
      "r528",
      "r546",
      "r547",
      "r599",
      "r600",
      "r601",
      "r602",
      "r610",
      "r614",
      "r615",
      "r626",
      "r633",
      "r637",
      "r646",
      "r647",
      "r651",
      "r652",
      "r657",
      "r815",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Credit-adjusted discount rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "verboseLabel": "Term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "verboseLabel": "Stock price (in dollars per share)",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r646"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r646"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r303",
      "r348",
      "r415",
      "r499",
      "r519",
      "r521",
      "r528",
      "r546",
      "r547",
      "r599",
      "r600",
      "r601",
      "r602",
      "r610",
      "r614",
      "r615",
      "r626",
      "r633",
      "r637",
      "r646",
      "r647",
      "r651",
      "r657",
      "r815",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r65",
      "r90",
      "r104",
      "r116",
      "r117",
      "r121",
      "r132",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r156",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r389",
      "r392",
      "r409",
      "r433",
      "r514",
      "r576",
      "r592",
      "r593",
      "r666",
      "r813"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income (loss)",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r142",
      "r143",
      "r144",
      "r145",
      "r152",
      "r153",
      "r157",
      "r160",
      "r392"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r727",
      "r736"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and Loans Payable, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Unsecured convertible promissory note",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r623",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease obligations",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r456"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating leases, Right-of-use asset",
        "verboseLabel": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases, Weighted-average discount rate (as a percent)",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases, Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r654"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "NOL carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Carryforwards",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "otlk_OrganizationAndDescriptionOfBusinessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "OrganizationAndDescriptionOfBusinessAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_OtherAssetsNoncurrentDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrentDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Commitments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r691",
      "r701",
      "r734"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r694",
      "r704",
      "r737"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r694",
      "r704",
      "r737"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriter",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "otlk_PRCJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "PRCJointVentureMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Syntone PRC.",
        "label": "PRC Joint Venture [Member]",
        "terseLabel": "Syntone PRC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "verboseLabel": "Non-cash interest expense",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Prepayment fee",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of financing costs",
        "terseLabel": "Payment of lender fees",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payment of fees to sales agent",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Investment in joint venture",
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "otlk_PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of aggregate number of Warrants the entity may require holders to exercise upon satisfaction of certain conditions.",
        "label": "Percentage Of Aggregate Number Of Warrants The Holders May Require To Exercise Upon Satisfaction Of Certain Conditions",
        "terseLabel": "Warrant holders exercise under certain conditions (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of aggregate gross proceeds from sale of common stock to be paid as commission under the agreement.",
        "label": "Percentage Of Gross Proceeds From Sale Of Common Stock To Be Paid As Commission",
        "terseLabel": "Common stock sale commission (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_PerformanceBasedShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "PerformanceBasedShareOptionsMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to performance based share options.",
        "label": "Performance Based Stock Options [Member]",
        "terseLabel": "Performance-based stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based stock units",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value per share (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r278"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosurePreferredStockDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r556"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r278"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosurePreferredStockDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r556",
      "r574",
      "r861",
      "r862"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosurePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "verboseLabel": "Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.01 per share: 10,000,000 shares authorized, no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r508",
      "r655"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from loan",
        "verboseLabel": "Proceeds from debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r295",
      "r303",
      "r334",
      "r335",
      "r336",
      "r348",
      "r415",
      "r473",
      "r482",
      "r499",
      "r519",
      "r521",
      "r528",
      "r546",
      "r547",
      "r599",
      "r600",
      "r601",
      "r602",
      "r610",
      "r614",
      "r615",
      "r626",
      "r633",
      "r637",
      "r646",
      "r647",
      "r651",
      "r652",
      "r657",
      "r660",
      "r811",
      "r815",
      "r837",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCostDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r295",
      "r303",
      "r334",
      "r335",
      "r336",
      "r348",
      "r415",
      "r473",
      "r482",
      "r499",
      "r519",
      "r521",
      "r528",
      "r546",
      "r547",
      "r599",
      "r600",
      "r601",
      "r602",
      "r610",
      "r614",
      "r615",
      "r626",
      "r633",
      "r637",
      "r646",
      "r647",
      "r651",
      "r652",
      "r657",
      "r660",
      "r811",
      "r815",
      "r837",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r729"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfUnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayments of unsecured debt",
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r253",
      "r280",
      "r463",
      "r483",
      "r505",
      "r619",
      "r620"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r616",
      "r624",
      "r857"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r687",
      "r697",
      "r730"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r688",
      "r698",
      "r731"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r695",
      "r705",
      "r738"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "terseLabel": "Estimated restructuring charges",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Positions eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Positions eliminated (as a percent)",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r75",
      "r510",
      "r526",
      "r527",
      "r535",
      "r557",
      "r655"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r213",
      "r214",
      "r223",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r399",
      "r401",
      "r402",
      "r404",
      "r407",
      "r443",
      "r444",
      "r523",
      "r525",
      "r537",
      "r861"
     ]
    },
    "otlk_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Reverse stock-split",
        "label": "Reverse Stock Split [Policy Text Block]",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesLeaseCashFlowDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations",
        "verboseLabel": "Right-of-use asset and lease liability recognized for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r654"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "otlk_ScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ScenarioOneMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the first scenario.",
        "label": "Scenario One [Member]",
        "terseLabel": "Scenario one"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_ScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ScenarioTwoMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the second scenario.",
        "label": "Scenario Two [Member]",
        "terseLabel": "Scenario two"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r304",
      "r760",
      "r794"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income tax expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r31",
      "r34",
      "r39",
      "r73",
      "r74",
      "r629",
      "r631",
      "r790",
      "r842"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of tax expense reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r642",
      "r819"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r210",
      "r385",
      "r761",
      "r762",
      "r763",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Investments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r207",
      "r208",
      "r210",
      "r211",
      "r433"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r132",
      "r207",
      "r208",
      "r210",
      "r211",
      "r433"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835"
     ]
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of performance-based stock units activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of option assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r71",
      "r73",
      "r74",
      "r75",
      "r110",
      "r111",
      "r112",
      "r166",
      "r278",
      "r279",
      "r280",
      "r282",
      "r285",
      "r290",
      "r292",
      "r531",
      "r532",
      "r533",
      "r534",
      "r633",
      "r759",
      "r784"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Schedule of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of unrecognized tax benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r641"
     ]
    },
    "otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtSummaryDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the unsecured promissory note issued in December 2022, originally maturing January 1, 2024.",
        "label": "Securities Purchase Agreement Unsecured Promissory Note [Member]",
        "terseLabel": "December 2022 Note",
        "verboseLabel": "Unsecured convertible promissory note"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "otlk_SelexisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "SelexisMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to Selexis SA.",
        "label": "Selexis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expirations in Period",
        "terseLabel": "Expired"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the expiration.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expirations, Weighted Average Grant Date Fair Value",
        "terseLabel": "Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance, Ending",
        "periodStartLabel": "Balance, Beginning",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Number of PSUs",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance, Ending",
        "periodStartLabel": "Balance, Beginning",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Base Price Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Share-based stock authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Share-based stock available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Grant date fair value of options (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance, Ending (in shares)",
        "periodStartLabel": "Balance, Beginning (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance, Ending (in dollars per share)",
        "periodStartLabel": "Balance, Beginning (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and exercisable",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "verboseLabel": "Vested and exercisable (in shares)",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Vested and exercisable (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r312",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r343",
      "r344",
      "r345",
      "r346"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Balance-Remaining contractual term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockBasedCompensationOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested and exercisable -Remaining contractual term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Shares issued price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r55",
      "r56",
      "r103",
      "r119",
      "r120",
      "r121",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r165",
      "r213",
      "r214",
      "r223",
      "r294",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r443",
      "r444",
      "r462",
      "r515",
      "r523",
      "r524",
      "r525",
      "r537",
      "r594"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r165",
      "r444",
      "r500",
      "r529",
      "r538",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r661"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r304",
      "r760",
      "r764",
      "r794"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r165",
      "r175",
      "r444",
      "r500",
      "r529",
      "r538",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r661"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r690",
      "r700",
      "r733"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock in connection with conversion of convertible promissory note (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r31",
      "r52",
      "r55",
      "r75",
      "r266"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "positiveTerseLabel": "Sale of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Common stock issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r75",
      "r531",
      "r594",
      "r611"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock in connection with conversion of convertible promissory note",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r55",
      "r56",
      "r75"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Sale of common stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r75",
      "r537",
      "r594",
      "r611",
      "r667"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r67",
      "r558",
      "r574",
      "r595",
      "r596",
      "r655",
      "r668",
      "r786",
      "r806",
      "r841",
      "r861"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "verboseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r131",
      "r277",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r294",
      "r406",
      "r597",
      "r598",
      "r612"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r466"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidityDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Liquidity",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_SyntoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "SyntoneMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureEquityMethodInvestmentSyntoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Syntone joint venture.",
        "label": "Syntone [Member]",
        "terseLabel": "Syntone"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "otlk_ThirteenAprilTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ThirteenAprilTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of April 13, 2025.",
        "label": "April 13, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_ThirtyFirstMayTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "ThirtyFirstMayTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of\nMay 31, 2025.",
        "label": "May 31, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r274",
      "r290",
      "r405",
      "r431",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r516",
      "r643",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r801",
      "r802",
      "r803",
      "r804",
      "r833",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "TwentyEighthDecemberTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of December 28, 2025.",
        "label": "Twenty Eighth December Two thousand Twenty Five [Member]",
        "terseLabel": "December 28, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_TwentyEighthJanuaryTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "TwentyEighthJanuaryTwoThousandTwentySixMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of January 28, 2026.",
        "label": "Twenty Eighth January Two Thousand Twenty Six [Member]",
        "terseLabel": "January 28, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "TwentyFourFebruaryTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of February 24, 2025.",
        "label": "Twenty Four February Two Thousand Twenty Five [Member]",
        "terseLabel": "February 24, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_TwentySecondJuneTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "TwentySecondJuneTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of June 22, 2025.",
        "label": "Twenty Second June Two Thousand Twenty Five [Member]",
        "terseLabel": "June 22, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_TwentyThirdNovemberTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "TwentyThirdNovemberTwoThousandTwentySixMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of November 23, 2026.",
        "label": "Twenty Third November Two Thousand Twenty-Six [Member]",
        "terseLabel": "November 23, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_TwentyTwoDecemberTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "TwentyTwoDecemberTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of December 22, 2024.",
        "label": "Twenty Two December Two Thousand Twenty Four [Member]",
        "terseLabel": "December 22, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r367",
      "r641"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureIncomeTaxesUnrecognizedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "verboseLabel": "Changes based on tax positions related to the current year",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "otlk_UnsecuredPromissoryNote2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "UnsecuredPromissoryNote2021Member",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the unsecured promissory note issued in November 2021.",
        "label": "Unsecured Promissory Note 2021 [Member]",
        "terseLabel": "November 2021 Note"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_UnsecuredPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "UnsecuredPromissoryNotesMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureDebtInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt obligation related to the aggregate unsecured promissory notes.",
        "label": "Unsecured promissory notes-aggregate",
        "terseLabel": "Unsecured promissory notes-aggregate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r96",
      "r97",
      "r98",
      "r99"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "otlk_WarrantExpirationDateFebruary22026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "WarrantExpirationDateFebruary22026Member",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock warrants with expiration date of February 2, 2026.",
        "label": "Warrant Expiration Date, February 2 2026 [Member]",
        "terseLabel": "February 2, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "otlk_WarrantLiabilityIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "WarrantLiabilityIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of warrant liability incurred but not yet paid.",
        "label": "Warrant Liability Incurred but Not Yet Paid",
        "terseLabel": "Recognition of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsFairValueChangesDetails",
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665"
     ]
    },
    "otlk_WarrantRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.outlooktherapeutics.com/20240930",
     "localname": "WarrantRelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses related to warrants.",
        "label": "Warrant Related Expenses",
        "terseLabel": "Warrant related expenses (Note 9)",
        "verboseLabel": "Warrants related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liability",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureFairValueMeasurementsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Warrant inputs",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants exercise term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r160"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.outlooktherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r160"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001558370-24-016491-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-016491-xbrl.zip
M4$L#!!0    ( ,N#FUE-%O)NYA   /VW   1    ;W1L:RTR,#(T,#DS,"YX
M<V3M74MSVS@2OD_5_@>N+CM[D/5R,F-7G"GY->LI.W+9RF3V- 61D(0-!2@
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MM_NV ZDQH>"R+5=+++)\UTDISHJ3)]?42<9O.F'BFM0OK,.@\\<MH9]C2HI
M*6F> KM',_;4T4FI&OB0L82Q2IZ "20DS)4MQ=,-. >37.77(4Y-9<$O[CR?
M7*6D=9:I\O- 5Z-W<G+2T:GKVA(WGRDDI'A2/%/&7*B(DPYG/NY$9&LY64 E
M+Q(S3$P5 \958!YQ2HI<R"4OJ#^D9 R)E.!(J)"(NFL<H;7EJ1!H>YT_[FX?
M=4-<@T.#13_/2/M=@$=B*LC$QVU%!JU2@E\2[;[R2V%V3_(ML5/U@^2.2E;\
M^NWNH#WH)?2E])ZO+YV2UA>TL0+Z=5(:#\E+((?4F!!)R<DDD#CE50*:\2LO
M@ICUVMY&P\-+CET;"]Q0;DQ7FLU6;DHB^18%"2G5>*6J\3:JT5Z*Y+JPMZ$+
M(S$ID_[GBLX\Y:W;>%+LL55BV@NMO#::MD4P*6B@Z_2T)W*] D?D>MN$Q<RC
MQ###^Q\<1_=OB%(F=0-1G^*/RR6A4Q9^@6_*@9TJW,;0*!SUQ\>'&RNU:; O
MB7!])@*.'\'&/,2](?4N B'98OA"Q"5;($(C$Q8MAX"TU;+$%8VKZN$IH40+
M!0ZXVW7:SH8A_(AY.L#4";DZBJT3\G5BQN\ZV^RV"@I@)#*B[_7?T H$=/):
MEZKOBS)')"497>2[@5\]WZ9:A=FBCS%TAP(4]"?UB.8"_"KSB:=:_SGRE0-Y
MG&,<HVA!5PK=&^6D-'QK3O!WDID3<7-"=@U@%0!;?Q2CZ6@9=Y,ER!5D,$+8
M+X=PP]9A4V?#N %S1S OD)A?^^S9%LL-O1'*XRI0*KZ.9MQ :>H9KQ'AOR,_
MP'<8J=]:B9=8(N)GNL12VO*^\!@0[&UWAXJ?HQDZ28[.CQ'/?S;PF> ;NBX/
ML'?ULH2I!RX"KH#*!-G;+&01)R=FU6!EC]4%6RR(U":N!I6,2D)G,/TG6-R"
M^4.ZD 4 5LEJ0O7G;G\;U01[!ZFA:;( 2-=E."X4TN!]$+SOH'*+8*'U>H]6
M24=Z 1+W*^!O9%5B#\H8CJL:0U2@XVNC6$9%;@S#49@Y_<8^7L<^#F,:%E[B
MS:$-H[$(DT7<4/B(Q^@%BP?L,E"L3[0D!=@;Z0TH]P;9OB#DZ6BF\#/-MP%S
M)S O\11SCCTSC-N49@ '!@!CC@UT^Z\NW2,.R7,,^9!OO=:TE<MBY>F-_<J3
M\V.:?8/NKJL7CY*YG^?,]S 75U\"(E?0=(A+I.5J1G%^(^*#*JL;R7+^X80E
MJ<:MRVK@WVW%8XPF/K9;\(A(RSWSH'N<]<R%ZQTARP8[BWT<L'T=AP&#4;4"
MH<7(!Z^4UH!>KY=%3_.+@D"2'!OXK.&[)>"M/.T9<P="F733+*6?7:%:\V@&
M//; @%43Z,+N$[+#9/(Q6"P07T'71F:40/^"J!RZ.IH#YGWWT#^IF5\!EH=@
M:8)_D(5?%ZNZR63!>KH:%:V[T$WASJ9T)RZ^L9P]>]/UQXLYHK-"$ZF4U[R_
MD)G*%O6W4<J33G'#8AK,]\1\*$2P6.H-U"IPYV0S(VT]LFH["?X-Q/80A].*
M.RSGS+NA3UCH=;_'%96,X@)\K?*8P'V3=>G1%"=D[&PXJS%9R+Q!UA[92SR1
M45=8@&,.A0FUG[*H*2X*H:C7;1"JA- -G3*^*%O[+: R(Y7I)B.D$LP:M ZR
MBU-]Q\9^=R;3WLIW9QI JZTQI-;QE&H9U=\+(+7*8P+U) MJ[EI?B#6T4IW:
M0+L/M)\0YZAX<]6<P0QJQM\6@!IS;@"U!Q0F^>'N5EGCS"<R[:QULZUQS:AI
M>8=9N#6/<JSSF>#L%3C7O 7=9BQT4)2C6,%*"&_E,:.;[V7ST8V8-\CNB^Q(
M+ZP,74F>BA?UJV0UXVR_+=-VPC(<%!72X'T@O(TK?15SFU'/!"F:46\6_@X(
M_(<8O6J(9[.9H<Z$'99 #?S;K,&X^I*%[Z,)"X\[#=6L8U9Z[L-(;T(U9YLV
MQ=-),FV0W"G&\ *FCRL8M3XC[A4!:2(WX3C(.N*M:,,4VP;)"GXWF C\)0"Y
MKYY*FF(1F0FYG--7&U9.R*N!RPA7='],_/^0>E=4PM R,5^,$+.A+ 5-Q05V
M3_01\OC6FL2?Z@!YR# Y5VUP,S6S$9\A2OZ*PU$NL7 YT2.(T?0\$(1BD6ES
M5GD,6/:Z.0L02<9ZS3[!6H6IQ,P;6*T#RPHCRLP E<62-0B\9@39(4/'S#B_
M4M!88R([A0U9!0F90;4_7=[@M%OLCUVTCQFI"@$^#505C_\;SOV;P;$X\=^
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MO-!A!@)R3Q5'_TZ\3<!1*F=W&!^@"R?^A%?AR9S'C61@.E9[6YB+R]5"!Q7
MWSCR.SIGFH#OYCL@0V A6KX#>=>\"8S%PK>'Y@:,Z*0.V!O&L2(V \$:)=V
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M7</(P.77J?==^Y[6P(EU,FM8E4CD49J3DC*VL]01Q$+(U#ZZ=^8[]L&/Z1/
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MB&^V]F;]Q1_9,IT?CHR?6$P]/U=0[H^@\.<WEJW7N!I;'P^/9QXL' ?_3+*
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M434>G"WO6[)%A8A[?FRS+#A\U_RC<9DO-.R1#UX86B\=%="EZ_EZQ=_UX3D
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MCKW[+6QO0P_W2X!,]W,@M8?75CT!Q,D:B+:4CSHT8?*1Y9*K/3ZPZ^HZ--=
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MJOE^&]%GO'Z5LD* SR1ZS@XD!:[LD<1>6/S]G+#X,XG_#\7WR">S2#SY5MC
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M.EG,+SAP3AY]!_Z4)1%1!#]9^I"5IMG$A 28>V<E3B??3HL!DV-GP5(_KTY
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M<J=H>I0Z?XIU.HWSHD1%11HJ6<I6M,:&"2#TY#V,\2P=]W;3X'?WGS.SWPE
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MW1:S5L>MJ#MB#7%19/D+2K,2N+7/&<[CYX#>; N.K[RYD,)"7HEIF.]>?TD
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M%AX._'I^JG1EN+-U(>#QZ5)/3*<3IBO0&U%7]OJ66!&@+ZI5ITY>766.EE@
MA?4_.?_7GU.B@J=X=X.)ZDBT?U0=[#K@PWF?LY"B\UDC@_B>(W?6A[PKU-!
M+1%@MQLK;"O2&U9#<\<1@).=;H(7?A:?K4,B8-XD^%^FXN&!0B?6V'#NYRB@
MZ'R6J""NY\1;_\"JPJ9+W0J_?882I]W#+&"_&R>I<'-$Y.HLYX%[JF7I(WWX
M>4,4]A04^#3;;F/&**_4J]"&&0VPKYJE2)W.:@8<F-YJ5DSU;ZX(V@E[DUPC
MHA9SA3@NL#<-%*UY*;/9L_/MN'$KX!7D=I=D+QC?XB0@[ DY?:?[/,=*-[+
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M_9D'ZW?@YU]V."ULIL >AA^SGT(0U<1W  X^YTGY,4UW38V!"LNCF<Y.GD:
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M5P!3"C!'T&+_AZK1$!\.N)ST HJKY=WIY5TNYCR8Q7TX%+=];,"%U:ES&OK
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M'"MFNT*<(CUR:6BBEBCX'FA"3;3R8;-\'CLW7RE6K7HF5=P!Y6-S>ZEBQL>
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M<X&;2X3M(DC:ZB1+ZWL0)+'XF/:;I,Q:C0A='8=[B&K*)K0,01JC<1Y':S^
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M^<;*B6Z"]3T7:!PC^.G@1^[OB8ZGL]-IHF?\S6\7:\M;H4'NVH)!<MJU6#X
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MLHOZ;;DW'@(F;N_O3'G+V&5//(V#!-WE$Q6P6BTW;D$8@O1U"<8E B7'B'G
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MU;JW<.YIA@'#%)^8QIA%O(/.I_J@0PA<I'(<,2*"41H4!$T?A=O\&<#.PGO
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M++=@:LV7_/CF!&D>Z5.D,2R3!D9.0CFW[=2L:_.K_!G&+"2C92GC=H*0TR!
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MC86'3/6:*WP>\$3'O.4K+4L5*L+0%O*+VFWW87%HX.GTG6;UGH0*GQN"!V"
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MP/K]#RKNN;)PW0Y<*H6+?:Y09<N_/RQU,M50$0^^-L)E4HBV8E[R_')IR:@
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M2O7BY\697&AAM[)A-N'7H L9S/J,YO/*M#!R\GRCV6&;2^=IHE??)C<1-=T
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MU56+$JD%T+38&,IE.!X0+;A&&=ZP')2^$RU*!HJJD]WL+4<#!"IQ.D&YD F
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MMM4I]U,)ADD\4VH[\>JI.?@N52:*[NTX^W(SY00-DSW(D/D($:YCJ%?_D20
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M>#;LLZ'>M#+X6T68MZ:H]?D<4"1N;EU^,G.^QH\YQT2DN4(KU2TW6$D-@+T
M0*?:D-\LJ@!O(;Q 2LB5"B18*5RV+RD9G?AD6FCA<U6&@(,P!:@H&P*$'-GK
M'MBK&^CL2V>%@(?3V/ AM,![PQQ3.92=0-O%)7RZ%)Z(@E(1\"%X&>H9G9+(
M-/%)EI#BD>Y05#@^?@TNVIA8Z$3SJ8&VB ]6^*,%  $.[3)WYRQU+>ICA!K_
MPW!.SP^X])9)T9<9FDE0_U+_F[FDZ4NJ!^!Z\7F9$.T0L<C0PZ<(HX<7<.$7
MD,8<#0)!A!\;0/#AH<BU ;ZK(Z6'CP"'$B $03@,/KP8 P?)/IL<&T_.%H<7
M/YMN7A3JW_.,R1>/&_1.\D1C?^X!46]?R?'.R4QE+KD=QV22 RVIP-]H(7_<
M09G)\SF9AS@GL[\^J*=?;W3XOG]4SX_?P>,RTY*2H!69Z2<2@T0_'I?3_0R(
MR_T4G:(3[" I90:)T!MO. #HB"=%[I:SZ_E1:(*4/T/*G6+,G2,%)PF=4'P:
M=K:>I\KUO-#NP-?RV4[VJ[0$-MJRNNY@M8N-(ZADUZZA;\,I[GE(FGL>DK7>
M"8GV;ZG$;)@ :+'!NY #VH <Z<ZFLJYY%3S=.BO9Z"J3X;@+9"! >TV']LB%
MFQ]R7V7X+:_ZAV*OQX@'Q[CTSV[:,M>0H0.M?V@Y/FM,, ":"A1B3HJ6Y4RF
MQ,;"QK8>.AV<6#DVM/S%N0A=!VP.&1L#$_LU, G7E!UA\;*^JE 0&;9A(B>;
M4D2)V*FNI[(;_IX#@RPKWZ(B8+, L?0LDK-6=4ES\.E6]LC ;AEB:/33H!3'
M=N#7P)S,Q<1K<"\J?L0,6LMX\>@P= 2.]9VA _T9>/D2.@.494R@&XBZ_UQ0
M*\.!?T*P046(B/$E2D)V(#"A'D#NSHH86!"Q+@C0?G:45+2?.7888_-GEQ'Q
MJKKS[#J 7#'9,@Q8(MM_\ZJ*)+F\>74B/G,X)TA<;%Z$9I3^[)II/&[Y$+11
M977+90-I$@CCS1O6"%FJS]Q>55L_B4UY,"2;_A%-0.A")U(= Y<\$*+7WI9)
M"'B- D0S2 ;H+D?BK9K(SI77S3O@L"Z=&*0G!^)_<SO18 ?7BQFL.=+0(0>Y
MRT>D2CCF!4(AE(P-<^+8O2#"0BP?9-X0RSJ6Y_H@MQS[189"Q-$"$#& O"+*
M&$#)2MY';TWQTP@BF%AW3QDN";D'T%% OJQ"V.NE!9)UR8;DX @UI#<* AD)
M+1M]>0"HA6GHPTLD!M'2UYQKNEU2T"NRJJ#X!:)V$^)"6UWB([U>^#+B53BX
MB(\ @T"#/ DQ*4%)AU<:D(<0+ICDX>AC3$D#+P "_W9T\J>)#A1#42.)%-A@
M$;X.6RCDO _BK!&:0I)SM19@^PVP#R' 1X;03H:0H&0 A]+0%116I9@L'%_&
M,AFA7L0RTN6GX+$DEQY?]9!XPT<'PC'FP,)3P+XEPNO /;1G0T2&A"<D2LL9
M(#& L(F"0&CO,WH,+QB_&EKS(4_K?BT \9I5$ [O>.(48LF5;&MUB7$4TI@&
M6A0Q$AQTBYRC>!$"'.$[;%#@MB06"1NX)5J03@#1+6N%!ME01 $A]_1&]*HW
M+136>R+2#VL]=\CU-U"I"B[=PE>@&)J+&OX)7_&^.4&R"4)#\OH169?!C88$
M]Q!HOJ )  6%1* RM,/PN7 G@M@5N@!0>*"XG1N G  X5QD'_="N>43>2")A
M2R- -L^90MP4!I)J0@F"B M%,[>*!$HQC8GW"AHD_ YTB=S# 3T>"^#SDA(V
MX\%0B\(E66BF.#)\@02%,4#3!+(W@(?U-<9=:*RI!J,43XU$[7#$SP65Y9AS
ML()7+!OBWUV[!SS\(IP#U&=$?FT"6E&1%@S$3D>J"1$OXM[[%X'9>5A'CPZ!
MCH-34P=J $ET<3C$NSNPA,:?#<[#@B0M?2+CGB- GQL!VGD",1L/'%9*ENV=
M/7F.^40AYL/1YZ#/08(^(,ZEZ23-]%,I2>S'E4RRGY8'4C^92+(#.4F#M!@/
M17/><(SM$:,Y+YT=OBE%O1E3>,J4/V<*3IKR9OV)MED9VYMN4@L931)IT&NA
MO1[(&D7GA%F4#MT&*% LSWX.^OZN40VM8$LRU0'1[*ZYVX1:D"I?>';Q)16T
M?SWS%]M2+YJ(%R0;HF.^6(Q4J'5)7B5@=HCR'!WWA/["SL:&";@VG'VCZ\+W
M;9 'Y7> O' --P/G[BS/R22+=%U%^ R$TI!H?)2!A%!0#$TS%JA, >,/5POX
M$AF+3R2--7%J@2OOCS?JPJURR--,@2M()&+LHSG$H.*%;MZ5HBZ!O(T@ KSH
MB7DBS,*E/>0Q#LG9'[^"-SZTALV"(30]7#4T4FT0@Y)/0N)R88I>(1&>0+@@
MY'_^DTFF,G]OEIAL5(T\D\4?$@"O"W+HU>%4("09%-=#EMQ05Q6X6&C>:89E
MN8:F'U&!5CVT)B$-6<1079,D?!5[$-C%D<#4;V%*8DS(>/>B4^AO_,6/?$XA
M*4BH5RS;C?HLD1BC(-';(^MORM=)SZICSF1_)GM,]CIT 4W7ST'N'I+@)G(+
M(8UB>H,25G8@\5K0/R:DB?Q)\MH AYH5%6/R[S.UG:EME[6, ADHI!&,><F&
M,[#=3K1(9HK$#PR)293A@?XV,F'<(!*.&J)X-Z1!%%HP*%/$%6F!D=%BD8A$
M*17H7KG9#A3MUH!-JH!D2,":,?5WSR*#"IC(\E"?2'0'%3[5V[$$S="_O-HK
MC\0_%W[!\F(%_X\XR?$T^S?U\VOF]./W ,Q%27UR)N(@-A0G$_$O%*:V5!EX
M^3O>0:56<%:"C@#Z$UUS+4Y><,U*4B ''T#"IP(Q)4.9$WQ2J(2>M)PIL3LA
MP014(=IMIN&@/:0S+[SO237X$FK3H2)<AV0;^@R1:]N03;GY35X@<ZRXY6Y;
MJ N+1,/&,70_P8"4OX3, #_!8GE%0YIV"<UK54,)%)0ZQ($R8E[K0(*6,&HM
M*XE3*%GAJD9 Q\0.B.R%:A]:&0XNII2AI[:ZH#1UHMIH<)+&P>5)$$">[ X2
M.U 4%%=;)X'64#Q+\+,$WWFP!12RN#'KFOA=^@RZF1-#QK8L84HW*0Z6*O%=
MW=(Z%9.2G]N_P$0MB8Z%LD&:XZ79T*O>N<!N629V!6U3E9[Q/\Z X7ICES%,
MH*DZO "-9QSA\&=C VFD>T%V8\TCT "7<77NF0W.;/"2V8PTS A>U5:4UP#
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MFAB8O;?LJL4-63&%GXGS3)P[B+-8:U-=:)0YIBN.2;MNMW@8RLG@ Q>0-'6
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MV5]%EMIEI8UU@@R:140EWI,V3>;,E'M$,MVU#4O48>5DDMRID<H>MN%"6K:
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MU1]K=/+%0I8K+"H+;E0TN3+ $GP>"9I?.@"/W8D3_S+K^9 B3LKC#*]/PKR
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M&K<SLEI?UW:")E#G68MZ &M^/8\)OD?=!QFW'%\_:XD1/*>#F8Z >1SHNM1
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M\N.>V.GX\ %IPW322'W0FAM%-9I4!)^;%,4Q^![R4$F+;B,0_[$JP+-]]$T
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MP")*P"J2B'O-?MR81E.5\EZ\@X&$RF'4A'3GFMN4BJD$5%652W2*=+>-:2N
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M]]N>'*&D._:V\RSZD6]RW(;I@\I5=\EE;*[+$R2H'CT_?AQ_]('(,(V:&E>
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MBA/=R.AIK<O1:WI(J#QVXI?I'Q'!=T21N_>YNO'Q%@EZ56,7%]O1N=4_;BO
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MT7L 2;O)@_[7G[_]ZNMO(?)L4O^YP@]MIR?_ '=X5VYS79FUE"1XTK;8(2+
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M?R *')<E)7SUJR)Z!MJ*;O;H$=WL$45SY(Y3YP("BJ.W;ES.ZQ:$'L_2A8X
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MU6[P,D^H7965%06_@"[54*L\MC/%O4@@0?#>,/7#"BMECN?^JWOSHL.RE)-
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MX3!).K\OX>N8G=%Y,(HXEA:?WCKL3#JJ<U>*I?-B@4BVE:+;A4Y:;-M6I*6
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MN-)/MH9TVSU9F?XQ?0+VXWS-T4)\KE#'59@;M3BPES^]04#G\XO KSP$Q4E
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M%6>-SV/[17%F:V4"=/5 _+R]W +!\[Z*6+0=8?CFH^ZK%PY"_TY[NA01AE3
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M&/W4ES>$: 8+WK6=1I!C[^G[0MBU22'SX?5)860?7(=K!]<);]P6?B^_)7[
MA59F$F:K\>]!<R>& E_NEJ&@JPX(\C3]X=5U*D]N/5)2>>#>I: L-.4I0H56
M"M&['@C2)-N9CDP&P+LJMF\M;<&!GW$7JJM_4G(8G0_L)A;J4;TFW(P=O-M,
M&'_M-/%B67]W1!D\I"XY]1O]I_>$D'-&].--+MU&TN$)KD@#(?[4KC:)SP[Q
M87W.6%)TR"SX5.&DD_A,XC,H/D)<P%0& =U/3\)ADJ1)DFZ2)'_JDU8%.\'0
M)$:3&.W@PEA@CXC']KZ6F>Q!/B)(5M3>Q]/P<V[BP!RBODGT)M';,;.];&2
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M951N@:E)KQ!L;SJ)\R3.@^+LC;L<J!%-XC.)S[#XV'03>E^8K<U8Y;G63P?
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M@DNN>0/C2CN;\ _TJL%"A_G($+13%8ZU) 5U7A3T@-YGRC+8[$F4*L2Q[)[
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MPG*_UOR,-%GN2)?7N&W<"]!(RU6DO =)UG.34$,PC0(3)]>S0SNP"8%1C?N
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M!!9/[@:Q+H)BJ8>] $68H=+GU>2YR1OJH.:,7H9!6;(PM;I[&L"2[K<BG?S
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M(ZK#D[N1'K$*2[H=MM5B]CL^3[\7D.)UM6S^S;]X1Z>+#]?O5;G/6M)'8W3
M)K3+)#9"-<0@SHV%?DV4N?]FRD9,//@HFE;KV=('=_3]J5)XMQUXAQDUOX Y
M".)(OV[K2^RU+AMM51COW89;E<+FAXS7A1'3653_X,S_7X5]3KG::IL!IM)K
M1:.'^+Z)"2$/X8O@(2#%S=T;_3XM]]Y]:?1A\U$_5.+UUMM%NVI<>H '?*;)
M!RWH(M/1*^C#?[%+-3B#2E9!D^R#5MM+M^"<$R1DPZ))7QR4$AI6JFB5GEJ0
M1WW>NA)C4QO'SF:F"&2(&1RA"$FBY/1!LTAX&'SSR\HZC]FN\IT/J9$RF#7V
M;OE(Z@.&.;\$7D:))!3CEU)A>/]5<96LL!+V*VRX2+4;CA'%%N(X3TAU5NUR
M$#'/Q3;8?[X@UC4=ST/6G)4 @<#(R%OG@JSK#AH<&SLW%Q27U((GO3V\05A*
MO![L?JV%LB=_'^WVC@-Y5(A/E"33B59<RK$YL8:R_.VJV6Z@EE(I/\F*Q44*
MUF1J;7#V^>:1J,BET^3TP,X!(J,Z[9061"U>RG=7O?6V!Q^;5U>_"SR@ .G1
M"$@&X2#?O:TKS@!5RV4XB\EJ>7%VJ+6?S[YK;VK72\\XM?T0$TD<SX7E=_-#
MHW(1(3/7;R49PP//>(G'!CP#Q,,2,!K- ED%R:=] [>PE.ZLF0;)CWGJKJGL
M9ZK6ZE@'ZJH+-ER==.Z!-ZB]A#YUM+P?,QOH5Z?ZV*D^=JJ/W==[N).80]*9
M=!M@1CE]+L']3YEQ,B\W;;=9/1X%CU3W7(O</&GATT:<&(NJ;UAB_@>+FD(/
M2B\JMI:+7Y?-HA&\MF/YU):+HY-("6RBZXG?%KZF9SJVB?H1Y(-%V@P<-A79
M][:OBW64#(*S9R$ W%,]$_7E6%AA9]!]<'P/."UI#&E/ /=UO0(9(]H$:13\
ME>7A60*=$4^J!P@>3H9_0A%<*,.FP-KH#)48(<5YFT]PHTK=^% $T<N[B$NQ
M."AWF_E!Z&:P:@=Y,2H#G.)QT]ZAWBWJ.5FV/CANR+W?UA-80&)=H25SJ6Z\
M"^-&NW5Z_[3:/MAX36.P/$9(3_)H%:>Y@_0>O6*:9P()%O4-^1!VM#P&PX>S
M@@H<IC:&LVYFIU)6L<?)Y!3#00QO.BNI.--;U5U'(VWJ? 2C+YV#,30K5158
MKQ@KCOW?[XGN9E9)ZK*\[W],DYRL,,!*;:S]5VK?<H" 8XUL<CK='HM=K814
MB]Q2R;:KM]9@0BNYNWA<\8688,?*6&F-TOA.X"J\-3&S]M(AC643DQ\O@-N,
ML)K!;$]3G,8=$/VAW]><7%8[X^1B<5B7 XC\[/<N;>8^*N85@H:<3>>]I'%2
ML<_S/KV+:25L6[U!H]2JH36G$$@H<SRA9YY9SK8:QQJP$.NX.9+^FNNFW>22
M.I;$DFFV'I5STMHT"K?B<;IM:>8QY]-A/KV*X]W:W<$[)AQ&E ?:FX9\[1AQ
M><ZS%**"S?6KJ"<MP2?OF8Z/FG9J1X^,]$3K)'/"/Q,JUJGDH7L@'VB1S!'I
M4&[&Q$@8BC,NZ NMY$BZ/9&Q<'QN8/TSTG.IP!CQGW&W,=6!)Z8C+1*"3! O
M)P#( I=PQBB1\J4$0 -RL//9MY;X..:@H&4(^T64B14J[58 -U="3K9CI>#8
M@<DEI+*H,$&IPGZZVNO=3!/U%!F*,%:ZPOVVR7;P45LC8/+H2!K3CU6^71=S
M8NB<RQ(3E$Y(]!BYAEZ;L?/J0TYB/A.$>)@"".-%B+CB2"C91V2S@DX9G*@9
M_DQL373JN&5%O9P$=3+JU?P05'2?"I)?,N91 ?I8&R!O2S&%R)_7U76ST>YY
M6/>)!OOL#K/,?9I/'L=0XMR,!V4"H-)WV,\H7'?>X%(B!+Y?I2L13:'HO5L#
MU-A.?/WX^YP;1C:>SFA!9Z'9T;.!@+&B0B%$2CU>*F)Q[P)%>+L*U10\K7>(
MFF8K8M* E007_*RKQ/.4*XW>:4OOV_0;22K&@A)][=_KZO)P]GI+B_TTG/7P
M8F%LUWBOIR06)2Y#\7=D*E ; J/]#:WTZV#!P#.HP,_/WB<TZBF,> H\+4UO
M<'1VG"R1>IWJSP()>K9OSRCJ4PU:=L3@Q8!-.H)XN.;47VIDKIU8EM@%)&1_
MTYK89^FJQ0V9]+TX3O-.R_]@RH7 /-12%&"7@%]A>^GC?;GXJ7$!Z@ "TS6D
MW%[/ ")$ODP+FA+(PNOPE.F^CB1"E]6*([P$:.P:Z E*B@\(8LF] +N_W*U#
MZW)L57 -Y1_@[]./-+TJ8.SML7=O BI(9Q=.05B"+85>2H&\-[;ZY"*=_FZ
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M3:Y"_@M_QCT$][""^\M!OQE*HV27=\I/[<'9!"PC'\FWH[0,L'ED34FOVD2
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MKOFN9KN7F7L_,*,O"U^%.V^*3PDFE1'B:TE'S!YREA[,RT1.02+3D'F'7=6
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M;QS.<(U',Y&SP#"(.VLL-"YC6'+71([(:#.ET33$MTS2_G0"]DS G@G8\P]
MXJ6Q9(H67>+,2'[/Z]!$145&$KZ("ZHUGB/%,J>.>[:;>D);9>M'65^JB]&W
M.S"'UB8*4-K$MX!*R^+MP^6 "0./^5UHER$M,@1&KE6;7/.'T@RQZ+:RDQ9Y
M8!RK<=@!EYN!I%CJ:<C,C+\VT H0KY?^9N2:QJ)L3^M&^_+8('F8@+=I^T[+
MKV'TXE<T[3,N%%QJMQM!\OJS4<E%'S-A[ EP.#_&ZMF<!Q<SU3R6!)&>.^I<
M9?8F-TW2</^><G0>/ SJ#BF&/GYH>B79AF)>H*C"*%JOZM@%2*\:?-X*]U;V
M2E]!?E:O32KKH3AGL\3Z9EM-^I^LKD./;349N*+[\8NM'DRAVX]20$F>G_L;
M9\.63&KMJWMC13^V5B'X+AE1E3.]E>ZL#] [,-9!M/UANG"5" M7#=@.2-LM
MJK:6Q_K'PZ;'O>"CPV[(]X"G1I>LK[F*XIU8U$VEY]54QR63\JXQTC ]F<&Q
M'4_T6S*B)2/?-HO2AW^D$J*5>=2?V22=I'*AJ+$1X;5UWZ&0.10W6^+4NVPP
M%:MKR"50W&:ZEN;FTL-_R7$#^I&R%:8_HC#IO(Z'-UV0Y,M4_DV)MS;AUZ:E
M37IP]]V$+YTBMB.VK'(LTEV^7)6+T+F/*(VU1=@P<!O,"PU#)4%=<.7QS0BU
MT71*UX'_M,P8_N_^4JTY3\4_2!KK#._];;M-RU<9X;I6P\+/ ZWV)FC*)/I7
MH"J]J0;SDWNV2VUFHGZUL3A=>E([S;:0U':/%%('YEKE,C(5GU11H)5C@8%E
M$M))2'=GU P%B69<"(\@J: TN\6Q4>)RFJ1JDJJ=4D7.K/M8!L);I'Y *23M
MC$39,>&-%[M%P&LQ$IS\66DKN@*94,_5\OX.[C:3Y$V2MU/RAH+6=KG_(/*=
MYZ?2 (L"4L:#NL$M/0G>)'@W5'F#J$,0O$@Y#Z3(@!4#&?TU(IR6;9^9 0Q!
M8.M62W\A;V;MIJ44&UC#)YF=9/;V,BLMUDONL'2E[A,PD0T5G[O*=2$$'B-,
MC'>9)&^2O*NHKC5F*[%$C?<((D+!Q8O-@I@_PK6^(?D49N1\P7RH4C_,.);N
MS)GF8XR@DNB2U$#%9NW^Y8[(UX2ND1E"I'XO95.2TF:$J>'41]H?B=4N"'-#
M;;IF="B6*Z1FV+J8SL)T%G:>A0K$Q$APEFW>=E1W$U(=:4H#^2!1P G/3X[?
M^%\VM1=H+K6+3^@KA$210^H(X$&@?R_W5,$^KS<++Q9$3F1RBTO@'@MGHJ(A
M06#CJY-83V*]VR 62"B!7EORQD1@$Q >!_'Y&Q39;'+B[";@K67CU@*1J49@
MDKNKY,[&S(DX-N J.",L0&I&2D8>5;$G>C%HTRI"I7FG7G.,K"9S(2)A0P9_
MF:]6VIM!V$*H(9NES_Y!+(?G==/TY]WL-57@ "))$%78Y/.Z_J!9,?1>;6VW
M(M"$=%+3, < J=F8/V<[T#<VW_55(*,_-]J "0V1=AE62;CJHFQJ2>IEBF$G
M:'N^=,)<L5T\$K@-MQ% A*(BMSPT]B+RE@5Y4*W6//#/ 5(:-K']HHR(-HHO
MI7S&I8M2K&6V7(9+,H\>K:T_3?FI-Q>0<N)P;LM<L"@(R/^>-P4R3O[ @+!^
MM<T!XK>BKBC/FB:L+$6I*:0(3Z0?H@WY_NPW%V!(80:6HG/&W3[Y.=\PK/?9
M!.N=8+T3K/?3T5,619*6-%'%ORD)RZ)B\WY[L=(T@=5N#,,<T7%4OF+;H^S\
M)CU3L_*7</&V2B&X*K9O!3[H1\5-2*'M_&#A\4$]GPN.T'S=#)=TY (-D[K8
M[)A+Q;SAPRTN_/U'GYO>"'Q%<=D1D9[!D>S/%?/,(<'8.8*-(BFPR@Q9JQ##
M!Y[#N-!4^L8_F'$W&$7?)5C5(KVF!?!KE@KU900@)2**:J\_%S .^\18(2%-
M.Z>J,!RW47#1B%C<5!+2794B'(3YL:^FW>V)MDPC_+"_K2Y<K*,1H\.T1NB[
M$ETY"@WFQRMN25S,6V,2Q.]P4-P-)! VFR+1-K2FDA99\U#(V>[BIKX,\G3:
MY^#5=6$2Z(;11NIO5#6-BIPWJ8DX(U^ETL?6TN]]LPDGP$Z$3Q?%!"M"UW86
M)4^UY:M2K5O"TT8Q$: X;Q!5FY4:M6991VV<"XAF1A&;PDB4%$D=4N#J,A(E
M?.XD;AB/!$[H<0+)B60+1EB^JYMXN%+PJP532U>Y->.*DP,Q*LO$R\*YIVPF
M\<=EP^WKA7.1"RACYQ(V9JD@#[$<_PLTF8C*PPM(42ZZ0225EI)?$%JZX]N
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M2T3$H/P(1D@B ]LH\O[+K!WWS236&)<8W>&44(O>"K*"!]"4 M*7:<B-S<6
MG5VJP@8GI'Y!I]CRXU?E!^":PC#GSB'2X"Z ;@*QKVNI\R(3FXZSSFNA2N(L
M;RK7H*\#S&:NRZ#SO G?1E\>@$F]>'LIH_!!!SR?AK(NG/9"$C BH** +9YR
M_86&).RV\?1+[MB 4Y9[_W9.32+$<2((YK9O<[4ZN#SSB]*C58KWKOP<:W[/
MAIMB;,87H(<68Z(+#AS43=!LL$:%L& HH@C&L)+I8X\41V#4NAV1:!4FTYW#
M2M)PVV6)-G?GNIG[ZU;7D-XF5# VN%&V)R@7"XXAZ48)@JGV9N>G-^LYU$I!
ME>/YVZI\3%^0 N!A)B>1[NP1(9!;[-)Q&;ZYS>PQ#E<90H<B$7/T3L,W36G7
M3:^4R,)\ZRU0GY3QB[TTHBE<2Q1$#;5_C,AI S4>2.U ,VF<TKF"NL;(C0>J
M[R[GKCE^6F(!2%,=Z8J0\8)H4'#0_M!5IX@C!NAXA-Y<GM6ZOU=KT$"%'&_^
MHIZU-2$\*0[KE23A.S/Z:(%N)?Q-],*D]>T0. C39!!S'>#6(U=B/FX[Q!A=
MQHDG^I1#A#@5]BFALWK\<PQLCL0.&WTB0>P7_J(*UAI5B2;M?V*AW3<$8D;Y
M8  L$'&[0QD*1>+JT%*3XB(( .34\#2*%OWMW-NA"#FM!%A;GLH?GK_YA;@_
M J(0E3+^Z: \HIN()1%JNFP1",'F!FD&<SP"$&9A;9!QC%7=]L$)!1$<QALK
MCKT[Y#1HZPGZ6^AU3A45I-3JKV-+;-^5K:TA@OM5L&'V9S_%#0Q5)YIW8 6I
MS1&YH8V0>S=N\6$E'/1P%"IWZE?1OI.61%K?M*2<DQJ68="9BBAXMV,20UL!
M$/%%3V3%8CYPF?=(6;CLBG_?T-\*@I69GD%:7&)Z*8S7W'!4>ZSAUU4C2Z80
M8X=)Z]^&+H8LI+W&KRY..;RJ3.P[8V66655FR[B2C)88^&:>VH]N6*WKCX2K
M6ABLHX4M) 92L@++FG)9$+ELIMV7(*A@0RO\RW14XGU@<!?:VQ)= F;O=A8Z
M2>\!:5I7-R$$[6^42[##T_2HQQKW:N.^P0CGTS_294&CO)IO&[X#J/L2M6M&
MDJ)%FT^J%(>07\26&F-D*W9E;W*$O)%0)T7<046*,["[H[$1%7-HN NK=S&8
MVCW\V8B5^F2R\7X@C51!I=9+6F\8(_1):[)J$1,PT*2H%:&8N&3\8N\/+Z/4
ML P6*D=63>^R6N?&><?"GY?&7"'1EO."M<A[<>R0'_H@/>W!22K;R:)')6^J
MSFR"F,/FE%:H0M$\A*&ON#^V%ZB^8AA6(3DB_]&J;ELM-@DDJ/B5(+H2&O*H
MHS7I(6*^"!] L'O8*R %7)LF6TI#'5K:#._$T)&-S1FK!4S@25_%)UKZ<!5)
MEPH))> ;6)M=73!(0*BG *P\ZB&FP#6F%LY$5:>E--P;+3'2M3BM&E1/I>P#
MU)N]U-1B C*X50>=:P[%L,%.VLDF[7)SM\UW_JVZX'S#+=Z>'$[YJ"D?->6C
MOK2[.];IE**^:8,V,O^O8G)B*T8UH"5K8JY)_\&B#EP+U,3TCCW/$[*"O..Y
ME2HQ2W%5SR1[]Q*L-[$!(VV$QOE'5O3YZY/="U<WH^N6)>8\+H5^)>@."78+
M] :7J\"TG/8Z(]> WQOI$]0%P$.6!$ZC.F-O0])_GI87]'\Q'H[S_;T,C':8
MRBE!_:H-!?M#[VA_\Y><_O)7[0)%\!*?XG]E?*OB(DQ6->FT3?'Q?)4T>/4&
M^:H7G(K\F8VG+(WL2<R;;DWZKU@M'M: ? BQ!E W/5\1=LGT'U_#2L86?7#N
M?(2IC!$DXIH*!X&W0AOJ*[%<.<&MI)7?TJ95# I%Q)$M?E$*TTGHBY(C#NJ'
MR"D36+SLW!#*<J6\L"4UA2:#W$\P.=G>EO>&E;?^0F<AR=9TVM0M=KY*+$Z\
M@L?,!HJLCRY[>@#T0[5N=FUJ.T0Z45XB=)(,TIL-7>O89QR1V4#L,>@%SD:[
M1(R4]*.TG8Z,0]0WB[.\E8;G8\\QLDB-C-%A)BX;]ZH3A[RU1EP8G025S)M&
M5$$\S\+IHKIA?_:&.D6O&-_Y]N5S>MH+!R-:(\%_AJ9;./89M!2AD&F3E'.?
M"39)$S5/04(":I+'5-:A)) %>=!F/1P,.D$0&[BDB@\%4?89![(#U"P&[C@E
M9X)M"3N11/!B."_!\>HG["G)L]'J8%6R'J8UM20P&,,UQ#B9"?KXGT&'233'
M7Y&S%>+D3",D5/<FE<HMN/^JW5+;]"];$9=A$$!\IN")F4C H TB'2HGLQ\L
M*&F0%9/C%.1Z+PU]TG8L4)8M#78.MB#QBV*;)FD\IHW _-"]6@GXU;%K$RAV
MF165,X<S709R"?VY\8*,U\:Q);J5E"Q#>/HX]IIV5&2,-3F*%W%7TDCK\''#
M7J"X^;;Z2]E^[O%>-50;PQ8<6V@4R2)*U84B0>Q[-$B)P1ILAC!"I8$@Z8[I
M+Y,B"TUC(AL]&3-MPEDUF&;>T1D3&>7=-8=T8 EE%LB]!7_D[X^!-[^H2??X
M'T-DZ6605@>0%O'WS)K3P\V'84 WD DQV!_7)Y:&*$^Y7I&-Y2V+C5>-;+:T
MYV_M+]?3&,F7.+()L .+O0BUVG1;FM]8A#DE1;6;((<7">R[V9_]SW\>/CXX
MAGV@KP6M9P-*>5?8^)E5IW2R[+M86KV75IC["U'-[>"=&#W',R@F_GQVSS1V
M7N4 )U&7^ONBDR@8[(^JV$;,5^^?P#RDI!LT4G4\BS0?VXU68V3D>+N3\C&%
M):G%)Z*>O9-H.#HJ']OPNL!"#)(J@NKOQ(F)$O^*U:*W1/TI;#8F(!V/,&7_
MJ8U )KT#A +.95HOE(DST#'MJ1!2+P&T1O#?KQ.1"<(2IC!G2<T'))";L72Y
M3,#I>+T\85V*M=6>X?C<TW8&X$D*+[\OG 3$@N?E-JY\BY2)1)O' O8SKH]R
MQ%3$2K1:<C#</RSL%V>"F.3=#]6KO59P W%I4+;1=^*YA1!EH$2J*F?LX*U@
M_VCKKLR,WW+2\G!BJ<PJIS:?QD$8*E:;@ABL87P%'GO_KC0O](DH'=K3% $0
M]";#0:I^[1HD.W:JJ507:@!8^;1&5.II7Q9<=3&F.)%\:S3F'1RGT1>KCDU5
ML[6+LJO4KU[SN_6OG-A!($%RIQDG3B4Q2MT\C./$%K[7? O\] :KR L5CPM]
M$U%1OYY5W9&?9\(*Z3'4)_+?N)#0-;:%'1F[]]S^Z7XV>RN?/5+G]@?)!K^C
M8_<\I 41*[IOUU!#'_9IER5LD_/S4CKFWM=[ZP=@HS[FZW-M?J))YS\QR_6K
M0*'W&DA8L7OPLA-VD_6C$S8B#Y\]>TS&]9]>O3XYR8CE:<V96/8<XX/C$7P7
MG20@D5YJQPJ\YKFJ!OD=<9S3\]^]?/ZGC/,S.!%:*)68W%:&.&-'>Y"%+17?
ME75KJWP)NQ.=LEM^.D(#;E3)E^3E%JD_S[USL_1/W3AJXQ%DF,PFDGUFZCXZ
MCE+[W#_7#[HJO=;\:XF'XK^>(PN0%S7^B[7SHI?+YM<N/Y.G)"<&%DWCSB0/
M;^6;'5?>FTCP: XWR"!P$)-ZZ<%-Y'> $!&ZLW)S4AD2I3WY?3AXRL&9PTHO
MQ*2FC1/+4\? .4*<OD4D<2V;]*AZ[Z<UWJXH3/DIDK?J C&R!EDNPM;RS8_H
MHA,I+1RA+?3MR5LRC5'5Y]T>[DK#_;E;]4?MW:$&G2)/!=7BMQIFA!M/?3*P
M('U7K\F*+?PJ0K[WO-GA_\PQ._<1D+3618?;SE(2I$DD%\\T7;PXA+3=ZLA+
M]04C)Y[+E%@8!63 @L&8"=>D9W;)5J-.?<?:14G98=3H,HF'&]2UBHW,#BGD
MMI4X&J,\&&O#D8?5JKYD>*3_L">+G(UF?%9Y*3(TI5NZ-!XTG"E6]Z_E]:(O
MCPX.GXYI2?-3_<4;WIGPPZ.#4'SW_/6;DVR6&C+T^?/7T,$4H&BYZYJ]D9C4
MF<;59K9)#Z)M'%*X4"\V.+44+(3Q:888#EMFX7"M.=I66&YSH,_JJF;Y<"W7
M-M.^1@7-X&T5XR LVOB=UHQE'8OQ+=<7'DWYW"F?.^5S/]FE$O7#JELZL"QG
M_3D4R'\]R1X='$ ]6@!IC'WRO8?+H&7=@@N"PB\$>"$0%ROOY 9GU\ )9G_!
M#8!,0BA>*H+_,9HJ&O2IF14MN]3B\CIP[>=*306L^6#!=176:Q1=-^\5E&\
M[6P&:-$=7W4+O-B$F"TUO^9*9@S?)<QQH$DIA8B[E2N^CT0)UT0*]V=OK4N#
MNV?N)#V'>Z?A*;;N@FG7V0L21]"$EH4_W\)JV26DW$2$H*&HPU^R0G%.5@MN
M+T31$M]J4(UV9Y$"3JB/.,'4D(&VA!#M5.E/;2W'0ZC;GKXXR]>'/[=,GY<]
M@C9^ 'Y(=27-@MK9'SE%/GN!![Z.GN^;,)9@T[S\=?;'%Z_?9'9B?_'S*.IU
M?!Q]07[PZU_DW]MV$'_^?9/_O5Q=.Y8?\\O9O1]=Z;] C14=__%__O/HP>&Q
M_]]'3XZ1=_"_*^IV]MH?L3HO(Q'"CW]\_>*^?X!_RL_U_NSP0?;DX-EWL//$
M2W]^5E9Y&,5KM<BL0YR.1A_]^M7K'U/3^4K#>>#2W)%X)I(1D[&\(W*"&",K
MI2\ID"\SX($!UH/.(%<"HH3&:S_OOS+*HW!>O[-/,,_9V]SRJ(QZ)7^-(!<:
M6A]<#T<',[]2*^P'!+LU$PEB>OAD_U'X%O>= IJV$32O?E^D=(9Z4^2*$#KB
MZM6'_\U+4"% =KJJYQ0GHT"ZH)^AX) B/O5'&L8BQ]?M;40B8_(69L)(R"?6
M_[Q!BQ%"@U/.@"=,?Y*5;B7?MA6HJAM_\4D94QLP+-QUQF\+7W?B1(B#35%"
MV/!\Q;V]++TZU9C6">-P!R<Q'*D?3EZ\SMAS-+X,7VE\U.6&OF*ZUF/DT,V>
MKE/B-LXW1N)P/? W,.#N[WXW.5'86'JG1=DL^C64)C4$&'V"@3V9)]WAI6%2
MWY( $AIC OM+]H(9QRBNR6%S1.510(.#Z1?AY-6 ])A=3"RG;#ON[X@/B0X?
M?21E!:E8$E]6>/O)J_0%9:(&-("=&$+Q9.O')O"D%]8?AU%@7.^"XJ'R&B[1
MUGO?@)ZE!(CO*R],R6!M.K#7L JXXV*$<PA>,(\>VDG9%8E +N 9E/T PJ]#
M&*NB'&PMMJ_4-H.4C4IB/50YY4)%=>08TSH HMB[H&W-BPMOT)()>W>9NZWJ
MUH0\0E-P WDC##V;*T9T?O?F35M(IV+5-BD"RQ3#*XZAZ%W(5I!IJ:6>R3V-
M>HL _>=0*%C*]MC?EE'!U="MO&9T24QV4*%&#^/B#1D0DR'0 +3&(:S,UF%$
M=#*=8Q"OM,8KL?E" /_$7U31H'MY$C5!:M 9&R[CZ1@O:17+JUQQ_7BW-\I>
M];I3EP3A2?2&/PD1P2E=M[1B1?&"X7R/; .UF2EJ^&#L):PV!M1 ]]\YLC 6
MX50V(\)"+M.61(1),UB*QQ$:A1&$CMLYA19)JAW7#HV7RG9M&LW.'7,K7',N
M9-\X"_"7\>4=*0I:P6@-<6I^1K!XU;M($H+> NFU$9Y_4_CRJP2.0P;".QWO
M22@+^0X(2.?=EW64L)>_[I&K+$8%;_0/3;YVC#Y10?R+EA(*C8'SD[S'*%]Q
M^*6Q-+U47'GO,<)_QPOVYH0.3$TBQ$BIN! V @K)S K1;1MJ=IP:P6%H][4;
MH-FW8:M2\J\CFW:8=8 0^DM+\G;*9+! 6,H/KUUN&,(+_' 57I5S&);[H"Y[
MG($=@C$F!.;2L:/@1P'#Y<^5>OTW$[DLZ(.@9Z_7R4IJU"FYJ'6-<EZVU2:X
M%UT<2$X8'3 ,4/[,4#QLD<LJ?,6B5K:JQI(^B'!(3IN\2"A#;?O"CEAGG6!_
MV&8D&1%6#(, C5"<*P$"07&GBW9/#R7KZOLPV.W<A'@P,[!7*B07"),EJ%#;
MPXLE3C0A1$;P1,J%:))&8=$#.H5.)".BA8PW"V7C47LG82(-6?S>#[&>DHL*
MCD \O,VH'U0Y0E\VC%ID5/^@WW*Y&P/W'_\GHO^_WY7_E^*P#>R=VAZ."[UD
M_K8U[<C^#2"VXT=@H"OB3K:+IO=WOO1,#'O)X#A)I\2H9A9,3!$I9!?.PTE_
MBSACN/'CPX3@L>&P7'"1; 5 V[=@'!"@G%<.TM&/0H?ZBZAPMS9,5DRLHB6?
M#W?J"MQY'+&58PA/.UPE5UVIT1S;#]MYUU;LE;@7B>&)A6]N4A@=<?,-T_ P
MM$>F"L>LPU]YBP4TN!DIVMS"+0YBH$(^0:[Z'#$0:DDJMM<H,O.&*,M?4NKL
M+2SEKJ>/<W'S]8Z_*>*2\9(&+W['<O";X^*0]BPL2$121<H TS3= ("@"!3_
M<IHWQ5;N>X"@TMR_?8/V'JV3YV%SE[2O[%,@T$;>8>8%<O&!6;CY7'E-!4)E
MD.& GH= DGV%2AZZI==EF^:9(Q68%,%9+R[19\8/SK9*,;#I\TVBW6+!^\C-
M_4U3SCZ84L)32GA*"7]Z&/26]]#LGH"B&3,CID7Z?<X>\D/OD\+T?LCB PP<
MM#\F9!9=K*PL-3UG@P52P((H/R</0D'8L-2/]?;PPDL5)I/?"T?A2AL.1.AN
M#$IDYF(DM@]*L+:=<"4 #+Y"UHGY*!/+5*_+UPU*Z8A A*IM)?F[P2>FG"\U
M  0MQ+YAX2[J;DBG9_ML,VT=F?>4!=>NTMKF6)!G*=&,#2)G4O49RJ*TZEKP
M>*&\B_EM;6Z:#'GM"3*P2H5'Q'FO?'EG@7UM=\R-OEIFR;Q7-\2-'ZI2_"3)
M3,=?77%_MMV;Q!I8=<2B7XTL5R&(W5 *UYZ7XDXE%50QW5 /'+N12B%+]WE5
M%4U*$E01/0AUD!Y#,MH>&39B+I'(=$RU*?RFR F&PP7<S>Z%Y8KLHFC$7T\*
M*F,QY0U1^[LC$KLB$0!UP/@E]X9&]X>T '?;=!*\>)IL"*PTQJO/_2LZ>AN5
ML\4\A 0_[U]9G[0G5= W*U.Z$>4,^-T"Z\QQR/ON2HA+05)32$RO0(BYIM 8
ME@R9DD$"?1#Q/E]!(Y?HRR DON0L)1J=("1YX'>:0S$RN)DV.V0@!]Y'\);M
M9MJZKBO7*_'0 ZY7?Q@ K1PC(TS2AIO[#;!(S+8)2%2$00GI)B5!RZ7_ ^.C
M%WG3,&XU\ETNJ<P3@'0BH=IZ/)3#N9(ZL1=Y4:]Z'G.(#'6A1071((1:U!
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M688[(L^C1D5^>HH;'?3^7E#],M$3DC'8KFJ, B.C=0E^5C@-][.A>T)V#0U
M1T7V?Q@L@=7L._:3?\6FWOY$N39I2,;MFWC=N"9/OX-W<R<W:?4D^<WTV6$)
M34I!CUKLG(1Y=F=DA;-7%AIJJ)IE[4#@^W,@DZI.>N)5.Y;?FY8UNJ L10%P
M,;6D.#A,X7\(9=97;4T=]*B=9"A0X?UKT3:J)C\+ZZI ?"U(8?$D&W-3]P+)
M6Y7N@EU4;\%N:'A^Q<+2D3170V,O+-_G[FER]1UP*\6#UB9_Z[U)[AH<X6"
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M^VJ97]0-;6O\PC8)WHWN ,+LIH0NR;5P9\A$U,CIP&0."G,UPR\<ZNA"41:
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M^T7\-':Q"=+2)$7M]'Q_5YY+J=J.QT=J7/<1/<&!_:,KKVK9(Y+W<_6[W^E
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M%\E-+@RE7[/I_XE82M8+%2F*(K'QL%R(7C,R$<MY5K8A%R9Y BZ5XJ TFNA
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MMZ_K'3_2'*++N<C0%FTFB40RC\[R]HJ$(8E_LRM?*-V5J+B-<=JHV.@K;."
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M(:/F9'^DA8:H+8!G-8I+V=_;-L4_C[_MT^O%3Q\.M[=%()GL!H:45JBJZB5
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MU"8I,"8V>5\,@9T]O)=@X,'I@-?+I=P$=I7(^L#!"$54X6"'.<=E<ADYWX)
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MRL:/E+ T4 _U>)<A#CV&IJ4Z MU.$+2(Y0\(4>MRO%$&-G205JSA=%R)484
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M 3]!Z[*DG0>C'1[-3;(9R\45S!FB]Q!2*V@CE\E"HN:6]%/23X'L4:#*9!B
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M"*6U%O]J9:181@+HR5_0 .N4_GWQ/V.>J),TL>L*\WS)V<EOC@0%5E<*)*!
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M-HZ<2>R,^TYH-*JF4:_6F_1(^$?C]2-N.4,D_!?EA,$EO;DEW8BSXL<(SAW
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M>$9OT7,<V2:YKE7-3JPPAA^BD3NYD='@V;*VF1<IB6 ^BZ^Y%Z]$,WI*7VS
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M:"UP*HF%[1FI0%.K\99F)0]$0\H94]1D9@+:ZWN.G_F]M$)F-HZ6XJ";QT6
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M**[2\4$R\.[X(Q0NV=P]IW+U7*)\4B;F7?A=UV>8/W<LV$#D LZP.QO%&'Q
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M=;$XLVXVJE6S7:T]\0#-*O)Q&=(IRUY6"-QN-0L]_WC2*&M"GCU_K*1S_CM
MRKNN17MW!11&% >#\Q'\S0DC/(1:YPT8,D-WX,8+15M>%::8.9(_L!!C26>P
MXH7CRSF5%?*1E\4:*U3>4'+&PD^E=$%+%[1T04L3NW1!2Q>TY(_GXH)F-BK'
M#WBI;UG.('@&?F)I_#ZB*OO_V?O2YL21;.WO]U<0-3/W[8XKW-J7ZGL[@GW?
M$6!_40A)@)"00 O;KW\S4X"QP2Y7E;$%SHGH&ALG4N99GK/DR9-?B^EQ"OJP
MF'^(18I%=[NH4Z[L^(86>@:\=]=!4X<;V7//G9F^[WJ;A.,&QFU$<=?1(QAW
M.+_ZNHCW+VFJ R7T4XY>=57';ZH;%2CIRXVL3,I_N%\Q4HFL5),=/6U,\F,E
MI5!1^SJ)8%F2(,E+G4C[\C$8OJC@-M3X_<N;?DZ-R25#^B&565OT.MSR]51E
MGKH?0S6&-4\<P7'4#]0XYO'R,X.<-QW5T8Q=+Y^C"/H* ^BK\#6^%BS'[20M
M*C&@_\8A,PZ9KT]XK\SP[DP+ZBRS+_O9O&QYB^-V=BEL9EQNP4A+/9^7V+X
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MU%EK&)"93+@0VUI5+)16"G?Z]F"\>*AF9*MLT3UQ+%DKO4!5Q@I_9B3)R8M
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M&<&?\(TZ,K&[%T8?O?#X/5=49!T4?22*K$0+P'AQ(X7E.$J1AJ*HB(8N\*+
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M?N_VY\_QB5UMNLK(4GHY7BQT_+1CTLT<PB=X-PLO$1+XC[G\;7,8H^*GAG'
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M*#)9 <Z:C5+ZP.:@2.A#?.#G&<C''H8HZSTT$F?S0E=:?R7A^BM<?W4[]5=
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M<!0>-W.?5%8=R>1O9J:.LD-PE@9\&]R^ HLPD0J'#C("/\CZQ6"3XD"3$YQ
M_N4$K!'!W!SF16&YDH,V%V=#0+5]W@QF"5WOB8C]8?X9;7."2=M1KNZ1*4BM
M;..0=#SG\^W*26 B;^@"<P.>N'OD*][EXRO .]%=]$<XX(ZBBH93[7.]_8R,
MO= F]Y57X(MSU0O +_[$G._@XADXH,GM9K>;POYM<,=6!3B)*' $&_ KRS]/
MP"0*#.9@PFA7*$!EDQ#HAWOK,32!'FD3!^[^1G0]6QN)9@7^2B2 VPYBHL"
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M<_@Q!IUN'+;G0LT+H7YU1W1@0H(O6QF%5[WFADZ"'^SYYI^IA9L6X_0Y.$/
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MA_[PQI\O\O?=5FO J]P#]K?]//B'>!_B?7@1/YH0Z.OTUKPU!'#<FE\6 [Z
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M(WBE;<),+9X8R1J0BKQ*J+P%^(A$S'514B,$8"#"E)#P<$AP0?"9"WX+T[P
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M*?TD&KC-6:8?,,@TF;Q+_M#IC%CCNR/CGN)W6W/F4O$0+K<(%SH5PN7VX)(
M&POA<GMP8>Z8'SHO\[;A0M[1H=R_0;B$\N4VX1+*E]N$"WU'A7"Y'%Q>&=A^
MUIR\VB5\XFC4IPVW:]R ^Y8<.,+(D,%32Y*ZDN"QX!MXS8R>ON8U:',\FC#Y
MGEF4E\V)?F[T8,!]/C6)\, /^:YQA"'MA+0#:8=Y\UA/\MH-AC^8MG ^TN@C
M,.LY<^?RPYM?16TGE_'I(]V3=\QU6W9_/"XQ'X1+6.6\=C[I-3#K;1+MJMG9
MIY?3E8PY\7LK\8;YDGJ\E\FL&SOC]<38>[P>MWR)GW(-V,EPF]7__IMY:8;4
MP]"^3\X>*2YF*(UFR9P.V'4SI61>EA_E2TQ"B4C=[4(Z2) Z7L!N%BC!!5*X
M$R"O%A_6DTY,5<FMLIUPU=7Z/IX^2%BG7I4UE9=&UCZ"?[R!@/2G@2DDUM/9
MI,=VQME)H[<S[^>5S)"!>9/DW5-#4=_I<O_QQ(15OA]_#2%K#5GK2:_;CV"M
MR\IPW'PLM!1R&UMKF8FY;)O=S">R5LD8M49\N5)@BXE%KK832G3+F #6FH2L
M]4WEAB]4_;\),7T]!U7/2\,,O4U74]-OYL8^47!\42FQ "QTF.C7UV.JGRNS
M'3+%KNN]KE(MOK!&X=6"H@GSI?=DZL@*LE"OB^1]J\,61[W,IJ)P#USVH'B!
MN82LB-*>L%@-'O5Z.\FWV82J]O.,533UCC.#.TW=O:ERZ;VY+Y<GE_^\A\-
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M\X]T-;^D;?MW=*A@;P;JRFY.>4,RA\652&X*I=2,;<1K>DKOJ_1"6U]("^[
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M>3_*/HFLZ&JCX!KWNW6N=O_A(4Q.KAK_$? _X3=<0?P_@D;?_'-<C'@(S;T
M\F"YL,X^W@6+UU<GM>2$H=K)%LFYU"3;2:V<S/"MH-Y'QH@W4[W"G%.V]U1O
MIG:3:GZQ#NI]U.H5HXW-<)DC&_GR.L-W'W:[:2NH]Y&6>Q22]FK64/IZB>:3
M\XX:O6\%]3ZR!O?Q.1!"O))+S^H)21Z.U\G WD</0R:=U&)5AN2CW&HYK5B=
MG+P.ZGW43V461G;=+7,2.Q!SI#48M)>MH-Y'R^10$YA,=,%%5TG)N-^QZ?1Z
M'=3[*+E.=7(VOZXI=M9>;K2AT#<9N/+TEBK2O2F,HGERV;"6PSI?-[O\&@<9
M#U>R.4D;3M;MCE)5-;,2+W2WV2P,1YZ<J*K-\A.FOXEQRY'6+3:+37DTF> (
MQJ=T2<I+(^NI+DC3="Z;WSW(!:XQ8TM,3$X.8K4,5C]D#2@%&>N)=4.XC/H:
M/9.2S[1"@C?UB>V/X.NNV?((OK^LF0!BN-7E"6;DD].BWA+;#PK=GFYHL[83
MTOF+M3K:BRT_RWY:IR-?KN1\5">D%[<Y<OGZ^_H<):F[U),S#\..!Y_4>H)^
M9L)F"(A/ZP%"/CE_.@3$9_4 H>ZHL%_.38#((8S$DY-C0W"$K"MD72'K^E00
MO3P#[^STP>=4X$^Y"/>Q&4/F5?"0DJ2N)'@,^$  J.C)4].ON+5W1L4N//L]
M?7(]H[??S><T1Z(3=^1EQZC?2G.DD'QNG7PN=S\G:/7YK9?H;]!TYZ-:+SVG
M@'_CWDO? 0W>UWO)X;/7SD[A-%,2;#C&2] UM%_H]UP8^EPV3=W8PE%G$O%[
MCD<"BP1O$6->-H@5K]K2GP](5J%_[+AO:-M=^]P?DH.#C:,?7085\R9Y'X9)
M?!."()FA5!EWBD_&G=CDT6#3([LZH#IGF%!FS%/W5)_OD)TV/=YFJ5A9YUMO
MS]TYW&".-XPM $SP(*&N,"R29D>L9G)]KM@:-J5.\C%6IIP>4'0Z$HL%SQ)Z
M!5[Y9.&UR2%D R$;>%^FW<780"?7V9&/T:1)]HO6(#IZ+-GWO7>D\+V6#;0>
M5I5F959CH^3&-$<C3DO5UKB-%!./Q./4,VS@;>K1IU)!33+-OX2 ,QF)A6Z\
MLB/E39B''VH#^UG4#Z^@<KC;[5900>;V^XM5$4#^9F8TL:;SFCN7[8DZ@I5*
MY=D"VU1R&V[:UFS+VK$3W%GJ"57D)5;*JP)C7PJA0Q(.2?B2I0"O(V&IDXM3
M*D?/6+ICF;W*?;O#2"W<9NH)->+/5W>SP FN44LRYN">1Z_I,!7Z2&ZRN.<3
MK:>KG_55YA4:(4W_\V'>\1#I;P<10J1_*=(?U*Q=IASLW5CZ"5GK)U.(Y8#"
M'C@:7A90@KN 7!T$T%-H NH5X.H^>:][H#8T8K\A.H(V%4%3[>&\"E[;$BAD
M)(F$K%DZP1-[SP[ANG8(S[>#>DS*I@F;-L%GG)Z56,O6%#QF#*B$X)$;!E8T
M_==%U$&*'M(TU ?IRSFL-%DSJK6:FB?YQ&.V')TEV"SS87[K KBF8&=5G3>,
M(2ULYN-D+]4A$US)VE7)^)8:KH&.244 (03JF 2 8L<"1P-07<DJX#4Y?@&1
M,T+4:CGB-P0;)".:_*<F:2),Q "_4/_\P5@QU57P&029#T<08TC^8P*HN6&V
MX]":@Q2R!K!@Y>$$=?"^P[_ .W;??4=T@[$)  K@'*$#YB7#SNCH-80HF\*E
M,&M?;[)'KJ[^*:@F,,UHNY2=%TAYK.UR139+ZJ/UVU$-F#&HQL4I>@%7QVN"
ME---RPS$MG)9WH@6U>RS<U;JB1-SGE!B:]AR[ARR8;BYG,0 \)-7  LTR8((
M F2@:(8P>AI&SC45P,M<"&%X!8*H:_33S"J=L]E<2JRWAX6&H'<S $2I"!FG
M([$$=<H0[ 6X<4B&L!@.:!B$[I<)*2P3"%3_"XXAVN!K8!'\PIY!(.I'J9D.
M! 6(19#< 5PT"7^&6#_\GNP<!(D+( ML5246&!E=SF)(<U[6T&YLRX0( ']>
M&+(FR M Z.B;3GM &4DHTR*<<YSR$8R'IY\3:\ _!+@5P A%?!.&Y&SE#L@Z
MB1A)JKZ&$".@_F7A 0RB5SEH$CB7%=Z(?N[MUQ+N9>V 9S)'@GUC0?AA20WP
M$2+\UKW_ %X[!BA(5'C-Y@%3IQ!:Q."A,P JJOO!(<4#:$$?"03R)6E\7_<'
M?F&H"X>H[DL[ )'-3")S':E/LN9R,:M](AOF'S/+1:;1[++RC.H/[7IM5TP#
M-AQ+QH,E/@(T[(X.!X><%:7 %I'VI,1;+PTA+L!%#1/]^GI,]7-EMD.FV'6]
MUU6JQ7,ZV<4AU"LGR]Q@9"9(6E$3*WOYH(W) ^=?N5YXAU96=FZIS5L2N <+
M;$,R8&X5/Y$\D$5I'\S(U(J_K_<2)KFD'O.9ZDCH,&W E]-W\1-X_8=8P-ZG
M&M@2($5@,$ZFQS1V+89R!G4@E &W!JP4/ &\%? ' 7!!C0=8'8%,0+41^^8)
M>&O .D3XY'#K8QT2]UK90LZR $QY AX/S&WP^'-*)V^:$GR/:8]F0-+ +[K?
MD#:"M( O W^&T@?(DB#!!<N-$<//2N#@FB,#_7?NL$[\/:!U8J:)3&;T/IQ4
M=HYS\I:S<;@*$6(37()$_ ;21Y3&L@8X))(SCJ+K$W/80H+23MA_>X&^?9Y3
MKP%V^J^#%R%HD7A%(LZ]'@"*R01@!3BOM((LZ(X (L.5<X?2XNR9>2"\H70$
M:YQ8LKLSO^0>\2J2^#:ZP#/[1B:F.>6A6 7/$/3Y7(?VOBXH9^]0'GO' 3O"
M.S?!;E=0=$L:,9<L][L6( 3\7/<9?N0$#^(M= RT#NL[\&NFO(F"?4"S%> &
M_"9$<.>,KLXD BZ +TSD 1T2*UT%K,+)IH0"$'P/<(=#T!T<$/Q0YTV17Q+2
MT@9,"EXJQ%^H(S\C///R2A8E)#KQ[0V+*Y'<%$JI&=N(U_24WE?IA;;^0EKR
M^QAT;I_DV8&7BU"EB[$]4*9J^<?X)*'T5%8BZYE981'OW5.M7__&R;L@B0H9
M-+IIXG<@F9E(8<1P-1> G9F(A/$' .HC8*PB1/V#-4OX0%D7(5Z\4.KFAZ5J
M/$DV$PF52]B;;G*EV]*#\I4,H0\#<7<*4!XZ)KH&#TDYSV_/&+!L>FWT*]9(
MR3T41K0ZVS#9P>37OTP B)%,$&Q8I08-&Q$3^1:P2%=? SKS%O 8\#\1\)KM
M ;?\+?]!Q@]O3B/@%_Q;,&>+[.TB< $C[%QQEHXDQ)LA/W#-BR,>RR\ >@FH
MBX-K03DR0T1,0=SO[%GA$X$L!VP6[);W8RG:,3@)QN' 0]P1&<C_]S=S>B7>
M=>Q9[L*SM1"W\WZ#C-@U2.#U  DS.A1HFM\: UKM*RCGQ?KJMR >-&[@<'][
M7;4QSGBW6)"DAN:B=EG+ 5 %J[+%S<XLQK5<3UF6M%)1B FE<BX#^\@$J+)W
M!.=Z%W0!IYQA\>=I:$CO  <S!4,>80]AL';@0YP(Q'&HI,%FQ&8D4"L< S$,
M[A>ID8!.,5& %]G8Z[# (?PG]9&(NSNP7Z#=ZBKX3=A"3!WQFF+8"TL Z.E[
MD3X".O9*VBN_KF:\/]?S[O-S>X%UM,(4DQZ@%$"$$(A8W8'?6P/@@'?")[_D
M71'O9<& \3ESS!?HSL1ON#M H^ _Z-; \UV_KB-X"19^?NA.=A1JP%0 C2.E
MS=,QGU7HP<< (\"MF/A;KHIY7B\&'"ED$J]G$F7GELL:7)/%UYS=8M@5=..>
MG^F& V0$XV#&,<\WDP]6,Y/G.OQP%.-8>1L=0]_DJ?3]CZ,6H2<3!_AS(+?.
M,HL_"+M#8%\ V++V$F!W99:F'YODC%MVI]-4JI ?+:)0H3X/:_C@-\$:6*W
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M9:$!H6<>5%HA?__SN2G10N6!3ZGU#B=9XU4E$Z>9 ;6^1FX*..<<>^V.4U0
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MMA3HKP.QM^@J>YCEW)O;[[J#KJ6,>@"=,=_X<7^27E<F2DZ)*=EJ\;&?VD
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M##0X)-U!(X[^4(M#6B:T9CG/=#DA6QZUEZ7P)JG>U2W)*0GZI70[725CB_Q
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M(]4?@A^)  H0N %5F2O(=#A0YR%D"$ #@[#A^0DLH+$E@*P,)";PI&6X\(E
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MI1B+']B1U#D<Y;KC=7J<,1TN/Y/& RW=#N?@B:*G^RP7+4U9#9>5V::\2%J
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M'EGMC%.N=_K.4?/@N]O6%EAH2![4G4N1_(\>?NL:V!@7[O\@:OR!!VL:%M]
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M?^\Q88^;KS"WX>7,>O/Q:[8(KCG,LQ(5BU$2R<=B-,5'$T*,3\2B(D_0B<1
M "S-#(</'B&$M0%M%^OY>:;,:.UI"M#56CP%GD4'.ARQ_9'R<W.:H?6*V&;S
M37.0SBD]HN7PU.'(8JJC5.6G5;XMI J99!&0R6HTZ9WX[XZDC6>1!M5B2[$=
MSAYG"KV%F?"/*7=' DD;C:9TC">:0LG)O,2BF>H8C3QX>[7%ST;QX6BJ3'-9
M><$L"NGTRC\FV!WI:(G8S'F9]]I-^X7@6TSVA5Z,O+CI[LAF=KRJ1G'.482T
M^+PB%_/<@G;@R(.W=RV0:_5EO$ZLGKB6;(@+^J6(GIG8'_G,5/-63\VJW+Q4
MSLNM)A_'GT9>S&!W9&6AD Y38N/<M#AZGN)V84()CN?D[(ZTGF=1)\G%.:59
M227C VJ0YVOHF0?S-,VZV:MF+8H :II(5!=X,:$AQ^E@GLRTKF353D?GJ$YS
M^%(39:6MUGF6)_9'4O%%M$W%2F5%L,O3E1D?=E4<C3R8)T6_C-67SD0B<JTE
M5\B8F90%N1D[?&8*Q'J#]'.\K'0+@B7P;-X$<72[W,%(P D\QP)Z2 AIQUF4
MA\,Z77&\>^AV1W)*;EYLI*<+A4W4F]2DYQ034$+BA_.,&L5)6UHQ,C&U> TL
M!1JJ:=V[*6I/C\H<7M-&,YQHEI0F&S?*8*FA9QY0WD@ETJU,X:7<MI4J59/9
M3I*9CN#( \K'\C-1G:G% 2=79JLF4<FI8A:MB#Q8O!E?9OK#9(/E[$Q>[3@%
MMKF<HM;F!R.3;>E)*Y*M(C$G4GJ!S9;3@U[2NS=A=V3F&;2BPSB]4IJ3')$O
MV+'52P8]\X!,6>M%S#*KDJ%TVR.5PNW\]*D_\AJK[XZ4JJEZP<EFTL0T3F94
MR] 8L^NWE-Z?IR&\: /NB;"'S"B^J,DJWT;S/"#3$UM*%XJ3;JTM+)_;!C",
M^DL'C=R0:<]L61>>3XM1:5374YP"-S(\E5R"J6PE>324/MEF=Y"JNK?[(?O+
MW_VVPC:XUPW!Z\2#(DGFA;L'K=M#C 43DTW3AI.I-=OF(P;-=7&,C8 &#$%5
MT8 %P 3LY.?6ZT^WB.(&D#8!K)+S[$CEQ4R9CPQ@)_*9PC1__%CNC6X?WSZ9
MXY8SV5O2^E+,31N0I31^YB&:9Q1(U?9">)XR3[/ZPV]HB>#H='#?&\!4>0BP
MH:%/#[M-1+#V# JKW[L9>&T[(!.P,10C8*#.%@#: B9J?3'5-5]8= ,3!7.,
M^<T\?#ZZ7EGL'Q.39%,T )J[WPYCTYW";U)@3Z$L0%$QW9^CJ-D"N@7;W3^0
M'&#2IJ&,%^H]VA5J4ZWC]AWYTQ87&O&LFMV7=I%+CT ?Z* &,3'Y=I.*BJXM
MW%Y]^^%0%) UD_[*WFA*T5QT5@EA*E%*3FOR\_F<ZI1:SIF:4GS&<XM]WDT+
M9+L)*L(DSM-Q(IJ(A/7S 2P'IB)T6#\?0+[$(D2H+P'D2Z@OP>0+&:'>O9,F
MY,MU^!)WHYPA7X+&%S*2"/>7(/*%C#!AWYP ,B;<^(/)EV@D$?(E@'R)1>+O
MWD<;\N7*C:8^BLC<?Q.9CR#]_BGP493A_BD0RL!'GO/]4^ C'_7^*?"1-_@#
M*/"1WQ6T5DKKNRI.U$XIQ,&/'(G[I\!')OO5KQ;;I<F!4ERVP#2TGT/,".WG
M4 9"^SFTGT/[^>;L9_^.M]!\#LWGT'P.S>?0=+I'\_G$>T;%1@G3/V'+^"-P
MV+[V@OKHVHNWR),X<V'QB47#OUD>8">2CM"BO#F+L@&F@JS!"?X$@ AMRM"F
M#&W*P,E+B!FW9E/JPU.9#('F?6A0?E$N:H8LGBHZ%1J3-V=,HL8HJ!V>+:@_
M 1XNC@8D%8G?U$6+R='( "/W1J3!SS&:_G3;"*BJ?'2[X+N2\/:%<R?!"<^
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MN^>(J$H2^FCN(^T96L-F:H]^8R_4.=-+5V>VYN-U_$%? FDM[(+K:3^Z+#"
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MS90UM[LB84W=8Z/HL]E0U&#Z1#IJ7W^Y4Y;:XN6YCL(@(MKO;V\_:]=1FF$
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MA*&&$!(&;12K* ORYDYY:9Z3H]7Z5=MG[+GI$(<A>SI]YM0 EM<Z!!'#R0E
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M.7>>>[\[6?]DO^O-6FNOM=?GLY/GQ<WB5H$;3]0TU0 \? # NWX!N 7@$4"
MC__7^WH07K^)2(F(" F)R$E(B$DIR2DI*<@I**BHZ6Y04=-24U#<8+I!2\_
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M-*7-:D/">]V[Q&H/%WTS7UPU* HY*!$KV:PP[E\(=9DXOB\U9)(FZWK$/2[
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MZ^-^%?C1E<NCO2*[[BCD>CO_PI1>B)YH]R6N*N:I+A^VU6EH2YA1$G]<+=N
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M#5AW* E6XD)CHVQ>YEH^\7&Z/S([:]E/)=2!$PG^$G/RLS\N/8-C>U$1E!)
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MZF2>13 *"W??T^CG%2Y<9@R)5V?EX5S^-Z;$O]T,Z %\&9=FARAH%C*9!1M
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MMA.NS7,LS*NB\]'X5233(I?,>6730U^/Q=40!7:,7@B[Z+8-I#U_;5+,SZ-
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M@#SF&&MJ3;;IIT:,@J)?8RD*%1)W'$B _S[]_+\/>,G*]$S+=A)M\ZM(2D=
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M>)P8LV =IK#G-E%?^OCD@AWO9N;Y1FW)P0B\0_?SOTJA[5/$!6E67I]O+?J
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M(("P3[.*R;.R@"3[@/;ND)4V2)?_B*$228S._,)TV]W/^J ,_+2Y>5+A'CJ
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M^%GD^E95;6X6E4EVZ*N8IV4?*\L!"=Z"O2V,E];'#.A^T&VNN1DU5V83"20
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MHMM$S9!/A9ZK9RPK,LY3V3HH3>K8XF4#^]S@^\7&CR3>NJU4WC@X6W<*^#4
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MO-WOVLTD:0)FB1D']!0&-C7''NWV2Z82X< /L*NUH'%ZIIS\0A>6U6><3+<
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M\T@I]_N+=;EIGZKQYX??FHH)[N*O&;>< H*_^@*D/V$49Y-ZG<Z1U5OCU+Q
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M^6;6^&NM,=?\S3G*;PQ", N8=0"YNK*:,@ +&P# NOL ,$L 10 .-O9?U]W
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M2)X35!H&\-'R\I0+G;(T7Y[F&!USB<K8V[KLZTK?]5J#OR2+9,C-^P8^7\<
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M+C+94-^LT+W55D>\3]8I4! PZ!)/:_6[A%VQV'&2S%9R,%=67IIXRB7>MF(
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M^S3Z =C.^>:\;'D@WXCQ&^6*%'U<?V&*_GVME<]$\G.D?+\G%CTVS/+P.K'
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MZ;5^*]V[RC)M->W)+ =\M#HF_*-,C8NCUBA)C?WNRDZVP(*7HPDWX$WK&,"
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M--N/XHZJFC%9G7!XODQVFO268T:6WMBCWN0-Y-(F;^QUGT0:H)F"S:^733"
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MING[K+TY7&TK89;\B_6?X:[J(MUYRW[@8C+S(WY)U^Z?5K"5+5<K:A[ZR[&
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M3#>)@&^9O0W],[N13@2MC@YP-,.6*VNC,-+_04>W+,OMW: 9Y?V>8&"\/%0
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MA8.>SW ]0(%#LZIJ<6JA[C/EKR;NWR0;EFCE>WP_E:OHAI/T<OSBZ2D(+Z9
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MT!*"_=TZ!!0+SX6PB\9[04LL)EMY%ZRLNEXZI;]Z>/#]#H6[>E"S_?Q)E_>
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MG&@?)-D 4N/IL[ &]VIQTK$Y,R+5]8P)USSLE:;";NFXJB,"$#AR>GV<AU2
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M-5X[-^F"/W/@Z3_[F$QOF"FKUJK-T13*XD:^SGI3/"$"[)M>UK\1D+%&M-*
M4]:;X?&#U%((O?NR&K1C0NN-B=.)WY\W3BL)'[%A#=SKK;,Q7AT)4&<$MH@_
M0KWFJZ7ZTYR;<U2'R#S9^'=;\8K/PD_K"^_72O_L9C).*%=A?_-0_9$1Z6L
MY;?\O^9[7UV85\**A2KGTO,XZ"Z+L [EE625_%D:J(G<\-]!?ND_D/] _M^
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M;_=A/>YO[CWF6'.OM>:8:UJ< -;9\QY:)?SA?7FZ-N76DHN0H, ) '+O%UI
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MU,JG;AP:+GY(C+/02(T]_*8>0-UUAW0[6L"LF?* '5[4,M#2DKB5PS?=));
M%P]ED%6]+^"^W_I;B=*+[$:3O4?1#;B#U:)FNXV E8\C-FH5]NHMUED4W\51
M_1L6R VH3P,$ZK $3F8T\"0-#BP.%V?RR7>).,>N%^=(!02_,TM85W/T53^P
M1,#R^L=#V5=;)U%I($MNLU87Y'FV1PRZ[M]@[W_LB2RU?XN$E;T\79QW>E*%
M,7B_ON&(%4Z7UD/'U2Z/SF#SG[@YOK6\]_4SZ8%TP3R4"G;[G;^*2"G-!P'G
M0[^-Z7HM1G2WACWG[M5E.AL+:!<]T@AL-E'-8>"A7[TKEGU&ZHK]EC>GTPE
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MM^4S-Y?!V8[S=L&[Y*&N/$;%XK *5VNF^M,J#]&)ZUEUG2"4;J: BH7+_9I
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M#)T[A](!730"PG2P<FO(IV2%--4K)NK-]#Z_=DAMOR8I'M!.ZHE04YC+0YX
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MTVR'R/5;C"$J(0[=*$6.$\!DP.B]7O7FJHAYN9M]!.- 6M[PP(CDX!IPSPF
M 7.5K#%DA"(#,R8,2F9*"EV$D0M[Z>#/@O?K0+5H9<'+6Q-T99P DGBHB+L
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MQ,Y>B\=W\"$18F^[&&X!A7[*0N=^RD(!V?_+<M[_'_\>S">3_P502P,$%
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M/Y6)TAA!53-0C]KD\)T09[40JDR<58.H346]]^M",5#47("&#\O2^Y@,L3=
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MMYT=,^>^^[)2RP<_9&KYX7GD6P%>P_PT\MY(.#/XRXVGWO'_ 5!+ P04
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MEFHXEHF9SLH*7P)[.2JK*=T+MRCXP@*?J).%KI-9,X1Y@TA2E\KD1 <[&UY
M4UB3Z7@4-UK+0:*&95/'D\5=YB]!S06V["<!RX@</:7+D&AIF>83D[86*YDH
MFPP;BR? PFF D1=CZP[XSSI53;3N>$3@LKJ$1Q@\&=WIA+4?XO>)2AR3Q)MF
M53D"'79D"C#%6/P#=0R;!6XS3,3J'%\_P+_A9EM.M4QKKA9N< -W(&4&))F^
M>VUA]<KT,]U+?^&@57'=JBSH8AA79FR:ES!/V\#JM&BDA"G 7$$"SE15+V !
MX?(2EM/ZZ>RH39^SVLQF6M^(-/9C2^@^L&"-RT<V#:ZS&BL@IEHHJJ)]0J(
M(E-#6^9-K?>3TSI1LUF.Q+RIE=:7NDC,:*VE)J++= K6*%,&$9/C($-ER2/
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M72N3VT$2?$,86,8(BZ68J%?>1TD*WU(PNL:XX+*O[/GWKVT/A6[)\6[(<?P
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M!C&+1- #IX3.!O*T QCL;"H"D+;:#R\":!-4Z0A%E&( $F5B0%"8W810H/L
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M[L3_QHSU2!@KK>1[XJU9%(-?AP=$$?N)SC/.<&OS;=QR.F0U)OZ3F>@O0==
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M5_K*Q"Z7YF(\IO60N0H^-.I,T4*GTHQ8QOVZT6//@&:>?<39%,V*@>MNO]
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M"I8H7!X/PW G*;D0J.:!A)F+A\/^X<&US> \OS9JBPXI' .2.UR ][[A-Y/
M39QJER?;4]PULNS&S;1RP8P7*%?Q[@F7F!K<_6GW(\@%.,PX/5NN;&#!X&PW
MJ;M;_ MH712A1 5!#LU"^\.CQ,&5"\C+G*;SUJ3!)"8XF/\,VP>_!N^K6X9
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MR7&NNW98A7=<RO:*E]DPZ42)2U]FN=(EZ''X\?OY:QC2O'[&^P)02P,$%
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M\[SID6R)>65OWX3T0R3 @7JDH$@0A&P%YSR7UKM\5!*%[X9RI56PZ :<<)(
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M!N-0-/([$7Y[,_0_W?D_4$L#!!0    ( ,N#FUFY:W;,D08  /\>   8
M;W1L:RTR,#(T,#DS,'AE>#,R9#$N:'1M[5EM4]LX$/XK>W1ZP$R<Q D4<%)F
MTA"FF=*$2<Q-[Z-LKV-=;<LGRX3<K[^57Q('N.L;T)8[9DK-:K7:?7976JWZ
MOQC&* Y8[*(';^WW%^ )-XLP5N!*9(JH2ZX"L$62L!C>HY0\#.&-Y-X" <QV
M\U73[!PWVX9QVB=9PW*2B"TP.ZW.4:O3[AQ ^\ Z.+&ZAW#Y'O:N[.&^9@]4
M%-)O9-YI/T+%P V83%&]WKFRSXWCG=.^XBK$TWZK^K_@=82W.NU[_!I2M0KQ
M]4[$Y(+'AA*)U6TGJD<S6S1\B^?&6')/!9;9;K_L)<SS>+PP0O0549K=PPU-
M\D6P(8J4*T[F2 R9XM>HI=?DNB$R:3E"!;W;2]PW,ZGF^2)6AL\B'JZLW2$+
MN2/Y;F/W+8;7J+C+Z#ME<6JD*+F_V\O94_X7DFRR,.0Q&@$6BC;-DY["&V60
ME 4MIZF] A.+F$'_,SO%A];!6>LN0B&M%YVNZ7?:O2V-;!YA"A-<PDQ$+"9M
M<HK6JJ;0LM# $:%'@D<W 7>X@FZG:?9;#CDA>1*#78I6E#6+']/(X6AFC\_'
MPX$]GD[F,#V'R]EX,AQ?#BY@]&$TO++'OXV(3"RC&0PF9[7Q\_%D0)_T58T_
M6Y@NKV;SJ\'$!GL*YC%<->?-81/FHZ&&#<SN8;OQ3&U?!ERAD2;,12N1:"PE
M2V@U&,QA<#:]M$<4$1MPOBL(3[8S5'X_:;_2&6._'<%\,'LSF(SFQO3#Q>AW
M& QM/=)IMSM/"<D?6:JXO_HW3+2TAX!EYW3<@ NVE$AG+0R:\ [CE8@;D&0R
MS1@MHD0]5=#5AT>1*L!28)Y(],E:9Z^8-*["!Q4@S)ET6(RI,;T)<04#5^D1
MC6L#7)3:6N)C*F<>Q''&0IAA(F3.-\U4*,1'L .DL,6,T$T;,([=)NSI";^^
M..Z0Y3-<\%1)TB(GF+U].O#A7,B(*@+C'?A"YO)7=#8"QAZI/4?2/G)00I?L
MR8N";8E:A;4T/PO#%;@B2D).L.8EB.:6^&?&)>KZ)-7Z;E#:8Z2#!/-PS]LO
M\$IHKLN<$!MK;-#-))W))'%T0\5&3"5,"9!YTCTHID6YOO0=>P50/"9S(I:O
MXY++&<631]1<9 F=S[@DA2G?TUPU&F54)M$L<CXA3/2$5$WS.3Z/J=[29!+G
MY35"OAHQ96%AET@(?SV05KIO(&_V6SKRBAS1E4@>RJ]W="FC:R9M<A6PCI >
M2H/B-F1)BE;U4<^15Q3G97KH"D:;2#9L5T@Z%[;+(TVI%3MZ85FM6B5;D4#*
MJ^C7.OY<%I;)1_5:*:)[TCPZ>%G?GLO%JJVZ5G#5A L2Z(=B:07<\S!>_YWO
MN99#I>A'8TD(?+*(6X\S)Q5AIK"G:\F[)A959?E;>9]EVV'S\+E:=O"3>JVE
MI [7APG-[W)*/>S!=$;;E%7M*G6Q7RH(SM M-OG.4;')U_>J!\J8QP+\L=!]
ML[+@JV HTJO<PNF&J41$"70#%.S<@Q?M_.=Y1V8K;=U3,]U!\T$3^@</TR=$
M?T+%D/7MH:MWY?]4W/[3%?"^+?;;//1_;GROW+!U2_);DN/Y''##@*,/Y^M;
MS=3W.5TU\SO-6+<<> 0%S^B&;F"ZDJMX?HIH_<D<RQ^LB9/+L;@B!5V2O'<I
M.7DX(1>O'=FH^5W[>^"Z(HL5&5VY>+_?XK<=W,HOJ55-_@"PF%\6[U^&Q;;@
MSG$IN"K)CDG^-4^YPT.N5M6M9N=4-S/:W5X]Q'^,CM:C!<@ 4E)!O_Y(3HM3
M2.3-"Y["4G*E,*:%Z:J1ORZ5G1P/G!7,LA#![#+#/-AS]K^Z6W-_\PP"XG.0
M%D^DN.:Z%Z7$K99*/GVI'[8<W6,J6SS.ZCXV/Y,Q3X.-F)J>>GRMZU!$$4]3
MK8>0P%6JK?=]R!*B:/,QU;T<_I\(#5M'0=%_)!N*EI>K^WLLUL!I'#?M0P*6
M2B@W(- @O_MCV@":'PL%'E+\D!=X6#U-?J8/-+V40?+)S[27"9D(F;]7DJ\E
M^E@44SPF#A:O]"IZ)[O3@H.,HD[>7GD3G-WMX!1W6#\=T'O+ &F2A(AY2.KZ
M0J(6Q'Q5KNR1XAO5=!MRGU"29:M1'[(TJ*U88(R2DG%CL,8CI/4S1BIL]333
MC& OS-[$9KV!$JR[? YS/RXD[?:>449+6=G7GD2W!\JX[-R*T^HNL/486Y*V
MWF)OO_,FI+Y1-(QR6"QV+;A7GL9')\WN^@I2D-KY:5X\'[?RU^>_ 5!+ P04
M    " #+@YM9.=4"(2L7  #4K0  %P   &]T;&LM,C R-# Y,S!X97@T9#$N
M:'1M[5U[<]LVMO\JN.G-MIV1%-EQ4L=.,Y.ZS]ETVVF\M[-_0B0DH28)%@ M
MZW[Z>QX "4J4G62SB7O#3AU;%/'&^9T'SCEX_E_3Z7?56E:9RL6/ES^_$KG)
MFE)57F1620]/-]JOQ:6I:UF)GY6UNBC$-U;G*R7$T7SV='9T?#J;3Z<OGD-=
M%Z&0J<[$T?&CXZ\>'<^/3\3\Y.SDV=GQ8_'KS^*+?UY>?(FOKWU9P+]*YB^>
ME\I+D:VE=<I__>"?E]]/3Q^\>.ZU+]2+YX_B;WYW8?+MB^>YOA;.;POU]8-2
MVI6NIM[49X_GM3^'DH_@ZYUW;J8;G?OUV=%\_O"\EGFNJ]6T4$M_]F1V>MH]
MLGJU;I\9I[V&P5A52*^O%=:=U)H52MJSA?'K\]T&ADK6L=S25'ZZE*4NMF>?
M7^I2.?$/M1&_F5)6GT_X"?QVRNKEY^?TMM/_JZ!J&)Y7-WXJ"[V"RK&OYSS^
MLS#T1:\1+G8$7]''C:+1+4R1P[O?W:SU0GMQ,CMZ_F@!LU:_KS[VNX1?QFJO
MM8,V"^VW9VN=YZJ"%_[VV>GQ_/'Y\T?XXOOL1C)5&>QI99.."?QYRK_WYZT_
M4=\JEUE=XX(*LQ2_J95VWLK*8\^/OCIWXK7*&@LKKMQ[GLED"'\TSNOEMC^Y
MEVLEEJ8HS 8VK]!.2)'W>^OAC4S6VLL">F2R*WSX2^,+8ZX$%+>R5HW7F9N(
MGZIL)K[  CBPX_GYA2F![K<3^GAT'A]OU.X3T]CVD;'Q:>/"LR]GHM]1UY0P
MC&VOK]#YA72$'M3IVAK<+:9RV&-H0;P$9,KA!5GEL C.$]9<* O3HC/X@._!
M&(RMC958YT1(F)%0JC>P6PK%/D\.M_G-MI ;F+"T2G[6%<8"^+6LZP(:6A2[
M(\(OOP5XV$BKQ ^J@I4HQ$77#_%*;GHM?/O#Q:MT0F'"=+4TMN372[D5E?%B
M >L-ZU8H&)NNA 3 MLK5*O...@7%_FQ@2RTUC 3(0@-&;<5B"V\ME57 "X0W
M!U;@]LG&-W@:VM%CGV>PW6XO2J^GI6%&EKK :7=",4PY[!6M2%5!]V$QH+3'
MS?(]3 'PHNG?\8W-6F=K:!I&N;.YV@H3W)M]0%*]%S@XW+/;P"_LS ^,:_=W
MLG OR\:OC84B^0ZT9D KP!N(7I[.)_,Y_0@'HHVBAT"9)6Q'>GLB:FG%M2P:
M)?Y[/IL?B5I9?G<7A;',:RS3QY>CH29JHF,+?7NK5GYMB_4:&BGD3@I)UV<D
MD]@SW1=$\>\SI!2=P;?_8SR* ;_A-(+(I,<YPYY])X%UK6%3 8'N8 4R,.35
M'GD8,L)*B6OC4::R0F$YIFC##!]$ A!W'<A9BU)[SV4DEPBB!U7+C3D6S^1R
MJ4F8N%;MF^$%PK.GXABFYJOC)^>/'\9:KGDA:[/A/F/CX2OXJ::F\2 S53D)
M?1T*IJ YB96@K"8<_ 6B4E9(!P+6!M5-$&BL^K/1-@P#)3*1@3@A0;QY6QE%
M5UG14'>2DJREP;-8/?[=R2,3%J*Q2RPU+8RT.3_%U8TMA\=6E0;P%I_FT.G,
M&PM5Q#]%H27O.!BXS$#WUC@I55H#2FL::BB5PFY!Z62U4,C3F8*',O/4?9#=
M-A:7N2(&A.H[<@=U T-UN)I_@'+B<DVOCX!^-SQ]JZ\U=# ?H2GV['6S^ .V
M+Q)(W>H)()*OI2?% [6<+9%/M14IT>])(PFBX([O@1PB6(IR0#$*]R\0+RA0
M6ZH\CVO#C;=4TR,WZE.N@&01$QN/7RX;+%2H%6 45'4M=4%:&2(H554W@!..
M,12(K)IF3=FP^08U4^U&TKF;=%YI0.J<P'8DGM"SG]B@H:X1F<.^+[IY0M[@
MG"D:-ME8X'I,.TW]=N3"(D DEJ#[ ]-2'EE<">R2V.P21 -0"K9EZ$YD2,B'
MHMZ>="\A>.+PMQ/X2"-WTPB+O337OW9@.I)+Z-F/MVSYM00PKH@)J;)&:)Z@
MS',-[Q,E@<";6#]!)(7-; 49REUKDP,B04*ID,'D5 V_#++G%6YIY!2I>)B8
M\((-*NT3"\^QB90[2JH&^!4P'=7:_.ZB:->Q6JP .1E(P#+',:*E#L1T^!JE
MT"W5QRT/U-[)VTBSN!:J;76':ID!;E3@FP[61K+Y$.M<-KZQ:J3L.RT!.S:4
MT1B0V,P&A+2U=&PB9W,::D1XW(CRVK*Q1+FLXN!6QUV;ZJP3)!#@FXT"/HE_
MOXDQ#'<TJLY [*5!6F.B(%PP8JEOJ#]54RZ4G0S1]"0E:"P&[7BK@R)&V&*6
M[Y-2_B(K#!#HW@@$,],4>=#"52O,MR4[+&\?!>M _ C"2TE+VV'WY("XPHWW
M4)U*=X<SO-()6*+^# )5PP:)!#8MO1^A,9RMN08-+_3&A 4C&RT@? X1P'M%
MY^*D9E0[F+W/27!/RR!L#4$US^ N/QBTQB3,H,]F6BGO2A5Z;4S.#(#&$PN1
M[25J8.U"!;DQK&O\T-10=[((,P$R+YZH\_+XG6$-#XEX.PG*/"+$"E7(+0P)
M1&0J0789FA*4I6F-T&^@6A&O@L7SUA0=WX^6'Q5P9"9&.+Z+A[U.+$WQI)OV
M>S36CCR->G81#) [XIQK/0%26V.V__*3AZT$V#M"VJP-B8%HC07-K/7!B56$
M0HEE<5<-C&\&D*'2X028C2K)HG8@%KLM "85HUWGU2!>,CT>/7O\.#U4)\1R
M*BU.*F@D;Y1A7=LB"M#=FXQVR8QXYB&#+P.F@1[K7+_W881U8Q%;?#RW3EC$
M_LMRA:H#HA:!U(J/-QFC]J:FE2/V)/7=-M6-LIEVZE"SJL(1N9Z,CD6MS%58
M FXL2D")8'%X239K5>UZ&?1:)X<%4O3I0)P,8GD 6,#UF?A=Q2D 5D((3!-$
M2P?POC\MZJ96%2P%V<VHX\,-PL9D$":F1R- (S520ZX=(#Z]0@3+[EK\[]I&
MZEW([&IEX;U\FIG"V+//YO3?>>)VU?]BS4!V#/19Z$I-P^=Y(-PI%/&F9"^Q
M\"CQ  M/4@>P7=>R6J[4= ',_&I*5I0S66SDUIVSY]?IZ>SXY.'YPE@8:_ &
MF^^XC/W_=$0;!$@03@K"/B ;8/ZL25>MPFEEY9:X/>0-8F4\E6(BX"T%4AP@
MS ]Q>T[(I)7L)3SP,+"5+4D(6!SZ+5=D.HOOH!RO20.>M/H&3>TD5;3IP(6.
M=D"&8*F%%8Q"E]H/BXHI):.<%V1:(JD2)D0TCCQQ2@0&(B_8.,X0#B %&LL^
M+5=*U?MDUA%N2ZPP**\+1AMI"\V](;&4SKJJ('2RQ\\@BF;F&B<5]:E;2)=Q
M8*%@>AT,<$)B;9 ./>P)%A;]'GH?;!46#7<#OJ-MG#\&M=\:>/?HY"16L0-P
M>6.C).[7@$M30&!@9S6LN<E'B\2=TMQ+V#+32WFE<.'%K[W#TM;Y#!W-D#+)
M30L6!U65;X,C\"CP#?9LWZP[)$HK9M_0W];A[X>+5Q^YZ_=J4G]7NS;/H4F[
M^.'5)(!;;4UP!Y3=!DY="9?6E"!MK9@/$,< ';QQ(! X!,!RH8,"3X(Q?JO1
M-QC$K:B/!NT'!1P9H(:[ @ DMH"]+ARBM-C;:<]I!0N5@9R,+&NX!39WL8FU
M=8U5-YDBJX8[N^<[! 40JO+K!RB_H,<^(W^0WU@. A&MD+539_&/M&M/H?$@
MI:'@@@H\8$Y?+&+!*Q6*\$DBXV##%G[RMO_H 9+)(@RXA#$4*I28S^9/'J9C
M#U7'>7CD\S>H:@V"Q=35,E-GE=E86;_7VJFJ9\\2$72H+IQ^GN.O'\P?@-97
M%.&-]C/V,'Z^:U5 **\+N3VC-3Q_#S;+*&XG3U"0IMV(;4RA-5!TSI;Z1N7I
M>G(7TV&&OO>Z.+5FL_-]J.,4"O9?Q;D8C L9>.W?&OG.@A+5P: /;QCJ;']A
M__;9LZ=?/3M_H\[N;(D]#O6NXTC86X4.YD6/O85'#UXLU)*LZ A\B(,LA ]8
M^F,<0NKR7>,)&RJC.JB):ABF@^F5%(9P'$!P"WC:%(BHX91J!WE-R8+C >SM
MD"Q1/L._2*2/$%(>T53'YQ\ B47\>?QT?T53E94VVPC3(TR/,#W"]%TP3:<S
M(28HB0I[SX@:CGF&96FSJ3#XQHM"2>?%Z9-=#^(V-&V73Z2^1L'J$&P0_1$L
MU$I6$W9ZI9=1? \N?8[/DM NS#Y0^PTGK7RQ:#Q%4N%;Z1?]$C2BX(,Q/.HO
MX3MT*(QF9"KQQ=&76 K4"H=Z>#3W=[P2-7%9.(.F+9VI\.2+XR^%@A4T6Z6B
M";J T>-:L6;4?EM+W-VZEG@REQL:2GNV1M",>E:<#ISM:HF'>YZM5)NU(H8<
M>KU619[J9Q08!BVWOMD>3P(L[QH9/B'3AI7@DSDRT9WC*$:>^S%X;FPUU'8R
M.^5QCIQXY,0C)_Z@G)C5&38>[6I-0[J/=IV>%%C-@'9%'*,+2908_@'_4Y@L
M'M+UHTF& H#8(X:BA_=B22:QY:'XH):C#T8''62>)&[ X+#%-V"DLT^&<7PP
MA_3VW#NUM^9JB7L0V'@("AW:E#'.']WO@AM7SX(YFBU'?7CDPB,7OK]<&,]\
M2F57K*<@FS-%]![5U;4IKJ..N)NCXC"+.F=O45D@.P^^#1-0E!1F2FH=$G$N
M@D<&N5/-'[:NR(%EAG"= 46XW[-#O4@TM>@'UITHL9/J ;W?1;6_\]2TG9M&
MX,\]S3P$%AS2W(.R.-I?1WXS\IN1WWS:_"8%W<,\AN XNJEU;O @9Z/O6"P!
M"B'F/H("Z'L0$C\D2AWIF- F92P@#;"-_=IM< %JP%('_[0WT,0^&FR/&#UB
M](C1(T;_IS":W5<SI6M_.P)&%&7D]%$*+HPD^3J_EAPGN&HDIHA4%#-(:H#K
M]("EKC#QBRQB-93$A3P=K&E6ZUV<'D]/1C0>T7A$XT\%C?5=!NHJ6JB'03K:
MJ"6]2L%Q!*]\ZHZ'[AC=L>*#[M8)E[]MD_JV$7CAA,4YD]''R9[8[":<M\6O
MR8;2^0G75B.JF\YO(?%$:,TH!S@-!F0T3N0ZQS8FXNC)GKGHL'O"GJQ_/P]1
M[K5W^B5I5+ (7H48Y>A^CNM P<G!D)CP=A^C+="VN!>;C(GYRIKCIS&#&RP0
M+AY&-U'N#0J-LQ(*M6]B$&5&^>\$[ :,?$:_$I02Z A1]G1+K(0<+O82)O!^
MJ5%S;"JD!XQ[2J)R.#+<H\N[U1FTOS#!9P3#K:6F8"Z8GBOE^8TQ_.;=PD+>
M.HTUO7EK(FK N?#]&%S2]>QE:?"X.[@7<R+%NS)$TOSRM(X'F7>*R<].9U]]
M%#DY2K+/3D9)=I1D[[$D6Z.D=S!-Y3ND,)IT<6MOD&Z'3<G;?EZO-#-%SR<T
M^!J1^Q!*'/&DLLVGLBO.C*=X'Q9LGSY^>[1]^A[1]O&(MB/:WF>TQ0#W/$E0
MD+A%=@D<^FF"\;X4PC6\>2;>A-*E8UT>P.X1^NZ[.?;9?]0<>ZL)]2W-L<<C
MK(ZP^E>!U0.BK';I#0FZ(ILG&D+I:0C!^O3 <\QM]6%S6_U5F=5X=C@RJY%9
MO6]F-=F-7.T2[_9SHN_E0S="%5ANX 8?5AM85U!\VP^4PW#C3#9.Q4Q%\1J@
MH&.HD+9]TD_PON44<\'%N\1H97+!*^2F#;Q*LJRU\582ZOV#DF;?<143LNM;
MKF+R>]>#IJE$*<RKRP_)D64T,4$W^@0Y^LAA1@XS<IB1PP1U"&&VO<<MM:Q7
M:@.0&>]1;X%RK6M'9_V3$)B#-GHRKV^T2VZZ:WD 785;=([9@V&X/6Z0G"]@
M?F!*&HVI)";L/*"7P$.<X\2\4OS9&-N4(WZ/^#WB]XC?GP)^!XP-^ TB> R&
M-)3/1EZIP1MG.*MS(LJSMU3>(,Q+@NA;DR[TZFKS+20-[E[BB4ET4-:VIM(9
M>WF%3-HC6G_":'TT.WD/1QOQ2/ED]*!Y%[2>STY&O/X8\G8/19U2=+<37TM+
MH$G!D4X63H3LI/(@!K-G=F7(%1O-(%6.:0#"W1:MF4.Z-->.OZ5"8A"QMR$4
M*%S73'G:^/Z+29?BC>\=V$:I/]RLY**U"KI1TLL!LUC4W_%S)U]U;F1D"Y\P
M6QB%^'O %D8A_N,PA;ZTW=W&U4/GX.S#HGKT]2$#^%JB2>46;Q]V',_66BWQ
MJJ>L(?-+R- 9KJ1SE$03/P3E8>"4/+TV2J9^1C(W=;C4==^T[PV:YSL'IL2K
MJ3/ CR&B(_Z/^#_B_R>"_V@\B3R SEZ;LBE:J[A.;XS%6WE9%8B7K.R>JNXA
M;G= VKOU;^]L--PO,W@DVATBAZ-8NBZF_;8]C$V5#;JLC#SVW9H"#D%)R-;&
M.#6&;[Y3^"9=5%E&W:F*"^Q4>L%[4+]BLE5,RW#XY'TPT^G;'+[?OJ.ZT_:0
MCFUP;[77(K=1S!CJC'<=KXK@<C>&9\8]T+M-9&#Y43 LY150L^?@ZERC8-<4
MGF@3%U'=:-=%5R<7>%H%N(BY\H;E/5B5#<;82K8IR(H#:3!%.P7@F@6EZ&MO
M+EYBB"]YH&.U9&,8K'@FOE'D;7*HX9A$BG<D=91:0FL"!AD#OJVX<$PS/]F?
MF'#5-%HJ;IF?X;D9&FW(:)7>V4PW-I+A8^#.Z"CGMDN'=P:&(*9\SV<'N^BP
MCWA7K$9I,*[>;9%7N[50=%4@KC;P*;H-V5ZL%:D>X4+SLE8A$:YKL@R/5P/>
MA#!N2L@8\N'37;*TX".-!AKM[SM,:(8Y$2C@&?=-M293VLZ=Y<2=\1KPAE9/
M\H B;N*%%TFNS4,$"O2 Z7=J4^A,AP ZO!ZA"\3/#-[@>:VZR/[:XHE1#+<#
M:,F!@= ]</&-A<Y=O!QY9V!$3KR->72P]YJ (-=-@>@?!@+?K0W,5]%5/-B_
MD.?34Z?"M@S*;N/X8@;HP\U6+&D;S\2/  K7F)^4$@CL$?S01>RQ.1TCJAW?
MM =$1VPH7/N F0=<2W=!BL(N8W]NN> ]T ;E($WH@])=) CQ$ID<'8_]V2 -
M#F 6-D13K"O.U+ LFLPW!"%MBM,TC4'/5I#2-*=%Y6%*K(*Z8QN$P+Q;ZIBG
M@2Y^7<#>5-=) %*;WVF \:3>(B'%'\$:B %9NFUKX_EV#I'LC$JM *1PTW7Y
M2]#T7;6R#J#ETFI8F()RGS24YC;3#)UL)$]S2^#8\,YIG"T;4:JLZ>9<$%](
M_@XBK"/;MI>KZ-:?;(Z$2((A?D(7(2*OBGV.C'COU?[,\W6_ *T8E!IE.,Y6
M05=\C^CY;@DH+M8F[/OOT?5G3!G1]>R7-TD/@:3!*2+$7L#A!7Q)^_2"6)9M
M-<K7/M37WEJJ64(#JE14+5U=Y)#1+'%9@L"(<=M67[-F&QP52 XQF5($'0M*
M&>>%8>A<J+4LEN>I8P,&X%B2:*3 $ \ ?>C(4@/?T1*ZF#>,*0VGL=DQG!ZL
M"M0,#="X N9#UUT#>].4I+1GY82R+>2EU^"^02Z.T!F>Z_.8UO1->A(OF%@A
MONQF-:T029=+J2W>CY1YJZLQF4VK+:D*-EZF(JO!,TX-K4DT?T?<X V:<%UD
MVYPB@%@&"%+A:)*DD[# +N2R3588U12Z:!SX?U$HBL*%N@JU@C7J]GBXH$33
MFK;B/7OXL_I4!99)S!"88)LHBW>+Z].,0P$LLWJ!/CN8YVA"<@62+G.@I0[9
MWF\9,\HHL.&XQW?N978N EFQK@&6R5A-3+F=[F+<@]RSV^XS?\6JYG@I><*O
M>O8DH(]"4R8Y>(3D_ _I<OFGN @Q'C^SY-N0N$[L9UO"W,9T>K]<OOI[2)XW
M[L8[=^-EO!WAY0JE4T[-M8+IM]*.6S3A*>TU$K*=*!LGJM46=_?Q=Z"7@-HC
M+BVZU5Q$7>35JXN9^ G]9/+<HJ$%7CTY%;^CR?6UMTH!3_B^,%#I\>,)C>-?
MQE[!7_\21_/Y_,GL@\;E_KM!N-=&QP.J@S&XCQ8FW\*OM2^+%_\'4$L! A0#
M%     @ RX.;64T6\F[F$   _;<  !$              ( !     &]T;&LM
M,C R-# Y,S N>'-D4$L! A0#%     @ RX.;62$DQIZG#@  P-@  !4
M         ( !%1$  &]T;&LM,C R-# Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M ,N#FUF7)J\"C"\  ,0> P 5              "  >\?  !O=&QK+3(P,C0P
M.3,P7V1E9BYX;6Q02P$"% ,4    " #+@YM95=!J!S!M  "4?@8 %0
M        @ &N3P  ;W1L:RTR,#(T,#DS,%]L86(N>&UL4$L! A0#%     @
MRX.;64+'*&I]2P  R*T% !4              ( !$;T  &]T;&LM,C R-# Y
M,S!?<')E+GAM;%!+ 0(4 Q0    ( ,N#FUG:F0IY6#@$ .F3(P 5
M      "  <$( 0!O=&QK+3(P,C0P.3,P>#$P:RYH=&U02P$"% ,4    " #+
M@YM9]_C2%#25   ,PP  &               @ %,004 ;W1L:RTR,#(T,#DS
M,'@Q,&LP,#8N:G!G4$L! A0#%     @ RX.;6<2@O(FFF   V<H  !@
M         ( !MM8% &]T;&LM,C R-# Y,S!X,3!K,# W+FIP9U!+ 0(4 Q0
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M,S)D,2YH=&U02P$"% ,4    " #+@YM9.=4"(2L7  #4K0  %P
M    @ %0T08 ;W1L:RTR,#(T,#DS,'AE>#1D,2YH=&U02P4&      \ #P $
)!   L.@&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>otlk-20240930x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:otlk="http://www.outlooktherapeutics.com/20240930"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="otlk-20240930.xsd" xlink:type="simple"/>
    <context id="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3nC_oDhzvUyW3kv-c_voPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_3_18_2024_To_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_3Dv-BLq7jECeFMzClAG8Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">otlk:GmsVenturesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_9gDHf8RsIEKIozNakQyBHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_tMGVlJe9F0SPML1If6N2Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">otlk:GmsVenturesInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:DirectRegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_14_2024_To_3_14_2024_VWPmRYi-3k6pXKO7spUdzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <startDate>2024-03-14</startDate>
            <endDate>2024-03-14</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aqpTcTgcvEKqWIkMkLyvSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_keL3bo7nE0CNPVnUOmT-gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UoWGYXeAcUmQc5T0sAOkNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eLtmRbHPMk-R2-bot8_N2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0N8PxP9kEu7Rni9SApcXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nab82IT-Gki9oEVbHZmkcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6NrSVQ0gRUCQVI56arDZNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tVVfsw2X4ku21-b-wI1Fsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_t3JCYhRKO0qAD5NVNkzh_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:DirectRegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Eds8gmT6BESQIrdG8MwAiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_pJJcoDJ6gU6lV4j5MOa6zA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2024_Z5sSwB3u8UeB-gHP0Yk07Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2024_To_8_31_2024_Xa-tuAfcY0uN_xgNYumOzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MinimumMember_8zXwjUyVUEWsaFBUXYo-Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MaximumMember_HtgYYVJwm0iJl8VrJguejw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yuNthvJ5dE-37kUZ9LB3Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_urH4VPBGPEWtUdqeC7Beig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-10</startDate>
            <endDate>2024-12-10</endDate>
        </period>
    </context>
    <context id="As_Of_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RHl_XSAP6E2hmGDCfAw-ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-10</instant>
        </period>
    </context>
    <context id="Duration_4_15_2024_To_4_15_2024_PCVHwACz-E-GaHioJ0Mb4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <startDate>2024-04-15</startDate>
            <endDate>2024-04-15</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2024_To_3_18_2024_T3YCPqRoGE2MDvlAJH7KjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_6SGXL8bLrEG6_8cW5MPZcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:DirectRegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2024_CMktv_oZdUe5aaSem6VwXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-05-13</instant>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_P56yKUXSbkSeAJyaiAzVzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_MHzt-sxje0CSeW0EsqpjLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_xm5rwmnSsUqyr_jq4s9uow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LKsDtuAd_kibOfWHNXl-Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5I3oWKzZqkyIrUS7CKXITQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DOx7DSkcUUK1qwvbqatS0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-22</startDate>
            <endDate>2020-05-22</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_Wd5dAA2oOEitqaUmu8NEFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_Q7ljKxKDCE6cUaMIlRBFDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_RangeAxis_srt_MaximumMember_jnZ5DzV7xUyhrtJAXYQ3mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_Sk5RTQxSUkKzLC9zG8VQXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_7Nz6MTqRk06UkjKgAzcXCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_SE9TpsNiB0SZh02vDR962A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_DIM-yieXZEii39hWIo3zyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_jrGO66RARkOJ5xdVUtPWcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_2gdPZ9SMLEuQPHawoXcHxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_5_22_2020_dei_LegalEntityAxis_otlk_PRCJointVentureMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_gJdyvVXshEuX-08Mf6ndHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">otlk:PRCJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-22</instant>
        </period>
    </context>
    <context id="As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">otlk:SyntoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-22</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_iTKqGJl7VU6tkLMN2O_qZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_22_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_bGKy_9nKJ0yCir38nGdxBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-16</startDate>
            <endDate>2021-11-16</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U7MnAhTIHkej02WiFwj3Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3IXjRjrvOUmxyOEeUsHZtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_0FNNd0MQSEGbVAxJkUYUBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_9bYKF4TI30O9lev1VzvfWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_tRV5Gx6Jz0y-S8KiNciwMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qZPC37xTWUe1Gonx3VN-Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kUMWn2QlUkGH1AcNmJxH4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7-lVNsEf202TYs18lInWUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qJ_fPZFQk0y4wnAgsqRsTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_7lqaz_2bqEqu4ykwZdkCvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bEUH4cZ0TUOwGFyu8Z-8Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_VI7IUXbs602kl6vuqYnf0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_tRxOTTUeTkW37kzoC2c6jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-16</instant>
        </period>
    </context>
    <context id="Duration_12_22_2022_To_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_9HupkBCxL0i0_z-wbjRQoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:DebtInstrumentFollowingToMajorTriggerEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_Q4I_32NkR0GngeV1BKZ52Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_9E7IaktkjkmxEa7PB2T1Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ynXa_bg7OkmqRB_LUbXGyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Vnv1HvGas0WeOr-RGPMVOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_md536lyF-ESJilyGxz3vZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_RQ1gGyRoQE2vajTWGBJEqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">otlk:DebtInstrumentFollowingToMajorTriggerEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="As_Of_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ninrKLLlD0a6ZBI-j6EB3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Afa1M1WaS0SR2fyB14IoaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_SCSz0Z-7s0WGtX-bZHuMVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_otlk_SelexisMember_H9U6x4CDa0-Y6bDTtuTUEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">otlk:SelexisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2024_lLMZhv4wdEyjXYMfzCMdRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="As_Of_3_6_2024_pDZUs5e-AkWbZ0eR564CBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_tR_1C3dSWUSlzc9QqxzIbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">otlk:GmsVenturesInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-18</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_WarrantExpirationDateFebruary22026Member_zdlkKXee3EeGESp4jsin-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:WarrantExpirationDateFebruary22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_5wnuAFtnzkWYbs_N6ZIXsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyTwoDecemberTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyThirdNovemberTwoThousandTwentySixMember_EB2rl2TAN0CnXGRhH5XKvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyThirdNovemberTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentySecondJuneTwoThousandTwentyFiveMember_ZSTbnrDNxUGsk02iJzVFvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentySecondJuneTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_VvsudmHpd0ulTJVNbJMjYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyFourFebruaryTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_z4Qp_byL30eF_-1LyvR3aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyEighthJanuaryTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_tHeUnkmGn0e6bXwpNgxn8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:TwentyEighthDecemberTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_7YfxW7oNqECNDRvtIT0roQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:ThirtyFirstMayTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirteenAprilTwoThousandTwentyFiveMember_UmZHRjMnC0qFpaKeOWRUqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:ThirteenAprilTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_FifteenthAprilTwoThousandTwentyNineMember_laMN9AKa2kC-sX-fpIwEWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:FifteenthAprilTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_EighteenMarchTwoThousandTwentyNineMember_0ANP-WX04kCa7auIEgQwfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">otlk:EighteenMarchTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2024_ktUhxMsOBk6ial5Q3nMCKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-03-18</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_feX5121kQ0qodVdS2YmgWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NSNiPG1XOE-noQA60o5JOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_CGyuX5E2Lk6tYUEmOYyhpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_JP8U0OONT0eXTY4nRn7zlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_o0ezSlIIp02ostECr3h3Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_9aSINsKIFUCWW7CgnYrY4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MSv0WissdE66_EmEuqeCpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_H3wdezVmCkeyQmMuA4qHQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_MSrK39kxQUu7ngOH5FFwIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_sI6h_SoIjUqmJoYH1Yzl-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:UnsecuredPromissoryNote2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rYTA6Gi8qkKqslIZHJezrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OOq4Je4wC0aStmP-fhnlkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">otlk:PerformanceBasedShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jYVe9FMFeUqI7idUL2hGsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3_uEMNY46EulPN5v_asqtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5GDfve-pQk2XYOfwNALJmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_ecX5SQhuQUOy_xktLgPaqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_Wo2tL6zH10-t08OvobXAMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">otlk:SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_A1DDuw-oSUK__0BNs8JxRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingBtigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="As_Of_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_KmQM4eVrbkSrlJCBAuGuLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">otlk:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_24_2024_AKL63YIT7E2IdW942ODtuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <instant>2024-12-24</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649989</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_HK570P66lU6uxT7voueYkg">
        <measure>otlk:D</measure>
    </unit>
    <unit id="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA">
        <measure>otlk:Y</measure>
    </unit>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g"
      id="Hidden_n00HlfZxbEWQPFKyyKwVxA">http://www.outlooktherapeutics.com/20240930#ChangeInFairValueOfRedemptionFeature</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw"
      id="Hidden_pvNgaBh-KEeANZaROKbW9w">http://www.outlooktherapeutics.com/20240930#ChangeInFairValueOfRedemptionFeature</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_2gdPZ9SMLEuQPHawoXcHxQ"
      id="Hidden_4wfYnlIqeUyLM7KCzyDFdQ">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg"
      id="Hidden_NEwt-f0xMESfNeKgTqHcvA">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MinimumMember_8zXwjUyVUEWsaFBUXYo-Ug"
      id="Hidden_bxPvBnUfBkO5HfmvqqI1rg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yuNthvJ5dE-37kUZ9LB3Fg"
      id="Hidden_aurQEKRsiUKUgtUDwMQVZw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_tgycmRkvhke6BQ4YjhYuuA_2_1">0001649989</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_PuVr5Rio9kidYD8nNWFcnA_3_1">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_ULe20hndIk6AsxvpYRzusg_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_jR6as82Bjk29tHvgqfx2ew_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_2M7ltNkD4U6yEoQOVNZmHg_6_1">false</dei:AmendmentFlag>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      id="Hidden_nriUGTcej0qNzzfpnoD1Jg">http://fasb.org/us-gaap/2024#WarrantsAndRightsOutstanding</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      id="Hidden_7BYTPZDFbEyyt_JlN9COqA">http://fasb.org/us-gaap/2024#WarrantsAndRightsOutstanding</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      id="Hidden_r2jARt1MuEKZ00q33FOojQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      id="Hidden_572yibkKwE-f5eshc-7l9Q"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      id="Hidden_iF2dUt8Qkkehhy_NkHzsNg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      id="Hidden_y3Ew4CJ85UmmLIFLRTmQzg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Hidden_EMW4HkbrgEKCDFUdDsHYag"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Hidden_0zcG2TyMaUiJsqqzBB469w"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Hidden_N4pkjJobP0maC3w1WPuLFw"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">23905635</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Hidden_XPEQyVvjd0uleb7M0shZcg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">13012833</us-gaap:CommonStockSharesIssued>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="2"
      id="Tc_D-F6tXftw0OusVdnRNHW7Q_2_1"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">-4.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="2"
      id="Tc_BOlNF9aIJkSieVBAzgG-Xw_2_2"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">-4.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="2"
      id="Tc_Welq6XENEU-kjp--uai4lw_3_1"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">-4.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="2"
      id="Tc_jBQsq4VCMUSwRRNkuQ8IFA_3_2"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">-4.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_wAXwmPhchUaRScUJ17vMxA_4_1"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">18548813</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_V3g8oG1nmUSHTqDoCDanCA_4_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">12508817</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_l5Bv_51kJEmc96wNN2XSrQ_5_1"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">18548813</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_Z-1gFlEx_0aYWeIEZQIiYQ_5_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">12508817</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_14_2024_To_3_14_2024_VWPmRYi-3k6pXKO7spUdzw"
      decimals="2"
      id="Hidden_35bPP_NyTECQ2xx8ssQR0g"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <otlk:DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      id="Hidden_nFi_I78LHEio1BmDRkU8nQ">P10D</otlk:DebtInstrumentThresholdTradingDaysOfWrittenNoticeFromLenderForCureOfTriggerEvent>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw"
      id="Hidden_-FJYa8lNSUetfvJA523X1w">http://fasb.org/us-gaap/2024#PrimeRateMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA"
      decimals="INF"
      id="Hidden_DkBDMcGwhUOfLjYffyDfaA"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <dei:DocumentType
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_BYVIonOw2UiMLPTvioMWVw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_mSNQlcmq_kq1YLTabQJfdg_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_4Twi5fDabkuazRqY5aQ-vQ">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_5eGuIl-ERUagllWfPrdWSw_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_qtm5DuQgG0yuV-4O4ri0Uw">001-37759</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_2vPzpNpRSEGzO7xgqRJRcg">OUTLOOK THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_pF-Y2eUyW0Gk-LdXqJhf8w_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_ex6nw9cB1UCl5Bc2PsChoQ_1_2">38-3982704</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_8Fjy8QrUg02UrLfbkDkkuw">111 S. Wood Avenue, Unit #100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_WFXBpVUbG0S1kADe5x8BaA">Iselin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_hvvKpFhuDEOPT2PxuzmnLw">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_Mz60zDFqFkalSKIpOzh34g_2_2">08852</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_nvnn9bLtZUSTWMZACPaipA">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_YAF_sb9cEUGMuYeFmOYeuQ">619-3990</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_89pc9UQEmUucQbHOk-NlIw_2_0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_Ixdw5VIQF06KbXI5jv9AQw_2_2">OTLK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_FAXHr0Hiq06ijLtrsGb40g_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_yigGQ98LWUmHI5Sye-8y9Q">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_Cha3AfbFUUOaAhRGIMHbuw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_-Wry71k0fEiWjE_52Hv6Wg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_xT4q6tj-dk65tY29kQ16vA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_4nEM3HuNkUyjjOuUo9tKBg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc_jwqENugvkUCrG3JNva8djw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tc__ZQb9thrF0Kf9EXAnbY0Xg_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_lJdZGVYJxUmdkZd1YMlBRw">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_kiNRNCARsUGOckv55ytAXQ">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_Z85DHOpuFESSVc--TTsXDg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA"
      decimals="-5"
      id="Narr_ssRA2bdC3UGgcmc2LujE2g"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">180400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_24_2024_AKL63YIT7E2IdW942ODtuQ"
      decimals="INF"
      id="Narr_zen5p-umNUC-uZAA78W7Bw"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">24905635</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_LdsNAI-HPkeOhJcmHuIwBw">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_k0llEx39AkOJ-BUJUfh1sA">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_EYDeJYl610uREyrB6UMI_A">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_t26dnrivYE-PHLR7ZL7rQQ_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">14927538</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_NM6xd6rHuUGNheoZm7bGyg_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">23391982</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_gMsLhczZrUmB7TxFF7xslA_7_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">12488498</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_gSPucFsrc0-43zoDVxWd4w_7_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">7587216</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_mjGNvgg4MUW3RlIdhb_COQ_8_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">27416036</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_m2ZtFiiqBU6YUF8MIGyQZw_8_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">30979198</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_6Y7FmaCsdUqsieqEd7JqtA_10_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">274645</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_6JsbaYoWJkaewLj61E5TBA_10_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">26172</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquityMethodInvestments
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_6DuoPC09GUepBDiUH5wjWQ_11_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">693190</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_mlkpSsBsmECmktH7UwghNg_11_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">793932</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_Ko2M1NJBdUWqNndbDrOiIw_12_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">439283</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_JwBWhHiVEE23PlsX9OgDzw_12_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">501299</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_FcWNM1FBwku8CLcUD_kp7w_13_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">28823154</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_zMVAqaN_fkGMnOCO1wzBAg_13_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">32300601</us-gaap:Assets>
    <us-gaap:NotesAndLoansPayableCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_i1sZYw39I0KL-SdBehFg_A_18_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">29440000</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:NotesAndLoansPayableCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_0v30su1Cxk2xuz6NAKpAYg_18_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">35551000</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_HgRDv7ym5Eq39vdFF94W7g_19_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4267</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_OgjKUSFlm0GWhPCjTzft3A_20_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">50907</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_Yn9RwdBh3E-1LDmVLH5NgQ_21_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">7968725</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_goSLm1IPwU6xNCze322Qwg_21_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6574523</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_v_TFnylnaU6npTV6wMJeXw_22_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3237468</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_kTjxF694JEWRG7Vg9_Zu_g_22_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2745740</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_oY5yoIDdHUWuoRrVca2CDg_23_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1856629</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_skL0GKyNwEOFB6K0Ptog2A_23_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1856629</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_VihIFBl4ykqaz2ABq5_lMQ_24_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">42553729</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_WzGzop8PVESoTNphFuLagg_24_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">46732159</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_2lf3NpCQKEWGz5NMWtgs_g_26_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">246922</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_0QRiuZO4skeEEsq3uEdzEw_27_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">59099013</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_ii3ThtF-a06i9C2DP3r_Yg_27_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6219</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_usaBEQGcAUKYp4mUTdofBg_28_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">101899664</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_zs9ALj8UjkW8A9F8d1zLqQ_28_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">46738378</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Narr_Uojy3gPTSUWIgh2oA1ub3Q"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr__GQD4RsT6Uqlm_TPhYr6dQ"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Narr_ckYmvGMXy0Kqgj-UWukytw"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr_-FUH5ecJDEKnSlIumQhqrQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Narr_k3skrFukHEG49YnQBjnevQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr_RPJvFPywSEKPphEomZuMbg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Narr_cMVL-Ge7WEilfnZUFwQ-ag"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr_fSaOe6tGrUev9kIfJScpoA"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Narr_ZO2DNgvY3U2t-M4CX7kcEg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr_AgiHiUInh0u9FcJ5yyHTfw"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr_VLWjxtsrlkSk8UhDos6kXQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">23905635</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="INF"
      id="Narr_x-QdmUz9JkGJIrEgnwR-Lw"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">13012833</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_N-8UAnfo3EqHbqZuLxIMDw_34_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">239057</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_PXsz6yMVMka1hoTTqw02YQ_34_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">130128</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_wcXTTktfxEuNFCd3WkgIdQ_35_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">469969333</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_-HOZfOxl9kuoP60CQzXFnA_35_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">453350281</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_M3zd9jJAiUWpioeLDxTNXA_36_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-543284900</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_u5cxtzIZk0WgCezW0bBMGw_36_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-467918186</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_V90n8go7OEq1AK7S42uq0Q_37_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-73076510</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_Fn4vo9I4LU-83B3yLPbw4w_37_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-14437777</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_iNNUjZp3PkOhk8Mz41Y6Eg_38_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">28823154</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_1FGum5ithkyXLca4ryhWDg_38_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">32300601</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_RLVmjJ1j4EGlJ9zYhr8Djw_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">41763047</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_YA1Uz6ylkESZ76J-PvJVwQ_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">26452942</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_MsCbzLipdUaMWSH9aFPGvA_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">29940188</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_IcC6WFuOrECxoRlNRW2fxg_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">26673440</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_dx6LAKuzkUq1YMxFO6qinA_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-71703235</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_6hc3wjinYkWbD9Gx-9Ytxw_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-53126382</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_4CAU7yh35kahLq0RJ94xSA_7_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-100742</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_ZVrcT7cG_kSJAhe5rCM0hg_7_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-10998</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_Etl8rRZeg0-qnVAHBcYcVw_8_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">906150</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_4kZJyg0ZjEmhX4kCZL7Phw_8_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">971480</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_MrpTSgsQnkiLma5-feUoaQ_9_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3156964</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_3WlZwBLo9UavaMO5SHJASg_9_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2531228</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_gmMANjhLj0mgizuuz4CdLA_10_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-577659</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <otlk:ChangeInFairValueOfRedemptionFeature
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_DxYsFuJktU2BEWwFgdqyaA_11_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2457153</otlk:ChangeInFairValueOfRedemptionFeature>
    <otlk:ChangeInFairValueOfRedemptionFeature
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_bYAoPov80k2Mp-de2gLgmA_11_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3756000</otlk:ChangeInFairValueOfRedemptionFeature>
    <otlk:WarrantRelatedExpenses
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_NRTHsOTc_kGn_e_KL6uz1Q_12_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">37490012</otlk:WarrantRelatedExpenses>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_Hlj_eFW8JU2v7Wh6tDSKug_13_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-38638042</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_lImBzmqAZUuRa0XZ_A6wzg_13_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-50919</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_P3rMUPM4b0GJVt63dgiHwg_14_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-75363914</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_Itd6CcnEhkq9XlZRLWlF7g_14_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-58979868</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_uQpQhiBK_kOrMtY5bSIkzg_15_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_fjq5LHO8ykaG9F4FwGPJUQ_15_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_veMVHoavDUWug-BDmdOGVQ_16_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-75366714</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_Z6KrS1WOwkCXaR2OAgBF7g_16_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-58982668</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="2"
      id="Tc_fqXj6TcqSUqne6X_aWYCMA_19_3"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">-4.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="2"
      id="Tc_9DkMDpDdUkiivJSPynRyqw_19_6"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">-4.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_1onzAclBv0yX_CbOAi-dRQ_20_3"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">18548813</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_6sQffL0gXk-OtvPYocPQkA_20_6"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">12508817</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw"
      decimals="INF"
      id="Tc_xyLJUczsLEWjWNfFeX2L9A_4_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">11365486</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5EE4OsgoAU2lfV_KUHblcw"
      decimals="0"
      id="Tc_Uu24kukzd0m0VvlFBu4J7A_4_5"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">113655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Nab82IT-Gki9oEVbHZmkcQ"
      decimals="0"
      id="Tc_j2d1aWghQ066peTCK8wfVw_4_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">417558434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_l0N8PxP9kEu7Rni9SApcXQ"
      decimals="0"
      id="Tc_FChBY2LO8U-XkiGqE-hAEA_4_11"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-408935518</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w"
      decimals="0"
      id="Tc_JAk9DE6R-UmhHk9RvOIKkg_4_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">8736571</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw"
      decimals="INF"
      id="Tc_MtZxorPnEUK0eE6Si0WaaA_5_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">625</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw"
      decimals="0"
      id="Tc_ZHoba5AJAESisz33mMzvQw_5_5"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw"
      decimals="0"
      id="Tc_u48aZnCjckaxoAQL79mm_A_5_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">24994</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_dZ4rzgeMf0uc0g3n29mo-Q_5_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">25000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw"
      decimals="INF"
      id="Tc_MjjLjHTdc0Sg4GQVpw8mGA_6_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1646722</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NPHmYOaID0yKx6xIIRSqdw"
      decimals="0"
      id="Tc_UKeJdF42w0iJn7ox-N-TFA_6_5"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">16467</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw"
      decimals="0"
      id="Tc_xr8nsNXmGU2i7Q7q616tng_6_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">30219834</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_mhpPshBy5EaEGGt4Ohvvfg_6_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">30236301</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mmzS9X3B1EG8kE3YeiI4Jw"
      decimals="0"
      id="Tc_gMvYC28xQU2_49AWDz4n8g_7_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5547019</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_s8qQpS08A0aFhfRV7IAmKg_7_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5547019</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DOx7DSkcUUK1qwvbqatS0w"
      decimals="0"
      id="Tc_ArMWz5CteUKcKig1N1ksiA_8_11"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-58982668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_LgTVb363dUqVOSfBiSUhng_8_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-58982668</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tVVfsw2X4ku21-b-wI1Fsw"
      decimals="INF"
      id="Tc_u_UVADY__UiVCwzXt1-F5A_9_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">13012833</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tVVfsw2X4ku21-b-wI1Fsw"
      decimals="0"
      id="Tc_uIr93YOFTUWXSHOFhuBDvA_9_5"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">130128</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eLtmRbHPMk-R2-bot8_N2A"
      decimals="0"
      id="Tc_qBjGSb0PkU2gAd4IpMKXtw_9_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">453350281</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UoWGYXeAcUmQc5T0sAOkNA"
      decimals="0"
      id="Tc_Bu6NE50Nd0K5UbWu1JSqkQ_9_11"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-467918186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_nBITLumU-kqaBe07i2_hnw_9_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-14437777</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg"
      decimals="INF"
      id="Tc_siplt-OoUkaevPM4NRfw_w_10_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1607093</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg"
      decimals="0"
      id="Tc_T7lz0vY2I028GRLLEzBnjg_10_5"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">16072</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5GDfve-pQk2XYOfwNALJmA"
      decimals="0"
      id="Tc_IIJDWfJhKUCbHD6xn-iZfw_10_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11233928</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_EUP5CsDxaku7FBcfytD_XA_10_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11250000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg"
      decimals="INF"
      id="Tc_BVHqvo2jx0KHhfu8t5HvAw_11_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">9285709</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uu47oVMgrEq3CtotmDaaCg"
      decimals="0"
      id="Tc_gIWQ_X2eCEG6Mz2AW4MdsA_11_5"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">92857</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_n2oR53jC9EKsbNI7JWLxNw_11_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">92857</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5GDfve-pQk2XYOfwNALJmA"
      decimals="0"
      id="Tc_IO4-Wikn4k2zsmYzf8boFg_12_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5385124</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_ETO-3j3ZrEqXhl-EFz9JRg_12_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5385124</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5I3oWKzZqkyIrUS7CKXITQ"
      decimals="0"
      id="Tc_v_C9zp_Y5UyntYj4oUjvog_13_11"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-75366714</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_9o4KfS1s-k2FfjgrNofFlQ_13_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-75366714</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6NrSVQ0gRUCQVI56arDZNQ"
      decimals="INF"
      id="Tc_3ZKhf06FnkSMCBTuOSar1w_14_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">23905635</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6NrSVQ0gRUCQVI56arDZNQ"
      decimals="0"
      id="Tc_T39hkl6xL0Czf3-UKl-Ktg_14_5"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">239057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_keL3bo7nE0CNPVnUOmT-gg"
      decimals="0"
      id="Tc_4wyT_fk_VE68GSsBni2PEg_14_8"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">469969333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aqpTcTgcvEKqWIkMkLyvSQ"
      decimals="0"
      id="Tc_7PC6rU-6okGitEO30XKQkg_14_11"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-543284900</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_6U809a0NoE2_CjpJiMH_Dg_14_14"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-73076510</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_hDNEbkMPNkeUY1I-0Ld9eg_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-75366714</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_Fg_FmnAV1kOtDmn6ecTVzA_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-58982668</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_qAmAYcWXNkCCyPfrBjGeOA_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">113859</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_W2FXpVczak2UJx7v8kSGEA_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">44188</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_MpHJwHjOCEqhrzXuMp-ePw_7_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-577659</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_z-p-H3hu4EGmVVzKzZXWDw_8_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2681847</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_14m09uxqkke7j4oMtX9v3A_8_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2529830</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_v-NKQFe4AUej2NxG5GenQQ_9_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5385124</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_zy4pQNNZrESLalQVu9QnJw_9_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5547019</us-gaap:ShareBasedCompensation>
    <otlk:ChangeInFairValueOfRedemptionFeature
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_E2hvBjVj6kOSbV7mCgeEMQ_10_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2457153</otlk:ChangeInFairValueOfRedemptionFeature>
    <otlk:ChangeInFairValueOfRedemptionFeature
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_599hbwVn-UWzXhAYpIu_4Q_10_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3756000</otlk:ChangeInFairValueOfRedemptionFeature>
    <otlk:WarrantRelatedExpenses
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_v7szLJ4W5EaYD7jIk5eTEQ_11_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">37490012</otlk:WarrantRelatedExpenses>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_JaU5U07USU-XykGenSNIBA_12_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-38638042</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_-PVCecac402CW4XORpoB-w_12_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-50919</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_rrHqkp5wKEG6H5D7NwvSFQ_13_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-100742</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_xazjJjSQZ0KXdmOKkIlVqQ_13_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-10998</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestPaid
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_9uGj78jGMkakpt8kU4AC3g_14_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1158609</us-gaap:InterestPaid>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_0waC805L9kaYCSH6-hA3VA_16_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4901282</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_VBdfOL3Mck6gRete1wdvTg_16_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-2616925</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_KUkAbdraT0-3R18x7Q9Gag_17_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5900</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_XCqAtqjZpUqxVLjehIP2dQ_17_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">208203</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_lqAlrbNlREyblpHoNL0hZw_18_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3413</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_SdowLSf1BU62SCMFtlQclA_18_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-26995</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_wPxBz_NLAkOgsdwGUFZPgg_19_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1394202</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_JoOdyWtru0eoMqVxlL2pFg_19_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3083038</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_9xk8G_m0HEKcc6Pb2mjUmQ_20_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">491728</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_pyLvwVniX02_V8dTehMgrg_20_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-711661</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_E7xv7oznhkCVgowE6VYC1Q_21_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-68793858</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_TXVkA2ruyUuoAeY4a4CzaA_21_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-42973398</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_VseG25c4bkmzRiFyIhiL4Q_24_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">60333681</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_hch24BlazEiKOD-EWfcwzQ_24_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">30024213</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_zxgMsSQQqUG9BZQzeS5AIA_25_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">30000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_7OSEWuCXQ0ubDdw2-wdRiw_26_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4267</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_JQkFmh7u2kGSdI3hCvt2jQ_26_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11751</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_-R6bBw8NF0uKdwuNVL_7Jg_27_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">10220000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_gwV7lhG8gEWVCJPrGTzwww_28_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">823894</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_fq3jEm7m2UGZ_DOXMBO46g_29_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">60329414</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_IKmZf604D02FVheb1oovDQ_29_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">48968568</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_fJw9Nh57hES4EKCFsrAc0Q_30_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-8464444</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_GdV7O8FBX0-mSlsU93znlA_30_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5995170</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_VbELQYIQ10Ck2d5sbpkawA_31_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">23391982</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w"
      decimals="0"
      id="Tc_Bgg7aDNJmEed0wnmrtvfnQ_31_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">17396812</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_1EP-_S1S4kKTcPOJa7TiJw_32_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">14927538</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_dW4uVf-GK0e73dy0Huc_cQ_32_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">23391982</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_mMUIXjYqnUClzHkHGPZX7g_34_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">475000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_0sdOVLCgIk6RoVanJ1zRNw_34_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1160008</us-gaap:InterestPaidNet>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_vXLSor6o10SWw-1wiRXLkg_36_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11250000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_Jzd_XSNNLUOAZ-umn_bf1Q_36_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">25000</us-gaap:DebtConversionOriginalDebtAmount1>
    <otlk:WarrantLiabilityIncurredButNotYetPaid
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_bdaj59BC0k2_KT9oZrHjcA_37_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">97730836</otlk:WarrantLiabilityIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_jKLYlTQa40O4EgK41JRS5Q_38_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">141600</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_HGqUAr_hbE6Zq6lYvIkSOA_39_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">294416</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_ZVke3geZOUyGBQIqHUwFcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;&#160;&#160;&#160;&#160;Organization and Operations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Description of the Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Outlook Therapeutics, Inc. (&#x201c;Outlook&#x201d; or the &#x201c;Company&#x201d;) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to &#x201c;Outlook Therapeutics, Inc.&#x201d; in November 2018. The Company is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA&lt;span style="background:#ffffff;"&gt;&#x2122; (&lt;/span&gt;bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2024, the Company received Marketing Authorization from the European Commission for ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (&#x201c;AMD&#x201d;) in the European Union (&#x201c;EU&#x201d;). &#160;Additionally, in July 2024 the Company also received marketing authorization for ONS-5010/LYTENAVA in the United Kingdom (&#x201c;UK&#x201d;) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). ONS-5010/LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the fourth quarter of calendar 2023, the Company agreed to conduct an additional adequate and well-controlled clinical trial following discussions with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in support of the Company&#x2019;s Biologics License Application (&#x201c;BLA&#x201d;) for ONS-5010/LYTENAVA. In December 2023, the Company submitted a Special Protocol Assessment (&#x201c;SPA&#x201d;) to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA&#x2019;s requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010/LYTENAVA BLA. In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA&#x2019;s requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter (&#x201c;CRL&#x201d;). In addition, through a Type A meeting and additional interactions, the Company has identified the approaches needed to resolve the chemistry, manufacturing and controls (&#x201c;CMC&#x201d;) comments in the CRL. In November 2024, the Company reported that &#160;ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010. Analysis of the data is ongoing as the month 3 data from NORSE EIGHT is being collected, which is expected to be available in January 2025.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_BE2UltUFTEyXT-T5yTEJiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;&#160;&#160;&#160;&#160;Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred recurring losses and negative cash flows from operations since its inception and has an accumulated deficit of $ 543,284,900 as of September 30, 2024. As of September 30, 2024, the Company had $31,352,857 of principal, accrued interest and exit fees due under an unsecured convertible promissory note issued in December 2022 (the &#x201c;December 2022 Note&#x201d;), maturing on July 1, 2025, as amended. &#160;As a result, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November 2024 and December 2024, the Company sold 1,000,000 shares of common stock under the BTIG ATM Offering and generated $1,742,343 in net proceeds after paying fees to BTIG and other issuance costs of $53,918. Refer to Note 9 for further details on the BTIG ATM Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Management does not believe that the Company&#x2019;s existing cash and cash equivalents as of September 30, 2024, together with $1,742,343 in net proceeds from the sale of shares of common stock under the BTIG ATM Offering since September 30, 2024, are sufficient to fund the Company&#x2019;s operations through one year from the Form 10-K filing date. As a result, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern and additional financing will be &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;needed by the Company to fund its operations in the future and to commercially develop ONS-5010/LYTENAVA and to develop any other product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations, including but not limited to, the exercise of outstanding warrants to purchase shares of the Company&#x2019;s common stock (subject to meeting the requirements for calling such warrants), proceeds from potential licensing and/or marketing arrangements or collaborations with pharmaceutical or other companies, sale of the development and commercial rights to the Company&#x2019;s drug product candidates in regions outside of the U.S., the issuance of additional debt, the issuance of equity securities, including accessing capital through at-the-market offering agreements (refer to Note 9 for further details), and revenues from potential future product sales, if any. There can be no assurance that these future funding efforts will be successful. The Company&#x2019;s consolidated financial statements do not include any adjustments that might be necessary if it is unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of additional financing discussed above; (ii) the Company&#x2019;s ability to successfully begin marketing of its product candidates or complete revenue-generating partnerships with other companies; (iii) the success of its research and development; (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies; and, ultimately, (v) regulatory approval and market acceptance of the Company&#x2019;s proposed future products.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Narr_-2oGEEHjAkaX2_USoOnP4w"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-543284900</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Narr_i9C3S-eX10qNTlrOxgk0hg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">31352857</us-gaap:DebtInstrumentFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw"
      decimals="INF"
      id="Narr_UBcSaeWKtU27QaE35aSKWg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw"
      decimals="0"
      id="Narr_8hgzxyDEOkaKEna1a7NmmA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1742343</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw"
      decimals="0"
      id="Narr_oG0g3Ju0x06-3B7duugbfA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">53918</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_11_1_2024_To_12_31_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Y28NgcuZikGcEJRIA7ypKw"
      decimals="0"
      id="Narr_B5BJaTy-nkCS0Cp3aQ3lRQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1742343</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_0cuEvmVP1EWfS_yVMUlGwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;&#160;&#160;&#160;&#160;Basis of Presentation and Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and Outlook Therapeutics Pty Ltd, its wholly-owned subsidiary incorporated in Australia (the &#x201c;Subsidiary&#x201d;). All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;The Company has determined the functional currency of the Subsidiary to be the U.S. dollar. The Company translates assets and liabilities of its foreign operations at exchange rates in effect at the balance sheet date. The Company records remeasurement gains and losses on monetary assets and liabilities, such as incentive and tax receivables and accounts payables, which are not in the functional currency of the operation. These remeasurement gains and losses are recorded in the consolidated statements of operations as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Reverse stock split&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Effective on March 14, 2024, the Company amended its amended and restated certificate of incorporation to implement a &lt;span style="-sec-ix-hidden:Hidden_35bPP_NyTECQ2xx8ssQR0g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-for-twenty&lt;/span&gt;&lt;/span&gt; reverse stock split of its common stock. As a result of the reverse stock split, the Company made corresponding adjustments to the share amounts under its employee incentive plans, outstanding options, and common stock warrant agreements with third parties. The disclosure of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Cash and cash equivalents include cash-on-hand and demand deposits with financial institutions and other short-term investments with maturities of less than three months when acquired and convertible to known cash amounts. At September 30, 2024 and 2023, the Company&#x2019;s cash equivalents consist of a money market account.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity method investment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company&#x2019;s share of equity in the earnings or loss of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. The Company has not elected the fair value option. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value of financial instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 &#x2014; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The asset&#x2019;s or liability&#x2019;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At September 30, 2024 and 2023, the Company&#x2019;s financial instruments included cash and cash equivalents, accounts payable, accrued expenses, unsecured convertible promissory note and warrant liabilities. The carrying amount of accounts payable, and accrued expenses approximates fair value due to the short-term maturities of these instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value Option&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company elected the fair value option to account for the December 2022 Note. Refer to Note 7 for further details on the December 2022 Note.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#x201c;Short-Term Leases&#x201d;). For Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the consolidated balance sheet. The Company had no Short-Term Leases as of September 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the re-measured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received, and any initial direct costs incurred are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures equity classified stock-based awards based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of stock option awards as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model, which is described more fully in Note&#160;11. The fair value of each restricted stock award is measured as the fair value per share of the Company&#x2019;s common stock on the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Upfront milestone payments made to third parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted net loss per common share, the denominator includes both the weighted average common shares outstanding and the number of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include convertible debt, warrants, performance-based stock options and units, and stock options the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company&#x2019;s losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September&#160;30, 2024 and 2023, as they would be antidilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.68%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:top;white-space:nowrap;width:29.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance-based stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance-based stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 666,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,946,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,197,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,207,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 366,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,171,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(i)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 854,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(ii)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The calculation for potentially dilutive securities pertaining to convertible debt is as follows: &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3,750,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of outstanding principal and accrued interest as of September 30, 2024, is converted at a rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, and the remaining amount is converted based on a fixed conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$40.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share, which is subject to change as described in Note 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$40.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share, which is subject to change as described in Note 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;. ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. &#160;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_Za3yzU8Kh06zzwruVjnhrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and Outlook Therapeutics Pty Ltd, its wholly-owned subsidiary incorporated in Australia (the &#x201c;Subsidiary&#x201d;). All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;The Company has determined the functional currency of the Subsidiary to be the U.S. dollar. The Company translates assets and liabilities of its foreign operations at exchange rates in effect at the balance sheet date. The Company records remeasurement gains and losses on monetary assets and liabilities, such as incentive and tax receivables and accounts payables, which are not in the functional currency of the operation. These remeasurement gains and losses are recorded in the consolidated statements of operations as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <otlk:ReverseStockSplitPolicyTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_I_CjvTvF_k6uU0wJJz9j4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Reverse stock split&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Effective on March 14, 2024, the Company amended its amended and restated certificate of incorporation to implement a &lt;span style="-sec-ix-hidden:Hidden_35bPP_NyTECQ2xx8ssQR0g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-for-twenty&lt;/span&gt;&lt;/span&gt; reverse stock split of its common stock. As a result of the reverse stock split, the Company made corresponding adjustments to the share amounts under its employee incentive plans, outstanding options, and common stock warrant agreements with third parties. The disclosure of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented.&lt;/p&gt;</otlk:ReverseStockSplitPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_vhXxTC6l80-K7wKH7kt8pg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Cash and cash equivalents include cash-on-hand and demand deposits with financial institutions and other short-term investments with maturities of less than three months when acquired and convertible to known cash amounts. At September 30, 2024 and 2023, the Company&#x2019;s cash equivalents consist of a money market account.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_k9Ry6sH0H0i38piN2Xp03g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity method investment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company&#x2019;s share of equity in the earnings or loss of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. The Company has not elected the fair value option. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:UseOfEstimates
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_xXTehD1xGUyu67lbfy9QUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_QaRrCdkKI0mfXj_x-dKVcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value of financial instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 &#x2014; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The asset&#x2019;s or liability&#x2019;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At September 30, 2024 and 2023, the Company&#x2019;s financial instruments included cash and cash equivalents, accounts payable, accrued expenses, unsecured convertible promissory note and warrant liabilities. The carrying amount of accounts payable, and accrued expenses approximates fair value due to the short-term maturities of these instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair Value Option&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company elected the fair value option to account for the December 2022 Note. Refer to Note 7 for further details on the December 2022 Note.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_OLl4_uAvxEKKUCVPiWCGuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (&#x201c;Short-Term Leases&#x201d;). For Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the consolidated balance sheet. The Company had no Short-Term Leases as of September 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the re-measured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received, and any initial direct costs incurred are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_xgzldccriU6rz0tiTPVB7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures equity classified stock-based awards based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of stock option awards as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model, which is described more fully in Note&#160;11. The fair value of each restricted stock award is measured as the fair value per share of the Company&#x2019;s common stock on the date of grant.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_kXQi00iKkUuoTVbLtYvIUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Upfront milestone payments made to third parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_5xq9NBeOK0SsHXM9KIkw8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_14h4HhEoy0mA5DhwLlAnQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted net loss per common share, the denominator includes both the weighted average common shares outstanding and the number of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include convertible debt, warrants, performance-based stock options and units, and stock options the treasury stock method. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares due to the Company&#x2019;s losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September&#160;30, 2024 and 2023, as they would be antidilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.68%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:top;white-space:nowrap;width:29.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance-based stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance-based stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 666,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,946,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,197,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,207,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 366,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,171,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(i)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 854,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(ii)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The calculation for potentially dilutive securities pertaining to convertible debt is as follows: &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3,750,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of outstanding principal and accrued interest as of September 30, 2024, is converted at a rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, and the remaining amount is converted based on a fixed conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$40.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share, which is subject to change as described in Note 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$40.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share, which is subject to change as described in Note 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_1Qw3UZLRFU-1tug-PjiUgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.68%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:top;white-space:nowrap;width:29.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance-based stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Performance-based stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 666,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,946,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,197,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,207,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 366,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,171,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(i)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 854,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:10.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(ii)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The calculation for potentially dilutive securities pertaining to convertible debt is as follows: &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3,750,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of outstanding principal and accrued interest as of September 30, 2024, is converted at a rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, and the remaining amount is converted based on a fixed conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$40.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share, which is subject to change as described in Note 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The potentially dilutive securities related to convertible debt are calculated based on a fixed conversion price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$40.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share, which is subject to change as described in Note 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_9aSINsKIFUCWW7CgnYrY4Q"
      decimals="INF"
      id="Tc_-3eMEXUZ8UqXxY4A5vvfiQ_3_4"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">123</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_JP8U0OONT0eXTY4nRn7zlw"
      decimals="INF"
      id="Tc_uF1HwD_CuUa0zvL4uZDrTg_4_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">666500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_otlk_PerformanceBasedShareOptionsMember_MSrK39kxQUu7ngOH5FFwIQ"
      decimals="INF"
      id="Tc_GE03VEJ-jECu83ydSdWnMA_4_4"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">35000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NSNiPG1XOE-noQA60o5JOA"
      decimals="INF"
      id="Tc_0EEVO6GVIEue252kUJN40g_5_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1946646</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MSv0WissdE66_EmEuqeCpQ"
      decimals="INF"
      id="Tc_A4tyDiOCoEyTw7KfguwY3w_5_4"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1197774</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_feX5121kQ0qodVdS2YmgWA"
      decimals="INF"
      id="Tc_Os68JzhT0ECoiqip0JA79Q_6_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">14207622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_o0ezSlIIp02ostECr3h3Zw"
      decimals="INF"
      id="Tc_Lqk-87NSD0ufXFCcCIMKLQ_6_4"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">366427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_CGyuX5E2Lk6tYUEmOYyhpw"
      decimals="INF"
      id="Tc_2k96Y919vkqfBS_sn71L8g_7_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1171100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_H3wdezVmCkeyQmMuA4qHQQ"
      decimals="INF"
      id="Tc_khYhlUrLK0i6cy-2Ldg16w_7_4"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">854962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_9E7IaktkjkmxEa7PB2T1Zw"
      decimals="0"
      id="Narr_I66hZpKaRUC2N3t6jB-1rA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_9E7IaktkjkmxEa7PB2T1Zw"
      decimals="INF"
      id="Narr_kFLH9WhKZ0iq0bXaLcAPFA"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_9_30_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_Q4I_32NkR0GngeV1BKZ52Q"
      decimals="INF"
      id="Narr_McLUE3T2YkKSKalcQcyZ7g"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_md536lyF-ESJilyGxz3vZw"
      decimals="INF"
      id="Narr_QDWrKu-wYU6sYQn7nbcUNw"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_d747MmsodEi_ScxU-SSWYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU 2023-07, which is applicable to entities with a single reportable segment and will primarily require enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-07 will have on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;. ASU 2023-09 which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of ASU 2023-09 will have on its consolidated financial statements and disclosures. &#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_47UxO6W_WEK4K3MZDbu3sA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;&#160;&#160;&#160;&#160;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents the Company&#x2019;s liabilities that are measured at fair value on a recurring basis:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unsecured convertible promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_nriUGTcej0qNzzfpnoD1Jg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,099,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,539,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unsecured convertible promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,551,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7BYTPZDFbEyyt_JlN9COqA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,557,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table presented below is a summary of changes in the fair value of the Company&#x2019;s Level 3 valuation for the warrant liability and the December 2022 Note for the&#160;years ended September&#160;30, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unsecured Convertible&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Promissory Note&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at October 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,820,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued interest converted to common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,756,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,919)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,551,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Issued in connection with sale of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 97,730,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Promissory note maturity extension fee added to outstanding balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,681,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal and accrued interest converted to common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,250,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_n00HlfZxbEWQPFKyyKwVxA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,457,153&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38,638,042)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,099,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As further described in Note 7, the Company elected the fair value option to account for the December 2022 Note. The fair value of the December 2022 Note is estimated using a binomial lattice model, which evaluates the payouts under hold, convert or call decisions. Significant estimates in the binomial lattice model include the Company&#x2019;s stock price, volatility, risk-free rate of return, and credit-adjusted discount rate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The fair values of the December 2022 Note as of September 30, 2024 and 2023 were estimated using a binomial lattice model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 91.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 71.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Credit-adjusted discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The warrants related to the Note and Warrant Purchase Agreement dated December 22, 2017 are classified as liabilities as the warrants include cash settlement features at the option of the holders under certain circumstances. The warrants issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 are classified as liabilities as the Company assessed that they are not indexed to the Company&#x2019;s own stock and must be classified as liabilities. For further details on the evaluation refer to Note 9. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The above warrant liabilities are revalued each reporting period with the change in fair values recorded in the accompanying consolidated statements of operations until the warrants are exercised or expire. The fair values of the warrant liabilities are estimated using the Black-Scholes option pricing model using the following weighted average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:22.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remaining contractual term of warrants (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 125.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 158.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Annual dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value of common stock (per share)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_Bu0QMHd9l0qNTO6JlXoI1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unsecured convertible promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_nriUGTcej0qNzzfpnoD1Jg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,099,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88,539,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unsecured convertible promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,551,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7BYTPZDFbEyyt_JlN9COqA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Warrant liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,557,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w"
      decimals="0"
      id="Tc_0sASjAaVGkSqx79EHS2uhQ_4_9"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">29440000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w"
      decimals="0"
      id="Tc_7rlrqpsFtUCQrG5Ul0vFyg_5_9"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">59099013</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SmPpIqsfUy73CO59A912w"
      decimals="0"
      id="Tc_upm0xUGrLEmcgrbcGtWsng_6_9"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">88539013</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g"
      decimals="0"
      id="Tc_Wu0buAVZE0S94lQCTKAtVA_11_9"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">35551000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g"
      decimals="0"
      id="Tc_DNJAgG4zPkiXYtzyCnSecA_12_9"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6219</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_jWqiazqfLUiwC4k0qjjV0g"
      decimals="0"
      id="Tc_bw7cTbbKBUOdh15EHpSvSQ_13_9"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">35557219</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_SwsNiiSa30qEB9_p9D8CjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unsecured Convertible&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Promissory Note&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at October 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 57,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,820,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued interest converted to common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,756,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,919)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at September&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,551,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Issued in connection with sale of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 97,730,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Promissory note maturity extension fee added to outstanding balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,681,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Principal and accrued interest converted to common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,250,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_n00HlfZxbEWQPFKyyKwVxA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,457,153&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38,638,042)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 59,099,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_jrGO66RARkOJ5xdVUtPWcw"
      decimals="0"
      id="Tc_quPodp76xkioI4bMj-za1w_3_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">57138</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g"
      decimals="0"
      id="Tc_Ix04Vwxdb0SVORpgvXJU6g_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">31820000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g"
      decimals="0"
      id="Tc_rALQHll9AEOVIXInBg34-g_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-25000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_HSWdrLsfbEasraTLEdTv3g"
      decimals="0"
      id="Tc_Qb1LYAcgika9eERaY3r1sQ_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3756000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_2gdPZ9SMLEuQPHawoXcHxQ"
      decimals="0"
      id="Tc_t7dkWl_4FkSylyG83zDbRg_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-50919</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_DIM-yieXZEii39hWIo3zyQ"
      decimals="0"
      id="Tc_Mx8_2Ty3FESf03imami8jg_7_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">35551000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_SE9TpsNiB0SZh02vDR962A"
      decimals="0"
      id="Tc_OQdZXtTv6U2rPj9AYiV6jA_7_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6219</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg"
      decimals="0"
      id="Tc_1udGIFm4l0W_C-rSzABzAw_8_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">97730836</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <otlk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw"
      decimals="0"
      id="Tc_xboAKg2b-UOpw4RPrBn5Xw_9_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2681847</otlk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCapitalizedExtensionFees>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw"
      decimals="0"
      id="Tc_cJRx9Rp7AE-hpmgq5XLAbg_10_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-11250000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw"
      decimals="0"
      id="Tc_r6stCpsdp0SzNVOWGscjeg_11_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2457153</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg"
      decimals="0"
      id="Tc_itg81tGgwESyESURGxWQMQ_11_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-38638042</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_7Nz6MTqRk06UkjKgAzcXCA"
      decimals="0"
      id="Tc_149Gd-EAEU-0EJaO5P2qqg_12_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">29440000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_Sk5RTQxSUkKzLC9zG8VQXQ"
      decimals="0"
      id="Tc_r4k2nT8qO0Kjb45tLrw04g_12_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">59099013</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_T1c4H3O2g0yXp-3JM-RZbw"
      id="Tb_lP3m7TNM90absnspWDq2Wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:20.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 91.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 71.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Credit-adjusted discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 20.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g"
      decimals="1"
      id="Tc_Xsc6whjgVESfBgOVzsMmJA_3_3"
      unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA">0.8</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qJ_fPZFQk0y4wnAgsqRsTA"
      decimals="1"
      id="Tc_erbQbaIJFEG6pCLzcH2Qrg_3_7"
      unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA">0.3</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_0FNNd0MQSEGbVAxJkUYUBQ"
      decimals="3"
      id="Tc_vXZoNR7aRE6llWD3tGsoSg_4_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.91</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7-lVNsEf202TYs18lInWUw"
      decimals="3"
      id="Tc_9mPY43KpH0un4ktH4vKJww_4_7"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.71</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3IXjRjrvOUmxyOEeUsHZtw"
      decimals="3"
      id="Tc_Wwg2cDaKlEKwa9Ls6jA54w_5_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.042</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kUMWn2QlUkGH1AcNmJxH4A"
      decimals="3"
      id="Tc_pTMUx__310ijonSneED_nA_5_7"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.055</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_9bYKF4TI30O9lev1VzvfWg"
      decimals="2"
      id="Tc_ETxeCa1k30CYi0EgH3uZ8Q_6_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_7lqaz_2bqEqu4ykwZdkCvg"
      decimals="2"
      id="Tc_XGFx-4KXLkqu071GKVuF3w_6_7"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_tRV5Gx6Jz0y-S8KiNciwMw"
      decimals="3"
      id="Tc_odBrQTxbWkCfgdNjSo6U2Q_7_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.204</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bEUH4cZ0TUOwGFyu8Z-8Ag"
      decimals="3"
      id="Tc_shniUkW9LkarPSyTGSQBcg_7_7"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.228</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U7MnAhTIHkej02WiFwj3Lw"
      decimals="2"
      id="Tc_GwH0En33nEK3A7klii2IZQ_8_3"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">5.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qZPC37xTWUe1Gonx3VN-Hw"
      decimals="2"
      id="Tc_sR6INJhvHkOFAb8G8eKssg_8_7"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">4.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_x5je_ThKPUKVmvQ0jxeqOg"
      id="Tb_9Yv0uFFQ4Eq0PEB7nRvmzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:22.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remaining contractual term of warrants (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 125.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 158.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Annual dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value of common stock (per share)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_3IXjRjrvOUmxyOEeUsHZtw"
      decimals="4"
      id="Tc_sicfwLAEgke9gjdiuKJM2A_3_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.0358</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_kUMWn2QlUkGH1AcNmJxH4A"
      decimals="4"
      id="Tc_ASWFv4YZ8kWP_xpUEff13Q_3_7"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.053</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KGYwgS4ll0ykygUKvwM59g"
      decimals="1"
      id="Tc_zZgEe-bt9Ea5Tl_R5ZMmTw_4_3"
      unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA">4.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qJ_fPZFQk0y4wnAgsqRsTA"
      decimals="1"
      id="Tc_O_8UisVKCkWYTz2fPwYbJQ_4_7"
      unitRef="Unit_Standard_Y_uM7jZ1U4rkOPHshXEwP8kA">1.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_0FNNd0MQSEGbVAxJkUYUBQ"
      decimals="3"
      id="Tc_MA0DvRbu_EKqenxbVqBf_Q_5_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_7-lVNsEf202TYs18lInWUw"
      decimals="3"
      id="Tc_ppnFijkmeEC7-bShCY4eQw_5_7"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1.583</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_9bYKF4TI30O9lev1VzvfWg"
      decimals="2"
      id="Tc_6yT-g8blL0qzaXN-juZz-Q_6_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_7lqaz_2bqEqu4ykwZdkCvg"
      decimals="2"
      id="Tc_PmWjf0ayG06wlHWBPAkC0A_6_7"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U7MnAhTIHkej02WiFwj3Lw"
      decimals="2"
      id="Tc_LO330uZ0gkeuTDdePaxPyQ_7_3"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">5.34</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qZPC37xTWUe1Gonx3VN-Hw"
      decimals="2"
      id="Tc_5D4Nri4rP0CPkv9d1EC8bA_7_7"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">4.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_TeDYNskLWkS3_a_rs70qQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. &#160;&#160;&#160;&#160;&#160;Equity Method Investment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In connection with the execution of a stock purchase agreement with Syntone Ventures LLC (&#x201c;Syntone Ventures&#x201d;), the U.S. based affiliate of Syntone Technologies Group Co. Ltd. (&#x201c;Syntone PRC&#x201d;) on May 22, 2020, the Company and Syntone PRC entered into a joint venture agreement pursuant to which they agreed to form a People&#x2019;s Republic of China (&#x201c;PRC&#x201d;) joint venture, Beijing Syntone Biopharma Ltd (&#x201c;Syntone JV&#x201d;), that is 80% owned by Syntone PRC and 20% owned by the Company. As the Company can exert significant influence over, but does not control, Syntone JV&#x2019;s operations through voting rights or representation on Syntone JV&#x2019;s board of directors, the Company accounts for this investment using the equity method of accounting. Upon formation of Syntone JV in April 2021, the Company entered into a royalty-free license with Syntone JV for the development, commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company made the initial investment of $900,000 in June 2020 and is committed to making capital contributions to Syntone JV of approximately $2,100,000, based upon the development plan contemplated in the license agreement. The maximum exposure to a loss as a result of the Company&#x2019;s involvement in Syntone JV is limited to the initial investment and the future capital contributions totaling approximately $2,100,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_5_22_2020_dei_LegalEntityAxis_otlk_PRCJointVentureMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_gJdyvVXshEuX-08Mf6ndHA"
      decimals="2"
      id="Narr__I31htUrDUKGfxF0nmf9fg"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg"
      decimals="2"
      id="Narr_dFqRCua5mUCQBzlFx5wdtA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="Duration_6_1_2020_To_6_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_P56yKUXSbkSeAJyaiAzVzA"
      decimals="0"
      id="Narr_Xofyi92cgEuCV5B-3l5gRw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">900000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg"
      decimals="0"
      id="Narr_J6G8j3rfvEGcpfplp5biQA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2100000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg"
      decimals="0"
      id="Narr_xL6bHMSSyk2WH1dXcqx4_A"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2100000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_1zeXI7nunkemLnsvjbXf1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;6&lt;/span&gt;.&#160;&#160;&#160;&#160;&#160;Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accrued expenses consists of:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:33.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,012,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 919,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,798,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 165,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 41,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,234,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 384,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 426,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,237,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,745,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_jA3VgMLtuEW1uAEhFeGgXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:33.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,012,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 919,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,798,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 165,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 41,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,234,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 384,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 426,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,237,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,745,740&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_x5W0xv-XM0KNsA8gb2LUbw_3_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1012962</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_7HAJxnFGmkqJvnx-li3plg_3_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">919970</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_Ft9a20nwPUiV9d1JkQ7agA_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1798767</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_KVQ8hs3qiEeflonmThYUzw_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">165192</us-gaap:AccruedProfessionalFeesCurrent>
    <otlk:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_RF3KqjpfOky7Dy0lZFzv_g_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">41373</otlk:AccruedResearchAndDevelopmentExpensesCurrent>
    <otlk:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_fBldgqHcPkuzgh0MSoVcLw_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1234192</otlk:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_Z-ei7isJHEuEbc257gv-vw_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">384366</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_PV5PAiK0uUGpYlRhllC3pQ_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">426386</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_JklChQwBqUiBrPV-l2jiRA_7_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3237468</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_rwxWTl-CE0m37e76TiHw1w_7_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2745740</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_h9CBDzYiFUOjEH34i7X4LA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;7.&#160;&#160;&#160;&#160;&#160;Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Debt consists of:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:26.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unsecured convertible promissory note (measured at fair value)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,551,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,440,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35,551,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;December 2022 Note&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On December 22, 2022, the Company entered into a Securities Purchase Agreement and issued the December 2022 Note with a face amount of $31,820,000 to Streeterville Capital, LLC (the &#x201c;Lender&#x201d;), the holder of the Company&#x2019;s unsecured promissory note issued in November 2021 (the &#x201c;November 2021 Note&#x201d;). The December 2022 Note has an original issue discount of $1,820,000. The Company received net proceeds of $18,052,461 upon the closing on December 28, 2022 after deducting the Lender&#x2019;s transaction costs in connection with the issuance and a full payment of the remaining outstanding principal and accrued interest on the November 2021 Note. The November 2021 Note was cancelled upon repayment. See below for additional disclosures relating to the November 2021 Note.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In December 2023, the Company extended the maturity of the December 2022 Note from January 1, 2024 to April 1, 2024. The Company incurred a $475,000 extension fee. The December 2022 Note bore interest at 9.5% per annum through April 1, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The December 2022 Note contains customary covenants, including a restriction on the Company&#x2019;s ability to pledge certain of the Company&#x2019;s assets, subject to certain exceptions, without the Lender&#x2019;s consent. Beginning on April 1, 2023, the Lender had the right to convert the December 2022 Note at the Conversion Price (as defined below). The principal amount and conversion price of the December 2022 Note were subject to adjustment upon certain triggering events. In addition, the Company had the right to convert all or any portion of the outstanding balance under the December 2022 Note into shares of common stock at the Conversion Price if certain conditions have been met at the time of conversion, including if at any time after the six-month anniversary of the closing date, the daily volume-weighted average price of the common stock on Nasdaq equals or exceeds $50.00 per share (subject to adjustments for stock splits and stock combinations) for a period of 30 consecutive trading days. Payments may be made by the Company (i) in cash, (ii) in shares of common stock, with the number of shares being equal to the portion of the applicable payment amount divided by the Conversion Price (as defined below), or (iii) a combination of cash and shares of common stock. Any payments made by the Company in cash, including prepayments or repayment at maturity, will be subject to an additional fee of 7.5%. Upon the occurrence of certain events described in the December 2022 Note, including, among others, the Company&#x2019;s failure to pay amounts due and payable under the December 2022 Note, events of insolvency or bankruptcy, failure to observe covenants contained in the Securities Purchase Agreement and the December 2022 Note, breaches of representations and warranties in the Securities Purchase Agreement, and the occurrence of certain transactions without the Lender&#x2019;s consent (each such event, a &#x201c;Trigger Event&#x201d;), the Lender shall have the right, subject to certain exceptions, to increase the balance of the December 2022 Note by 10% for a Major Trigger Event (as defined in the December 2022 Note) and 5% for a Minor Trigger Event (as defined in the December 2022 Note). If a Trigger Event is not cured within &lt;span style="-sec-ix-hidden:Hidden_nFi_I78LHEio1BmDRkU8nQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt; (10) trading days of written notice thereof from the Lender, it will result in an event of default (such event, an &#x201c;Event of Default&#x201d;). Following an Event of Default, the Lender may accelerate the December 2022 Note such that all amounts thereunder become immediately due and payable, and interest shall accrue at a rate of 22% annually until paid. Prior to April 1, 2024, under the December 2022 Note, &#x201c;Conversion Price&#x201d; meant, prior to a Major Trigger Event, $40.00 per share (subject to adjustment for stock splits and stock combinations), and following a Major Trigger Event, the lesser of (i) $40.00 per share (subject to adjustment for stock splits and stock combinations), and (ii) 90% multiplied by the lowest closing bid price of the Company&#x2019;s common stock in the three trading days prior to the date on which the conversion notice is delivered. If the Conversion Price is below $3.51 per share, the Company will be required to satisfy a conversion notice from the Lender in cash. Subject to certain exceptions, while the December 2022 Note is outstanding, the Lender will have a consent right on any future variable rate transactions or any debt and a 10% participation right in any future debt or equity financings.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On January 22, 2024, the Company entered into an amendment to the December 2022 Note (the &#x201c;January 2024 Note Amendment&#x201d;) with the Lender, which became effective on April 1, 2024 after satisfaction of certain conditions, including various required stockholder approvals and the closing of the private placement on March 18, 2024. The maturity of the December 2022 Note was extended to July 1, 2025. An extension fee of $2,681,847 (calculated as 7.5% of the outstanding balance of the December 2022 Note) was added to the outstanding balance on March 18, 2024. The extension fee was included in interest expense in the consolidated statement of operations for the year ended September 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under the January 2024 Note Amendment, the initial conversion price with respect to $15,000,000 in aggregate principal amount of the December 2022 Note was changed to $7.00, the price per share in the private placement that closed on March 18, 2024 and the remaining aggregate principal amount has a conversion price of $40.00 per share. Effective April 1, 2024, the December 2022 Note bears interest at the &lt;span style="-sec-ix-hidden:Hidden_-FJYa8lNSUetfvJA523X1w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;prime rate&lt;/span&gt;&lt;/span&gt; (as published in the Wall Street Journal) plus 3% (subject to a floor of 9.5%) and the Company has an obligation to repay at least $3,000,000 of the outstanding balance of the December 2022 Note for each calendar quarter beginning with the second calendar quarter of 2024 (subject to adjustment for conversions by the Lender and to payment of an exit fee as set forth in the January 2024 Note Amendment) and continuing until the December 2022 Note is repaid in full. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;During the year ended September 30, 2024, an aggregate of principal and accrued interest totaling $11,250,000 of the December 2022 Note was converted into 1,607,093 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company elected to account for the December 2022 Note at fair value (Note 4) and was not required to bifurcate the conversion option as a derivative and as a result the original issue discount of $1,820,000 and debt issuance costs were written off upon election to fair value and accounted for as interest. During the year ended September 30, 2024, the Company recognized $3,156,847 of interest expense related to extension fees. During the year ended September 30, 2023, the Company recognized $2,074,964 of interest expense related to original issue discount of $1,820,000 and other third party debt issuance costs of $254,964.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;November 2021 Note&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 16, 2021, the Company received $10,000,000 in net proceeds from the issuance of the November 2021 Note with a face amount of $10,220,000. Debt issuance costs totaling $820,000 were recorded as debt discount and were deducted from the principal in the accompanying consolidated balance sheets. The debt discount was amortized as a component of interest expense over the term of the underlying debt using the effective interest method. The note bore interest at a rate of 9.5% per annum compounding daily and was set to mature on January 1, 2023. The Company could prepay all or a portion of the note at any time by paying 105% of the outstanding balance elected for prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the November 2021 Note was cancelled using proceeds from the December 2022 Note issued to the same lender. The total repayment was $11,947,539, which represented 105% of the outstanding balance and included $1,158,609 of interest expense. The transaction has been accounted for as an extinguishment of the November 2021 Note. As a result, the Company recorded a loss on debt extinguishment of $577,659, which included $8,729 of unamortized debt discount, and prepayment fees of $568,930.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended September 30, 2023, the Company recognized $454,866 of interest expense related to the unsecured promissory note, of which $190,775 was related to the amortization of debt discount. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_D7hGoQdRYk2Rhx2sLzc9Dg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:26.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unsecured convertible promissory note (measured at fair value)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,551,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,440,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (35,551,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Afa1M1WaS0SR2fyB14IoaQ"
      decimals="0"
      id="Tc_G0sSdKACWUGQ_PeS7Z4I1w_3_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">29440000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_SCSz0Z-7s0WGtX-bZHuMVg"
      decimals="0"
      id="Tc_GQYvJPJjLE-0xssbbUn8Lw_3_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">35551000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:NotesAndLoansPayableCurrent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_Jvl1DEFEPkCxUhRnuttzEg_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">29440000</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:NotesAndLoansPayableCurrent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_eSC51lU2jE2StsVJMRS3eQ_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">35551000</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ninrKLLlD0a6ZBI-j6EB3Q"
      decimals="0"
      id="Narr_2cxmf7V8S06UHtzK05y1_w"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">31820000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="0"
      id="Narr_IIixdt1PWEmEeVdgsm6k4w"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1820000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="0"
      id="Narr_TrW93v9CuEC8dNR_FOcoTA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">18052461</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_12_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_MHzt-sxje0CSeW0EsqpjLw"
      decimals="0"
      id="Narr_aZAqpAOPTEij1W_uNLzG9w"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">475000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_VI7IUXbs602kl6vuqYnf0g"
      decimals="INF"
      id="Narr_08vaMNV6s0q1ZDAKbcS3RA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_nDZ5g6kVlEe0NAjFp5VM1Q"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">50</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_IE9wrWJtbkCYFb2ljx3BXg"
      unitRef="Unit_Standard_D_HK570P66lU6uxT7voueYkg">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <otlk:DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_GxzsG5nCVkqHnHGc4cHICA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.075</otlk:DebtInstrumentPercentageOfAdditionalFeeOnPaymentsInCash>
    <otlk:DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_mDP7YtPADUSa_b4UEiy-fA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.10</otlk:DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMajorTriggerEvent>
    <otlk:DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_TiE22ZP0jUqThh88FDbp-Q"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.05</otlk:DebtInstrumentPercentageOfIncreaseInDebtBalanceByLenderForMinorTriggerEvent>
    <otlk:DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_P7Ot9aVEX0Ko2LEJ-akpoA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.22</otlk:DebtInstrumentDebtDefaultAcceleratedInterestRateOnImmediateDueAndPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ninrKLLlD0a6ZBI-j6EB3Q"
      decimals="INF"
      id="Narr_XQoPdy_gn0m2be-Aqsz-UQ"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_RQ1gGyRoQE2vajTWGBJEqg"
      decimals="INF"
      id="Narr_p68WAEh2MkKPJNrvLCDzWw"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="Duration_12_22_2022_To_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_9HupkBCxL0i0_z-wbjRQoQ"
      decimals="INF"
      id="Narr_FEuJU4xH7EqILmGfwaHzSQ"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.90</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="Duration_12_22_2022_To_12_22_2022_srt_StatementScenarioAxis_otlk_DebtInstrumentFollowingToMajorTriggerEventMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_9HupkBCxL0i0_z-wbjRQoQ"
      decimals="INF"
      id="Narr_4AwL0JZs1EuoM0Uazu_YRQ"
      unitRef="Unit_Standard_D_HK570P66lU6uxT7voueYkg">3</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <otlk:DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_ilbS6x2kXkGTkkhJNaz6LQ"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">3.51</otlk:DebtInstrumentConvertibleThresholdConversionPriceRequiredToSatisfyConversionNoticeFromLender>
    <otlk:DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="INF"
      id="Narr_qRfGNZnkAUijU4wt0Jkv7g"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.10</otlk:DebtInstrumentPercentageOfParticipationRightToLenderInFutureDebtOrEquityFinancing>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw"
      decimals="0"
      id="Narr_EautLaMCKE-dCXo8OpRpjQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2681847</us-gaap:PaymentsOfDebtIssuanceCosts>
    <otlk:DebtModificationExtensionFeeAsPercentageOfOutstandingBalance
      contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw"
      decimals="INF"
      id="Narr_Baqrf_XcOkKx4k8fdYEoOw"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.075</otlk:DebtModificationExtensionFeeAsPercentageOfOutstandingBalance>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Vnv1HvGas0WeOr-RGPMVOw"
      decimals="0"
      id="Narr_4Ymn1fKqGkGRKrkR3zVGSQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioOneMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Vnv1HvGas0WeOr-RGPMVOw"
      decimals="INF"
      id="Narr_D5PRs6baakaa8yF8-TXRaA"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_1_22_2024_srt_StatementScenarioAxis_otlk_ScenarioTwoMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_ynXa_bg7OkmqRB_LUbXGyQ"
      decimals="INF"
      id="Narr_T8HhGk6rtEy_UoJcqPkGEg"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw"
      decimals="INF"
      id="Narr_HEIymDu_nkqjVbdvauJNhw"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="As_Of_1_22_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_bGKy_9nKJ0yCir38nGdxBA"
      decimals="3"
      id="Narr_UYwx2F6ntUuLzp4oQ0QG2w"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.095</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_1_22_2024_To_1_22_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_Z4f4lxL-pUuinxd-gzV-yw"
      decimals="0"
      id="Narr_z0Wf1cuLukuR71jlKjSUSA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3000000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA"
      decimals="0"
      id="Narr_IGXTmT7DsUKD4WRXp743Gg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11250000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA"
      decimals="INF"
      id="Narr_DafWg9wJgkCk4kBKGZW8xg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1607093</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_c3P-RHBmF0ifnzCGEB0obw"
      decimals="0"
      id="Narr_6qP7lToo5ki-9mO8Xmwc1A"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1820000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_t6bU4oNWgUm2vuLVxE7paA"
      decimals="0"
      id="Narr_pSv_0N9QZk-9eUpJt9P3ug"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">3156847</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA"
      decimals="0"
      id="Narr_DNQ2TLtSFUSJgIWYewHQGg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2074964</us-gaap:InterestExpenseNonoperating>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA"
      decimals="0"
      id="Narr_GCbV41JW2Ea3Q1NydJZdhQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1820000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_DebtInstrumentAxis_otlk_SecuritiesPurchaseAgreementUnsecuredPromissoryNoteMember_zdEKXI0vXUe_2-3FjZuifA"
      decimals="0"
      id="Narr_gNU-G18h00SE_pfhs4LfVw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">254964</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ"
      decimals="0"
      id="Narr_4t1RGiGd_ECAeEVF5UHs0w"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">10000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_tRxOTTUeTkW37kzoC2c6jg"
      decimals="0"
      id="Narr__nwwSyKfvkGVzIbuPpkcNA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">10220000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ"
      decimals="0"
      id="Narr_EWdibXn1kU--gjkAY3Bjxw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">820000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_tRxOTTUeTkW37kzoC2c6jg"
      decimals="3"
      id="Narr_GQ3Y7gyFwk-fAPbTx6HBoA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="Duration_11_16_2021_To_11_16_2021_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_pZDxJjKTkUK3Jg4zIu_anQ"
      decimals="2"
      id="Narr_3Zfv25h0sUGkhjzst0WHtQ"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1.05</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g"
      decimals="0"
      id="Narr_q3xGDZeKFEqPLbZ9Q1uSSA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11947539</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g"
      decimals="2"
      id="Narr_EJA_QHYZ7U2Xia1ZskbgtA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1.05</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:InterestPaid
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g"
      decimals="0"
      id="Narr_JJAUo7_pTU6o0N_GcPNaqw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1158609</us-gaap:InterestPaid>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g"
      decimals="0"
      id="Narr_XX_nKS4A40-PmkIvHxNZ5A"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">-577659</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g"
      decimals="0"
      id="Narr_lqhaG0DSSUKq26BQVWHBHQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">8729</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_nwCFX0_6S0eJBdbB7Uq22g"
      decimals="0"
      id="Narr_ShKl5XeOJEWGfJEkaSlilw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">568930</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_sI6h_SoIjUqmJoYH1Yzl-Q"
      decimals="0"
      id="Narr_rxpCPVQGoEuaXVfmA3Ev-A"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">454866</us-gaap:InterestExpenseNonoperating>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_DebtInstrumentAxis_otlk_UnsecuredPromissoryNote2021Member_sI6h_SoIjUqmJoYH1Yzl-Q"
      decimals="0"
      id="Narr_lVaUfCbgb0yFfTm3xr_Ugg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">190775</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_1BjdEIbM-UWLDCjijJM6XA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Selexis Commercial License Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In April&#160;2013, the Company entered into commercial license agreements with Selexis for each of the ONS-3010, ONS-1045 and ONS-1050 biosimilar product candidates (which agreements were subsequently amended on May&#160;21, 2014). Under the terms of each commercial license agreement, the Company acquired a non-exclusive worldwide license under the Selexis Technology to use the applicable Selexis expression technology along with the resulting Selexis &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;materials/cell lines, each developed under the research license, to manufacture and commercialize licensed and final products, with a limited right to sublicense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company paid an upfront licensing fee to Selexis for each commercial license and also agreed to pay a fixed milestone payment for each licensed product. In addition, the Company is required to pay a low single-digit royalty on a final product-by-final product and country-by-country basis, based on worldwide net sales of such final products by the Company or any of the Company&#x2019;s affiliates or sublicensees during the royalty term. The royalty term for each final product in each country is the period commencing from the first commercial sale of the applicable final product in the applicable country and ending on the expiration of the specified patent coverage. At any time during the term, the Company has the right to terminate its royalty payment obligation by providing written notice to Selexis and paying Selexis a royalty termination fee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Each of the Company&#x2019;s commercial agreements with Selexis will expire upon the expiration of all applicable Selexis patent rights. Either party may terminate the related agreement in the event of an uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, winding up or similar circumstances. Either party may also terminate the related agreement under designated circumstances if the Selexis Technology infringes third-party intellectual property rights. In addition, the Company has the right to terminate each of the commercial agreements at any time at its convenience; however, with respect to the agreements relating to ONS-3010 and ONS-1045, this right is subject to the licensee&#x2019;s consent pursuant to a corresponding letter the Company executed in conjunction with the standby agreement entered into between Selexis and Laboratories Liomont, S.A. de C.V. (&#x201c;Liomont&#x201d;) in November&#160;2014.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The standby agreement permits Liomont to assume the license under the applicable commercial agreement for Mexico upon specified triggering events involving the Company&#x2019;s bankruptcy, insolvency or similar circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Technology License&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a technology license agreement with Selexis that will require milestone payments of $332,779 (based on an exchange rate on September&#160;30, 2024 for converting Swiss Francs to U.S. dollars) to the licensor by the Company upon achievement of certain clinical milestones and pay a single digit royalty on net sales by the Company utilizing such technology. The Company also has the contractual right to buy out the royalty payments at a future date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Litigation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On November 3, 2023, a securities class action lawsuit was filed against the Company and certain of its officers in the United States District Court for the District of New Jersey. The class action complaint alleges violations of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in connection with allegedly false and misleading statements made by the Company related to the Company&#x2019;s BLA during the period from August 3, 2021 through August 29, 2023. The complaint alleges, among other things, that the Company violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by failing to disclose that there was an alleged lack of evidence supporting ONS-5010/LYTENAVA as a treatment for wet AMD and that the Company and/or their manufacturing partner had deficient CMC controls for ONS-5010/LYTENAVA, which remained unresolved at the time the Company&#x2019;s BLA was re-submitted to the FDA and, as a result, the FDA was unlikely to approve the Company&#x2019;s BLA, and that the Company&#x2019;s stock price dropped when such information was disclosed. The plaintiffs in the class action complaint seek damages and interest, and an award of reasonable costs, including attorneys&#x2019; fees. Defendants&#x2019; motion to dismiss is currently pending before the court.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 10, 2024, certain of the company&#x2019;s officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware. &#160;The derivative complaint alleges that defendants breached their fiduciary duties by causing and/or allowing the Company to violate federal securities laws based on the same alleged misstatements as the securities class action. &#160;The derivative complaint also alleges defendants violated Section 14(a) of the Exchange Act, as well as claims for contribution, unjust enrichment, and waste of corporate assets. &#160;The derivative complaint seeks unspecified damages, corporate governance reforms, restitution, contribution, attorneys&#x2019; fees, and other costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The pending lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of the pending lawsuits and any other related lawsuits is necessarily uncertain. The Company could be forced to expend significant resources in the defense of the pending lawsuits and any additional lawsuits, and the Company may not prevail. In addition, the Company may incur substantial legal fees and costs in connection with such lawsuits. The Company currently is not able to estimate the possible cost to it from these matters, as the pending lawsuits are currently at an early stage, and the Company cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that the Company may be required to pay. Such amounts could be material to the Company&#x2019;s financial statements if it does not prevail in the defense of the pending lawsuits and any other related lawsuits, or even if it does prevail. The Company has not established any reserve for any potential liability relating to the pending lawsuits and any other related lawsuits. It is possible that the Company could, in the future, incur judgments or enter into settlements of claims for monetary damages.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Corporate office &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In March 2021, the Company entered into a three-year term corporate office lease in Iselin, New Jersey that ended on April 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In March 2024, the Company entered into a five-year term corporate office lease for its new corporate headquarters in Iselin, New Jersey that commenced on May 1, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Equipment leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of September 30, 2024, all equipment leases had expired. The Company had equipment leases with terms between 12 and 36 months and had recorded those leases as finance leases. The equipment leases bore interest between 4.0% and 13.0% per annum. Payments due under the lease contracts included minimum payments that the Company was obligated to make under the non-cancelable initial terms of the leases as the renewal terms were at the Company&#x2019;s option. Lease expense was recorded as research and development or general and administrative based on the use of the leased asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The components of lease cost for the years ended September 30, 2024 and 2023 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:47.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease cost:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 57,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 44,867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 58,089&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 46,266&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amounts reported in the consolidated balance sheets for leases where the Company is the lessee were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:37.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 274,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 26,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 297,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining lease term (years):&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average discount rate:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.9%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.5%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;13.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Other information related to leases for the years ended September 30, 2024 and 2023 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:87.9%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash paid for amounts included in the measurement of lease obligations:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 294,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under noncancelable leases at September&#160;30, 2024 are as follows for the&#160;years ending September&#160;30:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 78,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 79,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 83,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 49,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 372,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 75,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 297,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Benefit Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company maintains a defined contribution 401(k)&#160;plan (the &#x201c;Plan&#x201d;) in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum contribution amounts. The Company matches 100% of the first 3% of employee contributions. The Company assumes all administrative costs of the Plan. For the&#160;years ended September&#160;30, 2024 and 2023, the expense relating to the matching contribution was $177,309 and $136,914, respectively.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_otlk_SelexisMember_H9U6x4CDa0-Y6bDTtuTUEQ"
      decimals="0"
      id="Narr_X_0sT8gRHEi-P2injdcw-w"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">332779</us-gaap:ContractualObligation>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_3_31_2021_Wd5dAA2oOEitqaUmu8NEFg"
      id="Narr_gWuGjYkt40ejdp5M4RFUxA">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_3_31_2024_xUn2oSPd-EKiWuozrntdYA"
      id="Narr_ekAVabpKiEyveqeP_tfQBQ">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_Q7ljKxKDCE6cUaMIlRBFDw"
      id="Narr_IxRVBVEy1U-g0cB1Rj0JxQ">P12M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MaximumMember_jnZ5DzV7xUyhrtJAXYQ3mA"
      id="Narr_Psm92n-OJk2YMwTDuZ5YFg">P36M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MinimumMember_Q7ljKxKDCE6cUaMIlRBFDw"
      decimals="3"
      id="Narr_QOkm1v7BS0K-GoamNzJ9bA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.04</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="As_Of_9_30_2024_srt_RangeAxis_srt_MaximumMember_jnZ5DzV7xUyhrtJAXYQ3mA"
      decimals="3"
      id="Narr_UTrWuKpAR0Gni7XwRb7jUA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.13</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_Z0TQqVzX80y-mu63Kv2KlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The components of lease cost for the years ended September 30, 2024 and 2023 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:47.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease cost:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 57,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 44,867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 58,089&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 46,266&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amounts reported in the consolidated balance sheets for leases where the Company is the lessee were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:37.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 274,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 26,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 297,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining lease term (years):&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average discount rate:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;9.9%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;7.5%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;13.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Other information related to leases for the years ended September 30, 2024 and 2023 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:87.9%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash paid for amounts included in the measurement of lease obligations:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 294,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_qiHalihVv0iQTtriAzJKrw_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">116</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_WhNmQjkMZ0OOqLyresPNxA_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1399</us-gaap:FinanceLeaseInterestExpense>
    <otlk:FinanceLeaseCost
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_jDBXp7MfGkuOGkD9dMLUFw_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">116</otlk:FinanceLeaseCost>
    <otlk:FinanceLeaseCost
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_wCUU7fu1_kS0slhrgF4N-g_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1399</otlk:FinanceLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_RWZs5W3xSEWuBMRrjiumpg_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">57973</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_YtX6bkHGT0azS7ibJmkt_Q_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">44867</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_nnktmdJQOUi_nmwalV1_nQ_7_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">58089</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_NkfhNIcA8EiE4EiRyB3p_Q_7_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">46266</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_JexQinfdQEiGq0gmsiz0wQ_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">274645</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_0LOj6sgAFE6JWgQPYtLOrg_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">26172</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_b1MC4RfiOE-KDmFeixl3JA_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">297829</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_TxQDUjJaz06V_dK4hUmx8Q_8_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4267</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      id="Tc_kFy5RT3eAUiPuRdalIc6tQ_10_3">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      id="Tc_Myv9H_cNv0amSEWb0xQY5A_10_6">P0Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      id="Tc_C2qDDy5LP0mYWiHcXHdWgQ_11_6">P0Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="3"
      id="Tc_vdyiUe03ZUanOdgnjEY1cQ_13_3"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="3"
      id="Tc_blcq1GGXA0msMvq0WIpGVQ_13_6"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="3"
      id="Tc_COOx1LcaC0OtgIYyBpzzQg_14_6"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.13</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_S9LYdyTF1E6Q9RzVo8eomQ_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">116</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_syOJAbPq9EGkW57xKZvweA_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1399</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_n1LqRAopuEyj2wr89lsexA_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">14514</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_zgAKz_l3qEeId38wCaU1cg_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">27675</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_7cF2-R7AXkSb6Zg4dAeHxg_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4267</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_4NHUMseGh0CR1QDcroso9Q_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11751</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_yFaPYG9GUEOF9iuE8vrjKw_8_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">294416</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_kXLh-i0RTUWEaqT-WoHL-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 78,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 79,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 83,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 49,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 372,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 75,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 297,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_N8Szvjj1SUa36DcmJuNT9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 78,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 79,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 81,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 83,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 49,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 372,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 75,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 297,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_R0bfEL3Ot0iLgpfb_jO1cg_2_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">78091</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_zhr9r25RdkWwv2uNGTD7hg_3_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">79954</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_ET3fV8E1hkStUHSf22g4mQ_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">81817</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_fSzo47tYhUaZS_WkYlqtgA_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">83680</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_WS9uVjbH40-anBl8lMe5OQ_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">49447</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_hmpGpoWC8UuiNiIj6FEo2g_7_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">372989</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_f95mxds67UeaKJaZRmcXnQ_8_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">75160</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_Lnr8aWrKk0G6lV3UgTXV7g_9_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">297829</us-gaap:OperatingLeaseLiability>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="2"
      id="Narr_lmPXGKGL2U6QZFBP99Pprw"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="2"
      id="Narr_QVN1LybTfkGecwya9Y5vXA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="2"
      id="Narr_iuJT_S7W2EyPCy0AmDdCOg"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Narr_NtQp7SZlG0q17Sxs-87DZQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">177309</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Narr_l05dg9jV8kOH5e0oKVs3Zw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">136914</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_w5coq2t7mUGH_jQ5zop-_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;9.&#160;&#160;&#160;Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On March 7, 2024, following receipt of stockholder approval at the Company&#x2019;s 2024 annual meeting of stockholders, the number of authorized shares of common stock under the Company&#x2019;s Certificate of Incorporation was increased from &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;21,250,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;60,000,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 18, 2024, in a private placement (the &#x201c;Private Placement&#x201d;) pursuant to a securities purchase agreement entered in January 2024 with certain institutional and accredited investors, including GMS Ventures and Investments (&#x201c;GMS Ventures&#x201d;), the Company&#x2019;s largest stockholder, the Company issued an aggregate of 8,571,423 shares of common stock and warrants to purchase an aggregate of 12,857,133 shares of common stock at a purchase price per share of $7.00 per share and accompanying warrant to purchase one and &lt;span style="-sec-ix-hidden:Hidden_DkBDMcGwhUOfLjYffyDfaA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-half shares of common stock for $55,498,311 in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of 2,305,714 shares of common stock and warrants to purchase an aggregate of 3,458,571 shares of common stock in the Private Placement. The Warrants have an exercise price of $7.70 per share of common stock and will expire on March 18, 2029.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On April 15, 2024, in a private placement with Syntone pursuant to a securities purchase agreement entered into in January &#160;2024 (the &#x201c;Syntone Private Placement&#x201d;), the Company issued 714,286 shares of common stock and accompanying warrants to purchase 1,071,429 shares of common stock for $4,835,371 in net proceeds on substantially the same terms as those in the Private Placement. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;The Company evaluated the equity classification for the common stock warrants and considered the conditions as prescribed within ASC 815-40,&#160;&lt;/span&gt;&lt;i style="color:#212529;font-style:italic;"&gt;Derivatives and Hedging, Contracts in an Entity&#x2019;s own Equity&lt;/i&gt;&lt;span style="color:#212529;"&gt;&#160;(&#x201c;ASC 815-40&#x201d;). The Company determined that the warrants did not meet the &#x201c;fixed for fixed&#x201d; settlement provision set forth in Step 2 of the indexation guidance and as a result they are not indexed to the Company&#x2019;s own stock and must be classified as liabilities. The warrants were measured at fair value at issuance and recorded as a liability and will be remeasured to fair value at each subsequent reporting date, with changes in fair value recorded in current earnings. The net proceeds from the Private Placement were allocated first to the warrants at fair value, with the residual amount recorded as common stock at par value. The Company will continue to classify such warrants as liabilities until they are exercised, expire, or are no longer required to be classified as liabilities&lt;/span&gt;&lt;span style="font-size:12pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In December 2022, in a registered direct equity offering to certain institutional and accredited investors, including GMS Ventures, the Company issued &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;1,423,041&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares of common stock at a purchase price per share of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$17.568&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; for &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$23,208,679&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; in net proceeds after payment of placement agent fees and other offering costs. GMS Ventures purchased an aggregate of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;711,520&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares of common stock in the registered direct equity offering. In connection with the registered direct equity offering, the Company issued to M.S. Howells &amp;amp; Co., the placement agent, warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;25,787&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares of common stock at an exercise price of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$21.00&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; per share, which warrants have a &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;three-year&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Subject to preferences that may apply to any outstanding preferred stock, holders of common stock are entitled to receive ratably any dividends that the Company&#x2019;s board of directors may declare out of funds legally available for that purpose on a non-cumulative basis. No dividends had been declared through September&#160;30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;H.C. Wainwright &amp;amp; Co. At-the-Market Offering Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On March 26, 2021, the Company entered into an At-the-Market Offering Agreement with H.C. Wainwright &amp;amp; Co., as sales agent (&#x201c;Wainwright&#x201d;), (the &#x201c;Wainwright ATM Agreement&#x201d; or the &#x201c;Wainwright ATM Offering&#x201d;), under which the Company may issue and sell shares of its common stock from time to time through Wainwright as sales agent. The Company filed a prospectus supplement, dated March 26, 2021, with the Securities and Exchange Commission pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to up to $40,000,000 from time to time through Wainwright. The Company incurred financing costs of $197,654 which were &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;capitalized and were being reclassified to additional paid in capital on a pro rata basis when the Company sold common stock under the Wainwright ATM Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Under the Wainwright ATM Offering, the Company paid Wainwright a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the Wainwright ATM Agreement. The Company terminated the Wainwright ATM Agreement effective May 15, 2023. As a result, the Company wrote off unamortized deferred costs under the Wainwright ATM Agreement. During the year ended September 30, 2023, the Company sold 44,769 shares of common stock under the Wainwright ATM Offering and generated $1,089,105 in net proceeds after paying fees to Wainwright of $38,799. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTIG, LLC At-the-Market Offering Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On May 16, 2023, the Company entered into an At-the-Market Sales Agreement with BTIG, LLC (&#x201c;BTIG&#x201d;), as sales agent (the &#x201c;BTIG ATM Agreement&#x201d; or the &#x201c;BTIG ATM Offering&#x201d;), under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100,000,000 from time to time through BTIG. The Company incurred financing costs of $353,688, which were capitalized and are being reclassified to additional paid in capital on a pro rata basis when the Company sells common stock under the BTIG ATM Offering. As of September 30, 2024, $331,512 of such deferred costs are included in other assets on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under the BTIG ATM Agreement, the Company pays BTIG a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the BTIG ATM Agreement. The offering of common stock pursuant to the BTIG ATM Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the BTIG ATM Agreement or (ii) termination of the BTIG ATM Agreement in accordance with its terms. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;During the year ended September 30, 2024, no shares of common stock were sold under the BTIG ATM Offering. During the year ended September 30, 2023, the Company sold 178,911 shares of common stock under the BTIG ATM Offering and generated $6,080,088 in net proceeds after paying fees to BTIG and other issuance costs of $188,044.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of September&#160;30, 2024, the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;common stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;issuable upon&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 22, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 240.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February 24, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,642&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;April 13, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 240.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;May 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 240.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 22, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 28, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;January 28, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February 2, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 93,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;November 23, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 104,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 18, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,857,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;April 15, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,071,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,207,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The warrants were issued in connection with the convertible senior secured notes originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017 and are classified as liabilities on the accompanying consolidated balance sheets, as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The warrants were issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 and are exercisable only for cash, except in limited circumstances, at any time after the date of issuance. The Company evaluated the warrants under ASC 815-40 guidance and determined that the warrants did not meet Step 2 of the indexation. As a result they are not indexed to the Company&#x2019;s own stock and must be classified as liabilities. Refer to the disclosure above under the header &#x201c;&#x2014;Common stock&#x201d; for further details.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"&gt;A holder of warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than a specified percentage of the outstanding common stock (4.99%, 9.99% or 19.99%, as applicable), immediately after giving effect to such exercise, which may be increased or decreased at the holders&#x2019; option (not to exceed 19.99%), effective 61 days after written notice to the Company. In addition, the Company may require the holders to cash exercise the warrants under certain circumstances as follows: (i) if the daily volume weighted average price (the &#x201c;VWAP&#x201d;) of the common stock equals or exceeds $20.00 per share (subject to adjustment in the event of stock splits, combinations or similar events, such as the reverse stock split implemented prior to closing) for 30 consecutive days (the &#x201c;Stock Price Condition&#x201d;) at any time after the Company publicly announces topline data from its NORSE EIGHT clinical trial evidencing satisfaction of the trial&#x2019;s primary endpoints (the &#x201c;NORSE EIGHT Announcement&#x201d;), upon the consent of a majority of the members of the Company&#x2019;s board of directors, the Company may require the holders to exercise up to 20% of the aggregate number of warrants issued to such holder on the issue date; and (ii) the Company may require up to the remainder of the warrants be exercised (A) if the Stock Price Condition is satisfied at any time after the Company publicly announces approval from the FDA of its BLA for ONS-5010/LYTENAVA, upon the consent of a majority of the members of the board of directors or (B) if the Stock Price Condition is satisfied at any time after the NORSE EIGHT Announcement, upon the unanimous consent of the members of the Company&#x2019;s Board of Directors present at a duly called meeting.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_6_2024_pDZUs5e-AkWbZ0eR564CBQ"
      decimals="INF"
      id="Narr_Xvx3G3GzuEq79kAGuWRfPQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">21250000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_7_2024_lLMZhv4wdEyjXYMfzCMdRA"
      decimals="INF"
      id="Narr_c2CFq4FjmEubXIYrOV9hKg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_18_2024_To_3_18_2024_T3YCPqRoGE2MDvlAJH7KjQ"
      decimals="INF"
      id="Narr_WopA9EXk70iNi2MtU2GT2g"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">8571423</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA"
      decimals="INF"
      id="Narr_OcV4V5B9J0KDIZdpGVW_bg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">12857133</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA"
      decimals="INF"
      id="Narr_CLpR9WxER0ymz7VuhpdaGQ"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_18_2024_To_3_18_2024_T3YCPqRoGE2MDvlAJH7KjQ"
      decimals="0"
      id="Narr_utc_NSBm9USUqY7ReoIl2w"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">55498311</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_18_2024_To_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_3Dv-BLq7jECeFMzClAG8Nw"
      decimals="INF"
      id="Narr_L54uZgdthE-8jiFMvJrEDw"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">2305714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_18_2024_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_tR_1C3dSWUSlzc9QqxzIbQ"
      decimals="INF"
      id="Narr_T7PzcCsE10CKsHfEIp8C1w"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">3458571</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_18_2024_6ID98Bnn8kmnFtvnUPKVXA"
      decimals="INF"
      id="Narr_iFIFdveCWk-Ii1giegZ4Qw"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_15_2024_To_4_15_2024_PCVHwACz-E-GaHioJ0Mb4Q"
      decimals="INF"
      id="Narr_nxqnRRhIq0K3zPWDV3T8wQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">714286</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_15_2024_ktUhxMsOBk6ial5Q3nMCKA"
      decimals="INF"
      id="Narr_qXJu2oi1YEGSDxYyp-D81g"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1071429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_15_2024_To_4_15_2024_PCVHwACz-E-GaHioJ0Mb4Q"
      decimals="0"
      id="Narr_A5VZTRbJW0SZ605Fi0sNfg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4835371</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_15_2024_ktUhxMsOBk6ial5Q3nMCKA"
      decimals="INF"
      id="Narr_s5pjUc_MZ0mu5DERhFCxbg"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_6SGXL8bLrEG6_8cW5MPZcg"
      decimals="INF"
      id="Narr_jVCcfBnR3Eu72H6xaecOOQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1423041</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_t3JCYhRKO0qAD5NVNkzh_w"
      decimals="4"
      id="Narr_oUHV2-OIfEmSugXjGsb74w"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">17.568</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_6SGXL8bLrEG6_8cW5MPZcg"
      decimals="0"
      id="Narr_4OSaVURwa0iKb-P7l_xCKw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">23208679</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_otlk_GmsVenturesInvestmentsMember_us-gaap_SubsidiarySaleOfStockAxis_otlk_DirectRegisteredOfferingMember_tMGVlJe9F0SPML1If6N2Lw"
      decimals="INF"
      id="Narr_9mcwaEt8-kymGqxYm01V6A"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">711520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA"
      decimals="INF"
      id="Narr_ZYcBnKUvwEek4lFXQ6H0rQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">25787</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA"
      decimals="2"
      id="Narr_yGTg4fY6l0yUvYmurUvJcw"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_jvT-XZQLcUmGZedw1CkzZA"
      id="Narr_C9WpZsk41kSJIrIrhSbGrg">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CommonStockVotingRights
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Narr_gKwikTpzyEq0Dk-G-tsTCA">one</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Narr_fDIULpkn5UeLrESZnPt4XQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">0</us-gaap:DividendsCommonStock>
    <otlk:AggregateOfferingPriceAuthorized
      contextRef="As_Of_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_KmQM4eVrbkSrlJCBAuGuLg"
      decimals="0"
      id="Narr_FS53WSW5f0ieufczKtaMVA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">40000000</otlk:AggregateOfferingPriceAuthorized>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_Wo2tL6zH10-t08OvobXAMA"
      decimals="0"
      id="Narr_QawwIP1b9UC6NuBd_eY2og"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">197654</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <otlk:PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission
      contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_Wo2tL6zH10-t08OvobXAMA"
      decimals="3"
      id="Narr_c2X1l5fyhkWbFkqqeOiiHQ"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.03</otlk:PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g"
      decimals="INF"
      id="Narr_AzYfGm-DQUeiUzR3Ala9dg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">44769</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g"
      decimals="0"
      id="Narr_fvKWlKfb6k-lHz4vVstHQg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1089105</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingMember_w6RORCnd2UyLWMl8pP1h0g"
      decimals="0"
      id="Narr_yvP2Xkcc10eKM8A_9zUDhw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">38799</us-gaap:PaymentsOfStockIssuanceCosts>
    <otlk:AggregateOfferingPriceAuthorized
      contextRef="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_A1DDuw-oSUK__0BNs8JxRw"
      decimals="0"
      id="Narr_T13G7iEQYkiAnrQaKJsNrA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">100000000</otlk:AggregateOfferingPriceAuthorized>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_ecX5SQhuQUOy_xktLgPaqg"
      decimals="0"
      id="Narr_fcp7HqvOl0G-4yflqfwxtw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">353688</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:DeferredCosts
      contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_iTKqGJl7VU6tkLMN2O_qZA"
      decimals="0"
      id="Narr_RCWMK2U7Sk2Pj_eoco0LQg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">331512</us-gaap:DeferredCosts>
    <otlk:PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission
      contextRef="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_ecX5SQhuQUOy_xktLgPaqg"
      decimals="3"
      id="Narr_n9dqHjCP2UWyC-4hNnZpRQ"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.03</otlk:PercentageOfGrossProceedsFromSaleOfCommonStockToBePaidAsCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_9gDHf8RsIEKIozNakQyBHA"
      decimals="INF"
      id="Narr_WLhaXY_Gdkmrh8i45ODJHA"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw"
      decimals="INF"
      id="Narr_E5JR6dFzSkSs2N2mels11g"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">178911</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw"
      decimals="0"
      id="Narr_KyEp-fSCbEGUWe9dAU5rBQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6080088</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_otlk_AtMarketOfferingBtigMember_j0uyM2m_4k2F9MdaIX_1Fw"
      decimals="0"
      id="Narr_4sMoVEWeTESuQ9EDRpJCKg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">188044</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_9_Sf7UephkmaZbBXC-cbvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;common stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;issuable upon&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.22%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 22, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 240.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February 24, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,642&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;April 13, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 240.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;May 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(i)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 240.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 22, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December 28, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;January 28, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February 2, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 93,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;November 23, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 104,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March 18, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,857,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;April 15, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(ii)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,071,429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,207,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The warrants were issued in connection with the convertible senior secured notes originally issued pursuant to the certain Note and Warrant Purchase Agreement dated December 22, 2017 and are classified as liabilities on the accompanying consolidated balance sheets, as the warrants include cash settlement features at the option of the holders under certain circumstances. Refer to Note 4 for fair value measurements disclosures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The warrants were issued in connection with private placements that closed on March 18, 2024 and April 15, 2024 and are exercisable only for cash, except in limited circumstances, at any time after the date of issuance. The Company evaluated the warrants under ASC 815-40 guidance and determined that the warrants did not meet Step 2 of the indexation. As a result they are not indexed to the Company&#x2019;s own stock and must be classified as liabilities. Refer to the disclosure above under the header &#x201c;&#x2014;Common stock&#x201d; for further details.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"&gt;A holder of warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than a specified percentage of the outstanding common stock (4.99%, 9.99% or 19.99%, as applicable), immediately after giving effect to such exercise, which may be increased or decreased at the holders&#x2019; option (not to exceed 19.99%), effective 61 days after written notice to the Company. In addition, the Company may require the holders to cash exercise the warrants under certain circumstances as follows: (i) if the daily volume weighted average price (the &#x201c;VWAP&#x201d;) of the common stock equals or exceeds $20.00 per share (subject to adjustment in the event of stock splits, combinations or similar events, such as the reverse stock split implemented prior to closing) for 30 consecutive days (the &#x201c;Stock Price Condition&#x201d;) at any time after the Company publicly announces topline data from its NORSE EIGHT clinical trial evidencing satisfaction of the trial&#x2019;s primary endpoints (the &#x201c;NORSE EIGHT Announcement&#x201d;), upon the consent of a majority of the members of the Company&#x2019;s board of directors, the Company may require the holders to exercise up to 20% of the aggregate number of warrants issued to such holder on the issue date; and (ii) the Company may require up to the remainder of the warrants be exercised (A) if the Stock Price Condition is satisfied at any time after the Company publicly announces approval from the FDA of its BLA for ONS-5010/LYTENAVA, upon the consent of a majority of the members of the board of directors or (B) if the Stock Price Condition is satisfied at any time after the NORSE EIGHT Announcement, upon the unanimous consent of the members of the Company&#x2019;s Board of Directors present at a duly called meeting.&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_5wnuAFtnzkWYbs_N6ZIXsQ"
      decimals="0"
      id="Tc_s12FDT5KyEW3z3oPBBuoaw_6_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">13850</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyTwoDecemberTwoThousandTwentyFourMember_5wnuAFtnzkWYbs_N6ZIXsQ"
      decimals="INF"
      id="Tc_j8Qwy8yI1USniUlwiODU7A_6_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">240</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_VvsudmHpd0ulTJVNbJMjYQ"
      decimals="0"
      id="Tc_ilMQp46UjEiGwQl_Vs5tJw_7_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">8642</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyFourFebruaryTwoThousandTwentyFiveMember_VvsudmHpd0ulTJVNbJMjYQ"
      decimals="INF"
      id="Tc_KkTwEjTQQk2-s_qnMRJa2g_7_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">25.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirteenAprilTwoThousandTwentyFiveMember_UmZHRjMnC0qFpaKeOWRUqw"
      decimals="0"
      id="Tc_4LMCrR1dGU6xINi9zOcP1Q_8_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">7284</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirteenAprilTwoThousandTwentyFiveMember_UmZHRjMnC0qFpaKeOWRUqw"
      decimals="INF"
      id="Tc_2GDx7S_efECbQvMKMcp5dw_8_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">240</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_7YfxW7oNqECNDRvtIT0roQ"
      decimals="0"
      id="Tc_nW2fKW3xzEyYNS4LGP6Htw_9_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">3121</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_ThirtyFirstMayTwoThousandTwentyFiveMember_7YfxW7oNqECNDRvtIT0roQ"
      decimals="INF"
      id="Tc_razAAv8q4UWwxIyQrs-6rg_9_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">240</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentySecondJuneTwoThousandTwentyFiveMember_ZSTbnrDNxUGsk02iJzVFvA"
      decimals="0"
      id="Tc_VxkagzBAKkygkZLD6n6Srg_10_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">9563</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentySecondJuneTwoThousandTwentyFiveMember_ZSTbnrDNxUGsk02iJzVFvA"
      decimals="INF"
      id="Tc_QoZ8SCJ5tUe5fGG30ys8fA_10_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">30.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_tHeUnkmGn0e6bXwpNgxn8w"
      decimals="0"
      id="Tc_BjzXLw-Yg0eE7qKpqHNCqA_11_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">25787</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthDecemberTwoThousandTwentyFiveMember_tHeUnkmGn0e6bXwpNgxn8w"
      decimals="INF"
      id="Tc_EpydL18cwkSkU0Y0XyQ7iQ_11_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_z4Qp_byL30eF_-1LyvR3aQ"
      decimals="0"
      id="Tc_4TZSXeaJxU-tLVOqU_4a2g_12_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">12576</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyEighthJanuaryTwoThousandTwentySixMember_z4Qp_byL30eF_-1LyvR3aQ"
      decimals="INF"
      id="Tc_gOevLIV3aEatVvJMYsKxtQ_12_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_WarrantExpirationDateFebruary22026Member_zdlkKXee3EeGESp4jsin-Q"
      decimals="0"
      id="Tc_yRHpddohgEeBCoe-8wJJPA_13_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">93238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_WarrantExpirationDateFebruary22026Member_zdlkKXee3EeGESp4jsin-Q"
      decimals="INF"
      id="Tc_AiK0TlKDMkKuIjlAlmlfjQ_13_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyThirdNovemberTwoThousandTwentySixMember_EB2rl2TAN0CnXGRhH5XKvQ"
      decimals="0"
      id="Tc_Yasj6GVOE0-9QJQAe8Xzvg_14_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">104999</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_TwentyThirdNovemberTwoThousandTwentySixMember_EB2rl2TAN0CnXGRhH5XKvQ"
      decimals="INF"
      id="Tc_Q4YHl593RkuT5SISDzT8fA_14_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">31.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_EighteenMarchTwoThousandTwentyNineMember_0ANP-WX04kCa7auIEgQwfQ"
      decimals="0"
      id="Tc_L2CtAwjmfUW0Nwx0R9sa6Q_15_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">12857133</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_EighteenMarchTwoThousandTwentyNineMember_0ANP-WX04kCa7auIEgQwfQ"
      decimals="INF"
      id="Tc_oz7gISmqx0yCE1JoZWwfcQ_15_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_FifteenthAprilTwoThousandTwentyNineMember_laMN9AKa2kC-sX-fpIwEWw"
      decimals="0"
      id="Tc_w7606cjiKEOja-KV2qwEIQ_16_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1071429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_otlk_FifteenthAprilTwoThousandTwentyNineMember_laMN9AKa2kC-sX-fpIwEWw"
      decimals="INF"
      id="Tc_plYVGIloOEO2XIsPC6G_Tg_16_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_j0eXJBSBM06qGYoCr_kw7Q_17_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">14207622</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <otlk:BeneficialOwnershipOneForHolderToNotExerciseWarrant
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="4"
      id="Narr_Af6dCgWpPUuI9hMBVTrPdA"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.0499</otlk:BeneficialOwnershipOneForHolderToNotExerciseWarrant>
    <otlk:BeneficialOwnershipTwoForHolderToNotExerciseWarrant
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="4"
      id="Narr_TcWo3YEKwkOLqkjV4rH_yg"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.0999</otlk:BeneficialOwnershipTwoForHolderToNotExerciseWarrant>
    <otlk:BeneficialOwnershipThreeForHolderToNotExerciseWarrant
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="4"
      id="Narr_AdIhFon2H0KFs1WSwtALIQ"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.1999</otlk:BeneficialOwnershipThreeForHolderToNotExerciseWarrant>
    <otlk:BeneficialOwnershipThreeForHolderToNotExerciseWarrant
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="4"
      id="Narr_-u5JZ-dLbkyp99VaKAjQ_g"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.1999</otlk:BeneficialOwnershipThreeForHolderToNotExerciseWarrant>
    <otlk:PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="4"
      id="Narr_-uyCpU-7Tkmc8ZKTJ4qUaQ"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.20</otlk:PercentageOfAggregateNumberOfWarrantsHoldersMayRequireToExerciseUponSatisfactionOfCertainConditions>
    <us-gaap:PreferredStockTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_0TrG-4B-mESfJ7zTxjDrdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;10.&#160;&#160;&#160;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May 13, 2024, the Company filed a Certificate of Elimination to its Certificate of Incorporation, as then amended, with the Secretary of State of the State of Delaware to eliminate from the Certificate of Incorporation all matters set forth in the Certificates of Designation filed with the Secretary of State of the State of Delaware on September 8, 2017 (with respect to its Series A Convertible Preferred Stock and the Series B Convertible Preferred Stock) and July 18, 2018, as amended on March 19, 2020 (with respect to its Series A-1 Convertible Preferred Stock) and returning each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series A-1 Convertible Preferred Stock to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series. There were no outstanding shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock or Series A-1 Convertible Preferred Stock as of May 13, 2024. Immediately following the filing of the Certificate of Elimination, the Company filed a Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, which restates and integrates but does not further amend the Company&#x2019;s Certificate of Incorporation, as then amended. The number of authorized shares of preferred stock under the Company&#x2019;s Certificate of Incorporation is 10,000,000 shares.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_5_13_2024_CMktv_oZdUe5aaSem6VwXg"
      decimals="INF"
      id="Narr_0gX0VFb1xka4lmJ1YTW2BQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr_sjbcPMMhoE-F-CimOjVRhQ"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_mK4dgQoBEkami-BAxemitA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2011 Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s 2011 Equity Compensation Plan (the &#x201c;2011 Plan&#x201d;) provided for the Company to sell or issue restricted common stock, restricted stock units (&#x201c;RSUs&#x201d;), performance-based awards (&#x201c;PSUs&#x201d;), cash-based awards or to grant stock options for the purchase of common stock to officers, employees, consultants and directors of the Company. The 2011 Plan was administered by the board of directors or, at the discretion of the board of directors, by a committee of the board. As of September 30, 2024, there were no equity awards outstanding under the 2011 Plan. In light of the December&#160;2015 adoption of the 2015 Equity Incentive Plan, (the &#x201c;2015 Plan&#x201d;) no future awards under the 2011 Plan will be granted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2024 Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December&#160;2015, the Company adopted the 2015 Plan. The 2015 Plan provided for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;compensation to Company employees, directors and consultants. In August 2024, the Company&#x2019;s stockholders approved the amendment and restatement of the 2015 Plan and, in connection with amending and restating the 2015 Plan, the name of the 2015 Plan was updated to the Outlook Therapeutics, Inc. 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;). The 2024 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards and other forms of equity compensation to Company employees, directors and consultants. The aggregate number of shares of common stock authorized for issuance pursuant to the Company&#x2019;s 2024 Plan is 7,293,901. As of September 30, 2024, 4,680,755 shares remained available for grant under the 2024 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Stock options and RSUs granted under the Company's 2024 Plan generally vest over a period of &lt;span style="-sec-ix-hidden:Hidden_bxPvBnUfBkO5HfmvqqI1rg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to four years from the date of grant and, in the case of stock options, have a term of 10 years. The Company recognizes the grant date fair value of each option and share of RSU over its vesting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the years ended September 30, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:46.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.12%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 800,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 986,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,584,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,560,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,385,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,547,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 11pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes all of the Company&#x2019;s stock option activity for the&#160;years ended September&#160;30, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at October 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,197,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 817,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,645)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,946,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,006,079&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value represents the total amount by which the fair market value of the common stock subject to options exceeds the exercise price of the related options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of each stock option award on the grant date using the Black-Scholes option pricing model, wherein expected volatility is based on a weighted average of the Company&#x2019;s historical volatility and the volatilities of similar entities within the Company&#x2019;s industry which are commensurate with the expected term assumption. The expected term calculation is based on the &#x201c;simplified&#x201d; method described in Staff Accounting Bulletin (&#x201c;SAB&#x201d;) No.&#160;107, &lt;i style="font-style:italic;"&gt;Share-Based Payment&lt;/i&gt;, and SAB No.&#160;110, &lt;i style="font-style:italic;"&gt;Share-Based Payment&lt;/i&gt;, since the simplified method provides a reasonable estimate in comparison to actual experience. The risk-free interest rate is based on the U.S. Treasury yield at the date of grant for an instrument with a maturity that is commensurate with the expected term of the stock options. The dividend yield is zero since the Company has never paid cash dividends on its common stock and has no present intention to pay cash dividends. Options granted under the 2024 Plan generally vest over &lt;span style="-sec-ix-hidden:Hidden_aurQEKRsiUKUgtUDwMQVZw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to four years and have a term of 10 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The weighted average grant date fair value of the options awarded to employees and directors for the&#160;years ended September&#160;30, 2024 and 2023 was $6.04 and $19.40 per option, respectively. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 111.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30, 2024, there was $7,508,106 of unrecognized compensation expense that is expected to be recognized over a weighted-average period of 1.3 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Performance-based stock options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company granted certain officers of the Company option awards where vesting was contingent upon meeting certain company-wide performance goals. The performance stock options were granted &#x201c;at-the-money&#x201d; and have a term of 10 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each option grant under the performance share option plan was estimated on the date of grant using the same option valuation model used for non-statutory options above. Compensation expense for performance-based stock options is only recognized when management determines it is probable that the awards will vest. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"&gt;The following table summarizes all of the Company&#x2019;s performance-based stock option activity for the years ended September 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at October 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 634,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 666,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The weighted average grant date fair value of the performance stock options awarded for the years ended September 30, 2024 and 2023 was $6.52 and $18.20 per option, respectively. During the year ended September 30, 2024, no expense was recognized because the performance conditions were not considered probable of achievement. As of September 30, 2024, the Company assessed that the performance conditions related to the performance options granted were not probable of achievement. The assessment was based on the relevant facts and circumstances and therefore no compensation costs were recognized. The fair value of the options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 125.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 91.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Performance-based stock units&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has issued PSUs, which generally have a ten-year life from the date of grant. Upon exercise, the PSU holder receives common stock or cash at the Company&#x2019;s discretion. The following table summarizes the activity related to PSUs during the&#160;years ended September&#160;30, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per PSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at October 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 999.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 999.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_8_31_2024_Z5sSwB3u8UeB-gHP0Yk07Q"
      decimals="INF"
      id="Narr_L9ekvSpDgkyYntLcTMvjXw"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">7293901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="INF"
      id="Narr_4HO4o6Fu4EGVt7Rau9w1sg"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">4680755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_1_2024_To_8_31_2024_srt_RangeAxis_srt_MaximumMember_HtgYYVJwm0iJl8VrJguejw"
      id="Narr_Rg2pWsQ7UE6UxOrPLujbuQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_1_2024_To_8_31_2024_Xa-tuAfcY0uN_xgNYumOzA"
      id="Narr_ed3yyXgILkOWqqYeGD5prQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_9UnFvFbYukyj3tDxG0lPUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:46.73%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.12%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 800,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 986,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,584,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,560,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,385,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,547,019&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rYTA6Gi8qkKqslIZHJezrg"
      decimals="0"
      id="Tc_kB6oOsQ5wUCte4S3LULOPg_3_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">800956</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_jYVe9FMFeUqI7idUL2hGsQ"
      decimals="0"
      id="Tc_CJvKwgkOGUGfh3pfwI3xZw_3_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">986598</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OOq4Je4wC0aStmP-fhnlkw"
      decimals="0"
      id="Tc_1160IBX6bESWRzHjoeuqWA_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4584168</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3_uEMNY46EulPN5v_asqtw"
      decimals="0"
      id="Tc_GFIcbu5pxEqOWT-WCy5fIw_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">4560421</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_d_UI10dn2E-HWXolhClVYg_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5385124</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_Rm48gu_MS0utEPDSGDIurQ_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5547019</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      id="Tb_eYOR7h830EeDSPaCBWN-cQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at October 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,197,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 817,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (59,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,645)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,946,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,006,079&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Eds8gmT6BESQIrdG8MwAiQ"
      decimals="INF"
      id="Tc_OWPiDge0A0GfsLHtgFI1sw_6_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1197774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Eds8gmT6BESQIrdG8MwAiQ"
      decimals="2"
      id="Tc_Q7RB74ePlkurtiK5fJqTrQ_6_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">28.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="INF"
      id="Tc_RGW452GvekWJs2wWjEeN1g_7_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">817729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="2"
      id="Tc_YRaIVnnc00KKV68lgajFWA_7_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">6.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="INF"
      id="Tc_3D3HShkMDEOtehuE2XqHWA_8_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">59212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="2"
      id="Tc_ug13uxfMCkmF0avuaQdlIg_8_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">26.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="INF"
      id="Tc_j55qaOi7e0GkjGnGqjP9OA_9_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">9645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="2"
      id="Tc_7G9jWjU7dEy8LoP2aIeUEQ_9_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">34.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"
      decimals="INF"
      id="Tc_0GBGSdyVM0CutjNMEV2p_A_10_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1946646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"
      decimals="2"
      id="Tc_YYBbRajJCUKgFFeK16iq_Q_10_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">19.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      id="Tc_6oAjZgj8RU-p66ekNP0j9A_10_7">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"
      decimals="0"
      id="Tc_-g-wYqjNwkKrEhNMz4qq-A_10_10"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">53985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"
      decimals="INF"
      id="Tc_NEI23IPLVUSCpD2NgoLB9Q_11_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">1006079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"
      decimals="2"
      id="Tc_pZkpfNfkZUacmsYRNZeG7g_11_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">26.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      id="Tc_wyOg2mYoP0Wp4r1mcbjLMQ_11_7">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"
      decimals="0"
      id="Tc_3T_QqIw4u06y5NTZYP36Tw_11_10"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">53985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="2"
      id="Narr_5rwPqNp1GEWO9fYcAtnr1Q"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_1_2023_To_9_30_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_urH4VPBGPEWtUdqeC7Beig"
      id="Narr_widPNIyONkOGT3ve6_VZyQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      id="Narr_b20xk0-ndEiwyo36kVe2Kw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="2"
      id="Narr_q8eLQBW9a0icy4p9E3z9Zw"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">6.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw"
      decimals="2"
      id="Narr_7uHsGXGVpk-TQ4T9LalHtw"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">19.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      id="Tb_4EcWMQ8wek-8G2DzhPtNjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 111.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="4"
      id="Tc_ZnAk24c3CEqaM1Kw3trNmA_3_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw"
      decimals="4"
      id="Tc_OF_8NUU1tUK0ns1auQHtdw_3_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      id="Tc_ex-cmMJ9c0Gm6cS2k52MuQ_4_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw"
      id="Tc_riB_UWgkE0C4pxMPFTHo9g_4_4">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      decimals="4"
      id="Tc_rHqF-CUoTkaUschULIs3Tw_5_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1.314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZPwMtV7OOUioRMWPcKuJgw"
      decimals="4"
      id="Tc_dSrSeIcdeUm4eL8Lh4Eihg_5_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1.116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ees7EpasGUmhlJfndqREhw"
      decimals="0"
      id="Narr_HacWQURGQEuXX1oC-6EP-A"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">7508106</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SBSnutf-K06L9Q_UsxJPkA"
      id="Narr_irvpxI6zDU6IC7aoVO9HKQ">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      id="Narr_el-qtTKfE0K2pK5bBnG9fQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      id="Tb_qeY_CQ-p3Ey2Mf84i2bYxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at October 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 634,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 666,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_pJJcoDJ6gU6lV4j5MOa6zA"
      decimals="INF"
      id="Tc_GaQfIpZVK0y28HwOYz5QnQ_6_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_pJJcoDJ6gU6lV4j5MOa6zA"
      decimals="2"
      id="Tc_LcCWCVMWTUK2mMG9pegoKw_6_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">28.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="INF"
      id="Tc_beTBNn91g02MpRcKc-0oZQ_7_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="2"
      id="Tc_d-ti5wq22kqfUsw1oAdXgQ_7_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">6.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="INF"
      id="Tc_gJhpRp05lECNS4m2k-8bEQ_8_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="2"
      id="Tc_dPWMMEss80GWexPnjM55dw_8_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">6.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA"
      decimals="INF"
      id="Tc_T_3gWRVQFke2_vNg3whqEw_9_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">666500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA"
      decimals="2"
      id="Tc_oe87xDv9wEq6o533d8uc0Q_9_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">7.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      id="Tc_JNo5kCZU0Eu-sA-R8j4Ijw_9_7">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA"
      decimals="INF"
      id="Tc_IVXlhgcMcU6PDbJ0vnbSkw_10_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_SqMGZY1aHUemRgUDYRMrSA"
      decimals="2"
      id="Tc_WRloIBxrD0y-222U7BhrVw_10_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">28.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      id="Tc_8GMVtJD8UkaR0EZ0_5fLiA_10_7">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="2"
      id="Narr_OIFD_-8aYkm7YoUKqinhsQ"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA"
      decimals="2"
      id="Narr_wZlXakRD2UGgtlbtxJnb5Q"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">18.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="0"
      id="Narr_0Fmy9LwzYk6ETEyEqDYRSA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      id="Tb_e26ii-rdQ0KyDR26MwZKwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:37.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 125.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 91.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="4"
      id="Tc_PJuJj6_mYEOJ17R7IxjTYQ_3_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA"
      decimals="4"
      id="Tc_cPNQrYgn3kGNOAGuz-qLfw_3_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      id="Tc_U_D6VM0V40iIFD2ao_YpgA_4_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA"
      id="Tc_8n7D2uRcvkmu14M3x59WGQ_4_4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_FSvu3eb82kehbLn1OeVt6w"
      decimals="3"
      id="Tc_Q7vkEjE2nEiiiqnG1aP4Hw_5_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">1.256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2022_To_9_30_2023_us-gaap_AwardTypeAxis_otlk_PerformanceBasedShareOptionsMember_-Va8BNXf90e7ZkKE8XWGvA"
      decimals="3"
      id="Tc_ayc6YCFlnE6BepaBoBNZhQ_5_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA"
      id="Narr_xdhX_MHiDkifyUvaXm5JpQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_SvVy9amd2kGnS_qqq2VLTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.59%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per PSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at October 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 999.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 999.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and exercisable at September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg"
      decimals="INF"
      id="Tc_rZA90vXOikO3jdT2EdMy6Q_6_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Fn6Kgr-kA0yEEwe9IYR_qg"
      decimals="2"
      id="Tc_zilKqq4P8USZhKiv789s1A_6_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">999.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <otlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA"
      decimals="INF"
      id="Tc___6K2-OB0Ei1TTvNOuFebQ_7_2"
      unitRef="Unit_Standard_shares_HxySrltcJ0ujBkSE4jqc2g">-123</otlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod>
    <otlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2023_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_-LwXwdMvpkqgreu9HDImHA"
      decimals="2"
      id="Tc_P0z4xq4FQ0KGa2ElYl45Gw_7_5"
      unitRef="Unit_Divide_USD_shares_Gvd0xFH8jEO5Lo8oWl2pnw">999.4</otlk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue>
    <otlk:CollaborationArrangementsTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_ncCIiD5GWU2bxLvycQUsTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;12.&#160;&#160;&#160;Collaboration Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Syntone Strategic Partnership and PRC Joint Venture&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with a stock purchase agreement entered in May 2020 between the Company and Syntone, the Company and Syntone entered into a joint venture agreement pursuant to which they agreed to form a PRC joint venture that will be 80% owned by Syntone and 20% owned by the Company. Upon formation of the PRC joint venture in April 2021, the Company entered into a royalty-free license with the PRC joint venture for the development, commercialization and manufacture of ONS-5010/LYTENAVA in the greater China market, which includes Hong Kong, Taiwan and Macau.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company made the initial investment of $900,000 in June 2020. The Company is committed to making up to $2,100,000 in additional capital contributions to the PRC joint venture, based upon the development plan contemplated in the license agreement or on such other terms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</otlk:CollaborationArrangementsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_5_22_2020_dei_LegalEntityAxis_otlk_PRCJointVentureMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_gJdyvVXshEuX-08Mf6ndHA"
      decimals="2"
      id="Narr_76rrhv2OH0alJoC4Qcbbvg"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_BI_7JYDvxk6VXAAFY0LAVg"
      decimals="2"
      id="Narr_K8vLKrXgSEWZnKrHbLvWFQ"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="Duration_6_1_2020_To_6_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_P56yKUXSbkSeAJyaiAzVzA"
      decimals="0"
      id="Narr_7Mq3cv9XbUC-nA1vi8AeYg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">900000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_5_22_2020_To_5_22_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_otlk_SyntoneMember_atTpZe-KyEusv8vCfGF3zg"
      decimals="0"
      id="Narr_UdeNXYb5m0mZFkOZFMM7Iw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2100000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_ibFFjlQeL0is6VnQfTatcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;13.&#160;&#160;&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Income tax benefit for the&#160;years ended September&#160;30, 2024 and 2023 consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.27%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;U.S. federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (21.0)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;%&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (21.0)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (6.2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (7.3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Deferred true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (0.7)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Foreign tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (2.4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (1.3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 29.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (0.1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (0.1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The tax effects of the temporary differences that gave rise to deferred taxes were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 102,906,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 92,961,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 15,200,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 6,531,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 6,463,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 5,066,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 83,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Research and development credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 13,748,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 11,953,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Foreign tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 290,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,562,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Accruals and others&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 144,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,656,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 138,836,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 119,732,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (138,759,510)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (119,725,078)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 77,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 7,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (77,203)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (7,357)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2024, the Company had approximately $406.7 million and $242.5 million of U.S. federal and New Jersey NOLs that will begin to expire in 2030 and 2039, respectively. As of September 30, 2024, the Company had federal and state research and development tax credit carryforwards of $13.0 million and $0.8 million, respectively, available to reduce future tax liabilities which will begin to expire in 2032 and 2033, respectively. As of September 30, 2024, the Company has federal foreign tax credit (&#x201c;FTC&#x201d;) carryforwards of $0.3 million available to reduce future tax liabilities which began to expire starting in 2023, of which $0.3 million of the FTC carryforward is included in the balance of unrecognized tax benefits. Realization of the deferred tax asset is contingent on future taxable income and based upon the level of historical losses, management has concluded that the deferred tax asset does not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance continues to be recorded against the Company&#x2019;s deferred tax assets as of September 30, 2024 and 2023. The valuation allowance increased by $19.0 million and $17.1 million during the year ended September 30, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely-than-not be realized. The determination as to whether the tax benefit will more-likely-than-not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes interest and penalties accrued on any unrecognized tax benefits within the provision for income taxes in its consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Changes based on tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not anticipate material change in the unrecognized tax benefits in the next 12&#160;months. These unrecognized tax benefits, if recognized, would affect the annual effective tax rate. The Company&#x2019;s income tax returns for the&#160;years from 2011 through 2023 remain open for examination by the Internal Revenue Service as well as various states and municipalities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Due to the change in ownership provisions of the Code, the availability of the Company&#x2019;s NOL carryforwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;on beneficial ownership and therefore no determination has been made whether the net operating loss carry forward is subject to any Code Section&#160;382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax assets with an offsetting reduction in the valuation allowance.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_VBqwtcoX8k61mEQH5tpQag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.27%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.17%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;State tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 2,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_3NyhiT4AWkyoXMtcmVdIlg_3_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_i4jzk2FIbES-kHhvkOGxTQ_3_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">2800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_463YxcLAJkS8mepYj6udhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;U.S. federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (21.0)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;%&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (21.0)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (6.2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (7.3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Deferred true-up&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (0.7)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Foreign tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (2.4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (1.3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 29.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (0.1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (0.1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_EWE-Lgy6lky7OVjRgJ54Pg_3_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_8w0YtfS-uEalT-9GyoqWnA_3_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_tZBewbsAr0ewyCu31OLSUQ_4_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_qjG4G0zLAkqZ0qah7MsCYQ_4_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <otlk:EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_51ezZWvA0EWNKJXa0z41yg_5_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">-0.002</otlk:EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent>
    <otlk:EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_45I20nF5ykW0hnj11SWO-w_5_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">-0.001</otlk:EffectiveIncomeTaxRateReconciliationDeferredTrueUpPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_6vFboXsZ90uySMkaAsM9bA_6_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_kVL0_96Hk06PT91qSGciGQ_6_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_Ng6jY5PNoEuG2JHSsYSxIg_7_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_zCtzjS98kE6_a5PZ6QCOgg_7_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_M9-WrBcjyk6e0eCICzpJ5A_8_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_8yzVpPI-NEyMzOrCepKA1A_8_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_j-dr263rWESwZs35NyUaoA_9_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">-0.253</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_PVAmnz7XqU6ViOsTAKTNSQ_9_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_UqRkB2-LAEO1yIV20_zjsw_10_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_HVjb3cWKNU6gdPhUgQxnWQ_10_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="3"
      id="Tc_N5_eIwCD_0aoNl3i3gE6Ig_11_2"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="3"
      id="Tc_7xLofhPdmEKabwF0dkZRAA_11_4"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_UyCHAerVBkC8LtnjVReHRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 102,906,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 92,961,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 15,200,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 6,531,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 6,463,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 5,066,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 83,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Research and development credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 13,748,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 11,953,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Foreign tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 290,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,562,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Accruals and others&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 144,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,656,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 138,836,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 119,732,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (138,759,510)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (119,725,078)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 77,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 7,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="color:#231f20;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (77,203)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt; (7,357)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_dQl3v3mp6E6IKo6ypR-lhw_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">102906140</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_O0Zj7giZSkOybifEemxMRQ_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">92961718</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_9-SxwEgGjkireON3xgCYOA_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">15200918</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_iixQiZIUKEu8GxU9tvUOvg_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6531508</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_uKg4hWmgA0CTbsPnUnlwDg_6_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">6463068</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_drKfaCd5PEyPaeDD3DmJRA_6_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5066375</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <otlk:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_KTUPt-FaUE6Ky5jkm6_BZA_7_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">83720</otlk:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_ugH6fa1E30aM4nXaD7R4WA_8_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">13748600</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_zrVKNQ6FhkS_qA1iPntfmA_8_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">11953956</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_-J5OFFilf0W3z6kSpzmr6g_9_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">290188</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_D1tfRQ--c0KbJNmQvmcxwA_9_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1562639</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_sKoV-iLD2EuxgUbjE0UYYA_10_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">144079</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_7N_BXObaD0uLC-8ttdfHUQ_10_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1656239</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_ISSrvGaxwUGuGDjSupkKsA_11_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">138836713</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_iAmwGCllhEyAppPH5FUzmw_11_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">119732435</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_ST-Kb8Ltz0KX5e7_J9GQ2g_12_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">138759510</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_EYJyLzqLx0afMecb96M9ow_12_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">119725078</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_gyf4ezea4U6pZRCwBcl2dA_13_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">77203</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_Vg_JWXX_j0C8kITWNqllnQ_13_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">7357</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_RN5-44KOM0-bbH4xLgRjqg_16_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">77203</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_a-xQMg9Ii0qsdxAnz_9MiQ_16_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">7357</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LKsDtuAd_kibOfWHNXl-Xg"
      decimals="-5"
      id="Narr_aK8Taf1KtEialAbH7XF6SQ"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">406700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_xm5rwmnSsUqyr_jq4s9uow"
      decimals="-5"
      id="Narr_3r26FFHcS0qfuZNczgHLew"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">242500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_LKsDtuAd_kibOfWHNXl-Xg"
      decimals="-5"
      id="Narr_nH_i_YRVEkqdzFZM2BS9Tg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">13000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_xm5rwmnSsUqyr_jq4s9uow"
      decimals="-5"
      id="Narr_uN4Y7vZjkUWMiPwM11VLfg"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3nC_oDhzvUyW3kv-c_voPw"
      decimals="-5"
      id="Narr_55OUToU4KkGpc-7a0l1kOA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_9_30_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3nC_oDhzvUyW3kv-c_voPw"
      decimals="-5"
      id="Narr_EZvOMbtStUKsWzqGM7jJfw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="-5"
      id="Narr_JQai6B1FyUiMnsjkjB574A"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">19000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="-5"
      id="Narr_EZhlNo5Wt02eRwpy2pgAYA"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">17100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_5nBa67hjs0aUWv8DN7UTcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="color:#231f20;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Changes based on tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;span style="color:#231f20;"&gt; 1,856,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_PaQwsUlNwkOFB6Rb1KZuVQ_3_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1856629</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_9_30_2022_mKb5gYFsE0O1SIgDQrJ05w"
      decimals="0"
      id="Tc_gkhEkiGlA0CdINxwaheBuA_3_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1856629</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      decimals="0"
      id="Tc_8xBhUsUCt0yK9bJOHr_Llg_4_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="Duration_10_1_2022_To_9_30_2023_q1JGnUe380Ge32wpaMiJug"
      decimals="0"
      id="Tc_-wTkUBI0bk62wOKFOMP0jQ_4_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_9_30_2024_dv8nQKG3VUaDKbSvJ-y9lA"
      decimals="0"
      id="Tc_3bXSF7U8H0GzjpWI7uRhqw_5_3"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1856629</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_9_30_2023_qKvFGQke9UeHOX_R8yfrng"
      decimals="0"
      id="Tc_KVjw9uSqKUi1ZVaq4l-xqw_5_6"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">1856629</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_10_1_2023_To_9_30_2024_n0XlsWzUKECgeZeoePyS0A"
      id="Tb_0Ys8T-g3GUqBd0gMI0L0Ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14.&#160;&#160;&#160;Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Departure of Chief Executive Officer&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 3, 2024, C. Russell Trenary III stepped down as the President and Chief Executive Officer the Company and as a member of the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;), effective immediately (the &#x201c;Effective Date&#x201d;). The Board has resolved to reduce its size to nine directors immediately upon Mr. Trenary&#x2019;s resignation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Mr. Trenary&#x2019;s departure constituted a termination of employment without &#x201c;cause&#x201d; for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Trenary is a party or otherwise participates, including that certain executive employment agreement, dated as of July 6, 2021, by and between Mr. Trenary and the Company (the &#x201c;Employment Agreement&#x201d;). Accordingly, subject to Mr. Trenary&#x2019;s execution and non-revocation of a separation agreement containing a release of claims against the Company, Mr. Trenary is entitled to continued payment of his base salary for 12 months following the termination, 100% of his target bonus for the calendar year of termination paid in a lump sum, employee benefit coverage for up to 12 months, full vesting of 50% of his then unvested equity awards, and reimbursement of expenses owed to him through the date of his termination. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 3, 2024, Lawrence A. Kenyon, the Company&#x2019;s Chief Financial Officer, was appointed Interim Chief Executive Officer of the Company, effective as of the Effective Date, to serve while the Board conducts a formal search process to identify and appoint a permanent Chief Executive Officer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reduction in Workforce &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 10, 2024, the Board approved a reduction of the Company&#x2019;s workforce in connection with its plans to reduce operating expenses and preserve capital. On December 13, 2024, the Company reduced its workforce by five people, or approximately 23% of its existing headcount. At a minimum, all employees affected by the workforce reduction are eligible to receive severance payments and paid COBRA premiums for a specified time period post-termination, subject to execution of a general release of claims against the Company. The Company estimates that it will incur approximately $336,000 in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and related costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA"
      decimals="INF"
      id="Narr_YaRjv0sVtUmmIVPNNkR7Tw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">5</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_12_10_2024_To_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_MWw2eXrHWkmfMODsZkKmnA"
      decimals="2"
      id="Narr_CBKAshr_hkaHAuMS7bRILg"
      unitRef="Unit_Standard_pure_6WNwf1WCIES08EwNVTkKGg">0.23</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1
      contextRef="As_Of_12_10_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_RHl_XSAP6E2hmGDCfAw-ng"
      decimals="0"
      id="Narr_-n9CrXjCbES_R4cm7FaCHw"
      unitRef="Unit_Standard_USD_-Pisz4kW1EuUUp3DEeoIvg">336000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ"
      id="Narr_oPfo8suufUi2rUr6rSuwAA">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ"
      id="Narr_tMjkZ2e5EEa5qtTnh0B4Jg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ"
      id="Narr_tK3y0mkWP0mine0-oKNh6g">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_7vRESEGDGEqsXzV6kM-msQ"
      id="Narr_JqsaAydKpk-MJSAD3tb-pg">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
